Emergency doses for dogs and cats

ALWAYS read the relevant monographs.

Cardiac emergencies

- **Asystole or pulseless electrical activity**
  Adrenaline: 10 μg (micrograms)/kg i.v every 3–5 minutes until return of spontaneous circulation – this is equivalent to 1 ml/10 kg using 1:10,000 concentration (100 μg/ml). Double dose if used intratracheally.

- **Hyperkalaemic myocardial toxicity**
  Calcium: 50–150 mg/kg calcium (boro)gluconate = 0.5–1.5 ml/kg of a 10% solution i.v. over 20–30 min
  or Soluble insulin: 0.5 IU/kg i.v. followed by 2–3 g of dextrose/unit of insulin (for urinary tract obstruction but not hypoadrenocorticism). Half the dextrose should be given as a bolus and the remainder administered i.v. over 4–6 h.

- **Other bradyarrhythmias**
  Atropine: 0.01–0.03 mg/kg i.v. – this is equivalent to 0.3–1 ml/20 kg using 0.6 mg/ml solution.

- **Ventricular tachycardia**
  Lidocaine:
  Dogs: 2–8 mg/kg i.v. in 2 mg/kg boluses, followed by a constant rate i.v. infusion of 0.025–0.1 mg/kg/min.
  Cats: 0.25–2.0 mg/kg i.v. slowly in 0.25–0.5 mg/kg boluses followed by a constant rate i.v. infusion of 0.01–0.04 mg/kg/min.

Pulmonary emergencies

- **Respiratory arrest**
  Doxapram: 5–10 mg/kg i.v., repeat according to need; duration of effect is approximately 15–20 min. Neonates: 1–2 drops under the tongue (oral solution) or 0.1 ml i.v. into the umbilical vein; this should be used only once.

Metabolic emergencies

- **Anaphylaxis**
  Adrenaline: 10 μg/kg i.v. – this is equivalent to 1 ml/10 kg using 1:10,000 concentration (100 μg/ml).

- **Hypocalcaemia**
  Calcium: 50–150 mg/kg calcium (boro)gluconate = 0.5–1.5 ml/kg of a 10% solution i.v. over 20–30 min.

- **Hypoglycaemia**
  Glucose: 1–5 ml 50% dextrose i.v. slowly over 10 min.

Neurological emergencies

- **Status epilepticus control**
  Diazepam: 0.5 mg/kg i.v. or rectal – repeat after 3 minutes for up to 3 doses or Midazolam: 0.3 mg/kg i.v. or rectal – repeat after 3 minutes for up to 3 doses.
  If the seizures have been controlled, maintain on an i.v. infusion of midazolam at 0.3 mg/kg/h while establishing or changing maintenance therapy
  If seizures not controlled by above: Propofol: induce with 1–4 mg/kg i.v. and then maintain on 0.1–0.4 mg/kg/min.

- **Raised intracranial pressure (impending herniation)**
  Mannitol: 0.25–0.5 g/kg i.v. infusion of 15–20% solution over 30 min. May repeat 1–2 times after 4–8 hours as long as hydration and electrolytes monitored. (For acute glaucoma see monograph.)

Anaesthesia emergencies

- **Reversing agents**
  Naloxone: 0.015–0.04 mg/kg i.v., i.m., s.c., intratracheal (give to effect).
  Atipamezole: Five times the previous medetomidine or dexmedetomidine dose i.m.; if that dose unknown, use 100 μg(micrograms)/kg i.m. or very slow i.v.
Contents

Editorial Panel iii
Preface v
Foreword vi

Introduction

Notes on the monographs vii
Distribution categories viii
The prescribing cascade ix
Drug storage and dispensing xii
Health and safety in dispensing xiii

Drug listings and monographs 1
(listed A–Z by generic name)

Appendix I: general information

Abbreviations 441
Writing a prescription 442
Topical polypharmaceuticals for ear disease 443
Guidelines for responsible antibacterial use 444
Guidelines on prescribing glucocorticoids 445
Radiographic contrast agents: MRI 448
Composition of intravenous fluids 451
Safety and handling of chemotherapeutic agents 451
Body weight to body surface area conversion tables 455
Percentage solutions 455
Drugs usage in renal and hepatic insufficiency 456
Suspected Adverse Reaction Surveillance Scheme 458
Further reading and useful websites 458

Appendix II: protocols

Chemotherapy protocols for lymphoma 460
Immunosuppression protocols 467
Sedation/immobilization protocols 471
  Sedative combinations for dogs 471
  Sedative combinations for cats 474

Index sorted by therapeutic class 476
Index (alphabetical by generic and trade names 484
Preface

Welcome to Part A of the 10th edition of the BSAVA Small Animal Formulary, providing up-to-date information about the drugs used for cats and dogs. I would like to start by thanking Professor Ian Ramsey for his tremendous work over the previous four editions of the Formulary, cementing this book as a superbly useful tool for small animal veterinary surgeons.

In revising the latest edition, several new drug monographs have been added, including additional chemotherapeutic agents. The introduction of bullet points within the description of uses should highlight where certain drugs have multiple, reported indications. Through ongoing veterinary research data relating to drug use, adverse reactions and drug interactions is developed regularly; veterinary surgeons and nurses are reminded to also consult other sources when confronted with a medication with which they are unfamiliar. As well as the cited references, textbooks such as the excellent series of manuals published by the BSAVA can provide a wealth of pertinent information.

This year, the guidelines on antibacterial use have been adapted to reflect the 2018 launch of the PROTECT ME initiative. Antimicrobial resistance is likely to represent a major challenge to human and animal healthcare in this new decade. Veterinary surgeons have a responsibility to pursue rational antibacterial use at all times and are encouraged to refer to the latest recommendations regarding the need for and selection of antibacterial medication for any particular condition.

An illustrative flowchart has been added to the information regarding the prescribing cascade following the clarifications published by the Veterinary Medicines Directorate in 2019. Veterinary surgeons are reminded of the need to ensure that their prescribing policies and practices comply with existing guidelines and legislation. The Formulary provides information about many drugs not authorized for use in animals. Authorized products should be considered first for every patient; when such products are not available, or not clinically suitable, unauthorized medicines may be used in accordance with the cascade. In such cases, a clear clinical justification, made on an individual basis, should be recorded in the clinical notes or on the prescription.

I would like to thank the Editorial Panel members for their efforts on this edition. I would also like to thank Alessandra Mathis, Jacques Ferreira, Gwen Covey-Crump, Tim Nuttall, Charlotte Robinson and James Swann for their invaluable advice with particular sections. My gratitude also goes to the editorial team members at BSAVA for their generous and enthusiastic assistance.

I would welcome all comments and feedback from BSAVA members on this latest edition of the Small Animal Formulary.

Fergus Allerton
January 2020
Foreword

The *BSAVA Small Animal Formulary* for the cat and dog, which was first published over twenty years ago, is recognized as an invaluable asset for the small animal clinician and is one of the Association’s most useful member benefits. Available as both a hard copy and as an App, it can be accessed quickly by the busy clinician as a resource to help with immediate prescribing advice, as well as by veterinary students during their training. As the numbers of licensed medications available to the small animal vet has increased, a reference source such as this can be a life saver during a hectic working day.

The 10th edition of the Formulary sees Fergus Allerton take up the reins from Ian Ramsey who has guided the editorial team for many years. Fergus has assembled a knowledgeable and experienced group of subject experts to review the Formulary, which has been fully updated. Thirteen new drug monographs have been added together with client information leaflets for a further nine drugs. The launch of the *Small Animal Formulary: Part A – Canine and Feline*, together with the updated *Small Animal Formulary: Part B – Exotic Pets*, provides primary care veterinary surgeons and specialists alike with a complete guide to prescribing across all of species encountered by veterinary surgeons in clinical practice.

Fergus and his team are to be congratulated on bringing out this new and updated 10th edition of the Formulary.

*Sue Paterson MA VetMB DVD DipECVD FRCVS*
BSAVA President 2019–2020
Introduction

Notes on the monographs

- **Name**. The rINN generic name is used where this has been agreed. When a choice of names is available the more commonly used in the UK has been provided. The list of trade names is not necessarily comprehensive, and the mention or exclusion of any particular commercial product is not a recommendation or otherwise as to its value. Any omission of a product that is authorized for a particular canine or feline indication is purely accidental. All monographs were updated in the period July–December 2019. Products that are not marketed for use in animals (whether authorized by the Veterinary Medicines Directorate or not) are marked with an asterisk. Note that an indication that a product is authorized does not necessarily mean that it is authorized for all species and indications listed in the monograph; users should check individual data sheets. You may also wish to refer to the VMD’s Product Information Database (www.vmd.defra.gov.uk/ProductInformationDatabase/).

- **Formulations**. Only medicines and formulations that are available in the UK have been included – many others are available outside the UK and some medicines in different formulations. Common trade names of human medicines are provided. In many cases they are available as generic formulations and may be cheaper. However, be careful of assuming that the bioavailability of one brand is the same as that of another. Avoid switching between brands unnecessarily.

- **Action and Use**. Veterinary surgeons using this publication are warned that many of the drugs and doses listed are not currently authorized by the Veterinary Medicines Directorate (VMD) or the European Agency for the Evaluation of Medicinal Products (EMEA) (either at all or for a particular species), or manufacturers’ recommendations may be limited to particular indications. The decision, and therefore the responsibility, for prescribing any drug for an animal lies solely with the veterinary surgeon. Expert assistance should be obtained when necessary. The ‘cascade’ and its implications are discussed below. For information on combination drugs, it is important to refer to all relevant monographs.

- **Safety and handling**. This section only outlines specific risks and precautions for a particular drug that are in addition to the general advice given below in the ‘Health and safety in dispensing’ section. A separate Appendix deals with chemotherapeutic drugs.

- **Contraindications** and **Adverse reactions**: The list of adverse reactions is not intended to be comprehensive and is limited to those effects that may be of clinical significance. The information for both of these sections is taken from published veterinary and human references and not just from product literature.
• **Drug interactions.** A listing of those interactions which may be of clinical significance.

• **Doses.** These are based on those recommended by the manufacturers in their data sheets and package inserts, or are based on those given in published articles or textbooks, or are based on clinical experience. **These recommendations should be used only as guidelines and should not be considered appropriate for every case.** Clinical judgement must take precedence. Doses for small mammals, birds, reptiles and other groups of animals should never be extrapolated from the doses provided in this book for dogs and cats. *The BSAVA Small Animal Formulary: Part B – Exotic Pets* and other sources should be consulted where such doses are required.

### Distribution categories

Authorized small animal medicines within Great Britain now fall within the first four categories below and all packaging supplied by drug manufacturers and distributors was changed in 2008. Medical products not authorized for veterinary use retain their former classification (e.g. GSL, P, POM). Other laws apply in other jurisdictions. Some nutritional supplements (nutraceuticals) are not considered medicinal products and therefore are not classified. Where a product does not have a marketing authorization it is designated ‘general sale’.

**AVM-GSL:** Authorized veterinary medicine – general sales list. This may be sold by anyone.

**NFA-VPS:** Non-food animal medicine – veterinarian, pharmacist, Suitably Qualified Person (SQP). These medicines for companion animals must be supplied by a veterinary surgeon, pharmacist or SQP. An SQP has to be registered with the Animal Medicines Training Regulatory Authority (AMTRA). Veterinary nurses can become SQPs but it is not automatic.

**POM-VPS:** Prescription-only medicine – veterinarian, pharmacist, SQP (formerly PML livestock products, MFSX products and a few P products). These medicines for food-producing animals (including horses) can only be supplied on an oral or written veterinary prescription from a veterinary surgeon, pharmacist or SQP and can only be supplied by one of those groups of people in accordance with the prescription.

**POM-V:** Prescription-only medicine – veterinarian. These medicines can only be supplied against a veterinary prescription that has been prepared (either orally or in writing) by a veterinary surgeon to animals under their care following a clinical assessment, and can only be supplied by a veterinary surgeon or pharmacist in accordance with the prescription.

**CD:** Controlled Drug. A substance controlled by the Misuse of Drugs Act 1971 and Regulations. The CD is followed by (Schedule 1), (Schedule 2), (Schedule 3), (Schedule 4) or (Schedule 5) depending
on the Schedule to The Misuse of Drugs Regulations 2001 (as amended) in which the preparation is included. You could be prosecuted for failure to comply with this act. Prescribers are reminded that there are additional requirements relating to the prescribing of Controlled Drugs. For more information see the BSAVA Guide to the Use of Veterinary Medicines at www.bsavalibrary.com.

**Schedule 1:** Includes LSD, cannabis, lysergide and other drugs that are not used medicinally. Possession and supply are prohibited except in accordance with Home Office Authority.

**Schedule 2:** Includes etorphine, ketamine, morphine, methadone, pethidine, secobarbital (quinalbarbitone), diamorphine (heroin), cocaine and amphetamine. Record all purchases and each individual supply (within 24 hours). Registers must be kept for 2 calendar years after the last entry. Drugs must be kept under safe custody (locked secure cabinet), except secobarbital. There are specific requirements regarding the destruction of Schedule 2 Controlled Drugs, which may require an independent veterinary surgeon or person authorized by the Secretary of State to witness.

**Schedule 3:** Includes buprenorphine, tramadol, the barbiturates (e.g. pentobarbital and phenobarbital but not secobarbital – which is Schedule 2), midazolam, gabapentin and others. Buprenorphine, with some others, must be kept under safe custody (locked secure cabinet) and it is advisable that all Schedule 3 drugs are locked away (although not compulsory for the rest). Retention of invoices for 2 years is necessary.

**Schedule 4:** Includes most of the benzodiazepines except midazolam (which is Schedule 3), and androgenic and anabolic steroids (e.g. nandralone). Exempted from control when used in normal veterinary practice.

**Schedule 5:** Includes preparations (such as several codeine products) which, because of their strength, are exempt from virtually all Controlled Drug requirements other than the retention of invoices for 2 years.

**The prescribing cascade**

Veterinary medicinal products must be administered in accordance with the prescribing cascade, as set out in the Veterinary Medicines Regulations 2013. These Regulations provide that when no authorized veterinary medicinal product exists for a condition in a particular species, veterinary surgeons exercising their clinical judgement may, in particular to avoid unacceptable suffering, prescribe for one or a small number of animals under their care other suitable medications in accordance with the following sequence:

- A veterinary medicine authorized in the UK for use in another species with the same condition, or for a different condition in the same species
- If there is no such product:
  - A medicine authorized in the UK for human use
- A veterinary medicine not authorized in the UK, but authorized in another EU member state for use in any species in accordance with the Special Import Scheme.
- A veterinary medicine prepared extemporaneously by a properly authorized person as prescribed by the veterinary surgeon
- In exceptional circumstances, medicines may be imported from outside Europe via the Special Import Scheme.

This flowchart shows the steps that should be taken when no authorized veterinary medicine is available or clinically suitable.
'Off-label' use of medicines

‘Off-label’ use is the use of medicines outside the terms of their marketing authorization. It may include medicines authorized outside the UK that are used in accordance with an import certificate issued by the VMD. A veterinary surgeon with detailed knowledge of the medical history and clinical status of a patient, may reasonably prescribe a medicine ‘off-label’ in accordance with the prescribing cascade. Authorized medicines have been scientifically assessed against statutory criteria of safety, quality and efficacy when used in accordance with the authorized recommendations on the product literature. Use of an unauthorized medicine provides none of these safeguards and may, therefore, pose potential risks that the authorization process seeks to minimize. Medicines may be used ‘off-label’ for a variety of reasons including:

- No authorized product is suitable for the condition or specific subpopulation being treated
- Need to alter the duration of therapy, dosage, route of administration, etc., to treat the specific condition presented
- An authorized product has proved ineffective in the circumstances of a particular case (all cases of suspected lack of efficacy of authorized veterinary medicines should be reported to the VMD).

Responsibility for the use of a medicine ‘off-label’ lies solely with the prescribing veterinary surgeon. He or she should inform the owner of the reason why a medicine is to be used ‘off-label’ and record this reason in the patient’s clinical notes. When electing to use a medicine ‘off-label’ always:

- Discuss all therapeutic options with the owner
- Use the cascade to determine your choice of medicine
- Obtain signed informed consent if an unauthorized product is to be used, ensuring that all potential problems are explained to the client
- Administer unauthorized medicines against a patient-specific prescription. Do not administer to a group of animals if at all possible.

An ‘off-label’ medicine must show a comparative clinical advantage to the authorized product in the specific circumstances presented (where applicable). Medicines may be used ‘off-label’ in the following ways (this is not an exhaustive list):

- Authorized product at an unauthorized dose
- Authorized product for an unauthorized indication
- Authorized product used outwith the authorized age range
- Authorized product administered by an unauthorized route
- Authorized product used to treat an animal in an unauthorized physiological state, e.g. pregnancy (i.e. an unauthorized indication)
- Product authorized for use in humans or a different animal species to that being treated.

Adverse effects may or may not be specific for a species, and idiosyncratic reactions are always a possibility. If no adverse effects
are listed, consider data from different species. When using novel or unfamiliar drugs, consider pharmaceutical and pharmacological interactions. In some species, and with some diseases, the ability to metabolize/excrete a drug may be impaired/enhanced. Use the lowest dose that might be effective and the safest route of administration. Ensure that you are aware of the clinical signs that may suggest toxicity.

Information on ‘off-label’ use may be available from a wide variety of sources (see Appendix).

**Drug storage and dispensing**

For further information on the storage and dispensing of medicines see the *BSAVA Guide to the Use of Veterinary Medicines* available at www.bsavalibrary.com. Note the recent change in legislation, which states that veterinary surgeons may only supply a veterinary medicine from practice premises that are registered with the RCVS and that these premises must be inspected. It is recommended that, in general, medications are kept in and dispensed in the manufacturer’s original packaging. Medicines can be adversely affected by adverse temperatures, excessive light, humidity and rough handling. Loose tablets or capsules that are repackaged from bulk containers should be dispensed in child-resistant containers and supplied with a package insert (if one exists). Tablets and capsules in foil strips should be sold in their original packaging or in a similar cardboard box for smaller quantities. Preparations for external application should be dispensed in coloured fluted bottles. Oral liquids should be dispensed in plain glass bottles with child-resistant closures.

All medicines should be labelled. The label should include:

- The owner’s name and address
- Identification of the animal
- Date of supply (and, if applicable, the expiry date)
- Product name (and strength)
- Total quantity of the product supplied in the container
- Instructions for dosage
- Practice name and address
- The name of the veterinary surgeon who prescribed the medication (if not an authorized use)
- Any specific pharmacy precautions (including storage, disposal, handling)
- The wording ‘Keep out of reach of children’ and ‘For animal treatment only’
- Withdrawal period, if relevant
- Any other necessary warnings.

The words ‘For external use only’ should be included on labels for products for topical use. All labels should be typed. If this information cannot be fitted on a single label, then it is permissible to include the information on a separate sheet.
For medicines that are not authorized for veterinary use, and even for some that are, it is useful to add to the label or on a separate sheet the likely adverse effects, drug interactions and the action to be taken in the event of inadvertent mis-dosing or incorrect administration written in plain English. Samples of such Client Information Leaflets (shown as CIL in the monographs) for many commonly used, but unauthorized, drugs are available for BSAVA members to download from www.bsavalibrary.com.

In order to comply with the current Veterinary Medicines Regulations, records of all products supplied on prescription must be kept for 5 years. When a batch is brought into use in a practice, the batch number and date should be recorded. It is not necessary to record the batch number of each medication used for a given animal.

**Health and safety in dispensing**

All drugs are potentially poisonous to humans as well as animals. Toxicity may be mild or severe and includes carcinogenic and teratogenic effects. Warnings are given in the monographs. However, risks to humans dispensing medicines are not always well characterized and idiosyncratic reactions may occur. **It is good practice for everyone to wear protective clothing (including gloves) when directly handling medicines, not to eat or drink (or store food or drink) near medicines, and to wash their hands frequently when working with medicines.** Gloves, masks and safety glasses should be worn if handling potentially toxic liquids, powders or broken tablets. Do not break tablets of antineoplastic cytotoxic drugs and use laminar flow cabinets for the preparation and dispensing of these medications. **See Appendix** for more information.

Many prescribers and users of medicines are not aware of the carcinogenic potential of the drugs they are handling. Below are lists of medicines included in the *BSAVA Formulary* that are known or potential carcinogens or teratogens. The lists are not all-inclusive: they include only those substances that have been evaluated. Most of the drugs are connected only with certain kinds of cancer. The relative carcinogenicity of the agents varies considerably and some do not cause cancer at all times or under all circumstances. Some may only be carcinogenic or teratogenic if a person is exposed in a certain way (for example, ingesting as opposed to touching the drug). For more detailed information, refer to the International Agency for Research on Cancer (IARC) or the National Toxicology Program (NTP) (information is available on their respective websites).
Examples of drugs known or suspected to be human carcinogens (c) or teratogens (t):

- ACE inhibitors (t), e.g. benazepril, enalapril, ramipril
- Androgenic (anabolic) steroids (t, c)
- Antibiotics (c), e.g. metronidazole, chloramphenicol
- Antibiotics (t), e.g. aminoglycosides, doxycycline, trimethoprim, sulphonamides
- Antifungals (c), e.g. fluconazole, itraconazole, flucytosine
- Antineoplastic drugs (c, t) – all
- Antithyroid drugs (t), e.g. carbimazole/methimazole
- Beta-blockers (t)
- Deferoxamine (t)
- Diltiazem (t)
- Finasteride (t)
- Immunosuppressives (c), e.g. azathioprine, ciclosporin
- Lithium (t)
- Methotrexate (t)
- Misoprostol (t)
- NSAIDs (t)
- Penicillamine (t)
- Phenoxybenzamine (c)
- Progestagens (c) and some oestrogens (c)
- Vitamin A (t)

Note that most carcinogens are also likely to be teratogens.
Acepromazine (ACP)
(Acecare, ACP) POM-V

Formulations: Injectable: 2 mg/ml solution. Oral: 10 mg, 25 mg tablets.

Action: Phenothiazine with depressant effect on the CNS, thereby causing sedation and a reduction in spontaneous activity.

Use:
- Sedation or pre-anaesthetic medication in dogs and cats.
- ACP raises the threshold for cardiac arrhythmias and has antiemetic properties.
- Sedation is unreliable when ACP is used alone; combining ACP with an opioid drug improves sedation (neuroleptanalgesia) and the opioid provides analgesia.
- Also used for the management of thromboembolism in cats because of its peripheral vasodilatory action.

The depth of sedation is dose-dependent up to a plateau (0.1 mg/kg). Increasing the dose above 0.1 mg/kg does little to improve the predictability of achieving adequate sedation but increases the risk of incurring adverse effects, the severity of adverse effects and the duration of action of any effects (desirable or adverse) that arise. The lower end of the dose range should be used for giant-breed dogs to allow for the effects of metabolic body size. Onset of sedation is 20–30 minutes after i.m. administration; clinical doses cause sedation for up to 6 hours. The oral dose of ACP tablets required to produce sedation varies between individual animals, and high doses can lead to very prolonged sedation. The use of ACP in the management of sound phobias in dogs, such as firework or thunder phobia, is not recommended.

Safety and handling: Normal precautions should be observed.

Contraindications: Hypotension due to shock, trauma or cardiovascular disease. Avoid in animals <3 months and animals with liver disease. Use cautiously in anaemic animals as it will exacerbate the anaemia by sequestration of red blood cells in the spleen. In Boxers, spontaneous fainting and syncope can occur due to sinoatrial block caused by excessive vagal tone; use low doses or avoid.

Adverse reactions: Rarely, healthy animals may develop profound hypotension following administration of phenothiazines. Supportive therapy to maintain body temperature and fluid balance is indicated until the animal is fully recovered.

Drug interactions: Other CNS depressant agents (e.g. barbiturates, propofol, alfaxalone, volatile anaesthetics) will cause additive CNS depression if used with ACP. Doses of other anaesthetic drugs should be reduced when ACP has been used for premedication. Increased levels of both drugs may result if propranolol is administered with phenothiazines. As phenothiazines block alpha-adrenergic receptors, concomitant use with adrenaline
may lead to unopposed beta activity, thereby causing vasodilation and tachycardia. Antidiarrhoeal mixtures (e.g. kaolin/pectin, bismuth salicylate) and antacids may cause reduced GI absorption of oral phenothiazines.

**DOSES**

When used for sedation and premedication is generally given as part of a combination with opioids. See Appendix for sedation protocols in cats and dogs.

**Dogs (not Boxers), Cats:** 0.01–0.02 mg/kg slowly i.v.; 0.01–0.05 mg/kg i.m., s.c.; 1–3 mg/kg p.o. **Boxers:** 0.005–0.01 mg/kg i.m.

**Acetaminophen** see **Paracetamol**

**Acetazolamide**

(Diamox*) POM

**Formulations:** Oral: 250 mg tablets, capsules.

**Action:** Systemic carbonic anhydrase inhibitor.

**Use:**

- Used as treatment for the management of episodic falling in the Cavalier King Charles Spaniel experiencing a high frequency of collapse episodes which are refractory to other treatments (clonazepam and diazepam). If there is no favourable response after 2 weeks on q12h dose, then the drug should be stopped.
- May be beneficial for other paroxysmal dyskinesias.

No longer used for canine glaucoma.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Avoid in anorexic dogs, those with hepatic or renal dysfunction and those with sulphonamide hypersensitivity. Cats are particularly susceptible to the adverse effects of systemic carbonic anhydrase inhibitors; avoid in this species.

**Adverse reactions:** Weakness, GI disturbances (anorexia, vomiting, diarrhoea), panting, metabolic acidosis, diuresis, electrolyte disturbances, in particular, potassium depletion.

**Drug interactions:** Acetazolamide alkalinizes urine; thus, excretion rate of weak bases may be decreased but weak acid excretion increased. Concomitant use of corticosteroids may exacerbate potassium depletion, causing hypokalaemia.

**DOSES**

**Dogs:** CKCS episodic falling syndrome: 4–8 mg/kg p.o. q8–12h.

**Cats:** Do not use.

**References**

Emilie Royaux, Sofie Bhatti, Robert Harvey *et al.* (2016) Acetazolamide–responsive paroxysmal dyskinesia in a 12-week-old female golden retriever dog. *Veterinary Quarterly* 36, 45–49
Acetylcysteine  
(IIube*, Parvolex*)  POM

**Formulations:** Injectable: 200 mg/ml solution. Topical: 5% ophthalmic solution in combination with 0.35% hypromellose ophthalmic drops in 10 ml bottle.

**Action:** Decreases the viscosity of bronchial secretions, maintains glutathione levels in the liver and has some anticollagenase activity.

**Use:** Reduces the extent of liver injury in cases of paracetamol poisoning and other forms of liver toxicity involving oxidative damage or impaired glutathione synthesis (e.g. xylitol poisoning).
- Has been used in non-specific acute hepatopathies of suspected toxic origin.
- Can also be used as a mucolytic in respiratory disease.
- Acetylcysteine may be useful in the treatment of keratoconjunctivitis sicca (KCS) (dry eye), or in ‘melting’ corneal ulcers although there is limited in vivo work to confirm this.

Oral solution should be diluted to a 5% solution and given via a stomach tube as it tastes unpleasant. In the eye it may be used in conjunction with hypromellose.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.

**Adverse reactions:** Acetylcysteine has caused hypersensitivity and bronchospasm when used in the pulmonary tree (use with care in bronchospastic respiratory disease, e.g. feline asthma). When given orally for paracetamol poisoning it may cause GI effects (nausea, vomiting) and, rarely, urticaria.

**Drug interactions:** In cases of paracetamol poisoning, the concurrent administration of activated charcoal is controversial as it may also reduce acetylcysteine absorption.

**DOSES**

**Dogs, Cats:**
- **Mucolytic:** either nebulize 50 mg as a 2% (dilute with saline) solution over 30–60 min or instil directly into the trachea 1–2 ml of a 20% solution.
- **Paracetamol poisoning:** (after inducing emesis if appropriate, i.e. presented within 2 hours of ingestion) give 140–280 mg/kg diluted to a 5% solution using 5% dextrose by slow i.v. infusion over 15–20 min, followed by further slow infusions of 70 mg/kg (similarly diluted) every 6 hours for at least 7 doses, depending on dose of paracetamol consumed (seek advice from a poisons information service). The intravenous solution can be administered orally but should be diluted to improve palatability; however, i.v. administration is preferred for serious intoxications as bioavailability is reduced with oral administration in cats.
- **KCS:** 1 drop of the ophthalmic solution topically to the eye q6–8h. Rarely used now for this indication.
• Melting corneal ulcers: 1 drop of the ophthalmic solution q1–4h in the affected eye for 24–48 hours. Topical autologous serum is more effective for the treatment of a melting corneal ulcer and is preferred.

References

**Acetylsalicyclic acid** see Aspirin

**Aciclovir**
(Zovirax®) POM

**Formulations:** Ophthalmic: 3% ointment in 4.5 g tubes.

**Action:** Inhibits viral replication (viral DNA polymerase); depends on viral thymidine kinase for phosphorylation.

**Use:**
• Management of ocular feline herpesvirus-1 (FHV-1) infections.

The clinical efficacy of aciclovir is questionable but frequent application (0.5% ointment 5 times daily) may achieve corneal concentrations. Aciclovir is virostatic and is unable to eradicate latent viral infection. Consider ganciclovir and famciclovir before aciclovir. In refractory and severe cases of FHV-1 ulceration, combined therapy including antiviral medication can be used.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available for the ophthalmic preparation. Systemic aciclovir is toxic in cats.

**Adverse reactions:** Ocular irritation may occur and the frequency of application should be reduced if this develops. Treatment should not be continued for >3 weeks.

**Drug interactions:** No information available.

**DOSES**

**Dogs:** Not applicable.

**Cats:** Apply a small amount to affected eye 5 times daily for a maximum of 3 weeks.

References

**ACP** see Acepromazine

**ACTH** see Tetracosactide
Actinomycin-D see Dactinomycin
Activated charcoal see Charcoal
ADH see Desmopressin

**Adrenaline (Epinephrine)**
(Adrenaline*, Epinephrine*) POM

**Formulations:** Injectable: Range of concentrations for injection: 0.1–10 mg/ml, equivalent to 1:10,000 to 1:100.

**Action:** Adrenaline exerts its effects via alpha-1, -2 and beta-1 and -2 adrenoreceptors.

**Use:**
- Cardiac resuscitation, status asthmaticus and to offset the effects of histamine release in severe anaphylactoid reactions.
- The ophthalmic preparation is used in open-angle glaucoma.

The effects of adrenaline vary according to dose. Infusions of low doses mainly result in beta-adrenergic effects (increases in cardiac output, myocardial oxygen consumption, and a reduced threshold for arrhythmias with peripheral vasodilation and a fall in diastolic blood pressure). At high doses alpha-1 effects predominate, causing a rise in systemic vascular resistance, diverting blood to the central organs; however, this may improve cardiac output and blood flow. Adrenaline is not a substitute for fluid replacement therapy. Respiratory effects include bronchodilation and an increase in pulmonary vascular resistance. Renal blood flow is moderately decreased. The duration of action of adrenaline is short (2–5 min). Beware of using in animals with diabetes mellitus (monitor blood glucose concentration), hypertension or hyperthyroidism. Use with caution in hypovolaemic animals. Overdosage can be fatal so check dose, particularly in small patients. Intracardiac injection is not recommended.

**Safety and handling:** Do not confuse adrenaline vials of different concentrations. Adrenaline is sensitive to light and air: do not use if it is pink, brown or contains a precipitate. It is unstable in 5% dextrose.

**Contraindications:** The use of human adrenaline pen injections is not recommended for the treatment of suspected anaphylaxis. The doses in such pens are usually too small to be effective in most normal animals and by the time the dog has collapsed would be unlikely to have any effect on outcome. If such pen injections are administered by owners, then, in common with medical practice, patients must be carefully monitored for at least 6 hours. Do not administer adrenaline directly into the myocardium because of the risk of arrhythmias.

**Adverse reactions:** Increases myocardial oxygen demand and produces arrhythmias including ventricular fibrillation. These may be ameliorated by administering oxygen and slowing the heart rate with beta-2 antagonists. Other adverse effects include tachycardia,
arrhythmias, dry mouth and cold extremities. Repeated injections can cause necrosis at the injection site.

**Drug interactions:** Toxicity may occur if used with other sympathomimetic amines because of additive effects. The effects of adrenaline may be potentiated by antihistamines and thyroxine. Propranolol may block the beta effects of adrenaline, thus facilitating an increase in blood pressure. Alpha blocking agents or diuretics may negate or diminish the pressor effects. When adrenaline is used with drugs that sensitize the myocardium (e.g. halothane, high doses of digoxin) monitor for signs of arrhythmias. Hypertension may result if adrenaline is used with oxytocic agents.

**DOSES**

**Dogs, Cats:**

**Cardiopulmonary arrest (CPA):**

- 10 μg (micrograms)/kg of a 1:1000 solution (1000 μg/ml) given i.v. or intraosseously every 3–5 min. Peripheral administration into a vein should be followed by a fluid bolus to push the drug into the central circulation. High dose epinephrine (0.1 mg/kg i.v.) maybe considered after prolonged CPA. Can be given intratracheally for resuscitation of intubated animals, but higher doses may be required. A long catheter should be used to ensure the drug is delivered into the bronchi beyond the end of the endotracheal tube.

**Bronchoconstriction and anaphylaxis:**

- 10 μg (micrograms)/kg of a 1:1000 solution (1000 μg/ml) i.v. or i.m. The i.v. route is preferred if hypotension accompanies an anaphylactoid reaction.

**References**

Fletcher DJ, Boller M, Brainard BM et al. (2012) RECOVER evidence and knowledge gap analysis on veterinary CPR. Part 7: Clinical guidelines. *Journal of Veterinary Emergency and Critical Care (San Antonio)* 22(S1), 102–131

**Afoxolaner**

*(Nexgard, Nexgard Spectra)* **POM-V**

**Formulations:** Oral: 11.3 mg, 28.3 mg, 68 mg, 136 mg tablets (Nexgard), also available in 5 tablet sizes with milbemycin oxime (Nexgard Spectra).

**Action:** Acts at ligand-gated chloride channels, in particular those gated by the neurotransmitter GABA, thereby blocking pre- and post-synaptic transfer of chloride ions across cell membranes.

**Use:**

- Used in the treatment of fleas and ticks in dogs. Kills fleas within 8 hours and ticks within 48 hours.
- Treatment of sarcoptic acariasis and demodicosis in dogs.

**Safety and handling:** Normal precautions should be observed. The tablets should not be divided.
Contraindications: Do not use in dogs <8 weeks old or <2 kg body weight.

Adverse reactions: Rare mild gastrointestinal signs (vomiting, diarrhoea), lethargy, anorexia, pruritus, neurological (convulsions, ataxia).

Drug interactions: No information available.

DOSES
Dogs: Administer monthly. The tablets supply 2.5–6.9 mg/kg of afoxolaner.
Cats: Do not use.

References

Aglepristone (Alizin) POM-V

Formulations: Injectable: 30 mg/ml solution.

Action: Progesterone receptor blockage leads to elimination of progesterone support for up to 7 days.

Use:
• Termination of pregnancy throughout pregnancy.
• Treatment of pyometra in dogs, although recurrence is not unusual especially in older bitches.
• Induction of parturition in cats and dogs.
• Treat of progesterone-induced acromegaly in dogs and progesterone-induced fibroadenomatous mammary hyperplasia in cats.

Best given in bitches at the end of oestrus or beginning of metoestrus and straight after suspected mating in queens as they are induced ovulators. When used after 30 days, bitches and queens will abort rather than absorb. May be unsuccessful when used in pro-oestrus and early oestrus in bitches as progesterone has not yet risen or sperm survival may be longer than activity of aglepristone. In bitches confirmed as pregnant, a partial abortion may occur in up to 5% of cases. In late abortions, clinical examination (ultrasound) is recommended 10 days after treatment in order to confirm termination. After induced abortion, an early return to oestrus is frequently observed (the oestrus-to-oestrus interval may be shortened by 1–3 months). Bitches will usually be able to carry subsequent pregnancies successfully.

Safety and handling: Use with care. Accidental injection may be a hazard to women who are pregnant or intending to become pregnant.

Contraindications: Consider avoiding in dogs with diagnosed or suspected hypoadrenocorticism.
Adverse reactions: Transient pain at the injection site; any local inflammation produced resolves uneventfully. In bitches/queens treated beyond the 20th day of gestation, abortion may be accompanied by the physiological signs of parturition, i.e. fetal expulsion, anorexia, mammary congestion.

Drug interactions: Aglepristone binds to glucocorticoid receptors and may therefore interfere with the actions of glucocorticoids; however, the clinical significance of this is unclear.

DOSES
Dogs: Maximum of 5 ml injected at any one site.
• Pregnancy termination: 10 mg/kg s.c. within 24 hours for 2 doses.
• Progesterone-induced acromegaly: 10 mg/kg s.c. q24h for 2 doses and then q7d for 3 more doses.
• Pyometra: 10 mg/kg s.c. on days 1, 2 and 7. Additional doses may be given on days 14 and 21 if there is an inadequate response.

Cats: Maximum of 5 ml injected at any one site.
• Pregnancy termination: 15 mg/kg s.c. within q24h for 2 doses.
• Fibroadenomatous hyperplasia: 20 mg/kg s.c. q7d (also consider atenolol if cat is tachycardic with heart rate >200 bpm).
• Pyometra: 15 mg/kg s.c. on days 1, 2 and 7. Additional doses may be given on days 14 and 21 if there is an inadequate response.

References

Alendronate (Alendronate sodium) POM
(Alendronate sodium) POM

Formulations: Oral: 10 mg, 70 mg tablets, 0.7 mg/ml solution.

Action: Primary action is to inhibit osteoclastic bone reabsorption (through inhibiting osteoclast function). Also promotes apoptosis, inhibits angiogenesis, cancer cell division and osteoclastogenesis.

Use:
• Treatment of idiopathic hypercalcaemia.
• To reduce pain associated with osteolytic conditions (e.g. bone tumours).

There is limited information in the literature regarding the use of alendronate in dogs. Poor absorption after oral administration limits efficacy in this species.

Safety and handling: Store at room temperature.

Contraindications: Alendronate is contraindicated in humans with oesophageal disease; however, it is unknown if this is necessary for dogs and cats. Use with caution in patients with renal
insufficiency and avoid in patients with renal failure. Avoid in patients with a history of hypersensitivity to bisphosphonates.

**Adverse reactions:** Alendronate is thought to cause oesophageal irritation (oesophagitis) and upper GI ulcers. There are limited reports of vomiting, and inappetance in dogs. Pathological fractures reported in cats after prolonged use (5–9 years). Other potential adverse effects include osteonecrosis and musculoskeletal pain. Hypocalcaemia is also possible.

**Drug interactions:** Do not use in combination with aspirin (increased risk of upper GI adverse events) and use with caution with other NSAIDs. Avoid drugs/supplements/diets that contain calcium as this is likely to decrease the bioavailability of alendronate.

**DOSES**

**Dogs:** Hypercalcaemia and/or to reduce bone pain: 0.5–1 mg/kg p.o. q24h on an empty stomach.

**Cats:** Hypercalcaemia: 5–10 mg/cat p.o. weekly on an empty stomach. Follow with a syringe of water (at least 6 ml). If tolerated well the dose can be increased to 30 mg/cat p.o. weekly.

**References**


---

**Alfaxalone**  
(Alfaxan) **POM-V**

**Formulations:** Injectable: 10 mg/ml solution; the alfaxalone is solubilized in a cyclodextrin.

**Action:** Anaesthesia induced by the CNS depressant effect of the alfaxalone.

**Use:**

- Induction agent used before inhalational anaesthesia, or as a sole anaesthetic agent for examination or surgical procedures.

As with all i.v. anaesthetic drugs, premedication will reduce the dose required for induction and maintenance of anaesthesia. The drug should be given slowly and to effect in order to prevent inadvertent overdose. The dose recommended by the manufacturer for induction of anaesthesia can usually be reduced in all animals. Analgesia is insufficient for surgery: other analgesic drugs such as opioids should be incorporated into the anaesthetic protocol. Alfaxalone can be given i.m. or s.c. to provide sedation in cats and dogs although it is not licensed for these routes. Do not use in combination with other i.v. anaesthetic agents. Although not licensed for animals <12 weeks of age, safety in dogs between 6 and 12 weeks old has been demonstrated using a similar dose for induction of anaesthesia as adult dogs.
**Safety and handling:** One preparation of alfaxalone does not contain an antimicrobial preservative; thus it is recommended that the remainder of an opened bottle is discarded after single use. A multidose preparation of alfaxalone is also available with a shelf life of 28 days once the vial has been broached.

**Contraindications:** No information available.

**Adverse reactions:** An increase in heart rate can occur immediately after i.v. injection as a compensatory response to maintain blood pressure in the face of mild hypotension. This effect can be minimized by slow i.v. injection. As with all anaesthetic drugs, respiratory depression can occur with overdoses.

**Drug interactions:** No information available.

**DOSES**

See Appendix for sedation protocols in cats and dogs.

**Dogs:**

- **Induction of anaesthesia:** 3 mg/kg i.v. in unpremedicated dogs; 2 mg/kg i.v. in premedicated dogs, although commonly lower doses can be used.
- **Maintenance:** 6–9 mg/kg/h is recommended as a continuous rate infusion or top-up boluses of 1–1.5 mg/kg q10min.

**Cats:**

- **Induction of anaesthesia:** 2–5 mg/kg i.v.; the lower end of the dose range is often adequate.
- **Maintenance:** 7–10 mg/kg/h is recommended as a continuous rate infusion or top-up boluses of 1–1.5 mg/kg q10min.

**References**


---

**Alfentanil** *(Rapifen*) POM CD SCHEDULE 2

**Formulations:** Injectable: 0.5 mg/ml solution, available in 2 ml or 10 ml vials.

**Action:** Pure mu agonist of the phenylpiperidine series.

**Use:** Very potent opioid analgesic (10–20 times more potent than morphine) used to provide intraoperative analgesia during anaesthesia in dogs and cats. Use of such potent opioids during anaesthesia contributes to a balanced anaesthesia technique but they must be administered accurately. It has a rapid onset (15–30 seconds) and short duration of action. It is best given using continuous rate infusions. The drug is not suited to provision of analgesia in the postoperative period.
Safety and handling: Normal precautions should be observed.

Contraindications: No information available.

Adverse reactions: A reduction in heart rate is likely whenever alfentanil is given; atropine can be administered to counter bradycardia if necessary. Respiratory depression leading to cessation of spontaneous respiration is likely following administration. Do not use unless facilities for positive pressure ventilation are available (either manual or automatic). Rapid i.v. injection can cause a severe bradycardia, even asystole.

Drug interactions: Alfentanil reduces the dose requirements of concurrently administered anaesthetics, including inhaled anaesthetics, by at least 50%. In humans it is currently recommended to avoid giving alfentanil to patients receiving monoamine oxidase inhibitors due to the risk of serotonin toxicity.

DOSES
- **Dogs:** 0.001–0.005 mg/kg i.v. as a single bolus or 0.001–0.0025 mg/kg/min continuous rate infusion.
- **Cats:** 0.001 mg/kg i.v. as a single bolus or 0.001 mg/kg/min continuous rate infusion.

References

---

**Allopurinol (Zyloric*)** POM

Formulations: Oral: 100 mg, 300 mg tablets.

Action: Xanthine oxidase inhibition decreases formation of uric acid by blocking the conversion of hypoxanthine to xanthine, and of xanthine to uric acid.

Use:
- Treatment and prevention of recurrent uric acid uroliths and hyperuricosuric calcium oxalate urolithiasis in dogs.
- In combination with meglumine antimonite or miltefosine, to treat leishmaniosis.

Use with caution in patients with impaired renal function.

Safety and handling: Normal precautions should be observed.

Contraindications: No information available.

Adverse reactions: May predispose to xanthine urolithiasis especially if used for several months and not fed a purine restricted diet.

Drug interactions: In humans, allopurinol may enhance the effects of azathioprine and theophylline.
DOSES

Dogs:
- Uric acid urolithiasis:
  - Dissolution: 10 mg/kg p.o. q8h or 15 mg/kg p.o. q12h for up to 4 weeks.
  - Prevention: 10–15 mg/kg p.o. q24h.
- Leishmaniosis: 10 mg/kg p.o. q12h for at least 6–12 months with meglumine antimonate for 1–2 months, or miltefosine for 1 month (NB: this does not result in complete parasitological cure).

Cats: Leishmaniosis: 10–20 mg/kg p.o. q12–24h has been shown to be effective (although experience is limited in this species).

References

Alphaxalone see Alfaxalone

Alprazolam (Alprazolam*, Xanax*) POM

Formulations: Oral: 0.25 mg, 0.5 mg, 1 mg, 2 mg tablets.

Action: Increases GABA activity within the CNS, resulting in anxiolysis and a range of cognitive effects including the inhibition of memory.

Use:
- Treatment of anxiety and fear-related disorders in dogs and cats, especially where there are signs of panic.
- As an adjunct to clomipramine or specific serotonin reuptake inhibitors for the management of phobic responses.
- It can also be used for the management of urine spraying in cats but a high relapse rate upon withdrawal should be expected.

Best if used approximately 30 minutes before a fear-inducing event although absorption characteristics have not been described for cats or dogs. Its short half-life and rapid onset of action make it useful for the management of acute episodes, with treatment given as needed within the dosing limits described. However, dosing limits and responses are very variable, with some animals showing no measurable effect at the recommended doses. Its anterograde and retrograde amnesic properties, especially on subjective memory, mean it can be used before (<1 hour), during or immediately following an aversive experience to minimize the emotional impact of such exposure. This may be necessary during a long-term behavioural therapy programme to avoid relapses due to exposure to an intense fear-inducing stimulus during treatment. In experimental circumstances, single higher range doses (>0.25 mg/kg) have been found to block memory significantly and may be
useful in companion animals, but may result in temporary sedation. As imepitoin is now licensed for use in the treatment of fears in dogs, if a benzodiazepine is indicated, it is preferable to use this.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Hypersensitivity to benzodiazepines, glaucoma, significant liver or kidney disease, although appears to be less hepatotoxic than diazepam or clorazepate. Not recommended in pregnant or lactating animals. There is concern over its use with anxiously aggressive animals due to the potential for disinhibition.

**Adverse reactions:** Drowsiness and mild transient incoordination may develop. A general concern with benzodiazepines concerns disinhibition and the subsequent emergence of aggression. Idiosyncratic hepatotoxicity associated with benzodiazepines (largely diazepam, but not alprazolam) has been reported in the cat.

**Drug interactions:** Caution is advised if used in association with antifungals such as itraconazole, which inhibit its metabolism.

**DOSES**

**Dogs:** For anxiolysis an initial dose within the range of 0.01–0.1 mg/kg p.o. as needed up to 4 times a day is recommended; the dose can be titrated up or down to the minimum effective dose, which may be below this level.

**Cats:** For anxiolysis an initial dose in the range of 0.125–0.25 mg/kg p.o. as needed up to twice a day is suggested, but doses as low as 0.25 mg/cat p.o. q8–12h and as high as 0.6 mg/kg p.o. have been reported. After initial medication, the dose should be titrated down to the minimum effective dose.

**References**


### Aluminium antacids (Aluminium hydroxide)


**Formulations:** Oral: Aluminium hydroxide is available as a dried gel. Other products are composite preparations containing a variety of other compounds including magnesium oxide, hydroxide or trisilicate, potassium bicarbonate, sodium carbonate and bicarbonate, alginates and dimeticone. Aluminium hydroxide content varies.
**Action:** Neutralizes gastric acid. May also bind bile acids and pepsin and stimulate local prostaglandin (PGE-1) production. Also binds inorganic phosphate in the GI tract, making it unavailable for absorption.

**Use:**
- Management of gastritis and gastric ulceration. Frequent administration is necessary to prevent rebound acid secretion.
- In kidney disease, to lower serum phosphate levels in cats and dogs with serum phosphate above recommended target according to IRIS stage. Phosphate-binding agents are usually only used if low-phosphate diets are unsuccessful. Monitor serum phosphate levels at 14–28 day intervals and adjust dosage accordingly if trying to normalize serum concentrations.

Thoroughly mix the drug with food to disperse it and to increase its palatability.

**Safety and handling:** Normal precautions.

**Contraindications:** No information available.

**Adverse reactions:** Constipation may occur. This is an effect of the aluminium compound and is counteracted by inclusion of a magnesium salt. Hypophosphataemia can develop. Long-term use (many years) of oral aluminium products in humans has been associated with aluminium toxicity and possible neurotoxicity. This is rarely a problem in veterinary medicine but is reported.

**Drug interactions:** Do not administer allopurinol, digoxin, fluoroquinolones, gabapentin, H2 antagonists, iron salts, itraconazole, mycophenolate, tetracyclines, or thyroid hormones orally within 2 hours of aluminium salts as their absorption may be impaired.

**DOSES**

**Dogs, Cats:** All uses: Initially 10–30 mg/kg p.o. q6–8h (tablets) or 0.5–1.0 ml/kg (2–30 ml) p.o. q6–8h (gel) with or immediately after meals. Dosages are empirical; none have been properly defined in dogs or cats.

**References**


**Aluminium hydroxide** see Aluminium antacids
Amantadine
(Lysovir*, Symmetrel*) POM

Formulations: Oral: 100 mg capsule; 10 mg/ml syrup.

Action: Provides analgesia through NMDA antagonist action which may potentiate the effects of other analgetics.

Use:
- Adjunctive analgesic in animals that are unresponsive to opioids, or that require chronic pain relief in a home environment (e.g. osteoarthritis or cancer pain).
- In dogs with osteoarthritis that were refractory to an NSAID physical activity was improved, suggesting that amantadine might be a useful adjunct in the clinical management of canine osteoarthritic pain.

Safety and handling: Normal precautions should be observed.

Contraindications: No information available.

Adverse reactions: In humans, minor GI and CNS effects have been reported, although these have not been reported in animals. Amantadine is renally excreted and is likely to accumulate in animals with renal dysfunction and therefore should be used cautiously in this patient population.

Drug interactions: No information available.

DOSES
Dogs: 3.0–5.0 mg/kg p.o. q24h.
Cats: 1.0–4.0 mg/kg p.o. q24h; start at the lowest dose and increase slowly. This dose recommendation is anecdotal and is not based on evidence from clinical research.

References

Amethocaine see Tetracaine

Amikacin
(Amikacin*, Amikin*) POM

Formulations: Injectable: 50 mg/ml, 250 mg/ml solutions.

Action: Aminoglycosides inhibit bacterial protein synthesis with a concentration-dependent mechanism of killing, leading to a marked post-antibiotic effect, allowing prolonged dosing intervals (which may reduce toxicity).

Use: Active against many Gram-negative bacteria, *Staphylococcus aureus* and *Nocardia* spp., including some that may be resistant to
gentamicin. Streptococci and anaerobes are usually resistant. Its use is only indicated after sensitivity testing has been performed and the organism shown to be resistant to other aminoglycosides such as gentamicin. Activity at low oxygen sites may be limited. Movement across biological membranes may also be limited, hence systemic levels require parenteral administration, and access to sites such as the CNS and ocular fluids is very limited. Monitoring serum amikacin levels should be considered to ensure therapeutic levels and minimize toxicity, particularly in neonates, geriatric patients and those with reduced renal function. Monitoring renal function is also advisable during treatment of any animal. Intravenous doses should be given slowly, generally over 30–60 minutes. Concurrent fluid therapy is advised.

Safety and handling: Normal precautions should be observed.

Contraindications: If possible, avoid use in animals with reduced renal function.

Adverse reactions: Nephrotoxic and ototoxic.

Drug interactions: Synergism may occur in vivo when aminoglycosides are combined with beta-lactam antimicrobials. Avoid the concurrent use of other nephrotoxic, ototoxic or neurotoxic agents (e.g. amphotericin B, furosemide). Aminoglycosides may be inactivated in vitro by beta-lactam antibiotics (e.g. penicillins, cephalosporins) or heparin; do not give these drugs in the same syringe. Can potentiate neuromuscular blockade so avoid use in combination with neuromuscular blocking agents.

DOSES
See Appendix for guidelines on responsible antibacterial use.

Dogs: 15–30 mg/kg i.v., i.m., s.c. q24h. Due to a lower volume of distribution in Greyhounds a lower dose of 12 mg/kg is recommended in this breed and other sight hounds.

Cats: 10–15 mg/kg i.v., i.m., s.c. q24h.

Dogs, Cats: For both dogs and cats, higher doses are recommended by some authors for managing sepsis, although there is an increased risk of adverse effects with such high doses. Local use may be considered, especially if the site of infection is easily accessible for direct delivery of the drug and if the animal is showing signs of nephrotoxicity. Amikacin has been used locally in joints and the bladder as specific examples.

**Amiloride**
(Amiloride Hydrochloride*) POM

Formulations: Oral: 5 mg tablets; 1 mg/ml solution (Amilamont).
Also present in compound preparations with hydrochlorothiazide (Moduret, Moduretic, Co-amilozide) and furosemide (Co-amilofruse, Frumil, Frumil LS).
**Action:** Potassium-sparing diuretic which inhibits sodium absorption in the cells of the distal tubule and collecting duct therefore leading to less available sodium for exchange with potassium. This leads to a failure of the normal renal concentration gradient and results in sodium loss and potassium retention. It is a weak diuretic when used alone, so is almost always used in combination with a thiazide or furosemide.

**Use:**
- Treatment of oedema or ascites due to liver or heart failure.

Often added to more potent diuretics such as furosemide or weaker diuretics such as hydrochlorothiazide in cases of refractory heart failure achieving sequential nephron blockade. Doses have not been widely reported in the veterinary literature. Monitor urea, creatinine, electrolytes and blood pressure before and after dose adjustments.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.

**Adverse reactions:** Hypotension, hyperkalaemia, acidosis and hyponatraemia may develop.

**Drug interactions:** Avoid the concomitant administration of potassium.

**DOSES**

**Dogs, Cats:** 0.1 mg/kg p.o. q12h is used in humans and has been suggested for dogs and cats. In combination with hydrochlorothiazide dose range will vary from 0.05–0.4 mg/kg p.o. (dogs) to 0.1–0.4 mg/kg p.o. (cats). Start at low dose and titrate upwards cautiously.

---

**Amino acid solutions**


**Formulations:** Injectable: synthetic crystalline l-amino acid solutions for i.v. use only. Numerous human products are available, varying in concentrations of amino acids. Most products also contain electrolytes. Some products contain varying concentrations of glucose.

**Action:** Support protein anabolism, arrest protein and muscle wasting, and maintain intermediary metabolism.

**Use:**
- Used parenterally in patients requiring nutritional support but unable to receive enteral support, amino acid solutions supply essential and non-essential amino acids for protein production.
• Infusions of amino acid solutions have also been used in the treatment of superficial necrolytic dermatitis in dogs. The authorized veterinary preparation (Duphalyte) contains insufficient amino acids to meet basal requirements for protein production and is intended as an aid for i.v. fluid support. None of the human formulations contains taurine, which is essential for cats and for specific conditions in dogs. All products are hyperosmolar. The use of concentrated amino acid solutions for parenteral nutrition support should not be undertaken without specific training and requires central venous access and intensive care monitoring. Parenteral nutrition may also be able to meet the patient’s requirements for fluids, essential electrolytes (sodium, potassium, magnesium) and phosphate. Additionally, if treatment is prolonged, vitamins and trace elements may need to be given. Intravenous lines for parenteral nutrition should be dedicated for that use alone and not used for other medications. As many of the available amino acid solutions contain potassium, the maximal acceptable rates of infusion will depend on the potassium content of the amino acid preparation.

Safety and handling: Normal precautions should be observed.

Contraindications: Dehydration, hepatic encephalopathy, severe azotaemia, shock, congestive heart failure and electrolyte imbalances.

Adverse reactions: The main complications of parenteral nutrition are metabolic, including hyperglycaemia, hyperlipidaemia, hypercapnia, acid–base disturbances and electrolyte disturbances. Other complications include catheter-associated thrombophlebitis, bacterial colonization of the catheter and resulting bacteraemia and septicemia. Potentially life-threatening electrolyte imbalances including hypophosphataemia may also be seen (also referred to as refeeding syndrome). As with other hyperosmolar solutions, severe tissue damage could occur if extravasated, although this has not been reported.

Drug interactions: Consult specific product data sheet(s).

DOSES

Dogs:
• Aid to i.v. fluid therapy: up to 10 ml/kg (Duphalyte).
• Parenteral nutritional support: 4–6 g protein/100 kcal (418 kJ) energy requirements.
• Superficial necrolytic dermatitis: 3 ml/kg/h i.v. over 24 hours (Aminoven 25).

Cats:
• Aid to i.v. fluid therapy: up to 10 ml/kg (Duphalyte).
• Parenteral nutritional support: 6–8 g protein/100 kcal (418 kJ) energy requirements.

References
Aminophylline
(Aminophylline*) POM

Formulations: Injectable: 25 mg/ml solution. Oral: 100 mg tablet. For modified-release preparations see Theophylline (100 mg of aminophylline is equivalent to 79 mg of theophylline).

Action: Aminophylline is a stable mixture of theophylline (q.v.) and ethylenediamine. Causes inhibition of phosphodiesterase, alteration of intracellular calcium, release of catecholamine, and antagonism of adenosine and prostaglandin, leading to bronchodilation and other effects. Spasmolytic agent and has a mild diuretic action.

Use:
- It is used in the treatment of small airway disease.

Beneficial effects include bronchodilation, enhanced mucociliary clearance, stimulation of the respiratory centre, increased sensitivity to P_{a}CO_{2}, increased diaphragmatic contractility, stabilization of mast cells and a mild inotropic effect. Aminophylline has a low therapeutic index and should be dosed on a lean body weight basis.

Administer with caution in patients with severe cardiac disease, gastric ulcers, hyperthyroidism, renal or hepatic disease, severe hypoxia or severe hypertension. Therapeutic plasma aminophylline values are 5–20 μg (micrograms)/ml.

Safety and handling: Do not mix aminophylline in a syringe with other drugs.

Contraindications: Patients with known history of arrhythmias or seizures.

Adverse reactions: Vomiting, diarrhoea, polydipsia, polyuria, reduced appetite, tachycardia, arrhythmias, nausea, twitching, restlessness, agitation, excitement and convulsions. Hyperaesthesia is seen in cats. Most adverse effects are related to the serum level and may be symptomatic of toxic serum concentrations. The severity of these effects may be decreased by the use of modified-release preparations. They are more likely to be seen with more frequent administration. Aminophylline causes intense local pain when given i.m. and is very rarely used or recommended via this route.

Drug interactions: Agents that may increase the serum levels of aminophylline include cimetidine, diltiazem, erythromycin, fluoroquinolones and allopurinol. Phenobarbital may decrease the serum concentration of aminophylline. Aminophylline may decrease the effects of pancuronium. Aminophylline and beta-adrenergic blockers (e.g. propranolol) may antagonize each other’s effects. Aminophylline administration with halothane may cause an increased incidence of cardiac dysrhythmias and with ketamine an increased incidence of seizures.
DOSES

**Dogs**: Bronchodilation: 10 mg/kg p.o. q8h or slowly i.v. (diluted) for emergency bronchodilation.

**Cats**: Bronchodilation: 5 mg/kg p.o. q12h or 2–5 mg/kg slowly i.v. (diluted) for emergency bronchodilation.

References


---

**Amiodarone**  
(Amiodarone*, Cordarone*) **POM**

**Formulations**: Oral: 100 mg, 200 mg tablets. Injectable: 50 mg/ml for dilution and use as an infusion.

**Action**: Antiarrhythmic agent with primarily class 3 actions (potassium-channel blocker), but also potent class 1 (sodium-channel blocker) and ancillary class 2 (beta-blocker) and class 4 (calcium-channel blocker) actions. Prolongs action potential duration and therefore effective refractory period in all cardiac tissues, including bypass tracts (class 3 action), inhibits sodium channels (class 1 action), blocks alpha- and beta-adrenergic receptors (class 2 action), slows the sinus rate, prolongs sinus node recovery time, and inhibits AV nodal conduction.

**Use**:

- To treat ventricular arrhythmias and supraventricular arrhythmias in dogs.
- May be useful in ventricular pre-excitation syndromes because it can prolong AV nodal and bypass tract effective refractory periods.
- Used successfully for rate control or conversion to sinus rhythm in some dogs with atrial fibrillation and as an adjunct to electrical cardioversion. Use as an i.v. infusion in dogs with recent onset atrial fibrillation has been reported, with a variable efficacy for restoring sinus rhythm but high frequency of severe adverse effects.

It has slow and variable GI absorption, a slow onset of action and a long elimination half-life (up to 3.2 days after repeated dosing). Because numerous side effects have been documented in humans and dogs, its use is advised for patients in which other antiarrhythmic agents have not been effective or are not tolerated. Owing to the risks of thyroid dysfunction and hepatotoxicity, it is advisable to evaluate hepatic enzyme activities and thyroid function prior to starting therapy and at 1–3 monthly intervals during maintenance therapy.

**Safety and handling**: Normal precautions should be observed.

**Contraindications**: Avoid in dogs with sinus bradycardia, AV block or thyroid dysfunction.
Adverse reactions: Amiodarone can cause bradycardia, AV block and prolongation of the QT interval. It is a negative inotrope and can cause hypotension. Systemic side effects described in dogs include anorexia, GI disturbances, hepatotoxicity, keratopathy and positive Coombs’ test. Pulmonary fibrosis and thyroid dysfunction have also been reported in humans. In dogs T4 level decreases with amiodarone administration, but clinically apparent hypothyroidism is less common. Adverse effects associated with i.v. administration include pain at injection site, hypotension, hypersalivation and hypersensitivity reactions, which may be a reaction to the carrier solvent. Should i.v. preparations be considered, prior treatment with dexamethasone should be considered to reduce risk of anaphylactic reactions.

Drug interactions: Amiodarone may significantly increase serum levels and/or pharmacological effects of anticoagulants, beta-blockers, calcium-channel blockers, ciclosporin, digoxin, lidocaine, methotrexate and theophylline. Cimetidine may increase serum levels of amiodarone.

DOSES

Dogs:
- Oral: 10–15 mg/kg p.o. q12h for 7 days, then 5–7.5 mg/kg p.o. q12h for 14 days; thereafter, 5–7.5 mg/kg p.o. q24h (loading dose leading to steady state doses). Serum amiodarone levels should be assessed at 3 weeks after starting therapy.
- Intravenous: not well defined. Doses of 0.03–0.05 mg/kg/min have been administered as a continuous rate infusion for cardioversion of atrial fibrillation and sustained supraventricular tachycardia non-responsive to other antiarrhythmics. Bolus administration of 2.5–5 mg/kg given very slowly i.v. has been used in ventricular tachycardia but is not recommended due to high risk of adverse event. Prior administration of dexamethasone/antihistamines for anaphylaxis prophylaxis could be considered in both scenarios.

Cats: No information available.

References

Amitraz
(Aludex) POM-V

Formulations: Topical: 5% w/v concentrated liquid (Aludex).

Action: Parasite octopamine receptor agonist resulting in detachment and death. Also has alpha-2 adrenergic action and weak H1 receptor activity.
Use: Dip is used to treat generalized mite infestations (canine demodicosis, sarcoptic acariasis and cheyletiellosis). Concentrated liquid is used diluted as a dip, which is then left on the coat. Clipping long-haired coats will improve penetration of dip. Animals should not be bathed or allowed to swim for 48 hours after application of spot-on product.

Safety and handling: Flammable, use in well ventilated area, do not smoke. Do not store diluted product (dip).

Contraindications: Do not use in dogs <3 months (<8 weeks or <2 kg body weight for spot-on product). Do not use on dogs with heat stress. Do not use in Chihuahuas, cats or diabetic animals.

Adverse reactions: Sedation and bradycardia; reversed with an alpha-2 agonist such as atipamazole or yohimbine. Can cause irritation of the skin, emesis and diarrhoea. Rarely, CNS depression is also seen.

Drug interactions: Do not use concurrent with an alpha-2 agonist sedative or other ectoparasiticides.

DOSES
Dogs:
• Generalized demodicosis: 0.05% solution (1 ml Aludex in 100 ml water) q5–7 days until 2 negative skin scrapings/hair plucks are achieved 2 weeks apart.
• Sarcoptic acariasis: 0.025% solution (1 ml Aludex in 200 ml water) weekly for 2–6 weeks.

Cats: Do not use.

Amitriptyline (Amitriptyline*) POM

Formulations: Oral: 10 mg, 25 mg, 50 mg tablets; 5 mg/ml, 10 mg/ml solutions.

Action: Blocks noradrenaline and serotonin reuptake in the brain, resulting in antidepressive activity. Also stabilizes mast cells so can reduce impact on inflammatory irritation.

Use:
• Management of chronic anxiety problems, including compulsive disorders and separation anxiety in dogs.
• Management of psychogenic alopecia, hypervocalization and idiopathic cystitis in cats.

The non-specific serotonergic reuptake inhibitor antidepressant clomipramine is an authorized preparation for use in dogs and is claimed to have better anticomulsive properties. Amitriptyline is bitter and can be very distasteful to cats. Some caution and careful monitoring is warranted in patients with cardiac or renal disease. Its antipruritic properties may make it useful in anxiety-related conditions featuring inflammation, such as certain acral lick lesions.
Safety and handling: Normal precautions should be observed.

Contraindications: Hypersensitivity to tricyclic antidepressants, glaucoma, history of seizures or urinary retention, severe liver disease.

Adverse reactions: Sedation, dry mouth, vomiting, excitability, arrhythmias, hypotension, syncope, increased appetite, weight gain and, less commonly, seizures and bone marrow disorders have been reported in humans. The bitter taste can cause ptyalism in cats.

Drug interactions: Should not be used with monoamine oxidase inhibitors or drugs metabolized by cytochrome P450 2D6, e.g. chlorphenamine, cimetidine. If changing medication from one of these compounds, a minimal washout period of 2 weeks is recommended (the washout period may be longer if the drug has been used for a prolonged period of time). Should not be used alongside serotonin reuptake inhibitors (e.g clopamidine, fluoxetine) and caution is warranted if using alongside tramadol, due to risk of serotonin syndrome. Concomitant use with diazepam may increase blood levels of amitriptyline.

DOSES
Dogs: 1–2 mg/kg p.o. q12–24h.
Cats: 0.5–1 mg/kg p.o. q24h.

Amlodipine
(Amodip, Amlodipine*, Istin*) POM-V, POM

Formulations: Oral: 1.25 mg (cats), 5 mg, 10 mg tablets; 1 mg/ml, 2 mg/ml sugar-free solutions. Special reformulations available: 0.3125 mg tablets, transdermal gel 12.5 mg/ml.

Action: Calcium-channel antagonist, with predominant action affecting peripheral arteriolar vasculature, causing vasodilation and reducing afterload. Has mild negative inotropic and chronotropic effects, which are negligible at therapeutic doses.

Use:
• Treatment of systemic hypertension in cats (appears to be safe even if concurrent renal failure).
• Treatment of systemic hypertension in dogs.
• It has also been shown to decrease proteinuria in cats with systemic hypertension.

When used as a single agent in dogs may increase RAAS and concurrent use of an ACE inhibitor should be considered. Amlodipine is metabolized in the liver and dosage should be reduced when there is hepatic dysfunction.

Safety and handling: Normal precautions should be observed.

Contraindications: Avoid in cardiogenic shock, severe hepatic failure and pregnancy.
**Adverse reactions:** Lethargy, hypotension or inappetence are rare side effects. Gingival hyperplasia reported in cats and dogs.

**Drug interactions:** Little is known in animals. Hepatic metabolism may be impaired by drugs such as cimetidine, cyclosporine, ketoconazole and itraconazole and therefore increase circulating doses. CYP3A4 inducers (such as rifampin) may reduce circulating amlodipine levels. Hypotension is a risk if combined with other antihypertensives, e.g. ACE inhibitors, diuretics, beta-blockers.

**DOSES**

**Dogs:** Initial dose 0.05–0.1 mg/kg p.o. q12–24h. The dose may be titrated upwards weekly as required, up to 0.5 mg/kg, monitoring blood pressure regularly.

**Cats:** 0.625–1.25 mg/cat p.o. q24h. The dose may be increased slowly or the frequency increased to q12h if necessary. Blood pressure monitoring is essential.

**References**


---

**Amoxicillin (Amoxycillin)**

(Amoxibactin, Amoxycare, Amoxypen, Betamox, Bimoxyl, Clamoxyl) **POM-V**

**Formulations:** *Injectable:* 150 mg/ml suspension. *Oral:* 40 mg, 50 mg, 200 mg, 250 mg, 500 mg tablets; suspension which when reconstituted provides 50 mg/ml.

**Action:** Binds to penicillin-binding proteins involved in bacterial cell wall synthesis, thereby decreasing cell wall strength and rigidity, affecting cell division, growth and septum formation. Acts in a time-dependent fashion.

**Use:** Active against certain Gram-positive and Gram-negative aerobic organisms and many obligate anaerobes although resistance is possible due to bacterial production of penicillinases (beta-lactamases), e.g. some *Escherichia coli*, *Staphylococcus aureus*. Gram-negative organisms (*Pseudomonas*, *Proteus*, *Klebsiella*) are usually resistant. Amoxicillin is excreted well in bile and urine achieving high concentrations in urine. Oral amoxicillin may be given with or without food. It is important to maintain levels above the MIC for a high percentage of the time by ensuring regular dosing; missing doses can seriously compromise efficacy.

**Safety and handling:** Refrigerate oral suspension after reconstitution; discard if solution becomes dark or after 7 days.

**Contraindications:** Avoid oral antibiotics in critically ill patients, as absorption from the GI tract may be unreliable.
Adverse reactions: Nausea, diarrhoea and skin rashes (type 1 (Ig-E mediated) reaction) are the commonest adverse effects.

Drug interactions: Avoid concurrent use with bacteriostatic antibiotics (e.g. tetracycline, erythromycin, chloramphenicol); clinical significance of antagonistic activity is unknown. Do not mix in the same syringe as aminoglycosides. A synergistic effect is seen when beta-lactam and aminoglycoside antimicrobials are used concurrently.

DOSES
See Appendix for guidelines on responsible antibacterial use.

Dogs, Cats:
• Parenteral: 7 mg/kg i.m. q24h; 15 mg/kg i.m. q48h for depot preparations.
• Oral:
  ▪ 10 mg/kg p.o. q8–12h.
  ▪ 11–15 mg/kg p.o. q8h for bacterial cystitis. Evidence of a need for clavulanic acid is lacking even in infections with beta-lactamase producing bacteria.

Dose chosen will depend on site of infection, causal organism and severity of the disease. (Doses of 16–33 mg/kg i.v. q8h are used in humans to treat serious infections.)

References

Amoxicillin/Clavulanate see Co-amoxiclav
Amoxycillin see Amoxicillin

Amphotericin B
(Abelcet*, AmBisome*, Amphocil*, Fungizone*)
POM

Formulations: Injectable: 50 mg/vial powder for reconstitution.

Action: Binds to sterols in fungal cell membrane creating pores and allowing leakage of contents.

Use:
• Management of systemic fungal infections and leishmaniosis.

Given the risk of severe toxicity it is advisable to reserve use for severe/potentially fatal fungal infections only. Abelcet, AmBisome, Amphocil are lipid formulations that are less toxic. Physically incompatible with electrolyte solutions. Lipid formulations are far less toxic than conventional formulations for i.v. use because the drug is targeted to macrophages, but these preparations are far more expensive. Solutions are usually given i.v. but if regular venous
catheterization is problematic then an s.c. alternative has been used for cryptococcosis and could potentially be used for other systemic mycoses. Renal values and electrolytes should be monitored pre- and post-each treatment; urinalysis and liver function tests weekly. If considering use in patients with pre-existing renal insufficiency (where other treatment options have failed and benefits outweigh risks), consider lipid formulations, concurrent saline administration and dose reduction.

Safety and handling: Keep in the dark, although loss of drug activity is negligible for at least 8 hours in room light. After initial reconstitution (but not further dilution), the drug is stable for 1 week if refrigerated and stored in the dark. Do not dilute in saline. Pre-treatment heating of the reconstituted concentrated solution to 70°C for 20 minutes produces superaggregates which are less nephrotoxic. To produce a lipid-formulated product if not commercially available, mix 40 ml sterile saline, 10 ml of lipid infusion (q.v.) and 50 mg of the reconstituted concentrated solution.

Contraindications: Do not use in renal or hepatic failure.

Adverse reactions: Include hypokalaemia, leading to cardiac arrhythmias, phlebitis, hepatic failure, renal failure, vomiting, diarrhoea, pyrexia, muscle and joint pain, anorexia and anaphylactoid reactions. Nephrotoxicity is a major concern; do not use other nephrotoxic drugs concurrently. Nephrotoxicity may be reduced by saline or lactated Ringer’s infusion (5 ml/kg/hr) for 30 minutes prior to and 120 minutes following administration of amphotericin B (taking care to flush i.v. line thoroughly with 5% dextrose water in between). Fever and vomiting may be decreased by pre-treating with aspirin, diphenhydramine or an antiemetic.

Drug interactions: Amphotericin may increase the toxic effects of fluorouracil, doxorubicin and methotrexate. Flucytosine is synergistic with amphotericin B in vitro against Candida, Cryptococcus and Aspergillus.

DOSES

Dogs:

- **Systemic mycoses**: Conventional amphotericin: 0.25–1 mg/kg i.v. q48h. Administer slowly over 4–6 hours. Reconstitute vial with 10 ml water giving 5 mg/ml solution; dilute required volume further 1:50 with 5% dextrose water to give 0.1 mg/ml solution. Alternatively, 0.25–1 mg/kg may be dissolved in 10–60 ml 5% dextrose given over 10 min i.v. 3 times a week. Start at the lower end of the dose range and increase gradually as the patient tolerates therapy. Several months of therapy are often necessary. A total cumulative dose of 4–8 mg/kg is recommended by some authors.

- **Cryptococcosis (conventional amphotericin, subcutaneous alternative)**: 0.5–0.8 mg/kg added to 400–500 ml of 0.45% saline/2.5% dextrose. This total volume is then administered s.c. 2–3 times a week to a cumulative level of 8–26 mg/kg. Do not inject solutions more concentrated than 20 mg/l as they will
cause subcutaneous abscesses. Intralesional injections may also be performed in this condition at a dose of 1 mg/kg q7d in combination with oral itraconazole.

- **Irrigation of bladder:** Conventional amphotericin: 30–50 mg in 50–100 ml of sterile water infused at a rate of 5–10 ml/kg into the bladder lumen daily for 5–15 days.

- **Systemic mycoses:** Lipid formulations (general guidelines): 1 mg/kg q48h to cumulative dose of 12 mg/kg. Higher doses are tolerated (e.g. 1–2.5 mg/kg i.v. q48h for 4 weeks/to cumulative dose of 24–30 mg/kg). Reconstitute to 5 mg/ml with sterile water, then dilute required volume to 1 mg/kg with 5% dextrose water.

- **Leishmaniosis (lipid formulations):** 1–2.5 mg/kg i.v. twice weekly for 8 injections. Increase dose rate gradually. A total cumulative dose of at least 10 mg/kg is required but treatment may be continued long term depending on clinical response. Use in this context is discouraged to avoid resistance developing to therapy for humans.

**Cats:**

- **Systemic mycoses:** Conventional amphotericin: 0.1–0.25 i.v. q48h. For details on administration, see doses for dogs.

- **Cryptococcosis (conventional amphotericin, subcutaneous alternative):** Conventional amphotericin: 0.5–0.8 mg/kg added to 400–500 ml of 0.45% saline/2.5% dextrose. This total volume is then administered s.c. 2–3 times a week to a cumulative level of 10–15 mg/kg. Do not inject solutions more concentrated than 20 mg/l as they will cause subcutaneous abscesses. Intralesional injections may also be performed in this condition at a dose of 1 mg/kg q7d in combination with oral itraconazole.

- **Systemic mycoses:** Lipid formulations (general guidelines): 1 mg/kg q48h to cumulative dose of 12 mg/kg. Higher doses are tolerated (e.g. 1–2.5 mg/kg i.v. q48h for 4 weeks/to cumulative dose of 24–30 mg/kg).

**References**


**Ampicillin**

(Amfipen, Ampicare) **POM-V**

**Formulations:** Injectable: Ampicillin sodium 250 mg, 500 mg powders for reconstitution (human licensed product only); 100 mg/ml long-acting preparation. Oral: 250 mg capsule.

**Action:** Binds to penicillin-binding proteins involved in bacterial cell wall synthesis, thereby decreasing cell wall strength and rigidity, affecting cell division, growth and septum formation. It acts in a time-dependent fashion.
Use: Active against many Gram-positive and Gram-negative aerobic organisms and obligate anaerobes, but not against those that produce penicillinases (beta-lactamases), e.g. *Escherichia coli*, *Staphylococcus aureus*. The difficult Gram-negative organisms such as *Pseudomonas aeruginosa* and *Klebsiella* are usually resistant. Ampicillin is excreted well in bile and urine. Maintaining levels above the MIC is critical for efficacy and thereby prolonged dosage intervals or missed doses can compromise therapeutic response. Dose and dosing interval is determined by infection site, severity and organism. Oral bioavailability is reduced in the presence of food.

**Safety and handling:** After reconstitution the sodium salt will retain adequate potency for up to 8 hours if refrigerated, but use within 2 hours if kept at room temperature.

**Contraindications:** Avoid the use of oral antibiotic agents in critically ill patients, as absorption from the GI tract may be unreliable. Do not use in animals with hypersensitivity to penicillins.

**Adverse reactions:** Nausea, diarrhoea and skin rashes are the commonest adverse effects.

**Drug interactions:** Avoid the concurrent use of ampicillin with bacteriostatic antibiotics (e.g. tetracycline, erythromycin, chloramphenicol). Do not mix in the same syringe as aminoglycosides. A synergistic effect is seen when beta-lactam and aminoglycoside antimicrobials are used concurrently.

**DOSES**

See Appendix for guidelines on responsible antibacterial use.

**Dogs:**
- Routine infections: 10–20 mg/kg i.v., i.m., s.c., p.o. q6–8h.
- CNS or serious bacterial infections: up to 40 mg/kg i.v. q6h has been recommended.

**Cats:** 10–20 mg/kg i.v., i.m., s.c., p.o. q6–8h.

### Amprolium

*(Harkers Pigeon Coccidiosis Treatment)* AVM-GSL

**Formulations:** Oral: 3.84% solution for dilution in water.

**Action:** Thiamine analogue that disrupts protozoal metabolism.

**Use:**
- Treatment of coccidiosis in dogs and cats.

Limit duration of therapy to 2 weeks.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not use for more than 2 weeks to minimize risk of thiamine deficiency in the host animal.

**Adverse reactions:** Anorexia, diarrhoea and depression in dogs. Prolonged high doses can cause thiamine deficiency and may result in neurological signs.
Drug interactions: Exogenously administered thiamine may reduce efficacy.

DOSES

**Dogs:** For coccidiosis various doses are suggested. 200–300 mg/dog p.o. q24h for 7–12 days. Small puppies reduce to 60–100 mg/dog p.o. q24h, larger puppies use 200 mg/dog p.o. q24h.

**Cats:** 60–100 mg/cat p.o. q24h for 7 days or 110–220 mg/kg on food q24h for 7–12 days.

**Antivenom (European Adder)**

**POM**

**Formulations:** Injectable: 10 ml vial for injection (100mg/ml).

**Action:** Immunoglobulin raised against venom inhibits toxic effects.

**Use:**
- Used in the management of snake bites by the European Adder (Viper).

Current approved suppliers can be found on the VMD website and a special dispensation from the VMD can enable supply, purchase and use prior to STC approval in urgent cases (contact the VMD). Before submitting an application, contact the relevant manufacturer to ensure they are able to supply the quantity of product you wish to import. Urgent provision may also be possible via the VPIS ToxBox service. The value of antivenom decreases with time following the bite (benefits to local swelling are limited to administration within 24 hours post-bite; however, benefits towards systemic signs, when present, continue even with administration >24 hours post-bite). There are no published studies conclusively supporting improved recovery time in small animals. This antivenom is unlikely to work for other snake bites and specialist help should be urgently sought for such bites.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.

**Adverse reactions:** Anaphylactic reactions may develop. Milder reactions reported include facial swelling unrelated to snake bite, profound panting, unproductive cough.

**Drug interactions:** No information available.

**DOSES**

**Dogs, Cats:** Adder bite envenomation: 10 ml per animal slow i.v. (regardless of size). Consider giving 0.5 ml i.v. first and then wait 20 min to test for anaphylaxis.

**References**

Hodgson L and Brambilla G (2017) Dogs with a European adder bite, does the use of antivenom with supportive treatment compared to supportive treatment alone improve time to recovery? *Veterinary Evidence* 2, 1–11

Lund HS, Kristiansen V, Eggertsdóttir AV et al. (2013) Adverse reactions to equine-derived F(ab')2 -antivenin in 54 dogs envenomated by *Vipera berus berus*. *Journal of Veterinary Emergency and Critical Care* 23, 532–53
Apomorphine  
(Apometric) POM-V

**Formulations:** Injectable: 10 mg/ml solution in 2 ml ampoules. Other non-authorized formulations available.

**Action:** Stimulates emesis through D2 dopamine receptors in the chemoreceptor trigger zone.

**Use:** Induction of self-limiting emesis within a few minutes of administration in dogs where vomiting is desirable, e.g. following the ingestion of a toxic, non-caustic substance. Emesis generally occurs rapidly and within a maximum of 10 minutes. If emesis is not induced following a single injection, repeated injections will also prove ineffective and should not be given.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Induction of emesis is contraindicated if strong acid or alkali has been ingested, due to the risk of further damage to the oesophagus. Do not use in cases of gastric foreign bodies. Do not use in cases of poisoning due to pyrethroids. Induction of vomiting is contraindicated if the dog is unconscious, fitting, or has a reduced cough reflex, or if the poison has been ingested for >2 hours, or if the ingesta contains paraffin, petroleum products or other oily or volatile organic products, due to the risk of inhalation.

**Adverse reactions:** Apomorphine may induce excessive vomiting, respiratory depression and sedation. Dose-dependent hypotension can be seen. Ivermectin-sensitive (MDR1 mutation) collies may be more susceptible to the effects of apomorphine and for this reason the drug should be avoided if possible in such animals. If use is unavoidable, then the dose should be reduced.

**Drug interactions:** In the absence of compatibility studies, apomorphine must not be mixed with other products. Antiemetic drugs, particularly antidopaminergics (e.g. phenothiazines) may reduce the emetic effects of apomorphine. Additive CNS or respiratory depression may occur when apomorphine is used with opiates or other CNS or respiratory depressants.

**DOSES**

**Dogs:** 0.2 mg/kg s.c. (authorized dose), 20–40 μg (micrograms)/kg i.v. (non-authorized dose and route but some evidence to suggest is at least as effective).

**Cats:** Not recommended; xylazine is a potent emetic in cats and at least as safe.

**References**
Apraclonidine (Iopidine*) POM

Formulations: Ophthalmic: 0.5% solution (5 ml bottle); preservative-free 1% solution (single-dose vials).

Action: Topical alpha-2-selective agonist that decreases aqueous humour production by inhibition of adenylate cyclase activity in the ciliary body.

Use:
- Reducing intraocular pressure in glaucoma; however, effect in dogs is inconsistent and it is unlikely to be effective as the sole agent in most forms of canine glaucoma.
- It may be most useful in alleviating pressure rises after intraocular surgery.

It is prudent to monitor heart rate before and after topical application of apraclonidine, particularly with initial use and in small dogs. To limit systemic absorption, raise head and compress lower nasolacrimal punctum for every topical administration.

Safety and handling: Normal precautions should be observed.

Contraindications: Commercial preparations are considered too toxic for use in cats. Do not use in dogs with uncontrolled cardiac disease.

Adverse reactions: Causes blanching of conjunctival vessels and bradycardia in dogs and cats. Causes mydriasis in dogs, miosis and severe vomiting in cats.

Drug interactions: No information available.

DOSES
Dogs: 1 drop per eye q8–12h for short-term use only.
Cats: Do not use.

Ara-C see Cytarabine

Asparaginase (L-Aspariginase, Crisantaspase) (Asparginase*, Elspar*, Erwinase*) POM

Formulations: Injectable: vials of 5,000 or 10,000 IU powder for reconstitution.

Action: Lymphoid tumour cells are not able to synthesize asparagine and are dependent upon supply from the extracellular fluid. Asparaginase deprives malignant cells of this amino acid, which results in cessation of protein synthesis and cell death.
Use: Treatment of lymphoid malignancies.

Safety and handling: Cytotoxic drug; see Appendix and specialist texts for further advice on chemotherapeutic agents.

Store in a refrigerator.

Contraindications: Patients with active pancreatitis or a history of pancreatitis. History of anaphylaxis associated with previous administration. Use with caution in patients with pre-existing liver dysfunction.

Adverse reactions: Anaphylaxis may follow administration, especially if repeated. Premedication with an antihistamine is recommended 30 minutes before administration. Haemorrhagic pancreatitis has been reported in dogs. Gastrointestinal disturbances, hepatotoxicity including acute hyperammonaemia (presenting with encephalopathy) and coagulation deficits may also be observed. Bone marrow depression is very rare.

Drug interactions: Administration with or before vincristine may reduce clearance of vincristine and increase toxicity; thus, if used in combination, the vincristine should be given 12–24 hours before the enzyme.

DOSES

See Appendix for chemotherapy protocols and conversion of body weight to body surface area.

Dogs, Cats: 10,000 IU/m² or 400 IU/kg i.m. or s.c. q7d or less frequently.

References

MacDonald VS, Thamm DH, Kurzman ID et al. (2005) Does l-Asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma? Journal of Veterinary Internal Medicine 19, 732–736


Aspirin (Acetylsalicylic acid)

(Aspirin BP* and component of many others)

Formulations: Oral: 75 mg, 300 mg tablets.

Action: Produces irreversible inhibition of cyclo-oxygenase (COX-1, prostaglandin synthetase) by acetylation, thereby preventing the production of both prostaglandins and thromboxanes from membrane phospholipids.

Use:

- Prevention of arterial thromboembolism. Recent evidence suggests that clopidogrel may be superior to aspirin in cats for prevention of recurrence of cardiogenic thromboembolic events.
- Also can be used to control mild to moderate pain, although NSAIDs that are more selective for the COX-2 enzyme have a better safety profile; not an NSAID of choice for analgesia in dogs or cats.
In one study the use of ultralow dose aspirin (0.5 mg/kg q12h) may have improved the short-term and long-term survival in dogs with immune-mediated haemolytic anaemia when combined with glucocorticoid and azothioprine therapy. Administration of aspirin to animals with renal disease must be carefully evaluated. It is advisable to stop aspirin before surgery (at least 2 weeks) to allow recovery of normal platelet function and prevent excessive bleeding.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not give aspirin to dehydrated, hypovolaemic or hypotensive patients, or those with GI disease. Do not give to pregnant animals or animals <6 weeks old.

**Adverse reactions:** GI ulceration and irritation are common side effects of all NSAIDs. It is advisable to stop therapy if diarrhoea or nausea persists beyond 1–2 days. Stop therapy immediately if GI bleeding is suspected and begin symptomatic treatment. There is a small risk that NSAIDs may precipitate cardiac failure in humans and this risk in animals is unknown. All NSAIDs carry a risk of renal papillary necrosis due to reduced renal perfusion caused by a reduction in the production of renal prostaglandins. This risk is greatest when NSAIDs are given to animals that are hypotensive or animals with pre-existing renal disease.

**Drug interactions:** Do not administer concurrently or within 24 hours of other NSAIDs and glucocorticoids (exception – treatment of IMHA). Do not administer with other potentially nephrotoxic agents, e.g. aminoglycosides.

**DOSES**

**Dogs:** Doses are anecdotal and the ideal doses are unknown. Reduction of platelet aggregation (e.g. IMHA): 0.5–1 mg/kg p.o. q24h or 0.5 mg/kg p.o. q12h. Analgesia, pyrexia, inflammation: doses range from 10 mg/kg to 20 mg/kg p.o. q12h. The safety and efficacy of this dose has not been established.

**Cats:** Reduction of platelet aggregation: ¼ of a 75 mg tablet (18.75 mg) p.o for an average sized cat 3 days a week (low dose) or, alternatively, 75 mg for an average sized cat 3 days a week (high dose); this dose may be associated with a higher risk of GI side effects. Some authors suggest a very low dose (0.5 mg/kg p.o. q24h) to inhibit platelet COX without preventing the beneficial effects of prostacyclin production. The safety and efficacy of these different doses have not been evaluated in clinical or experimental studies.

**References**

Hogan DF, Fox PR, Jacob K et al. (2015) Secondary prevention of cardiogenic arterial thromboembolism in the cat: The double-blind, randomized, positive-controlled feline arterial thromboembolism; clopidogrel versus aspirin trial (FAT CAT). Journal of Veterinary Cardiology 17, s306–s317

Atenolol
(Atenolol*, Tenormin*) POM

Formulations: Oral: 25 mg, 50 mg, 100 mg tablets; 5 mg/ml sugar-free syrup. Injectable: 0.5 mg/ml. Special reformulations available: 6.25 mg tablets.

Action: Cardioselective beta-adrenergic blocker. It is relatively specific for beta-1 adrenergic receptors but can antagonize beta-2 receptors at high doses. Blocks the chronotropic and inotropic effects of beta-1 adrenergic stimulation on the heart, thereby reducing myocardial oxygen demand. Bronchoconstrictor, vasodilatory and hypoglycaemic effects are less marked due to its cardioselective nature.

Use:
• Treatment of cardiac tachyarrhythmias (including those associated with feline hyperthyroidism).
• Treatment of hypertrophic obstructive cardiomyopathy (cats) or obstructive cardiac disease (severe aortic or pulmonic stenosis).
• Treatment of systemic hypertension.
• Can be used following introduction of alpha-blockade in management of phaeochromocytoma.

It is recommended to withdraw therapy gradually in patients who have been receiving the drug chronically. Contraindicated in patients with heart failure.

Safety and handling: Normal precautions should be observed.

Contraindications: Patients with bradyarrhythmias, acute or decompensated congestive heart failure. Relatively contraindicated in animals with medically controlled congestive heart failure as it is poorly tolerated.

Adverse reactions: Most frequently seen in geriatric patients with chronic heart disease or in patients with acute or decompensated heart failure. Include bradycardia, AV block, myocardial depression, heart failure, syncope, hypotension, hypoglycaemia, bronchospasm and diarrhoea. Depression and lethargy may occur as a result of atenolol's high lipid solubility and its penetration into the CNS.

Drug interactions: Do not administer concurrently with alpha-adrenergic agonists (e.g. phenylpropanolamine) unless specific indication (phaeochromocytoma). The hypotensive effect of atenolol is enhanced by many agents that depress myocardial activity including anaesthetic agents, phenothiazines, antihypertensive drugs, diuretics and diazepam. There is an increased risk of bradycardia, severe hypotension, heart failure and AV block if atenolol is used concurrently with calcium-channel blockers. Concurrent digoxin administration potentiates bradycardia. The metabolism of atenolol is accelerated by thyroid hormones; thus, the dose of atenolol may need to be decreased when initiating carbimazole therapy. Atenolol enhances the effects of muscle relaxants (e.g. suxamethonium,
tubocurarine). Hepatic enzyme induction by phenobarbital may increase the rate of metabolism of atenolol. The bronchodilatory effects of theophylline may be blocked by atenolol. Atenolol may enhance the hypoglycaemic effect of insulin.

**DOSES**

**Dogs:** 0.2–2 mg/kg p.o. q12h; a lower dose is often used initially with gradual titration upwards if necessary.  
**Cats:** 6.25–12.5 mg/cat p.o. q12–24h; a lower dose is often used initially with gradual titration upwards if necessary. If using the oral liquid doses of 0.2–2 mg/kg p.o. q12h can be used, with gradual titration upwards as necessary.

**References**

Schober KE, Zientek J, Li X et al. (2013) Effect of treatment with atenolol on 5-year survival in cats with preclinical (asymptomatic) hypertrophic cardiomyopathy. Journal of Veterinary Cardiology 15, 93–104

**Atipamezole**  
(Alzane, Antisedan, Atipam, Revertor, Sedastop, Tipafar) **POM-V**

**Formulations:** Injectable: 5 mg/ml solution.

**Action:** Selective alpha-2 adrenoreceptor antagonist.

**Use:** Reverses the sedative effects of medetomidine or dexmedetomidine; will also reverse other alpha-2 agonists to provide a quick recovery from anaesthesia and sedation. It also reverses other effects such as the analgesic, cardiovascular and respiratory effects of alpha-2 agonists. Atipamezole does not alter the metabolism of medetomidine or dexmedetomidine but occupies the alpha-2 receptor preventing binding of the drug. The duration of action of atipamezole and medetomidine or dexmedetomidine are similar, so resedation is uncommon. Atipamezole should not be administered until at least 30 minutes after medetomidine/ketamine combinations have been given to cats, to avoid CNS excitation in recovery. Routine administration of atipamezole i.v. is not recommended because the rapid recovery from sedation is usually associated with excitation, although i.v. administration may be indicated in an emergency (e.g. excessive sedation from medetomidine or dexmedetomidine or cardiovascular complications).

**Safety and handling:** Normal precautions should be observed. In particular, skin contact with atipamezole should be avoided and impervious gloves should be worn during administration.

**Contraindications:** Atipamezole has been administered to a limited number of pregnant dogs and cats and therefore cannot be recommended in pregnancy.

**Adverse reactions:** Transient over-alertness and tachycardia may be observed after overdosage. This is best handled by minimizing external stimuli and allowing the animal to recover quietly.
Drug interactions: No information available.

DOSES

**Dogs:**
- 5 times the previous medetomidine dose or 10 times the previous dose of dexmedetomidine (0.5 mg/ml solution) i.m. (i.e. equal volume of solution to medetomidine or dexmedetomidine 0.5 mg/ml solution given). When medetomidine or dexmedetomidine has been administered at least an hour before, the dose of atipamezole can be reduced by half and repeated if recovery is slow.
- **Amitraz toxicity:** 25 μg (micrograms)/kg i.m. but if there is no benefit within 30 minutes this can be repeated or incrementally increased every 30 minutes up to 200 μg/kg.

**Cats:** 2.5 times the previous medetomidine or 5 times the previous dose of dexmedetomidine (0.5 mg/ml solution) i.m. (i.e. half the volume of medetomidine or dexmedetomidine 0.5 mg/ml solution given). When medetomidine or dexmedetomidine has been administered at least an hour before, the dose of atipamezole can be reduced by half and repeated if recovery is slow.

References


### Atracurium (Tracrium*) POM

**Formulations:** Injectable: 10 mg/ml solution.

**Action:** Inhibits the actions of acetylcholine at the neuromuscular junction by binding competitively to the nicotinic acetylcholine receptor on the post-junctional membrane.

**Use:**
- Neuromuscular blockade during anaesthesia.
- To improve surgical access through muscle relaxation, to facilitate positive pressure ventilation or for intraocular surgery.

Atracurium has an intermediate duration of action (15–35 min) and is non-cumulative due to non-enzymatic (Hofmann) elimination. It is therefore suitable for administration to animals with renal or hepatic disease. Monitoring (using a nerve stimulator) and reversal of the neuromuscular blockade is recommended to ensure complete recovery before the end of anaesthesia. Hypothermia, acidosis and hypokalaemia will prolong the duration of action of neuromuscular blockade. Use the low end of the dose range in patients with myasthenia gravis and ensure that neuromuscular function is monitored during the period of the blockade and recovery using standard techniques.
Safety and handling: Store in refrigerator.

Contraindications: Do not administer unless the animal is adequately anaesthetized and facilities to provide positive pressure ventilation are available.

Adverse reactions: Can precipitate the release of histamine after rapid i.v. administration, resulting in bronchospasm and hypotension. Diluting the drug in normal saline and giving the drug slowly i.v. minimizes these effects.

Drug interactions: Neuromuscular blockade is more prolonged when atracurium is given in combination with volatile anaesthetics, aminoglycosides, clindamycin or lincomycin.

DOSES
Dogs, Cats: 0.2–0.5 mg/kg i.v. initially, followed by increments of 0.2 mg/kg.

References
Kastrup MR, Marsico FF, Ascoli FO et al. (2005) Neuromuscular blocking properties of atracurium during sevoflurane or propofol anaesthesia in dogs. Veterinary Anaesthesia and Analgesia 32, 222–227

Atropine
(Atrocare, Atropine) POM-V

Formulations: Injectable: 0.6 mg/ml. Ophthalmic: 1% solution in single-use vials, 10 ml bottle.

Action: Blocks the action of acetylcholine at muscarinic receptors at the terminal ends of the parasympathetic nervous system, reversing parasympathetic effects and producing mydriasis, tachycardia, bronchodilation and general inhibition of GI function.

Use:
• Prevent or correct bradycardia and bradyarrhythmias.
• To dilate pupils.
• Management of organophosphate and carbamate toxicities.
• In conjunction with anticholinesterase drugs during antagonism of neuromuscular blockade.

Routine administration prior to anaesthesia as part of premedication is no longer recommended; it is better to monitor heart rate and give atropine to manage a low heart rate if necessary. Atropine has a slow onset of action (10 min i.m., 2–3 min i.v.); therefore, it is important to wait for an adequate period of time for the desired effect before redosing. The ophthalmic solution tastes very bitter and can cause hypersalivation in cats (and in some dogs).

Safety and handling: The solution does not contain any antimicrobial preservative, therefore, any remaining solution in the vial should be discarded after use. The solution should be protected from light.
**Contraindications:** Glaucoma, lens luxation, keratoconjunctivitis sicca.

**Adverse reactions:** Include sinus tachycardia (usually of short duration after i.v. administration), blurred vision from mydriasis, which may worsen recovery from anaesthesia, and drying of bronchial secretions. Atropine increases intraocular pressure and reduces tear production. Ventricular arrhythmias may be treated with lidocaine if severe. Other GI side effects such as ileus and vomiting are rare in small animals.

**Drug interactions:** Atropine is compatible (for at least 15 min) mixed with various medications but not with bromides, iodides, sodium bicarbonate, other alkalis or noradrenaline. The following may enhance the activity of atropine: antihistamines, pethidine, benzodiazepines, phenothiazines, thiazide diuretics and sympathomimetics. Combining atropine and alpha-2 agonists is not recommended. Atropine may aggravate some signs seen with amitraz toxicity, leading to hypertension and gut stasis.

**DOSES**

**Dogs, Cats:**
- **Ophthalmic:** 1 drop in the affected eye q12–24h to cause mydriasis, then once q24–96h to maintain mydriasis.
- **Bradyarrhythmias:** 0.01–0.03 mg/kg i.v. Low doses may exacerbate bradycardia; repetition of the dose will usually promote an increase in heart rate. 0.03–0.04 mg/kg i.m. can be given to prevent development of bradycardia during administration of potent opioids such as fentanyl.
- **Organophosphate poisoning:** dose 0.2–0.5 mg/kg (¼ dose i.v., ¾ i.m., s.c.) to effect; repeat as necessary; or 0.1–0.2 mg/kg (½ i.v., ½ i.m.) then i.m. q6h.
- **Neuromuscular blockade antagonism:** 0.04 mg/kg i.v. with edrophonium (0.5–1.0 mg/kg).

---

**Azathioprine**

(*Azathioprine*, *Imuran*) **POM**

**Formulations:** Oral: 25 mg, 50 mg tablets.

**Action:** Inhibits purine synthesis, which is necessary for cell proliferation especially of leucocytes and lymphocytes. Although exact mechanism is unknown, it suppresses cell-mediated immunity, alters antibody production and inhibits cell growth.

**Use:**
- Management of immune-mediated diseases such as immune-mediated haemolytic anaemia and immune-mediated polyarthritis. Often used in conjunction with corticosteroids.

Routine haematology (including platelets) and biochemistry should be monitored closely: initially every 1–2 weeks; and every 1–2 months when on maintenance therapy. Use with caution in patients...
with hepatic disease. In animals with renal impairment, dosing interval should be extended. Clinical responses can take up to 6 weeks. Alternative immunosuppressants may be preferred if a more rapid response is required.

**Safety and handling:** Cytotoxic drug; see Appendix and specialist texts for further advice on chemotherapeutic agents. Azathioprine tablets should not be divided and should be stored at room temperature in well closed containers and protected from light.

**Contraindications:** Do not use in patients with bone marrow suppression, in those at high risk of infection or with hepatic disease. Use with caution in patients with a history of pancreatic disease. Not recommended for use in cats.

**Adverse reactions:** Bone marrow suppression is the most serious adverse effect. This may be influenced by the activity of thiopurine s-methyltransferase, which is involved in the metabolism of the drug and which can vary between individuals due to genetic polymorphism. GI upset/anorexia, poor hair growth, acute pancreatitis and hepatotoxicity have been seen in dogs (the latter typically within 4 weeks of starting treatment). Cats in particular often develop a severe, non-responsive fatal leucopenia and thrombocytopenia. Avoid rapid withdrawal as this may cause a rebound hyperimmune response.

**Drug interactions:** Enhanced effects and increased azathioprine toxicity when used with allopurinol. Increased risk of azathioprine toxicity with aminosalicylates and corticosteroids, avoid with ACE inhibitors as this may increase potential for haematological adverse events.

**DOSES**

*See Appendix for immunosuppression protocols.*

**Dogs:** 2 mg/kg p.o. q24h for a maximum of 2–3 weeks, then 0.5–2 mg/kg p.o. q48h.

**Cats:** Not recommended.

**References**


**Azidothymidine** see Zidovudine
Azithromycin
(Azyter*, Clamelle*, Zedbac*, Zithromax*) POM

Formulations: Oral: 250 mg, 500 mg capsules and tablets; 200 mg/5 ml suspension (reconstitute with water). Injectable: 500 mg powder for reconstitution.

Action: Time-dependent macrolide that binds to the 50S bacterial ribosome (like erythromycin), inhibiting peptide bond formation. Azithromycin has a longer tissue half-life than erythromycin, shows better oral absorption and is better tolerated in humans.

Use:
• Alternative to penicillin in allergic individuals as it has a similar, although not identical, antibacterial spectrum. It is active against Gram-positive cocci (some Staphylococcus species are resistant), Gram-positive bacilli, some Gram-negative bacilli (Haemophilus, Pasteurella), mycobacteria, obligate anaerobes, Chlamydia, Mycoplasma and Toxoplasma. Some strains of Actinomyces, Nocardia and Rickettsia are also inhibited. Most strains of the Enterobacteriaceae (Pseudomonas, Escherichia coli, Klebsiella) are resistant. Useful in the management of respiratory tract, mild to moderate skin and soft tissue, and non-tubercular mycobacterial infections. Is used to treat chlamydophilosis in birds, but it has not proved possible to eliminate Chlamydia felis from chronically infected cats using azithromycin, even with once daily administration.
• Also reported for the treatment of Babesia gibsoni and Cytauxzoon felis.
• In addition to its antimicrobial activity, it has been reported for use in reducing gingival hyperplasia secondary to ciclosporin administration in cases where cessation of treatment is not possible.

Little information is available on the use of this drug in animals and drug pharmacokinetics have not been studied closely in the dog and cat. Doses are empirical and subject to change as experience with the drug is gained. More work is needed to optimize the clinically effective dose rate. Azithromycin activity is enhanced in an alkaline pH; administer on an empty stomach.

Safety and handling: Normal precautions should be observed.

Contraindications: Avoid in renal and hepatic failure in all species.

Adverse reactions: In humans, similar adverse effects to those of erythromycin are seen, i.e. vomiting, cholestatic hepatitis, stomatitis and glossitis, but the effects are generally less marked than with erythromycin.

Drug interactions: Azithromycin may increase the serum levels of methylprednisolone, theophylline and terfenadine. The absorption of digoxin may be enhanced.
DOSES
See Appendix for guidelines on responsible antibacterial use.
Dogs: 5–10 mg/kg p.o. q24h. May increase dosing interval to q48h after 3–5 days of treatment.
Cats: Various regimes are suggested: 5–10 mg/kg p.o q24h for 3–5 days; 5 mg/kg p.o. q24h for 2 days then every 3–5 days up to a total of 5 doses; for upper respiratory tract disease: 5–10 mg/kg p.o. q24h for 5 days then q72h. Specialist texts should be consulted.

AZT see Zidovudine
Benazepril
(Benazecare Flavour, Benefortin, Cardalis, Fortekor, Fortekor-Plus, Kelapril, Nelio, Prilben, Vetpril) POM-V

Formulations: Oral: 2.5 mg, 5 mg, 20 mg tablets. Available in compound preparations with spironolactone (2.5 mg benazepril/20 mg spironolactone; 5 mg benazepril/40 mg spironolactone; 10 mg benazepril/80 mg spironolactone) (Cardalis) and pimobendan (1.25 mg pimobendan/2.5 mg benazepril; 5 mg pimobendan/10 mg benazepril) (Fortekor-Plus).

Action: Angiotensin converting enzyme (ACE) inhibitor. It inhibits conversion of angiotensin I to angiotensin II and inhibits the breakdown of bradykinin. Overall effect is a reduction in preload and afterload via venodilation and arteriodilation, decreased salt and water retention via reduced aldosterone production and inhibition of the angiotensin-aldosterone-mediated cardiac and vascular remodelling. Efferent arteriolar dilation in the kidney can reduce intraglomerular pressure and therefore glomerular filtration. This may decrease proteinuria.

Use:
• Treatment of congestive heart failure in dogs and cats. Often used in conjunction with diuretics when heart failure is present as most effective when used in these cases. Can be used in combination with other drugs to treat heart failure (e.g. pimobendan, furosemide, spironolactone, digoxin).
• Management of proteinuria associated with chronic renal insufficiency, glomerular disorders and protein-losing nephropathies.
• May reduce blood pressure in hypertension, and may be more potent in dogs. Less potent in reducing blood pressure compared with amlodipine in cats but sometimes used together.

Benazepril undergoes significant hepatic metabolism and may not need dose adjustment in renal failure. ACE inhibitors are more likely to cause or exacerbate prerenal azotaemia in hypotensive animals and those with poor renal perfusion (e.g. acute, oliguric renal failure). Use cautiously if hypotension, hyponatraemia or outflow tract obstruction are present. Regular monitoring of blood pressure, serum creatinine, urea and electrolytes is strongly recommended with ACE inhibitor treatment. The use of ACE inhibitors in cats with cardiac disease stems from extrapolation from theoretical benefits and studies showing a benefit in other species with heart failure and different cardiac diseases (mainly dogs and humans) and is not proven.

Safety and handling: Normal precautions should be observed.

Contraindications: Do not use in cases of cardiac output failure or hypotension.
Adverse reactions: Potential adverse effects include hypotension, hyperkalaemia and azotaemia. Monitor blood pressure, serum creatinine and electrolytes when used in cases of heart failure. Dosage should be reduced if there are signs of hypotension (weakness, disorientation). Anorexia, vomiting and diarrhoea are rare. In pre-clinical trials there were no serious reactions when the drug was given to normal dogs at 200 times the label dose. It is not recommended for breeding, or pregnant or lactating dogs and cats, as safety has not been established. The safety of benazepril has not been established in cats <2.5 kg.

Drug interactions: Concomitant usage with potassium-sparing diuretics (e.g. spironolactone) or potassium supplements could result in hyperkalaemia. However, in practice, spironolactone and ACE inhibitors appear safe to use concurrently. There may be an increased risk of nephrotoxicity and decreased clinical efficacy when used with NSAIDs. There is a risk of hypotension with concomitant administration of diuretics, vasodilators (e.g. anaesthetic agents, antihypertensive agents) or negative inotropes (e.g. beta-blockers).

DOSES

Dogs: Heart failure: 0.25–0.5 mg/kg p.o. q24h. Adjunctive treatment of hypertension/proteinuria: 0.25–0.5 mg/kg p.o. q12–24h.

Cats: Chronic renal insufficiency: 0.5–1.0 mg/kg p.o. q24h. Adjunctive therapy in heart failure: 0.25–0.5 mg/kg p.o. q24h.

References


Benzyl penicillin see Penicillin G

Betamethasone
(Isaderm, Osurnia, Otomax, Betnesol*, Maxidex*)

POM-V, POM

Formulations: Injectable: 4 mg/ml solution for i.v. or i.m. use. Oral: 0.25 mg tablet. Topical: 0.1% cream with 0.5% fusidic acid. Ophthalmic/Otic: 0.1% solution; 0.88% mg/ml suspension with clotrimazole and gentamicin; 0.1% gel with florfenicol and terbinafine. Betamethasone is also present in varying concentrations in several topical preparations with or without antibacterials.

Action: Alters the transcription of DNA, leading to alterations in cellular metabolism which causes reduction in inflammatory responses. Has high glucocorticoid and virtually no mineralocorticoid activity. Betamethasone also antagonizes insulin and ADH.
Use:
- Short-term relief of many inflammatory but non-infectious conditions.

Long duration of activity makes it unsuitable for long-term daily or alternate-day use. On a dose basis, 0.12 mg betamethasone is equivalent to 1 mg prednisolone. Prolonged use of glucocorticoids suppresses the hypothalamic-pituitary axis, resulting in adrenal atrophy. Animals on chronic corticosteroid therapy should be given tapered decreasing doses when discontinuing the drug. The use of long-acting steroids in most cases of shock is of no benefit, and may be detrimental. It is recommended to clean and dry the external ear canal before the first administration of the combination formulation with florfenicol and terbinafine product. It is recommended not to repeat ear cleaning until 21 days after the second administration of the product.

Safety and handling: Wear gloves when applying cream.

Contraindications: Do not use in pregnant animals. Systemic corticosteroids are generally contraindicated in patients with renal disease and diabetes mellitus. Topical corticosteroids are contraindicated in ulcerative keratitis.

Adverse reactions: Catabolic effects of glucocorticoids lead to weight loss and cutaneous and muscle atrophy. Chronic therapy may lead to iatrogenic hyperadrenocorticism. Vomiting, diarrhoea and GI ulceration may develop. Glucocorticoids may increase glucose levels and decrease serum T3 and T4 values. Impaired wound healing and delayed recovery from infections may be seen.

Drug interactions: There is an increased risk of GI ulceration if used concurrently with NSAIDs. Glucocorticoids antagonize the effect of insulin. Phenobarbital may accelerate the metabolism of corticosteroids and antifungals (e.g. itraconazole) may decrease it. There is an increased risk of hypokalaemia when used concurrently with acetazolamide, amphotericin and potassium-depleting diuretics (furosemide, thiazides).

DOSES

Dogs:
- Otic: 4 drops of polypharmaceutical to affected ear q12h. If using combination formulation with florfenicol and terbinafine then administer into affected ear and repeat once after 7 days.
- Ocular: 1 drop of ophthalmic solution to affected eye q6–8h.
- Skin: apply cream to affected area q8–12h.
- Anti-inflammatory: 0.04 mg/kg i.v., i.m. q3wk prn for up to 4 injections, 0.025 mg/kg p.o. q24h.

Cats:
- Ocular: dose as for dogs.
- Skin: dose as for dogs.
- Anti-inflammatory: 0.04 mg/kg i.v. q3wk prn for up to 4 injections.
Betaxolol
(Betoptic*) POM

**Formulations:** Ophthalmic: 0.25% suspension in 5ml bottle or single-use vials; 0.5% solution.

**Action:** Betaxolol is a beta-1 selective beta-blocker that decreases aqueous humour production via beta-adrenoreceptor blockade in the ciliary body.

**Use:** Management of glaucoma. It can be used alone or in combination with other topical glaucoma drugs, such as a topical carbonic anhydrase inhibitor. Betaxolol can be used in the prophylactic management of glaucoma in the other eye of dogs with unilateral primary closed-angle glaucoma.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Avoid in uncontrolled heart failure and asthma.

**Adverse reactions:** Ocular adverse effects include miosis, conjunctival hyperaemia and local irritation.

**Drug interactions:** Additive adverse effects may develop if given concurrently with oral beta-blockers. Prolonged atrioventricular conduction times may result if used with calcium antagonists or digoxin.

**DOSES**
- **Dogs:** 1 drop per eye q12h.
- **Cats:** No information available.

**References**

Bethanecol
(Myotonine*) POM

**Formulations:** Oral: 10 mg tablets.

**Action:** A muscarinic agonist (cholinergic or parasympathomimetic) that increases urinary bladder detrusor muscle tone and contraction.

**Use:**
- Management of urinary retention with reduced detrusor tone. It does not initiate a detrusor reflex and is ineffective if the bladder is areflexic.

Best given on an empty stomach to avoid GI distress.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not use when urethral resistance is increased unless in combination with agents that reduce urethral outflow pressure (e.g. phenoxybenzamine).
Adverse reactions: Vomiting, diarrhoea, GI cramping, anorexia, salivation and bradycardia (with overdosage). Treat overdoses with atropine.

Drug interactions: No information available.

DOSES
Dogs: Detrusor atony: 2.5–15 mg/dog p.o. q8h. Titrate dose upwards to avoid side effects.
Cats: Detrusor atony: 1.25–5 mg/cat p.o. q8h. Titrate dose upwards to avoid side effects.

References

Bisacodyl
(Dulcolax*, Entrolax*) P

Formulations: Oral: 5 mg yellow, enteric-coated tablet.
Rectal: 10 mg suppository.

Action: Mild stimulant laxative that increases intestinal motility, but inhibits absorption of water. It is locally active with <5% systemic absorption.

Use: Constipation. Doses are empirical; none have been defined in the veterinary literature. Onset of action 6–10 hours (oral use), or 15–60 minutes (rectal use).

Safety and handling: Normal precautions should be observed.
Do not crush or split the tablets (may lead to cramping).

Contraindications: Must not be used in patients with ileus, intestinal obstruction or dehydration. Not suitable for long-term use.

Adverse reactions: Abdominal discomfort and diarrhoea.

Drug interactions: No information available.

DOSES
Dogs: Constipation: 5–15 mg/dog prn.
Cats: Constipation: 2–5 mg/cat prn.

Bismuth salts (Bismuth carbonate, subnitrate and subsalicylate: tri-potassium di-citrato bismuthate (bismuth chelate)) (Pepto-Bismol*) AVM-GSL, P

Formulations: Oral: bismuth subsalicylate suspension in various forms typically 17.5 mg/ml (1.75%). Tablets containing 30 mg bismuth subcarbonate and 240 mg calcium carbonate.
Action: Bismuth is a gastric cytoprotectant with activity against spiral bacteria. Bismuth chelate is effective in healing gastric and duodenal ulcers in humans, with direct toxic effects on gastric *Helicobacter pylori* and by stimulating mucosal prostaglandin and bicarbonate secretion. It is often used in conjunction with an acid-blocking drug. Bismuth subsalicylate has a mild anti-inflammatory effect. Bismuth subsalicylate should be used with great caution in cats because of its subsalicylate content.

Use: Gastric ulceration, diarrhoea, or as part of combination therapy for gastric *Helicobacter* infections. Doses are empirical; none have been defined in dogs and cats.

Safety and handling: Normal precautions should be observed.

Contraindications: Use bismuth subsalicylate with caution in cats.

Adverse reactions: Avoid long-term use as absorbed bismuth is neurotoxic. Bismuth chelate is contraindicated in renal impairment. Nausea and vomiting reported in humans. Bismuth may cause grey/green/black discolouration of the faeces.

Drug interactions: Absorption of tetracyclines is reduced by bismuth.

**DOSES**

**Dogs:** All uses: 17.5 mg/ml suspension: 0.25–1 ml/kg p.o. q4–8h.

**Cats:** All uses: 17.5 mg/ml suspension: 0.25–1 ml/kg p.o. q4–8h; use with caution.

---

**Bleomycin**

**POM**

Formulations: Injectable: Lyophilized powder for reconstitution before use. 15 units and 30 units per vial.

Action: Bleomycin is an antibiotic; however, its cytotoxicity prevents it from being a useful antimicrobial agent. Causes DNA cleavage and hence prevents cell replication.

Use:

- Used occasionally in canine and feline lymphoma, oral squamous carcinoma, teratomas and thyroid tumours.
- Used in veterinary electro-chemotherapy and intralesionally in canine acanthomatous ameloblastoma and melanoma.

Low therapeutic index when used systemically, consult with a specialist before use.

Safety and handling: Potent cytotoxic drug that should only be prepared and administered by trained personnel. See Appendix and specialist texts for further advice on chemotherapeutic agents.

Contraindications: Contraindicated in patients with known hypersensitivity to bleomycin and in patients with pre-existing
pulmonary disease. Do not use in patients with pre-existing bone marrow suppression. Should be used with caution in patients with reduced renal function.

**Adverse reactions:** Dermatopathies, conjunctivitis, stomatitis, gastrointestinal toxicity (e.g. anorexia, vomiting and diarrhoea), pyrexia, increased liver enzyme activities and nephrotoxicity are described. Pulmonary toxicity (pneumonitis or pulmonary fibrosis) is the most severe side effect in both veterinary and human patients (this can rarely progress to fatal pulmonary fibrosis). Unlike many other cytotoxic drugs myelosuppression is rare but possible.

**Drug interactions:** The use of general anaesthesia in patients previously exposed to bleomycin should be done with extreme caution. Prior or concomitant use of radiotherapy or other chemotherapy drugs may lead to increased toxicity from bleomycin.

**DOSES**

See Appendix for chemotherapy protocols and conversion of body weight to body surface area.

**Dogs:** 0.3–0.5 IU/kg s.c. or i.m. once weekly (note there is a very narrow safety margin – use under the supervision of a veterinary specialist only). A total cumulative dose of 125–250 mg/m² should not be exceeded to reduce the risk of pulmonary toxicity.

**Cats:** Doses as for dogs.

**References**

Kelly JM, Belding BA and Schaefer AK (2010) Acanthomatous ameloblastoma in dogs treated with intralesional bleomycin. *Veterinary and Comparative Oncology* 2, 81–86


---

**Bowel cleansing solutions**

**(Macrogol, Polyethylene glycol)**

**(Klean-Prep*, Moviprep*)

**Formulations:** Oral: powder for reconstitution.

**Action:** Bowel cleansing solutions contain polyethylene glycol as an osmotic laxative and balanced electrolytes to maintain isotonicity and prevent net fluid loss or gain. When administered orally they rapidly empty the bowel.

**Use:**

- Bowel preparation before colonoscopy or radiographic examination; some authorities do not use in cats before colonoscopy.
- May also be used for constipation.

Powder may take several minutes to dissolve, and reconstitution is best performed by adding warm water to the powder.

**Safety and handling:** Normal precautions should be observed.
Contraindications: GI obstruction or perforation. Do not administer to heavily sedated patients or animals with a reduced gag reflex.

Adverse reactions: Diarrhoea is an expected outcome. Occasional vomiting is seen, especially if the maximum volume is administered. Inhalation can cause severe, and even fatal, aspiration pneumonia.

Drug interactions: Oral medication should not be taken within 1 hour of administration as it may be flushed from the GI tract and not absorbed.

DOSES
Dogs: Prior to lower GI examination: 22–33 ml/kg p.o. or by stomach tube, 2 or 3 times, at least 4 hours apart.
Cats: Prior to lower GI examination: 22–33 ml/kg p.o. or by naso-oesophageal tube.

Brinzolamide
(Azarga*, Azopt*) POM

Formulations: Ophthalmic drops: 10 mg/ml (1%) in 5 ml bottle (Azopt); 1% brinzolamide + 0.5% timolol in 5 ml bottle (Azarga).

Action: Reduces intraocular pressure by reducing the rate of aqueous humour production by inhibition of the formation of bicarbonate ions within the ciliary body epithelium.

Use: In the control of all types of glaucoma in dogs, either alone or in combination with other topical drugs. It may be better tolerated than dorzolamide because of its more physiological pH of 7.5. Brinzolamide is ineffective in normal cats but may reduce IOP in glaucomatous cats; by contrast dorzolamide is effective in both dogs and cats.

Safety and handling: Normal precautions should be observed.

Contraindications: Severe hepatic or renal impairment. Timolol causes miosis and is therefore not the drug of choice in uveitis, anterior lens luxation or pupil block.

Adverse reactions: Local irritation, keratitis, blepharitis. Brinzolamide may cause less ocular irritation than dorzolamide. Timolol can cause bradycardia and hypotension. Rarely, carbonic anhydrase inhibitors have been reported to cause hypokalaemia in cats, and metabolic acidosis in dogs, as a result of systemic absorption.

Drug interactions: No information available.

DOSES
Dogs, Cats: 1 drop/eye q8–12h.
References

British anti-lewisite see Dimercaprol

Bromhexine
(Bisolvon) POM-V

Formulations: Injectable: 3 mg/ml solution. Oral: 10 mg/g powder.

Action: A bronchial secretolytic that disrupts the structure of acid mucopolysaccharide fibres in mucoid sputum and produces a less viscous mucus, which is easier to expectorate.

Use: Mucolytic activity could aid the management of respiratory disease.

Safety and handling: Normal precautions should be observed.

Contraindications: No information available.

Adverse reactions: No information available.

Drug interactions: No information available.

DOSES
Dogs: Mucolysis: 3–15 mg/dog i.m. q12h; 2 mg/kg p.o. q12h.
Cats: Mucolysis: 3 mg/cat i.m. q24h; 1 mg/kg p.o. q24h.

Budesonide
(Benacort*, Budelin*, Budenofalk*, Budenofalk Rectal Foam*, Cortiment*, Entocort*, Pulmicort*, Rhinocort*) P

Formulations: Oral: 3 mg gastroresistant capsule, 3 mg capsule containing gastroresistant slow-release granules, 9 mg sustained-release gastrointestinal tablet. Rectal: 2 mg (total dose) rectal foam, 0.02 mg/ml enema. Inhaled powder: 100–400 µg per dose. Nasal spray: 64–100 µg per dose.

Action: Anti-inflammatory and immunosuppressive steroid.

Use:
- Use in the treatment of chronic enteropathy as a potent corticosteroid that is metabolized on its first pass through the liver in humans and therefore might be expected to have
reduced systemic side effects. In a prospective study, dogs with inflammatory bowel disease received monotherapy with either pure powder budesonide (not the available enteric coated formulation), or prednisolone; remission rates were similar between groups. Frequency of adverse effects was also similar between the two groups. The dose of this drug is unclear and is extrapolated from humans. For enteric use, compounding will be required for small/medium dogs, and cats.

- Inhaled formulations are used in humans for asthma or allergic rhinitis. The use of inhaled budesonide has been reported in cats with bronchial disease; cats in which therapy was not withdrawn by the owners showed improved clinical signs and pulmonary function tests. The uncoated powder for inhalant use in people should not be used for oral administration because of hydrolysis by gastric acid.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Intestinal perforation; severe hepatic impairment.

**Adverse reactions:** In theory, the rapid metabolism should give minimal systemic adverse effects. However, signs of iatrogenic hyperadrenocorticism (hair loss, muscle wastage, increases in liver enzymes, hepatomegaly, lethargy, polyphagia and polyuria/polydipsia) may develop. Adrenal suppression has been documented in dogs and cats and iatrogenic hypocortisolaemia is a potential risk if budesonide is withdrawn rapidly following prolonged use. In theory, sudden transfer from other steroid therapy might result in signs related to reductions in steroid levels.

**Drug interactions:** Additive effect if given with other corticosteroids. The metabolism of corticosteroids may be decreased by antifungals. Avoid using with erythromycin, cimetidine, itraconazole and other drugs that inhibit the liver enzymes that metabolize budesonide. The dissolution of the drug’s enteric coating depends on pH, therefore do not administer at the same time as oral antacids.

**DOSES**

**Dogs:**
- **Intestinal diseases:** dose based on body size ranging from 1 mg/day p.o. q24h for small dogs to 3 mg/day p.o. q12–24h for large/giant dogs. The total dose should probably not exceed 3 mg p.o. q12h.
- **Inhaled:** no information available.

**Cats:**
- **Intestinal diseases:** Total oral dose should probably not exceed 1 mg p.o. q8h.
- **Inhaled:** 400 µg (micrograms) q12h reported.

**References**


Bupivacaine
(Marcain*, Sensorcaine*) POM

**Formulations:** Injectable: 2.5, 5.0, 7.5 mg/ml solutions, 2.5, 5.0 mg/ml solution with 1:200,000 adrenaline.

**Action:** Reversible blockade of the sodium channel in nerve fibres produces local anaesthesia.

**Use:** Provision of analgesia by perineural nerve blocks, regional and epidural techniques. Onset of action is significantly slower than lidocaine (20–30 minutes for epidural analgesia) but duration of action is relatively prolonged (6–8 hours). Lower doses should be used when systemic absorption is likely to be high (e.g. intrapleural analgesia). Small volumes of bupivacaine can be diluted with normal saline to enable wider distribution of the drug for perineural blockade. Doses of bupivacaine up to 2 mg/kg q8h are unlikely to be associated with systemic side effects if injected perineurally, epidurally or intrapleurally. Combining bupivacaine with lidocaine can prolong the duration of the sensory block while limiting the duration of the motor block compared with administration of bupivacaine alone.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not give i.v. or use for i.v. regional anaesthesia. Use of bupivacaine with adrenaline is not recommended when local vasoconstriction is undesirable (e.g. end arterial sites) or when a significant degree of systemic absorption is likely.

**Adverse reactions:** Inadvertent intravascular injection may precipitate severe cardiac arrhythmias that are refractory to treatment.

**Drug interactions:** All local anaesthetics share similar side effects, therefore the dose of bupivacaine should be reduced when used in combination with other local anaesthetics.

**DOSES**

**Dogs:**
- **Perineural:** volume of injection depends on the site of placement and size of the animal. As a guide: 0.1 ml/kg per injection site for femoral and sciatic nerve blocks; 0.1 ml/kg for each of the three injection sites for the combined radial, ulnar, musculocutaneous and median nerve blocks; 0.3 ml/kg for brachial plexus nerve block; 0.25–1 ml total volume for blockade of the infraorbital, mental, maxillary and mandibular nerves. Choose an appropriate concentration of bupivacaine to achieve a 1–2 mg/kg dose within these volume guidelines.
- **Epidural:** 1.6 mg/kg (analgesia to level of L4), 2.3 mg/kg (analgesia to level of T11–T13); 1 mg/kg bupivacaine combined with preservative-free morphine 0.1–0.2 mg/kg. Limit the total volume of solution injected into the epidural space to 1 ml/4.5 kg up to a maximum volume of 6 ml in order to limit the cranial
distribution of drugs in the epidural space and prevent adverse pressure effects.

- **Interpleural:** 1 mg/kg diluted with normal saline to a total volume of 5–20 ml depending on the size of the animal. The solution can be instilled via a thoracotomy tube. Dilution reduces pain on injection due to the acidity of bupivacaine.

**Cats:** Doses as for dogs. Accurate dosing in cats is essential to prevent overdose.

**References**

**Buprenorphine**
(Bupaq, Buprecare, Bupre nodale, Buprevet, Vetergesic) **POM-V CD SCHEDULE 3**

**Formulations:** *Injectable:* 0.3 mg/ml solution; available in 1 ml vials that do not contain a preservative, or in 10 ml multidose bottle that contains chlorocresol as preservative.

**Action:** Analgesia through high affinity, low intrinsic activity and slow dissociation with the mu receptor.

**Use:**
- Relief of mild to moderate perioperative pain.
- It may antagonize the effects of full opioid agonists (e.g. methadone, fentanyl), although the clinical relevance of interactions between full mu agonists and buprenorphine has recently been questioned.

However, in practice it is not recommended to administer buprenorphine when the subsequent administration of full mu agonists is likely. If analgesia is inadequate after buprenorphine, a full mu agonist may be administered without delay. Buprenorphine may be mixed with acepromazine or dexmedetomidine to provide sedation for minor procedures or pre-anaesthetic medication. Response to all opioids is variable between individuals; therefore, assessment of pain after administration is imperative. Onset of action of buprenorphine may be slower than methadone (>15 min). Duration of effect is approximately 6 hours in cats and is likely to be similar in dogs. Buprenorphine is metabolized in the liver; some prolongation of effect may be seen with impaired liver function. The multidose preparation is unpalatable given sublingually due to the preservative. There is emerging evidence that analgesic efficacy of buprenorphine s.c. may be less than similar doses of buprenorphine administered i.m. or i.v. to cats, therefore, this route is not recommended in cats or dogs.

**Safety and handling:** Normal precautions should be observed.
Contraindications: Combination with full mu agonists is not recommended for analgesia; therefore, do not use for premedication when administration of potent opioids during surgery is anticipated.

Adverse reactions: Side effects are rare after clinical doses. Buprenorphine crosses the placenta and may exert sedative effects in neonates born to bitches and queens treated prior to parturition. Pain on i.m. injection of the multidose preparation has been anecdotally reported.

Drug interactions: In common with other opioids, buprenorphine will reduce the doses of other drugs required for induction and maintenance of anaesthesia.

DOSES
When used for sedation is generally given as part of a combination. See Appendix for sedation protocols in cats and dogs.

Dogs: Analgesia: 0.02 mg/kg i.v., i.m., s.c. q6h.

Cats: Analgesia: 0.02–0.03 mg/kg i.v., i.m., s.c. q6h. Also well tolerated and effective when given oral transmucosally.

References
Giordano T, Steagall PV, Ferreira TH et al. (2010) Postoperative analgesic effects of intravenous, intramuscular, subcutaneous or oral transmucosal buprenorphine administered to cats undergoing ovariohysterectomy. Veterinary Anaesthesia and Analgesia 37, 357–366

Butorphanol
(Alvegesic, Dolorex, Torbugsic, Torbutrol, Torphasol) POM-V

Formulations: Injectable: 10 mg/ml solution. Oral: 5 mg, 10 mg tablets.

Action: Analgesia resulting from affinity for the kappa opioid receptor. Also has mu receptor antagonist properties and an antitussive action resulting from central depression of the cough mechanism.

Use:
- Management of mild perioperative pain.
- Provision of sedation through combination with acepromazine or alpha-2 agonists.
- Potent antitussive agent indicated for the relief of acute or chronic non-productive cough associated with tracheobronchitis, tracheitis, tonsillitis or laryngitis resulting from inflammatory conditions of the upper respiratory tract.

Butorphanol has a very rapid and relatively short duration of action; in different models analgesia has been shown to last between 45 minutes
and 4 hours. Butorphanol is metabolized in the liver and some prolongation of effect may be seen with impaired liver function. Butorphanol crosses the placenta and may exert sedative effects in neonates born to bitches and queens treated prior to parturition. Butorphanol is unlikely to be adequate for the management of severe pain. Higher doses of full mu agonists may be needed to provide additional analgesia after butorphanol but it is not necessary to wait 4 hours after butorphanol administration to give other opioids. Response to all opioids appears to be very variable between individuals; therefore, assessment of pain after administration is imperative.

**Safety and handling:** Protect from light.

**Contraindications:** Animals with diseases of the lower respiratory tract associated with copious mucus production. Premedication when administration of potent opioids during surgery is anticipated.

**Adverse reactions:** As a kappa agonist/mu antagonist, side effects such as respiratory depression, bradycardia and vomiting are rare after clinical doses. Cough suppression following torbugesic tablets may be associated with mild sedation.

**Drug interactions:** In common with other opioids, butorphanol will reduce the doses of other drugs required for induction and maintenance of anaesthesia. Combination with full mu agonists is not recommended for analgesia, addition of butorphanol will reduce analgesia produced from the full mu agonist.

**DOSES**

*When used for sedation is generally given as part of a combination. See Appendix for sedation protocols in cats and dogs.*

**Dogs:**
- **Analgesia:** 0.2–0.5 mg/kg i.v., i.m., s.c.
- **Antitussive:** 0.05–0.1 mg/kg i.v., i.m., s.c., 0.5–1 mg/kg p.o. q6–12h.

**Cats:** **Analgesia:** 0.2–0.5 mg/kg i.v., i.m., s.c.

**References**

Simon BT, Steagall PV, Monteiro BP et al. (2016) Antinociceptive effects of intravenous administration of hydromorphone hydrochloride alone or followed by buprenorphine hydrochloride or butorphanol tartrate to healthy conscious cats. *American Journal of Veterinary Research* 77, 245–251

---

**Butylscopolamine (Hyoscine)** *(Buscopan)* **POM-V, POM**

**Formulations:** Injectable: 4 mg/ml butylscopolamine + 500 mg/ml metamizole in 100 ml multidose bottle (Buscopan Compositum); 20 mg/ml butylscopolamine only, in 2 ml ampoules. Oral: 10 mg tablet containing butylscopolamine only.

**Action:** Inhibits M1 muscarinic acetylcholine receptors in the GI and urinary tracts causing smooth muscle relaxation but does not cross the blood–brain barrier.
Use:
• Control of diarrhoea in dogs, particularly when pain or abdominal discomfort is present.
• Control of pain associated with urinary obstruction in dogs.
Should only be used in combination with investigations into the cause of abdominal pain or definitive relief of urinary obstruction.

Safety and handling: Avoid self-injection: metamizole can cause reversible but potentially serious agranulocytosis and skin allergies. Protect solution from light.

Contraindications: Intestinal obstruction.

Adverse reactions: Dry mouth, blurred vision, hesitant micturition and constipation at doses acting as gut neuromuscular relaxants. The i.m. route may cause a local reaction.

Drug interactions: Metamizole should not be given to dogs that have been treated with a phenothiazine, as hypothermia may result. Effects may be potentiated by concurrent use of other anticholinergic or analgesic drugs.

DOSES
Dogs: Control of diarrhoea and/or abdominal discomfort: 0.1 ml/kg i.v., i.m. q12h (Buscopan Compositum); 0.5 mg/kg i.m., p.o. q12h (butylscopolamine only).
Cats: Do not use.
**Cabergoline**  
*(Galastop, Kelactin)* **POM-V**

**Formulations:** Oral: 50 μg/ml solution.

**Action:** Potent selective inhibition of prolactin, dopamine (D2) agonist.

**Use:**
- Induction of oestrus.
- Control of false pregnancy in the bitch, including associated behavioural problems.
- Treatment of galactostasis in lactating bitches.
- Also used to induce abortion in bitches and queens.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not use in pregnant bitches unless abortion is desired. Should not be used in combination with hypotensive drugs or in animals in a hypotensive state.

**Adverse reactions:** Vomiting or anorexia may occur after the first one or two doses in a small proportion of cases; there is no need to discontinue treatment unless vomiting is severe or it persists beyond the second dose. In some animals a degree of drowsiness may be seen in the first 2 days of dosing. May induce transient hypotension.

**Drug interactions:** Metoclopramide antagonizes the effects on prolactin. Cabergoline may increase the hypotensive effects of other drugs.

**DOSES**

**Dogs:** 5 μg (micrograms)/kg p.o. q24h for 4–6 days. Control of aggression-related signs may require dosing for 2 weeks. To induce abortion: 15 μg/kg p.o. between days 30 and 42.

**Cats:** To induce abortion: 15 μg (micrograms)/kg p.o. between days 30 and 42.

**References**

**CaEDTA** see **Edetate calcium disodium**

**Calcium acetate**  
*(Phosex*, PhosLo*) **POM**

**Formulations:** Oral: 1 g tablet; 667 mg capsule (calcium 169 mg, Ca^{2+} 4.2 mmol).

**Action:** Binds phosphorus in GI tract, thus lowering serum phosphate levels over a wider range of pH than calcium carbonate.
Use:
- Phosphate reduction in chronic renal failure.

Phosphate-binding agents are usually only used if low phosphate diets are unsuccessful. Monitor serum phosphate levels at 4–6 week intervals and adjust dosage accordingly if trying to achieve target serum concentrations. Monitor for hypercalcaemia.

Safety and handling: Normal precautions should be observed.

Contraindications: Hypercalcaemia and calcium urolithiasis.

Adverse reactions: Risk of increasing the calcium:phosphate ratio and thus the incidence of soft tissue and vascular calcification.

Drug interactions: May affect absorption of tetracycline and fluoroquinolone antibiotics. Increased risk of hypercalcaemia with concurrent calcitriol administration.

DOSES

Dogs, Cats: Chronic kidney disease: 60–90 mg/kg p.o. q24h divided (give with each meal).

References

Calcium salts (Calcium borogluconate, Calcium carbonate, Calcium chloride, Calcium gluconate, Calcium lactate) (Calcichew*) Many cattle preparations, e.g. Calcibor) POM-V, POM

Formulations: There are many formulations available; a selection is given here.
- Injectable: 200 mg/ml calcium borogluconate solution equivalent to 15 mg/ml calcium formed from 168 mg/ml of calcium gluconate and 34 mg/ml boric acid (Calcibor 20); 100 mg/ml (10%) calcium chloride solution containing 27.3 mg/ml elemental calcium (= 1.36 mEq calcium/ml = 680 μmol (micromoles)/ml); 100 mg/ml calcium gluconate solution 10 ml ampoules containing 9 mg elemental calcium/ml (= mEq calcium/ml).
- Oral: 600 mg calcium gluconate tablets (= 53.4 mg elemental calcium); 1250 mg chewable calcium carbonate tablets (Calcichew) (= 500 mg elemental calcium).
- Note on other formulations: 11.2 mg calcium gluconate, 13.3 mg calcium borogluconate, 7.7 mg calcium lactate, 3.6 mg calcium chloride; each contains 1 mg elemental calcium = 0.5 mEq calcium.
- Minor component of Aqupharm No.9 and No.11.
Action: Calcium is an essential element involved in maintenance of numerous homeostatic roles and key reactions including activation of enzymes, cell membrane potentials and nerve and musculoskeletal function.

Use:
- Management of hypocalcaemia.
- Management of hyperkalaemic cardiotoxicity associated with urinary obstruction.

Calcium gluconate and borogluconate are preferred. Serum calcium levels and renal function tests should be assessed before starting therapy. ECG monitoring during i.v. infusions is advised. Avoid using mixed electrolyte solutions intended for cattle use if possible. Treatment of hyperkalaemic cardiotoxicity with calcium rapidly corrects arrhythmias but effects are short-lived (5–10 min to effect) and i.v. glucose 0.5–1 g/kg ± insulin may be needed to decrease serum potassium. Parenteral calcium should be used very cautiously in patients receiving digitalis glycosides or those with cardiac or renal disease.

Safety and handling: Normal precautions should be observed.

Contraindications: Ventricular fibrillation or hypercalcaemia. Calcium should be avoided in pregnancy unless there is a deficient state. Hyperkalaemia associated with hypoadrenocorticism is often associated with hypercalcaemia and therefore additional calcium is not recommended in those cases.

Adverse reactions: Hypercalcaemia can occur, especially in renal impairment or cardiac disease. Tissue irritation is common and can occur with injectable preparation regardless of route. Rapid injection may cause hypotension, cardiac arrhythmias and cardiac arrest. Perivascular administration is treated by stopping the infusion, infiltrating the tissue with normal saline and topical application of corticosteroids. Note that some chewable formulations of calcium (e.g. Calcichew) may contain xylitol and overdosage could produce hypoglycaemia.

Drug interactions: Patients on digitalis glycosides are more prone to develop arrhythmias if given i.v. calcium. All calcium salts may antagonize verapamil and other calcium-channel blockers. Calcium borogluconate is compatible with most i.v. fluids except those containing other divalent cations or phosphorus. Calcium borogluconate is reportedly compatible with lidocaine, adrenaline and hydrocortisone. Calcium chloride is incompatible with amphotericin B, cefalotin sodium and chlorphenamine. Calcium gluconate is incompatible with many drugs, including lipid emulsions, propofol, amphotericin B, cefamandole, naftate, cefalotin sodium, dobutamine, methylprednisolone sodium succinate and metoclopramide. Consult manufacturers’ data sheets for incompatibilities with other solutions.
DOSES

**Dogs:**
- **Parenteral treatment of hypocalcaemia or hyperkalaemic cardiotoxicity:** 50–150 mg/kg calcium (boro)gluconate (which is equivalent to 3.8–11.4 mEq/kg of elemental calcium when borogluconate is used or 4.5–14 mg/kg of elemental calcium when gluconate is used). Alternatively, 5–10 mg/kg calcium chloride or 0.05–0.1 ml/kg of a 10% solution i.v. (equivalent to 0.068–0.136 mEq/kg). Additional doses to a maximum of 1–1.5 g/kg calcium boro(gluconate) may need to be administered i.v. over the next 24 hours. Adjust dose by monitoring serum calcium and phosphorus levels.
- **Oral treatment of hypocalcaemia:** 5–22 mg of elemental calcium/kg p.o. q8h; adjust dose by monitoring serum calcium and phosphorus levels.

**Cats:**
- **Parenteral treatment of hypocalcaemia:** 95–140 mg calcium gluconate/kg slowly i.v. to effect. Using 10% calcium gluconate this is equivalent to 1–1.5 ml/kg slowly i.v. over 10–20 min. Monitor ECG if possible. If bradycardia or Q–T interval shortening occurs, slow rate or temporarily discontinue. Once life-threatening signs are resolved, add calcium gluconate to i.v. fluids and administer slowly at 60–90 mg/kg/day elemental calcium. This converts to 2.5 ml/kg of 10% calcium gluconate q6–8h or the equivalent as a constant rate infusion over 24 hours. Monitor serum calcium and adjust as needed.
- **Oral treatment of hypocalcaemia:** Begin oral therapy at 10–25 mg elemental calcium/kg q6–8h; adjust dose by monitoring serum calcium and phosphorus levels.

---

**Carbimazole (Vidalta) POM-V**

**Formulations:** Oral: 10 mg, 15 mg tablets in a sustained-release formulation.

**Action:** Carbimazole is metabolized to the active drug methimazole, which interferes with the synthesis of thyroid hormones in a dose-dependent fashion.

**Use:** Control of thyroid hormone levels in cats with hyperthyroidism. Carbimazole has also been used in canine hyperthyroidism but there are no data on the use of the sustained-release formulation in dogs.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Animals that have an adverse reaction to methimazole are likely also to have an adverse reaction to carbimazole.

**Adverse reactions:** Vomiting and inappetence/anorexia may be seen but are often transient. Jaundice, cytopenias, immune-mediated...
diseases and dermatological changes (pruritus, alopecia and self-induced trauma) are reported but rare. Treatment of hyperthyroidism can decrease glomerular filtration rate, thereby increasing serum urea and creatinine values, and can occasionally unmask occult renal failure.

**Drug interactions:** Carbimazole should be discontinued before iodine-131 treatment. Do not use with low iodine prescription diets.

**DOSES**

**Dogs, Cats:** Hyperthyroidism: starting dose 15 mg/animal p.o. q24h unless total thyroxine concentrations are <100 nmol (nanomoles)/l in which case starting dose is 10 mg p.o. q24h. Adjust dose in 5 mg increments but do not break tablets.

**References**


---

**Carbomer 980**

*(Lubrithal, Ocry-gel, OptixCare, Viscotears*)

**P, general sale**

**Formulations:** Ophthalmic: 0.2% (10 g tube, single-use vial), 0.25% (10 g tube) gel. This formulation is marketed specifically for small animals. Other formulations are widely available for general sale.

**Action:** Linear polymer (polyacrylic acid). Replaces the aqueous and mucin layers of the trilaminar tear film (mucinomimetic).

**Use:**
- Tear replacement.
- Management of quantitative (keratoconjunctivitis sicca (KCS) or dry eye) and qualitative tear film disorders.

It has longer corneal contact time than the aqueous tear substitutes (e.g. polyvinyl alcohol).

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.

**Adverse reactions:** It is tolerated well and ocular irritation is unusual.

**Drug interactions:** No information available.

**DOSES**

**Dogs, Cats:** 1 drop per eye q4–6h.
Carboplatin
(Carboplatin*, Paraplatin*) POM

Formulations: Injectable: 10 mg/ml solution.

Action: Binds to DNA to form intra- and interstrand cross-links and DNA-protein cross-links, resulting in inhibition of DNA synthesis and function.

Use:
- May be of use in a number of neoplastic diseases including anal sac adenocarcinoma, squamous cell carcinoma, ovarian carcinoma, mediastinal carcinoma, pleural adenocarcinoma, nasal carcinoma and thyroid adenocarcinoma.
- Improves survival times when used as an adjunct to amputation in dogs with appendicular osteosarcoma.

The drug is highly irritant and must be administered via a preplaced i.v. catheter. Do not use needles or i.v. sets containing aluminium as precipitation of the drug may occur. This drug is generally now preferred over cisplatin due to reduced GI and renal toxicity. Use with caution in patients with abnormal renal function, active infections, hearing impairment or pre-existing hepatic disease.

Safety and handling: Potent cytotoxic drug that should only be prepared and administered by trained personnel. See Appendix and specialist texts for further advice on chemotherapeutic agents.

Contraindications: Contraindicated in patients with known hypersensitivity to platinum containing compounds. Do not use in patients with pre-existing bone marrow suppression.

Adverse reactions: Include myelosuppression, nephrotoxicity, ototoxicity, nausea, vomiting, electrolyte abnormalities, neurotoxicity and anaphylactic reactions (including a delayed cutaneous hypersensitivity). However, produces fewer adverse reactions than cisplatin.

Note that there may be delayed or unpredictable side effects in cats (thought to be due to GFR changes in older cats).

Drug interactions: Concomitant use of aminoglycosides or other nephrotoxic agents may increase risk of nephrotoxicity. May adversely affect the safety and efficacy of vaccinations. Potential to act as a radiosensitizer for patients receiving concommitant radiotherapy.

DOSES
See Appendix for chemotherapy protocols and conversion of body weight to body surface area.

Dogs: All uses: 300 mg/m² i.v. q3–4wk injected into the side port of a freely running i.v. infusion of 0.9% NaCl over a 10–15 min period. Intrapleural/intraperitoneal dose: 225–300 mg/m² diluted in 0.9% NaCl or 5% dextrose water (in one text this is diluted to 10 mg/ml then again in 1 ml per 4.5 kg body weight) over a 5–10 min period.
(it is advised to consult a veterinary oncology specialist before administering via this route).

**Cats:** All uses: 200 mg/m^2 i.v. q3–4wk injected into the side port of a freely running i.v. infusion of 0.9% NaCl over a 10–15 min period. Intrapleural/intraperitoneal dose: 200–240 mg/m^2 diluted in 0.9% NaCl or 5% dextrose water over a 5–10 min period (it is advised to consult a veterinary oncology specialist before administering via this route).

**References**
Skorupski KA, Uhl JM, Szivek A et al. (2016) Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma: a randomized, phase III trial. *Veterinary and Comparative Oncology* 14, 81–87

**Carprofen**
*(Canidryl, Carprofyl, Carprox Vet, Dolagis, Rimadyl, Rimifin)*  **POM-V**

**Formulations:**
- **Injectable:** 50 mg/ml. **Oral:** 20 mg, 50 mg, 100 mg tablets (in plain and palatable formulations).

**Action:** Preferentially inhibits COX-2 enzyme, thereby limiting the production of prostaglandins involved in inflammation. Other non-COX-mediated mechanisms are suspected to contribute to the anti-inflammatory effect but these have not yet been identified.

**Use:**
- Control of postoperative pain and inflammation following surgery.
- Reduction of chronic inflammation, e.g. degenerative joint disease, osteoarthritis.

In cats, carprofen is only licensed as a single perioperative dose for the control of postoperative pain. Carprofen also has antipyretic effects. All NSAIDs should be administered cautiously in the perioperative period. Although carprofen preferentially inhibits COX-2, it may still adversely affect renal perfusion during periods of hypotension. If hypotension during anaesthesia is anticipated, delay carprofen administration until the animal is fully recovered from anaesthesia and normotensive. Liver disease will prolong the metabolism of carprofen, leading to the potential for drug accumulation and overdose with repeated dosing. Prolonged long-term treatment should be under veterinary supervision. In cats, due to the longer half-life and narrower therapeutic index, particular care should be taken not to exceed the recommended dose and the use of a 1 ml graduated syringe is recommended to measure the dose accurately. Tablets are not authorized for use in cats.

**Safety and handling:** Formulations that use palatable tablets can be extremely palatable. Animals have been reported to eat tablets spontaneously, resulting in overdose. Ensure that tablets are stored...
out of animal reach. Store injectable solution in the refrigerator; once broached the product is stable for use at temperatures up to 25°C for 28 days.

**Contraindications:** Do not give to dehydrated, hypovolaemic or hypotensive patients or those with GI disease or blood clotting abnormalities. Administration of carprofen to animals with renal disease must be carefully evaluated and is not advisable in the perioperative period. Do not give to pregnant animals or animals <6 weeks old.

**Adverse reactions:** GI signs may occur in all animals after NSAID administration. Stop therapy if this persists beyond 1–2 days. Some animals develop signs with one NSAID and not another. A 3–5 day wash-out period should be allowed before starting another NSAID after cessation of therapy. Stop therapy immediately if GI bleeding is suspected. There is a small risk that NSAIDs may precipitate cardiac failure in humans and this risk in animals is unknown.

**Drug interactions:** Different NSAIDs should not be administered within 24 hours of each other or glucocorticoids as they are more ulcerogenic when used concurrently. The nephrotoxic tendencies of all NSAIDs are significantly increased when administered concurrently with other nephrotoxic agents, e.g. aminoglycosides.

**DOSES**

**Dogs:** 4 mg/kg i.v., s.c. preoperatively or at time of anaesthetic induction; single dose should provide analgesia for up to 24 hours. Continued analgesia can be provided orally at 4 mg/kg/day, in single or divided doses for up to 5 days after injection. In dogs started on oral medication, subject to clinical response the dose may be reduced to 2 mg/kg/day, single dose, after 7 days.

**Cats:** 4 mg/kg i.v., s.c., single dose preoperatively or at time of anaesthetic induction.

**References**

---

**Carvedilol**

(Carvedilol<sup>®</sup>) POM

**Formulations:** Oral: 3.125 mg, 6.25 mg, 12.5 mg, 25 mg tablets.

**Action:** Non-selective beta-adrenergic blocker with the afterload reduction properties of an alpha-1 adrenergic blocker. Additional antioxidant properties may decrease the oxidant stress associated with heart failure.

**Use:**
- Has been advocated for use as an adjunctive therapy in the management of chronic heart failure due to valvular disease or DCM.
- Potential antihypertensive drug in patients that do not respond to first-line therapy.

Veterinary experience is limited and benefit has not been established. Limited data on pharmacokinetics and pharmacodynamics in dogs. Treatment should not be started until congestive heart failure has been stabilized for at least 2 weeks initially. Since it undergoes extensive hepatic metabolism, caution should be exercised in patients with hepatic insufficiency.

Safety and handling: Normal precautions should be observed.

Contraindications: Patients with bradyarrhythmias, acute or decompensated heart failure and bronchial disease. Do not administer concurrently with alpha-adrenergic agonists (e.g. adrenaline).

Adverse reactions: Potential side effects include lethargy, diarrhoea, bradycardia, AV block, myocardial depression, exacerbation of heart failure, syncope, hypotension and bronchospasm. A reduction in the glomerular filtration rate may exacerbate pre-existing renal impairment.

Drug interactions: The hypotensive effect of carvedilol is enhanced by many agents that depress myocardial activity including anaesthetic agents, phenothiazines, antihypertensive drugs, diuretics and diazepam. There is an increased risk of bradycardia, severe hypotension, heart failure and AV block if carvedilol is used concurrently with calcium-channel blockers. Hypotensive effect may be antagonized by NSAIDs. Concurrent digoxin administration potentiates bradycardia. Carvedilol may enhance the hypoglycaemic effect of insulin. Carvedilol increases plasma concentration of ciclosporin. Rifampin can decrease carvedilol plasma concentrations.

DOSES
Dogs: Start at 0.05–0.1 mg/kg p.o. q12h and gradually increase at 2-week intervals to target dose of 0.3–0.4 mg/kg p.o. q12h, if tolerated. Doses of 0.3 mg/kg p.o. q12h and then increased at intervals up to 1.1 mg/kg p.o. q12h in ACVIM stage B2 (cardiac remodelling, no signs on cardiac failure) degenerative mitral valve disease, have been reported.

Cats: No information available.

References
α-Casozepine (Benzodiazepine-like decapeptide)
(Zylkene) general sale

Formulations: 75 mg, 225 mg, 450 mg capsules also included in some other formulations alongside other potentially calming nutraceuticals.

Action: GABA<sub>B</sub> agonist.

Use:
- Used to reduce the impact of a range of stressors, including unusual and unpredictable situations or before changes to the normal environment, such as kennelling or the arrival of a new baby.

It is suggested that dosing should start before exposure to the stressor; however, a recent online review of the literature concluded that the evidence in support of the use of α-casozepine for the management of anxiety was weak.

Safety and handling: Normal precautions apply.

Contraindications: None.

Adverse reactions: Occasional reports of diarrhoea noted.

Drug interactions: None.

DOSES
**Dogs:** 15 mg/kg p.o. q24h.
**Cats:** 15 mg/kg p.o. q24h.

References

Cat appeasing pheromone
(Feliway Friends) general sale

Formulations: Diffuser.

Action: The mixture is based on derivatives of the dermal secretions produced by the queen after giving birth which help to keep kittens within the safety of the nest. The signal causes an innate emotional bias in the perception of the environment that does not require learning, but makes the cat feel more secure. This sense of safety and security appears to reduce antagonism between cats living in the same home.

Use: When there are signs of conflict between cats within the same household, including overt aggression, hissing, growling and chasing (not play related) and more subtle signs of social tension
such as consistent blocking behaviour, and staring down or consistent avoidance. In these circumstances some cats can also show repetitive minor medical ailments as a result of chronic stress, such as persistent vomiting, cystitis and overgrooming. In these cases the animal should be carefully checked for medical causes before considering behaviour management. Should be used alongside a behaviour management plan that allows different cats access to their own core resources. Published reports show marginal effects.

**Safety and handling:** Normal precautions apply.

**Contraindications:** None.

**Adverse reactions:** None reported; if no improvement within 1 month, reassess diagnosis.

**Drug interactions:** None.

**DOSES**

**Cats:** Plug-in diffuser which should be left on the whole time (not switched on and off), ideally where the cats rest; not where they come into conflict.

**Dogs:** Not applicable.

**References**


**CCNU** see *Lomustine*

**Cefalexin (Cephalexin)**

(Cefaseptin, Cephacare, Cephorum, Ceporex, Rilexine, Therios, Tsefalen) POM-V

**Formulations:** Injectable: 180 mg/ml (18%) suspension. Oral: 50 mg, 75 mg, 120 mg, 250 mg, 300 mg, 500 mg, 600 mg, 750 mg, 1000 mg tablets.

**Action:** 1st generation cephalosporin. Binds to penicillin-binding proteins involved in bacterial cell wall synthesis, decreasing cell wall strength and rigidity, and affecting cell division. Resistant to some penicillinases produced by *Staphyloccoccus* spp. but ineffective against meticillin-resistant staphylococci. Works in a time-dependent fashion.

**Use:** Active against most Gram-positive (not *Enterococcus*) and some Gram-negative organisms (*Pasteurella, Klebsiella* and *Escherichia coli*). *Pseudomonas* and *Proteus* are often resistant. Maintaining levels above the MIC is critical for efficacy and prolonged dosage intervals or missed doses can compromise
therapeutic response. Dose and dosing interval is determined by infection site, severity and organism. In severe or acute conditions, doses may be doubled or given at more frequent intervals. 

**Safety and handling:** Normal precautions should be observed. 

**Contraindications:** Avoid use in animals with hypersensitivity to other beta-lactam antimicrobials (cross-hypersensitivity in <10% of human patients). 

**Adverse reactions:** Vomiting and diarrhoea most common; administration with food may reduce these reactions. Injection may be painful. 

**Drug interactions:** May be an increased risk of nephrotoxicity if cephalosporins are used with aminoglycosides, amphotericin or loop diuretics (e.g. furosemide); monitor renal function. Do not mix in the same syringe as aminoglycosides. 

**DOSES**

See Appendix for guidelines on responsible antibacterial use. 

**Dogs:** 15 mg/kg p.o. q8–12h; 10 mg/kg i.m., s.c. q24h. 

**Cats:** 15 mg/kg p.o. q8–12h; 10 mg/kg i.m., s.c. q24h. 

Increased doses (20–30mg/kg p.o. q8–12h) should be used for superficial pyoderma and to treat severe, Gram-negative or orthopaedic infections. 

---

**Cefotaxime** 
(Cefotaxime*) POM 

**Formulations:** Injectable: 500 mg, 1 g, 2 g powders for reconstitution. 

**Action:** It binds to proteins involved in bacterial cell wall synthesis, thereby decreasing cell wall strength and rigidity, and affecting cell division. Resistant to many bacterial beta-lactamases, particularly those produced by *Staphylococcus* spp. As other beta-lactam antibacterials, works in a time-dependent fashion. 

**Use:** As a 3rd generation cephalosporin, it is classified as a highest priority critically important antibiotic by the World Health Organization and European Medicines Agency, emphasizing the need for prudent use. Good activity against many Gram-negative organisms, especially Enterobacteriaceae (not *Pseudomonas*) but lower activity against many Gram-positive organisms than 1st and 2nd generation cephalosporins. It is important to maintain tissue concentrations above the MIC. Use should be reserved for: patients with acute sepsis or serious infection where cultures are pending or culture and sensitivity testing shows sensitivity; or where other licensed preparations are not appropriate, and the animal is not a good candidate for intensive aminoglycoside therapy (e.g. pre-existing renal dysfunction). Use with care in patients with renal disease and consider increasing dose interval. There are few published studies evaluating appropriate dosing rates and suggested dose rates are largely extrapolated from human pharmacokinetic information.
Safety and handling: The reconstituted solution is stable for 24 hours when refrigerated.

Contraindications: Patients hypersensitive to penicillins may also be sensitive to cephalosporins (cross-hypersensitivity in <10% of human patients); avoid use in animals with reported sensitivity to other beta-lactam antimicrobials.

Adverse reactions: May produce pain on injection. GI disturbance and superinfection with resistant microorganisms is a potential risk.

Drug interactions: Bactericidal activity may be affected by concomitant use of bacteriostatic agents (e.g. oxytetracycline, erythromycin). The cephalosporins are synergistic with the aminoglycosides, but should not be mixed in the same syringe. May be increased risk of nephrotoxicity if cephalosporins are used with amphotericin or loop diuretics (e.g. furosemide); monitor renal function.

DOSES
See Appendix for guidelines on responsible antibacterial use.

Dogs, Cats: Various doses have been suggested and vary. 40–50 mg/kg i.v., i.m., s.c. q8h. Some authors have suggested that lower doses of 10–20 mg/kg q12h have good clinical efficacy in the dog.

References

Cefovecin
(Convenia) POM-V

Formulations: Injectable: lyophilized powder which when reconstituted contains 80 mg/ml cefovecin.

Action: It binds to penicillin-binding proteins involved in bacterial cell wall synthesis, decreasing cell wall strength and rigidity, and affecting cell division. Resistant to some penicillinases produced by Staphylococcus spp. but ineffective against meticillin-resistant staphylococci. Works in a time-dependent fashion.

Use: As a 3rd generation cephalosporin, it is classified as a highest priority critically important antibiotic by the World Health Organization and European Medicines Agency, emphasizing the need for prudent use. Cefovecin should not be considered if a 14-day course of antimicrobial would not ordinarily be required for the infection being treated. Indicated for the prolonged treatment of skin, soft tissue and urinary tract infections. Also used as part of the management of severe periodontal disease. Good efficacy against Staphylococcus, Streptococcus, Pasteurella multocida and Proteus, and anaerobes such as Prevotella, Fusobacterium, Bacteroides and Clostridium. Not active against Pseudomonas spp., Enterococcus spp., or Bordetella
*bronnchiseptica*. Its high protein binding may prohibit reaching effective serum levels to treat systemic *Escherichia coli*. Due to its unique pharmacokinetic profile, cefovecin has an extremely long half-life and only requires administration every 14 days.

**Safety and handling:** Store in the refrigerator even prior to reconstitution; use reconstituted drug within 28 days.

**Contraindications:** Do not use in cats and dogs <8 weeks old. Avoid use during lactation and in pregnant animals, as safety has not been established.

**Adverse reactions:** Appears to be relatively safe but has not been assessed in renal disease. Reported adverse reactions include mild GI disturbance and transient swelling at the injection site, as well as type I, II and III hypersensitivity reactions.

**Drug interactions:** Highly bound to plasma proteins, therefore it would be prudent to exhibit caution when using in conjunction with other highly protein-bound drugs such as furosemide and NSAIDs.

**DOSES**

See Appendix for guidelines on responsible antibacterial use.

**Dogs, Cats:** 8 mg/kg s.c., equivalent to 1 ml/10 kg of reconstituted drug subcutaneously. May be repeated after 14 days up to 3 times.

**Ceftazidime**

*(Fortum*) **POM**

**Formulations:** Injectable: 500 mg, 1 g, 2 g, 3 g powders for reconstitution.

**Action:** It binds to proteins involved in bacterial cell wall synthesis, thereby decreasing cell wall strength and rigidity, and affecting cell division. Resistant to some bacterial beta-lactamases. It works in a time-dependent fashion.

**Use:** As a 3rd generation cephalosporin, it is classified as a highest priority critically important antibiotic by the World Health Organization and European Medicines Agency, emphasizing the need for prudent use. Higher activity against many Gram-negative organisms but lower activity against many Gram-positives when compared with 1st and 2nd generation cephalosporins. Very good activity against *Pseudomonas* in humans. Use should be limited to cases with a confirmed susceptibility and acute sepsis or serious infections where licensed preparations are found to be inappropriate. Limited information on clinical pharmacokinetics in animal species and doses given below are empirical. Important to maintain tissue concentrations above the MIC with regular doses.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Patients hypersensitive to penicillins may also be sensitive to cephalosporins (cross-hypersensitivity in <10% of human patients); avoid use in animals with reported sensitivity to
other beta-lactam antimicrobials. Use with caution in animals with significantly impaired renal function, and consider dose adjustment.

**Adverse reactions:** GI disturbances associated with drug use in humans. Pain may be noted following injection.

**Drug interactions:** Bactericidal activity may be affected by concomitant use of bacteriostatic agents (e.g. oxytetracycline, erythromycin). May be an increased risk of nephrotoxicity if cephalosporins are used with amphotericin or loop diuretics (e.g. furosemide); monitor renal function. Do not mix in the same syringe as aminoglycosides. Ceftazidime is synergistic with the aminoglycoside antimicrobials in vivo (often used in humans for pseudomonal infection in neutropenic patients).

**DOSES**

See Appendix for guidelines on responsible antibacterial use.

**Dogs:** Various doses suggested. **Susceptible infections:** 30 mg/kg i.v, i.m., s.c. q8h. Increased frequency for susceptible infections with *Pseudomonas aeruginosa* q4h or as CRI with a loading dose of 4.4 mg/kg followed by 4.1 mg/kg/h.

**Cats:** Various doses suggested. **Susceptible infections:** 30 mg/kg i.m. q8h. If *Pseudomonas*, more frequent dosing recommended q2–4h.

**References**


**Ceftiofur**

(Cefenil) POM-V

**Formulations:** Injectable: 1 g, 4 g powder for reconstitution; 50 mg/ml suspension. Only licensed for use in large animals.

**Action:** It binds to penicillin-binding proteins involved in bacterial cell wall synthesis, decreasing cell wall strength and rigidity and affecting cell division. Resistant to some penicillinases produced by *Staphylococcus* spp., but ineffective against meticillin-resistant staphylococci. Works in a time-dependent fashion. Uniquely among the cephalosporins, ceftiofur is metabolized to desfuroylceftiofur, which is an active metabolite.

**Use:** As a 3rd generation cephalosporin, it is classified as a highest priority critically important antibiotic by the World Health Organization and European Medicines Agency, emphasizing the need for prudent use. It should be reserved for patients suffering from acute sepsis or serious infections where cultures are pending, other licensed preparations are not appropriate and the animal is not a good candidate for intensive aminoglycoside therapy (pre-existing renal dysfunction). Important to maintain tissue concentrations above the MIC. Authorized for use in dogs in other countries where...
the main indication for use is in the treatment of urinary tract infections. Use with care in patients with renal disease and consider increasing dose interval.

**Safety and handling:** Store powder and diluent in the refrigerator; once reconstituted store in the refrigerator and discard within 24 hours.

**Contraindications:** Avoid use in animals with hypersensitivity to other beta-lactam antimicrobials (cross-hypersensitivity in <10% of human patients).

**Adverse reactions:** May produce pain on injection. GI disturbance and superinfection with resistant microorganisms is a potential risk. Type I, II and III hypersensitivity reactions rarely reported. May be an increased risk of nephrotoxicity if cephalosporins are used with amphotericin or loop diuretics (e.g. furosemide); monitor renal function. In dogs, a dose- and duration-dependent anaemia and thrombocytopenia has been recorded, although this should not occur with recommended doses.

**Drug interactions:** The cephalosporins are synergistic with the aminoglycosides, but should not be mixed in the same syringe.

**DOSES**

See Appendix for guidelines on responsible antibacterial use.

**Dogs:** For susceptible urinary tract infections 2.2 mg/kg s.c. q24h.

**Cats:** Dose not established.

Higher (double) dose indicated to treat sepsis/bacteraemia.

**References**


---

**Cefuroxime**

(Aprokam*, Zinacef*, Zinnat*) **POM**

**Formulations:** Injectable: 50 mg, 250 mg, 750 mg, 1.5 g powders for reconstitution (sodium salt). Oral (as cefuroxime axetil): 125 mg, 250 mg tablets; 125 mg/5 ml suspension.

**Action:** A 2nd generation cephalosporin that binds to proteins involved in bacterial cell wall synthesis, thereby decreasing cell wall strength and rigidity, and affecting cell division. Resistant to some bacterial beta-lactamases. Cefuroxime axetil is hydrolysed in intestinal mucosa and liver to yield active drug conferring oral bioavailability.

**Use:** Higher activity against many Gram-negative organisms when compared with 1st generation cephalosporins. Good activity against a wider spectrum of Enterobacteriaceae (not *Pseudomonas*). Many obligate anaerobes also susceptible. It is a time-dependent antimicrobial, so maintaining levels above the MIC are important for
efficacy. Limited applications in veterinary species and limited pharmacokinetic data make appropriate dose selection problematical. Can be considered for surgical prophylaxis especially when increased Gram-negative activity is desirable, and may be associated with fewer adverse effects than co-amoxiclav in this setting.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Patients hypersensitive to penicillins may also be sensitive to cephalosporins (cross-hypersensitivity in <10% of human patients); avoid use in animals with reported sensitivity to other beta-lactam antimicrobials.

**Adverse reactions:** May cause pain on i.m. and s.c. injection. GI disturbance has been reported in humans, particularly associated with the oral axetil formulation.

**Drug interactions:** Bactericidal activity may be affected by concomitant use of bacteriostatic agents (e.g. oxytetracycline, erythromycin). May be an increased risk of nephrotoxicity if cephalosporins are used with amphotericin or loop diuretics (e.g. furosemide); monitor renal function. Synergistic with aminoglycosides, do not mix in the same syringe.

**DOSES**

*See Appendix for guidelines on responsible antibacterial use.*

**Dogs, Cats:** For surgical prophylaxis: 20 mg/kg i.v. slowly (over 5 min) 30 min prior to surgery and then repeat q1.5–3h during surgery. For susceptible infections: 10–30 mg/kg i.v. q8–12h.

**References**


---

**Cephalexin** see **Cefalexin**

---

**Cetirizine**

(Piriteze*, Zirtec*) *GSL*

**Formulations:** Oral: 10 mg tablets; 5 mg/5 ml solution.

**Action:** Binds to H1 histamine receptors to prevent histamine from binding.

**Use:**
- Management of allergic disease.
- Prevention and early treatment of anaphylaxis.

Cetirizine is a metabolite of hydroxyzine. Less sedative effect in humans than chlorpheniramine.

**Safety and handling:** Normal precautions should be observed.
Contraindications: None reported.

Adverse reactions: May reduce seizure threshold.

Drug interactions: None reported.

DOSES

**Dogs:** Antihistamine 1 mg/kg p.o. q24h.

**Cats:** 5 mg/cat p.o. q24h.

References


**Charcoal** *(Activated charcoal)*

*(Actidose-Aqua*, Charcodote*, Liqui-Char*)

Formulations: Oral: 50 g activated charcoal powder or premixed slurry (200 mg/ml or 300 mg/ml available).

Action: Absorbs toxins, fluids and gases in the GI tract. Activated charcoal has increased porosity and enhanced absorptive capacity.

Use:

- In acute poisoning with organophosphates, carbamates, chlorinated hydrocarbons, strychnine, ethylene glycol, inorganic and organic arsenical and mercurial compounds, polycyclic organic compounds (most pesticides), and dermal toxicants that may be ingested following grooming.

As a general rule, administer at a dose of at least 10 times the volume of intoxicant ingested. Repeat dosing as required if emesis or massive toxin ingestion occurs. Repeated dosing necessary if highly lipid-soluble toxins, which are likely to undergo enterohepatic recirculation, have been ingested. The addition of dog food to activated charcoal (up to 14 times the amount of charcoal used) slightly reduced its total adsorptive capacity for paracetamol but this effect is likely to be clinically insignificant.

Safety and handling: Activated charcoal powder floats, covering everything in the area; prepare very carefully as it will stain permanently.

Contraindications: Activated charcoal should not be used prior to the use of emetics.

Adverse reactions: Charcoal colours stools black, which is medically insignificant but may be alarming to the owner.

Drug interactions: Activated charcoal reduces the absorption and therefore efficacy of orally administered drugs.

DOSES

**Dogs, Cats:** After toxin ingestion: 0.5–4 g/kg p.o. of activated charcoal/kg as a slurry in water.
References

Chitosan
(Ipakitine) general sale

Formulations: Oral: powder containing 8% chitosan, 10% calcium carbonate and 82% lactose.

Action: Adsorbent for intestinal uraemic toxins, including phosphate.

Use:
• The combination product has been shown to reduce serum urea and phosphate in chronic renal disease in cats.

Phosphate-binding agents are usually only used if low phosphate diets are unsuccessful. Monitor serum phosphate levels at 4–6 week intervals and adjust dosage accordingly if trying to achieve target serum concentrations. Monitor for hypercalcaemia. As formulation contains lactose, use with care in diabetic and lactose-intolerant animals.

Safety and handling: Normal precautions should be observed.

Contraindications: None reported.

Adverse reactions: Hypercalcaemia, possibly due to the calcium carbonate component.

Drug interactions: Increased risk of hypercalcaemia with concurrent calcitriol administration.

DOSES
Dogs, Cats: Chronic kidney disease: 200 mg/kg p.o. q12h (mixed with food).

Chlorambucil
(Leukeran*) POM

Formulations: Oral: 2 mg tablet.

Action: Alkylating agent that inhibits DNA synthesis and function through cross-linking with cellular DNA. Cell cycle non-specific.

Use:
• Management of some malignancies including in some metronomic chemotherapy protocols.
• May be useful in the treatment of feline pemphigus foliaceus and severe feline eosinophilic granuloma complex.
• Management of lymphoproliferative, myeloproliferative and immune-mediated diseases including protein-losing enteropathy.
Safety and handling: Cytotoxic drug; see Appendix and specialist texts for further advice on chemotherapeutic agents. Tablets should be stored in a closed, light-protected container under refrigeration (2–8°C).

Contraindications: Bone marrow suppression, factors predisposing to infection.

Adverse reactions: Anorexia, nausea, vomiting, leucopenia, thrombocytopenia, anaemia (rarely), neurotoxicity (one case reported in a cat), alopecia (rarely) and slow regrowth of clipped hair coat. Chlorambucil was suspected to have caused seizures in one dog.

Drug interactions: Drugs that stimulate hepatic cytochrome P450 system increase cytotoxic effects. Prednisolone has a synergistic effect in the management of lymphoid neoplasia.

DOSES
See Appendix for chemotherapy protocols and conversion of body weight to body surface area.

Dogs: Give with food:

- Chronic lymphocytic leukaemia: 2–6 mg/m² p.o. q24h initially until remission achieved, then at reduced dosage/frequency as required to maintain remission; or 0.2 mg/kg q24h for 7 days then 0.1 mg/kg q24h for maintenance; or 20 mg/m² every 1–2 weeks. Often used with prednisolone 40 mg/m² p.o. q24h for 7 days then 20 mg/m² q48h.

- Lymphoma: 15–20 mg/m² p.o. q2wk with prednisolone; or 2–6 mg/m² q24–48h. 1.4 mg/kg p.o. as single dose as substitute for cyclophosphamide in CHOP-type protocols.

- Pemphigus complex (in combination with corticosteroids): 0.1–0.2 mg/kg p.o. q24h initially until marked improvement of clinical signs; then alternate-day dosing, often for several weeks.

- Protein-losing enteropathy and other immune-mediated diseases: 2–6 mg/m² p.o. q24h until clinical remission, then tapered to the minimum effective dose.

- For metronomic chemotherapy: 4 mg/m² p.o. q24h.

Cats: Give with food:

- Immune-mediated disease: cats >4 kg: 2 mg (total dose) p.o. q48h for 2–4 weeks, then tapered to lowest effective dose; cats <4 kg started at 2 mg (total dose) q72h.

- Chronic lymphocytic leukaemia: 2 mg/m² p.o. q48h or 20 mg/m² q14d, with or without prednisolone.

- For low grade/small cell lymphoma: 20 mg/m² p.o. once every two weeks with prednisolone.

- As a substitute for cyclophosphamide in the CHOP protocol: 1.4 mg/kg p.o. once.

- Feline pemphigus foliaceus or severe feline eosinophilic granuloma complex (in combination with corticosteroids): 0.1–0.2 mg/kg p.o. q24h until marked improvement of clinical signs; then alternate-day dosing, often for several weeks.
Chloramphenicol


Formulations: Injectable: 1 g powder for reconstitution. Topical: Ophthalmic 1% ointment; 0.5% solution. Oral: 250 mg capsules.

Action: Time-dependent antimicrobial that acts by binding to the 50S ribosomal subunit of susceptible bacteria, preventing bacterial protein synthesis.

Use: Broad spectrum of activity against Gram-positive (e.g. Streptococcus, Staphylococcus), Gram-negative (e.g. Brucella, Salmonella, Haemophilus) and obligate anaerobic bacteria (e.g. Clostridium, Bacteroides fragilis). Other sensitive organisms include Chlamydia, Mycoplasma (unreliable in treatment of ocular mycoplasmosis) and Rickettsia. Resistant organisms include Nocardia and Mycobacterium. Acquired resistance may occur in Enterobacteriaceae. High lipid solubility makes it suitable for the treatment of intraocular infections. It will also access the CNS. However, due to concerns of resistance development and human toxicity, systemic use should be restricted to life-threatening infections resistant to other antimicrobials (e.g. meticillin-resistant staphylococci). Patients with hepatic or renal dysfunction may need adjustment to the dose. Use with caution or avoid in nursing bitches or queens as crosses into milk.

Safety and handling: Humans exposed to chloramphenicol may have an increased risk of developing a fatal aplastic anaemia. Products should be handled with care; use impervious gloves and avoid skin contact.

Contraindications: No information available.

Adverse reactions: Reversible dose-related reversible bone marrow suppression can develop in all species. Unlike humans, the development of irreversible aplastic anaemia in veterinary species does not appear to be a significant problem. Owing to a reduced capacity to metabolize chloramphenicol, the cat is more susceptible to bone marrow suppression. Other adverse effects include nausea, vomiting, diarrhoea and anaphylaxis.

Drug interactions: Irreversible inhibition of hepatic cytochrome P450-dependent enzymes increases plasma levels of pentobarbital,

References
phenobarbitol, propofol and oral hypoglycaemic agents. Recovery requires synthesis of new liver enzymes and can take up to 3 weeks. Rifampin accelerates the metabolism of chloramphenicol, thus decreasing serum levels. Chloramphenicol may inhibit activity of aminoglycosides and beta-lactams. May also competitively inhibit macrolide or lincosamide antimicrobials.

DOSES
See Appendix for guidelines on responsible antibacterial use.

**Dogs:**
- **Ophthalmic:** 1 drop q4–8h; ointment q8–12h.
- **Systemic:** 40–50 mg/kg i.v., i.m., s.c., p.o. q8h.
- **CNS infections:** 10–15 mg/kg p.o. q4–6h is recommended in some texts.

**Cats:**
- **Ophthalmic:** 1 drop q4–8h; ointment q8–12h.
- **Systemic:** 10–20 mg/kg slow i.v., i.m., s.c., p.o. q12h.

**Chlorhexidine**
(Adaxio, Antisept, Clorexyderm shampoo, spray, gel, CLX wipes, Douxo Pyo, Ermidra foam, Hibiscrub, Iryplus eye wipes, Malaseb, Microbex, Otodine, Stomidine F, Corsodyl*, Savlon*, TrizChlor*) **POM-V, GSL, general sale**

**Formulations:**
- **Topical shampoo:** 2% chlorhexidine + 2% miconazole (Malaseb); 31.2 mg/ml chlorhexidine (Microbex); 11.26 mg/ml chlorhexidine + 17.37 mg/ml miconazole (Adaxio); 3% chlorhexidine + 0.5% clindamycin + phytosphingosine (Duoxo Pyo shampoo/mousse/pads); 4% chlorhexidine (Clorexyderm 4% shampoo, spray, Ermidra foam);
- **Cleansing solution:** sodium acetate, chlorhexidine digluconate, acetic acid (antisept spray);
- **Spot gel:** chlorhexidine 4%, Triz-EDTA, polyvinylpyrrolidone, lanolin, glycerine (clorexyderm spot gel); 1.5% chlorhexidine + cetrimide (Savlon);
- **Surgical scrub solution:** 4% chlorhexidine + isopropyl alcohol (Hibiscrub);
- **Mouthwash:** 0.12% chlorhexidine (Chlorohex);
- **Topical skin cleaner:** chlorhexidine, Triz-EDTA, zinc gluconate, glycerine, clindamycin, benzyl alcohol, propylene glycol (CLX wipes);
- **Ear/wound cleaner:** 0.15% chlorhexidine + EDTA (TrizChlor);
- **Ear cleaner:** chlorhexidine, Triz-EDTA, lactic acid (Otodine);
- **Toothpaste:** 0.07% chlorhexidine, Triz-EDTA (Stomidine F).

**Action:** Chemical antiseptic that disrupts bacterial cell membrane.

**Use:**
- Topical treatment of bacterial, dermatophyte and *Malassezia* skin infections in dogs as a shampoo (Adaxio, Douxo, Malaseb, Microbex). Concurrent systemic antibacterial therapy may be required when treating bacterial skin infections. Leave in contact with the skin for 5–10 minutes prior to washing off.
• Local infection can be treated with mousse spray, gel or wipes (Douxo, CLX, Antisept, Clorexyderm).
• Ear flush for cleansing; Tris-EDTA and chlorhexidine have synergistic antimicrobial action. Chlorhexidine as a single agent is not consistently effective as a treatment for dermatophytosis.
• Washing surgical instruments, routine antisepsis for surgical operations (Savlon, Hibiscrub) and dental hygiene (Corsodyl).

Safety and handling: Normal precautions should be observed.
Contraindications: Do not instil into ears where the integrity of the tympanum is unknown. Do not use on eyes.
Adverse reactions: Ototoxic. May irritate mucous membranes.
Drug interactions: Not known.

DOSES
Dogs, Cats: Antisptic: topical agents may be used daily to weekly.

References

**Chlorphenamine**
*(Chlorpheniramine)*
*(Piriton*)
*POM, GSL*

**Formulations:** Injectable: 10 mg/ml solution. Oral: 4 mg tablet, 0.4 mg/ml syrup.

**Action:** Binds to H1 histamine receptors to prevent histamine binding.

**Use:**
• Management of allergic disease.
• Prevention and early treatment of anaphylaxis.
• Commonly used as premedication before transfusions and certain chemotherapeutic agents.

Specific doses for dogs and cats have not been determined by pharmacokinetic studies. Use with caution in cases with urinary retention, angle-closure glaucoma and pyloroduodenal obstruction.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.

**Adverse reactions:** May cause mild sedation. May reduce seizure threshold.

**Drug interactions:** No information available.
DOSES

**Dogs:** Antihistamine: 4–8 mg/dog p.o. q8h; 2.5–10 mg/dog i.m. or slow i.v.

**Cats:** Antihistamine: 2–4 mg/cat p.o. q8–12h; 2–5 mg/cat i.m. or slow i.v.

---

**Chlortetraacycline hydrochloride**
(Ophtocycline) **POM-V**

**Formulations:** Topical: Ophthalmic ointment, 5 g tube.

**Action:** 1st generation time- and concentration-dependent antimicrobial that inhibits bacterial protein synthesis by binding to the 30S subunit of the bacterial ribosome.

**Use:**
- Treatment of feline chlamydial conjunctivitis (oral doxycycline is the treatment of choice).
- Treatment of mycoplasmal conjunctivitis and canine spontaneous chronic corneal epithelial defects (via an immunomodulatory mechanism).
- Chlortetracycline is authorized for treatment of keratitis, conjunctivitis and blepharitis caused by *Staphylococcus* spp., *Streptococcus* spp., *Proteus* spp. and/or *Pseudomonas* spp.

Tetracyclines have a broad spectrum including both aerobic and anaerobic Gram-positive and Gram-negative bacteria, mycoplasmas, rickettsiae and *Chlamydia* spp. *Pseudomonas* spp. and *Staphylococci* spp. may be resistant.

**Safety and handling:** Normal precautions should be observed; avoid direct skin contact.

**Adverse reactions:** Safety during pregnancy and lactation unknown.

**Adverse reactions:** None known.

**Drug interactions:** No information specified.

**DOSES**

**Dogs:** 0.5–2 cm of ointment to affected eye q6h for 5 days.

**Cats:** Doses as for dogs.

---

**References**


Kimmitt BA, Moore GE and Stiles (2018) Comparison of the efficacy of various concentrations and combinations of serum, ethylenediaminetetraacetic acid,

Cholestyramine see Colestyramine

Chorionic gonadotrophin (Human chorionic gonadotrophin, hCG) (Chorulon) POM-V

Formulations: Injectable: 1500 IU powder for reconstitution.

Action: Luteinizing hormone analog.

Use:
• Induction of ovulation in the queen especially later part of oestrus.
• In the bitch, although it is indicated for the treatment of delayed ovulation it does not appear to induce ovulation.
• In males, short-term stimulation of testosterone secretion is possible, although this may increase aggression without improving libido.

Safety and handling: Reconstituted vials do not contain any preservative and so should be discarded within 24 hours.

Contraindications: No information available.

Adverse reactions: Anaphylactic reactions may occasionally occur.

Drug interactions: No information available.

DOSES

Dogs:
• Delayed ovulation: 22 IU/kg i.m. q24–48h or 44 IU/kg i.m. once; mate on behavioural oestrus.
• Deficient male libido: 100–500 IU/dog i.m. twice weekly for up to 6 weeks.

Cats: Not authorized for use in cats. Doses as for dogs.

Ciclosporin (Cyclosporin(e)) (Atopica, Atopica Cat, Cyclavance, Modulis, Optimmune, Sporimmune) POM-V

Formulations: Ophthalmic: 0.2% ointment (Optimmune). Oral: 10 mg, 25 mg, 50 mg, 100 mg capsules; 100 mg/ml solution; 50 mg/ml solution (Sporimmune). Injectable: 50 mg/ml solution.
Action: T-lymphocyte inhibition.

Use:
- Topical ophthalmic preparation for immune-mediated keratoconjunctivitis sicca in dogs. May also be useful as an immunosuppressant in chronic superficial keratoconjunctivitis (pannus).
- Oral preparation licensed for atopic dermatitis in dogs and cats.
- Used for perianal fistula, sebaceous adenitis and immune-mediated disease.

It is recommended that bacterial and fungal infections are treated before use. While the nephrotoxicity seen in human patients does not appear to be common in dogs, care should be taken in treating dogs with renal impairment, and creatinine levels should be monitored regularly. In dogs with atopic dermatitis, ciclosporin may reduce circulating levels of insulin and cause an increase in blood glucose and fructosamine. In dogs with diabetes mellitus, the effect of treatment on glycaemia must be carefully monitored.

Safety and handling: Use gloves to prevent cutaneous absorption.

Contraindications: Systemic use is not recommended in dogs and cats up to 6 months old or in dogs <2 kg or in cats <2.3 kg. Do not use in progressive malignant disorders. Do not give live vaccines during treatment or within a 2-week interval before or after treatment. Ciclosporin may reduce the immune response to vaccines. The manufacturer does not recommend use in diabetic dogs or cats infected with FeLV, FIV.

Adverse reactions: Immediate discomfort on topical application (blepharospasm) has been reported in dogs. Transient vomiting and diarrhoea may follow systemic administration; these are usually mild and do not require cessation of treatment. Infrequently observed adverse effects include: anorexia; mild to moderate gingival hyperplasia; hypertrichosis; papillomatous lesions of the skin; red and swollen pinnae; muscle weakness; and muscle cramps. These effects resolve spontaneously after treatment is stopped. Systemic and topical treatment may be associated with an increased risk of malignancy. Cats that are seronegative for Toxoplasma gondii may be at risk of developing clinical toxoplasmosis if they become infected while undergoing treatment.

Drug interactions: The metabolism of ciclosporin is reduced, and thus serum levels increased, by various drugs that competitively inhibit or induce enzymes involved in its metabolism, particularly cytochrome P450, including diltiazem, doxycycline and imidazole antifungal drugs. Itraconazole and ketoconazole at 5–10 mg/kg are known to increase the blood concentration of ciclosporin in dogs up to five-fold, which is considered to be clinically relevant. During concomitant use of itraconazole and ciclosporin consider halving the dose or doubling the treatment interval if the dog is on daily treatment. In humans, there is
increased risk of nephrotoxicity if ciclosporin is administered with aminoglycosides, NSAIDs, quinolones, or trimethoprim/sulphonamides; concomitant use of ciclosporin not recommended. Increased risk of hyperkalaemia if used with ACE inhibitors. As a substrate and inhibitor of the MDR 1 P-glycoprotein transporter, co-administration of ciclosporin with P-glycoprotein substrates such as macrocyclic lactones (e.g. ivermectin and milbemycin) could decrease the efflux of such drugs from blood–brain barrier cells, potentially resulting in signs of CNS toxicity.

**DOSES**

*See Appendix for immunosuppression protocols.*

**Dogs:**
- **Ocular disease:** apply approximately 0.5 cm of ointment to the affected eye q12h. It may take 2–4 weeks for improvement to occur (occasionally up to 12 weeks). Maintenance treatment should be continued with application q12h; in cases of excessive tear production, application can be reduced to q24h but only with caution and long-term, regular monitoring of tear production.
- **Atopic dermatitis:** 5 mg/kg p.o. q24h until signs controlled.
- **Perianal fistula, sebaceous adenitis:** 5 mg/kg p.o. q24h – may be increased in non-responsive cases to q12h.
- **Immune-mediated disease:** 5 mg/kg p.o. q12h. A proportion of dogs may require higher doses and pharmacodynamic monitoring is therefore advisable.

**Cats:**
- **Atopic dermatitis:** 7 mg/kg p.o. q24h until signs controlled.
- **Immune-mediated disease:** dosing strategies are not well defined but typically 3–5 mg/kg p.o. q12h or 5–7 mg/kg p.o. q24h.

**References**


---

**Cimetidine**

*(Zitac, Cimetidine*, Tagamet*) **POM-V, POM**

**Formulations:** *Injectable:* 100 mg/ml solution in 2 ml ampoule.  
*Oral:* 100 mg, 200 mg tablets, 40 mg/ml syrup.

**Action:** Histamine (H2) receptor antagonist, reducing histamine-induced gastric acid secretion. Rapidly absorbed with high bioavailability; undergoes hepatic metabolism and renal excretion. Plasma half-life is about 2 hours. It is not an antiemetic. Has weak anti-androgenic effects.

**Use:**
- Management of idiopathic, uraemic or drug-related erosive gastritis, gastric and duodenal ulcers, oesophagitis, and
hypersecretory conditions secondary to gastrinoma, mast cell neoplasia or short bowel syndrome. Efficacy against NSAID-induced ulcers is controversial.

Rebound gastric acid secretion may be seen on cessation of cimetidine, so therapy should be tapered. Concomitant treatment with sucralfate may be helpful. If used i.v., should be administered over 30 minutes to prevent cardiac arrhythmias and hypotension. Dosage should be reduced for animals with renal impairment. Less effective at reducing gastric acidity than more modern H2 blockers and proton pump inhibitors. Cimetidine has minimal prokinetic effects.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.

**Adverse reactions:** Rare, although hepatotoxicity and nephrotoxicity have been reported in humans. Adverse reactions are generally minor even at high doses, but thrombocytopenia has been reported in dogs. Transient and self-resolving slight swelling of mammary glands may be observed in female dogs. In humans, cimetidine has also been associated with headache and decreased libido.

**Drug interactions:** Retards oxidative hepatic drug metabolism by binding to the microsomal cytochrome P450. May increase plasma levels of beta-blockers (e.g. propranolol), calcium-channel blockers (e.g. verapamil), diazepam, lidocaine, metronidazole, pethidine and theophylline. When used with other agents that cause leucopenia may exacerbate the problem. Sucralfate may decrease bioavailability: although there is little evidence to suggest this is of clinical importance, it may be a wise precaution to administer sucralfate at least 2 hours before cimetidine. Stagger oral doses by 2 hours when used with other antacids, digoxin, itraconazole or maropitant.

**DOSES**

**Dog:** All uses: 5 mg/kg p.o., i.v., i.m. q8h.

**Cats:** All uses: 2.5–5 mg/kg p.o., i.v., i.m. q12h.

**References**


---

**Cimicoxib**  
(Cimalgex) **POM-V**

**Formulations:** Oral: 8 mg, 30 mg, 80 mg chewable tablets.

**Action:** Selectively inhibits COX-2 enzyme, thereby limiting the production of prostaglandins involved in inflammation.
Use:
• For the treatment of pain and inflammation associated with osteoarthritis and the management of perioperative pain due to orthopaedic or soft tissue surgery in dogs.
For perioperative use, one dose 2 hours before surgery, followed by 3–7 days of treatment, is indicated. All NSAIDs should be administered cautiously in the perioperative period. Although cimicoxib preferentially inhibits COX-2, it may still adversely affect renal perfusion during periods of hypotension. If hypotension during anaesthesia is anticipated, delay cimicoxib administration until the animal is fully recovered from anaesthesia and normotensive. Liver disease will prolong the metabolism of cimicoxib, leading to the potential for drug accumulation and overdose with repeated dosing. For the relief of pain and inflammation associated with osteoarthritis, an initial treatment period of 6 months is indicated; this can be extended depending on clinical need for analgesic treatment.

Safety and handling: Normal precautions should be observed.

Contraindications: Do not give to dogs <10 weeks of age; the safety of cimicoxib has not been determined in dogs <6 months of age, therefore, monitor dogs in this age group carefully for signs of NSAID-related adverse effects. Do not give to dehydrated, hypovolaemic or hypotensive patients, or those with GI disease or blood clotting problems. Administration to patients with concurrent renal or hepatic disease may carry additional risk, careful monitoring of patients is required if cimicoxib is administered to these patient groups. Do not give to pregnant or lactating bitches. Do not administer concurrently or within 24 hours of other NSAIDs and glucocorticoids.

Adverse reactions: GI signs are commonly reported but most cases are mild and recover without treatment. Stop therapy if signs persist beyond 1–2 days. Some animals develop signs with one NSAID and not another. A 3–5 day wash-out period should be allowed before starting therapy with another NSAID. Stop therapy immediately if GI bleeding is suspected. There is a small risk that NSAIDs may precipitate cardiac failure in humans and this risk in animals is unknown.

Drug interactions: No information available.

DOSES
Dogs: 2 mg/kg p.o. q24h administered with or without food.
Cats: Not authorized for cats.

Cinchophen
(PLT tablets) POM-V

Formulations: Oral: 200 mg tablets in combination with prednisolone 1 mg.

Action: Anti-inflammatory agent via non-steroidal action.
Use:
• Management of osteoarthritis pain in dogs.

Animals should be monitored for signs of GI ulceration and deterioration in liver function. At the end of treatment, the dose should be reduced gradually as with any glucocorticoid.

Safety and handling: Normal precautions should be observed.

Contraindications: Only commercially available in tablets combined with prednisolone, therefore do not administer to animals that are receiving therapy with other steroids or with NSAIDs. Do not give in perioperative period or to animals that are shocked, hypotensive or have renal insufficiency. Do not give to animals with hepatic disease or with pre-existing GI ulceration. Do not use in cats.

Adverse reactions: GI ulceration and irritation are common side effects of all NSAIDs and particularly so with cinchophen. Advisable to stop therapy if diarrhoea or nausea persists beyond 1–2 days. Stop therapy immediately if GI bleeding suspected and begin symptomatic treatment. There is a small risk that NSAIDs may precipitate cardiac failure in animals with cardiovascular disease. Cinchophen has been associated with liver damage in dogs after prolonged oral administration (6 weeks).

Drug interactions: Increased risk of GI ulceration if administered concurrently or within 24 hours of other NSAIDs and glucocorticoids. Increased risk of nephrotoxicity if administered with other potentially nephrotoxic agents, e.g. aminoglycosides.

DOSES
Dogs: 12.5 mg/kg cinchophen/0.0625 mg/kg prednisolone p.o. q12h. This equates to 1 tablet twice daily for a 16 kg body weight dog.
Cats: Do not use.

Ciprofloxacin
(Ciloxan*) POM

Formulations: Ophthalmic: 0.3% solution in 5 ml bottle.

Action: Concentration-dependent inhibition of bacterial DNA gyrase.

Use: Ideally fluoroquinolone use should be reserved for infections where culture and sensitivity testing predicts a clinical response and where first- and second-line antimicrobials would not be effective. Broad-spectrum activity against wide range of Gram-negative and some Gram-positive aerobes; some activity against Mycoplasma and Chlamydia. Active against many ocular pathogens, including Staphylococcus and Pseudomonas aeruginosa, although there is increasing resistance among staphylococci and streptococci.

Safety and handling: Normal precautions should be observed.

Contraindications: No information available.
Adverse reactions: May cause local irritation after application. In humans the following are reported: local burning and itching; lid margin crusting; hyperaemia; taste disturbances; corneal staining, keratitis, lid oedema, lacrimation, photophobia, corneal infiltrates; nausea; and visual disturbances.

Drug interactions: No information available.

DOSES
See Appendix for guidelines on responsible antibacterial use.

Dogs, Cats: 1 drop to affected eye q6h; intensive therapy q30–120mins for short-term use (1–2 days).

Cisapride
(Cisapride) POM

Formulations: 2.5 mg, 5 mg tablets. Must be obtained from a compounding pharmacy.

Action: GI prokinetic action by acting on 5-HT4 receptors on enteric cholinergic neurons, inducing depolarization and contraction of gastrointestinal smooth muscle.

Use:
- Potentially useful in cases where there is reduced gastric motility, where obstruction has been ruled out.
- May be part of the management of constipation and megacolon in cats that are mildly or moderately affected.
- Has been shown to increase lower oesophageal sphincter pressure in dogs so may be of benefit in canine patients for which this is desirable. Cisapride also decreased the frequency of gastro-oesophageal reflux in anesthetized dogs.

No evidence that cisapride is effective in the treatment of megaoesophagus in dogs; canine oesophagus primarily striated muscle with little smooth muscle to respond to cisapride.

Safety and handling: Because of the potential for side effects in humans, gloves should be worn when handling this drug and particular care taken to avoid accidental ingestion.

Contraindications: Do not use in cases of suspected gastrointestinal obstruction or perforation.

Adverse reactions: Vomiting, diarrhoea, abdominal pain. In human medicine, the drug was removed from the market because it was shown to cause QT prolongation and increase the risk of serious cardiac arrhythmias. This has not been reported in dogs or cats.

Drug interactions: Effects on motility could affect the absorption of other oral drugs so caution should be used when using drugs with a narrow therapeutic index. Metabolized by cytochrome P450 enzymes so use with caution if used with other drugs metabolized by these enzymes (e.g. ketoconazole, itraconazole, cimetidine,
amiodarone, chloramphenicol). Drugs such as amiodarone, procainamide, sotalol, and tricyclic antidepressants (e.g. amitriptyline) may increase the QT interval and this risk may be increased by concurrent use of cisapride. Use with caution in animals with hepatic or renal dysfunction; may require reduced dosing due to decreased metabolism or clearance.

DOSES

**Dogs:** All uses: 0.1–0.5 mg/kg p.o. q8–12h; some recommend giving 30 minutes before feeding. Some sources state that gradually increasing doses up to 1 mg/kg p.o. q8h may be required (if tolerated).

**Cats:** All uses: Various doses have been suggested including 2.5–5.0 mg per cat p.o. 2–3 times daily and 0.5 mg/kg 2–3 times daily. Dosages may be titrated upwards, if tolerated, to as high as 7.5 mg per cat p.o. 3 times daily in large cats.

References


**Cisatracurium** *(Nimbex*) **POM**

**Formulations:** Injectable: 2 mg/ml, 10 mg/ml solutions.

**Action:** Inhibits actions of acetylcholine at neuromuscular junction by binding competitively to the nicotinic acetylcholine receptor on the post-junctional membrane.

**Use:**

- Provision of neuromuscular blockade during anaesthesia.
- To improve surgical access through muscle relaxation, to facilitate positive pressure ventilation or for intraocular surgery.

Cisatracurium is one of the isomers that comprise atracurium; it is 3–5 times more potent than atracurium in dogs. This means that the plasma concentration of the epileptogenic by-product laudanosine is lower and there is less histamine release. Monitoring (using a nerve stimulator) and reversal of the neuromuscular blockade is recommended to ensure complete recovery before the end of anaesthesia. Hypothermia, acidosis and hypokalaemia will prolong the duration of action of neuromuscular blockade. There are no published clinical studies describing the use of cisatracurium in cats; limited experimental studies suggest that cisatracurium has similar characteristics in cats to those described for dogs.

**Safety and handling:** Store in refrigerator.
**Contraindications:** Do not administer unless the animal is adequately anaesthetized and facilities to provide positive pressure ventilation are available.

**Adverse reactions:** Can precipitate the release of histamine after rapid i.v. administration, resulting in bronchospasm and hypotension. Diluting the drug in normal saline and giving the drug slowly i.v. minimizes these effects.

**Drug interactions:** Neuromuscular blockade is more prolonged when given in combination with volatile anaesthetics, aminoglycosides, clindamycin and lincomycin.

**DOSES**

**Dogs:** 0.05–0.1 mg/kg i.v. followed by additional doses of 0.03 mg/kg as required (based on monitoring of neuromuscular blockade).

**Cats:** No information available.

**References**

Adams WA, Senior JM, Jones RS et al. (2006) cis-Atracurium in dogs with and without porto-systemic shunts. *Veterinary Anaesthesia and Analgesia* 33, 17–23

---

**Clarithromycin**

(Klaricid*) POM

**Formulations:** Oral: 250 mg, 500 mg tablets; 125 mg/5 ml suspension; 250 mg/5 ml suspension; 250 mg granules sachet (to be dissolved in water). Injectable: 500 mg vial for reconstitution.

**Action:** Derived from erythromycin and with greater activity. Time-dependent macrolide antibacterial that binds to the 50S ribosome, inhibiting peptide bond and therefore protein formation.

**Use:** Alternative to penicillin in penicillin-allergic humans as it has a similar, although not identical, antibacterial spectrum. Active against Gram-positive cocci (some *Staphylococcus* spp. resistant), Gram-positive bacilli, some Gram-negative bacilli (e.g. *Pasteurella*) and some spirochaetes (e.g. *Helicobacter*). Some strains of *Actinomyces, Nocardia, Chlamydia* and *Rickettsia* also inhibited. Most strains of *Enterobacteriaceae* (*Pseudomonas, Escherichia coli, Klebsiella*) are resistant. Highly lipid-soluble and useful against intracellular pathogens. Particularly useful in management of respiratory tract infections, mild to moderate skin and soft tissue infections, and non-tubercular mycobacterial infections. For the latter, used in combination with enrofloxacin and rifampin. Activity is enhanced in an alkaline pH; administer on an empty stomach. There is limited information regarding use in animals. Use with caution in animals with hepatic dysfunction. Reduce dose in animals with renal impairment.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.
Adverse reactions: In humans, similar adverse effects to those of erythromycin are seen, i.e. vomiting, cholestatic hepatitis, stomatitis and glossitis.

Drug interactions: May increase serum levels of several drugs, including methylprednisolone, theophylline, omeprazole and itraconazole. The absorption of digoxin may be enhanced.

DOSES
See Appendix for guidelines on responsible antibacterial use.

Dogs: 4–12 mg/kg i.v. infusion, p.o. q12h. Doses of 15–25 mg/kg p.o. total daily dose divided q8–12h are recommended in the treatment of lepromid granuloma syndrome combined with rifampin 10–15 mg/kg p.o. q24h. These doses are empirical and are based on only a few reports.

Cats: 5–10 mg/kg i.v. infusion, p.o. q12h or 62.5 mg/cat p.o. These doses are empirical and are based on only a few reports. A variety of combination protocols have been used in the treatment of feline leprosy syndrome, e.g. combination of clarithromycin with a fluoroquinolone and either rifampin or clofazamine.

Clemastine (Meclastin) (Tavegil*) GSL

Formulations: Oral: 1 mg tablet.

Action: Binds to H1 histamine receptors and prevents histamine from binding.

Use:
• Management of allergic disease.

Specific doses for cats have not been determined by pharmokinetic studies and in dogs therapeutic levels are not usually achieved by oral administration. Use with caution in cases with urinary retention, angle-closure glaucoma and pyloroduodenal obstruction.

Safety and handling: Normal precautions should be observed.

Contraindications: No information available.

Adverse reactions: May cause sedation or hyperexcitability in high doses. May reduce seizure threshold.

Drug interactions: No information available.

DOSES

Dogs: 0.05–0.1 mg/kg p.o. q12h.

Cats: 0.1 mg/kg p.o. q12h.
Climbazole
(CLX wipes, Douxo Pyo) general sale

Formulations: Topical 3% chlorhexidine + 0.5% climbazole + phytosphingosine (Douxo Pyo shampoo/mousse/pads); chlorhexidine, Tris-EDTA, zinc gluconate, glycerine, climbazole, benzyl alcohol, propylene glycol (CLX wipes).

Action: Inhibits cytochrome P450-dependent synthesis of ergosterol in fungal cells causing increased cell wall permeability and allowing leakage of cellular contents.

Use: Topical treatment of dermatophyte and Malassezia skin infections. Additional systemic antifungal treatment may be required in generalized cases. For shampoo formulations 5–10 minutes contact time is required.

Safety and handling: Normal precautions should be observed.

Contraindications: None known.

Adverse reactions: None known.

Drug interactions: No information available.

DOSES
Dogs, Cats: May be applied daily–weekly.

References

Clindamycin
( Antirobe, Clinacin, Clindacyl, Clindaseptin, Mycinor, Zodon) POM-V

Formulations: Oral: 25 mg, 75 mg, 88 mg, 150 mg, 264mg, 300 mg capsules and tablets; 25 mg/ml solution.

Action: Time-dependent lincosamide antibiotic that binds to the 50S ribosomal subunit, inhibiting peptide bond formation.

Use: Bone and joint infections associated with Gram-positive bacteria; pyoderma; toxoplasmosis; and infections associated with the oral cavity. It is also recommended as part of the treatment for sepsis/bacteraemia and hospital-acquired pneumonia. Active against Gram-positive cocci (including penicillin-resistant staphylococci), many obligate anaerobes, mycoplasmas and protozoal infections (Neospora caninum, Toxoplasma gondii). Attains high concentrations in bone and bile. Being a weak base, it becomes ion-trapped (and therefore concentrated) in fluids that are more acidic than plasma, such as prostatic fluid, milk and intracellular fluid. There is complete cross-resistance between lincomycin and...
clindamycin, and partial cross-resistance with erythromycin. Use with care in individuals with hepatic or renal impairment.

**Safety and handling**: Normal precautions should be observed.

**Contraindications**: No information available.

**Adverse reactions**: Colitis, vomiting and diarrhoea are reported. Although not a major problem in dogs and cats, discontinue drug if diarrhoea develops. In cats may be associated with oesophagitis and oesophageal stricture; therefore, consider following solid dosage forms such as tablet administration with a small water or food bolus.

**Drug interactions**: May enhance the effect of non-depolarizing muscle relaxants, (e.g. tubocurarine) and may antagonize the effects of neostigmine and pyridostigmine. Do not administer with macrolide, chloramphenicol or other lincosamide antimicrobials as these combinations are antagonistic.

**DOSES**

See Appendix for guidelines on responsible antibacterial use.

**Dogs**:
- 5.5 mg/kg p.o. q12h or 11 mg/kg q24h; in severe infection can increase to 11 mg/kg q12h.
- **Toxoplasmosis/neosporosis**: 25 mg/kg p.o. daily in divided doses.

**Cats**:
- 5.5 mg/kg p.o. q12h or 11 mg/kg q24h.
- **Toxoplasmosis**: 25 mg/kg p.o. daily in divided doses; increased doses of 30–50 mg/kg p.o. daily have been recommended for CNS involvement.

**References**


**Clofazimine**

(Clofazimine*) **POM**

**Formulations**: Oral: 100 mg capsule.

**Action**: Not entirely clear but appears to be antimycobacterial and has membrane disrupting properties.

**Use**: Mycobacterial infections including feline leprosy. Limited information available with most derived from human medicine. For feline mycobacterial infection long-term treatment is required and combination therapy is utilized, e.g. with clarithromycin and doxycycline or fluoroquinolones. Monitor hepatic and renal function during treatment. Use with caution in hepatic and renal impairment.

**Safety and handling**: Normal precautions should be observed.
Contraindications: No information available.

Adverse reactions: In humans the major adverse effects are nausea, diarrhoea, discoloration of skin, eyes and body fluids and renal and hepatic impairment (monitor functions during therapy). Photosensitization can also occur and treated animals should be housed indoors.

Drug interactions: No information available.

DOSES
See Appendix for guidelines on responsible antibacterial use.

Dogs, Cats: 4–8 mg/kg p.o. q24h for 2–6 months. For the management of mycobacterial infections, the drug is generally used in combination therapy with other antimicrobials including fluoroquinolones and clarithromycin. Refer to specialist texts.

Clomipramine (Clomicalm) POM-V

Formulations: Oral: 5 mg, 20 mg, 80 mg tablets.

Action: Both clomipramine and its primary metabolite desmethylclomipramine are active in blocking serotonin and noradrenaline reuptake in the brain, with resultant anxiolytic, antidepressant and anticomulsive effects.

Use:
- Licensed for use in association with a behaviour modification plan for the management of separation-related disorders in dogs.
- Also used in management of a wider range of anxiety-related disorders in dogs and cats, including compulsive behaviours, noise fears and urine spraying.
- Has been reported in the treatment of cataplexy in the dog, with resolution of signs after 3-months treatment.

Care required before use in animals with a history of constipation, epilepsy, glaucoma, urinary retention or arrhythmias. Can be used with benzodiazepines.

Safety and handling: Normal precautions should be observed.

Contraindications: Patients sensitive to tricyclic or serotonin reuptake inhibitor antidepressants. Do not give with, or within 2 weeks of, monoamine oxidase inhibitors (e.g. selegiline). Not recommended for use in male breeding animals, as testicular hypoplasia may occur.

Adverse reactions: May cause sporadic vomiting, changes in appetite or lethargy. Vomiting may be reduced by co-administration with a small quantity of food. May cause urinary retention in cats. The safety margin is quite low with toxic side effects observed at 2–3 mg/kg, although fatal does is >10 times the recommended dose.
Drug interactions: May potentiate the effects of anticholinergic agents (e.g. atropine), other CNS active drugs (e.g. barbiturates, benzodiazepines, general anaesthetics, neuroleptics), sympathimimetics (e.g. adrenaline) and coumarin derivatives. Simultaneous administration with cimetidine may lead to increased plasma levels of clomipramine. Plasma levels of certain antiepileptic drugs, e.g. phenytoin and carbamazepine, may be increased by co-administration with clomipramine. Should not generally be used alongside other serotonergic agents given risk of serotonin syndrome, although use alongside trazodone may be considered in exceptional cases, so long as patient carefully monitored for signs of serotonin syndrome.

DOSES
Dogs: 1–2 mg/kg p.o. q12h.
Cats: 0.25–1 mg/kg p.o. q24h.

References

Clonazepam
(Klonopin*, Linotril*, Rivotril* and several others)

POM

Formulations: Oral: 500 mcg, 0.25 mg, 0.5 mg, 1.0 mg, 2 mg tablets. 500 mcg/5 ml, 2 mg/5 ml oral solution.

Action: Long-acting benzodiazepine with anticonvulsant, muscle relaxant and anxiolytic properties. Enhances activity of gamma-aminobutyric acid (GABA), through binding at the benzodiazepine site of the GABA_A receptor. In addition, affects glutamate decarboxylase activity.

Use:
- Management of muscular hypertonicity (episodic falling) in the Cavalier King Charles Spaniel.
- Anxiolytic for behaviour modification in both cats and dogs and for hyperaesthesia in cats.
- It has been used to treat epilepsy in cats but more suitable medications are available, including phenobarbital, imepitoin (although to date there have been no publications on its efficacy in cats), levetiracetam and diazepam.

Tolerance may develop following prolonged therapy, with reduction in clinical effect. Care is required when withdrawing clonazepam after prolonged therapy and the dose should be tapered off.

Safety and handling: Normal precautions should be observed.
**Contraindications:** Avoid use in patients with marked CNS depression, respiratory depression, severe muscle weakness or hepatic impairment (may worsen hepatic encephalopathy). Also contraindicated in patients with acute narrow angle glaucoma.

**Adverse reactions:** Generally mild; sedation and respiratory suppression at higher doses are the most important. In cats, potential adverse effects include acute hepatic necrosis, sedation and ataxia.

**Drug interactions:** Drugs that result in hepatic enzyme induction, e.g. phenobarbital and phenytoin, may accelerate metabolism of clonazepam. Antifungal imidazoles may increase clonazepam levels.

**DOSES**

**Dogs:** 0.5 mg/kg p.o. q8–12h (suggested starting dose but there is a wide range of recommendations).

**Cats:** 0.5 mg/cat p.o. q12–24h (suggested starting dose but there is a wide range of recommendations).

**References**


---

**Clonidine**

(Catapres®) **POM**

**Formulations:** Injectable: 150 μg/ml solution. Oral: 25 μg tablets.

**Action:** Stimulates the secretion of growth hormone releasing hormone (GHRH) from the hypothalamus.

**Use:**

- Diagnostic test used in patients suspected of pituitary dwarfism (hyposomatotropism) to assess the pituitary’s ability to produce growth hormone (GH). Specialist texts should be consulted if attempting a clonidine stimulation test. Assessment of plasma insulin-like growth factor-1 (IGF-1) concentration in a single sample is a useful screening test for growth hormone disorders.
- Used in dogs to control panic-like responses and fear-based behavioural problems. Effect develops in about 30 minutes and lasts for 3–4 hours, so often needs to be used tactically (prn). Can be used over longer term but may take 1–2 weeks to see full response. Withdrawal must be done gradually to avoid hypertension.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Use very cautiously in animals with renal or cardiovascular disease.

**Adverse reactions:** Transient sedation and bradycardia may develop.
Drug interactions: Care should be exercised when using with drugs that also lower blood pressure or heart rate. Should not be used concurrently with barbiturates, opiates or hypotensive agents, (e.g. beta-blockers).

DOSES

Dogs:
- Growth hormone stimulation: 3–10 μg (micrograms)/kg i.v. once.
- Behavioural modification: 0.01–0.05 mg/kg as needed up to q12h (often with food).

Cats: No information available.

References

Clopidogrel (Clopidogrel*, Plavix*) POM

Formulations: Oral: 75 mg tablets. Special reformulations: 18.75 mg tablet.

Action: Clopidogrel irreversibly binds to the ADP(2Y12) receptor on platelets, preventing both primary and secondary platelet aggregation in response to stimuli.

Use:
- Thromboprophylaxis in cats and dogs.

Commonly used to reduce the risk of thrombus formation in cats with advanced cardiac disease, to reduce the risk of thromboembolism in cats with a pre-existing thrombus, or recurrence of embolism in cats with a previous arterial thromboembolic event. Recent evidence (FATCAT study) suggests clopidogrel is superior compared with aspirin in delay of feline recurrent thromboembolic events secondary to cardiac disease. May be used in conjunction with aspirin (as the drugs act on different parts of the platelet activation cycle). May be substituted for aspirin if aspirin is not tolerated. Use with care in patients with renal or hepatic impairment.

Safety and handling: Normal precautions should be observed.

Contraindications: Bleeding disorders, GI ulceration.

Adverse reactions: Tablet formulations for humans are film-coated, which needs to be broken for appropriate dosing in cats. Many cats dislike the taste of the tablets when the film-coating is broken so it is recommended that the tablet be administered in a gelatin capsule to improve patient compliance. Taste of newer resized formulations anecdotally still not tolerated. In humans, skin reactions have been reported. Overdoses will be expected to lead to bleeding disorders.
Drug interactions: High risk of bleeding complications if used with anticoagulants.

DOSES

**Dogs:** 1.1–4 mg/kg p.o. q24h. A single loading dose of 4–10 mg/kg p.o. may help achieve therapeutic concentrations more rapidly.

**Cats:** 18.75 mg/cat p.o. q24h. A single loading dose of 4–10 mg/kg p.o. may help achieve therapeutic concentrations more rapidly.

References


Hogan DF, Fox PR, Jacob K et al. (2015) Secondary prevention of cardiogenic arterial thromboembolism in the cat: The double-blind, randomized, positive-controlled feline arterial thromboembolism; clopidogrel versus aspirin trial (FATCAT). *Journal of Veterinary Cardiology* 17(S1), 306–317

---

**Clotrimazole**

(Canesten*, Clotrimazole*, Lotriderm*) POM

Formulations: Topical: 1% cream; 1% solution. Many other products available; some contain corticosteroids.

Action: Topical imidazole with an inhibitory action on the growth of pathogenic dermatophytes, *Aspergillus* and yeasts by inhibiting cytochrome P450-dependent ergosterol synthesis.

Use:

- Superficial fungal infections.
- Naso-sinal infections including aspergillosis. Although evidence of additional benefit from clotrimazole administration is limited.

Safety and handling: Normal precautions should be observed.

Contraindications: No information available.

Adverse reactions: No information available.

Drug interactions: No information available.

DOSES

**Dogs, Cats:**

- **Otic:** instil 3–5 drops in ear q12h.
- **Topical:** apply to affected area and massage in gently q12h; if no improvement in 4 weeks re-evaluate therapy or diagnosis.
- **Nasal:** instil 10 g (dogs up to 10 kg) or 20 g (dogs >10 kg) of 1% cream in each frontal sinus via trephine holes. Do not use this route if cribiform plate not intact.
**Cloxacillin**  
(Opticlox, Orbenin) **POM-V**

**Formulations:** Ophthalmic: Cloxacillin benzathine ester 16.7% suspension.

**Action:** Beta-lactamase-resistant penicillin which works in a time-dependent fashion. Binds to penicillin-binding proteins involved in cell wall synthesis, thereby decreasing bacterial cell wall strength and rigidity, and affecting cell division, growth and septum formation.

**Use:** Narrow-spectrum antimicrobial. Less active than penicillin G or V against *Streptococcus*. Specifically indicated for ocular infections with beta-lactamase-producing *Staphylococcus*.

**Safety and handling:** May cause a reaction in penicillin-sensitive individuals. Normal precautions should be observed.

**Contraindications:** No information available.

**Adverse reactions:** No information available.

**Drug interactions:** No information available.

**DOSES**  
See Appendix for guidelines on responsible antibacterial use.

**Dogs, Cats:** Apply 1/10 of a tube (0.3 g) q24h.

---

**Co-amoxiclav (Amoxicillin/Clavulanate, Amoxycillin/Clavulanic acid)**  
(Clavabactin, Clavaseptin, Clavucill, Clavudale, Combimox, Kesium, Nisinject, Noroclav, Synuclav, Synulox, Twinox, Augmentin*) **POM-V, POM**

**Formulations:** Injectable: 175 mg/ml suspension (140 mg amoxicillin, 35 mg clavulanate); 600 mg powder (500 mg amoxicillin, 100 mg clavulanate); 1.2 g powder (1 g amoxicillin, 200 mg clavulanate) for reconstitution (Augmentin). Oral: 40/10 mg, 50/12.5 mg, 200/50 mg, 250/62.5 mg, 400/100 mg, 500/125 mg tablets each containing amoxicillin and clavulanate in a ratio of 4:1. Palatable drops which when reconstituted with water provide 40 mg amoxicillin and 10 mg clavulanic acid per ml. Note variation in labelling of products. The preparation size may be labelled in relation to amoxicillin quantity only or the combined amoxicillin/clavulanic acid quantity.

**Action:** Amoxicillin binds to penicillin-binding proteins involved in bacterial cell wall synthesis, thereby decreasing cell wall strength and rigidity, affecting cell division, growth and septum formation. The addition of the beta-lactamase inhibitor clavulanate increases
the antimicrobial spectrum against those organisms that produce beta-lactamase, such as *Staphylococcus* and *Escherichia coli*. Time-dependent action.

**Use**: Active against Gram-positive and Gram-negative aerobic organisms and many obligate anaerobes. Beta-lactamase-producing *Escherichia coli* and *Staphylococcus* are susceptible, but difficult Gram-negative organisms such as *Pseudomonas aeruginosa* and *Klebsiella* are often resistant. Dose and dosing interval will be determined by infection site, severity and organism. May be an appropriate choice for surgical prophylaxis, please refer to separate surgical prophylaxis guidelines but also see the adverse reactions comment below.

**Safety and handling**: Tablets are wrapped in foil moisture-resistant packaging; do not remove until to be administered. Refrigerate oral suspension after reconstitution and discard after 10 days. The i.v. solution should be used immediately after reconstitution.

**Contraindications**: Avoid oral antibiotic agents in critically ill patients, as absorption from the GI tract may be unreliable; such patients may require i.v. formulation. Avoid use in animals which have displayed hypersensitivity reactions to other antimicrobials within the beta-lactam family (which includes cephalosporins).

**Adverse reactions**: Nausea, diarrhoea and skin rashes are the commonest adverse effects. There are reports of adverse reactions associated with the soluble intravenous preparations, particularly under general anaesthesia during use as surgical prophylaxis. This has included signs of allergic oedema, allergic pruritis, development of urticaria and hypotension. Some centres have opted to use alternative preparations such as the 2nd generation cephalosporin cefuroxime, and this may be associated with fewer adverse reactions.

**Drug interactions**: Avoid the concurrent use of amoxicillin with bacteriostatic antibiotics (e.g. tetracycline, erythromycin). Do not mix in the same syringe as aminoglycosides. Synergism may occur between the beta-lactam and aminoglycoside antimicrobials *in vivo*.

**DOSES**

See Appendix for guidelines on responsible antibacterial use.

**Dogs, Cats**:

- **Parenteral**:
  - 8.75–25 mg/kg (combined) i.v. q8h, i.m, s.c q24h (some susceptible infections require doses higher than the authorized dose or increased administration frequency, doses up to 25 mg/kg i.v. q8h are used to treat serious infections in humans).
  - For surgical prophylaxis: 22–25 mg/kg i.v. 30 min prior to surgery and then repeated q1.5–2h during surgery.
- **Oral**: 12.5–25 mg/kg (combined) p.o. q8–12h.

**References**
**Codeine**  
(Pardale-V, Codeine*) **POM-V, POM**

**Formulations:** Oral: 3 mg/5 ml paediatric linctus; 3 mg/ml linctus; 5 mg/ml syrup; 15 mg, 30 mg, 60 mg tablets.

**Action:** Opioid analgesic.

**Use:**
- Cough suppression.
- Analgesia.
- Treatment of diarrhoea.

Pardale-V is a veterinary formulation with 400 mg paracetamol + 9 mg codeine. However, to deliver the dose of codeine listed below would result in a very high dose of paracetamol and therefore Pardale-V tablets cannot be recommended as a source of codeine for general usage.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Renal insufficiency, hypoadrenocorticism, increased intracranial pressure, hypothyroidism. Care with severe respiratory compromise. Never administer Pardale-V to cats.

**Adverse reactions:** Sedation, ataxia, respiratory depression and constipation. May cause CNS stimulation in cats.

**Drug interactions:** No information available.

**DOSES**

**Dogs:**
- Antitussive: 1–2 mg/kg p.o. q6–12h. Do not use Pardale-V for codeine at this dose rate.
- Analgesia: 1–2 mg/kg p.o. q6–12h. Do not use Pardale-V for codeine at this dose rate.

**Cats:** Analgesia: 0.5–2 mg/kg p.o. q6–8h. Do not use formulation with paracetamol.

**References**

**Colchicine**  
(Colchicine*) **POM**

**Formulations:** Oral: 0.5 mg tablets.

**Action:** Colchicine inhibits collagen synthesis, may enhance collagenase activity and blocks the synthesis and secretion of serum amyloid A.

**Use:**
- Management of fibrosis in liver diseases, and renal amyloidosis (including that caused by ‘Shar pei fever’). Prophylactic use in Shar pei fever cannot be recommended at this time.
• Reported to reduce granulation tissue formation after endotracheal stent placement.

Only very limited and anecdotal evidence for its efficacy as an antifibrotic in dogs. No evidence for its efficacy as an antifibrotic in cats. No data to suggest it is beneficial in management of chronic hepatitis. Due to the relatively high incidence of adverse reactions, this drug should be used with caution.

**Safety and handling:** Protect from light.

**Contraindications:** Pregnancy, severe renal impairment.

**Adverse reactions:** Adverse effects include vomiting, abdominal pain and diarrhoea. Rarely, renal damage, bone marrow suppression, myopathy and peripheral neuropathy may develop. Colchicine may increase serum ALP, decrease platelet counts and cause false-positive results when testing urine for RBCs and haemoglobin. Overdoses can be fatal.

**Drug interactions:** Possible increased risk of nephrotoxicity and myotoxicity when colchicine given with ciclosporin. NSAIDs, especially phenylbutazone, may increase the risks of thrombocytopenia, leucopenia or bone marrow depression when used concurrently with colchicine. Many anticancer chemotherapeutics may cause additive myelosuppressive effects when used with colchicine.

**DOSES**

**Dogs:** Initial dose 0.01 mg/kg p.o. q24h and, if no adverse GI effects, increase in incremental amounts every 3–4 days to a maximum dose of 0.03 mg/kg p.o. q12h.

**Cats:** Not recommended.

---

**Colestyramine (Cholestyramine)**

*(Questran*) **POM**

**Formulations:** Oral: 4 g powder/sachet.

**Action:** Ion-exchange resin.

**Use:**

- In dogs for the reduction of serum cholesterol in idiopathic hypercholesterolaemia.
- Bile acid sequestration (may help alleviate diarrhoea in cases of fat malabsorption).
- May be used in digoxin overdose in dogs.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.

**Adverse reactions:** Constipation may develop. May cause taurine depletion in cats.
Drug interactions: Colestyramine reduces the absorption of digoxin, anticoagulants, diuretics and thyroxine.

DOSES

Dogs:
- Hyperlipidaemia: 1–2 g/dog p.o. q12h.
- Bile acid sequestration: 1–2 g/dog p.o. q12h.

Cats: Anecdotally: 0.5 g/cat p.o q24h titrated upwards to effect.

Crisantaspase see Asparaginase

Cyclophosphamide (Cyclophosphamide*, Endoxana*) POM

Formulations: Injectable: 100 mg, 200 mg, 500 mg, 1000 mg powder for reconstitution. Oral: 50 mg tablets.

Action: Metabolites cross-link DNA resulting in inhibition of DNA synthesis and function.

Use:
- Treatment of lymphoproliferative diseases and myeloproliferative disease.
- May have a role in management of certain sarcomas and carcinomas when included in metronomic chemotherapy protocols.

Use with caution in patients with renal failure; dose reduction may be required. The use of cyclophosphamide is no longer recommended as an immunosuppressant drug.

Safety and handling: Cytotoxic drug; see Appendix and specialist texts for further advice on chemotherapeutic agents.

Contraindications: No information available.

Adverse reactions: Myelosuppression, with the nadir usually occurring 5–14 days after the start of therapy; regular monitoring of WBCs recommended. A metabolite of cyclophosphamide (acrolein) may cause a sterile haemorrhagic cystitis. The cystitis may be persistent and may lead to bladder fibrosis and/or transitional cell carcinoma. This risk may be reduced by increasing water consumption and by giving furosemide to ensure adequate urine production. Other effects include vomiting, diarrhoea, hepatotoxicity, nephrotoxicity, pulmonary infiltrates and fibrosis, and a reduction in hair growth rate.

Drug interactions: Increased risk of myelosuppression if thiazide diuretics given concomitantly. Absorption of orally administered digoxin may be decreased, may occur several days after dosing. Barbiturates increase cyclophosphamide toxicity due to increased rate of conversion to metabolites. Phenothiazines, ondansetron
and chloramphenicol reduce cyclophosphamide efficacy. If administered with doxorubicin there is an increased risk of cardiotoxicity. Insulin requirements are altered by concurrent cyclophosphamide.

**DOSES**

*See Appendix for chemotherapy protocols and conversion of body weight to body surface area.*

**Dogs:**
- **Lymphoid neoplasia:** generally 50 mg/m$^2$ p.o. q48h or 3–4 consecutive days/week; or 200–250 mg/m$^2$ p.o or i.v. q3wk.
- **Metronomic chemotherapy:** 10–15 mg/m$^2$ p.o. q24h.
- **Multiple myeloma in patients refractory to melphalan:** 1 mg/kg p.o. q24h.
- **Macroglobulinaemia in patients refractory to chlorambucil:** 1 mg/kg p.o. q24h.

**Cats:**
- **Lymphoid neoplasia:** as for dogs, except 200–300 mg/m$^2$ in ‘high dose’ COP regimes.

**References**


**Cyclosporin(e) see Ciclosporin**

**Cyproheptadine**

*(Periactin*)  **POM**

**Formulations:** Oral: 4 mg tablet.

**Action:** Binds to and blocks the activation of H1 histamine and serotonin receptors.

**Use:**
- Management of allergic disease.
- Appetite stimulation.
- Also used in cats with aortic thromboembolism as serotonin, along with other mediators, is involved in collateral vasoconstriction. Maintenance of this collateral supply is important in recovery.

Use with caution in cases with urinary retention, angle-closure glaucoma and pyloroduodenal obstruction. Specific doses for dogs and cats have not been determined by pharmokinetic studies and clinical effectiveness has not been established.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.
**Adverse reactions:** May cause mild sedation, polyphagia, weight gain. May reduce seizure threshold.

**Drug interactions:** No information available.

**DOSES**

**Dogs, Cats:** 0.1–0.5 mg/kg p.o. q8–12h.

---

**Cytarabine (Cytosine arabinoside, Ara-C)**

*(Cytarabine*, *Cytosar-U*) POM

**Formulations:** Injectable: 100 mg, 500 mg powders for reconstitution.

**Action:** The active nucleotide metabolite ara-CTP is incorporated into DNA and inhibits pyrimidine and DNA synthesis. Cytarabine is therefore S-phase-specific.

**Use:**
- Management of lymphoproliferative and myeloproliferative disorders. For dogs diagnosed with lymphoma with bone marrow involvement, addition of cytarabine into a VCAA combination protocol may improve survival time.
- Cytarabine is widely used for the treatment of meningoencephalitis of unknown origin (MUO, previously GME) and other suspected immune-mediated encephalitides in the dog. There is currently no general agreement on the best treatment protocol, but combination therapy of prednisolone and cytarabine is widely reported.

**Safety and handling:** Cytotoxic drug; see Appendix and specialist texts for further advice on chemotherapeutic agents. After reconstitution, store at room temperature and discard after 48 hours or if a slight haze develops.

**Contraindications:** Do not use if there is evidence of bone marrow suppression or substantial hepatic impairment.

**Adverse reactions:** Vomiting, diarrhoea, leucopenia. As it is a myelosuppressant, careful haematological monitoring is required. Conjunctivitis, oral ulceration, neurotoxicity, hepatotoxicity and fever have also been seen. Calcinosus cutis has been reported at the site of injection in three dogs.

**Drug interactions:** Oral absorption of digoxin is decreased. Activity of gentamicin may be antagonized. Simultaneous administration of methotrexate increases the effect of cytarabine.

**DOSES**

See Appendix for chemotherapy protocols and conversion of body weight to body surface area.

**Dogs, Cats:**
- Lymphoproliferative neoplastic disease: 100–150 mg/m² given i.v. or s.c. over 2–5 days (as part of a VCAA-based protocol), or
100 mg/m$^2$ by continuous i.v. infusion over 24–96h, or 20 mg/m$^2$ intrathecally q1–5d. Or 200 mg/m$^2$ given i.v. (over 4 hours) or s.c. once every two weeks as part of the DMAC protocol.

- **MUO/GME:** 50 mg/m$^2$ s.c. q12h for 4 doses. Repeat at 3, 7, 11, 16, 21, 27 and 33 weeks (if clinical benefit seen), then stop. CRI (100 mg/m$^2$ CRI over 24h) at the same intervals.

**References**


**Dacarbazine**

*(Carboxamide*, Dacarbazine*, DTIC*, Imidazole*)

**POM**

**Formulations:** Injectable: 100 mg, 200 mg, 500 mg powders for reconstitution.

**Action:** Methylates nucleic acids and inhibits DNA, RNA and protein synthesis.

**Use:**
- Management of lymphoproliferative diseases (e.g. relapsed lymphoma), melanoma and soft tissue sarcoma.

Use with caution in patients with renal or hepatic insufficiency. Can cause severe pain and extensive tissue damage with extravasation, and therefore must be administered via a preplaced i.v. catheter.

**Safety and handling:** Cytotoxic drug; see Appendix and specialist texts for further advice on chemotherapeutic agents.

**Contraindications:** Bone marrow suppression. Not recommended in cats, as unknown whether they can metabolize it adequately.

**Adverse reactions:** May be severe; include myelosuppression, intense nausea and vomiting (consider premedication with an antiemetic).

**Drug interactions:** Phenobarbital and phenytoin increase the metabolic activation of dacarbazine. Do not use with other myelosuppressive drugs.

**DOSES**

*See Appendix for chemotherapy protocols and conversion of body weight to body surface area.*

**Dogs:** All uses: 200–250 mg/m$^2$ i.v. q24h on days 1–5. Repeat cycle q21–28d. Or, dependent upon the chemotherapy protocol, 800–1000 mg/m$^2$ i.v. over a 4–8h period, may repeat q21d provided the bone marrow has recovered.

**Cats:** Not recommended.

**References**


---

**Dactinomycin** *(Actinomycin-D)*

*(Cosmegen*, Dactinomycin*, Lyovac*)

**POM**

**Formulations:** Injectable: 0.5 mg powder for reconstitution.

**Action:** An antibiotic antineoplastic that inhibits DNA synthesis and function. Inhibition of RNA and protein synthesis may also contribute to cytotoxic effects.
Use:

- Has been used in rescue protocols for canine lymphoma and also in some sarcomas and carcinomas.

Use with caution with pre-existing bone marrow depression, hepatic dysfunction or infection. The drug is vesicant and tissue damage will result from extravasation, and therefore must be administered via a preplaced catheter.

Safety and handling: Potent cytotoxic drug that should only be prepared and administered by trained personnel. See Appendix and specialist texts for further advice on chemotherapeutic agents.

Contraindications: The P-glycoprotein pump actively transports dactinomycin, hence use with caution in breeds susceptible to the ABCB1 (MDR1) mutation (e.g. Collies, Australian Shepherds).

Adverse reactions: Myelosuppression is the main dose-limiting toxicity. GI and hepatic toxicity may also occur. Can increase the risk of urate stone formation in susceptible breeds.

Drug interactions: May add to cardiotoxicity if used concurrently or sequentially with doxorubicin.

DOSES

See Appendix for chemotherapy protocols and conversion of body weight to body surface area.

**Dogs:** All uses: 0.5–0.75 mg/m$^2$ slow i.v. (over 20 min) q2–3wk.

**Cats:** No information available.

References


**Dantrolene**

(Dantrium*) POM

Formulations: Oral: 25 mg, 100 mg capsules. Injectable: Vials of 20 mg dantrolene powder, 3 g mannitol and sodium hydroxide for reconstitution.

Action: Uncouples the excitation contraction process by preventing the release of calcium ions from the sarcoplasmic reticulum in striated muscle. As vascular smooth muscle and cardiac muscle are not primarily dependent on calcium release for contraction they are not usually affected.

Use:

- Management of muscle spasms (e.g. urethral muscle spasm, tetanus).
- Prevention (oral) or treatment (i.v.) of malignant hyperthermia.
Each vial should be reconstituted with 60 ml of water. Before administration the solution must be clear and without visible particles. Protect prepared solution from light; use within 6 hours.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.

**Adverse reactions:** Injectable preparation has pH 9.5 and is highly irritant when extravasated. Ideally administer via a large vein or inject into a fast-running infusion to reduce the likelihood of thrombophlebitis. A diuresis follows i.v. administration, reflecting its formulation with mannitol. Chronic use is associated with hepatitis and pleural effusion; monitor liver function during therapy. Generalized muscle weakness, including the respiratory muscles, has been reported after overdose; initiate symptomatic supportive therapy and monitor the patient carefully, particularly with respect to efficacy of respiration.

**Drug interactions:** Do not combine with calcium-channel blockers.

**DOSES**

_Dogs, Cats:_

- **Malignant hyperthermia:** 2–5 mg/kg i.v.
- **Other indications:** 0.5–2 mg/kg p.o. q12h.

---

**Darbepoetin (Aranesp*) POM**

**Formulations:** Injectable: 10–500 μg pre-filled syringes for injection.

**Action:** Stimulates division and differentiation of RBCs. Darbepoetin is a derivative of human erythropoietin, which has been chemically modified to prolong its half-life. It may be less prone to produce anti-EPO antibodies than other rhEPO.

**Use:**

- Treatment of anaemia associated with chronic renal failure and cats with FeLV-associated anaemia.

Monitoring and/or supplementation of iron may be necessary, especially if the response to treatment is poor. It is also used to treat anaemic human patients with cancer and rheumatoid arthritis.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Conditions where high serum concentrations of erythropoietin already exist (e.g. haemolytic anaemia, anaemia due to blood loss), where anaemia is due to iron deficiency or where uncontrolled systemic hypertension is present.

**Adverse reactions:** Local and systemic allergic reactions may rarely develop (skin rash at the injection site, pyrexia, arthralgia and
mucocutaneous ulcers). The production of cross-reacting anti-EPO antibodies can cause pure red cell aplasia. Hypertension and seizures have also been reported.

**Drug interactions:** No information available.

**DOSES**

**Dogs, Cats:** For stimulating erythropoiesis (induction dose): 0.25–1 μg (micrograms)/kg s.c. weekly until PCV is normal, then increasing dose interval for maintenance. Some authors recommend starting at the 1 μg/kg dose for improved efficacy.

**References**


---

**Deferoxamine (Desferrioxamine)**

*(Desferal*) **POM**

**Formulations:** Injectable: 500 mg vial for reconstitution.

**Action:** Deferoxamine chelates iron, and the complex is excreted in the urine.

**Use:** To remove iron from the body following poisoning.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Avoid in severe renal disease.

**Adverse reactions:** Administration i.m. is painful. Anaphylactic reactions and hypotension may develop if administered rapidly i.v.

**Drug interactions:** No information available.

**DOSES**

**Dogs, Cats:** Iron toxicity: 40 mg/kg i.m. q4–8h or 15 mg/kg/h slow i.v. infusion.

---

**Delmadinone**

*(Tardak)* **POM-V**

**Formulations:** Injectable: 10 mg/ml suspension.

**Action:** Progestogens suppress FSH and LH production.

**Use:**

- Used in the treatment of hypersexuality (male dog and cat).
- Treatment of prostatic hypertrophy.
- Management of peri-anal gland adenomas.
- Treatment of hormonally driven canine aggression.
Dogs that show a reduced level of aggression when treated with delmadinone will not automatically show the same behavioural response to surgical castration because the drug also has a central calming effect. In situations of fear- or anxiety-related aggressive behaviour, the surgical approach can exacerbate the behaviour.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Avoid in patients with severe renal or hepatic impairment or diabetes mellitus.

**Adverse reactions:** Possible adverse effects include a transient reduction in fertility and libido, polyuria and polydipsia, an increased appetite and hair colour change at the site of injection.

**Drug interactions:** Cortisol response to ACTH stimulation is significantly suppressed after just one dose of delmadinone.

**DOSES**

**Dogs:** Benign prostatic hypertrophy: 1.5–2 mg/kg (dogs <10 kg); 1–1.5 mg/kg (10–20 kg); 1 mg/kg (>20 kg) i.m., s.c. repeated after 8 days if no response. Animals that respond to treatment may need further treatment after 3–4 weeks.

**Cats:** Hypersexuality: 1.5 mg/kg repeated after 8 days if no response. Animals that respond to treatment may need further treatment after 3–4 weeks.

**References**


---

**Deltamethrin**

*(Canishield, Scalibor Protectorband)* **NFA-VPS**

**Formulations:** Topical: 4% deltamethrin collar: 0.76 g (for small and medium dogs), 1 g (for large dogs).

**Action:** Acts as a sodium ‘open channel blocker’ resulting in muscular convulsions and death in arthropods. It also repels ticks and insects.

**Use:**

- Control of tick infestation (*Ixodes ricinus, Rhipicephalus sanguineus*).
- Prevention of feeding by phlebotomine sandflies and mosquitoes (*Culex pipiens pipiens*) on dogs for up to 6 months.
- Persistent flea (*Ctenocephalides felis*) killing activity for 16 weeks (Canishield).

Collar exerts full effect after 1 week.

**Safety and handling:** Wash hands after fitting the collar. Avoid letting children, in particular those under 2-years of age, touch the collar, play with it or put it into their mouth. Highly toxic to aquatic animals (remove collar before letting dog swim in rivers) and bees, also toxic to birds.
Contraindications: Do not use on dogs <7 weeks old. Avoid use in dogs with skin lesions. Do not use on cats.

Adverse reactions: Rarely, dermatitis around the neck, GI and neuromuscular disturbances can occur. Diazepam should be administered in the event of accidental ingestion.

Drug interactions: No information available.

DOSES
Dogs: Prevention against ticks, fleas, sandflies and mosquitoes: One collar q5–6months.
Cats: Do not use.

**l-Deprenyl** see **Selegiline**

**Desferrioxamine** see **Deferoxamine**

**Deslorelin** (Suprelorin) **POM-V**

Formulations: Implant containing 4.7 mg (6 months) or 9.4 mg (12 months) of active product.

Action: GnRH superagonist. Receptors are stimulated in the first 2 weeks after application, but then die down through overstimulation, thereby decreasing release of LH and FSH. This leads to cessation of testosterone and sperm production.

Use:
• Temporary chemical castration.

Infertility is achieved from 6 weeks for up to 6 or 12 months. Treated dogs should still be kept away from bitches in heat for 6 weeks following initial treatment (separation unnecessary following subsequent implantations provided the product is administered every 6 or 12 months). Rarely, matings may occur during the treatment period but will not result in pregnancy. Dogs <10 kg may not recover their testosterone concentrations for 18 months. In toms, deslorelin implants cause chemical castration for 2–4 years. Disinfection of the site should be undertaken prior to implantation to avoid introduction of infection. The product should be implanted subcutaneously in the loose skin on the back between the lower neck and the lumbar area. Avoid injection of the implant into fat, as release of the active substance might be impaired in areas of low vascularization. The biocompatible implant does not require removal; however, should it be necessary to end treatment, implants can be removed under local anaesthesia.

Safety and handling: Pregnant women should not administer the product.

Contraindications: Use in bitches causes induction of oestrus within a few days, followed by a long anoestrus period.
**Adverse reactions:** Moderate swelling at the implant site may be observed for 14 days. A significant decrease in testicle size will be seen during treatment.

**Drug interactions:** No information available.

**DOSES**

**Dogs:** 1 implant per male dog repeat after 6 or 12 months (depending on size of implant).

**Cats:** 1 implant (4.7 mg) per male cat.

**References**


---

**Desmopressin**  
*(DDAVP*, Desmospray*, Desmotabs*)  
POM

**Formulations:** Intranasal: 100 μg/ml solution; 10 μg metered spray. Injectable: 4 μg/ml solution. Oral: 100 μg, 200 μg tablets.

**Action:** Binds to and stimulates ADH receptors in the collecting ducts of the kidney. Desmopressin, a vasopressin analogue, has a longer duration of action than vasopressin and, unlike vasopressin, has no vasoconstrictor activity. Also increases von Willebrand factor, factor VIII and plasminogen concentrations.

**Use:**
- Diagnosis and treatment of central diabetes insipidus.

Further advice on the use of this drug in the modified water deprivation test should be obtained from *BSAVA Manual of Canine and Feline Endocrinology* and specialist laboratories. Assess adrenocortical function before performing the test.
- To boost plasma levels of factor VIII and von Willebrand factor in patients with mild to moderate haemophilia A or von Willebrand's disease. Severe forms of these diseases are not successfully treated with desmopressin.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not perform the modified water deprivation test in patients with hyponatraemia, renal disease, dehydration or hypercalcaemia.

**Adverse reactions:** No information available.

**Drug interactions:** No information available.

**DOSES**

**Dogs:**
- Coagulopathies: 1–4 μg (micrograms)/kg i.v. once; dilute in 20 ml saline and administer over 10 min.
- Diabetes insipidus diagnosis: (using modified water deprivation test): 1–4 μg/dog i.v. once.
• **Diabetes insipidus treatment:** 1–4 μg/dog i.v., i.m. or 5–20 μg/ dog or 0.05–0.2 ml/dog intranasally or on to the conjunctiva q8–24h, or 5 μg/kg p.o. q8–24h initially (maximum dose 400 μg p.o. q8h). The dose and frequency of dosing can be increased or decreased according to response.

**Cats:** 5 μg (micrograms)/cat or 0.05 ml (1–2 drops) intranasally or on to the conjunctiva q8–24h, or 5 μg/cat p.o. q8–24h initially. The dose and frequency of dosing can be increased or decreased according to response.

**References**


**Desoxycortone pivalate**

(Desoxycortisone pivalate)

(Zycortal) POM-V

**Formulations:** Injectable: 25 mg/ml for subcutaneous injection.

**Action:** Mineralocorticoid.

**Use:**

• Long-acting, replacement therapy for mineralocorticoid deficiency in dogs and cats with primary hypoadrenocorticism.

It is important that Addison’s disease has been definitively diagnosed before starting treatment. Any dog presenting with severe hypovolaemia, dehydration, pre-renal azotaemia and inadequate tissue perfusion (also known as ‘Addisonian crisis’) must be rehydrated with intravenous fluid (saline) therapy before starting treatment with the veterinary medicinal product. Use lower doses in dogs with congestive heart disease, severe renal disease, primary hepatic failure or oedema. Many dogs when given the authorized dose of 2.2 mg/kg require lower doses subsequently. For this reason many authorities start at the lower dose of 1.5 mg/kg s.c. particularly in larger dogs. Subsequent dose reduction or increase may still be necessary and the final dose can be between 1.0 and 2.7 mg/kg.

**Safety and handling:** Normal precautions should be observed. The vials, once opened are stable for several months. Before use, shake gently to resuspend the product and continue to move the loaded syringe before injection to prevent precipitation.

**Contraindications:** None.

**Adverse reactions:** Rarely, pain is seen on injection but repeated injections are not painful in the same animal. Overdoses may cause polyuria and hypokalaemia. Vomiting, anorexia, polyuria/polydipsia, muzzle swelling and anaphylaxis have been reported.
**Drug interactions:** Avoid concurrent use of aldosterone antagonists (spironolactone) and other drugs that may reduce potassium (e.g. furosemide, thiazides).

**DOSES**

*Dogs:* Initial dose 1.5–2.2 mg/kg s.c. See note above.

*Cats:* Initial dose 2.2 mg/kg. Experience is limited but higher doses seem to be needed.

**References**


**Dexamethasone**

*(Aurizon, Dexadreson, Dexafort, Dexta-ject, Duphacort Q, Rapidexon, Voren, Dexamethasone*, Maxidex*, Maxitrol*) *POM-V, POM*

**Formulations:** *Ophthalmic:* 0.1% solution (Maxidex, Maxitrol). Maxitrol also contains polymyxin B and neomycin. *Injectable:* 2 mg/ml solution; 1 mg/ml, 3 mg/ml suspension; 4 mg/ml (1.32 mg/ml sodium phosphate and 2.67 mg/ml of the phenylpropionate salts) (Voren); 2.5 mg/ml suspension with 7.5 mg/ml prednisolone. *Topical:* 0.9 mg/ml suspension with clotrimazole and marbofloxacin (Aurizon). *Oral:* 0.5 mg tablet (1 mg of dexamethasone is equivalent to 1.1 mg of dexamethasone acetate, 1.3 mg of dexamethasone isonicotinate or dexamethasone sodium phosphate, or 1.4 mg of dexamethasone trioxa-undecanoate).

**Action:** Alters the transcription of DNA, leading to alterations in cellular metabolism which cause reduction in inflammatory response.

**Use:**
- Anti-inflammatory drug.
- Assessment of adrenal function in suspected hyperadrenocorticism (HAC). Consult specialist texts and laboratories for advice on the performance and interpretation of dexamethasone suppression tests.
- Emergency treatment of hypoadrenocorticism.
- To prevent and treat anaphylaxis associated with transfusion or chemotherapeutic agents.

Anti-inflammatory potency is 7.5 times greater than prednisolone. On a dose basis 0.15 mg dexamethasone is equivalent to 1 mg prednisolone. Dexamethasone has a long duration of action and low mineralocorticoid activity and is particularly suitable for short-term high-dose therapy in conditions where water retention would be a disadvantage. Unsuitable for long-term daily or alternate-day use. Animals on chronic therapy should be tapered off steroids when discontinuing the drug. The use of long-acting steroids in most cases of shock and spinal injury is of no benefit and may be detrimental.

**Safety and handling:** Normal precautions should be observed.
Contraindications: Do not use in pregnant animals. Systemic corticosteroids are generally contraindicated in patients with renal disease and diabetes mellitus. Impaired wound healing and delayed recovery from infections may be seen. Topical corticosteroids are contraindicated in ulcerative keratitis.

Adverse reactions: A single dose of dexamethasone or dexamethasone sodium phosphate suppresses adrenal gland function for up to 32 hours. Prolonged use of glucocorticoids suppresses the hypothalamic–pituitary axis (HPA), causing adrenal atrophy, increased liver enzyme activities, cutaneous atrophy, weight loss, PU/PD, vomiting and diarrhoea. GI ulceration may develop. Hyperglycaemia and decreased serum T4 values may be seen in patients receiving dexamethasone.

Drug interactions: There is an increased risk of GI ulceration if used concurrently with NSAIDs. The risk of developing hypokalaemia is increased if corticosteroids are administered concomitantly with amphotericin B or potassium-depleting diuretics (furosemide, thiazides). Dexamethasone antagonizes the effect of insulin. The metabolism of corticosteroids may be enhanced by phenytoin or phenobarbital and decreased by antifungals such as itraconazole.

DOSES
See Appendix for immunosuppression protocols.

Dogs:
- Ophthalmic: Apply small amount of ointment to affected eye(s) q6–24h or 1 drop of solution in affected eye(s) q6–12h.
- Otic: 10 drops to ear once daily for 7–14 days (authorized dose; many authorities use less).
- Cerebral oedema associated with tumours: anti-inflammatory dose 0.1–0.3 mg/kg.
- Hypoadrenocorticism: 0.2 mg/kg i.v. repeat daily until able to use oral medication.
- Inflammation: 0.01–0.16 mg/kg i.m., s.c., p.o. q24h for 3–5 days maximum.
- Prevention and treatment of anaphylaxis: 0.5 mg/kg i.v. once.
- Immunosuppression: 0.3–5 mg/kg i.m., s.c., p.o. q24h for up to 5 days.
- Assessment of adrenal function: low dose dexamethasone suppression test (0.01–0.015 mg/kg i.v.).

Cats:
- Ophthalmic, cerebral oedema, inflammation, anaphylaxis, immunosuppression: doses as for dogs.
- Assessment of adrenal function: dexamethasone suppression test (0.1–0.15 mg/kg i.v.). Note difference to dogs.
Dexmedetomidine
(Dexdomitor, Sedadex, Sileo) POM-V

**Formulations:** Injectable: 0.5 mg/ml solution. Oral gel: 0.1 mg/ml.

**Action:** Agonist at peripheral and central alpha-2 adrenoreceptors producing dose-dependent sedation, muscle relaxation and analgesia.

**Use:**
- To provide sedation and premedication when used alone or in combination with opioid analgesics.
- For the alleviation of acute noise anxiety.
- Dexmedetomidine combined with ketamine is used to provide a short duration (20–30 min) of surgical anaesthesia in cats.
- Dexmedetomidine is also being increasingly used in very low doses to manage emergence excitation in dogs and cats during recovery from anaesthesia and for the provision of analgesia when administered by constant rate infusion.

A gel formulation has also been developed for application to the oral mucosa of dogs for the control of fear and anxiety associated with noise. Dexmedetomidine is the pure dextroenantiomer of medetomidine. As the levomedetomidine enantiomer is largely inactive, dexmedetomidine is twice as potent as the racemic mixture (medetomidine). Administration of dexmedetomidine reduces the biological load presented to the animal, resulting in quicker metabolism of concurrently administered anaesthetic drugs and a potentially faster recovery from anaesthesia. Dexmedetomidine is a potent drug that causes marked changes in the cardiovascular system, including an initial peripheral vasoconstriction that results in an increase in blood pressure and a compensatory bradycardia. After 20–30 minutes vasoconstriction wanes, while blood pressure returns to normal values. Heart rate remains low due to the central sympatholytic effect of alpha-2 agonists. These cardiovascular changes result in a fall in cardiac output; central organ perfusion is well maintained at the expense of redistribution of blood flow away from the peripheral tissues. Respiratory system function is well maintained; respiration rate may fall but is accompanied by an increased depth of respiration. Oxygen supplementation is advisable in all animals that have received dexmedetomidine for sedation. The duration of analgesia from a 5 μg (micrograms)/kg dose of dexmedetomidine is approximately 1 hour. Combining dexmedetomidine with an opioid provides improved analgesia and sedation. Lower doses of dexmedetomidine should be used in combination with other drugs. Reversal of dexmedetomidine sedation or premedication with atipamezole at the end of the procedure shortens the recovery period, which is advantageous. Analgesia should be provided with other classes of drugs before atipamezole. The authorized dose range of dexmedetomidine for dogs and cats is very broad. High doses (>10 μg (micrograms)/kg) are associated with greater physiological disturbances than doses of 1–10 μg/kg. Using dexmedetomidine in combination with opioids in
the lower dose range can provide good sedation and analgesia with minimal side effects.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not use in animals with cardiovascular or other systemic disease. Use of dexmedetomidine in geriatric patients is not advisable. It should not be used in pregnant animals, nor in animals likely to require or receiving sympathomimetic amines.

**Adverse reactions:** Causes diuresis by suppressing ADH secretion, a transient increase in blood glucose by decreasing endogenous insulin secretion, mydriasis and decreased intraocular pressure. Vomiting after i.m. administration is common, so dexmedetomidine should be avoided when vomiting is contraindicated (e.g. foreign body, raised intraocular pressure). Due to effects on blood glucose, use in diabetic animals is not recommended. Spontaneous arousal from deep sedation following stimulation can occur with all alpha-2 agonists, aggressive animals sedated with dexmedetomidine must still be managed with caution.

**Drug interactions:** No information available.

**DOSES**

When used for sedation is generally given as part of a combination. See Appendix for sedation protocols in cats and dogs.

**Dogs:**

- Control of noise related anxiety: 125 μg (micrograms)/m² applied to the oral mucosa as a gel 30–60 minutes before the onset of the noise stimulus, or after the first signs. Dosing can be repeated after 2–3 hours for a maximum of occasions.

**Dogs, Cats:**

- Premedication: 2–10 μg (micrograms)/kg i.v., i.m, s.c. in combination with an opioid (use lower end of dose range i.v.).
- Emergence excitation: 1 μg/kg i.v. can be given to manage emergence excitation during recovery from anaesthesia, although administration around the time of extubation will prolong the recovery period from anaesthesia and treated animals should be monitored carefully.
- Perioperative analgesia and rousable sedation: 1–2 μg/kg/h constant rate infusion is indicated, although the efficacy of analgesia will be improved in most animals if dexmedetomidine is used as an adjunct to opioid analgesia.

**References**


Dexrazoxane
(Cardioxane*, Zinecard*) POM

Formulations: Intravenous: 500 mg vials which when correctly reconstituted produce a 20 mg/ml solution for infusion.

Action: Prevents the formation of anthracycline-iron complex free radicals thought to be the cause of anthracycline induced cardiotoxicity and extravasation reactions.

Use: Used to manage complications associated with the use of anthracycline chemotherapeutics.

Safety and handling: Wear gloves when handling.

Contraindications: Unknown.

Adverse reactions: Myelosuppression is documented in humans; it may also decrease the clinical efficacy of anthracycline anti-neoplastic agents.

Drug interactions: Unknown.

DOSES

Dogs:
- Extravasation injury: terminate doxorubicin infusion and administer 1000 mg/m$^2$ i.v. into a separate infusion (ideally within 6 hours). Repeat on day 2 (1000 mg/m$^2$ i.v.) and day 3 (500 mg/m$^2$ i.v.). Lower doses have also been shown to be effective (250–500 mg/m$^2$ i.v.).
- Prevention of doxorubicin cardiotoxicity: 10 minutes prior to doxorubicin 10 times the administered milligram dose of doxorubicin i.v. over 5–10 minutes.

Cats: Unknown.

References


Dextrose see Glucose

Diazepam
(Diazedor, Diazemuls*, Diazepam Rectubes*, Stesolid*, Valium* and several others) POM-V, POM

Formulations: Injectable: 5 mg/ml emulsion (2 ml ampoules, Diazemuls). Oral: 2 mg, 5 mg, 10 mg tablets; 2 mg/5 ml solution. Rectal: 2 mg/ml (1.25, 2.5 ml tubes), 4 mg/ml (2.5 ml tubes) solutions; 10 mg suppositories.
Action: Enhances activity of the major inhibitory central nervous system neurotransmitter, gamma-aminobutyric acid (GABA), through binding to the benzodiazepine site of the GABA<sub>δ</sub> receptor.

Use:
- Anticonvulsant: diazepam is the drug of choice for the short-term emergency control of severe epileptic seizures and status epilepticus in dogs and cats.
- Anxiolytic: used in behavioural medicine for anxiety and fear-related disorders in dogs and cats, especially where there are signs of panic.
- Skeletal muscle relaxant (e.g. urethral muscle spasm and tetanus).
- Used in cats as an appetite stimulant.

The anti-seizure effect in the dog is only maintained for around 20 minutes and should always be used as part of a balanced emergency seizure protocol; not effective as maintenance anti-seizure medication in the dog due to its short half-life. In cats the half-life is longer and it may be effective as a maintenance medication. Diazepam is indicated in dogs with marked spinal pain due to muscle spasm, in combination with conventional analgesics. It may also be used in combination with ketamine to offset muscle hypertonicity associated with ketamine, and with opioids and/or acepromazine for pre-anaesthetic medication in the critically ill. It provides very poor sedation or even excitation when used alone in healthy animals. Its amnesic properties mean it can be used during or immediately following an aversive experience to minimize the impact of such exposure. Best if used approximately 30 minutes before a fear-inducing event. Higher range doses are required for amnesic activity. Although it has been used for the management of urine spraying in cats, a high relapse rate upon withdrawal should be expected. Diazepam has a high lipid solubility, which facilitates its oral absorption and rapid central effects. Liver disease will prolong duration of action. In the short term, repeated doses of diazepam or a constant rate infusion will lead to drug accumulation and prolonged recovery in both species but particularly in cats in which it may also cause liver injury. Flumazenil (a benzodiazepine antagonist) will reverse the effects of diazepam. The development of dependence to benzodiazepines may occur after regular use, even with therapy of only a few weeks, and the dose should be gradually reduced in these cases if the benzodiazepine is being withdrawn. Chronic dosing leads to a shortened half-life due to activation of the hepatic microsomal enzyme system and tolerance to the drug may develop in dogs.

Safety and handling: Substantial adsorption of diazepam may occur on to some plastics and this may cause a problem when administering diazepam by continuous i.v. infusion. The use of diazepam in PVC infusion bags should be avoided; giving sets should be kept as short as possible and should not contain a cellulose propionate volume-control chamber. If diazepam is given by continuous i.v. infusion the compatible materials include glass, polyolefin, polypropylene and polyethylene.
Contraindications: Benzodiazepines should be avoided in patients with CNS depression, respiratory depression, severe muscle weakness or hepatic impairment (as may worsen hepatic encephalopathy). They are also contraindicated in the long-term treatment of canine and feline behavioural disorders due to the risks of disinhibition and interference with memory and learning.

Adverse reactions: Sedation, muscle weakness and ataxia are common. Rapid i.v. injection or oral overdose may cause marked paradoxical excitation (including aggression) and elicit signs of pain in normal dogs; i.v. injections should be made slowly (over at least 1 min for each 5 mg). Intramuscular injection is painful and results in erratic drug absorption. Rectal administration is effective for emergency control of seizures if i.v. access is not possible, but the time to onset is delayed to 5–10 min. The duration of action may be prolonged after repeated doses in rapid succession, in older animals, those with liver dysfunction, and those receiving beta-1 antagonists. Fulminant hepatic necrosis in cats has been associated with repeated oral administration. The propylene glycol formulation of injectable diazepam can cause thrombophlebitis, therefore the emulsion formulation is preferred for i.v. injection.

Drug interactions: Do not dilute or mix with other agents. Due to extensive metabolism by the hepatic microsomal enzyme system, interactions with other drugs metabolized in this way are common. Cimetidine and omeprazole inhibit metabolism of diazepam and may prolong clearance. Concurrent use of phenobarbital may lead to a decrease in the half-life of diazepam. An enhanced sedative effect may be seen if antihistamines or opioid analgesics are administered with diazepam, and diazepam will reduce the dose requirement of other anaesthetic agents. When given with diazepam the effects of digoxin may be increased. Diazepam may be used in combination with tricyclic antidepressant therapy for the management of more severe behavioural responses.

DOSES
When used for sedation is generally given as part of a combination. See Appendix for sedation protocols in cats and dogs.

Dogs:
- Anxiolytic: 0.5–2.0 mg/kg p.o as required.
- Sedation and premedication: 0.2–0.5 mg/kg i.v., i.m.
- Skeletal muscle relaxation: 2–10 mg/dog p.o. q8–12h.
- Emergency management of seizures, including status epilepticus: bolus dose of 0.5–1 mg/kg i.v. or intrarectally (if venous access is not available). Time to onset of clinical effect is 2–3 min for i.v. use; therefore, repeat every 10 min if no clinical effect, up to 3 times. Additional doses may be administered if appropriate supportive care facilities are available (for support of respiration). Constant rate i.v. infusion for control of status epilepticus or cluster seizures: initial rate 0.5–2 mg/kg/h, titrated to effect.

Cats:
- Anxiolytic: 0.2–0.4 mg/kg p.o. q8h.
- Appetite stimulant: 0.1–0.2 mg/kg i.v. once.
• **Behavioural modification of urine spraying and muscle relaxation:** 1.25–5 mg/cat p.o. q8h. The dose should be gradually increased to achieve the desired effect without concurrent sedation.

• **Emergency management of seizures including status epilepticus:** bolus dose of 0.5–1 mg/kg i.v. or intrarectally if venous access is not available. Time to onset of clinical effect is 2–3 min for i.v. use, therefore, repeat every 10 min if there is no clinical effect, up to maximum of 3 times. Constant rate i.v. infusion for the control of status epilepticus or cluster seizures: initial rate of 0.5 mg/kg/h. Care should be taken in cats to avoid overdosing; if cats demonstrate excessive sedation then diazepam should be discontinued. Consider monitoring liver parameters.

**References**


---

**Diazoxide**
(Eudemine*) POM

**Formulations:** Injectable: 15 mg/ml solution (special order). Oral: 50 mg tablet.

**Action:** A diuretic that causes vasodilation and inhibits insulin secretion by blocking calcium mobilization.

**Use:**
- Used to manage hypoglycaemia caused by hyperinsulinism in dogs.
- In humans it is also used in the short-term management of acute hypertension.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.

**Adverse reactions:** The commonest adverse effects are anorexia, vomiting and diarrhoea (potentially alleviated by administering drug with food). Hypotension, tachycardia, bone marrow suppression, pancreatitis, cataracts and electrolyte and fluid retention may occur. Drug efficacy may diminish over a period of months.

**Drug interactions:** Phenothiazines and thiazide diuretics may increase the hyperglycaemic activity of diazoxide, while alpha-adrenergic blocking agents (e.g. phenoxybenzamine) may antagonize the effects of diazoxide.

**DOSES**

**Dogs:** Hypoglycaemia: 5 mg/kg p.o. q12h initially, increasing gradually to 30 mg/kg p.o. q12h.

**Cats:** No information available.
Dichlorophen
(Various authorized proprietary products)
AVM-GSL

Formulations: Oral: 250 mg, 500 mg, 750 mg tablets.

Action: Cestocide which acts by interfering with oxidative phosphorylation.

Use: Control of tapeworm infections in dogs and cats >6 months old. Effective against *Taenia* and *Dipylidium* but not *Echinococcus*. Affected worms are dislodged and disintegrate during their passage along the alimentary tract so they are not easily recognizable when passed 6–8 hours after dosing. Administer tablets whole or crushed in food.

Safety and handling: Normal precautions should be observed.

Contraindications: Do not repeat the treatment if vomiting occurs shortly after dosing. Do not administer to animals weighing <1.25 kg or under 6 months of age. Do not repeat the treatment in <10 days.

Adverse reactions: Vomiting may be seen. Rarely, salivation, hyperaesthesia and loss of coordination.

Drug interactions: No information available.

DOSES

*Dog*, *Cat*: 250 mg total dose (dogs, cats <2.5 kg), 500 mg/2.5 kg (larger animals) p.o. Give maximum 6 tablets at one time, and give the rest 3 hours later if there is no vomiting. The tablets are best administered immediately before the main feed of the day and may be given whole or crushed and given in food. Animals should be treated every 4–6 months.

Diclofenac
(Voltarol Ophtha*, Voltarol Ophtha Multidose*)
POM

Formulations: Ophthalmic: 0.1% solution in 5 ml bottle and in single-use vial.

Action: COX inhibitor that produces local anti-inflammatory effects.

Use:
- Used in cataract surgery to prevent intraoperative miosis and reflex (axonal) miosis caused by ulcerative keratitis.
- Used to control pain and inflammation associated with corneal surgery and in ulcerative keratitis when topical corticosteroid use is contraindicated.

Safety and handling: Normal precautions should be observed.
Contraindications: No information available.

Adverse reactions: As with other topical NSAIDs, diclofenac may cause local irritation. Topical NSAIDs should be used with caution in ulcerative keratitis as they can delay epithelial healing. Topical NSAIDs, and most specifically diclofenac, have been associated with an increased risk of corneal ‘melting’ (keratomalacia) in humans, although this has not been reported in the veterinary literature. Topical NSAIDs have the potential to increase intraocular pressure and should be used with caution in dogs and cats with glaucoma. Regular monitoring is advised.

Drug interactions: Ophthalmic NSAIDs may be used safely with other ophthalmic pharmaceuticals, although concurrent use of drugs which adversely affect the corneal epithelium (e.g. gentamicin) may lead to increased corneal penetration of the NSAID. The concurrent use of topical NSAIDs with topical corticosteroids has been identified as a risk factor in humans for precipitating corneal problems.

DOSES

Dogs, Cats: 1 drop q30min for 2 hours prior to cataract surgery (there is a wide variation in protocols for cataract surgery).

References


Digoxin

(Digoxin*, Lanoxin*, Lanoxin PG*) POM

Formulations: Oral: 62.5 μg, 125 μg, 250 μg tablets; 50 μg/ml elixir. Injectable: 250 μg/ml.

Action: Acts as an antiarrhythmic. Digoxin slows the ventricular response rate (heart rate) in atrial fibrillation by having a vagomimmetic effect, predominantly acting at the AV node therefore slowing AV nodal conduction. May also be used in other supraventricular tachyarrhythmias. Also, has a secondary mild positive inotropic effect. Inhibits Na⁺–K⁺ATPase, leading to an increase in intracellular sodium. Sodium is exchanged for calcium, resulting in an increase in intracellular calcium and hence positive inotropic effect. The combination of a slower heart rate and increased force of contraction increases cardiac output in patients with supraventricular tachyarrhythmias. Digoxin improves baroreceptor reflexes that are impaired in heart failure.

Use:

• Management of supraventricular tachyarrhythmias.
• It is primarily used to control the ventricular rate in cases of heart failure with concurrent atrial fibrillation. Effective to decrease the ventricular rate in dogs with atrial fibrillation either as
monotherapy or in combination with diltiazem. Digoxin/diltiazem combination therapy results in more effective rate control than monotherapy.

Serum levels should be checked after 7–10 days, with a sample taken at 6–8 hours post-pill. The bioavailability of digoxin varies between the different formulations: tablets approx. 60%; elixir approx. 75%; and i.v. approx. 100%. If toxic effects are seen or the drug is ineffective, serum levels of digoxin should be assessed; the ideal therapeutic level is a trough serum concentration in the region of 0.6–1.2 ng (nanograms)/ml. The dose shown below achieves a therapeutic serum digoxin concentration (1.0–2.0 ng/ml) while minimizing adverse effects in dogs. Decreased dosages or an increase in dosing intervals may be required in geriatric patients, obese animals or those with significant renal dysfunction. The intravenous route is rarely indicated and, if used, should be administered very slowly and with extreme care.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Frequent ventricular arrhythmias or atrio-ventricular block. Considered to be contraindicated in cases of feline hypertrophic cardiomyopathy. Do not use if hypokalaemia present.

**Adverse reactions:** Cats are more sensitive to the toxic effects of digoxin than dogs. Hypokalaemia predisposes to toxicity in all species. Signs of toxicity include anorexia, vomiting, diarrhoea, depression or trigger arrhythmias (e.g. AV block, bigeminy, paroxysmal ventricular or atrial tachycardias with block, and multiform ventricular premature contractions). Lidocaine and phenytoin may be used to control digoxin-associated arrhythmias. Intravenous administration may cause vasoconstriction.

**Drug interactions:** Antacids, chemotherapy agents (e.g. cyclophosphamide, cytarabine, doxorubicin, vincristine), cimetidine and metoclopramide may decrease digoxin absorption from the GI tract. The following may increase the serum level, decrease the elimination rate or enhance the toxic effects of digoxin: amiodarone, antimuscarinics, diazepam, erythromycin, loop and thiazide diuretics (hypokalaemia), oxytetracycline and verapamil. Spironolactone may enhance or decrease the toxic effects of digoxin.

**DOSES**

**Dogs:** Tablets: 2.5–3.5 μg (micrograms)/kg p.o. q12h based on lean body weight (decrease dose by 10% for elixir). Maximum dose 0.25 mg/dog p.o. q12h. Start at lower end of dose range and up-titrate carefully based on clinical response and serum therapeutic levels. Only use i.v. if essentially indicated: 2.2–4.4 μg/kg i.v. q12h.

**Cats:** Tablets: 10 μg (micrograms)/kg p.o. q24–48h, equating to ¼ of a 125 μg tablet q24–48h. Start at lower dose range and titrate up. Only use i.v. if essentially indicated: 1–1.6 μg/kg i.v. q12h.

**References**

Diltiazem

Formulations: Oral: 10 mg (Hypercard), 60 mg (generic) modified-release (-MR) tablets. Long-acting (-SR) preparations authorized for humans, such as Dilcardia SR (60 mg, 90 mg, 120 mg capsules), are available but their pharmacokinetics have been little studied in animals to date. Injectable: 10 mg/ml (check concentration prior to use as strength may vary).

Action: Diltiazem is a non-dyhydropyridine calcium-channel blocker. It inhibits inward movement of calcium ions through slow (L-type) calcium channels in myocardial cells, cardiac conduction tissue and vascular smooth muscle. Diltiazem is less potent than the dihydropyridine calcium channel blockers (e.g. amlodipine) at causing vasodilation of coronary and peripheral vessels. Diltiazem causes a reduction in myocardial contractility (negative inotrope, although less marked than verapamil), depressed electrical activity (retarded atrioventricular conduction) and decreases vascular resistance (vasodilation of cardiac vessels and peripheral arteries and arterioles).

Use:
- Primarily used to control supraventricular tachyarrhythmias in dogs and cats.
- Authorized for use in cats with hypertrophic cardiomyopathy although beta-adrenergic blockers are more commonly used.
- Effective to decrease the ventricular rate in dogs with atrial fibrillation either as monotherapy or in combination with digoxin. Digoxin/diltiazem combination therapy results in more effective rate control than monotherapy. Diltiazem is preferred to verapamil by many because it has effective antiarrhythmic properties with minimal negative inotropy. Diltiazem is less effective than amlodipine in the management of hypertension. Reduce the dose in patients with hepatic or renal impairment.

Safety and handling: Normal precautions should be observed.

Contraindications: Diltiazem is contraindicated in patients with second or third degree AV block, marked hypotension or sick sinus syndrome, and should be used cautiously in patients with systolic dysfunction or acute or decompensated congestive heart failure.

Adverse reactions: In dogs, bradycardia is the commonest adverse effect, while in cats it is vomiting. Lethargy can be seen in both species.

Drug interactions: If diltiazem is administered concurrently with beta-adrenergic blockers (e.g. propranolol), there may be additive negative inotropic and chronotropic effects. The co-administration...
of diltiazem and beta-blockers is not recommended. The activity of
diltiazem may be adversely affected by calcium salts or vitamin D.
There are conflicting data regarding the effect of diltiazem on serum
digoxin levels and monitoring of these levels is recommended if the
drugs are used concurrently. Cimetidine inhibits the metabolism of
diltiazem, thereby increasing plasma concentrations. Diltiazem
enhances the effect of theophylline, which may lead to toxicity. It
may affect ciclosporin concentrations. Diltiazem may displace highly
protein-bound agents from plasma proteins. Diltiazem may increase
intracellular vincristine levels by inhibiting outflow of the drug from
the cell.

DOSES

Dogs: 0.05–0.25 mg/kg i.v. over 1–2 min, 0.5–2.0 mg/kg p.o. q8h
for -MR products or up to 3.0 mg/kg p.o. q12h for sustained/
extended release preparations (little evidence established with -SR
released products). Lower doses are preferred in the presence of
heart failure. Long-acting preparations have been used at a dose of
10 mg/kg p.o. q24h but there is little experience with such
formulations in animals. In refractory supraventricular
tachyarrhythmias doses up to 4 mg/kg p.o. q8h have been reported.
Cats: 0.05–0.25 mg/kg i.v. over 1–2 min, 0.5–2.5 mg/kg p.o. q8h, or
one 10 mg tablet for cats of 3–6.25 kg p.o. q8h.

References

Gelzer ARM, Kraus MS, Rishniw M et al. (2009) Combination therapy with digoxin and
diltiazem controls ventricular rate in chronic atrial fibrillation in dogs better than digoxin
or diltiazem monotherapy: A Randomized Crossover Study in 18 Dogs. Journal of
Veterinary Internal Medicine 23, 499–508
Johnson LM, Atkins CE, Keene BW et al. (1996) Pharmacokinetic and pharmacodynamic
properties of conventional and CD-formulated diltiazem in cats. Journal of Veterinary
Internal Medicine 10, 316–320

Dimercaprol (British anti-lewisite)
(Dimercaprol*) POM

Formulations: Injectable: 50 mg/ml solution in peanut oil.
Action: Chelates heavy metals.
Use:
• Treatment of acute toxicity caused by arsenic, gold, bismuth and
mercury.
• Used as an adjunct (with edetate calcium disodium) in lead
poisoning.
Safety and handling: Normal precautions should be observed.
Contraindications: Severe hepatic failure.
Adverse reactions: Intramuscular injections are painful.
Dimercaprol-metal complexes are nephrotoxic. This is particularly
so with iron, selenium or cadmium; do not use for these metals.
Alkalization of urine during therapy may have protective effects for
the kidney.
Drug interactions: Iron salts should not be administered during therapy.

DOSES

**Dogs, Cats:** Heavy metal toxicity: 2.5–5 mg/kg i.m. q4h for 2 days, then progressively increase dosing interval to q12h until recovery. (Note: the 5 mg/kg dose should only be used on the first day when severe acute intoxication occurs.) Aggressive supportive therapy should be maintained throughout the treatment period.

References

**Dimethylsulfoxide (DMSO)**
(Rimso-50*) POM

Formulations: Injectable: 50%, 90% liquid; medical grade only available as a 50% solution, other formulations are available as an industrial solvent. Topical: 70%, 90% gel; 70% cream.

Action: The mechanism of action is not well understood. Antioxidant activity has been demonstrated in certain biological settings and is thought to account for the anti-inflammatory activity.

Use:
- Treatment of extravasation of cytotoxic vesicant (e.g. doxorubicin).
- Intravesical administration for haemorrhagic cystitis induced by cyclophosphamide.
- Although efficacy is unproven it has been used in the treatment of renal amyloidosis.
- Anecdotal evidence for use in the resolution of canine calcinosis cutis.

DMSO is very rapidly absorbed through the skin following administration by all routes and is distributed throughout the body. Metabolites of DMSO are excreted in the urine and faeces. DMSO is also excreted through the lungs and skin, producing a characteristic sulphuric odour. Humans given DMSO experience a garlic-like taste sensation after administration.

Safety and handling: Should be kept in a tightly closed container because it is very hygroscopic. Gloves should be worn during topical application and the product should be handled with care.

Contraindications: Unknown.

Adverse reactions: Changes in refractive index and lens opacities have been seen in dogs given high doses of DMSO chronically; these are slowly reversible upon discontinuation of the drug. Other adverse effects include local irritation and erythema caused by local histamine release. Administration of i.v. of solutions with concentrations >20% may cause haemolysis and diuresis.
In the treatment of calcinosis cutis rapid resorption of calcium could result in calcification of renal tissue. Monitoring serum calcium is recommended.

**Drug interactions:** DMSO should not be mixed with other potentially toxic ingredients when applied to the skin because of profound enhancement of systemic absorption. The use of dexrazoxane and DMSO in combination should possibly be discouraged (as DMSO may decrease the activity of dexrazoxane).

**DOSES**

*Dogs:*
- Calcinosis cutis: apply 90% solution to half the affected area every other day.
- Renal amyloidosis: 80 mg/kg s.c. 3 times/week; 125–300 mg/kg p.o. q24h.
- Topical: apply 90% solution to affected areas q8–12h. Total daily dose should not exceed 20 ml. Do not apply for longer than 14 days.

*Cats:* No information available.

**References**

Tolon JMC, Jimenez JJE, Irizar IG and Trasobares PC (2018) Resolution of iatrogenic calcinosis cutis in a dog through topical application of DMSO. *Veterinary Record Case Reports* 6, 1–2


**Dinetofuran**

*(Vectra 3D) POM-V*

**Formulations:** Topical spot-on available in 5 sizes: 6.4 mg dinetofuran/kg, 0.6 mg pyriproxyfen/kg and 46.6 mg permethrin/kg.

**Action:** Flea adulticide. Nicotinic acetylcholine receptor agonist. Synergist activity with permethrin observed *in vitro*.

**Use:**
- For the treatment and prevention of ticks and fleas.
- The product has repellent activity against sandflies, mosquitoes and stable flies.

Remains effective after animal is immersed in water (swimming/bathing).

**Safety and handling:** Do not smoke when handling product.

**Contraindications:** Not for dogs <7 weeks or <1.5 kg.

**Adverse reactions:** In rare cases, behavioural disorder signs such as hyperactivity, vocalization or anxiety, lethargy or anorexia, vomiting and diarrhoea and neurological signs such as muscle tremor have been reported.

**Drug interactions:** No information available.
DOSES

**Dogs:** One spot-on monthly.

**Cats:** Not for use in cats.

References


---

**Dinoprost tromethamine** *(Prostaglandin F2)*

(Enzaprost, Lutalyse) **POM-V**

**Formulations:** Injectable: 5 mg/ml solution.

**Action:** Stimulates uterine contraction, causes cervical relaxation.

**Use:** Stimulation of uterine contractions in the treatment of open pyometra.

**Safety and handling:** Pregnant women and asthmatics should avoid handling this agent.

**Contraindications:** Do not use for the treatment of closed pyometra as there is a risk of uterine rupture.

**Adverse reactions:** Hypersalivation, panting, tachycardia, vomiting, urination, defecation, transient hyperthermia, locomotor incoordination and mild CNS signs have been reported. Such effects usually diminish within 30 minutes of drug administration. There is no adverse effect on future fertility.

**Drug interactions:** No information available.

**DOSES**

**Dogs:** Open pyometra: 0.1–0.25 mg/kg s.c. q12h until the uterus is empty; usually 3–5 days treatment required.

**Cats:** 0.1 or 0.25 mg/kg s.c. q12–24h.

**Dioctyl sodium sulfosuccinate** see **Docusate sodium**

**Diphenhydramine** *(Benadryl*, *Nytol*) **P**

**Formulations:** Oral: 25 mg tablet; 2 mg/ml solution. Other products are available of various concentrations and most contain other active ingredients.

**Action:** The antihistaminergic (H1) effects are used to reduce pruritus and prevent motion sickness. It is also a mild anxiolytic and sedative.
Use:
• To control mild pruritus (cats, dogs).
• Prevent motion sickness in dogs.

Safety and handling: Normal precautions should be observed.

Contraindications: Urine retention, glaucoma and hyperthyroidism.

Adverse reactions: Paradoxical excitement may be seen in cats.

Drug interactions: An increased sedative effect may occur if used with benzodiazepines or other anxiolytics/hypnotics. Avoid the concomitant use of other sedative agents. Diphenhydramine may enhance the effect of adrenaline and partially counteract anticoagulant effects of heparin.

DOSES

Dogs:
• Antiemesis: 2–4 mg/kg p.o. q6–8h.
• Suppression of pruritus: 1–2 mg/kg p.o. q8–12h.

Cats: 2–4 mg/kg p.o. q6-8h, 1 mg/kg i.v., i.m. q8h.

Diphenoxylate (Co-phenotrope)
(Co-phenotrope*, Lofenoxal*, Lomotil* (with atropine)) POM

Formulations: Oral: 2.5 mg diphenoxylate + 0.025 mg atropine tablet.

Action: Opioid that increases intestinal segmental smooth muscle tone, decreases the propulsive activity of smooth muscle, and decreases electrolyte and water secretion into the intestinal lumen. Atropine is added in a sub-therapeutic dose to discourage abuse by diphenoxylate overdose.

Use:
• Management of acute diarrhoea and irritable bowel syndrome in dogs. Concurrent correction of water and electrolyte imbalance is indicated while investigations into the cause of the diarrhoea are undertaken.
• Treatment of chronic cough due to its antitussive properties.

Safety and handling: Normal precautions should be observed.

Contraindications: Intestinal obstruction.

Adverse reactions: Sedation, constipation and ileus. Do not use in animals with liver disease, intestinal obstruction, neoplastic or toxic bowel disease. Little is known about the safety and efficacy of diphenoxylate in cats- adverse behavioural effects (excitement) may occur.

Drug interactions: Diphenoxylate may potentiate the sedative effects of barbiturates and other tranquillizers.
DOSES

**Dogs:** Antidiarrhoeal: 0.05–0.1 mg/kg diphenoxylate p.o. q6–8h. Antitussive: 0.2–0.4 mg/kg diphenoxylate p.o. q8–12h (monitor for constipation and use stool softeners if required).

**Cats:** No information available.

---

**Dobutamine**  
*(Dobutamine*, *Dobutrex*, *Posiject*) **POM**

**Formulations:** Injectable: 12.5 mg/ml, 50 mg/ml solution (NB: check vial strength prior to administration).

**Action:** Dobutamine is a direct-acting synthetic catecholamine and derivative of isoprenaline with direct beta-1 adrenergic agonist effects and mild beta-2 and alpha-1 adrenergic effects at standard doses. Positive inotropy results primarily from stimulation of the beta-1 adrenoreceptors of the heart, while producing less marked chronotropic, arrhythmogenic and vasodilatory effects. Dobutamine does not cause the release of endogenous noradrenaline.

**Use:**
- Short-term inotropic support of patients with heart failure due to systolic dysfunction (e.g. dilated cardiomyopathy), septic and cardiogenic shock.
- It is used to support myocardial function during anaesthesia in animals that are hypotensive when reduced myocardial contractility is suspected as the primary cause.

Dobutamine is a potent and short-acting drug, therefore, it should be given in low doses by continuous rate infusion; accurate dosing is important. The dose of dobutamine should be adjusted according to clinical effect, therefore, monitoring of arterial blood pressure during administration is advisable. Ideally blood pressure should be measured directly via an arterial catheter during dobutamine infusion for greater accuracy. All sympathomimetic drugs have proarrhythmic properties, therefore ECG should be monitored during drug infusion. The dose should be titrated upwards until improvement in blood pressure, perfusion or clinical status is seen, or adverse effects (usually tachyarrhythmias) develop. The beneficial effects of dobutamine diminish over 48 hours due to down regulation of beta receptors.

**Safety and handling:** Dilute to a 25 μg (micrograms)/ml solution in dextrose or normal saline and store solution in the fridge when not in use. Degradation of dobutamine solution causes a pink discoloration. The reconstituted solution is stable for at least 24 hours, after which time, discoloured solutions should be discarded.

**Contraindications:** Avoid in patients with a cardiac outflow obstruction (e.g. aortic stenosis).
**Adverse reactions:** Dobutamine is short-acting, therefore, adverse reactions such as tachycardia, proarrhythmia and hypertension can usually be managed by stopping the drug infusion. Hypokalaemia can develop with prolonged use; this can predispose to tachyarrhythmias. Complex ventricular arrhythmias may also be treated with lidocaine. Use cautiously in cases of atrial fibrillation as may increase ventricular rate. Prior and concurrent treatment with digoxin is recommended. Nausea, vomiting and seizures (particularly in cats) are also possible.

**Drug interactions:** Diabetic patients treated with dobutamine may experience increased insulin requirements. Increased systemic vascular resistance may develop if dobutamine is administered with beta-blocking drugs such as propranolol, doxapram or monoamine oxidase inhibitors (e.g. selegiline). Concomitant use with halothane may result in an increased incidence of arrhythmias.

**DOSES**

**Dogs:** Lower end of dose range 2.5–5 μg (micrograms)/kg/min i.v. by constant rate infusion. Start at the bottom end of the dose range and increase slowly until the desired effect is achieved. Higher end dose ranges up to 20 μg/kg/min i.v. by constant rate infusion have been reported. Adverse effects (tachycardia, arrhythmia) are more commonly seen at doses >10 μg/kg/min. Administer with an i.v. infusion pump or other i.v. flow controlling device.

**Cats:** 1–5 μg (micrograms)/kg/min i.v. by constant rate infusion. Start at the bottom end of the dose range and increase slowly until the desired effect is achieved. Adverse effects are more commonly seen at doses >2.5 μg/kg/min. Administer with an i.v. infusion pump or other i.v. flow controlling device. Doses over 5 μg/kg/min i.v. by constant rate infusion are reported; may cause seizures.

**References**


**Docusate sodium (Dioctyl sodium sulfosuccinate, DSS)**

*(Co-danthrusate*, *Dioctyl*, *Docusol*, *DulcoEase*, *Norgalax*, *Waxsol*) *P, GSL*

**Formulations:** **Oral:** 100 mg capsule (Dioctyl); 2.5 mg/ml liquid (Docusol Paediatric Solution), 10 mg/ml liquid (Docusol), 50 mg dantron plus 60 mg docusate/5 ml (Co-danthrusate). **Rectal:** 120 mg enema (Norgalax). **Topical:** 0.5% docusate in water-miscible base (Waxsol). Docusate is also a component of many other mixed topical preparations.

**Action:** Anionic surfactant acting as emulsifying, wetting and dispersing agent.
Use: Constipation and ceruminous otitis.

Safety and handling: Normal precautions should be observed.

Contraindications: Intestinal obstruction.

Adverse reactions: Avoid the concurrent use of docusate and mineral oil.

Drug interactions: No information available.

DOSES

Dogs:
- Constipation: 50–100 mg p.o. q12–24h or 10–15 ml of 5% solution mixed with 100 ml of water instilled per rectum prn.
- Otitis: a few drops in the affected ear q8–12h or 5–15 min prior to flushing.

Cats:
- Constipation: 50 mg p.o. q12–24h or 2 ml of a 5% solution mixed with 50 ml of water instilled per rectum prn.
- Otitis: dose as for dogs.

Dog appeasing pheromone
(Adaptil) general sale

Formulations: Plug-in diffuser, topical environmental spray, collar. NOT to be confused with Adaptil tablets which are a nutraceutical.

Action: The mixture is based on derivatives of the dermal secretions produced by the bitch after whelping, which help to keep pups within the safety of the den. The signal causes an innate emotional bias in the perception of the environment and does not require learning. A similar signal appears to form part of the social signal regulating maintenance of stable social groups of adult dogs. Associated limbic activity is believed to help antagonize the effect of certain perceived potential threats in the environment, but does not cause sedation or reduce the startle response.

Use:
- Helps control signs of stress associated with separation, noise sensitivity, travel, introduction to a new home, visits to a novel environment (e.g. veterinary clinic) and other anxiogenic circumstances (e.g. kennels).

The diffuser should be placed in the room most frequently occupied by the dog or where the inappropriate behaviour most frequently occurs. For behavioural problems involving attachment-related issues with the owner, a treatment period of 3 months is recommended. The spray can be used inside and outside the home environment. It can be used in cars, hospitalization cages, kennels, indoor pens or refuge areas, and applied directly on to bedding. The collar formulation is particularly useful to help control reactions which occur outside the home. If multiple dogs are affected by a
problem, each dog should wear a collar and/or possibly a diffuser considered for problems based around the home. Do not spray directly on to animals or near an animal’s face. The collar formulation should not be used for animals with a known reactivity to collars. Avoid contact with water when the collar is in use as this may wash out the active ingredients.

Safety and handling: Normal precautions should be observed.
Contraindications: No information available.
Adverse reactions: No information available.
Drug interactions: None known, although anecdotally an apparently synergistic action with benzodiazepines has been reported in some instances. Can be used safely alongside psychopharmacy.

APPLICATION

Dogs: The diffuser is active over an area of approximately 50–70 m², although this may be reduced in the presence of air-conditioning. If the total target area exceeds this, a second diffuser should be used; a collar may be preferable in the case of an air-conditioned environment. One vial will last for approximately 4 weeks of continuous use. It should not be repeatedly switched on and off. Follow manufacturer’s instructions for each formulation. In the house, DAP spray can complement the use of the diffuser device where a more local application is needed. Spray 8–10 pumps of DAP on to the required surface 15 minutes before the effect is required, and before the dog is introduced into the environment, to allow the alcohol carrier to evaporate. The effect should last for 1–2 hours, although each animal will respond individually. The application can be renewed after 1–2 hours or when the effects appear to be reducing.

Cats: Not applicable.

References


Domperidone
(Domperidone*, Motilium*) POM

Formulations: Oral: 10 mg tablet; 1 mg/ml suspension.

Action: Antiemetic with a similar mechanism of action to metoclopramide, but with fewer adverse CNS effects as it cannot penetrate the blood–brain barrier. It is gastrokinetic in humans but may not be a prokinetic in dogs. It has also been shown to enhance the innate cell-mediated immune response.
Use:
- Treatment of vomiting; however, maropitant is authorized for veterinary use and there is more clinical experience with metoclopramide and ondansetron.
- A strategic domperidone-based treatment programme has shown some efficacy in reducing the risk of developing clinical canine leishmaniosis in a high prevalence area.

Safety and handling: Normal precautions should be observed.

Contraindications: Intestinal obstruction or perforation, severe hepatic impairment. Contraindicated in humans with known existing prolongation of cardiac conduction intervals, significant electrolyte disturbances, or underlying cardiac disease, but no information available for dogs and cats. Use with caution in dog breeds (e.g. collies) that may have MDR1 (ABCB1) mutations.

Adverse reactions: There is little information on the use of this drug in veterinary medicine, but it may cause gastroparesis in dogs. May increase plasma prolactin, leading to galactorrhoea. Domperidone is banned for human use in the USA because it has been associated with prolongation of the QT interval and has been linked to increased risk of cardiac arrhythmias or sudden cardiac death in humans. Dose-dependent adverse behavioural effects (excitement, aggression) and motor impairment have been seen in cats.

Drug interactions: Do not use concurrently with Class 1A or Class III antiarrhythmics (e.g. amiodarone, sotalol), erythromycin or cisapride.

DOSES
Dogs:
- Vomiting: 2–5 mg per animal q8h.
- Preventive strategy for leishmaniosis in a high prevalence area: 0.5 mg/kg q24h for 30 consecutive days, repeated every 4 months.

Cats: Vomiting: 2–5 mg per animal q8h.

References

Dopamine
(Dopamine*) POM

Formulations: Injectable: 200 mg in 5 ml vial (40 mg/ml solution), 800 mg in a 5 ml vial (160 mg/ml solution) (NB: check vial strength prior to administration).
**Action:** Dopamine is an endogenous catecholamine and precursor of noradrenaline, with direct and indirect (via release of noradrenaline) agonist effects on dopaminergic and beta-1 and alpha-1 adrenergic receptors.

**Use:**
- Treatment of shock following correction of fluid deficiencies.
- Treatment of acute heart failure.
- Support of blood pressure during anaesthesia.

Dobutamine is preferred for support of systolic function in patients with heart failure. Dopamine is a potent and short-acting drug, therefore it should be given in low doses by continuous rate infusion, and accurate dosing is important. Dopamine should be diluted in normal saline to an appropriate concentration. At low doses (<10 μg (micrograms)/kg/min) dopamine acts on dopaminergic and beta-1 adrenergic receptors, causing some vasodilation, increased force of contraction and heart rate, and resulting in an increase in cardiac output and organ perfusion; systemic vascular resistance remains largely unchanged. At higher doses (>10 μg/kg/min) dopaminergic effects are overridden by the alpha effects, resulting in an increase in systemic vascular resistance and reduced peripheral blood flow. Dopamine has been shown to vasodilate mesenteric blood vessels via DA1 receptors. There may be an improvement in urine output but this may be entirely due to inhibition of proximal tubule sodium ion reabsorption and an improved cardiac output and blood pressure rather than directly improving renal blood flow. The dose of dopamine should be adjusted according to clinical effect, therefore, monitoring of arterial blood pressure during administration is advisable. In order to improve accuracy of monitoring clinical effect, direct arterial blood pressure monitoring via an arterial catheter is advisable. All sympathomimetic drugs have pro-arrhythmic properties, therefore ECG monitoring is advised.

**Safety and handling:** Solution should be discarded if it becomes discoloured.

**Contraindications:** Discontinue or reduce the dose of dopamine should cardiac arrhythmias arise.

**Adverse reactions:** Extravasation of dopamine causes necrosis and sloughing of surrounding tissue due to tissue ischaemia. Should extravasation occur, infiltrate the site with a solution of 5–10 mg phentolamine in 10–15 ml of normal saline using a syringe with a fine needle. Nausea, vomiting, tachyarrhythmias and changes in blood pressure are the most common adverse effects. Hypotension may develop with low doses, and hypertension may occur with high doses. Sudden increases in blood pressure may cause a severe bradycardia. All dopamine-induced arrhythmias are most effectively treated by stopping the infusion.

**Drug interactions:** Risk of severe hypertension when monoamine oxidase inhibitors, doxapram and oxytocin are used with dopamine.
Halothane may increase myocardial sensitivity to catecholamines. The effects of beta-blockers and dopamine are antagonistic.

**DOSES**

**Dogs:** 2–10 μg (micrograms)/kg/min i.v. as a constant rate infusion; titrate to effect. Ensure adequate volume replacement prior to use.

**Cats:** 1–5 μg (micrograms)/kg/min i.v. as a constant rate infusion; titrate to effect. Ensure adequate volume replacement prior to use.

NB: in dogs and cats a CRI of 1–10 μg/kg/min i.v. will have predominantly beta-1 effects and from 10–15 μg/kg/min i.v. will have beta-1 and alpha-1 effects. Monitor closely for adverse effects during administration.

**Dorzolamide**  
(-CoSopt*, Dorzolamide*, Dorzolamide with Timolol*, Trusopt*)  
**POM**

**Formulations:** Ophthalmic drops: 20 mg/ml (2%) (Trusopt), 2% dorzolamide + 0.5% timolol (CoSopt); 5 ml bottle, single-use vials (CoSopt, Trusopt).

**Action:** Reduces intraocular pressure by reducing the rate of aqueous humour production by inhibiting the formation of bicarbonate ions within the ciliary body epithelium.

**Use:** In the control of all types of glaucoma in dogs and cats, either alone or in combination with other topicals. Dorzolamide/timolol combination may be more effective in dogs than either drug alone; in cats, maximal IOP lowering efficiency occurs with dorzolamide alone. It may be less tolerated than brinzolamide because of its pH of 5.6.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Severe hepatic or renal impairment. Timolol causes miosis and is therefore not the drug of choice in uveitis or anterior lens luxation.

**Adverse reactions:** Local irritation, blepharitis, keratitis, salivation, inappetance. Dorzolamide may cause more local irritation than brinzolamide. Timolol can cause bradycardia and hypotension. Rarely, dorzolamide has been reported to cause hypokalaemia in cats, and metabolic acidosis in dogs, as a result of systemic absorption.

**Drug interactions:** No information available.

**DOSES**

**Dogs, Cats:** 1 drop/eye q8–12h.

**References**


**Doxepin**  
(Sinepin*, Sinequan*, Zonalon*) **POM**

**Formulations:** Oral: 25 mg, 50 mg capsules.

**Action:** Doxepin blocks noradrenaline and serotonin reuptake in the brain, resulting in antidepressive activity, while the H1 and H2 blockage result in antipruritic effects. Its metabolite, desmethyldoxepin, is also psychoactive.

**Use:**
- Management of pruritus and psychogenic dermatoses where there is a component of anxiety, including canine acral lick dermatitis and compulsive disorders.

There are no good published trial data as to its efficacy in this context at the suggested doses, so other agents e.g. amitriptyline or clomipramine (which is an authorized preparation in dogs) are preferable.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Hypersensitivity to tricyclic antidepressants, glaucoma, history of seizure or urinary retention and severe liver disease.

**Adverse reactions:** Sedation, dry mouth, diarrhoea, vomiting, excitability, arrhythmias, hypotension, syncope, increased appetite, weight gain and, less commonly, seizures and bone marrow disorders have been reported in humans.

**Drug interactions:** Should not be used with monoamine oxidase inhibitors or drugs which are metabolized by cytochrome P450 2D6, e.g. chlorphenamine and cimetidine. Should not generally be used alongside other serotonergic agents given risk of serotonin syndrome, although use alongside trazodone may be considered in exceptional cases, so long as patient carefully monitored for signs of serotonin syndrome.

**DOSES**
- **Dogs:** 3–5 mg/kg p.o. q8–12h, maximum dose 150 mg q12h.
- **Cats:** 0.5–1.0 mg/kg p.o. q12–24h.

---

**Doxorubicin (Adriamycin)**
(Doxorubicin*) **POM**

**Formulations:** Injectable: 10 mg, 50 mg powders for reconstitution; 10 mg (2 mg/ml) solutions.

**Action:** Inhibits DNA synthesis and function.

**Use:**
- Treatment of lymphoma, soft tissue sarcomas, osteosarcoma and haemangiosarcoma.
• May have a role in the management of carcinomas in the dog and soft tissue sarcomas in the cat.

It may be used alone or in combination with other antineoplastic therapies. Premedication with i.v. chlorphenamine or dexamethasone is recommended. Doxorubicin is highly irritant and must be administered via a preplaced i.v. catheter. The reconstituted drug should be administered over a minimum period of 10 minutes into the side port of a freely running i.v. infusion of 0.9% NaCl. Do not use heparin flush. Use with care in breeds predisposed to cardiomyopathy. May need to reduce dose in patients with liver disease. Use with caution in patients previously treated with radiation as can cause radiation recall. See specialist texts for protocols and further advice.

Safety and handling: Potent cytotoxic drug that should only be prepared and administered by trained personnel. See Appendix and specialist texts for further advice on chemotherapeutic agents. After reconstitution the drug is stable for at least 48 hours at 4°C. A 1.5% loss of potency may occur after 1 month at 4°C but there is no loss of potency when frozen at −20°C. Filtering through a 0.22 μm filter will ensure adequate sterility of the thawed solution. Store unopened vials under refrigeration.

Contraindications: Do not use in patients with existing cardiac disease. Do not use in cats with renal disease/dysfunction.

Adverse reactions: Allergic reactions have been reported; acute anaphylactic reactions should be treated with adrenaline, steroids and fluids. Doxorubicin causes a dose-dependent cumulative cardiotoxicity in dogs (leading to cardiomyopathy and congestive heart failure). The risk of cardiotoxicity is greatly increased when the cumulative dose is >240 mg/m². It may also cause tachycardia and arrhythmias on administration; monitor with clinical exam/auscultation, ECG and/or echocardiograms. Anorexia, vomiting, severe leucopenia, thrombocytopenia, haemorrhagic gastroenteritis and nephrotoxicity (in cats if dosages >100 mg/m²) are the major adverse effects. A CBC and platelet count should be monitored whenever therapy is given. If neutrophil count drops below 2.5 × 10⁹/l or platelet count drops below 50 × 10⁹/l, treatment should be suspended. Once counts have stabilized, doxorubicin can be restarted at the same dose. If haematological toxicity occurs again, or if GI toxicity is recurrent, the dose should be reduced by 10–25%. Extravasation injuries secondary to perivascular administration may be serious, with severe tissue ulceration and necrosis possible. Dexrazoxane can be used to treat extravasation if it occurs. Ice compresses may also be beneficial (applied for 15 min q6h). Dogs with the ABCB1 (MDR1) mutation may be at higher risk of toxicity.

Drug interactions: Barbiturates increase plasma clearance of doxorubicin. Concurrent administration with cyclophosphamide increases the risk of nephrotoxicity in cats. The agent causes a reduction in serum digoxin levels. Do not mix doxorubicin with other drugs. Doxorubicin is incompatible with dexamethasone,
5-fluorouracil and heparin; concurrent use will lead to precipitate formation. Do not use with spinosad: increased risk of toxicity.

**DOSES**

*See Appendix for chemotherapy protocols and conversion of body weight to body surface area.*

**Dogs:** All uses: 30 mg/m$^2$ i.v. q3wk. In dogs weighing <10 kg a dose of 1 mg/kg should be used. Maximum total dose not to exceed 240 mg/m$^2$.

**Cats:** All uses: 1 mg/kg or 20–25 mg/m$^2$ i.v. q3–5wk. Maximum total dose not to exceed 240 mg/m$^2$.

**References**


---

**Doxycycline**

(Doxybactin, Ronaxan) **POM-V**

**Formulations:** Oral: 20 mg, 50 mg, 100 mg, 200 mg, 400 mg tablets. A paste is available on a named patient basis.

**Action:** Time-dependent antimicrobial agent inhibiting protein synthesis at the initiation step by interacting with the 30S ribosomal subunit.

**Use:**

- Antibacterial (including spirochaetes such as *Helicobacter* and *Campylobacter*), antirickettsial, antimycoplasmal (e.g. *Mycoplasma haemofelis*) and antichlamydial activity.
- It is the drug of choice to treat feline chlamydiosis; treatment may be required for 3–4 weeks in cats.
- It is also an adjunctive treatment for canine heartworm disease as it eliminates the symbiont *Wolbachia*.

It is not affected by, and does not affect, renal function as it is excreted in faeces, and is therefore recommended when tetracyclines are indicated in animals with renal impairment. Being extremely lipid-soluble, it penetrates well into prostatic fluid and bronchial secretions. Administer with food.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not administer to pregnant animals. Do not administer if there is evidence of oesophagitis or dysphagia.

**Adverse reactions:** Nausea, vomiting and diarrhoea. Oesophagitis and oesophageal ulceration may develop; administer with food or a water bolus to reduce this risk. Administration during tooth development may lead to discoloration of the teeth, although the risk is less than with other tetracyclines. Doxycycline hyclate (the salt used in the authorized form of doxycycline in the UK) produces an acidic solution, while doxycycline monohydrate is much less
acidic. Doxycycline monohydrate has been associated with reduced development of oesophageal ulceration in humans.

**Drug interactions:** Absorption of doxycycline is reduced by antacids, calcium, magnesium and iron salts, although the effect is less marked than seen with water-soluble tetracyclines. Phenobarbital and phenytoin may increase its metabolism, thus decreasing plasma levels.

**DOSES**

*See Appendix for guidelines on responsible antibacterial use.*

**Dogs, Cats:** 10 mg/kg p.o. q24h with food.

**References**


Edetate calcium disodium
(CaEDTA) (Ledclair*) POM

Formulations: Injectable: 200 mg/ml solution.

Action: Heavy metal chelating agent.

Use:
- Treatment of lead and zinc poisoning.

Dilute strong solution to a concentration of 10 mg/ml in 5% dextrose before use. Blood lead levels may be confusing, therefore, monitor clinical signs during therapy. Measure blood lead levels 2–3 weeks after completion of treatment in order to determine whether a second course is required or if the animal is still being exposed to lead. Ensure there is no lead in the GI tract before administering (e.g. use laxatives).

Safety and handling: Normal precautions should be observed.

Contraindications: Use with caution in patients with impaired renal function.

Adverse reactions: Reversible nephrotoxicity is usually preceded by other clinical signs of toxicity (e.g. depression, vomiting, diarrhoea). Dogs showing GI effects may benefit from zinc supplementation. Injections are painful.

Drug interactions: No information available.

DOSES
Dogs, Cats: Lead or zinc toxicity: 25 mg/kg s.c. q6h for 2–5 days. The total daily dose should not exceed 2 g. Dogs that respond slowly or have an initial (pretreatment) blood lead level of >4.5 μmol/l may need another 5-day course of treatment after a rest period of 5 days.

Edrophonium
(Edrophonium Injection BP*, Enlon*(US)) POM

Formulations: Injectable: 10 mg/ml solution. Currently only available through import license in the UK.

Action: Edrophonium is a reversible and short-acting competitive inhibitor of acetylcholinesterase with a very rapid onset of action. It blocks the breakdown of acetylcholine at the neuromuscular junction, thereby prolonging its action.

Use:
- To differentiate myasthenia gravis from other causes of exercise intolerance (previously known as the Tensilon test).
- Used to treat atrial tachycardia (vagal effects) and to antagonize non-depolarizing neuromuscular blockade.
• Also used to distinguish between under- and over-treatment of myasthenia gravis with other anticholinesterases by giving doses at the lower end of the range for diagnostic tests. If treatment has been inadequate, edrophonium will improve muscle weakness; in over-treatment, edrophonium will temporarily exacerbate muscle weakness.

Use with caution in patients with bronchial disease (especially feline asthma), bradycardia (and other arrhythmias), hypotension, renal impairment or epilepsy. If availability is limited then neostigmine may be used as an alternative diagnostic test for myasthenia gravis.

Safety and handling: Normal precautions should be observed.

Contraindications: Do not use in patients with mechanical GI or urinary tract obstructions or peritonitis.

Adverse reactions: Include nausea, vomiting, increased salivation and diarrhoea. Overdosage may lead to muscle fasciculations and paralysis. Severe bradyarrhythmias, even asystole, may occur if edrophonium is used to antagonize neuromuscular block without the co-injection of atropine. In overdose, respiration should be supported and atropine administered i.v. to counteract muscarinic effects.

Drug interactions: Do not use at higher doses in conjunction with depolarizing neuromuscular relaxants (e.g. suxamethonium) as this may potentiate neuromuscular blockade.

DOSES

Dogs:
• Diagnosis of myasthenia gravis: 0.1 mg/kg i.v. (maximum 5 mg). Improvement should be noted within 30 seconds, with the effects dissipating within 5 minutes, for a positive test. Atropine should be available (0.05 mg/kg) to control cholinergic side effects (e.g. salivation, urination). If there is no response, repeat test after 10–20 minutes using 0.2 mg/kg.
• Atrial tachycardia after failure of vagal manoeuvres: 1.5 mg i.v. once (NB: this procedure is not advised in cases of heart failure).
• Antagonism of non-depolarizing neuromuscular blockade: edrophonium (0.5–1.0 mg/kg) is mixed with atropine (0.04 mg/kg) and injected i.v. over 2 minutes once signs of spontaneous recovery from block, e.g. diaphragmatic ‘twitching’, are present. Continued ventilatory support should be provided until full respiratory muscle activity is restored.

Cats:
• Diagnosis of myasthenia gravis: 0.25–0.5 mg total dose/cat i.v. Doses >6 mg/kg have been experimentally reported in cats but will result in bradycardia and are not required for confirmation of myasthenia gravis. Improvement should be noted within 30 seconds, with the effects dissipating within 5 minutes, for a positive test. Atropine should be available (0.04 mg/kg) to control cholinergic side effects (e.g. salivation, urination).
• Atrial tachycardia after failure of vagal manoeuvres: doses as for dogs.
References
Clutton RE (1994) Edrophonium for the antagonism of neuromuscular blockade in dogs. Veterinary Record 134, 674–678

Emodepside (Dronspot, Procox, Profender) POM-V

Formulations: Topical: 21.4 mg/ml emodepside with praziquantel solution in spot-on pipettes (Profendor: 3 sizes) for cats. An oral formulation (0.9 mg/ml) with toltrazuril (q.v.) for dogs is available in several European countries (Procox).

Action: Stimulates pre-synaptic secretin receptors resulting in paralysis and death of the parasite.

Use:
• Treatment of roundworms (adult and immature) and tapeworms (adult) in cats including Toxocara cati, Toxascaris leonina, Ancylostoma tubaeforme, Aelurostrongylus abstrusus, Dipylidium caninum, Taenia taeniaeformis, Echinococcus multilocularis.
• Treatment of queens during late pregnancy to prevent lactogenic transmission to the offspring of Toxocara cati (L3 larvae).

Do not shampoo until substance has dried.

Safety and handling: Women of child-bearing age should avoid contact with this drug or wear disposable gloves when handling. Harmful to aquatic organisms.

Contraindications: Do not use in cats <8 weeks or <0.5 kg.

Adverse reactions: Ingestion may result in salivation or vomiting. Harmful to aquatic animals.

Drug interactions: Emodepside is a substrate for P-glycoprotein. Co-treatment with other drugs that are P-glycoprotein substrates/inhibitors (these include ciclosporin, ivermectin, ranitidine and many steroids and opiates) could cause problems but there are no reports of this.

DOSES
Dogs: No information available – see Toltrazuril for dose.
Cats: Endoparasites: minimum dose 0.14 ml/kg applied topically once per treatment cycle. For the lungworm Aelurostrongylus abstrusus, two treatments administered 2 weeks apart are effective.
Enalapril
(Enacard) POM-V

Formulations: Oral: 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg tablets.

Action: Angiotensin converting enzyme (ACE) inhibitor. It inhibits conversion of angiotensin I to angiotensin II and inhibits the breakdown of bradykinin. Overall effect is a reduction in preload and afterload via venodilation and arteriolar dilation, decreased salt and water retention via reduced aldosterone production and inhibition of the angiotensin-aldosterone-mediated cardiac and vascular remodelling. Efferent arteriolar dilation in the kidney can reduce intraglomerular pressure and therefore glomerular filtration. This may decrease proteinuria.

Use:
- Indicated for treatment of congestive heart failure caused by mitral regurgitation or dilated cardiomyopathy in dogs. Can be used in combination with other drugs to treat heart failure (e.g. pimobendan, spironolactone, digoxin).
- Can also be used for heart failure in cats.
- Management of proteinuria associated with chronic renal insufficiency, glomerular disorders and protein-losing nephropathies.
- May reduce blood pressure in hypertension.

ACE inhibitors are more likely to cause or exacerbate prerenal azotaemia in hypotensive animals and those with poor renal perfusion (e.g. acute, oliguric renal failure). Use cautiously if hypotension, hyponatraemia or outflow tract obstruction are present. Regular monitoring of blood pressure, serum creatinine, urea and electrolytes is strongly recommended with ACE inhibitor treatment. The use of ACE inhibitors in cats with cardiac disease stems from extrapolation from theoretical benefits and studies showing a benefit in other species with heart failure and different cardiac diseases (mainly dogs and humans).

Safety and handling: Normal precautions should be observed.

Contraindications: Do not use in cases of cardiac output failure or hypotension.

Adverse reactions: Potential adverse effects include hypotension, hyperkalaemia and azotaemia. Monitor blood pressure, serum creatinine and electrolytes when used in cases of heart failure. Dosage should be reduced if there are signs of hypotension (weakness, disorientation). Anorexia, vomiting and diarrhoea are rare. No adverse effects were seen in normal dogs given 15 mg/kg/day for up to 1 year. It is not recommended for breeding, pregnant or lactating bitches, as safety has not been established.

Drug interactions: Concomitant treatment with potassium-sparing diuretics (e.g. spironolactone) or potassium supplements could result in hyperkalaemia. However, in practice, spironolactone and ACE inhibitors appear safe to use concurrently. There may be an increased risk of nephrotoxicity and decreased clinical efficacy when
used with NSAIDs. There is a risk of hypotension with concomitant administration of diuretics, vasodilators (e.g. anaesthetic agents, antihypertensive agents) or negative inotropes (e.g. beta-blockers).

DOSES

**Dogs:**
- **Cardiac disease:** 0.5 mg/kg p.o. q24h increasing to 0.5 mg/kg p.o. q12h after 2 weeks in the absence of a clinical response.
- **Protein-losing nephropathy:** 0.25–1 mg/kg p.o. q12–24h.
- **Hypertension:** 0.5 mg/kg p.o. q12h. Can be up-titrated slowly to effect. Doses up to 3 mg/kg have been used.

**Cats:** **Cardiac disease, protein-losing nephropathy:** 0.25–0.5 mg/kg p.o. q12–24h.

---

**Enilconazole**

(Imaverol) **POM-VPS**

**Formulations:** Topical: 100 mg/ml (10%) liquid.

**Action:** Inhibition of cytochrome P450-dependent synthesis of ergosterol in fungal cells, causing increased cell wall permeability and allowing leakage of cellular contents.

**Use:**
- Fungal infections of the skin.
- Topical treatment of sinonasal aspergillosis.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.

**Adverse reactions:** Hepatotoxic if swallowed. Avoid contact with eyes. Hypersalivation, GI signs and muscle signs reported in cats.

**Drug interactions:** No information available.

**DOSES**

**Dogs:**
- **Dermatological indications:** dilute 1 volume enilconazole in 50 volumes of water to produce a 2 mg/ml (0.2%) solution. Apply every 3 days for 3–4 applications.
- **Nasal aspergillosis:** 10 mg/kg instilled once via endoscopically-placed sinus catheter or administered q12h into the nasal cavities and sinuses through indwelling tubes for 7–10 days. Dilute the solution of enilconazole (100 mg/ml) 50:50 with water. The instilled volume should be kept low (<10 ml) to reduce the risk of inhalation and the tubes flushed with an equivalent volume of air. Make up a fresh solution as required.

**Cats:** **Dermatological indications:** doses as for dogs.

**References**


Enrofloxacin
(Baytril, Enrocare, Enrotron, Enrox, Enroxil, Fenoflox, Floxabactin, Powerflox, Quinoflox, Xeden, Zobuxa) POM-V

Formulations: Injectable: 25 mg/ml, 50 mg/ml. Oral: 15 mg, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg tablets; 25 mg/ml solution.

Action: Enrofloxacin is a concentration-dependent antimicrobial which inhibits bacterial DNA gyrase. Pulse dosing regimens may be effective, particularly against Gram-negative bacteria.

Use: Ideally fluoroquinolone use should be reserved for infections where culture and sensitivity testing predicts a clinical response and where lower tier antimicrobials would not be effective. Active against *Mycoplasma* and many Gram-positive and Gram-negative organisms, including *Pasteurella*, *Staphylococcus*, *Pseudomonas aeruginosa*, *Klebsiella*, *Escherichia coli*, *Mycobacterium*, *Proteus* and *Salmonella*. Relatively ineffective against obligate anaerobes. Fluoroquinolones are highly lipophilic drugs that attain high concentrations within cells in many tissues and are particularly effective in the management of soft tissue, urogenital (including prostatic) and skin infections. For the treatment of non-tubercular mycobacterial disease, enrofloxacin can be combined with clarithromycin and rifampin. Administration by i.v. route is not authorized but has been used in cases of severe sepsis. If this route is used, dilute to 10 times the volume in 0.9% sodium chloride and administer slowly as the carrier contains potassium (ideally 35–45 minutes).

Safety and handling: Normal precautions should be observed.

Contraindications: Fluoroquinolones are relatively contraindicated in growing dogs, as cartilage abnormalities have been reported in young dogs (but not cats). Enrofloxacin is not authorized in cats <8 weeks of age; dogs <1 year of age; large-breed dogs <18 months of age.

Adverse reactions: In cats, irreversible retinal blindness has occurred at dosing rates higher than those currently recommended, although at least one case reported in the literature was being dosed within the 5 mg/kg q24h rate. Enrofloxacin should be used with caution in epileptic animals until further information is available, as in humans they potentiate CNS adverse effects when administered concurrently with NSAIDs. Careful dosing in cats is facilitated by accurate body weight and use of a 1 ml syringe, and doses higher than 5 mg/kg/day are not recommended in cats.

Drug interactions: Absorbents and antacids containing cations (Mg$^{2+}$, Al$^{3+}$) may bind fluoroquinolones, preventing their absorption from the GI tract. Their absorption may also be inhibited by sucralfate and zinc salts; separate dosing by at least 2 hours. Fluoroquinolones increase plasma theophylline concentrations.
Cimetidine may reduce the clearance of fluoroquinolones and so should be used with caution with these drugs. Some fluoroquinolones may decrease the metabolism and increase nephrotoxicity of ciclosporin and tacrolimus in humans and therefore concurrent use in animals is best avoided until more research has been performed. May increase the action of orally administered anticoagulants.

DOSES
See Appendix for guidelines on responsible antibacterial use.

**Dogs:** 5 mg/kg s.c. q24h. Higher doses (10 mg/kg q24h) should be considered for certain sites, including prostatitis. Even higher doses may be necessary for certain isolates of *Pseudomonas aeruginosa*. Contact the manufacturer to discuss individual cases.

**Cats:** 5 mg/kg s.c. q24h; 2.5 mg/kg p.o. q12h or 5 mg/kg p.o. q24h.

References

**Ephedrine**
(Enurace, Ephedrine hydrochloride*) **POM-V, POM**

**Formulations:** 10 mg, 15 mg, 30 mg, 50 mg tablets; 3 mg/ml, 30 mg/ml solutions for injection; 0.5% and 1% nasal drops.

**Action:** Non-catecholamine sympathomimetic stimulates alpha- and beta-adrenergic receptors directly, and indirectly through endogenous release of noradrenaline. Also causes contraction of internal urethral sphincter muscles and relaxation of bladder muscles. Compared with more powerful sympathomimetics, e.g. oxymetazoline and xylometazoline, there is less of a rebound effect.

**Use:**
- Treatment of hypotension during anaesthesia. As well as constricting peripheral vessels, it has a positive inotropic effect and accelerates heart rate, therefore assisting in bradycardia. Effects tend to wane after 2–3 doses have been administered, due to exhaustion of endogenous noradrenaline stores.
- Also used orally in the treatment of urinary incontinence. Can be used in conjunction with phenylpropanolamine. Polyuria should be excluded before treatment is given for urinary incontinence, as many conditions that cause polyuria would be exacerbated by ephedrine.
- Proposed for treatment of nasal congestion (and may be of some benefit in cat ‘flu’).
Use with caution in dogs and cats with cardiovascular disease, partial urethral obstruction, hypertension, diabetes mellitus, hyperadrenocorticism, hyperthyroidism or other metabolic disorders.

**Safety and handling:** Pregnant women should take particular care to wear gloves for administration.

**Contraindications:** Do not use in pregnant or lactating patients or those with glaucoma.

**Adverse reactions:** Even at recommended therapeutic doses may cause more generalized sympathetic stimulation (panting, mydriasis, CNS stimulation) and cardiovascular effects (tachycardia, atrial fibrillation and vasoconstriction). May also cause reduction of the motility and tone of the intestinal wall.

**Drug interactions:** Synergistic with other sympathomimetics. Volatile anaesthetics will enhance the sensitivity of the myocardium to the effects of ephedrine. Concomitant use with cardiac glycosides (digoxin) and tricyclic antidepressants (amitriptyline) can cause arrhythmias. Will enhance effects of theophylline and may cause hypertension when given with MAO inhibitors (e.g. selegeline).

**DOSES**

**Dogs:**
- **Hypotension:** 0.05–0.2 mg/kg i.v.; repeat as necessary; duration of effect is short (5–15 min). Effects tend to wane after 2–3 doses have been administered.
- **Urinary incontinence:** 1 mg/kg p.o. q12h. Dose should be adjusted according to effect but there is a maximum dose of 2.5 mg/kg p.o. q12h.
- **Nasal congestion:** No dose determined. Suggest start at 1 drop of 0.5% solution intranasally q12h. If giving orally, suggest 0.5 mg/kg p.o. q12h.

**Cats:**
- **Hypotension:** 0.05–0.1 mg/kg i.v.; repeat as necessary; duration of effect is short (5–15 min). Effects tend to wane after 2–3 doses have been administered.
- **Nasal congestion:** 1 drop of 0.5% solution intranasally q12h. Oral formulations not convenient for administration to most cats.

**Epinephrine** see Adrenaline

**Epirubicin (4’-Epi-doxorubicin)**
(Epirubicin*, Pharmorubicin* POM

**Formulations:** Injectable: 10 mg, 20 mg, 50 mg powder for reconstitution; 2 mg/ml solution.

**Action:** Epirubicin is a semisynthetic stereoisomer of doxorubicin. Intracellularly its metabolism results in production of cytotoxic free radicals. It also binds irreversibly to DNA, thereby preventing
replication and can alter cell membrane functions. Cytotoxic anthracycline glycoside antibiotic that has demonstrated efficacy against several human neoplasms.

**Use:**
- Treatment of lymphoma (similar efficacy to doxorubicin) and also as an adjunct in the management of splenic haemangiosarcoma, canine histiocytic sarcoma and sporadically in other sarcomas and carcinomas.
- Epirubicin has been used in cats with feline injection site sarcoma.

It may be used alone or in combination with other antineoplastic therapies. The drug must be given i.v. Premedication with i.v. chlorphenamine or dexamethasone is recommended. As extravasation of the drug is likely to result in severe tissue necrosis, use of an indwelling catheter taped in place is essential. The reconstituted drug should be administered over a minimum period of 10 minutes into the side port of a freely running i.v. infusion of 0.9% NaCl. Reported to be less cardiotoxic than doxorubicin, epirubicin should still be used with caution in patients with or predisposed to cardiac disease.

**Safety and handling:** Potent cytotoxic drug that should only be prepared and administered by trained personnel. See Appendix and specialist texts for further advice on chemotherapeutic agents. After reconstitution the drug is stable for 24 hours at room temperature. Store under refrigeration up to 28 days. Protection from light is not necessary.

**Contraindications:** No information available.

**Adverse reactions:** Acute anaphylactic reactions should be treated with adrenaline, steroids and fluids. Epirubicin may cause a dose-dependent cumulative cardiotoxicity in dogs (leading to cardiomyopathy and congestive heart failure) but possibly at a lower incidence than that of doxorubicin. This rarely develops in dogs given a total dose of <240 mg/m². It may also cause tachycardia and arrhythmias on administration. Dogs with pre-existing cardiac disease should be routinely monitored with physical examination/auscultation, ECGs and/or echocardiograms. Anorexia, vomiting, pancreatitis, severe leucopenia, thrombocytopenia, haemorrhagic gastroenteritis and nephrotoxicity are major adverse effects. A CBC and platelet count should be monitored whenever therapy is given. If the neutrophil count drops below 2.5 × 10⁹ or if the platelet count drops below 50 × 10⁹, treatment should be suspended. Once the counts have stabilized, epirubicin can then be restarted at the same dose. If haematological toxicity occurs again, or if GI toxicity is recurrent the dose should be reduced by 10–25%. Dogs with the *ABCB1 (MDR1)* mutation may be at higher risk of toxicity.

**Drug interactions:** Epirubicin is incompatible with heparin; a precipitate will form. Increased risk of myelosuppression when used in combination with cyclophosphamide. In humans, cimetidine increased the area under the dose curve of epirubicin by 50% and should not be used concurrently.
DOSES
See Appendix for chemotherapy protocols and conversion of body weight to body surface area.

**Dogs:** All uses: 30 mg/m² i.v. q3wk; maximum total dose not to exceed 240 mg/m². In dogs weighing <10 kg a dose of 1 mg/kg should be used.

**Cats:** 25 mg/m² or 1 mg/kg i.v. q3wk.

**References**

---

**Eprinomectin**  
*(Broadline)* **POM-V**

**Formulations:** Topical: spot-on solution containing 4 mg/ml eprinomectin, fipronil, S-methoprene and praziquantel (2 pipette sizes).

**Action:** Interacts with GABA and glutamate-gated channels, leading to flaccid paralysis of parasites.

**Use:**
- Treatment and prevention of fleas, ticks and the treatment of nematodes, including feline lungworm and vesical worms (*Capillaria plica*), in cats.
- Prevention of heartworm disease (*Dirofilaria immitis* larvae) for 1 month.

The praziquantel component of the authorized product confers tapeworm control. The fipronil component treats notoedric mange (*Notoedres cati*) and aids in the control of *Neotrombicula autumnalis*, and *Cheyletiella* spp. The S-methoprene component confers ovicidal and larvicidal activity against fleas.

**Safety and handling:** Normal precautions should be observed when administering. Likely to be toxic to aquatic organisms. Care with disposal.

**Contraindications:** Cats <0.6kg or 7 weeks of age. Not intended for use in dogs.

**Adverse reactions:** Mild clumping of the hair is often seen after application.

**Drug interactions:** May have interactions with other P-glycoprotein substrates such as ciclosporin, itraconazole, loperamide and many steroids and opiates but none reported.

**DOSES**

**Dogs:** No information available.
**Cats:** Monthly application.

**References**

**Epoetin alfa, Epoetin beta** see Erythropoietin

**Erythromycin**  
*(Erythrocinc®, Erythromycin®, Erythroped®)*  
**POM-V, POM**

**Formulations:** Oral: 250 mg, 500 mg tablets/capsules; 250 mg/5ml suspension.

**Action:** Time-dependent macrolide antibacterial that binds to the 50S ribosome (close to binding site for chloramphenicol), inhibiting peptide bond formation.

**Use:** Not commonly used in dogs and cats.
- Has a similar antibacterial spectrum to penicillins. It is active against Gram-positive cocci (some *Staphylococcus* species are resistant), Gram-positive bacilli and some Gram-negative bacilli (*Pasteurella*). Some strains of *Actinomyces*, *Nocardia*, *Chlamydia* and *Rickettsia* are also inhibited by erythromycin. Most of the Enterobacteriaceae (*Pseudomonas*, *Escherichia coli*, *Klebsiella*) are resistant. It may be considered to treat canine enteric *Campylobacter*, although isolation rates are similar between healthy dogs and those with diarrhoea. Being a lipophilic weak base, it is concentrated in fluids that are more acidic than plasma, including milk, prostatic fluid and intracellular fluid. Resistance to erythromycin can be quite high, particularly in staphylococcal organisms.
- Erythromycin acts as a GI prokinetic by stimulating motilin receptors.

Different esters of erythromycin are available. It is likely that the kinetics and possibly the toxicity will differ, depending on the ester used. Erythromycin’s activity is enhanced in an alkaline pH. As the base is acid-labile it should be administered on an empty stomach.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** In humans the erythromycin estolate salt has been implicated in causing cholestatic hepatitis. Although not demonstrated in veterinary medicine, this salt should be avoided in animals with hepatic dysfunction.

**Adverse reactions:** The commonest adverse effect is GI upset. Care should be taken in cases of hepatic or renal impairment.

**Drug interactions:** Erythromycin may enhance the absorption of digoxin from the GI tract and increase serum levels of ciclosporin,
cisapride, methylprednisolone, theophylline and terfenadine. The interactions with terfenadine and cisapride proved particularly significant in human medicine, leading to fatal or near-fatal arrhythmias in some patients receiving both drugs. Erythromycin should not be used in combination with other macrolide, lincosamide or chloramphenicol antimicrobials as antagonism may occur.

**DOSES**

*See Appendix for guidelines on responsible antibacterial use.*

**Dogs, Cats:**
- **Antibiosis:** 10–20 mg/kg p.o. q8–12h.
- **GI prokinetic:** 0.5–1 mg/kg p.o. q8h.

**References**

---

**Erythropoietin (Epoetin alfa, Epoetin beta)**

*(Eprex*, *Neorecormon*) **POM**

**Formulations:** *Injectable*: 1000 IU, 2000 IU, 5000 IU powders for reconstitution; 2000 IU/ml, 4000 IU/ml, 10,000 IU/ml, 40,000 IU/ml solutions. Eprex is epoetin alfa. Neorecormon is epoetin beta.

**Action:** Stimulates division and differentiation of RBCs.

**Use:**
- Recombinant human erythropoietin (r-HuEPO) is predominantly used to treat anaemia associated with chronic renal failure and cats with FeLV-associated anaemia.

Monitoring and/or supplementation of iron may be necessary, especially if response to treatment is poor. Darbepoetin may be a better choice in many cases. Also used to treat anaemic human patients with cancer and rheumatoid arthritis.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Conditions where high serum concentrations of erythropoietin already exist (e.g. haemolytic anaemia, anaemia due to blood loss), where the anaemia is due to iron deficiency or where uncontrolled systemic hypertension is present.

**Adverse reactions:** Local and systemic allergic reactions may rarely develop (skin rash at the injection site, pyrexia, arthralgia and mucocutaneous ulcers). The production of cross-reacting antibodies to r-HuEPO occurs in 20% to 70% of treated dogs and cats 4 weeks or more after treatment. These antibodies reduce the efficacy of the drug and can cause pure red cell aplasia. The drug should be discontinued if this develops.

**Drug interactions:** No information available.
DOSES

**Dogs, Cats:** For stimulating erythropoiesis (induction dose):
Epoetin alfa/beta: 100 IU/kg i.v., s.c. 3 times/week until PCV is at lower end of target range, then gradually reduce frequency of dosing to maintain this PCV (typical maintenance dose is 50–100 IU/kg once to twice a week). Dose changes should only be made at 3-weekly intervals.

**References**

**Esmolol (Brevibloc*) POM**

**Formulations:** Injectable: 10 mg/ml solution.

**Action:** An ultra-short-acting beta-blocker. It is relatively cardioselective and blocks beta-1 adrenergic receptors in the heart. It has a negative inotropic and chronotropic action which can lead to a decreased myocardial oxygen demand. Blood pressure is reduced. It has an antiarrhythmic effect through its blockade of adrenergic stimulation of the heart.

**Use:**
- Therapy of, or as an assessment of the efficacy of beta-adrenergic blockers in the treatment of, supraventricular tachycardias (including atrial fibrillation, atrial flutter and atrial tachycardia).

Its effect is brief, persisting only 10–20 minutes after i.v. infusion. Other antiarrhythmic therapy must be used for chronic or maintenance therapy.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Patients with bradyarrhythmias, acute or decompensated congestive heart failure. Relatively contraindicated in animals with medically controlled congestive heart failure as it is poorly tolerated. Do not administer concurrently with alpha-adrenergic agonists.

**Adverse reactions:** Most frequently seen in geriatric patients with chronic heart disease or in patients with acute or decompensated heart failure. Include bradycardia, AV block, myocardial depression, heart failure, syncope, hypotension, hypoglycaemia, bronchospasm and diarrhoea. Depression and lethargy are occasionally seen and are a result of esmolol’s high lipid solubility and penetration into the CNS. Esmolol may reduce the glomerular filtration rate and therefore exacerbate any pre-existing renal impairment.
**Drug interactions:** The hypotensive effect of esmolol is enhanced by many agents that depress myocardial activity including anaesthetics, phenothiazines, antihypertensives, diuretics and diazepam. There is an increased risk of bradycardia, severe hypotension, heart failure and AV block if esmolol is used concurrently with calcium-channel blockers. Concurrent digoxin administration potentiates bradycardia. Esmolol may increase serum digoxin levels by up to 20%. Morphine may increase esmolol serum concentration by up to 50%. Esmolol may enhance the effects of muscle relaxants. The bronchodilatory effects of theophylline may be blocked by esmolol.

**DOSES**

_Dogs, Cats:_ 0.05–0.5 mg/kg i.v. bolus over 5 min; 25–200 μg (micrograms)/kg/min constant rate infusion.

---

**Estriol (Oestriol)**

_(Incurin) POM-V_

**Formulations:** Oral: 1 mg tablet.

**Action:** Synthetic, short-acting oestrogen with a high affinity for oestrogen receptors in the lower urogenital tract. It increases muscle tone, improving urodynamic function.

**Use:** Management of urethral sphincter mechanism incompetence (USMI) that develops in spayed bitches.

**Safety and handling:** Normal precautions should be observed. Pregnant or breastfeeding women should handle with caution.

**Contraindications:** Do not use in intact bitches. Do not use if PU/PD present. Manufacturer states that this drug should not be used in animals <1 year old.

**Adverse reactions:** Oestrogenic effects are seen in 5–9% of bitches receiving 2 mg q24h. Low risk of bone marrow suppression (consider monitoring CBC for long-term use).

**Drug interactions:** Concurrent administration with phenylpropanolamine may potentiate efficacy.

**DOSES**

_Dogs:_ USMI in spayed bitches: starting dose = 1 mg/dog p.o. q24h. If treatment is successful reduce the dose to 0.5 mg/dog p.o. q24h. If treatment is unsuccessful increase to 2 mg/dog p.o. q24h. Alternate-day dosing can be considered once a response has been seen. The minimum effective dose is 0.5 mg/dog p.o. q24–48h. The maximum dose is 2 mg/dog p.o. q24h.

_Cats:_ Do not use.

**References**

Ethanol
(Alcohol*) POM

Formulations: Injectable: medical grade alcohol is a 95% solution. To prepare a solution for i.v. use, dilute to 20% in sterile water and administer through a 22 μm filter. Other commercially available forms of alcohol are less safe as they usually contain other substances which make i.v. administration hazardous (vodka is likely to be the least dangerous).

Action: Competitive inhibition of alcohol dehydrogenase.

Use:
- Prevents metabolization of ethylene glycol (antifreeze) or methanol to toxic metabolites.
- Also used to cleanse and degrease skin.

When treating ethylene glycol toxicity, adjust dose to maintain blood ethanol levels above 35 mg/dl in dogs (which as a guide is about half the legal limit to drive). Monitor fluid and electrolyte balance during ethanol therapy. Unlikely to be effective if administered >8 hours after toxin ingestion or acute renal failure has already developed. Fomepizole, if available, is safer and more effective than ethanol.

Safety and handling: Normal precautions should be observed.

Contraindications: No information available.

Adverse reactions: Ethanol will cause diuresis and may cause additive depression that will mask CNS signs of ethylene glycol toxicity. Adverse events occur frequently with intravenous ethanol infusions.

Drug interactions: Avoid concurrent fomepizole administration (increases risk of alcohol toxicity).

DOSES

Dogs: Ethylene glycol toxicity: 5.5 ml of 20% ethanol solution/kg given i.v. q4h for 5 treatments, then i.v. q6h for 4 additional treatments. Alternatively, give an i.v. loading dose of 1.3 ml/kg of 30% solution then begin a constant rate infusion of 0.42 mg/kg/h for 48 hours. For clinically mild cases (minimal CNS signs), particularly if using vodka, oral administration is also possible.

Cats: Ethylene glycol toxicity: 5 ml of 20% ethanol solution/kg i.v. q6h for 5 treatments, then q8h for 4 additional treatments.

References
Famciclovir  
\((\text{Famciclovir*}, \text{Famvir*}) \text{ POM}\)

**Formulations:** Oral: 125 mg, 250 mg, 500 mg tablets; 100 mg/ml oral paste.

**Action:** Inhibits viral replication (viral DNA polymerase); depends on viral thymidine kinase for phosphorylation.

**Use:** Management of feline herpesvirus (FHV-1) infections. Famciclovir is a prodrug for penciclovir, which is closely related to aciclovir. Famciclovir is virostatic and is unable to eradicate latent viral infection. Dose recommendations have varied because of complex and non-linear pharmacokinetics in cats.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.

**Adverse reactions:** Gastrointestinal signs most common side effect. Monitor haematology, biochemistry and urinalysis in cats with known concurrent disease and/or if expected to receive the drug for long periods. Reduce dose frequency in cats with renal insufficiency (as in humans).

**Drug interactions:** No information available.

**DOSES**

**Dogs:** No information available.

**Cats:** 90 mg/kg q12h.

**References**

Thomasy SM and Maggs DJ (2016) A review of antiviral drugs and other compounds with activity against feline herpesvirus type 1. Veterinary Ophthalmology 19(S1), 119–130

Famotidine  
\((\text{Famotidine*}) \text{ POM}\)

**Formulations:** Oral: 20 mg, 40 mg tablets.

**Action:** Histamine (H2) receptor antagonist blocking histamine-induced gastric acid secretion. It is many times more potent than cimetidine, but has poorer oral bioavailability (37%). It is not antiemetic.

**Use:**
- Management of gastric and duodenal ulcers, idiopathic, uraemic or drug-related erosive gastritis, oesophagitis, and hypersecretory conditions secondary to gastrinoma, mast cell neoplasia or short bowel syndrome.

Currently cimetidine is the only anti-ulcer drug with a veterinary market authorization. Famotidine has little effect on GI motility in humans. In healthy dogs, famotidine did increase intragastric pH, but to a lesser degree than omeprazole, and not to a degree that would suggest therapeutic efficacy when assessed by criteria used...
for humans with acid-related disease. Famotidine was less effective than omeprazole in preventing exertion-induced gastritis in racing sled dogs. Serum gastrin increases transiently in dogs receiving famotidine but returns to baseline by 14 days even with ongoing administration. When given every day, effect on gastric pH diminished with time in studies in dogs and cats. Combination therapy with pantoprazole was not superior to pantoprazole alone.

Safety and handling: Normal precautions should be observed.

Contraindications: No information available.

Adverse reactions: Good safety profile. In humans, famotidine has fewer side effects than cimetidine.

Drug interactions: Famotidine is devoid of many of the interactions of the H2 related antagonist cimetidine.

DOSES

Dogs, Cats: All uses: 0.5–1.0 mg/kg p.o. q12–24h.

References

Febantel see Pyrantel

Feline facial fraction F3 (Feline facial pheromone F3)
(Feliway, Zenifel) general sale

Formulations: Plug-in diffuser, topical environmental spray. Feliway spray also contains Valerian extract and Zenifel has historically contained Nepeta (catnip) extract.

Action: A synthetic analogue of the F3 fraction of the ‘feline facial pheromones’ that are used in facial marking of the physical environment by cats. F3 stimulates receptors in the vomeronasal organ, resulting in limbic activity that has a calming effect in the presence of particular classes of stimuli, especially those associated with threats to physical resources.

Use:
• Management of indoor urine marking, inappropriate scratching and changes to the animal’s physical environment at home or outside (e.g. during transport, within the cattery or the veterinary clinic).
• Management of situational anxiety-related disorders.
• It can aid handling for anaesthesia induction and during other medical examinations when the spray may be applied to the consultation or preparation table.
The diffuser should be placed in the room most frequently occupied by the cat and/or where the inappropriate behaviour most frequently occurs. The pump spray should not mark or stain but it is sensible to patch-test fabrics and polished surfaces before using extensively. For best results allow the spray to come to room temperature before it is applied and adopt appropriate cleaning regimes for indoor marking. Rinse well after using an enzymatic cleaner and allow areas to dry after cleaning before applying the F3 spray; residual enzymatic action may break down the active ingredient. The diffuser is active over an area of approximately 50–70 m$^2$. If the total target area exceeds this or air conditioning is in use, a second diffuser should be used, or the spray form used as well. Do not repeatedly switch the diffuser on and off; it is designed to be left on at all times.

**Safety and handling:** Humans with known sensitivity to the ingredients should avoid using the product in their homes.

**Contraindications:** No information available.

**Adverse reactions:** No information available.

**Drug interactions:** None.

**DOSE**

**Cats:** Pump spray: F3 is applied to the environment in locations where the inappropriate behaviour is occurring and in locations that are of behavioural significance. Familiarization signal for cats in potentially stressful situations, or in new environments: apply spray 30 minutes before the cat has access to the area. Existing urine marking: apply one dose (one depression of the nozzle) daily from about 10 cm from the soiled site at a height of about 20 cm from the floor. In multicat households the spray should be applied 2–3 times/day on previously marked sites and once a day on other locations which are of behavioural significance. When using to prevent urine marking, spray once per day in locations of behavioural significance.

**Dogs:** Not applicable.

**References**


---

**Fenbendazole**

*(Granofen, Panacur, Wormazole, Various authorized proprietary products)*  

**AVM-GSL, NFA-VPS**

**Formulations:** Oral: 222 mg/g granules (22%); 440 mg/g granules (44%); 880 mg/g granules (88%); 25 mg/ml oral suspension (2.5%); 100 mg/ml oral suspension (10%); 187.5 mg/g oral paste (18.75%).
**Action:** Inhibits fumarate reductase system of parasites thereby blocking the citric acid cycle and also reduces glucose absorption by the parasite.

**Use:** Treatment of ascarids (including larval stages), hookworms, whipworms, tapeworms (*Taenia*), *Giardia* species, *Oslerus osleri*, *Aelurostrongylus abstrusus*, *Angiostrongylus vasorum*, *Capillaria aerophila*, *Ollulanus tricuspis*, *Physaloptera rara* and *Paragonimus kellicotti* infections. There is 60–70% efficacy against *Dipylidium caninum*. Unlike some other benzimidazoles, fenbendazole is safe to use in pregnant animals.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.

**Adverse reactions:** Bone marrow hypoplasia has been reported in a dog.

**Drug interactions:** No information available.

**DOSES**

**Dogs:**
- **Roundworms, tapeworms:** dogs <6 months old: 50 mg/kg p.o. q24h for 3 consecutive days; >6 months old: 100 mg/kg as a single dose p.o. Treatment of *Capillaria* may need to be extended to 10 days. Repeat q3 months. For **pregnant bitches:** 25 mg/kg p.o. q24h from day 40 until 2 days post-whelping (approximately 25 days).
- **Angiostrongylus vasorum:** 50 mg/kg p.o. q24h for a minimum of 10 days, although the duration of treatment has yet to be defined.
- **Oslerus osleri:** 50 mg/kg p.o. q24h for 7 days, although a repeat course of treatment may be required in some cases.
- **Aelurostrongylus abstrusus:** 20 mg/kg p.o. q24h for 3 days.
- **Giardiasis:** 50 mg/kg p.o. q24h for 5 days.

**Cats:**
- **Roundworms, tapeworms:** cats <6 months old: 20 mg/kg p.o. q24h for 5 days; >6 months old: 100 mg/kg as a single dose p.o.
- **Aelurostrongylus abstrusus:** 20 mg/kg p.o. q24h for 5 days.
- **Giardiasis:** 20 mg/kg q24h for 5 days.

**References**

**Fentanyl**

(Fentadon, Durogesic*, Fentanyl*, Fentora*, Sublimaze*) **POM-V CD SCHEDULE 2, POM CD SCHEDULE 2**

**Formulations:** Oral: 100 μg, 200 μg, 400 μg, 600 μg, 800 μg tablets. Injectable: 50 μg/ml solution. Transdermal 12.5 μg/h, 25 μg/h, 50 μg/h, 75 μg/h, 100 μg/h patches.
Action: Synthetic pure mu (OP3) receptor agonist.

Use:
- Very potent opioid analgesic (50 times more potent than morphine) used to provide profound intraoperative analgesia in dogs and cats.
- Can also be used at low dose rates for postoperative analgesia.
- Transdermal fentanyl patches can be used to provide analgesia for up to 72 hours after surgery or for the management of chronic pain.

Use of potent opioids during anaesthesia contributes to a balanced anaesthesia technique, therefore the dose of other concurrently administered anaesthetic agents should be reduced. Fentanyl has a rapid onset of action after i.v. administration and short duration of action (10–20 min depending on dose). After prolonged administration (>4 hours) or high doses, its duration of action is significantly prolonged as the tissues become saturated. It can be used intraoperatively to provide analgesia by intermittent bolus doses or by a continuous rate infusion. Postoperatively fentanyl can be given by continuous rate infusion to provide analgesia, doses at the low end of the dose range should be used and respiratory function monitored. Its clearance is similar to morphine while its elimination half-life is longer, reflecting its higher lipid solubility and volume of distribution. Following transdermal patch application, it takes approximately 7 hours in cats and 24 hours in dogs to attain adequate plasma concentrations to provide analgesia. Alternative forms of analgesia must be provided during this period, or patches must be placed before surgery. Systemic plasma concentrations of fentanyl can be very variable after transdermal absorption from patches and some animals may not develop adequate plasma concentrations to achieve analgesia. Therefore, it is preferable to use transdermal fentanyl as an adjunctive analgesic in combination with other drugs. Direct application of heat sources to transdermal fentanyl patches (e.g. during anaesthesia) will significantly increase the uptake of fentanyl and may result in higher than expected plasma concentrations.

Safety and handling: If animals are sent home with transdermal fentanyl patches the owners must be warned about the dangers of patch ingestion by humans or other animals.

Contraindications: No information available.

Adverse reactions: Intraoperative administration is likely to cause respiratory depression, therefore, respiration should be monitored and facilities must be available to provide positive pressure ventilation. Rapid i.v. injection can cause severe bradycardia, even asystole, therefore, the drug should be given slowly. A reduction in heart rate is likely whenever fentanyl is given, atropine can be administered to counter bradycardia if necessary. Apart from the effects on heart rate, fentanyl has limited other effects on cardiovascular function when used at clinical dose rates.
Drug interactions: Fentanyl can be used to reduce the dose requirement for other anaesthetic drugs in patients with cardiovascular instability or systemic disease.

DOSES

Dogs:

- Intraoperative analgesia: 5 μg (micrograms)/kg i.v. q20min; 2.5–10 μg/kg/h by continuous rate infusion during anaesthesia, reduced to 1–5 μg/kg/h during the postoperative period. Continuous rate infusions should be preceded by a loading dose given slowly i.v. (2.5–10 μg/kg).
- Transdermal patch: 4 μg/kg/h patch (e.g. 100 μg/h patch for a 25 kg dog).

Cats:

- Intraoperative analgesia: 5 μg (micrograms)/kg bolus, repeated injections may be required q20min.
- Anaesthesia: continuous rate infusions as for dogs.
- Transdermal patch: 25 μg/h patch for cats 3–5 kg; in smaller cats and kittens the 12.5 μg/h patch can be applied.

References

Ambros B, Alcorn J, Duke-Novakovski T et al. (2014) Pharmacokinetics and pharmacodynamics of a constant rate infusion of fentanyl (5 μg/kg/h) in awake cats. American Journal of Veterinary Research 75, 716–721

Collection of articles describing the pharmacokinetics and pharmacodynamics of transdermal fentanyl solution in dogs (2012) Journal of Veterinary Pharmacology and Therapeutics 35(S2), 1–72

Filgrastim (Granulocyte colony stimulating factor, G-CSF) (Neupogen*) POM

Formulations: Injectable: 30 million IU (300 μg)/ml solution.


Use:

- Management of febrile patients, particularly those receiving cytotoxic drugs with neutrophil counts <1 x 10⁹/l.
- Also as an adjunct in the treatment of neutropenia due to infections (e.g. canine ehrlichiosis, parvovirus, FeLV or FIV), bone marrow neoplasia or cyclic haemopoiesis in dogs.

There are few reports on the use of G-CSF in dogs or cats. In humans it is indicated in the management of neutropenia, especially in patients receiving high-dose chemotherapy. Neutrophil counts rise within 24 hours. Following discontinuation of therapy, neutrophil counts drop to normal after 5 days.

Safety and handling: Normal precautions should be observed.

Contraindications: Dogs or cats that have developed antibodies to G-CSF (with resultant neutropenia) should not receive it in the future.
**Adverse reactions:** Normal dogs produce neutralizing antibodies to rhG-CSF. This limits repeated use and may result in neutropenia. This does not appear to be the case in canine chemotherapy patients. A variety of adverse effects have been reported in humans, including musculoskeletal pain, transient hypotension, dysuria, allergic reactions, proteinuria, haematuria, splenomegaly and increased liver enzymes. Reported adverse effects are bone pain at high doses and irritation at the injection site.

**Drug interactions:** Steroids and lithium may potentiate the release of neutrophils during G-CSF therapy. Concurrent administration with chemotherapy may increase incidence of adverse effects. G-CSF should be given at least 24 hours after the last dose of chemotherapy, as the stimulatory effects of G-CSF on haemopoietic precursors renders them more susceptible to the effects of chemotherapy.

**DOSES**

**Dogs, Cats:** 100,000–500,000 IU (1–5 micrograms)/kg s.c. q24h for 3–5 days.

**References**


---

**Finasteride**  
*(Proscar™)*  
**POM**

**Formulations:** Oral: 5 mg tablet.

**Action:** Competitively inhibits dihydrotestosterone (DHT) production within the prostate. DHT is the main hormonal stimulus for the development of benign prostatic hypertrophy.

**Use:** Treatment of benign prostatic hypertrophy as an alternative to castration. Extended treatment course (<8 weeks) may be required for full efficacy. Not authorized for veterinary use and therefore should only be used when delmadinone or osaterone are not appropriate.

**Safety and handling:** Women of child-bearing age should avoid handling crushed or broken tablets as finasteride is potentially teratogenic.

**Contraindications:** Do not use in sexually-developing dogs.

**Adverse reactions:** Secreted into semen and causes fetal anomalies.

**Drug interactions:** No information available.

**DOSES**

**Dogs:** 5 mg per dog p.o. q24h.

**Cats:** Not used.
**Fipronil**
(Broadline, Frontect, Frontline, Frontline Combo/Plus and many others) AVM-GSL, NFA-VPS, POM-V

**Formulations:** Topical: 10% w/v fipronil spot-on pipettes in a wide range of sizes (Frontline and many others); some formulations combined with other drugs including S-methoprene (Frontline Combo/Plus), pyriproxyfen (Effipro Duo); permethrin (Frontect); eprinomectin, S-methoprene and praziquantel (Broadline). Also 0.25% w/v fipronil spray in alcohol base (Effipro and Frontline sprays) in a range of sizes.

**Action:** Fipronil interacts with ligand-gated (GABA) chloride channels, blocking pre- and post-synaptic transfer of chloride ions, resulting in death of parasites on contact.

**Use:**
- Exhibits an insecticidal and acaricidal activity against fleas (*Ctenocephalides* spp.), ticks (*Rhipicephalus* spp., *Dermacentor* spp., *Ixodes* spp.) and feline and canine lice (*Felicola subrostratus*, *Trichodectes canis*).
- May aid in the control of *Neotrombicula autumnalis*, *Sarcoptes* spp. and *Cheyletiella* spp.

Effective against flea infestation for approximately 2 months and against tick infestations for up to 1 month. For additional information on efficacy of other compounds included in specific formulations see relevant monographs. Bathing between 48 hours before and 24 hours after application is not recommended. Can be used in pregnant and lactating females. When treating flea infestations, treatment of the environment is also recommended.

**Safety and handling:** Normal precautions should be observed. Spray contains alcohol use away from naked flames.

**Contraindications:** Fipronil spot-on: do not use in dogs and cats <8 weeks of age and <2 kg (dogs) or <1 kg (cats). Fipronil spray may be used in puppies and kittens from 2 days old. Fipronil may be harmful to aquatic organisms. Do not use fipronil, S-methoprene, eprinomectin and praziquantel combination (Broadline) in dogs.

**Adverse reactions:** Local pruritus or alopecia may occur at the site of application.

**Drug interactions:** No information available.

**DOSES**

**Dogs:**
- *Flea infestations:* spray 3–6 ml/kg (6–12 pumps/kg 100 ml application, 2–4 pumps/kg 250 ml or 500 ml application) or apply 1 pipette per dog according to body weight. Treatment should be repeated not more frequently than every 4 weeks.
• *Neotrombicula autumnalis, Sarcoptes* spp. and *Cheyletiella* spp. infestations: spray should be used every 1–2 weeks.

**Cats:** Spray 3–6 ml/kg (6–12 pumps/kg 100 ml application) or apply 1 pipette per cat. Treatment should be repeated monthly.

**References**

**Firocoxib** (Previcox) POM-V

**Formulations:** Oral: 57 mg, 227 mg tablets.

**Action:** NSAID that selectively inhibits the COX-2 enzyme thereby limiting the production of prostaglandins involved in inflammation. It also has analgesic and antipyretic effects.

**Use:**
- Relief of pain and inflammation associated with osteoarthritis and with soft tissue, orthopaedic and dental surgery in dogs.

When used for perioperative pain, it is recommended to give the first dose 2 hours before surgery. Studies investigating the safety of firocoxib in dogs were only carried out for 90 days, therefore, animals receiving firocoxib for more prolonged periods should be monitored carefully for NSAID-induced side effects. Administration of firocoxib to animals with renal disease must be carefully evaluated. Firocoxib may have a synergistic role with platinum-based chemotherapeutic agents in the treatment of transitional cell carcinomas of the urinary bladder and may have some antitumour effects on its own.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** All NSAIDs should be administered cautiously in the perioperative period as they may adversely affect renal perfusion during periods of hypotension. If hypotension during anaesthesia is anticipated, delay firocoxib administration until the animal is fully recovered and normotensive. Do not give to dehydrated, hypovolaemic or hypotensive patients or those with GI disease or blood clotting problems. Do not give to pregnant or lactating bitches, animals <10 weeks old or <3 kg. Do not use in cats.

**Adverse reactions:** GI signs may occur in all animals after NSAID administration. Stop therapy if this persists beyond 1–2 days. Some animals develop signs with one NSAID and not another. A 3–5-day wash-out period should be allowed before starting another NSAID after cessation of therapy. Stop therapy immediately if GI bleeding is suspected. There is a small risk that NSAIDs may precipitate cardiac failure in humans and this risk in animals is unknown. Liver disease will prolong the metabolism of firocoxib, leading to the potential for drug overdose with repeated dosing.
Drug interactions: Do not administer concurrently or within 24 hours of other NSAIDs and glucocorticoids. Do not administer with other potentially nephrotoxic agents, e.g. aminoglycosides.

DOSES
**Dogs:** 5 mg/kg p.o. q24h, with or without food.
**Cats:** Do not use.

References

Florfenicol (Osurnia) **POM-V**

Formulations: **Topical:** ear gel where each dose (1.2 g) contains 10 mg of florfenicol, combined with terbinafine (10 mg) and betamethasone acetate (1 mg).

Action: Florfenicol inhibits bacterial protein synthesis and is a broad-spectrum time-dependent antimicrobial. Its activity includes Gram-negative and Gram-positive bacteria including *Staphylococcus pseudintermedius*.

Use:
- Although licensed for systemic use in some food animals, florfenicol is currently only licensed for use in the treatment of otitis externa in the dog.

It is recommended to clean and dry the external ear canal before the first administration of the product. It is recommended not to repeat ear cleaning until 21 days after the second administration of the product.

Safety and handling: Store in the refrigerator.

Contraindications: **Aural preparation:** do not use in pregnant or breeding animals; do not use in dogs with generalized demodicosis; do not use if the tympanic membrane is not intact. Not for use in dogs <2 months or 1.4 kg.

Adverse reactions: Rare incidence of transient deafness mainly in older dogs.

Drug interactions: None reported when used by aural route.

DOSES
**Dogs:** Aural use: Single use tube (1.2 g containing 10 mg florfenicol) administered into affected ear and repeated once after 7 days.
**Cats:** Not licensed.

References
Fluconazole
(Diflucan*, Fluconazole*) POM

Formulations: Oral: 50 mg, 150 mg, 200 mg capsules; 40 mg/ml suspension. Injectable: 2 mg/ml solution.

Action: Inhibition of the synthesis of ergosterol in fungal cell membranes, thus causing increased cell wall permeability and allowing leakage of cellular contents.

Use:
- Effective against *Blastomyces, Candida, Cryptococcus, Coccidioides, Histoplasma* and *Microsporum canis* infections and variably effective against *Aspergillus* and *Penicillium* infections.

It attains therapeutic concentrations in the CNS and respiratory tract. It is excreted by the kidney, producing high concentrations in urine. Reduce dose in animals with renal impairment and liver disease. This drug should be used until clinical signs have resolved and the organism is no longer present; this may take up to 2 months in some cases.

Safety and handling: Normal precautions should be observed.

Contraindications: Do not use in pregnant/lactating animals.

Adverse reactions: Adverse effects may include nausea and diarrhoea. May be hepatotoxic.

Drug interactions: Fluconazole (due to inhibition of cytochrome P450-dependent liver enzymes) may increase plasma theophylline concentrations. In humans, fluconazole has led to terfenadine toxicity when the two drugs were administered together. Fluconazole increases ciclosporin blood levels.

DOSES

Dogs:
- Fungal infections: 2.5–5 mg/kg p.o. q12h.

Cats:
- Ocular/CNS cryptococcosis: 50 mg/cat i.v. infusion, p.o. q24h.
- Systemic infections: give double the calculated dose on day 1. Doses up to 100 mg/cat q12h are sometimes used for systemic/ CNS *Cryptococcus* infection.
- Dermatophytosis, nasal cryptococcosis: 5 mg/kg p.o. q24h. For dermatophytosis, administer for 3 periods of 7 days, with 7 days without treatment in between.

Dogs, Cats: Urinary candidiasis: 5–10 mg/kg q24h.

References
Flucytosine
(Ancotil*) POM

Formulations: Injectable: 10 mg/ml solution. Flucytosine tablets are available from special order manufacturers or specialist importing companies.

Action: Fungal cells convert flucytosine (5-FC) into 5-fluorouracil (5-FU), which inhibits DNA and RNA synthesis in the cell. Mammalian cells are spared. Penetrates well into cerebrospinal fluid.

Use: • Treatment of cryptococcosis (often in conjunction with amphotericin B or itraconazole) particularly if involving meninges; systemic and urinary yeast infections (e.g. candidiasis).

Little used in veterinary medicine compared with other antifungals. Use flucytosine with caution in patients with hepatic or renal impairment; reduce the dose and monitor haematological, renal and hepatic parameters. Resistance can develop quickly when used as a sole agent.

Safety and handling: Normal precautions should be observed.

Contraindications: No information available.

Adverse reactions: Drug eruptions, including toxic epidermal necrolysis. Vomiting and diarrhoea may develop as well as myelosuppression, renal and hepatic toxicity; alleviate by dosing over 15 minutes. Flucytosine may be teratogenic.

Drug interactions: Synergy with amphotericin B has been demonstrated, although there is an increased risk of nephrotoxicity.

DOSES

Dogs: Fungal infections: 25–35 mg/kg i.v. q8h or 50–65 mg/kg p.o. q8h.

Cats: Fungal infections: 25–50 mg/kg i.v. q6h or 50–65 mg/kg p.o. q8h.

References

Fludrocortisone
(Fludrocortisone acetate*) POM

Formulations: Oral: 0.1 mg tablets. Also available on a named patient basis in 0.25 mg and 0.5 mg sizes.

Action: Aldosterone analogue that increases potassium excretion and sodium retention but which also has some glucocorticoid properties.
Use: Treatment of adrenocortical insufficiency (Addison’s disease) when authorized product (desoxycortone pivalate) is not suitable in an individual patient. Fludrocortisone is about 125 times more potent as a mineralocorticoid than is hydrocortisone but it is also about 12 times more potent as a glucocorticoid (and therefore about 3 times more potent than prednisolone). Monitor absolute sodium and potassium concentrations (not just the ratio) 4–6 hours post pill. Some dogs only require q24h dosing but in such cases the sodium and potassium concentrations should also be checked pre-pill. Supplemental doses of prednisolone may be required at times of metabolic or physical stress.

Safety and handling: Normal precautions should be observed. Some formulations require refrigeration.

Contraindications: No information available.

Adverse reactions: Hypertension, oedema (including cerebral oedema) and hypokalaemia with overdosages. Long-term overdose may result in clinical signs of hypercortisolism.

Drug interactions: Hypokalaemia may develop if fludrocortisone is administered concomitantly with amphotericin B or potassium-depleting diuretics (furosemide, thiazides).

DOSES
Dogs: Hypoadrenocorticism: start at 0.01 mg/kg p.o. q12h. Most patients when stable require <0.05 mg/kg p.o. q12h.
Cats: Hypoadrenocorticism: doses as for dogs (very few reports).

References
Roberts E, Boden LA and Ramsey IK (2016) Factors that affect stabilisation times of canine spontaneous hypoadrenocorticism. *Veterinary Record* 179, 98

Flumethrin see Imidacloprid

Flumazenil (Romazicon*) POM

Formulations: Injectable: 0.1 mg/ml solution available as 5 ml and 10 ml vials.

Action: Flumazenil binds to and rapidly displaces benzodiazepines from the benzodiazepine receptor, thereby reversing their sedative and anxiolytic effects within 1–2 minutes. The duration of action of flumazenil is short (1 hour), therefore dosing may need to be repeated.

Use: To reverse the sedative and respiratory depressant effects of benzodiazepines such as midazolam and diazepam.

Safety and handling: Normal precautions should be observed.

Contraindications: Flumazenil is contraindicated in human patients suspected of tricyclic antidepressant overdose as it can cause seizures.
Adverse reactions: The use of flumazenil has also been associated with seizures in humans receiving long-term benzodiazepine administration for sedation. Be prepared to manage seizures should they occur.

Drug interactions: Can cause seizures in human patients suspected of tricyclic antidepressant overdose.

DOSES
*Dogs, Cats*: 0.01–0.1 mg/kg i.v., can be repeated if marked respiratory depression reoccurs. It takes 6–10 minutes for flumazenil to reach peak effects after i.v. administration. Start at the low end of the dose range.

**Fluorouracil (5-FU)***(Efudix*, Fluorouracil*) POM

Formulations: Injectable: 250 mg/vial, 500 mg/vial, 2500 mg/vial solutions. Topical: 5% cream (Efudix).

Action: Metabolites of fluorouracil inhibit pyrimidine synthesis, resulting in inhibition of DNA synthesis and function.

Use: Treatment of basal cell and squamous cell carcinoma (topically), and systemically in a number of canine carcinomas. Consult relevant texts for specific protocols prior to use. Rarely used in small animal practice.

Safety and handling: Cytotoxic drug; see Appendix and specialist texts for further advice on chemotherapeutic agents.

Contraindications: Do not use in cats in any form (including topical) as it can cause a potentially fatal neurotoxicity.

Adverse reactions: Anorexia, vomiting, stomatitis, diarrhoea, leucopenia with a nadir between 7 and 14 days, thrombocytopenia, anaemia, alopecia, hyperpigmentation, dermatitis, cerebellar ataxia and seizures.

Drug interactions: Cimetidine inhibits the metabolism of 5-FU. In human oncology there is synergism between 5-FU and carboplatin but this combination has not been widely used in small animals and may be more toxic. Methotrexate is synergistic if administered before 5-FU but is antagonistic if administered afterwards. Vincristine increases the cytotoxicity of 5-FU.

DOSES
See Appendix for chemotherapy protocols and conversion of body weight to body surface area.

*Dogs*: All uses: 150 mg/m² i.v. once weekly for 6 weeks or once every 3 weeks when combined with carboplatin. In patients that have liver, renal or bone marrow impairment, reduce dose by half.

Topical use: Apply to affected area q24h.

*Cats*: Do not use.
Fluoxetine
(Reconcile, Prozac*) POM-V, POM

Formulations: Oral: 8 mg, 16 mg, 20 mg, 32 mg, 64 mg tablets. A veterinary formulation (Reconcile) is licensed within Europe and North America, but is not currently available in the UK.

Action: Fluoxetine and its primary metabolite norfluoxetine block serotonin reuptake in the brain, resulting in antidepressive activity and a raising in motor activity thresholds. It also has minor noradrenaline reuptake inhibition properties, but is considered a specific serotonin reuptake inhibitor.

Use:
• Originally authorized as a veterinary product for the management of canine separation anxiety in association with a behaviour modification plan.
• Also used for the management of a wider range of anxiety related condition, including compulsive disorders and some forms of aggression in dogs. Use in the latter indication should be with a specifically constructed behaviour modification plan and with caution.
• Fluoxetine has been used in the cat to control urine spraying and other anxiety-related behaviour problems, such as psychogenic alopecia and certain forms of aggression. Similar precautions are warranted when used for aggression in cats as apply to its use in dogs.

Safety and handling: Normal precautions should be observed.

Contraindications: Known sensitivity to fluoxetine or other SSRIs, history of seizures.

Adverse reactions: Common reactions include lethargy, decreased appetite and vomiting, which may result in minor weight loss. Trembling, restlessness and other GI disturbances may also occur and must be distinguished from a paradoxical increase in anxiety which has been reported in some cases. Owners should be warned of a potential increase in aggression in response to medication.

Drug interactions: Fluoxetine should not be used within 2 weeks of treatment with an MAOI (e.g. selegiline) and an MAOI should not be used within 6 weeks of treatment with fluoxetine. Fluoxetine, like other SSRIs, antagonizes the effects of anticonvulsants and so is not recommended for use with epileptic patients or in association with other agents which lower seizure threshold, e.g. phenothiazines.
Caution is warranted if fluoxetine is used concomitantly with aspirin or other anticoagulants since the risk of increased bleeding in the case of tissue trauma may be increased. Should not generally be used alongside other serotonergic agents given risk of serotonin syndrome, although use alongside trazodone may be considered in exceptional cases, so long as patient carefully monitored for signs of serotonin syndrome.

**DOSES**

**Dogs:** 1–2 mg/kg p.o. q24h.

**Cats:** 0.5–1.0 mg/kg p.o. q24h.

**References**

Simpson BS, Landsberg GM, Reisner IR et al. (2007) Effects of reconcile (fluoxetine) chewable tablets plus behavior management for canine separation anxiety. Veterinary Therapeutics 8, 18–31

---

**Fluralaner**

(Bravecto, Bravecto spot-on, Bravecto plus spot-on solution for cats) **POM-V**

**Formulations:** Oral: chewable tablets (dogs), 5 sizes delivering 25–56 mg fluralaner/kg. **Topical spot-on for dogs and cats:** 280 mg/ml fluralaner, 3 sizes cats, 5 sizes dogs. **Topical spot-on for cats:** 280 mg/ml fluralaner and 14 mg/ml moxidectin, 3 sizes.

**Action:** Fluralaner acts at ligand-gated chloride channels, in particular those gated by the neurotransmitter gamma-aminobutyric acid (GABA), thereby blocking pre- and post-synaptic transfer of chloride ions across cell membranes.

**Use:**

- Treatment of fleas and ticks in dogs/cats.
- Treatment of ear mite (*Otodectes cynotis*) in cats.
- Fluralaner has action against *Demodex* mites. Specific treatment regimes have yet to be determined.

Onset of action: fleas within 8 hours and ticks within 12 hours (*Ixodes ricinus*). Immediate and persistent tick killing activity for 12 weeks for *Ixodes ricinus, Dermacentor reticulatus* and *D. variabilis*, 8 weeks for *Rhipicephalus sanguineus*. Parasites need to start feeding on the host to become exposed to fluralaner; therefore the risk of the transmission of parasite-borne diseases cannot be excluded. Can be used in breeding, pregnant and lactating dogs.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not use in dogs <8 weeks or <2 kg. Should not be used on kitten <11 weeks and/or cats weighing less than 1.2 kg. Use with caution in dogs with pre-existing epilepsy. The product should not be administered at intervals shorter than 8 weeks.

**Adverse reactions:** Oral product dogs: Mild GI signs may occur; convulsions and lethargy has been reported very rarely.
Spot-on: erythema, alopecia at application site. **Cats:** apathy, tremors, anorexia, vomiting, hypersalivation.

**Drug interactions:** Fluralaner is highly bound to plasma proteins and might compete with other highly bound active substances such as NSAIDs and the coumarin derivative warfarin.

**DOSES**
**Dogs:** 25–56 mg fluralaner/kg p.o. q3months or apply 1 pipette per dog according to body weight q3months.
**Cats:** Apply 1 pipette per cat according to body weight q3months.

**References**

---

**Flurbiprofen**  
(*Ocufen*) **POM**

**Formulations:** Ophthalmic: 0.03% solution in single-use vials.

**Action:** Inhibits prostaglandin synthesis producing an anti-inflammatory and analgesic action. Prostaglandins also play a role in the miosis produced during intraocular surgery by constricting the iris sphincter independently of cholinergic mechanisms.

**Use:**
- Before cataract surgery.
- It is also useful for anterior uveitis and ulcerative keratitis when topical corticosteroids are contraindicated.

Topical NSAIDs have the potential to increase intraocular pressure and should be used with caution in dogs and cats with glaucoma.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.

**Adverse reactions:** As with other topical NSAIDs, flurbiprofen may cause local irritation. Topical NSAIDs can be used in ulcerative keratitis but with caution as they can delay epithelial healing. Topical NSAIDs have been associated with an increased risk of corneal ‘melting’ (keratomalacia) in humans, although this has not been reported in the veterinary literature. Regular monitoring is advised.

**Drug interactions:** Ophthalmic NSAIDs may be used safely with other ophthalmic pharmaceuticals, although concurrent use of drugs which adversely affect the corneal epithelium (e.g. gentamicin) may lead to increased corneal penetration of the NSAID. The concurrent use of topical NSAIDs with topical corticosteroids has been identified as a risk factor in humans for precipitating corneal problems.
DOSES

**Dogs, Cats:** 1 drop per eye q6–12h depending on severity of inflammation. 1 drop q30min for 4 doses preoperatively (pre-surgery protocols vary widely).

**References**

---

**Fluticasone**
*(Flixotide*) **POM**

**Formulations:** Inhalational: 50 μg, 125 μg, 250 μg metered inhalations (Evohaler).

**Action:** Binds to specific nuclear receptors and affects gene transcription such that many aspects of inflammation are suppressed.

**Use:**
- Used as an inhaled corticosteroid in the management of inflammatory airway disease in dogs and cats.

Administer via commercially available chambers and masks specifically designed for veterinary use. Not useful for acute bronchospasm (and cases of fluticasone-induced bronchospasm reported in humans).

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.

**Adverse reactions:** Inhaled steroids are known to suppress the hypothalamic-pituitary-adrenal axis, although they are considered generally safer than systemic steroids.

**Drug interactions:** No information available.

**DOSES**

**Dogs:** Chronic inflammatory tracheobronchial disease: 125–500 μg (micrograms)/dog q12–24h.

**Cats:** Feline lower airway disease: 50–250 μg (micrograms)/cat q12–24h.

**References**

**Fomepizole (4-Methylpyrazole) (Antizol*) POM**

**Formulations:** Injectable: 1.5 g/1.5 ml vial; dilute 1:19 (i.e. 1.5 ml vial added to 28.5 ml of 0.9% saline, giving a 50 mg/ml solution) solution. Discard after 72 hours. Available from special order manufacturers or specialist importing companies.

**Action:** Competitive inhibition of alcohol dehydrogenase.

**Use:** Treatment of ethylene glycol (antifreeze) toxicity in dogs. Available for import on a named-patient basis.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.

**Adverse reactions:** No information available.

**Drug interactions:** Increases risk of ethanol toxicity if co-administered.

**DOSES**

**Dogs:** Ethylene glycol toxicity: 20 mg/kg i.v. infusion over 30 min initially, then 15 mg/kg i.v. slowly over 15–30 min 12 h and 24 h later, then 5 mg/kg i.v. q12h until ethylene glycol concentration is negligible or the dog has recovered. Most effective if started within 8 hours of intoxication.

**Cats:** Ethylene glycol toxicity: 125 mg/kg slow i.v. then 31.25 mg/kg i.v. q12h for 3 additional doses. Efficacy has been shown if treated within 3 hours of ingestion.

**References**

---

**Framycetin (Canaural) POM-V**

**Formulations:** Topical: 5 mg/g suspension (Canaural also contains fusidic acid, nystatin and prednisolone).

**Action:** Aminoglycosides inhibit bacterial protein synthesis and require an oxygen-rich environment to be effective, thus they are ineffective in low-oxygen sites (abscesses, exudates), making all obligate anaerobic bacteria resistant. Their mechanism of killing is concentration-dependent, leading to a marked post-antibiotic effect, allowing pulse-dosing regimens which may limit toxicity.

**Use:** Treatment of aural infections. Framycetin is particularly effective against Gram-negative bacteria, although the combination preparation Canaural has a broad spectrum of activity.

**Safety and handling:** Normal precautions should be observed.
Contraindications: Do not use in animals with a perforated tympanum. Do not use in conjunction with other products known to be ototoxic.

Adverse reactions: Aminoglycosides are potentially ototoxic, and ataxia, deafness and nystagmus may be observed in animals where drops have been administered with a perforated tympanum. Local irritation.

Drug interactions: No information available.

DOSES
See Appendix for guidelines on responsible antibacterial use.

Dogs, Cats: 5–10 drops per ear q12h. In small animals, 2–5 drops may be a more feasible volume to instill.

Furosemide (Frusemide)
(Dimazon, Frusecare, Frusedale, Libeo, Frusol*)
POM-V, POM

Formulations: Injectable: 50 mg/ml solution. Oral: 10 mg, 20 mg, 40 mg tablets; 20 mg/5 ml, 40 mg/5 ml, 50 mg/5 ml sugar-free oral solutions.

Action: Loop diuretic, inhibiting the Na⁺/K⁺/Cl⁻ cotransporter in the thick ascending limb of the loop of Henle. The net effect is a loss of sodium, potassium, chloride and water in the urine. It also increases excretion of calcium, magnesium and hydrogen as well as renal blood flow and glomerular filtration rate. Transient venodilation may occur following i.v. administration and in some species, bronchodilation may occur; the exact mechanism for both is unclear.

Use:
• Management of congestive heart failure (acute and chronic). The use of diuretic monotherapy for the chronic management of heart failure due to mild regurgitation or dilated cardiomyopathy in dogs is not recommended, as patients receiving concomitant therapy with pimobendan, ACE inhibitors (and spironolactone in dogs with mitral regurgitation) have a better clinical outcome.
• Treatment of hypercalcaemia.
• Promotion of diuresis in acute renal failure (questionable efficacy).

Use with caution in patients with severe electrolyte depletion, hepatic failure and diabetes mellitus. Evidence for efficacy in non-cardiogenic pulmonary oedema is lacking.

Safety and handling: Normal precautions should be observed.

Contraindications: Dehydration and anuria. Do not use in pericardial effusion where cardiac tamponade is confirmed. Can be used post-effusion drainage to assist in management of right-sided heart failure symptoms if necessary.
**Adverse reactions:** Hypokalaemia, hypochloraemia, hypocalcaemia, hypomagnesaemia and hyponatraemia; dehydration, polyuria/polydipsia and prerenal azotaemia occur readily. A marked reduction in cardiac output can occur in animals with severe pulmonary disease, low-output heart failure, hypertrophic cardiomyopathy, pericardial or myocardial disorders, cardiac tamponade and severe hypertension. Other adverse effects include ototoxicity (especially in cats), GI disturbances, leucopenia, anaemia, weakness and restlessness.

**Drug interactions:** Nephrotoxicity/ototoxicity associated with aminoglycosides may be potentiated when furosemide is also used. Furosemide may induce hypokalaemia, thereby increasing the risk of digoxin toxicity. Increased risk of hypokalaemia if furosemide given with acetazolamide, corticosteroids, thiazides and theophylline. Concurrent administration of NSAIDs with furosemide may decrease efficacy and may predispose to nephrotoxicity, particularly in patients with poor renal perfusion. Furosemide may inhibit the muscle relaxation qualities of tubocurarine, but increase the effects of suxamethonium.

**DOSES**

**Dogs, Cats:**
- **Acute, life-threatening congestive heart failure:** 1–2 mg/kg i.v., i.m. q0.5–4h as required, based on improvement in respiratory rate and effort. Once clinical signs improve, increase dosing interval to q6–12h, monitor urea, creatinine and electrolytes, and start oral therapy once tolerated. Use lower end of dose range for cats and monitor response. Ensure no pleural effusion present.
- **Chronic, congestive heart failure:** 1–5 mg/kg p.o. q6–12h. Typical maintenance doses for mild to moderate CHF are 1–2 mg/kg p.o. q8–24h (dogs) and 1–2 mg/kg p.o. q12–48h (cats). The goal is to use the lowest dose of furosemide that effectively controls clinical signs. Doses in excess of 12 mg/kg/day are unlikely to be beneficial and warrant the addition of a different class of diuretic (e.g. thiazide) or transfer to alternative diuretic (e.g. torasemide) to control refractory failure. In patients with ascites, use of s.c. instead of p.o. furosemide can have a marked clinical benefit due to improved bioavailability.
- **Hypercalcaemia:** hydrate before therapy. Give 2–4 mg/kg i.v., s.c., p.o. q8–24h. Maintain hydration status and electrolyte balance with normal saline and added KCl. Furosemide generally reduces serum calcium levels by 0.5–1.5 mmol/l.
- **Acute renal failure/oliguria:** Replace fluid deficit and subsequently closely monitor fluid input and output. Give furosemide at 2 mg/kg i.v. If no diuresis within 1 hour, repeat dose at 2–4 mg/kg i.v. If no response within 1 hour give another dose at 2–4 mg/kg i.v. Alternatively, bolus dose with 1–2 mg/kg i.v. followed by constant rate infusion at 0.1–2 mg/kg/h.

**References**


Fusidic acid
(Betafuse, Canaural, Isaderm, Isathal, Trigoderm)

Formulations: Topical: 5 mg/g fusidate suspension (Canaural also contains framycetin, nystatin and prednisolone); 0.5% fusidic acid + 0.1% betamethasone gel (Trigoderm, Isaderm); 1% fusidic acid viscous solution (Isathal).

Action: Inhibits bacterial protein synthesis.

Use: Active against Gram-positive bacteria, particularly Staphylococcus pseudintermedius. It is used topically in the management of staphylococcal infections of the conjunctiva, skin or ear. Fusidic acid is able to penetrate skin and penetrate the cornea gaining access to the anterior chamber of the eye. The carbomer gel vehicle in the ocular preparation may also be efficacious as a surface lubricant.

Safety and handling: Avoid contamination of the container on application.

Contraindications: Do not use preparations containing corticosteroids in pregnant animals.

Adverse reactions: No information available.

Drug interactions: No information available.

DOSES
See Appendix for guidelines on responsible antibacterial use.

Dogs:
• Otic: 5–10 drops per affected ear q12h. In small animals, 2–5 drops may be a more feasible volume to instill.
• Ophthalmic: 1 drop per eye q12h.
• Skin: apply to affected area q12h for 5 days.

Cats: Otic, Ophthalmic: doses as for dogs.

References
Gabapentin (Gabapentinum) (Neurontin*) POM CD Schedule 3

Formulations: Oral: 100 mg, 300 mg, 400 mg capsules; 600 mg, 800 mg film-coated tablets; 50 mg/ml solution.

Action: The precise mechanism of action of gabapentin is unknown but it appears to bind to a specific modulating protein of the voltage-gated calcium channels resulting in a decreased release of excitatory neurotransmitters. Gabapentin is structurally related to gamma-aminobutyric acid (GABA) and does increase levels of GABA in the CNS but does not appear to alter GABA binding, uptake or release. The mode of action of the analgesic effect may be due to down-regulation of excitatory neurotransmitter in the dorsal horn of the spinal cord or its inhibitory effect on dorsal horn NMDA receptors.

Use:
• Adjunctive therapy in the treatment of seizures refractory to treatment with conventional therapy although the supporting evidence in dogs is weak.
• Treatment of chronic pain states, such as neuropathic pain and possibly postoperative pain.
• Recent studies have shown it to be effective in improving quality of life in dogs with syringomyelia and effective in reducing the amount of opioid required in dogs postoperatively.

Recent studies have shown it to be effective in improving quality of life in dogs with syringomyelia and effective in reducing the amount of opioid required in dogs postoperatively. After multiple dosing, peak plasma concentrations of gabapentin are usually achieved within 2 hours of a dose, and steady state achieved within 1–2 days. It is partially metabolized by the liver before renal excretion and has an elimination half-life of 3–4 hours. Abrupt discontinuation of the drug has precipitated seizures in humans; therefore, tapered withdrawal is recommended. Monitoring of serum levels in dogs and in human patients does not appear useful. Use with caution in patients with renal impairment, behavioural abnormalities or severe hepatic disease.

Safety and handling: Normal precautions should be observed.

Contraindications: Avoid oral solutions containing xylitol which may be toxic to dogs at higher doses.

Adverse reactions: The most commonly reported adverse effect in dogs is mild sedation and ataxia. False-positive readings have been reported with some urinary protein tests in human patients taking gabapentin. Hepatic toxicity has been reported as a rare side effect in human patients.

Drug interactions: The absorption of gabapentin from the GI tract is reduced by antacids containing aluminium with magnesium; it is recommended that gabapentin is taken at least 2 hours after the administration of such an antacid. Cimetidine has been reported to reduce the renal clearance of gabapentin but the product information does not consider this to be of clinical importance.
DOSES

**Dogs:** 10–20 mg/kg p.o. q6–8h (starting dose; incremental dose increases are recommended).

**Cats:** 5–10 mg/kg p.o. q8–12h (starting dose; incremental dose increases are recommended).

References

---

**Ganciclovir** *(Virgan*) **POM**

**Formulations:** Topical: 0.15% eye gel in 5 g tube.

**Action:** Inhibits viral replication (viral DNA polymerase); depends on viral thymidine kinase for phosphorylation.

**Use:**
- Management of ocular feline herpesvirus-1 (FHV-1) infections.

*In vitro* studies show that ganciclovir is at least 10 times more effective against FHV-1 than aciclovir. Anecdotal reports of its topical use are promising, but neither the safety nor the pharmacokinetics has been reported in cats. Cannot eradicate latent viral infection. In refractory and severe cases of FHV-1 ulceration, combined therapy, including topical or systemic antiviral medication can be used.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.

**Adverse reactions:** Ocular irritation may occur and the frequency of application should be reduced if this develops. Treatment should not be continued for >3 weeks.

**Drug interactions:** No information available.

**DOSES**

**Dogs:** No information available.

**Cats:** Apply small amount to affected eye q4–6h (maximum 3 weeks).

References

---

**Gelatine** *(Oxypolygelatine, Polygeline)* *(Geloferusine, Haemaccel) **POM-V**

**Formulations:** Injectable: 4% solution of succinylated gelatine in 0.7% sodium chloride (Geloferusine); 35 g/dl degraded urea-linked gelatine with NaCl, KCl, CaCl₂ (Haemaccel).
**Action:** Promotes retention of fluid within the vascular system through the exertion of oncotic pressure.

**Use:**
- The expansion and maintenance of blood volume in various forms of shock, including hypovolaemic and haemorrhagic shock.

The main difference between gelatine-based solutions and other synthetic colloids is that they have lower molecular weights (and hence are excreted rapidly), appear to have few antigenic or anticoagulative effects. The plasma half-life of most gelatines is approximately 8 hours (oxy-polygelatine 2–4 hours), so that the duration of plasma expansion is much shorter than with hydroxyethyl starch. There appears to be little effect on coagulation or blood loss following gelatine administration. Use with caution in animals with congestive heart failure or renal insufficiency as will increase risk of circulatory overload.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.

**Adverse reactions:** Anaphylactoid reactions to gelatine solutions are rare; it is uncertain whether these reactions represent a specific immune response. In human medicine there are concerns over the safety of these solutions when used in patients with kidney disease.

**Drug interactions:** No information available.

**DOSES**

**Dogs, Cats:** Plasma volume expander: 10–20 ml/kg i.v. bolus. In normal circumstances do not exceed replacement of >25% of circulating blood volume with gelatines in a 24-hour period.

**References**


---

**Gemcitabine**

*(Gemzar®)* **POM**

**Formulations:** Injectable: Lyophilized powder for reconstitution before use. 200 mg (in 10 ml vials) and 1 g (in 50 ml vials).

**Action:** Metabolites of the drug inhibit the enzyme ribonucleotide reductase and compete with endogenous nucleotides for incorporation into DNA strands, thereby inhibiting DNA synthesis. Acts primarily in S phase.

**Use:**
- Used in dogs with bladder urothelial carcinoma, lymphoma and various carcinomas.
- Described for use in cats with exocrine pancreatic carcinoma.
- May also be useful as a radiosensitizer for some tumours.
Limited clinical use at present. In humans, gemcitabine has been used in cases of pancreatic carcinoma, small cell lung carcinoma, lymphoma, bladder and other soft tissue carcinomas. Seek specialist advice before using this drug.

**Safety and handling:** Potent cytotoxic drug that should only be prepared and administered by trained personnel. See Appendix and specialist texts for further advice on chemotherapeutic agents.

**Contraindications:** Contraindicated in patients with known hypersensitivity to gemcitabine. Do not use in patients with pre-existing bone marrow suppression. Should be used with caution in patients with reduced hepatic or renal function.

**Adverse reactions:** May cause myelosuppression and gastrointestinal adverse events. Retinal haemorrhage may also occur. Death due to treatment-related complications has been described.

**Drug interactions:** Not reported at present.

**DOSES**
See Appendix for chemotherapy protocols and conversion of body weight to body surface area.

**Dogs:** High dose: 800–900 mg/m² i.v. over 20–60 minutes every 7–14 days for 4 doses. Low dose: 25–50 mg/m² i.v. over 20–60 minutes once or twice a week as per protocols. Some studies report doses of 2 mg/kg i.v. over 20–30 minutes (in 0.9% NaCl) combined with carboplatin every 7 days.

**Cats:** Low dose: 20–25 mg/m² or 2 mg/kg as a 20 minute i.v. infusion every 7 days.

**References**


---

**Gentamicin**
(Clinagel Vet, Easotic, Genta, Otomax, Tiacil, Genticin*) **POM-V, POM**

**Formulations:** Injectable: 40 mg/ml solution for i.v., i.m., s.c. injection (human preparation), 100 mg/ml solution for i.v., i.m., s.c. injection (Genta). **Ophthalmic:** 0.3% w/w gel, 0.5% w/v drops. Aural: 1505 IU/ml in combination with miconazole and hydrocortisone (Easotic), 2640 IU/ml in combination with clotrimazole and betamethasone (Otomax).

**Action:** Aminoglycosides irreversibly bind to the 30S ribosome subunit inhibiting bacterial protein synthesis. They require an oxygen-rich environment to be effective, thus they are ineffective in low-oxygen sites (abscesses, exudates), making all obligate anaerobic bacteria resistant. Their mechanism of killing is
concentration-dependent, leading to a marked post-antibiotic effect, allowing pulse-dosing regimens which may limit toxicity.

**Use:** Active against Gram-negative bacteria, but some staphylococcal and streptococcal (Streptococcus faecalis) species are also sensitive. All obligate anaerobic bacteria and many haemolytic streptococci are resistant. Use in domestic animals is limited by nephrotoxicity and, more rarely, ototoxicity and neuromuscular blockade. Cats are more sensitive to toxic effects. Microbial resistance is a concern, although many bacteria resistant to gentamicin may be susceptible to amikacin. When used for empiric therapy of serious infections, gentamicin is usually given in conjunction with a penicillin and/or metronidazole to provide broad-spectrum cover. Aminoglycosides are more active in an alkaline environment. Geriatric animals or those with reduced renal function should only be given this drug systemically when absolutely necessary, although dosing q24h should reduce the likelihood of nephrotoxicity. Sepsis, dehydration, hypokalaemia, prolonged treatment and fever all increase the risk of nephrotoxicity. Therapeutic drug monitoring should be considered if possible and is highly recommended if nephrotoxicity risk factors are present. A peak level (30–60 minutes post i.v. dose) should be >20 μg (micrograms)/ml and a trough level should be <1 μg/ml.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not use the aural preparation if the tympanum is perforated. Do not use in conjunction with other drugs considered to be nephrotoxic. For systemic use do not exceed 7 days treatment duration.

**Adverse reactions:** Gentamicin delays epithelial healing of corneal ulcers and may cause local irritation. Nephrotoxicity and ototoxicity (auditory and vestibular) are potential side effects. Cellular casts in urine sediment are an early sign of impending nephrotoxicity; however, urine must be examined immediately to detect their presence, and their absence is not a guarantee of safety. Serum creatinine levels rise later and fatal acute renal failure may be inevitable when they do. Gentamicin should not be used during pregnancy.

**Drug interactions:** Avoid concurrent use of other nephrotoxic, ototoxic or neurotoxic agents (e.g. amphotericin B, furosemide). Increase monitoring and adjust dosages when these drugs must be used together. Aminoglycosides may be chemically inactivated by beta-lactam antibiotics (e.g. penicillins, cephalosporins) or heparin in vitro (avoid mixing in the same syringe). The effect of non-depolarizing muscle relaxants (e.g. atracurium, pancuronium, vecuronium) may be enhanced by aminoglycosides. Synergism may occur when aminoglycosides are used with beta-lactam antimicrobials.

**DOSES**

See Appendix for guidelines on responsible antibacterial use.

**Dogs:**
- **Otic:** 4–8 drops (depending on weight of the animal) in affected ear or apply ointment to affected area q12h.
Easotic preparation: apply 1 ml to each ear q24h using a metered or single dose delivery system.

- Ophthalmic: 1 drop per eye q6–8h. 1 cm gel per eye q8–12h.
- Systemic: 5–10 mg/kg slowly i.v. (over 30 min), i.m., s.c. q24h.

**Cats:**

- Ophthalmic: Dose as for dogs.
- Systemic: 5–8 mg/kg slowly i.v. (over 30 min), i.m., s.c. q24h.

---

**Glipizide**

*(Glipizide*, Minodiab*) **POM**

**Formulations:** Oral: 2.5 mg, 5 mg tablets.

**Action:** Increases insulin secretion (if functional reserve of β-cells), thereby reducing blood glucose.

**Use:**

- Management of type II diabetes mellitus in cats whose owners are unwilling or unable to give insulin.

Glipizide use may accelerate β-cell loss. May be effective alone or administered with insulin to reduce insulin requirements. It is ineffective when there is an absolute insulin deficiency or when insulin resistance is present, or ketosis. An effect on blood glucose may not be seen for 4–8 weeks. Administer with food. Preferred to metformin and glibenclamide, as better researched.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not use if ketosis present. Do not use if there is evidence of reduced hepatic or renal function.

**Adverse reactions:** Glipizide may cause GI disturbances (e.g. vomiting) and sensitivity reactions (e.g. jaundice, rashes, fever). May cause hypoglycaemia.

**Drug interactions:** The effects of glipizide may be enhanced by ACE inhibitors, NSAIDs, chloramphenicol, potentiated sulphonamides and fluoroquinolones.

**DOSES**

**Dogs:** Do not use.

**Cats:** Non-ketotic diabetes mellitus: 2.5–5 mg per cat p.o. q12h. Start at the lower end of the dose range, increasing the dose as required if no adverse effects are reported after 2 weeks.

**References**

**Glucagon** *(Glucagen) POM*

**Formulations:** Injectable: 1 mg vial for reconstitution.

**Action:** Binds to specific receptor and counteracts most of the effects of insulin.

**Use:** Insulin overdose. Use only when feeding and glucose administration has failed to maintain a response. Duration of activity is unknown in dogs but likely to be 1–2 hours. When using glucagon, blood glucose levels should be monitored hourly.

**Safety and handling:** Store at room temperature until reconstituted and then use immediately.

**Contraindications:** Normoglycaemia.

**Adverse reactions:** Vomiting is the main adverse reaction reported in humans. Anaphylaxis may occur but is rare. Experience with dogs is too limited to provide clear guidance.

**Drug interactions:** No information available.

**DOSES**

**Dogs, Cats:** Hypoglycaemia: 50 ng (nanograms)/kg i.v., i.m. once followed by infusion of 10–15 ng/kg/min i.v., i.m.; may increase up to 40 ng/kg/min i.v., i.m., depending on blood glucose measurements.

**References**


**Glucose** *(Dextrose)* *(Aqupharm, Vetivex, 50% Glucose for injection*)

**POM-V, POM-VPS, POM**

**Formulations:** Injectable: sodium chloride 0.9% w/v, glucose monohydrate 5.5% w/v (Aqupharm No. 3 and Vetivex 3); sodium chloride 0.18% w/v, glucose monohydrate 4.4% w/v (Aqupharm No. 18 and Vetivex 6); other electrolyte solutions with glucose for i.v. use: glucose 40% and 50% w/v.

**Action:** Source of energy for cellular metabolism. Osmotic agent.

**Use:**
- Dilute glucose solutions are used for fluid replacement (primarily where intracellular and interstitial losses have occurred).
- Concentrated glucose solutions are used parenterally as an energy source or in the treatment of hypoglycaemia.

Patients requiring parenteral nutritional support will require mixtures comprising combinations of amino acids, glucose solutions and fat.
Solutions containing >5% glucose are hypertonic and irritant if administered other than i.v. The 50% solutions contain 1.7 kcal/ml (8.4 kJ/ml) glucose and are extremely hypertonic (2525 mOsm/l). Use with caution in patients with insulin resistance and diabetes mellitus.

**Safety and handling:** Multi-use vials of 5% glucose or higher rapidly support bacterial growth and strict aseptic technique is required, single patient use is advised.

**Contraindications:** No information available.

**Adverse reactions:** 10–50% solutions are irritant and hyperosmolar; administer through a jugular catheter or dilute appropriately. Glucose infusions may produce severe hypophosphataemia in some patients with prolonged starvation. If glucose loading produces signs of hyperglycaemia, insulin may be added to correct it. See comments under Amino acid solutions for use in parenteral nutrition solutions.

**Drug interactions:** No information available.

**DOSES**

**Dogs:**

- **Fluid therapy:** fluid requirements depend upon the degree of dehydration and ongoing losses. See Parenteral fluids table in Appendix.
- **Parenteral nutrition:** the amount required will be governed by the animal’s physiological status, the parenteral nutrition admixture and its ability to tolerate high blood glucose levels. Generally, glucose is used to supply 40–60% of the energy requirement. Seek specialist advice before giving parenteral nutrition. See Amino acid solutions.
- **Hypoglycaemia:** 1–5 ml 50% dextrose i.v. slowly over 10 min. (NB: to meet minimum needs for maintenance 1 ml/kg/h of 50% glucose is needed.)

**Cats:** Doses as for dogs for fluid therapy and hypoglycaemia. Specific advice regarding nutrient admixtures and the use of concentrated glucose solutions for provision of energy in cats requiring nutritional support should be sought.

---

**Glyceryl trinitrate** *(Nitroglycerin(e))*


**Formulations:** Topical: 2% ointment to be applied to skin (Percutol) equating to dose of up to 800 μg (micrograms)/kg/h per inch of treatment. 5 mg/24 h, 10 mg/24 h, 15 mg/24 h transdermal patches (Deponit, Minitran, Nitro-Dur, Transderm-Nitro). Oral: 0.003 mg, 0.005 mg sub-lingual tablet (Glyceryl trinitrate). Injectable: 1 mg/ml solutions (Nitrocin, Nitronal).

**Action:** Systemic vasodilator. Although a potent coronary vasodilator, its major benefit in small animals follows from a...
reduction in venous return as a consequence of venodilation. A
decrease in venous return reduces left ventricular filling pressures.

Use:
- Short-term management of cardiogenic oedema (particularly
  acute pulmonary oedema) in animals with congestive heart
  failure.

It is normally only used for 1–2 days. Its efficacy is debatable. Rotate
application sites; suggested sites include the thorax, groin and inside
the ears. Rub ointment well into the skin.

Safety and handling: Owners should be cautioned to avoid
contact with areas where the ointment has been applied and to
wear non-permeable gloves when applying.

Contraindications: Hypotension, hypovolaemia, cerebral
haemorrhage, head trauma.

Adverse reactions: Hypotension (reduce dose), tachycardia and a
rash at the site of application. Tachyphylaxis can occur. Headaches
are common in humans and may be an adverse effect in animals too.

Drug interactions: Concurrent use of ACE inhibitors, anaesthetics,
beta-blockers, calcium-channel blockers, corticosteroids and diuretics
may enhance the hypotensive effect. NSAIDs may antagonize its
hypotensive effects.

DOSES

Dogs, Cats: 6–50 mm (¼–1 inch) Percutol applied topically to the
skin q6–8h; extrapolate dose to transdermal patches when Percutol
not available. Closely monitor clinical signs and blood pressure.
Where it is used chronically for the management of heart failure (e.g.
nocturnal dyspnoea) use q24h to avoid tolerance. Anecdotal use of
patches has been reported: dogs <5kg: 1 x 5 mg/24-hour patch in
24 hours. Small/medium dogs: 1 x 10 mg/24-hour patch in 24 hours.
Large/giant dogs: 2 x 10 mg/24-hour patch in 24 hours.

Cats: 3–6 mm (¼ inch) topically to the skin q6–8h; extrapolate
dose to transdermal patches when Percutol not available. Closely
monitor clinical signs and blood pressure. Anecdotal use of patches:
cats 1 x 5 mg/24-hour patch in 24 hours.

References
151–159

Glycopyrronium (Glycopyrrolate)
( Robinul*) POM

Formulations: Injectable: 200 µg/ml solution.
Action: Blocks the action of acetylcholine at muscarinic receptors at
the terminal ends of the parasympathetic nervous system, reversing
parasympathetic effects. Its quaternary structure prevents it from
crossing the blood–brain barrier and so it is devoid of central effects.
Use:

- Potent antisialagogue agent and has been used preoperatively to decrease oral and bronchial secretions.
- It is also used to inhibit vagal efferent activity and manage bradycardias caused by the administration of potent opioid drugs.
- Glycopyrronium is used with long-acting anticholinesterase drugs (e.g. neostigmine, pyridostigmine) during antagonism of neuromuscular block.

Glycopyrronium is longer acting than atropine. Routine administration of glycopyrronium prior to anaesthesia as part of premedication is no longer recommended. It causes a reduction in oral and bronchial secretions by decreasing the water content, therefore, secretions become more sticky. Administration of potent opioids in the perioperative period can promote bradyarrhythmias but it is better to monitor heart rate and give glycopyrronium to manage a low heart rate if necessary. Administration of very low doses of glycopyrronium i.v. can cause exacerbation of bradyarrhythmias due to a vagal stimulatory effect; giving another dose i.v. will usually cause an increase in heart rate. Glycopyrronium is devoid of central effects and therefore does not cause mydriasis.

Safety and handling: Normal precautions should be observed.

Contraindications: No information available.

Adverse reactions: Tachycardias following overdose of glycopyrronium are usually transient and do not require management. Ventricular arrhythmias may be treated with lidocaine if severe. The incidence of adverse effects is lower than that seen with atropine.

Drug interactions: When mixed with alkaline drugs (e.g. barbiturates), a precipitate may form. Antimuscarinics may enhance the actions of sympathomimetics and thiazide diuretics. The following may enhance the activity of glycopyrronium: antihistamines, pethidine, benzodiazepines and phenothiazines. Combining glycopyrronium and alpha-2 adrenergic agonists is not recommended.

DOSES

Dogs, Cats:

- Management of vagally mediated bradyarrhythmias: 2–10 μg (micrograms)/kg i.v., i.m.
- Neuromuscular blockade antagonism: glycopyrronium (10 μg/kg i.v. once) with neostigmine (50 μg/kg i.v. once).

References


Sinclair MD, OGrady MR, Kerr CL et al. (2003) The echocardiographic effects of romifidine in dogs with and without prior or concurrent administration of glycopyrrolate. Veterinary Anaesthesia and Analgesia 30, 211–219
Grapiprant
(Galliprant) POM-V

Formulations: Oral: 20 mg, 60 mg, 100 mg tablets.

Action: Grapiprant is a piprant non-steroidal anti-inflammatory drug. It is a specific EP4 receptor antagonist; this receptor normally binds PGE2 to produce pain and inflammation associated with osteoarthritis.

Use: Management of mild to moderate pain caused by osteoarthritis in dogs >9 months of age.

Safety and handling: Wash hands after handling the product.

Contraindications: Mild decreases in serum albumin and total protein, most often within the reference range, have been observed in dogs treated with grapiprant but were not associated with any clinically significant observations or events. Use with caution in dogs suffering from pre-existing liver, cardiovascular or renal dysfunction or from gastrointestinal disease. The EP4 receptor is involved in ulcer healing in the GI tract and is abundant in cardiac tissue, the clinical significance of this is unknown. The safety of the veterinary medicinal product has not been established in dogs <9 months of age and in dogs weighing <3.6 kg. It is not authorized for use in cats.

Adverse reactions: In clinical studies, the following mild and generally transient adverse reactions were observed: vomiting, soft-formed faeces, diarrhoea and inappetence. In very rare cases, haematemesis or haemorrhagic diarrhoea was reported following clinical use post authorization in the USA.

Drug interactions: The concurrent use of grapiprant with other anti-inflammatory agents, such as NSAIDs and steroids, has not been studied and should be avoided.

DOSES
Dogs: 2 mg/kg once daily.
Cats: Not authorized for use in cats.

References
**Halothane**  
(Fluothane, Halothane) **POM-V**

**Formulations:** Inhalational: 250 ml bottle.

**Action:** The mechanism of action of volatile anaesthetic agents is not fully understood.

**Use:**
- Induction and maintenance of anaesthesia.

Halothane is potent and highly volatile so should only be delivered from a suitable calibrated vaporizer. It is more soluble in blood than isoflurane and sevoflurane; therefore, induction and recovery from anaesthesia are slower than with the other agents. The concentration of halothane required to maintain anaesthesia depends on the other drugs used in the anaesthesia protocol; the concentration should be adjusted according to clinical assessment of anaesthetic depth. MAC is approximately 0.9% in most species.

**Safety and handling:** Unstable when exposed to light and corrodes certain metals. It dissolves into rubber and may leach out into breathing circuits after the vaporizer is turned off. Thymol 0.01% is included as a preservative; as halothane vaporizes, the concentration of thymol increases and this can cause vaporizer controls to stick and ports to be occluded. Periodic servicing and recalibration of precision vaporizers is essential to ensure delivery of known concentration of halothane vapour. Measures should be adopted to prevent contamination of the environment with halothane during anaesthesia and handling of the agent.

**Contraindications:** Do not use in patients with liver disease.

**Adverse reactions:** Dose-dependent hypotension through depression of heart rate and myocardial contractility, although these adverse effects wane with time. Reduces blood flow in the liver. Halothane facilitates the generation of ventricular arrhythmias in the presence of other arrhythmogenic factors, e.g. catecholamines, hypoxia and hypercarbia. Halothane crosses the placental barrier and will affect neonates delivered by caesarean section. Up to 25% of inhaled halothane undergoes oxidative metabolism by hepatic cytochrome.

**Drug interactions:** Sedatives, opioid agonists and N₂O reduce the concentration of halothane required to achieve surgical anaesthesia.

**DOSES**

**Dogs, Cats:** The expired concentration required to maintain surgical anaesthesia in 50% of recipients is 0.8–1.0% in animals (minimum alveolar concentration). Administration of other anaesthetic agents and opioid analgesics reduces the dose requirement of halothane, therefore, the dose should be adjusted according to individual requirement. Halothane at 3–4% concentration is required to induce anaesthesia in unpremedicated patients.
References
Teixeira Neto FJ, Luna SP, Cruz ML et al. (2007) A study of the effect of haemorrhage on the cardiorespiratory actions of halothane, isoflurane and sevoflurane in the dog. Veterinary Anaesthesia and Analgesia 34, 107–116

Heparin (low molecular weight)
(Dalteparin, Enoxaparin)
(Clexane (enoxaparin)*, Fragmin (dalteparin)*)
POM

Formulations: Injectable: 2,500 IU/ml, 100,000 IU/ml ampoules (dalteparin); 25,000 IU/ml multidose vial plus various pre-filled syringes at concentrations of 12,500 IU/ml and 25,000 IU/ml (dalteparin); pre-filled syringes of 100 mg/ml (enoxaparin). 100 mg enoxaparin is equivalent to 10,000 IU of anti-Factor Xa activity.

Action: Low molecular weight heparin (LMWH) is an anticoagulant that inhibits Factor Xa and thrombin. When compared with unfractionated heparin (UFH), LMWH has reduced anti-IIa activity relative to anti-Xa activity (ratio of anti-Xa to anti-IIa is 2–4:1 compared with UFH 1:1). Thus, at therapeutic doses LMWH has minimal effect on aPTT. Therapeutic monitoring of LMWH is by anti-Xa activity (but this may not be practical or necessary given its more reliable and consistent pharmacokinetics).

Use:
• Treatment of thromboembolic complications and hypercoagulable syndromes (e.g. pulmonary thromboembolism, immune-mediated haemolytic anaemia (IMHA)).
• LMWH is also used in the treatment of myocardial infarction, atrial fibrillation, deep vein thrombosis and pulmonary thromboembolism in humans.
• Its use in DIC is controversial as no beneficial effect has been shown in controlled clinical trials in humans. LMWH is no longer used to try to prevent DIC.

Heparins are only effective if sufficient AT III is present. Heparin therapy is only one aspect of the management of DIC: addressing the precipitating cause, administration of fluids, fresh whole blood, aspirin and diligent monitoring of coagulation tests (aPTT, PT), fibrin degradation products and fibrinogen are all important factors. The doses of heparin are controversial, with some texts recommending lower or higher doses, the use of constant i.v. infusions, or preincubation with plasma. The aim of therapy is to achieve anti-Factor Xa activity of 0.35–0.7 IU/ml (although in many cases this may not be practical to measure). This therapeutic target is extrapolated from humans but no data are available to determine if this decreases risk for thromboembolic complications in dogs or cats. Cats appear to require higher dosages of LMWH to achieve proposed therapeutic targets. LMWH has better pharmacokinetic properties than UFH and its actions are more predictable in humans. It is considerably more expensive than UFH.
Safety and handling: Normal precautions should be observed.

Contraindications: Bleeding disorders or severe renal dysfunction.

Adverse reactions: If an overdose occurs protamine can be used as an antidote. Heparin should not be administered i.m. as it may result in haematoma formation. Its use in DIC may worsen haemorrhage especially if the patient is thrombocytopenic. Heparin-induced thrombocytopenia syndrome is a serious concern in human patients but has not been reported in dogs or cats.

Drug interactions: Use with caution with other drugs that can cause changes in coagulation status (e.g. aspirin, NSAIDs). Heparin may antagonize ACTH, corticosteroids or insulin. Heparin may increase plasma levels of diazepam. The actions of heparin may be partially counteracted by antihistamines, digoxin and tetracyclines. Do not mix other drugs in the same syringe as heparin.

DOSES

Dogs:
- 100–175 IU/kg s.c. q8h (Dalteparin).
- 0.08 mg/kg s.c. q6h (Enoxaparin).

Cats:
- 75 IU/kg s.c. q6h (Dalteparin).
- 0.75–1 mg mg/kg s.c. q6–12h (Enoxaparin).

Dogs, Cats: Anticoagulation: 80–150 IU/kg s.c. q4–8h.

References

Heparin (unfractionated) (UFH)
(Heparin*, Hepsal*) POM

Formulations: Injectable: 1,000–25,000 IU/ml solutions; 10 IU/ml in saline, 100 IU/ml in saline.

Action: Heparin is an anticoagulant that exerts its effects primarily by enhancing the binding of antithrombin III (AT III) to factors IIa, IXa, Xa, Xla and XIIa; it is only effective if adequate AT III is present. The AT III/clotting factor complex is subsequently removed by the liver. Heparin inactivates thrombin and blocks the conversion of fibrinogen to fibrin. The inhibition of Factor XII activation prevents the formation of stable fibrin clots. Heparin does not significantly change the concentrations of clotting factors, nor does it lyse pre-existing clots.

Use:
- Management of hypercoagulable conditions with associated increased risk of thromboembolic events (e.g. immune-mediated haemolytic anaemic, cardiomyopathy in cats, protein-losing nephropathy).
Therapy must be carefully monitored as the activity of UFH is somewhat less predictable than LMWH, ideally via Anti-Xa activity (which may not be practical).

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Major bleeding disorders, increased risk of haemorrhage, thrombocytopenia.

**Adverse reactions:** If an overdosage occurs protamine can be used as an antidote. Heparin should not be administered i.m. as it may result in haematoma formation. Its use in DIC may worsen haemorrhage especially if the patient is thrombocytopenic. Heparin-induced thrombocytopenia syndrome is a serious concern in human patients but has not been reported in dogs or cats.

**Drug interactions:** Use with caution with other drugs that can cause changes in coagulation status (e.g. aspirin, NSAIDs). Heparin may antagonize ACTH, corticosteroids and insulin. Heparin may increase plasma levels of diazepam. The actions of heparin may be partially counteracted by antihistamines, digoxin and tetracyclines. Do not mix other drugs in the same syringe as heparin.

**DOSES**

**Dogs:** Anticoagulation: 150–300 IU/kg s.c. q6; adjust dosage so that the aPTT is 1.5–2.0 times normal or anti-Factor Xa activity between 0.35 and 0.7 IU/ml (see LMWH for more information); 100 IU/kg bolus i.v., then 480–900 IU/kg/24h (20–37.5 IU/kg/h).

**Cats:** Anticoagulation: 250–300 IU/kg s.c. q8h.

**References**


Diquelou A, Barbaste C, Gabaig AM et al. (2005) Pharmacokinetics and pharmacodynamics of a therapeutic dose of unfractionated heparin (200 U/kg) administered subcutaneously or intravenously to dogs. *Veterinary Clinical Pathology* 34, 237–242


**Human chorionic gonadotrophin** see Chorionic gonadotrophin

**Hyaluronate**

(An-HyPro, ClinaDry, Remend Corneal Lubricant, Remend Corneal Repair Gel, Hyabak*, Hylo-Forte*, Hylo-Tear*, Vismed Multi*)

**Formulations:** Ophthalmic: 0.1%, 0.15%, 0.2%, 0.4% solution in 10 ml bottle; 0.4% and 0.75% Hyasent-S (modified, cross-linked hyaluronic acid) in Remend products.
**Action:** Viscoelastic fluid with mucomimetic properties; increases corneal epithelial migration. Sodium hyaluronate is also available in different formulations as a viscoelastic for intraocular surgery.

**Use:**
- Used as a tear replacement.
- Management of quantitative (keratoconjunctivitis sicca (KCS) or dry eye) and qualitative tear film disorders.

It has longer corneal contact time than the aqueous tear substitutes.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.

**Adverse reactions:** It is tolerated well and ocular irritation is unusual.

**Drug interactions:** No information available.

**DOSES**
- **Dogs, Cats:** 1 drop per eye q4–6h, although it can be used hourly if required.

---

**Hydralazine**
*(Hydralazine)*

**(Hydralazine)**

**Formulations:** Oral: 25 mg, 50 mg tablets.

**Action:** Hydralazine acts chiefly on arteriolar smooth muscle causing vasodilation; it is able to decrease systemic vascular resistance to about 50% of the baseline value. The effects of hydralazine are to reduce afterload and increase heart rate, stroke volume and cardiac output.

**Use:**
- Afterload reducer as adjunctive therapy of congestive heart failure in dogs secondary to severe or refractory mitral valve insufficiency.
- It can be used to treat systemic hypertension (not typically as a first-line drug).

Hospitalization with frequent monitoring of blood pressure is advised during its use. As hydralazine may cause sodium and water retention, concomitant use of diuretic therapy is often necessary. Give with food if possible.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Hypovolaemia, hypotension, renal impairment or cerebral bleeding.

**Adverse reactions:** Reflex tachycardia, severe hypotension (monitor and adjust doses as necessary), anorexia and vomiting (the latter two effects commonly seen in cats).
Drug interactions: The hypotensive effects of hydralazine may be enhanced by ACE inhibitors (e.g. enalapril, benazepril), anaesthetics, beta-blockers (e.g. propranolol), calcium-channel blockers (e.g. diltiazem, verapamil), corticosteroids, diuretics and NSAIDs. Sympathomimetics (e.g. phenylpropanolamine) may cause tachycardia. The pressor response to adrenaline may be reduced.

DOSES
*Dogs*: 0.5–3 mg/kg p.o. q8–12h. Start at low dose (0.5–1 mg/kg q12h), monitor blood pressure regularly and increase to 2 mg/kg or even 3 mg/kg q12h if necessary.
*Cats*: 2.5–10 mg/cat p.o. q12h. Start at low dose and titrate upwards cautiously as above if necessary.

References

**Hydrochlorothiazide**
*(Co-amilozide*, *Moduret*, *Moduretic*)  POM

Formulations: Oral: 25 mg hydrochlorothiazide + 2.5 mg amiloride, 50 mg hydrochlorothiazide + 5 mg amiloride tablets.

Action: Thiazide diuretic that inhibits reabsorption of sodium and chloride in the distal convoluted tubule by blocking the sodium/chloride symporter, resulting in sodium, chloride and water loss in the urine. It also causes excretion of potassium, magnesium and bicarbonate. It is formulated with a potassium-sparing diuretic (amiloride).

Use:
- Additional therapy for congestive heart failure when the clinical signs have become refractory to furosemide/torasemide. However, loop-diuretic therapy should still be continued when using hydrochlorothiazide to gain the beneficial effect of sequential nephron blockade.
- It may also be used in the prevention of calcium oxalate urolithiasis.
- Thiazides have antihypertensive effects, although the exact mechanism is unclear.

Safety and handling: Normal precautions should be observed.

Contraindications: Renal impairment, as it tends to reduce glomerular filtration rate.

Adverse reactions: Hyperglycaemia, hypokalaemia, hyponatraemia, hypochloraemia and volume contraction. It enhances the effects of the renin-angiotensin-aldosterone system in heart failure.
Drug interactions: Increased possibility of hypokalaemia developing if thiazides are used concomitantly with corticosteroids or loop diuretics (furosemide). Thiazide-induced hypokalaemia may increase the risk of digoxin toxicity. Thus, concomitant use of potassium-sparing diuretics (e.g. spironolactone) or potassium supplementation may be necessary during prolonged administration. The concurrent administration of vitamin D or calcium salts with thiazides may exacerbate hypercalcaemia.

DOSES
Dogs: 0.5–4 mg/kg p.o. q12–24h. Start at low dose and titrate upwards every 5–10 days, to effect. Monitor urea, creatinine, electrolytes and blood pressure before increasing dose.
Cats: 1–2 mg/kg p.o. q12–24h. Start at low dose and titrate upwards cautiously as above.

References

Hydrocortisone
(Efcortesol®, Solu-cortef®) POM

Formulations: Topical: 0.5%, 1% creams, 1% solution (Hydrocortisone). Injectable: 25 mg/ml solution; 100 mg, 500 mg powders for reconstitution (Solu-cortef). Oral: 10 mg, 20 mg tablets (Hydrocortisone).

Action: Alters the transcription of DNA, leading to alterations in cellular metabolism. It has both glucocorticoid and mineralocorticoid activity.

Use:
• Topical anti-inflammatory drug.
• Early management of acute hypoadrenocorticism.
• Treatment of critical illness-related corticosteroid insufficiency (CIRCI) has been described in dogs and cats with fluid-loaded, vasopressor-resistant septic shock, but a dose has not been established.

Hydrocortisone has only a quarter of the glucocorticoid potency of prednisolone and one thirtieth that of dexamethasone. On a dose basis 4 mg of hydrocortisone is equivalent to 1 mg prednisolone. Animals on chronic therapy should be tapered off steroids when discontinuing the drug (even following topical administration). The use of steroids in most cases of shock or spinal cord injury is of no benefit and may be detrimental.

Safety and handling: Wear gloves when applying topically as the cream is absorbed through skin.

Contraindications: Do not use in pregnant animals. Systemic corticosteroids are generally contraindicated in patients with renal disease and diabetes mellitus.
Adverse reactions: Excessively rapid correction of hyponatraemia in cases of acute hypoadrenocorticism may cause brain damage and so, in severely hyponatraemic animals, initial doses should be reduced by 50% or postponed until the rate of correction using saline has been established. Catabolic effects of glucocorticoids lead to weight loss and cutaneous atrophy. Iatrogenic hyperadrenocorticism may develop (PU/PD, elevated liver enzymes). Vomiting and diarrhoea, or GI ulceration may develop. Glucocorticoids may increase urine glucose levels and decrease serum T3 and T4 values. Prolonged use of glucocorticoids suppresses the hypothalamic-pituitary axis and causes adrenal atrophy. Impaired wound healing and delayed recovery from infections may be seen.

Drug interactions: Increased risk of GI ulceration if used concurrently with NSAIDs. Glucocorticoids antagonize the effect of insulin. Antiepileptic drugs (phenobarbital) may accelerate the metabolism of corticosteroids and antifungals (e.g. itraconazole) may decrease it. There is an increased risk of hypokalaemia when corticosteroids are used with acetazolamide, amphotericin and potassium-depleting diuretics (furosemide, thiazides).

DOSES
Dogs:
• Topically: apply a thin layer of cream to affected area q6–12h.
• Hypoadrenocorticism: 0.5 mg/kg/h i.v. by constant rate infusion, in acute Addisonian crisis and 0.125 mg/kg p.o. q12h for maintenance.
• Anti-inflammatory: 0.5 mg/kg p.o. q12h.
Cats: Topical use as for dogs. Its use in feline hypoadrenocorticism has not been documented.

References

Hydrocortisone aceponate (Cortavance, Easotic) POM-V

Formulations: Topical: 76 ml spray (0.584 mg/ml) (Cortavance); suspension for ears: 1.11 mg/ml combined with 15.1 mg/ml miconazole and 1505 IU/ml gentamicin (Easotic).

Action: Hydrocortisone aceponate is a pro-drug that is biotransformed in the epidermis to its active form hydrocortisone 17-propionate.

Use:
• Treatment of inflammatory and pruritic dermatoses, including acute otitis externa and acute exacerbations of recurrent otitis externa associated with bacteria and Malassezia.
Minimizes systemic side effects (such as increases in liver enzyme activities, depression of cortisol response to ACTH stimulation). Microbial infections should be treated appropriately prior to use. Patients should be monitored appropriately during long-term use. Use with caution in dogs <7 months old as glucocorticoids are known to slow growth. Total body surface treated should not exceed a surface corresponding for example to a treatment of two flanks from the spine to the mammary chains including the shoulders and the thighs.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not use on ulcerated skin (Cortavance). Do not use if the ear drum is perforated (Easotic).

**Adverse reactions:** Protracted use of any topical glucocorticoid can result in epidermal atrophy. The otic preparation may result in aural erythema and rarely transient hearing loss in geriatric dogs.

**Drug interactions:** No information available.

**DOSES**

**Dogs:** Cortavance: 2 pumps of spray per 10 cm x 10 cm square of skin for 7 days. This delivers 1.52 μg (micrograms) of hydrocortisone aceponate per cm². Easotic: 1 pump (1 ml) per ear q24h for 5 days.

**Cats:** Dose not established.

**References**


---

**Hydroxycarbamide (Hydroxyurea)** *(Hydrea*) **POM**

**Formulations:** Oral: 100 mg and 1 g tablet; 300 mg and 500 mg capsule.

**Action:** Inhibits ribonucleotide reductase, which converts ribonucleotides to deoxyribonucleotides (important precursors for DNA synthesis and repair). It acts primarily in the S-phase, but may also arrest cells at the G1-S border.

**Use:**

- Treatment of polycythaemia vera, chronic myeloid leukaemia and chronic granulocytic leukaemia.
- Treatment of mast cell tumours and part of adjunctive treatment of canine meningiomas.

Once in remission, reduce dosage frequency as required. Perform haematology initially weekly for one month, then every two weeks for one month, then monthly if tolerated. Haematology must be monitored weekly at the start of drug therapy in cats, as they are at greater risk of myelosuppression compared to dogs. Use with caution in patients with renal dysfunction; dose reduction may be required.
Safety and handling: Cytotoxic drug; see Appendix and specialist texts for further advice on chemotherapeutic agents.

Contraindications: Patients with bone marrow suppression. Use with caution in patients with a history of urate stones, renal disease/dysfunction and those that have received previous chemotherapy and/or radiotherapy.

Adverse reactions: Myelosuppression, GIT signs (nausea, vomiting, diarrhoea, anorexia), dysuria and skin reactions (stomatitis, sloughing of nails, alopecia). Myelosuppression is dose-limiting; monitor haematological parameters at regular intervals. In cats given very high doses (>500 mg) methaemoglobinaemia is reported. Normal doses are associated with increased diastolic blood pressure and heart rate but decreased systolic blood pressure, QT and PR intervals, maximum left ventricular systolic and end diastolic pressures.

Drug interactions: No information available but advisable not to use with other myelosuppressive agents.

DOSES
See Appendix for chemotherapy protocols and conversion of body weight to body surface area.

Dogs:
- CML: 50 mg/kg p.o. q24h for 1–2 weeks then q48h.
- Polycythaemia vera or CML: 50–80 mg/kg p.o. q3d or 1 g/m² p.o. q24h until haematology is normal.
- Mast cell tumours: 60 mg/kg p.o. q24h for 14 days; then 30 mg/kg p.o. q24h.
- Meningioma: 20 mg/kg p.o. q24h or 50 mg/kg p.o. 3 times a week.

Cats:
- 10 mg/kg q12–24h until remission; then taper to lowest effective frequency by monitoring haematocrit; or 25 mg/kg p.o. 3 times a week.
- Meningioma: 20 mg/kg p.o. q24h.

References

Hydroxyurea see Hydroxycarbamide

Hydroxyzine
(Atarax*, Ucerax*) POM

Formulations: Oral: 10 mg, 25 mg tablets; 2 mg/ml syrup.

Action: Binds to H1 histamine receptors preventing histamine from binding. Hydroxyzine is metabolized to cetirizine.
Use:
- Management of allergic disease in dogs and cats, although specific doses have not been determined by pharmacokinetic studies.

Use with caution in cases with urinary retention, angle-closure glaucoma and pyloroduodenal obstruction.

Safety and handling: Normal precautions should be observed.

Contraindications: No information available.

Adverse reactions: May cause mild sedation. May reduce seizure threshold.

Drug interactions: No information available.

DOSES
Dogs, Cats: Antihistamine: 2.0–2.2 mg/kg q8–12h.

Hyoscine see Butylscopolamine

Hypromellose
(Hypromellose*, Isopto Plain*)

Formulations: Ophthalmic: 0.3%, 0.5% solutions in 10 ml dropper bottle; 0.32% (single-use vial). Large variety of other formulations also available.

Action: Cellulose based, aqueous tear substitute to replace aqueous component of trilaminar tear film (lacrimomimetic).

Use:
- Lubrication of dry eyes.
- In cases of keratoconjunctivitis (KCS or dry eye) it will improve ocular surface lubrication, tear retention and patient comfort while lacrostimulation therapy (e.g. topical ciclosporin) is initiated.
- It may also be used as a vehicle base for compounding ophthalmic drugs.

Patient compliance is poor if used >q4h, consider using a longer acting tear replacement.

Safety and handling: Normal precautions should be observed.

Contraindications: No information available.

Adverse reactions: No information available.

Drug interactions: No information available.

DOSES
Dogs, Cats: 1 drop per eye q1h.

References
Imepitoin
(Pexion) POM-V

Formulations: Oral: 100 mg, 400 mg tablets.

Action: Imepitoin inhibits seizures via potentiation of the GABA<sub>A</sub> receptor-mediated inhibitory effects on the neurons. Imepitoin also has a weak calcium-channel blocking effect, which may contribute to its anticonvulsive properties.

Use:
• Imepitoin and phenobarbital are the initial medications of choice for the management of epileptic seizures due to idiopathic epilepsy in dogs. The choice of initial medication is guided by patient requirements: imepitoin has a more rapid onset of action than phenobarbital (a steady state does not need to be achieved), does not require the determination of serum concentrations and has a less severe adverse effect profile; however, phenobarbital is less expensive and more efficacious. Imepitoin is well tolerated in healthy cats at similar doses to dogs but its efficacy to control seizures is yet to be proven.
• Imepitoin may also be used in combination with a behaviour modification plan for the control of anxiety in dogs in relation to both social stimuli (e.g. crowds, strangers) and non-social stimuli (e.g. noises, novel items, new environments), once any role of pain has been controlled. Use in dogs displaying aggressive behaviour should be done with caution and management of associated risk put in place.

Safety and handling: Normal precautions should be observed.

Contraindications: The medication should not be used with severely impaired liver, kidney and heart function.

Adverse reactions: The most frequent adverse effect reported is sedation, particularly in dogs on higher doses or already on phenobarbital therapy. A cutaneous adverse reaction has been reported. Other adverse effects are generally mild and transient and include polyphagia, hyperactivity, polyuria, polydipsia, somnolence, hypersalivation, emesis, ataxia, apathy, diarrhoea, prolapsed nictitating membrane, decreased sight and a paradoxical increase in sensitivity to sound.

Drug interactions: Imepitoin has been used in combination with phenobarbital in a small number of cases and no harmful clinical interactions were reported.

DOSES
Dogs: 10–30 mg/kg p.o. q12h. Doses towards the higher end of the range appear to be more effective. For the control of anxiety, an initial dose of 10 mg/kg p.o. q12h is recommended, but the dose may be titrated up to 30 mg/kg p.o. q12h or down to 5 mg/kg p.o. q12h as necessary, dependent on initial response.
**Cats:** Imepitoin is well tolerated in healthy cats at similar doses to dogs (10–30 mg/kg p.o. q12h) but its efficacy to control seizures or anxiety remains unproven.

**References**
Rundfeldt C, Tipold A and Löscher W (2015) Efficacy, safety, and tolerability of imepitoin in dogs with newly diagnosed epilepsy in a randomized controlled clinical study with long-term follow up. *BMC Veterinary Research* 11, 228

**Imidacloprid**
(Advantage, Advantix, Advocate, Moxiclear, Prinovox, Seresto, several other products)
**POM-V, AVM-GSL**

**Formulations:** **Topical:** 100 mg/ml imidacloprid either as sole agent or else in combination with moxidectin or permethrin (e.g. Advantix, Advocate, Moxiclear, Prinovox) in spot-on pipettes of various sizes. Also used in collars impregnated with 1.25 g/4.5 g imidacloprid combined with flumethrin (Seresto). Numerous GSL and non-authorized formulations.

**Action:** Binds to post-synaptic nicotinic receptors resulting in paralysis and death of fleas and their larvae.

**Use:**
- Treatment and prevention of flea infestations in dogs and cats.
For the treatment of flea infestations the additional use of an approved insect growth regulator is recommended and the product should be applied every 4 weeks to all in-contact cats and dogs. May be used in nursing bitches and queens. The combined product with flumethrin or moxidectin has additional preventative and treatment indications.

**Safety and handling:** Many combinations contain products that are dangerous to aquatic organism and birds. Treated dogs should not swim in surface water for 48 hours and collars should be removed before swimming.

**Contraindications:** Do not use in unweaned puppies and kittens <8 weeks. The flumethrin impregnated collar is not recommended in pregnancy and lactation and should not be used in kittens <10 weeks of age or puppies <7 weeks of age. Do not use the permethrin-containing product on cats. Moxidectin/imadocloprid not for kittens <9 weeks, <1kg, puppies <7 weeks.

**Adverse reactions:** Transient pruritus and erythema at the site of application may occur. Diazepam should be administered in the event of accidental ingestion of the combined product with flumethrin. Spot-on product taste bitter, may cause salivation if ingested. Transient lethargy, agitation and inappetence may occur.
Drug interactions: No information available.

DOSES

**Dogs:** Fleas and ticks: 10 mg/kg topically every month. In dogs >40 kg the appropriate combination of pipettes should be applied. Collars should be replaced every 8 months.

**Cats:** Fleas: 10–20 mg/kg topically every month. Collars should be replaced every 8 months.

References

Horak IG, Fourie JJ and Stanneck D (2012) Efficacy of slow-release collar formulations of imidacloprid/flumethrin and deltamethrin and of spot-on formulations of fipronil/(s)-methoprene, dinotefuran/pyriproxyfen/permethrin and (s)-methoprene/amitraz/fipronil against *Rhipicephalus sanguineus* and *Ctenocephalides felis felis* on dogs. Parasites and Vectors 5, 79

---

**Imidapril**

*(Prilium)* **POM-V**

**Formulations:** Oral: 75 mg, 150 mg powders for reconstitution.

**Action:** Angiotensin converting enzyme (ACE) inhibitor. It inhibits conversion of angiotensin I to angiotensin II and inhibits the breakdown of bradykinin. Overall effect is a reduction in preload and afterload via venodilation and arteriodilation, decreased salt and water retention via reduced aldosterone production and inhibition of the angiotensin-aldosterone-mediated cardiac and vascular remodelling. Efferent arteriolar dilation in the kidney can reduce intraglomerular pressure and therefore glomerular filtration. This may decrease proteinuria.

**Use:**

- Treatment of congestive heart failure caused by mitral regurgitation or dilated cardiomyopathy in dogs. No data available on cats. Often used in conjunction with diuretics when heart failure is present as most effective when used in these cases. Can be used in combination with other drugs to treat heart failure (e.g. pimobendan, spironolactone, digoxin).
- Management of proteinuria associated with chronic renal insufficiency, glomerular disorders and protein-losing nephropathies.
- May reduce blood pressure in hypertension.

ACE inhibitors are more likely to cause or exacerbate prerenal azotaemia in hypotensive animals and those with poor renal perfusion (e.g. acute, oliguric renal failure). Use cautiously if hypotension, hyponatraemia or outflow tract obstruction are present. Regular monitoring of blood pressure, serum creatinine, urea and electrolytes is strongly recommended with ACE inhibitor treatment. The use of ACE inhibitors in cats with cardiac disease stems from extrapolation from theoretical benefits and studies showing a benefit in other species with heart failure and different cardiac diseases (mainly dogs and humans).
Safety and handling: Normal precautions should be observed.

Contraindications: Do not use in animals with acute renal failure, congenital heart disease, haemodynamically relevant stenoses (e.g. aortic stenosis), obstructive hypertrophic cardiomyopathy or hypovolaemia.

Adverse reactions: Potential adverse effects include hypotension, hyperkalaemia and azotaemia. Monitor blood pressure, serum creatinine and electrolytes when used in cases of heart failure. Dosage should be reduced if there are signs of hypotension (weakness, disorientation). Anorexia, vomiting and diarrhoea are rare. Doses of up to 5 mg/kg/day have been well tolerated in healthy dogs. It is not recommended for breeding, pregnant or lactating bitches, as safety has not been established. The safety of imidapril has not been established in dogs <4 kg.

Drug interactions: Concomitant use of potassium-sparing diuretics (e.g. spironolactone) or potassium supplements could result in hyperkalaemia. However, in practice, spironolactone and ACE inhibitors appear safe to use concurrently. There may be an increased risk of nephrotoxicity and decreased clinical efficacy when used with NSAIDs. There is a risk of hypotension with concomitant administration of diuretics, vasodilators (e.g. anaesthetic agents, antihypertensive agents) or negative inotropes (e.g. beta-blockers).

DOSES

Dogs: 0.25 mg/kg p.o. q24h (for dogs weighing >4 kg).
Cats: 0.5 mg/kg p.o. q24h (anecdotal dose; no data available).

References


Imidocarb dipropionate (Imizol) POM-V

Formulations: Injectable: 85 mg/ml imidocarb solution, containing 121.15 mg/ml imidocarb dipropionate (active agent). Licensed for use in cattle.

Action: Interferes with parasite nucleic acid metabolism.

Use:

• Treatment of Babesia canis infection in dogs.

The safety and effectiveness of imidocarb have not been fully determined in puppies or in breeding, lactating or pregnant animals. Reduce dose with renal, hepatic or pulmonary compromise. Clinical/parasitological cure is often not achieved with other smaller Babesia species, although one prospective study showed an
imidocarb-containing multidrug protocol to have reasonable efficacy against *B. gibsoni*.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not administer i.v.

**Adverse reactions:** Cholinergic signs (e.g. salivation, vomiting and occasionally diarrhoea, panting, restlessness) may develop after dosing. These may be alleviated by atropine. Mild injection site inflammation lasting one to several days and which may ulcerate has been reported. Anaphylactoid reactions have been reported in cattle but not in dogs.

**Drug interactions:** Avoid concurrent use of anticholinesterases.

**DOSES**

**Dogs:** Treatment of *Babesia canis* infection: 6.6 mg/kg imidocarb dipropionate i.m., s.c. once, repeated in 2–3 weeks. Dose should be calculated based on Imizol containing 121.15 mg/ml imidocarb dipropionate. Premedication with atropine (0.05 mg/kg) to minimize side effects could be considered.

**Cats:** Treatment of *Babesia canis* infection: 2.5 mg/kg imidocarb dipropionate i.m. once can improve clinical signs in cats infected with large babesial species. Dose should be calculated based on Imizol containing 121.15 mg/ml imidocarb dipropionate. Alternative agents are preferable for smaller species (e.g. *Babesia felis*); however, parasitological cure is rare and controlled therapeutic trials are lacking.

**References**


**Imipramine**

(Tofranil, Imipramine*) **POM**

**Formulations:** Oral: 10 mg, 25 mg tablets.

**Action:** Imipramine blocks noradrenaline and serotonin reuptake in the brain, resulting in antidepressive activity.

**Use:**

- Can be used in the management of panic-related, generalized and separation anxieties, especially when these conditions are associated with urine elimination.
- It may also be used to aid control of supersubmissive urination and excitatory urination, narcolepsy, and may assist learning in anxious subjects.

It has been suggested that it may be particularly useful for the control of panic disorders, but good quality evidence is lacking; indeed there are not good quality clinical trials to support its efficacy in behavioural medicine.
Veterinary authorized products, e.g. clomipramine or imepitoin, may be preferable for initial use, although not authorized for all of these indications. It is suggested that imipramine is less sedating than amitriptyline. Use with caution in young animals.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Glaucoma, history of seizures or urinary retention, severe liver disease, hypersensitivity to tricyclic antidepressants.

**Adverse reactions:** Sedation, dry mouth, diarrhoea, vomiting, excitability, arrhythmias, hypotension, syncope and increased appetite are reported in humans.

**Drug interactions:** Should not be used with monoamine oxidase inhibitors or drugs that are metabolized by cytochrome P450 2D6 (e.g. chlorphenamine, cimetidine). Should not generally be used alongside other serotonergic agents given risk of serotonin syndrome, although use alongside trazodone may be considered in exceptional cases, so long as patient carefully monitored for signs of serotonin syndrome.

**DOSES**
- **Dogs:** 1–2 mg/kg p.o. q12h or 2–4 mg/kg p.o. q24h.
- **Cats:** 0.5–1 mg/kg p.o. q12–24h.

---

**Immunoglobulins**
(Flebogamma*, Gammagard*, Kiovig*) **POM**

**Formulations:** Injectable: 2.5 g, 5 g, 10 g vials for reconstitution.

**Action:** Has both immediate and long-term effects; however, the exact modes of action are unclear. Binding to Fc receptors and providing anti-idiotype antibodies may explain the immediate effects. The longer term effects on immune system autoregulation may be associated with a reaction with a number of membrane receptors on T cells, B cells and monocytes, which are pertinent to autoreactivity and induction of tolerance to self.

**Use:** Treatment of some severe immune-mediated diseases in dogs. Efficacy has been demonstrated in immune-mediated thrombocytopenia (comparable to that achieved with vincristine) and in acute canine polyradiculoneuritis. However, use in immune-mediated haemolytic anaemia remains controversial. Its use has not been systematically investigated for other immune-mediated diseases. Use should therefore be reserved for exceptional cases where other treatments have failed.

**Safety and handling:** Vials may be stored at room temperature but once reconstituted must be used immediately.

**Contraindications:** Avoid in patients with increased plasma protein levels.
**Adverse reactions:** Anaphylactic reactions are a risk but have not been recorded in dogs.

**Drug interactions:** None known but use with care in patients receiving drugs with strong protein-binding action and vaccines.

**DOSES**

*See Appendix for immunosuppression protocols.*

**Dogs:** 0.5–1.0 g/kg i.v. over 6–8 hours. Higher doses of up to 2.2 g/kg are used in some studies.

**Cats:** No information available.

**References**


---

**Indoxacarb**

*(Activyl, Activyl Tick Plus) POM-V*

**Formulations:** Topical: spot-on solution for dogs and cats containing 195 mg/ml in pipettes of various sizes (Activyl); spot-on solution for dogs and cats containing 150 mg/ml indoxacarb and permethrin (Activyl Tick Plus).

**Action:** Acts on voltage-dependent sodium channels in susceptible insects.

**Use:**

- Treatment of flea infestations (*Ctenocephalides felis*).

Developing stages of fleas in the immediate environment are killed on contact. As indoxacarb is a pro-drug bioactivated by insect enzymes and the active component has a much higher affinity for insect sodium channels, it is very specific for insect cells. Developing stages of fleas in the immediate environment of the treated pet are killed on contact. Formulations with permethrin also provide prevention of tick infestations (*Ixodes ricinus* and *Rhipicephalus sanguineus*). If ticks are present on the dog at the time of application, they may not be killed within 48 hours.

**Safety and handling:** Normal precautions should be observed. May be harmful to aquatic organisms.

**Contraindications:** Do not use on dogs and cats <8 weeks old or on dogs <1.5 kg (<1.2 kg Activyl plus) or on cats <0.6 kg. Do not use permethrin product on cats.

**Adverse reactions:** Transient pruritus at the site of application can occur, and rarely GI signs.

**Drug interactions:** No information available.
DOSES

**Dogs:** Fleas: 15 mg/kg (equivalent to 0.077 ml/kg Activyl or 0.1 ml/kg Activyl Tick Plus). Apply monthly.

**Cats:** Fleas: 25 mg/kg (equivalent to 0.128 ml/kg Activyl). Apply monthly. The combined formulation is not authorized for cats.

References

Dryden MW, Payne PA, Smith V *et al.* (2013) Evaluation of indoxacarb and fipronil (s)-methoprene topical spot-on formulations to control flea populations in naturally infested dogs and cats in private residences in Tampa FL, USA. *Parasites and Vectors* 28, 6


Insulin

(Caninsulin, Prozinc, Actrapid*, Humulin*, Hypurin*, Insulatard*, Lantus*) **POM-V, POM**

**Formulations:** Injectable: 40 IU/ml, 100 IU/ml suspensions (for s.c. injection) or 100 IU/ml solutions (for s.c., i.v. or i.m. injection).

There are many preparations (including soluble) authorized for use in humans; however, veterinary authorized preparations (lente and PZI), when available, are preferential for both legal and clinical reasons. Both PZI and the lente formulation are authorized for cats and dogs. An injection pen and cartridges are available for the lente formulation.

**Action:** Binds to specific receptors on the cell surface that stimulate the formation of glycogen from glucose, lipid from free fatty acids, protein from amino acids and many other metabolic effects.

**Use:**

- Treatment of diabetes mellitus.
- Adjunctive therapy in the management of hyperkalaemia associated with urinary tract obstruction.

There are various formulations of insulins from various species. Neutral (soluble) insulin is the normal crystalline form. Lente insulins rely on a combination of different concentrations of zinc to produce a range of sizes of zinc-insulin crystals to provide different durations of activity and should be shaken vigorously prior to administration. Protamine zinc uses zinc and protamine (a protein) to provide an extended duration of action. Glargine insulin (Lantus) is a pH sensitive, long-acting formulation that precipitates at the site of injection. Further advice on the use of insulin should be obtained from an authoritative source such as the *BSAVA Manual of Canine and Feline Endocrinology.*

Hyperkalaemia associated with hypoadrenocorticism is often associated with hypoglycaemia and insulin should be avoided in those cases.
BSAVA Small Animal Formulary 10th edition: Part A – Canine and Feline

<table>
<thead>
<tr>
<th>Type</th>
<th>Route</th>
<th>Onset</th>
<th>Peak effect in dog (hours)</th>
<th>Peak effect in cat (hours)</th>
<th>Duration of action in dog (hours)</th>
<th>Duration of action in cat (hours)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soluble (neutral)</td>
<td>i.v.</td>
<td>Immediate</td>
<td>0.5–2</td>
<td>0.5–2</td>
<td>1–4</td>
<td>1–4</td>
</tr>
<tr>
<td></td>
<td>i.m.</td>
<td>10–30 min</td>
<td>1–4</td>
<td>1–4</td>
<td>3–8</td>
<td>3–8</td>
</tr>
<tr>
<td></td>
<td>s.c.</td>
<td>10–30 min</td>
<td>1–5</td>
<td>1–5</td>
<td>4–8</td>
<td>4–8</td>
</tr>
<tr>
<td>Isophane (NPH)</td>
<td>s.c.</td>
<td>0.5–3 h</td>
<td>2–10</td>
<td>2–8</td>
<td>6–24</td>
<td>4–12</td>
</tr>
<tr>
<td>Lente (mixed IZS)</td>
<td>s.c.</td>
<td>30–60 min</td>
<td>2–10</td>
<td>2–8</td>
<td>8–24</td>
<td>6–14</td>
</tr>
<tr>
<td>Ultralente (crystalline IZS)</td>
<td>s.c.</td>
<td>2–8 h</td>
<td>4–16</td>
<td>4–16</td>
<td>8–28</td>
<td>8–24</td>
</tr>
<tr>
<td>PZI</td>
<td>s.c.</td>
<td>1–4 h</td>
<td>4–14</td>
<td>3–12</td>
<td>6–28</td>
<td>6–24</td>
</tr>
<tr>
<td>Glargine</td>
<td>s.c.</td>
<td>1–4 h</td>
<td>6–10</td>
<td>3–12</td>
<td>18–28</td>
<td>12–24</td>
</tr>
</tbody>
</table>

IZS = insulin zinc suspension; NPH = neutral protamine Hagedorn; PZI = protamine zinc insulin. Note that all times are approximate averages and insulin doses need to be adjusted for individual patients.

<table>
<thead>
<tr>
<th>Trade name</th>
<th>Species of insulin</th>
<th>Types available</th>
</tr>
</thead>
<tbody>
<tr>
<td>Caninsulin</td>
<td>Porcine</td>
<td>Lente</td>
</tr>
<tr>
<td>Lantus*</td>
<td>Human</td>
<td>Glargine</td>
</tr>
<tr>
<td>Humulin*</td>
<td>Human</td>
<td>Neutral, Isophane</td>
</tr>
<tr>
<td>Hypurin*</td>
<td>Bovine</td>
<td>Neutral, Isophane, Lente, PZI</td>
</tr>
<tr>
<td></td>
<td>Porcine</td>
<td>Neutral, Isophane</td>
</tr>
<tr>
<td>Insulatard*</td>
<td>Human or porcine</td>
<td>Isophane</td>
</tr>
<tr>
<td>Prozinc</td>
<td>Human</td>
<td>PZI</td>
</tr>
</tbody>
</table>

**Safety and handling:** Normal precautions should be observed. Insulin should be stored in a refrigerator (preferably not in the door); however, formulations using insulin pens have been shown to be stable at room temperature. Ensure use of appropriate syringes for the concentration of insulin.

**Contraindications:** Hypoglycaemia.

**Adverse reactions:** Overdosage results in hypoglycaemia and hypokalaemia.

**Drug interactions:** Corticosteroids, ciclosporin, thiazide diuretics and thyroid hormones may antagonize the hypoglycaemic effects of insulin. Anabolic steroids, beta-adrenergic blockers (e.g. propranolol), phenylbutazone, salicylates and tetracycline may increase insulin's effect. Administer with caution and monitor patients closely if digoxin is given concurrently. Beta-adrenergic agonists, such as terbutaline, may prevent or lessen insulin-induced hypoglycaemia in humans. This effect has not been investigated in dogs or cats.
DOSES

Dogs:
- **Diabetes mellitus:** initially 0.25–0.5 IU/kg (dogs >25 kg) or 0.5–1 IU/kg (dogs <25 kg) of lente insulin s.c. q12h. Adjust dose and frequency of administration by monitoring clinical effect. Urine results, blood glucose and/or fructosamines may assist this process.
- **Diabetic ketoacidosis:** 0.2 IU/kg soluble insulin i.m. initially followed by 0.1 IU/kg i.m. q1h. Alternatively, i.v. infusions may be given at 0.025–0.06 IU/kg/h of soluble insulin. Run approximately 50 ml of i.v. solution through tubing as insulin adheres to plastic; change insulin/saline solution q6h.
- **Hyperkalaemic myocardial toxicity (not in hypoadrenocorticism):** give a bolus of 0.5 IU/kg of soluble insulin i.v. followed by 2–3 g of dextrose/unit of insulin. Half the dextrose should be given as a bolus and the remainder administered i.v. over 4–6 hours.

Cats:
- **Diabetes mellitus:** initially 0.25 IU/kg of lente insulin s.c. q12h or 0.2–0.4 IU/kg of PZI insulin s.c. q12h. Adjust dose and frequency of administration by monitoring clinical effect, urine results, blood glucose and/or fructosamine levels.
- **Diabetic ketoacidosis:** doses as for dogs.
- **Hyperkalaemic myocardial toxicity:** doses as for dogs.

References


Interferon omega
(Virbagen omega) POM-V

Formulations: 10 million units/vial powder with solvent for reconstitution.

Action: Interferons are cytokines that have many effects on immunity and immune-cell function.

Use:
- Shown to reduce mortality and clinical signs of the enteric form of parvovirus infection in dogs.
- Treatment of early-stage FeLV infection, albeit with limited success as shown by a reduction in mortality.
- Limited reports of use in feline infectious peritonitis, acute feline calicivirus infection and feline chronic gingivostomatitis.

The effect of treatment on cats with an FeLV-associated tumour is not known. No reduction in mortality is seen if the drug is used to treat FIV-infected cats. In refractory and severe cases of feline herpesvirus-1 infection, combined therapy including oral or topical antiviral medication and topical interferon can be used. Has also been used topically in the management of herpetic keratitis in cats, however, is of questionable efficacy.
**Safety and handling:** In case of accidental self-injection, seek medical advice immediately and show the package insert or the label to the physician.

**Contraindications:** No information available.

**Adverse reactions:** Transient fatigue, hyperthermia, vomiting and mild diarrhoea may be observed (i.v. administration to cats increases the risk of these reactions). In addition, a slight decrease in WBCs, platelets and RBCs, and increases in the concentration of liver enzyme activities may be observed. Side effects such as the induction of immune-mediated diseases have been reported with long-term administration in humans. Ocular irritation has been seen in cats.

**Drug interactions:** Vaccines should not be administered concurrently until the animal has clinically recovered. The use of supplementary supportive treatments such as antibiotics and NSAIDs improves prognosis, and no interactions have been observed with these.

**DOSES**

**Dogs:** Parvovirus: 2.5 million units/kg i.v. q24h for 3 days.

**Cats:**
- **Parenteral:** 1–2.5 million units/kg i.v., s.c. q24–48h for up to 5 doses; then reduced, according to clinical effect, to twice weekly and then once weekly. Specific protocols within this dose range have been published for FeLV, FIP, FCV and chronic gingivostomatitis; users should consult the manufacturer for further advice.
- **Ophthalmic:** For ophthalmic use, reconstitute a 10 million unit vial with 1 ml of the solvent supplied and make up to 4 ml with sterile saline; decant into 0.2 ml aliquots and keep in freezer. To use, take a 0.2 ml aliquot of the diluted solution and add to 0.8 ml hypromellose. 1 drop of a diluted solution per eye up to q6h for 10 days, then 1 drop q8–12h for a further 3 weeks.

**References**


**Iron salts** *(Ferrous fumarate, Ferrous gluconate, Ferrous sulphate, Iron dextran)*

(Gleptrosil, CosmoFer*, Diafer*, Monofer*, Venofer*) POM-VPS, POM, GSL

**Formulations:** Injectable: 50 mg/ml iron dextran (CosmoFer), 50 mg/ml iron(III) isomaltoside (Monofer), 100 mg/ml iron(III) isomaltoside (Monofer), 200 mg/ml iron dextran (Gleptosil and several other formulations licensed for pigs), 20 mg/ml iron sucrose (Venofer). Oral: 200 mg FeSO₄ tablet (ferrous sulphate), ferrous
gluconate and other formulations in variable tablet and liquid preparations; ferrous fumarate preparations also typically contain folic acid.

**Action:** Essential for oxygen-binding in haemoglobin, electron transport chain and oxidative phosphorylation, and other oxidative reactions in metabolism.

**Use:**
- Treatment of iron-deficiency anaemia and conditions where RBC synthesis is high and iron stores are depleted.

The oral route should be used if possible. Iron absorption is complex and dependent in part on physiological demand, diet composition, current iron stores and dose. Valid reasons for administering iron parenterally are failure of oral therapy due to severe GI adverse effects, continuing severe blood loss, iron malabsorption, or a non-complaint patient. Modified-release preparations should be avoided as they are ineffective; iron is absorbed in the duodenum and the release of iron from modified-release preparations occurs lower down the GI tract. Absorption is enhanced if administered 1 hour before or several hours after feeding. Reduce dosage if GI side effects occur.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Severe infection or inflammation, intolerance to the oral preparation, any anaemia other than iron-deficiency anaemia, presence of GI ulcers. Also contraindicated in patients with hepatic, renal (particularly pyelonephritis) or cardiac disease, and untreated urinary tract infections.

**Adverse reactions:** Parenteral iron may cause arrhythmias, anaphylaxis, shunting of iron to reticuloendothelial stores and iron overload. Pain often seen when injecting. Oral iron may cause nausea, vomiting, constipation and diarrhoea. The faeces of animals treated with oral iron may be dark in appearance. High doses may be teratogenic and embryotoxic (injectable iron dextran).

**Drug interactions:** Chloramphenicol can delay the response to iron dextran and its concurrent use should be avoided. Oral preparations bind to tetracyclines and penicillamine causing a decrease in efficacy. Antacids, milk and eggs significantly decrease the bioavailability of oral iron.

**DOSES**

**Dogs:** Treatment of iron-deficiency anaemia: 100–600 mg/dog p.o. q24h or 10–20 mg/kg i.m. once only, followed by oral therapy.

**Cats:** Treatment of anaemia associated with chronic kidney failure: 50 mg/cat i.m. iron dextran every 3–4 weeks in conjunction with erythropoietin in chronic renal failure or 20–25 mg/cat i.m. once, followed by 50–100 mg/cat p.o. q24h. Note that the majority of cats do not tolerate oral iron therapy and require parenteral treatment.
**Isoflurane**
(Isoba, Isocare, Isofane, IsoFlo, Isoflurane Vet, Vetflurane) POM-V

**Formulations:** Inhalational: 250 ml bottle of liquid isoflurane.

**Action:** The mechanism of action of volatile anaesthetic agents is not fully understood.

**Use:**
- Induction and maintenance of anaesthesia.

Isoflurane is potent and highly volatile so should only be delivered from a suitable calibrated vaporizer. It is less soluble in blood than halothane but more soluble than sevoflurane, therefore, induction and recovery from anaesthesia are quicker than halothane but slower than sevoflurane. The concentration of isoflurane required to maintain anaesthesia depends on the other drugs used in the anaesthesia protocol; the concentration should be adjusted according to clinical assessment of anaesthetic depth. MAC approximately 1.2–1.7% in most species. Isoflurane has a pungent smell and induction to anaesthesia using chambers or masks may be less well tolerated in small dogs and cats compared with halothane and sevoflurane.

**Safety and handling:** Measures should be adopted to prevent contamination of the environment with isoflurane during anaesthesia and when handling of the agent.

**Contraindications:** No information available.

**Adverse reactions:** Isoflurane causes dose-dependent hypotension by causing vasodilation, particularly in skeletal muscle. This adverse effect does not wane with time. Isoflurane is a more potent respiratory depressant than halothane, respiratory depression is dose-dependent. Isoflurane does not sensitize the myocardium to catecholamines to the extent that halothane does, but can generate arrhythmias in certain conditions. Isoflurane is not metabolized by the liver (0.2%) and has less effect on liver blood flow compared with halothane.

**Drug interactions:** Sedatives, opioid agonists and N₂O reduce the concentration of isoflurane required to achieve surgical anaesthesia. The duration of action of non-depolarizing neuromuscular blocking agents is longer with isoflurane compared with halothane anaesthetized animals.

**DOSES**

**Dogs:** The expired concentration required to maintain surgical anaesthesia in 50% of dogs is 1.2% (minimum alveolar concentration). Administration of other anaesthetic agents and opioid analgesics reduces the dose requirement of isoflurane, therefore, the dose should be adjusted according to individual requirement. 3–5% isoflurane concentration is required to induce anaesthesia in unpremedicated patients.
**Cats:** The expired concentration required to maintain surgical anaesthesia in 50% of cats is 1.6% (minimum alveolar concentration).

**References**

**Ispaghula (Psyllium) (Fybogel*, Ispagel*) **<sup>GSL</sup>

**Formulations:** Oral: granules, powder.

**Action:** Bulk-forming agent that increases faecal mass and stimulates peristalsis. Moderately fermentable in the colon and the resultant volatile fatty acids exert an osmotic laxative effect.

**Use:**
- Management of impacted anal sacs, diarrhoea and constipation, and the control of stool consistency after surgery.
- May be used as part of the management of canine idiopathic large bowel diarrhoea/irritable bowel syndrome.

Available preparations are for humans and often fruit-flavoured and may be effervescent when mixed with water. They can be added to food for animals.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Bowel obstruction.

**Adverse reactions:** Constipation or, if excess is given, diarrhoea and bloating may occur.

**Drug interactions:** No information available.

**DOSES**
**Dogs:** All uses: 1–2 teaspoonfuls with meals (anecdotal).
**Cats:** All uses: ½–1 teaspoonful with meals (anecdotal).

**References**

**Itraconazole** *(Itrafungol, Sporanox*) **<sup>POM-V, POM</sup>*

**Formulations:** Oral: 100 mg capsule, 10 mg/ml oral solution.

**Action:** Triazole antifungal agent that inhibits the cytochrome systems involved in the synthesis of ergosterol in fungal cell
membranes, causing increased cell wall permeability and allowing leakage of cellular contents.

**Use:**
- Treatment of aspergillosis, candidiasis, blastomycosis, coccidioidomycosis, cryptococcosis, sporotrichosis, histoplasmosis, dermatophytosis and *Malassezia*.
- Itraconazole is authorized in the form of an oral solution for the treatment of *Microsporum canis* dermatophytosis in cats and has been used successfully to treat ringworm in Persian cats without the need for clipping.

It is widely distributed in the body, although low concentrations are found in tissues with low protein contents, e.g. CSF, ocular fluid and saliva. Itraconazole extends the activity of methylprednisolone. In humans, antifungal imidazoles and triazoles inhibit the metabolism of antihistamines, oral hypoglycaemics and anti-epileptics. Concomitant use of itraconazole is likely to increase blood levels of ciclosporin.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Pregnancy. Avoid use if liver disease is present.

**Adverse reactions:** Vomiting, diarrhoea, anorexia, salivation, depression and apathy, abdominal pain, hepatic toxicosis, ulcerative dermatitis, limb oedema and occasional serious cutaneous drug eruptions have been reported. Reasonable to assume dose-related suppression of adrenal function (similar to that described for ketoconazole).

**Drug interactions:** In humans, antifungal imidazoles and triazoles inhibit the metabolism of antihistamines (particularly terfenadine), oral hypoglycaemics, antiepileptics, cisapride, ciclosporin and glucocorticoids). Although not as well studied in veterinary species, itraconazole is known to increase the bioavailability of ciclosporin in cats. Antacids, omeprazole, H2 antagonists and adsorbents may reduce the absorption of itraconazole. Plasma concentrations of digoxin, benzodiazepines, glucocorticoids and vincristine may be increased by itraconazole. Datasheet advises against concurrent administration with cefovecin or tolfenamic acid in cats.

**DOSES**

**Dogs, Cats:** General use: 5 mg/kg p.o. q24h. 4–20 weeks of treatment may be needed, dependent upon culture results. Pulse dosing (7 days on, 7 days off repeated x3) has been described for dermatophytosis in cats.

**References**
**Ivermectin** (Ostimectin Vet) **POM-V**

**Formulations:** Injectable: 10 mg/ml various products licensed for use in farm animals (pour on, drenches, pastes not employed in cats and dogs) Topical: 1 mg/g ear gel for cats.

**Action:** Interacts with GABA and glutamate-gated channels leading to flaccid paralysis of parasites.

**Use:**
- Authorized for (*Otodectes cynotis*) infestation in cats.
- Also used for dogs with generalized demodicosis, sarcoptic acariasis or cheyletiellosis, and cats with cheyletiellosis when approved treatments have failed or cannot be employed.

Use of this product has generally been superceded by the development of safer, licensed ectoparasiticides.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Administration to collies and related breeds is not recommended. Consider multiple drug resistance gene testing in these breeds before use. Highly toxic to aquatic organisms.

**Adverse reactions:** Neurotoxicity may be seen if it crosses mammalian blood–brain barrier.

**Drug interactions:** Dose adjustments may be required when administered concurrently with other therapeutic agents transported by P-glycoprotein.

**DOSES**

**Dogs:**
- **Generalized demodicosis:** 300–600 μg (micrograms)/kg p.o. daily.
- **Effective for sarcoptic mange** (200–400 μg/kg p.o., s.c. q2wks for 4–6 weeks) and cheyletiellosis (200–300 μg/kg p.o., s.c. q1–2wks for 6–8 weeks) but other options (selamectin, moxidectin) are available.

**Cats:**
- **Otoacariasis (*Otodectes cynotis* infestation):** apply ear gel weekly for 3 weeks.
- **Generalized demodicosis:** 300–600 μg (micrograms)/kg p.o. daily.

**References**

Kaolin
(Kaogel VP, Prokolin) **AVM-GSL, general sale**

**Formulations:** Oral: Kaogel VP: aqueous suspension containing 0.99 g Kaolin Light per 5 ml. Combination products with pectin, magnesium trisilicate, aluminium hydroxide and phosphate, bismuth salts, calcium carbonate or tincture of morphine are also available.

**Action:** Adsorbent antidiarrhoeal agent with possible antisecretory effect.

**Use:** Treatment of diarrhoea of non-specific origin in cats and dogs. Although stool consistency may improve, studies do not show that fluid balance is corrected or that the duration of morbidity is shortened.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Intestinal obstruction or perforation.

**Adverse reactions:** No information available.

**Drug interactions:** May decrease the absorption of lincomycin, trimethoprim and sulphonamides.

**DOSES**
**Dogs, Cats:** All uses: 0.5–1.0 ml/kg p.o. as a total daily dose. May be given as a divided dose 3–4 times daily.

Ketamine
(Anaestamine, Anesketin, Ketaset injection, Ketavet, Narketan-10, Vetalar-V) **POM-V CD**

**Formulations:** Injectable: 100 mg/ml solution.

**Action:** Antagonizes the excitatory neurotransmitter glutamate at N-methyl-d-aspartate (NMDA) receptors in the CNS. It interacts with opioid receptors in a complex fashion, antagonizing mu receptors, while showing agonist actions at delta and kappa receptors. It does not interact with GABA receptors.

**Use:**
- Provision of chemical restraint or dissociative anaesthesia.
- Ketamine may also provide profound visceral and somatic analgesia and inhibits central sensitization through NMDA receptor blockade.
- Used to provide perioperative analgesia as an adjunctive agent, although optimal doses to provide analgesia have not been elucidated.

Dissociative anaesthesia is associated with mild stimulation of cardiac output and blood pressure, modest respiratory depression
and the preservation of cranial nerve reflexes. For example, the eyes remain open during anaesthesia and should be protected using a bland ophthalmic ointment. Used alone at doses adequate to provide general anaesthesia, ketamine causes skeletal muscle hypertonicity and movement may occur that is unrelated to surgical stimulation. These effects are normally controlled by the co-administration of alpha-2 adrenergic agonists and/or benzodiazepines. When ketamine is combined with alpha-2 agonists (such as medetomidine or dexmedetomidine) reversal of the alpha-2 agonist should be delayed until 45 minutes after ketamine administration.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Not recommended for animals whose eyes are at risk of perforation or who have raised intraocular pressure. Not recommended in animals with raised intracranial pressure.

**Adverse reactions:** Cardiovascular depression, rather than stimulation, and arrhythmias may arise in animals with a high sympathetic nervous system tone (e.g. animals in shock or severe cardiovascular disease). Tachycardias can also arise after administration of high i.v. doses. Respiratory depression may be marked in some animals. Ketamine may result in spacey, abnormal behaviour for 1–2 hours during recovery. Prolonged administration of ketamine by infusion may result in drug accumulation and prolong recovery.

**Drug interactions:** No information available.

**DOSES**

*When used for sedation is generally given as part of a combination. See Appendix for sedation protocols in cats and dogs.*

**Dogs:**
- **Perioperative analgesia:** intraoperatively: $10 \text{ } \mu\text{g} / \text{kg/min}$; postoperatively: $2–5 \text{ } \mu\text{g} / \text{kg/min}$; both preceded by a $250–500 \text{ } \mu\text{g} / \text{kg}$ loading dose. There is some evidence to suggest that a $10 \text{ } \mu\text{g} / \text{kg/min}$ dose may be too low to provide adequate analgesia continuously, although other evidence-based dose recommendations are lacking.
- **Induction of anaesthesia (combined with diazepam or midazolam) as part of a volatile anaesthetic technique:** $2 \text{ } \text{mg} / \text{kg}$ i.v.
- **Induction of general anaesthesia combined with medetomidine or dexmedetomidine to provide a total injectable combination:** ketamine ($5–7 \text{ } \text{mg/kg i.m.}$) combined with medetomidine ($40 \text{ } \mu\text{g/kg i.m.}$) or dexmedetomidine ($20 \text{ } \mu\text{g/kg i.m.}$).

**Cats:**
- **General anaesthesia:** combinations of ketamine ($5–7.5 \text{ } \text{mg/kg i.m.}$) combined with medetomidine ($80 \text{ } \mu\text{g (micrograms)/kg i.m.}$) or dexmedetomidine ($40 \text{ } \mu\text{g/kg i.m.}$) will provide 20–30 min general anaesthesia. Reduce the doses of both drugs when given i.v.
- **Perioperative analgesia:** doses are the same as those for dogs.
Ketoconazole
(Fungiconazole) POM-V

Formulations: Oral: 200 mg tablet.

Action: Broad-spectrum imidazole that inhibits the cytochrome systems involved in the synthesis of ergosterol in fungal cell membranes, causing increased cell wall permeability and allowing leakage of cellular contents. It also inhibits the synthesis of cortisol in mammalian adrenal glands.

Use:
- Licensed for the treatment of Microsporum canis, Microsporum gypseum and Trichophyton mentagrophytes.
- May also be useful in the treatment of aspergillosis, candidiasis, blastomycosis, coccidiodomycosis, cryptococcosis, sporotrichosis and Malassezia dermatitis.
- May be effective in medical management of hyperadrenocorticism where trilostane and mitotane are not available or tolerated but is generally less effective than either.
- In combination with ciclosporin to reduce the dose of ciclosporin required. Concomitant use of ketoconazole is likely to increase blood levels of ciclosporin.
- Can be used with amphotericin B in systemic fungal disease and in such cases the dose of amphotericin is reduced. See specialist texts for details.

Safety and handling: Normal precautions should be observed.
Contraindications: Do not use in animals with hepatic insufficiency.

Adverse reactions: Hepatotoxicity (not recognized in the dog unless high doses are used but routine monitoring of liver function tests is recommended), anorexia, vomiting and alterations in hair-coat colour. Thrombocytopenia and adrenal insufficiency at high doses. Ketoconazole possibly has teratogenic effects. Has been associated with cataract development in dogs.

Drug interactions: Ketoconazole inhibits cytochrome P450 and may decrease elimination of drugs metabolized by this system. The absorption of ketoconazole may be impaired by drugs that increase the pH of gastric contents, e.g. antacids, antimuscarinics proton-pump inhibitors and H2 blockers; stagger dosing of these drugs around ketoconazole dose. Ketoconazole extends the activity of methylprednisolone. In humans, antifungal imidazoles and triazoles inhibit the metabolism of antihistamines, oral hypoglycaemics and antiepileptics.
DOSES

Dogs:
• **Antifungal therapy:** 5–10 mg/kg p.o. after meals, once daily. Several months of treatment may be required depending on the organism and site of infection. Doses up to 40 mg/kg/day are recommended to treat CNS or nasal infections (often in conjunction with amphotericin B); ketoconazole does not attain therapeutic levels in the CNS at ‘normal’ doses.

• **Hyperadrenocorticism:** 5 mg/kg p.o. q12h for 7 days, increasing to 10 mg/kg p.o. q12h for 14 days if no adverse effects seen. Perform an ACTH stimulation test after 14 days and if there is inadequate suppression gradually increase the dose to 15–30 mg/kg p.o. q12h.

Cats: Not recommended.

References

**Ketoprofen**
(Ketofen) POM-V

Formulations: Injectable: 1% solution. Oral: 5 mg, 20 mg tablets.

Action: COX-1 inhibition reduces the production of prostaglandins, while lipoxygenase enzyme inhibition has a potent effect on the vascular and cellular phases of inflammation. It has antipyretic, analgesic and anti-inflammatory effects.

Use:
• Relief of acute pain from musculoskeletal disorders and other painful disorders in the dog and cat.
• Management of chronic pain from osteoarthritis in the dog.

Ketoprofen is not COX-2 selective and is not authorized for preoperative administration to cats and dogs. Do not administer perioperatively until the animal is fully recovered from anaesthesia and normotensive. Liver disease will prolong the metabolism of ketoprofen, leading to the potential for drug accumulation and overdose with repeated dosing. Accurate dosing of ketoprofen in cats is essential. Administration of ketoprofen to animals with renal disease must be carefully evaluated.

Safety and handling: Normal precautions should be observed. Contraindications: Do not give to dehydrated, hypovolaemic or hypotensive patients or those with GI disease or blood clotting problems. Do not give to pregnant animals or animals <6 weeks of age.

Adverse reactions: GI signs may occur in all animals after NSAID administration. Stop therapy if this persists beyond 1–2 days. Some animals develop signs with one NSAID and not another. A 3–5-day wash-out period should be allowed before starting another NSAID after cessation of therapy. Stop therapy immediately if GI bleeding is
suspected. There is a small risk that NSAIDs may precipitate cardiac failure in humans and this risk in animals is unknown.

Drug interactions: Do not administer concurrently or within 24 hours of other NSAIDs and glucocorticoids. Do not administer with other potentially nephrotoxic agents, e.g. aminoglycosides.

DOSES

Dogs: 2 mg/kg s.c., i.m., i.v. q24h, may be repeated for up to 3 consecutive days; 0.25 mg/kg p.o. q24h for up to 30 days in total; or 1 mg/kg p.o. q24h for up to 5 days. Oral dosing for 4 days may follow a single injection of ketoprofen on day one.

Cats: 2 mg/kg s.c. q24h, may be repeated for up to 3 consecutive days; 1 mg/kg p.o. q24h for up to 5 days. Oral dosing for 4 days may follow a single injection of ketoprofen on day one.

References


Ketorolac

(Acular*) POM

Formulations: Ophthalmic: 0.5% drops in 5 ml bottle.

Action: COX inhibitor that reduces the production of prostaglandins and therefore reduces inflammation.

Use: Treatment of anterior uveitis and ulcerative keratitis when topical corticosteroids are contraindicated. Topical NSAIDs have the potential to increase intraocular pressure and should be used with caution in dogs predisposed to glaucoma.

Safety and handling: Normal precautions should be observed.

Contraindications: No information available.

Adverse reactions: As with other topical NSAIDs, ketorolac may cause local irritation. Topical NSAIDs can be used in ulcerative keratitis but with caution as they can delay epithelial healing. Topical NSAIDs have been associated with an increased risk of corneal ‘melting’ (keratomalacia) in humans, although this has not been reported in the veterinary literature. Regular monitoring is advised.

Drug interactions: Ophthalmic NSAIDs may be used safely with other ophthalmic pharmaceuticals although concurrent use of drugs which adversely affect the corneal epithelium (e.g. gentamicin) may lead to increased corneal penetration of the NSAID. The concurrent use of topical NSAIDs with topical corticosteroids has been identified as a risk factor in humans for precipitating corneal problems.

DOSES

Dogs, Cats: 1 drop per eye q6–24h depending on severity of inflammation.
Lactulose  
(Duphalac*, Lactugal*, Lactulose*, Laevolac*)

Formulations: Oral: 3.1–3.7 g/5 ml (or 10 g/15 ml) lactulose in a syrup base. Lactugal is equivalent to 62.0–74.0% w/v of lactulose.

Action: Metabolized by colonic bacteria resulting in the formation of low molecular weight organic acids (lactic, formic and acetic acids). These acids increase osmotic pressure, causing a laxative effect, acidifying colonic contents and thereby trapping ammonia as ammonium ions, which are then expelled with the faeces.

Use:
- Used to reduce blood ammonia levels in patients with hepatic encephalopathy.
- Treatment of constipation in dogs and cats.

Reduce the dose if diarrhoea develops. Cats and some dogs do not like the taste of lactulose. An alternative is lactitol (β-galactosidosorbitol) as a powder to add to food (500 mg/kg/day in 3 or 4 doses, adjusted to produce 2 or 3 soft stools per day), although its efficacy in the management of hepatic encephalopathy has not been extensively evaluated.

Safety and handling: Normal precautions should be observed.

Contraindications: Do not administer orally to severely encephalopathic animals at risk of inhalation. Do not use in animals with GI obstruction or those at risk of perforation.

Adverse reactions: Excessive doses cause flatulence, diarrhoea, cramping and dehydration.

Drug interactions: Synergy may occur when lactulose is used with oral antibiotics (e.g. neomycin) and other laxatives. Oral antacids may reduce the colonic acidification efficacy of lactulose. Lactulose syrup contains some free lactose and galactose, and so may alter insulin requirements in diabetic patients. With increasing dose, the pH of the colon decreases, and therefore drugs which are released in the colon pH-dependently (e.g. 5-aminosalicylic acid) can be inactivated.

DOSES

Dogs:
- Constipation: 0.5–1.0 ml/kg p.o. q8–12h. Monitor and adjust therapy to produce 2 or 3 soft stools per day.
- Acute hepatic encephalopathy: 18–20 ml/kg of a solution comprising 3 parts lactulose to 7 parts water per rectum as a retention enema for 4–8 hours.
- Chronic hepatic encephalopathy: 0.5–1.0 ml/kg p.o. q8–12h. Monitor and adjust therapy to produce 2 or 3 soft stools per day.

Cats:
- Constipation and chronic hepatic encephalopathy: 0.5–5 ml p.o. q8–12h. Monitor and adjust therapy to produce 2 or 3 soft stools per day.
Lamivudine (3TC)  
(Epivir*, Zeffix*, several generics) POM

Formulations: Oral: 10 mg/ml solution; 100 mg tablets.

Action: A nucleoside reverse transcriptase inhibitor that inhibits viral replication.

Use:
- Treatment of FIV-positive cats.

In cats not showing clinical signs, it may delay the onset of the clinical phase. In cats showing clinical signs, it may improve recovery in combination with other therapies. Lamivudine (3TC) when combined with zidovudine seems to be more effective at reducing viral load and increasing CD4/CD8 ratios over a 1-year period than zidovudine on its own. These studies used small numbers of cats. Haematological monitoring is recommended.

Safety and handling: Normal precautions should be observed.

Contraindications: Anaemia.

Adverse reactions: Unknown, but cytopenias can be predicted.

Drug interactions: Unknown.

DOSES

Cats: 25 mg/kg p.o. q12h.

Dogs: Not applicable.

References


Lanthanum carbonate (Lantharenol)  
(Fosrenol®) POM, general sale

Formulations: Oral: 500 mg, 750 mg, 1 g chewable tablets (lanthanum carbonate).

Action: Binds ingested phosphate in the gut and the insoluble complexes are not absorbed.

Use:
- Reduction of serum phosphate in azotaemia.

Hyperphosphataemia is implicated in the progression of chronic renal failure. Phosphate-binding agents are usually only used if low

References


phosphate diets are unsuccessful. Monitor serum phosphate levels at 4–6 week intervals and adjust dosage accordingly if trying to achieve target serum concentrations. When using lanthanum, water should be available at all times. Dose adjustments should be based on serum phosphate levels.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** It is not advisable to introduce the drug for the first time during an acute crisis: always stabilize the patient before making any dietary alterations to enhance acceptance.

**Adverse reactions:** None known.

**Drug interactions:** Should be given at least 1 hour before or 3 hours after other medications.

**DOSES**

**Dogs:** Chronic kidney disease: 100 mg/kg/day p.o. divided between meals.

**Cats:** Chronic kidney disease: 400–800 mg/cat/day with a recommended starting dose of 400 mg per day. The dose should be divided according to the feeding schedule (it is important to give some with every meal).

**References**


---

**Latanoprost**

(Latanoprost*, Xalatan*) POM

**Formulations:** Ophthalmic: 50 μg/ml (0.005%) solution in 2.5 ml bottle (Xalatan), or 0.2 ml vials (Monopost).

**Action:** Agonist for receptors specific for prostaglandin F. It reduces intraocular pressure by increasing outflow.

**Use:**

- Its main indication is in the management of primary canine glaucoma and it is useful in the emergency management of acute primary glaucoma. Often used in conjunction with other topical antiglaucoma drugs such as carbonic anhydrase inhibitors.
- It may be useful in the management of lens subluxation and posterior luxation despite being contraindicated in anterior lens luxation.

Latanoprost has comparable activity to travoprost. Efficacy in the cat is variable; it has been shown to reduce IOP acutely in cats with primary glaucoma but suitability and efficacy for long-term use is unknown.

**Safety and handling:** Check requirements for storage at room temperature or refrigeration.
Contraindications: Uveitis and anterior lens luxation. Avoid in pregnant animals.

Adverse reactions: Miosis in dogs and cats; blood-aqueous barrier disruption; conjunctival hyperaemia and mild irritation may develop. Increased iridal pigmentation has been noted in humans but not in dogs.

Drug interactions: Do not use in conjunction with thiomersal-containing preparations.

DOSES
Dogs: 1 drop per eye once daily (evening), or q8–12h.
Cats: Detailed information not available.

References
McDonald JE, Kiland JA, Kaufman PL et al. (2016) Effect of topical latanoprost 0.005% on intraocular pressure and pupil diameter in normal and glaucomatous cats. Veterinary Ophthalmology 19(S1), 13–23

Leflunomide (Arava*) POM

Formulations: Oral: 10 mg, 15 mg, 20 mg, 100 mg tablets.

Action: Inhibits T and B lymphocyte proliferation, suppresses immunoglobulin production, and interferes with leucocyte adhesion and diapedesis, usually through inhibition of tyrosine kinases. Also inhibits dihydro-orotate dehydrogenase, an enzyme involved in de novo pathway of pyrimidine synthesis.

Use:
- Treatment of systemic histiocytosis.
- Used in canine immune-mediated diseases.

Clinical veterinary experience of this drug is limited.

Safety and handling: Disposable gloves should be worn to handle or administer tablets. Staff and clients should be warned that excreta (including saliva) may contain traces of the parent drug or its metabolites, and should be handled with due care. Do not split or crush the tablets.

Contraindications: Bone marrow suppression, pre-existing infections, liver dysfunction.

Adverse reactions: Anorexia, lethargy, myelosuppression and haematemesis. In humans leflunomide can cause severe hepatotoxicity, myelosuppression and interstitial lung disease.

Drug interactions: In humans, live virus vaccines, tolbutamide, rifampin and isoniazid should not be given concomitantly.

DOSES
See Appendix for immunosuppression protocols.
Dogs: 2.0 mg/kg p.o. q24h.
Cats: Rheumatoid arthritis (in combination with methotrexate): 10 mg (total dose) p.o. q24h, after significant improvement, reduce to 10 mg p.o. twice weekly.

References

Lenograstim (rhG-CSF) (Granocyte*) POM

Formulations: Injectable: 33.6 million IU (263 μg) vial for reconstitution.


Use:
• Management of febrile patients with neutrophil counts <1 x10⁹/l.
There are few reports on the use of G-CSF in dogs and cats; filgastrim is more commonly used.

Safety and handling: Normal precautions should be observed.

Contraindications: No information available.

Adverse reactions: Normal dogs produce neutralizing antibodies to rhG-CSF. This limits repeated use and may result in neutropenia. This does not appear to be the case in canine chemotherapy patients. A variety of adverse effects have been reported in humans, including musculoskeletal pain, transient hypotension, dysuria, allergic reactions, proteinuria, haematuria and increased liver enzymes. Reported adverse effects are bone pain at high doses and irritation at the injection site.

Drug interactions: In humans, steroids and lithium may potentiate the release of neutrophils during G-CSF therapy. Concurrent administration with chemotherapy may increase incidence of adverse effects. G-CSF should be given at least 24 hours after the last dose of chemotherapy as the stimulatory effects of G-CSF on haemopoietic precursors renders them more susceptible to the effects of chemotherapy.

DOSES
See Appendix for conversion of body weight to body surface area.
Dogs: 19.2 million IU/m² i.v. (over 30 min), s.c. q24h for 3–5 days.
Cats: No information available.
Levetiracetam (S-Etiracetam)
(Desitrend*, Keppra*) POM

Formulations: Oral: 250 mg, 500 mg, 750 mg and 1 g tablets; 100 mg/ml oral 300 ml solution; coated granules 250 mg/sachet. Injectable: 100 mg/ml intravenous solution (5 ml vial); formulated with sodium chloride for injection at 500 mg/100 ml, 1000 mg/100 ml and 1500 mg/100 ml.

Action: The mechanism of anticonvulsant action is unknown but it has been shown to bind to the pre-synaptic vesicle protein SV2A within the brain, modulating the release of neurotransmitters, which may protect against seizures.

Use:
- As an adjunctive maintenance therapy in dogs and cats for management of epileptic seizures refractory to conventional therapy.
- Also as a primary therapy where phenobarbital is contraindicated; however, efficacy is significantly worse than phenobarbital in newly diagnosed epileptic dogs.
- Used at a higher dose, in addition to conventional maintenance therapy, as pulse therapy for cluster seizures. A constant intravenous infusion can be used for emergency control of status epilepticus.

Levetiracetam is rapidly absorbed from the GI tract with peak plasma concentrations reached in <2 hours of oral dosing. Steady state is rapidly achieved within 2 days. Plasma protein binding is minimal. The plasma half-life is around 3–4 hours in dogs. It will also reach target serum concentrations if administered rectally. Withdrawal of levetiracetam therapy or transition to or from another type of antiepileptic therapy should be done gradually. Use with caution and in reduced doses in patients with renal impairment; in humans, renal elimination of levetiracetum correlates with creatinine clearance.

Safety and handling: Normal precautions should be observed.

Contraindications: Severe renal disease.

Adverse reactions: The most commonly reported adverse effects include sedation and ataxia in dogs and reduced appetite, hypersalivation and lethargy in cats.

Drug interactions: Minimal, although there is some evidence to suggest that phenobarbital increases levetiracetam clearance, reducing the half-life and peak levels.

DOSES
Dogs, Cats:
- Maintenance therapy (as adjunct or sole anticonvulsant): 20–30 mg/kg p.o. q8–12h.
- Pulse therapy for severe cluster seizures (in addition to maintenance therapy): 30 mg/kg p.o. q6–8h for the duration of
the cluster (usually for 2–3 days) and then incrementally reduced and stopped until the start of the next cluster. Incremental increases in dose if required.

- **Status epilepticus:** 60 mg/kg i.v. bolus q8h or continuous intravenous infusion of 8 mg/kg/h, incrementally increased to effect if required.
- The parenteral preparation can be given at 40 mg/kg per rectum, if oral or i.v. administration is not possible.

**References**


**Levothyroxine** see *L-Thyroxine*

**Lidocaine** (*Lignocaine*)

(EMLA, Intubeaze, Lignadrin, Lignol, Locaine, Locovetic, Lidoderm*) POM-V

**Formulations:** Injectable: 1%, 2% solutions (some contain adrenaline). **Topical:** 2% solution (Intubeaze), 4% solution (Xylocaine); 2.5% cream with prilocaine (EMLA); 5% transdermal patches (Lidoderm).

**Action:** Local anaesthetic action is dependent on reversible blockade of the sodium channel, preventing propagation of an action potential along the nerve fibre. Sensory nerve fibres are blocked before motor nerve fibres, allowing a selective sensory blockade at low doses. Lidocaine also has class 1b antiarrhythmic actions, decreasing the rate of ventricular firing, action potential duration and absolute refractory period, and increasing relative refractory period. Lidocaine has a rapid onset of action and intermediate duration of action. Addition of adrenaline to lidocaine increases the duration of action by reducing the rate of systemic absorption.

**Use:**

- Provision of local or regional analgesia using perineural, infiltration, local i.v. or epidural techniques. It is generally recommended that adrenaline-free solutions be used for epidural administration.
- Intratesticular lidocaine has been shown to reduce haemodynamic responses to castration in dogs and cats and is recommended to provide intraoperative analgesia during castration and reduce the requirement for inhalant anaesthetic agents.
- Also used to provide systemic analgesia when given i.v. by continuous rate infusion.
- First-line therapy for rapid or haemodynamically significant ventricular arrhythmias.
• May also be effective for some supraventricular arrhythmias, such as bypass-mediated supraventricular tachycardia, and for cardioversion of acute-onset or vagally-mediated atrial fibrillation.
• Widely used topically to desensitize mucous membranes (such as the larynx prior to intubation).
• EMLA cream is used to anaesthetize the skin before vascular cannulation.

EMLA cream must be placed on the skin for approximately 45–60 minutes to ensure adequate anaesthesia; covering the skin with an occlusive dressing promotes absorption. EMLA is very useful to facilitate venous catheter placement in small puppies and kittens. The pharmacokinetics of transdermal lidocaine patches have been evaluated in dogs and cats; bioavailability of transdermal lidocaine is low in cats and dogs compared with humans. The analgesic efficacy and clinical usefulness of transdermal lidocaine has not yet been evaluated in either species. Infusions of lidocaine reduce the inhaled concentrations of anaesthetic required to produce anaesthesia and prevent central sensitization to surgical noxious stimuli. Systemic lidocaine is best used in combination with other analgesic drugs to achieve balanced analgesia. Lidocaine will accumulate after prolonged administration, leading to a delayed recovery. Cats are very sensitive to the toxic effects of local anaesthetics, therefore, it is important that doses are calculated and administered accurately.

Safety and handling: Normal precautions should be observed.

Contraindications: Do not give to cats by continuous rate infusion during the perioperative period due to the negative haemodynamic effects. Do not give lidocaine solutions containing adrenaline i.v. Do not use solutions containing adrenaline for complete ring block of an extremity because of the danger of ischaemic necrosis.

Adverse reactions: Depression, seizures, muscle fasciculations, vomiting, bradycardia and hypotension. If reactions are severe, decrease or discontinue administration. Seizures may be controlled with i.v. diazepam. Monitor the ECG carefully during therapy. Cats tend to be more sensitive to the CNS effects. The CFC propellant used in unlicensed aerosol preparations (e.g. Xylocaine spray) is alleged to have caused laryngeal oedema in cats and should not be used to desensitize the larynx prior to intubation.

Drug interactions: Cimetidine and propranolol may prolong serum lidocaine clearance if administered concurrently. Other antiarrhythmics may cause increased myocardial depression.

DOSES
Note: 1 mg/kg is 0.05 ml/kg of a 2% solution.

Dogs:
• Local anaesthesia: apply to the affected area with a small gauge needle to an appropriate volume. Total dose that should be injected is 4 mg/kg.
• Oesophagitis: 2 mg/kg p.o. q4–6h.
• Topical: apply thick layer of cream to the skin and cover with a bandage for 45–60 min prior to venepuncture.
• **Intraoperative analgesia given by constant rate infusion:** 1 mg/kg loading dose (given slowly over 10–15 min) followed by 20–50 μg (micrograms)/kg/min. Postoperatively, similar dose rates can be used but should be adjusted according to pain assessment and be aware of the likelihood of accumulation allowing an empirical reduction in dose rate over time.

• **Ventricular arrhythmias:** 2–8 mg/kg i.v. in 2 mg/kg boluses followed by a constant rate i.v. infusion of 0.025–0.1 mg/kg/min.

**Cats:**

• **Local anaesthesia, topical, oesophagitis:** doses as for dogs.
  Avoid systemic lidocaine for analgesia in cats due to the risk of drug accumulation, toxicity and negative haemodynamic effects.

• **Ventricular arrhythmias:** 0.25–2.0 mg/kg i.v. slowly in 0.25–0.5 mg/kg boluses followed by a constant rate i.v. infusion of 0.01–0.04 mg/kg/min.

**References**

Huuskonen V, Hughes JM, Estaca Baron E et al. (2013) Intratesticular lidocaine reduce the response to surgical castration in dogs. *Veterinary Anaesthesia and Analgesia* 40, 74–82

Modal ER, Erikson T, Kirpensteijn J et al. (2013) Intratesticular and subcutaneous lidocaine alters the intraoperative haemodynamic responses and heart rate variability in male cats undergoing castration. *Veterinary Anaesthesia and Analgesia* 40, 63–73

**Lignocaine** see **Lidocaine**

**Lincomycin** *(Lincocin, Lincoject)* POM-V

**Formulations:** Injectable: 100 mg/ml solution for i.v. or i.m. use. Oral: powder for solution.

**Action:** Binds to 50S ribosomal subunit inhibiting bacterial protein synthesis with a time-dependent mechanism. Being a weak base, it is ion-trapped in fluid that is more acidic than plasma and therefore concentrates in prostatic fluid, milk and intracellular fluid.

**Use:** Active against Gram-positive cocci (including penicillin-resistant staphylococci) and many obligate anaerobes. The lincosamides (lincomycin and clindamycin) are particularly indicated for staphylococcal bone and joint infections. Clindamycin is more active than lincomycin, particularly against obligate anaerobes, and is better absorbed from the gut. Administer slowly if using i.v. route.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Rapid i.v. administration should be avoided since this can result in collapse due to cardiac depression and peripheral neuromuscular blockade.

**Adverse reactions:** Human patients on lincomycin may develop colitis. Patients developing diarrhoea (particularly if it is haemorrhagic) while taking the medication should be monitored carefully. Toxicity is a possibility in patients with liver disease; weigh
the risk versus the potential benefits before use of this drug in such patients.

**Drug interactions:** The action of neuromuscular blocking agents may be enhanced if given with lincomycin. The absorption of lincomycin may be reduced by kaolin. Lincosamide antimicrobials should not be used in combination with chloramphenicols or macrolides as these combinations are antagonistic.

**DOSES**

*See Appendix for guidelines on responsible antibacterial use.*

**Dogs, Cats:**
- **Parenteral:** 22 mg/kg i.m. q24h or 11 mg/kg i.m. q12h or 11–22 mg/kg slow i.v. q12–24h.
- **Oral:** 22 mg/kg p.o. q12h or 15 mg/kg p.o. q8h.

### Liothyronine (T3, L-Tri-iodothyronine)

**POM**

**Formulations:** Oral: 20 μg tablets.

**Action:** Increases T3 concentrations.

**Use:**
- Diagnosis of feline hyperthyroidism (T3 suppression test).
- Suggested in the treatment of canine hypothyroidism where levothyroxine has been unsuccessful; however, evidence is scant.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.

**Adverse reactions:** Signs of overdosage include tachycardia, excitability, nervousness and excessive panting.

**Drug interactions:** The actions of catecholamines and sympathomimetics are enhanced by thyroxine. Diabetic patients receiving thyroid hormones may have altered insulin requirements; monitor carefully during the initiation of therapy. Oestrogens may increase thyroid requirements by increasing thyroxine-binding globulin. The therapeutic effect of digoxin may be reduced by thyroid hormones. In addition, many drugs may affect thyroid function tests and therefore monitoring of therapy.

**DOSES**

**Dogs:** Hypothyroidism: 2–6 μg (micrograms)/kg p.o. q8–12h.

**Cats:** T3 suppression test: administer 20 μg (micrograms)/cat p.o. q8h for 7 doses.
Lipid infusions
(ClinOleic*, Intralipid*, Ivelip*, Lipidem*, Lipofundin*, Omegaven*)

Formulations: Injectable: 10% solution contains soya oil emulsion, glycerol, purified egg phospholipids and phosphate (15 mmol/l) for i.v. use only. Contains 2 kcal/ml (8.4 kJ/ml), 268 mOsm/l. Other human products are available and vary in composition and concentration.

Action: Support intermediary metabolism, reverse negative energy balance, provide some essential fatty acids and sequester lipid-soluble substances in plasma compartment.

Use:
• Used parenterally in animals receiving nutritional support, to provide fat for energy production and essential fatty acids for cellular metabolism and support of the immune system.
• Can also be used to bind lipid-soluble toxins such as unintentional intravenous administration of bupivacaine or avermectins.

Lipid emulsions are isosmolar with plasma and can be infused into a peripheral vein to provide parenteral nutrition. Due to the complex requirements of providing i.v. nutrition, including careful patient monitoring and the need for strict aseptic practice, in all cases product literature and specialist advice should be consulted. Use with caution in patients with known insulin resistance or at risk of developing pancreatitis. See also Amino acid solutions and Glucose.

Safety and handling: Do not use if separation of the emulsion occurs.

Contraindications: Insulin resistance (e.g. diabetes mellitus) and hyperlipidaemia.

Adverse reactions: Reactions include occasional febrile episodes mainly seen with 20% emulsions. 20% and 30% lipid products have a higher rate of complications including vasculitis, thrombosis, fever and other metabolic complications and are not recommended. Rare anaphylactic responses are reported in humans. Early reports of hepatic failure, pancreatitis, cardiac arrest and thrombocytopenia detailed in human literature appear to have been complications of prolonged treatment.

Drug interactions: Consult specific product data sheet(s). Lines for i.v. parenteral feeding (lipid, glucose, amino acids or nutrient admixtures) should be dedicated for that use alone and should not be used for administration of other medications. Interference with biochemical measurements, such as those for blood gases and calcium, may occur if samples are taken before fat has been cleared. Daily checks are necessary to ensure complete clearance from the plasma in conditions where fat metabolism may be disturbed. Additives may only be mixed with fat emulsions where compatibility is known. See Amino acid solutions for additional information.
DOSES

**Dogs:** Parenteral nutrition: the amount required will be governed by the patient’s physiological status and whether partial or total parenteral nutrition is provided. Generally, lipid infusions are used to supply 30% (partial peripheral) to 40–60% of energy requirements.

**Cats:** Parental nutrition: the amount required will be governed by the patient’s physiological status and its tolerance of lipids. Generally, peripheral parenteral nutrition is provided by amino acids in cats and lipids are used as an energy source in a nutrient admixture for infusion through central venous access (total parenteral nutrition) to supply 40–60% of energy requirements.

**Dogs, Cats:** Treatment of lipid-soluble toxicosis such as ivermectin or moxidectin toxicosis: administer 1.5–5 ml/kg i.v. of 20% lipid solution as bolus, followed by 0.25–0.50 ml/kg/min i.v. infusion for 30–60 min. Boluses of 1.5 ml/kg can be repeated. Infusions of 0.5 ml/kg/min can be administered for a maximum of 24 hours.

**References**


---

**Liquid paraffin** see *Paraffin*

**Lithium carbonate**

(Camcolit*, Liskonum*, Priadel*) **POM**

**Formulations:** **Oral:** 250 mg, 400 mg tablets.

**Action:** Stimulates bone marrow stem cells, causing an increase in the production of haemopoietic cell lines, particularly granulocytes.

**Use:**
- Treatment of idiopathic aplastic anaemia, cytotoxic drug-induced neutropenia or thrombocytopenia, oestrogen-induced bone marrow suppression and cyclic haemopoiesis.

There is a lag phase of up to 4 weeks before its effects may be seen. Experimental studies show that lithium may prevent neutropenia associated with cytotoxic drugs when administered concomitantly; clinical trials showing this are lacking. The recommended serum lithium concentration is 0.5–1.8 mmol/l; assess every 3 months if possible.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Avoid in patients with renal impairment (nephrotoxic at high doses), cardiac disease and conditions with sodium imbalance (e.g. hypoadrenocorticism). Only use in patients that show no signs of dehydration. Do not use in cats.
Adverse reactions: Nausea, diarrhoea, muscle weakness, fatigue, polyuria and polydipsia. Seizures are reported. The release of T3 and T4 may be blocked by lithium; assess thyroid status every 6 months. Lithium is toxic to cats.

Drug interactions: The excretion of lithium may be reduced by ACE inhibitors, loop diuretics, NSAIDs and thiazides, thus increasing the risk of toxicity. Lithium toxicity is made worse by sodium depletion; avoid concurrent use with diuretics. The excretion of lithium may be increased by theophylline. Lithium antagonizes the effects of neostigmine and pyridostigmine. Neurotoxicity may occur if lithium is administered with diltiazem or verapamil.

DOSES
Dogs: 10 mg/kg p.o. q12h give with food.
Cats: Do not use.

References

Lokivetmab
(Cytopoint) POM-V

Formulations: Injectable: 10 mg, 20 mg, 30 mg, 40 mg solution.

Action: Lokivetmab is a caninized monoclonal antibody (mAb) specifically targeting canine interleukin-31. The blocking of IL-31 by lokivetmab prevents IL-31 from binding to its co-receptor and thereby inhibits IL-31 mediated cell signalling, providing relief from atopic dermatitis-related pruritus and anti-inflammatory activity.

Use:
• Indicated for the treatment of clinical manifestations of atopic dermatitis in dogs.

If the dog does not respond to 2 doses 1 month apart, then alternative treatment should be considered. After repeated doses, the clinical efficacy may persist beyond 1 month.

Safety and handling: Avoid shaking vial. Store in fridge. Do not mix with other injectable products.

Contraindications: Not for use in dogs <3 kg.

Adverse reactions: Hypersensitivity reactions (anaphylaxis, facial oedema, urticaria) may occur in rare cases.

Drug interactions: None reported.

DOSES
Dogs: 1 mg/kg s.c. monthly.
Cats: Not indicated.

References
Michels GM, Walsh KF, Kryda KA et al. (2016) A blinded, randomized, placebo-controlled trial of the safety of lokivetmab (ZTS-00103289), a caninized anti-canine IL-31 monoclonal antibody in client-owned dogs with atopic dermatitis. Veterinary Dermatology 27, 505–e136
Lomustine (CCNU) (Lomustine*) POM

Formulations: Oral: 40 mg capsule.

Action: Interferes with the synthesis and function of DNA, RNA and proteins. Antitumour activity correlates best with formation of interstrand cross-linking of DNA. Lomustine is highly lipid-soluble, allowing rapid transport across the blood–brain barrier.

Use:
- Reported to have some efficacy in the treatment of brain tumours, mast cell tumours, refractory lymphoma, histiocytic sarcoma and epitheliotrophic lymphoma.
- Component of the modified CHOP protocol for treatment of T-cell lymphoma.

S-Adenosylmethionine and silybin may be used to prevent or treat lomustine hepatotoxicity. Used in the treatment of primary and metastatic brain tumours in humans.

Safety and handling: Cytotoxic drug: see Appendix and specialist texts for further advice on chemotherapeutic agents.

Contraindications: Bone marrow suppression. Pre-existing liver disease.

Adverse reactions: Myelosuppression is the dose-limiting toxicity, with neutropenia developing 7–14 days after administration (although onset of myelosuppression can range from 1–6 weeks and can be particularly delayed in cats). Neutropenia may be severe and life-threatening at the higher end of the dose range in some dogs. Thrombocytopenia can also be seen, often with no other concurrent cytopenias. GI and cumulative dose-related and potentially irreversible hepatic toxicity have been reported in the dog.

Drug interactions: Do not use with other myelosuppressive agents. Lomustine requires hepatic microsomal enzyme hydroxylation for the production of antineoplastic metabolites. It should be used with caution in dogs being treated with agents that induce liver enzyme activity, e.g. phenobarbital. In humans, cimetidine enhances the toxicity of lomustine.

DOSES
See Appendix for chemotherapy protocols and conversion of body weight to body surface area.

Dogs: All uses: 60–80 mg/m² p.o. q3–4wk.
Cats: All uses: A dose of 30–60 mg/m² p.o. q4–6wk has been suggested but is not well established. If using this drug in the cat, specialist advice should be sought, as dosing intervals may need to be increased.

References
**Loperamide**  
(Diah-Limit*, Diarolaeze*, Entrocalm*, Imodium*, Norimode*) **POM, P, GSL**

**Formulations:** Oral: 2 mg capsule, 2 mg tablet; 0.2 mg/ml syrup.

**Action:** Opioid agonist that alters GI motility by acting on receptors in the myenteric plexus. It normally has no central action.

**Use:** Management of non-specific acute and chronic diarrhoea, and irritable bowel syndrome. Use with care in cats.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Intestinal obstruction. Do not use in dogs likely to be ivermectin-sensitive, e.g. collies. The mutation of the multiple drug resistance (*MDR1* or *ABCB1*) gene in these dogs allows loperamide (a P-glycoprotein substrate) to penetrate the CNS and cause profound sedation.

**Adverse reactions:** Constipation will occur in some cases. In cats excitability may be seen.

**Drug interactions:** Avoid concurrent use with other drugs that reduce GI motility.

**DOSES**  
**Dogs, Cats:** All uses: 0.04–0.2 mg/kg p.o. q8–12h.

**References**  

---

**Loratadine**  
(Loratadine*) **GSL**

**Formulations:** Oral: 10 mg tablet; 1 mg/ml syrup.

**Action:** Binds to H1 histamine receptors preventing histamine from binding.

**Use:**  
- Management of allergic disease.

Specific doses for dogs and cats have not been determined by pharmokinetic studies. Use with caution in cases with urinary retention, angle-closure glaucoma and pyloroduodenal obstruction.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.

**Adverse reactions:** May cause mild sedation. May reduce seizure threshold.
Drug interactions: No information available.

DOSES
Dogs: 5–15 mg p.o. q24h.
Cats: No information available.

Lorazepam
(Ativan*, Intensol*) POM

Formulations: Oral: 1 mg tablets; 2 mg/ml suspension. Injectable: 4 mg/ml solution.

Action: Increases the activity of GABA (a major inhibitory transmitter) within the CNS, resulting in anxiolysis.

Use:
• Used for short-term management of anxiety disorders in dogs and cats, but there is a lack of controlled studies to support its use.

This may be necessary during a prolonged behavioural therapy programme to avoid relapses due to exposure to an intensely fear-inducing stimulus during treatment. However, as benzodiazepines may inhibit memory, their routine use as part of a behaviour plan is not recommended except under careful management. Withdrawal of treatment should be gradual, as acute withdrawal may result in signs of tremor and inappetence.

Safety and handling: Normal precautions should be observed. There is some concern over the risk of acute hepatic necrosis associated with the use of benzodiazepines in cats, but it has not been reported in relation to lorazepam.

Contraindications: Glaucoma, significant liver or kidney disease, hypersensitivity to benzodiazepines. Not recommended in pregnant or lactating animals.

Adverse reactions: A general concern with benzodiazepines concerns disinhibition and the subsequent emergence of aggression. Drowsiness and mild transient incoordination may develop.

Drug interactions: Caution is advised if used in association with antifungals such as itraconazole, which inhibit its metabolism.

DOSES
Dogs, Cats: 0.02–0.1 mg/kg p.o. q12–24h; start at lower dose and gradually increase.

References
**Lotilaner**  
(Credelio) **POM-V**

**Formulations:** Oral: Chewable tablets, 5 sizes dogs (56.25 mg, 112.5 mg, 225 mg, 450 mg and 900 mg); 2 sizes cats (12 mg and 48 mg).

**Action:** Inhibitor of gamma-aminobutyric acid (GABA)-gated chloride channels leading to death of parasites.

**Use:**
- Prophylaxis and treatment of fleas and ticks.
- Likely to be active against other ectoparasites such as *Sarcoptes scabiei*, *Demodex canis*.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not use in dogs <8 weeks and 1.3 kg, kittens <8 weeks and 0.5 kg, pregnant or lactating animals.

**Adverse reactions:** None known.

**Drug interactions:** No information available.

**DOSES**
- **Dogs:** 20–43 mg/kg monthly.
- **Cats:** 6–24 mg/kg monthly.

---

**Lufenuron**  
(Program) **POM-V**

**Formulations:** Oral: 67.8 mg, 204.9 mg, 409.8 mg tablets (Program); 133 mg, 266 mg suspension (Program for cats); 46 mg, 115 mg, 230 mg, 460 mg lufenuron combined with milbemycin (ratio of 20 mg lufenuron:1 mg milbemycin) (Program plus).  
Injectable: 40 mg, 80 mg pre-filled syringes containing 100 mg/ml suspension (Program).

**Action:** Inhibition of chitin synthetase leading to a failure of chitin production, which means that flea eggs fail to hatch.

**Use:**
- Prevention of flea infestation (*Ctenocephalides felis*, *C. canis*).
- Lufenuron has an additional antifungal action but specific doses for the effective treatment of dermatophytosis are currently unknown.

For treatment of flea infestations, the additional use of an approved adulticide is recommended. All animals in the household should be treated. Tablets/suspension should be administered with food. Can be administered during pregnancy and lactation (Program, Program plus). Can be administered to puppies from 2 weeks or >1 kg (Program plus), weaned puppies (Program). **See Milbemycin for further details.**

**Safety and handling:** Normal precautions should be observed.
Contraindications: Should not be administered to unweaned kittens.

Adverse reactions: On very rare occasions, nervous signs, itching, vomiting or diarrhoea have been reported in dogs following treatment with Program tablets. Rarely lethargy may be seen after injection in cats.

Drug interactions: No information available.

DOSES

Dogs: Fleas: 10 mg/kg p.o., s.c. q1month (equivalent to a dose of 0.5 mg/kg milbemycin in combined preparations).

Cats: Fleas: 10 mg/kg s.c. q6months or 30 mg/kg p.o. q1month.

Lysine (L-Lysine)
(Enisyl) general sale

Formulations: Oral: 250 mg/ml paste in 100 ml bottle; 250 mg, 500 mg capsules.

Action: Antagonizes arginine, which is required for viral replication.

Use:
• Has been used in the management of feline herpesvirus-1 infection. Dietary lysine supplementation is used in an attempt to suppress FHV-1 infection and reactivation.

Oral lysine is safe and may reduce viral shedding in latently infected cats and clinical signs in cats undergoing primary exposure. However, there is limited clinical evidence regarding its efficacy in treating FHV-1. Cats are very sensitive to arginine deficiency and dietary arginine must not be reduced.

Safety and handling: Normal precautions should be observed.

Contraindications: Do not use preparations containing propylene glycol as they may be toxic to cats.

Adverse reactions: Diarrhoea may be seen (mild, reversible).

Drug interactions: No information available.

DOSES

Cats: Adults: 500 mg p.o. q12–24h (equivalent to 2 ml/2 pumps q12h); Kittens: 250 mg p.o. q12–24h (equivalent to 1 ml/1 pump q12h).

Dogs: Not applicable.

References
Thomasy SM and Maggs DJ (2016) A review of antiviral drugs and other compounds with activity against feline herpesvirus type 1. Veterinary Ophthalmology 19(S1), 119–130
**Magnesium salts**  
(Magnesium sulphate injection BP (Vet) 25% w/v)  
POM-VPS, POM

**Formulations:** Injectable: 25% w/v, 50% w/v solutions containing 1 mEq and 2 mEq magnesium per ml. Dilute to a 20% or lower solution prior to use.

**Action:** Critical role in muscular excitement and neurological transmission. It is a cofactor in a variety of enzyme systems and maintenance of ionic gradients.

**Use:**
- Treatment of unresponsive ventricular arrhythmias especially in the presence of hypokalaemia (when hypomagnesaemia may be present).
- Used as infusions and orally to treat hypomagnesaemia.

Reduce i.v. potassium supplementation to avoid hyperkalaemia. Monitoring of serum magnesium is essential: 30–35% is bound to protein and the remainder is free as the ionized form. Magnesium is compatible in solution with 5% dextrose and calcium gluconate. Treatment of potential overdose or complications should be anticipated and ventilatory support and i.v. calcium gluconate may be required. Product information should be consulted on an individual case basis.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not use in patients with heart block or myocardial damage. Do not use in renal impairment or failure (magnesium is excreted by the kidneys at a rate proportional to serum levels).

**Adverse reactions:** Somnolence, CNS depression and possibly coma, muscular weakness, bradycardia, hypotension, respiratory depression and prolonged Q-T intervals have been seen, typically following overdosage. Very high levels can cause neuromuscular blockade and cardiac arrest.

**Drug interactions:** Additive effects can be seen with other CNS depressants including barbiturates and general anaesthetics. Do not use with non-depolarizing neuromuscular blocking agents because of the risk of severe neuromuscular blockage. Because serious conduction disturbances can occur, use with extreme caution with digitalis glycosides.

**DOSES**

**Dogs, Cats:**
- **Life-threatening ventricular arrhythmia:** 0.15–0.3 mEq/kg i.v. administered over 5–15 min.
- **Magnesium replacement:** 0.75–1.0 mEq/kg/day by continuous rate infusion in 5% dextrose has been advocated for the first 24–48 hours, followed by a lower dose of 0.3–0.5 mEq/kg/day for 3–5 days to allow complete repletion of magnesium stores.
Mannitol (Cordycepic acid) (Mannitol*) POM

Formulations: Injectable: 10%, 15%, 20% (50 g/500 ml, 75 g/500 ml, 100 g/500 ml) solutions.

Action: Mannitol is an inert sugar alcohol that acts as an osmotic diuretic.

Use:
- Reduction of intracranial pressure (ICP) (most effective in acute increases).
- Treatment of acute glaucoma.
- May also be used in the treatment of oliguric renal failure.

Reduction in intracranial and intraocular fluid pressure occurs within 15 minutes of the start of a mannitol infusion and lasts for 3–8 hours after the infusion is discontinued; diuresis occurs after 1–3 hours. There is some evidence that bolus administration (over 20–30 minutes) may be more effective for reduction of intracranial pressure than continuous administration. When used as treatment for raised intracranial pressure, hypovolaemia should be avoided to maintain cerebral perfusion pressure.

Safety and handling: Any crystals that have formed during storage should be dissolved by warming prior to use. The formation of crystals is a particular problem with the 20% formulations, which are supersaturated. An in-line filter should be used when infusing mannitol.

Contraindications: In patients with severe dehydration, severe pulmonary congestion or pulmonary oedema. Mannitol is labelled ‘use with care’ in intracranial haemorrhage (except during intracranial surgery), but there appears to be little evidence to support this and it is used commonly in humans with traumatic brain injury and cerebral bleeds. There is some evidence for accumulation of mannitol where there has been breakdown of the blood–brain barrier and this may cause rebound increases in ICP following administration or raised ICP with prolonged therapy.

Adverse reactions: The most common adverse reactions seen are fluid and electrolyte imbalances. Infusion of high doses may result in circulatory overload and acidosis. Thrombophlebitis may occur and extravasation of the solution may cause oedema and skin necrosis. Mannitol causes diarrhoea if given orally. Rarely mannitol may cause acute renal failure in human patients.

Drug interactions: Diuretic-induced hypokalaemia may occur when used with potassium-depleting diuretics. Concurrent use of

References
potassium-depleting diuretics should be used with care in conjunction with beta-blockers. Nephrotoxicity has been described with concurrent use of mannitol and ciclosporin in human patients. Mannitol may result in temporary impairment of the blood–brain barrier for up to 30 minutes after administration of high doses. Mannitol should never be added to whole blood for transfusion or given through the same set by which the blood is being infused. Do not add KCl or NaCl to concentrated mannitol solutions (20% or 25%) as a precipitate may form.

DOSES

**Dogs, Cats:**

- **Raised intracranial pressure:** 0.25–2 g/kg i.v. infusion of 15–20% solution. There is some evidence that higher doses have greater clinical effect, but lower doses allow for repeated boluses. Doses of 0.25–1.0 g/kg are recommended. The dose is given over 20–30 min. The dose may be repeated once or twice after 4–8 hours as long as hydration and electrolyte levels are monitored.

- **Acute glaucoma (if refractory to topical treatments):** 0.5–2 g/kg i.v. infusion over 30 min. Withholding water for the first few hours after administering is recommended. May repeat 2–4 times over next 48 hours; monitor for dehydration.

- **Early oliguric or anuric renal failure (as an alternative to using furosemide):** 0.25–0.5 g/kg i.v. infusion over 5–10 min. If successful can repeat in 4 hours. Rehydrate the patient prior to the use of mannitol.

**References**


---

**Marbofloxacin**

*(Actimarbo, Aurizon, Efex, Marbocare, Marbocyl, Marbodex, Marbotab, Marboxidin, Marfloquin, NorOtic, Quiflor, Softiflox, Ubiflox)* **POM-V**

**Formulations:** *Injectable:* 200 mg powder for reconstitution giving 10 mg/ml when reconstituted. *Oral:* 5 mg, 20 mg, 80 mg tablets. *Topical:* compound preparation containing 3 mg/ml of marbofloxacin along with clotrimazole and dexamethasone (aural use).

**Action:** Broad-spectrum antibiotic inhibiting bacterial DNA gyrase via a concentration-dependent mechanism particularly against Gram-negative bacteria, meaning that pulse-dosing regimens may be effective. Low urinary pH may reduce the activity.
Use: Fluoroquinolone use should be reserved for infections where culture and sensitivity testing predicts a clinical response and where first- and second-line antimicrobials would not be effective. Active against mycoplasmas and many Gram-positive and particularly Gram-negative organisms, including *Pasteurella*, *Staphylococcus*, *Pseudomonas aeruginosa*, *Klebsiella*, *Escherichia coli*, *Proteus* and *Salmonella*. Fluoroquinolones are effective against beta-lactamase-producing bacteria. Marbofloxacin is relatively ineffective in treating obligate anaerobic infections. Fluoroquinolones are highly lipophilic drugs that attain high concentrations within cells in many tissues and are particularly effective in the management of soft tissue, urogenital (including pyelonephritis and prostatitis) and skin infections. May allow clearance of *Mycoplasma haemofelis* in cats persistently infected after doxycycline treatment.

Safety and handling: Normal precautions should be observed.

Contraindications: The 20 mg and 80 mg tablets should not be administered to cats.

Adverse reactions: Some animals show GI signs (nausea, vomiting). Use with caution in epileptics until further information is available, as fluoroquinolones potentiate CNS adverse effects when administered concurrently with NSAIDs in humans. Enrofloxacin, particularly at high doses, has caused retinal blindness in cats; although not reported with marbofloxacin, caution should be exercised before using dose rates above those recommended by the manufacturer for cats. Cartilage abnormalities have been reported following the use of other fluoroquinolones in growing animals. Such abnormalities have not been specifically reported following the use of marbofloxacin, but the drug is not authorized for use in dogs <12 months of age and cats <16 weeks. In giant-breeds should not be administered to animals <18 months.

Drug interactions: Absorbents and antacids containing cations (Mg$^{2+}$, Al$^{3+}$) may bind fluoroquinolones, preventing their absorption from the GI tract. Their absorption may also be inhibited by sucralfate and zinc salts; separate dosing by at least 2 hours. Fluoroquinolones increase plasma theophylline concentrations. Cimetidine may reduce the clearance of fluoroquinolones and so should be used with caution with these drugs. Some fluoroquinolones may decrease the metabolism and increase nephrotoxicity of ciclosporin and tacrolimus in humans and therefore concurrent use in animals is best avoided until more research has been performed. May increase the action of orally administered anticoagulants.

DOSES
See Appendix for guidelines on responsible antibacterial use.

Dogs: Oral and parenteral: 2 mg/kg i.v., s.c., p.o. q24h. Higher doses should be considered for certain sites, including in prostatitis, and for certain isolates of *Pseudomonas aeruginosa*. Topical: 10 drops per ear once daily.

Cats: 2 mg/kg i.v., s.c., p.o. q24h.
References

Maropitant
(Cerenia, Prevomax, Vetemex) POM-V

Formulations: Injectable: 10 mg/ml solution. Oral: 16 mg, 24 mg, 60 mg, 160 mg tablets.

Action: Inhibits vomiting reflex by blocking NK-1 receptors in medullary vomiting centre. Highly protein bound, with a long duration of activity (24 hours). Maropitant is not known to have any prokinetic effect.

Use:
• Treatment and prevention of vomiting in dogs, including that caused by chemotherapy and motion sickness (although not all preparations are specifically licensed for these purposes).
• Maropitant is well tolerated and has potent antiemetic activity in cats.

In cases of frequent vomiting, treatment by injection is recommended. Treatment by injection and/or tablets can be given for up to 5 days. In some individual dogs, repeat treatment at a lower dose may be adequate. For motion sickness, treatment for up to 2 days can be given. If longer periods of treatment are required, the recommended interval between the last dose of one course and the first dose of a subsequent course is 72 hours. It should be used in combination with investigation into the cause of vomiting and with other supportive measures and specific treatments. Tablets best given with food; avoid prolonged fasting before administration.

Safety and handling: Normal precautions should be observed. Do not attempt to remove the tablet by pushing through the blister packing as this will damage the tablet.

Contraindications: No specific contraindications but it would be sensible not to use maropitant where GI obstruction or perforation could be present or for longer than 48 hours without a definitive diagnosis. Metabolized by the liver so use with caution in patients with hepatic disease.

Adverse reactions: Transient pain reaction during injection is reported as a very common occurrence especially in cats, but no significant lasting adverse reactions. Very high doses in cats may cause haemolysis. Pain on injection can be reduced by injecting the product at refrigerated temperatures.

Drug interactions: No compatibility studies exist, and therefore the injection should not be mixed with any other agent. Should not
be used concurrently with calcium-channel antagonists as maropitant has an affinity to calcium-channels. Highly bound to plasma proteins and may compete with other highly bound drugs.

**DOSES**

**Dogs:**
- **Vomiting:** 1 mg/kg i.v. or s.c. q24h or 2 mg/kg p.o. q24h.
- **Motion sickness:** tablets at a dose rate of 8 mg/kg q24h for a maximum of 2 days given 1 hour before journey.
- **Prevention of chemotherapy-induced emesis:** 1 mg/kg s.c. q24h or 2 mg/kg p.o. q24h, given at least 1 hour in advance.

**Cats:** **Vomiting:** 1 mg/kg i.v., s.c. or p.o. q24h.

**References**


---

**Masitinib mesylate**

*(Masivet) POM-V*

**Formulations:** Oral: 50 mg, 150 mg film-coated tablets.

**Action:** Protein tyrosine kinase inhibitor, which showed *in vitro* selectively and effectively highest affinity for mutated forms of the c-KIT tyrosine kinase receptor. Tyrosine kinase inhibitors block the TK receptor pathways essential for cell replication.

**Use:**
- Treatment of dogs with non-resectable mast cell tumours (Patnaik grade 2 or 3), preferably with a confirmed mutated c-KIT tyrosine kinase receptor.
- Studies indicate that masitinib may be useful for the treatment of some dogs with atopic dermatitis, inflammatory bowel disease, osteosarcoma, anal sac adenocarcinoma and haemangiosarcoma.
- Early studies have investigated the use of masitinib in cats with injection site sarcoma and asthma.

Preliminary studies have investigated safety in healthy cats, but this drug is not licensed in this species and further clinical trials are likely to be required. Patients should be monitored closely during treatment. As a guideline blood pressure, urinalysis, haematology and biochemistry should be undertaken before starting therapy, and then at least once a month (clinicians may also check these parameters 1–2 weeks after drug initiation). Full coagulation profiles and faecal occult blood tests should be undertaken if adverse clinical signs are witnessed. It is good practice to contact owners once a week for the first 6 weeks of therapy to check for potential
side effects, so if these occur, prompt action can be taken. Use with caution if pre-existing renal or hepatic dysfunction is present.

**Safety and handling:** Cytotoxic drug; see Appendix or specialist texts for further advice on chemotherapeutic agents.

**Contraindications:** Do not use in pregnant or lactating bitches, in dogs <24 months old, in dogs <7 kg, if there are any pre-existing signs of myelosuppression, or if the patient has shown previous hypersensitivity to masitinib.

**Adverse reactions:** Mild to moderate GI reactions (diarrhoea, vomiting) and hair coat changes/hair loss are common. Renal toxicity, anaemia, protein loss, myelosuppression, increased liver enzyme activity, lethargy, cough and lymphadenomegaly have also been described.

**Drug interactions:** Concurrent use of drugs that are highly protein bound or interact with the cytochrome P450 enzyme pathway may increase the risk of adverse side effects.

**DOSES**

See Appendix for chemotherapy protocols.

**Dogs:** All uses: 11–14 mg/kg p.o. q24h (usually 12.5 mg/kg p.o. q24h).

**Cats:** Limited evidence: 50 mg per cat p.o. q24–48h has been administered to healthy cats.

**References**


---

**Mavacoxib**

(Trocoxil) POM-V

**Formulations:** Oral: 6 mg, 20 mg, 30 mg, 75 mg, 95 mg chewable tablets.

**Action:** Selectively inhibits COX-2 enzyme, thereby limiting the production of prostaglandins involved in inflammation. The prolonged duration of action of mavacoxib means that animals should be carefully evaluated for their suitability for NSAID therapy before the onset of treatment.

**Use:**

- Treatment of pain and inflammation associated with degenerative joint disease in dogs at least 12 months old in cases where continuous treatment exceeding 1 month is indicated.

Continuous treatment may have the potential to reduce central sensitization and breakthrough pain. Approximately 5% of dogs are poor metabolizers of mavacoxib. The treatment regimen recommended below is designed to prevent drug accumulation in this sub-population of animals. Preliminary clinical evidence
suggests that treatment can be re-started after a 1-month break from dosing. No recommendations have yet been made regarding whether to give a loading dose (first and second doses separated by 14 days) each time treatment is re-started. If necessary, analgesia should be provided in the 1-month break from treatment using a different class of drug.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not give to dehydrated, hypovolaemic or hypotensive patients or those with GI disease or blood clotting problems. Administration of mavacoxib to animals with renal disease must be carefully evaluated. Liver disease prolongs the metabolism of mavacoxib, leading to the potential for drug accumulation and overdose with repeated dosing, therefore, use is not recommended. Do not give to pregnant animals or animals <12 months or <5 kg.

**Adverse reactions:** Should an animal require anaesthesia or develop any illness while receiving mavacoxib, then care must be taken to avoid dehydration, hypotension and hypovolaemia, and prompt intervention to manage these conditions should be implemented if they occur. Although the duration of action of mavacoxib is prolonged, symptomatic management of any side effects associated with drug administration is recommended only until the clinical signs resolve. There is a small risk that NSAIDs may precipitate cardiac failure in humans and this risk in animals is unknown.

**Drug interactions:** Do not administer concurrently with other NSAIDs and glucocorticoids. Do not administer another NSAID within 1 month of dosing with mavacoxib. Do not administer with other potentially nephrotoxic agents, e.g. aminoglycosides.

**DOSES**

**Dogs:** 2 mg/kg p.o. q14d for 2 doses then q1month for a total maximum of 7 doses. Should be given immediately before or with the dog’s main meal.

**Cats:** Do not use.

**References**


---

**Medetomidine**

*(Domitor, Dorbene, Dormilan, Medetor, Sedastart, Sedator, Sededorm) POM-V*

**Formulations:** Injectable: 1 mg/ml solution.

**Action:** Agonist at peripheral and central alpha-2 adrenoreceptors producing dose-dependent sedation, muscle relaxation and analgesia.
Use:

- Provides sedation and premedication when used alone or in combination with opioid analgesics.
- Medetomidine combined with ketamine is used to provide a short duration (20–30 min) of surgical anaesthesia.

Specificity for the alpha-2 receptor is greater for medetomidine than for xylazine, but is lower than for dexmedetomidine. Medetomidine is a potent drug that causes marked changes in the cardiovascular system including an initial peripheral vasoconstriction that results in an increase in blood pressure and a compensatory bradycardia. After 20–30 min, vasoconstriction wanes while blood pressure returns to normal values. Heart rate remains low due to the central sympatholytic effect of alpha-2 agonists. These cardiovascular changes result in a fall in cardiac output; central organ perfusion is well maintained at the expense of redistribution of blood flow away from the peripheral tissues. Respiratory system function is well maintained; respiration rate may fall but is accompanied by an increased depth of respiration. Oxygen supplementation is advisable in all animals. The duration of analgesia from a 10 μg (micrograms)/kg dose is approximately 1 hour. Combining medetomidine with an opioid provides improved analgesia and sedation. Lower doses of medetomidine should be used in combination with other drugs. Reversal of sedation or premedication with atipamezole shortens the recovery period, which may be advantageous. Analgesia should be provided with other classes of drugs before atipamezole. The authorized dose range of medetomidine for dogs and cats is very broad. High doses (>20 μg/kg) are associated with greater physiological disturbances than doses between 5–20 μg/kg. Using medetomidine in combination with other drugs in the lower dose range can provide good sedation and analgesia with minimal side effects. Similarly, to dexmedetomidine, medetomidine may be used in low doses to manage excitation during recovery from anaesthesia and to provide perioperative analgesia when administered by continuous rate infusion.

Safety and handling: Normal precautions should be observed.

Contraindications: Do not use in animals with cardiovascular or other systemic disease. Use in geriatric patients is not advisable. Do not use in pregnant animals. Do not use when vomiting is contraindicated. Not recommended in diabetic animals.

Adverse reactions: Causes diuresis by suppressing ADH secretion, a transient increase in blood glucose by decreasing endogenous insulin secretion, mydriasis and decreased intraocular pressure. Vomiting after i.m. administration is common, so medetomidine should be avoided when vomiting is contraindicated (e.g. foreign body, raised intraocular pressure). Due to effects on blood glucose, use in diabetic animals is not recommended. Spontaneous arousal from deep sedation following stimulation can occur with all alpha-2 agonists; aggressive animals sedated with medetomidine must still be managed with caution.
Drug interactions: When used for premedication, medetomidine will significantly reduce the dose of all other anaesthetic agents required to maintain anaesthesia. Drugs for induction of anaesthesia should be given slowly and to effect to avoid inadvertent overdose; the dose of volatile agent required to maintain anaesthesia can be reduced by up to 70%. Do not use in patients likely to require or receiving sympathomimetic amines.

DOSES
When used for sedation is generally given as part of a combination. See Appendix for sedation protocols in cats and dogs.

Dogs, Cats: Premedication: 5–20 μg (micrograms)/kg i.v., i.m, s.c. in combination with an opioid. Use lower end of dose range i.v. Doses of 1–2 μg/kg i.v. can be used to manage excitation in the recovery period, although following administration animals must be monitored carefully. A continuous rate infusion of 2–4 μg/kg/h can be used to provide perioperative analgesia and rousable sedation, particularly when administered as an adjunct to opioid-mediated analgesia.

Meglumine antimonate (Glucantime®) POM

Formulations: Injectable: 300 mg/ml solution.

Action: Reported to interfere with glucose metabolism of Leishmania parasites.

Use:
- Treatment of canine leishmaniosis.

Animals may be clinically normal after treatment but parasitological cure is extremely difficult to achieve. Concurrent treatment with allopurinol may be appropriate depending on disease severity/clinical condition. It is advisable to consult specialist texts or seek expert advice when treating leishmaniosis.

Safety and handling: Normal precautions should be observed.

Contraindications: Do not use where severe liver dysfunction, renal dysfunction or heart disease exists.

Adverse reactions: No information available. Pain at injection site has been reported.

Drug interactions: Care with agents that can also cause QT interval prolongation.

DOSES
Dogs: Leishmaniosis: 75–100 mg/kg s.c. q24h or 40–75 mg/kg s.c. q12h until clinical remission achieved. Treat for at least 28 days.

Cats: No information available.

References
Melatonin
(Circadin) POM

Formulations: Oral: 2 mg and 3 mg tablets. Melatonin is also available in many over-the-counter formulations of various sizes and often with other drugs added.

Action: Hormone which is involved in the neuroendocrine control of seasonal hair loss, although the exact mechanism is not known.

Use:
- Treatment of hair cycling disorders in dogs; in particular, the treatment of alopecia X and seasonal flank alopecia.

A 4–6 week trial is recommended, if no growth is noted then treatment should be discontinued. For seasonal flank alopecia, treatment may have to be repeated the following year. The effect of melatonin on hair regrowth in dogs with non-pruritic alopecia of unknown aetiology is variable and every effort should be made to identify the underlying disorder before starting this therapy. Oral bioavailability of melatonin in dogs is unknown.

Safety and handling: Normal precautions should be observed.

Contraindications: No information available.

Adverse reactions: No information available.

Drug interactions: No information available.

DOSES

Dogs: Hair cycling disorders: 3–6 mg p.o. q8h.
Cats: No information available.

References
Frank LA, Hnilica KA and Oliver JW (2006) Adrenal steroid hormone concentrations in dogs with hair cycle arrest (Alopecia X) before and during treatment with melatonin and mitotane. Veterinary Dermatology 1, 278–284

Meloxicam
(Inflacam, Loxicom, Meloxidyl, Meloxivet, Metacam, Rheumocam) POM-V

Formulations: Oral: 0.5 mg/ml suspension for cats, 1.5 mg/ml oral suspension for dogs; 1.0 mg, 2.5 mg tablets for dogs. Injectable: 2 mg/ml solution for cats, 5 mg/ml solution.

Action: Preferentially inhibits COX-2 enzyme thereby limiting the production of prostaglandins involved in inflammation.

Use:
- Alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders and the reduction of postoperative pain and inflammation following orthopaedic and soft tissue surgery.
All NSAIDs should be administered cautiously in the perioperative period as they may adversely affect renal perfusion during periods of hypotension. If hypotension during anaesthesia is anticipated, delay meloxicam administration until the animal is fully recovered from anaesthesia and normotensive. Liver disease will prolong the metabolism of meloxicam leading to the potential for drug accumulation and overdosage with repeated dosing. The oral dose (standard liquid preparation) may be administered directly into the mouth or mixed with food. In the cat, due to the longer half-life and narrower therapeutic index of NSAIDs, particular care should be taken to ensure the accuracy of dosing and not to exceed the recommended dose. Administration to animals with renal disease must be carefully evaluated.

**Safety and handling:** After first opening a bottle of liquid oral suspension use contents within 6 months. Shake the bottle of the oral suspension well before dosing. The shelf-life of a broached bottle of injectable solution is 28 days.

**Contraindications:** Do not give to dehydrated, hypovolaemic or hypotensive patients or those with GI disease or blood clotting problems. Administration of meloxicam to animals with renal disease must be carefully evaluated and is not advisable in the perioperative period. Do not give to pregnant animals or animals <6 weeks of age.

**Adverse reactions:** GI signs may occur in all animals after NSAID administration. Stop therapy if this persists beyond 1–2 days. Some animals develop signs with one NSAID and not another. A 3–5-day wash-out period should be allowed before starting another NSAID after cessation of therapy. Stop therapy immediately if GI bleeding is suspected. There is a small risk that NSAIDs may precipitate cardiac failure in humans and this risk in animals is not known.

**Drug interactions:** Do not administer concurrently or within 24 hours of other NSAIDs and glucocorticoids. Do not administer with other potentially nephrotoxic agents, e.g. aminoglycosides.

**DOSES**

**Dogs:** Initial dose is 0.2 mg/kg s.c., p.o.; if given as a single preoperative injection effects last for 24 hours. Can be followed by a maintenance dose of 0.1 mg/kg p.o q24h.

**Cats:**
- Initial injectable dose is 0.2 mg/kg s.c.; if given as a single preoperative injection effects last for 24 hours. To continue treatment for up to 5 days, may be followed 24 hours later by the oral suspension for cats at a dosage of 0.05 mg/kg p.o.
- **Postoperative pain/inflammation:** single injection of 0.3 mg/kg s.c. has been shown to be safe and efficacious. It is not recommended to follow this with oral meloxicam 24 hours later.
- **Chronic pain:** initial oral dose is 0.1 mg/kg p.o. q24h, which can be followed by a maintenance dose of 0.05 mg/kg p.o q24h. Treatment should be discontinued after 14 days if no clinical improvement is apparent.
References
Aragon CL, Hofmeister EH and Budsberg SC (2007) Systematic review of clinical trials of
treatments for osteoarthritis in dogs. Journal of the American Veterinary Medical
Association 230, 514–521
Leece EA, Brearley JC and Harding EF (2005) Comparison of carprofen and meloxicam
for 72 h following ovariohysterectomy in dogs. Veterinary Anaesthesia and Analgesia 32,
184–192

Melphalan
(Alkeran*) POM

Formulations: Oral: 2 mg tablet. Injection: 50 mg powder in vial
plus diluent.
Action: Forms inter- and intrastrand cross-links with DNA, resulting
in inhibition of DNA synthesis and function.

Use:
• Treatment of multiple myeloma.
• May also be used as a substitute for cyclophosphamide in the
treatment of canine lymphoma and in some rescue protocols for
lymphoma.
• Treatment of some solid tumours (e.g. ovarian carcinoma,
osteosarcoma, pulmonary and mammary neoplasia).

Take care in dosing small dogs using their body surface area as there
is a risk of overdose due to the tablet sizes (tablets should not be
split). Give tablets on an empty stomach.

Safety and handling: Cytotoxic drug; see Appendix and
specialist texts for further advice on chemotherapeutic agents.
Tablets should be stored in a closed, light-protected container under
refrigeration (2–8°C).

Contraindications: Bone marrow suppression, concurrent
infection and impaired renal function.

Adverse reactions: Myelosuppression is dose-limiting toxicity
with leucopenia, thrombocytopenia; effect may be prolonged and
cumulative. GI adverse reactions include anorexia, nausea and
vomiting. Pulmonary infiltrates or fibrosis can also occur. Oral
ulceration is seen in humans.

Drug interactions: Cimetidine decreases the oral bioavailability
of melphalan. Steroids enhance the antitumour effects of
melphalan. In humans ciclosporin enhances the risk of renal toxicity.

DOSES
See Appendix for chemotherapy protocols and conversion of body
weight to body surface area.

Dogs:
• Myeloma: 2 mg/m² p.o. q24h for 1–2 weeks then reduce to 2–4
mg/m² p.o. q48h. Or 0.1 mg/kg p.o. q24h for 10 days then 0.05
mg/kg p.o. q24–48h thereafter. Or 7 mg/m²/day (rounded to the
nearest whole 2 mg tablet) for 5 consecutive days every 21 days.
Often used with prednisolone, see specialist texts for regimes.
• Lymphoma: 20 mg/m\(^2\) q14d.
• Adjunctive treatment of ovarian carcinoma, lymphoreticular neoplasms, osteosarcoma, mammary/pulmonary neoplasia: 2–4 mg/m\(^2\) p.o. q48h.

**Cats:**
• Chronic lymphocytic leukaemia: 2 mg/m\(^2\) p.o. q48h, with or without prednisolone.
• Multiple myeloma: 0.1 mg/kg p.o. q24h for 14 days then q48h until improvement or leucopenia detected. Cats already with leucopenia and anaemia should be treated q72h. Often used with prednisolone, see specialist texts for regimes.

**References**

**Mepivacaine**
(Intra-epicaine) POM-V

**Formulations:** Injectable: 2% solution (only authorized for horses).

**Action:** Local anaesthetic action is dependent on reversible blockade of the sodium channel, preventing propagation of an action potential along the nerve fibre. Sensory nerve fibres are blocked before motor nerve fibres, allowing a selective sensory blockade at low doses.

**Use:**
• Blockade of sensory nerves to produce analgesia following perineural or local infiltration.
• Instillation into joints to provide intra-articular analgesia.

Mepivacaine has less intrinsic vasodilator activity than lidocaine and is thought to be less irritant to tissues. It is of equivalent potency to lidocaine but has a slightly longer duration of action (100–120 min). It does not require addition of adrenaline to prolong its effect.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Mepivacaine should not be injected i.v.

**Adverse reactions:** Inadvertent i.v. injection may cause convulsions and/or cardiac arrest.

**Drug interactions:** No information available.

**DOSES**
**Dogs, Cats:** Inject the minimal volume required to achieve an effect. 2 mg/kg of the 2% solution injected into the elbow joint prior to arthroscopy was found to decrease the haemodynamic response to surgery in dogs. Toxic doses of mepivacaine have not been established in companion animals.
References


Methadone

(Comfortan, Synthadon) POM-V CD

SCHEDULE 2

Formulations: Injectable: 10 mg/ml solution (generic preservative-free preparations are also available). Oral: 10 mg tablets.

Action: Analgesia mediated by the mu opioid receptor.

Use:
- Management of moderate to severe pain in the perioperative period.
- Incorporation into sedative and pre-anaesthetic medication protocols to provide improved sedation and analgesia.
- Methadone may be administered epidurally to provide analgesia; the duration of analgesia following methadone at a dose of 0.1–0.3 mg/kg epidurally is approximately 8 hours in dogs.

Methadone has similar pharmacological properties to morphine, and is useful in similar situations. It provides profound analgesia with a duration of action of 3–4 hours in dogs and cats. Accumulation is likely to occur after prolonged repeated dosing which may allow the dose to be reduced or the dose interval extended. Methadone can be given i.v. without causing histamine release and does not cause vomiting when given to animals preoperatively. Transient excitation may occur when methadone is given i.v. Oral methadone is rarely used in cats and dogs due to a high first-pass metabolism leading to low plasma concentrations after administration. Methadone is absorbed into the systemic circulation after oral transmucosal (OTM) administration to cats and provides pain relief when administered by this route. However, the authorized preparation contains preservative and causes salivation when given by the OTM route. Respiratory function should be monitored when given i.v. to anaesthetized patients. The response to all opioids appears to vary between individual patients, therefore, assessment of pain after administration is imperative. Methadone is metabolized in the liver, and some prolongation of effect may be seen with impaired liver function.

Safety and handling: Normal precautions should be observed.

Contraindications: No information available.

Adverse reactions: In common with other mu agonists methadone can cause respiratory depression, although this is unlikely when used at clinical doses in conscious cats and dogs. Respiratory depression may occur when given i.v. during general anaesthesia due to increased depth of anaesthesia. Vomiting is rare,
although methadone will cause constriction of GI sphincters (such as the pyloric sphincter) and may cause a reduction in GI motility when given over a long period. Methadone crosses the placenta and may exert sedative effects in neonates born to bitches treated prior to parturition. Severe adverse effects can be treated with naloxone.

**Drug interactions:** Other CNS depressants (e.g. anaesthetics, antihistamines, barbiturates, phenothiazines, tranquillisers) may cause increased CNS or respiratory depression when used concurrently with narcotic analgesics.

**DOSES**

When used for sedation is generally given as part of a combination. See Appendix for sedation protocols in cats and dogs.

**Dogs:** Analgesia: 0.1–0.5 mg/kg i.m. or 0.1–0.3 mg/kg i.v. prn.

**Cats:** Analgesia: 0.1–0.5 mg/kg i.m. or 0.1–0.3 mg/kg i.v. prn. Doses in the range of 0.6 mg/kg are appropriate for oral transmucosal administration in cats.

**References**

Ferreira TH, Rezende ML, Mama KR et al. (2011) Plasma concentrations and behavioural, antinociceptive and physiological effects of methadone after intravenous or oral transmucosal administration in cats. American Journal of Veterinary Research 72, 764–771


**Methenamine (Hexamine hippurate) (Hiprex®) POM**

**Formulations:** Oral: 150 mg methenamine + 116 mg monosodium phosphate tablet; 1 g methenamine hippurate (Hiprex) tablet.

**Action:** Urinary antiseptic.

**Use:**

- Long-term control of recurrent urinary tract infections (UTIs).

It is bacteriostatic and mainly indicated for prevention of recurrent infection. It requires an acidic urine to be effective. Evidence for efficacy currently lacking in animals.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Severe renal or hepatic impairment, dehydration and metabolic acidosis.

**Adverse reactions:** Methenamine may cause GI disturbances, bladder irritation or a rash. Often poorly tolerated by cats.

**Drug interactions:** Efficacy is reduced when drugs that alkalinize urine (potassium citrate) are used concurrently.

**DOSES**

**Dogs:** Management of recurrent UTI: 1–3 tablets p.o. q24h (methenamine/sodium acid phosphate) or 500 mg/dog p.o. q12h (methenamine).
Cats: Management of recurrent UTI: 1 tablet p.o. q24h (methenamine/sodium acid phosphate) or 250 mg/cat p.o. q12h (methenamine).

References

Methimazole see Thiamazole

Methionine
(Methionine*) general sale

Formulations: Oral: 500 mg tablets.

Action: Urinary acidifier.

Use:
• Treatment of struvite urolithiasis.

There is an increased risk of acidosis if used with other urinary acidifying treatments. Used to be recommended for paracetamol poisoning, but alternative anti-oxidants now preferred (e.g. acetylcysteine, S-adenosylmethionine).

Safety and handling: Normal precautions should be observed.

Contraindications: Renal failure or severe hepatic disease. Young age.

Adverse reactions: Overdosage may lead to metabolic acidosis.

Drug interactions: No information available.

DOSES
Dogs: Urine acidification: 100 mg/kg p.o. q12h. Adjust the dose until urine pH is 6.5 or lower.
Cats: Urine acidification: 200 mg/cat p.o. q8h. Adjust the dose until urine pH is 6.5 or lower.

References

Methocarbamol
(Robaxin*) POM

Formulations: Oral: 500 mg, 750 mg tablets.

Action: Carbamate derivative of guaifenesin that is a CNS depressant with sedative and musculoskeletal relaxant properties. The mechanism of action has not been fully established; it has no direct action on the contractile mechanism of skeletal muscle, the motor endplate or the nerve fibre.
Use:
- Treatment of tetanus and some toxicities (e.g. pyrethroid, strychnine).
- General muscle relaxant for muscular spasms.

The clearance of methocarbamol is significantly impaired in human patients with renal and hepatic disease. There is very limited literature on the use of methocarbamol in cats; case reports describing the use of methocarbamol by intravenous bolus injection and continuous rate infusion in dogs and cats have been published.

Safety and handling: Normal precautions should be observed.

Contraindications: No information available.

Adverse reactions: Salivation, emesis, lethargy, weakness and ataxia.

Drug interactions: As methocarbamol is a CNS depressant, additive depression may occur when given with other CNS depressant agents.

DOSES
Dogs, Cats: 20–45 mg/kg p.o. q8h. Very high doses may be required for tetanus. It is recommended that the dose does not exceed 330 mg/kg, although serious toxicity or death has not been reported after overdoses.

References
Nielsen C and Pluhar GE (2005) Diagnosis and treatment of hindlimb muscle strain injuries in 22 dogs. Veterinary and Comparative Orthopaedics and Traumatology 18, 247–253

Methoprene (S-Methoprene)
(Acclaim spray, Broadline, Duoflect, Fiprotec, Fleascreen Combo, Frontline Combo/Plus, R.I.P. fleas, Staykill) POM-V, NFA-VPS, general sale

Formulations: Always in combination with other agents. Topical: 9% S-methoprene with fipronil in spot-on pipettes of various sizes (e.g. Frontline Combo/Plus). A combination with eprinomectin, fipronil and praziquantel (Broadline). Environmental: S-methoprene with permethrin (Acclaim) or tetramethrine + permethrin (R.I.P. Fleas) household sprays.

Action: Juvenile hormone analogue that inhibits larval development.

Use:
- Treatment and prevention of flea infestations (*Ctenocephalides canis* and *C. felis*).
- Environmental sprays also have some efficacy against house dust mites *Dermatophagoides farinae* and *D. pteronyssinus*. 
For treatment of flea infestations, the topical products should be applied every 4 weeks to all in-contact cats and dogs (Spot-on products). Bathing between 48 hours before and 24 hours after topical application is not recommended. Minimum treatment interval 4 weeks. Can be used in pregnant and lactating females. Treat infested household as directed with spray; keep away from birds (and fish).

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** None (but see entries for other active agents).

**Adverse reactions:** Local pruritus or alopecia may occur at the site of application. May be harmful to aquatic organisms.

**Drug interactions:** No information available.

**DOSES**

**Dogs, Cats:** Fleas: 1 pipette per animal monthly according to body weight.

**References**


**Methotrexate** (Matrex*, Methotrexate*) **POM**

**Formulations:** Oral: 2.5 mg, 10 mg tablets.

**Action:** An S-phase-specific antimetabolite antineoplastic agent; competitively inhibits folic acid reductase which is required for purine synthesis, DNA synthesis and cellular replication. This results in inhibition of DNA synthesis and function.

**Use:**
- Treatment of lymphoma, although its use in animals is often limited by toxicity.
- Also reports of use in canine atopic dermatitis.

In humans it is used to treat refractory rheumatoid arthritis; however, data are lacking with regards to its use in canine and feline immune-mediated polyarthritis. Monitor haematological parameters regularly.

**Safety and handling:** Cytotoxic drug; see Appendix and specialist texts for further advice on chemotherapeutic agents.

**Contraindications:** Pre-existing myelosuppression, severe hepatic or renal insufficiency, or hypersensitivity to the drug.

**Adverse reactions:** Particularly with high doses GI ulceration, mucositis, hepatotoxicity, nephrotoxicity, alopecia, depigmentation, pulmonary infiltrates, and haemopoietic toxicity may be seen. Low blood pressure and skin reactions are seen in humans. Rarely anaphylaxis can be seen.
Drug interactions: Methotrexate is highly bound to serum albumin and thus may be displaced by phenylbutazone, phenytoin, salicylates, sulphonamides and tetracycline, resulting in increased blood levels and toxicity. Folic acid supplements may inhibit the response to methotrexate (but folate deficiency increases toxicity). Methotrexate increases the cytotoxicity of cytarabine. Cellular uptake is decreased by hydrocortisone, methylprednisolone and penicillins, and is increased by vincristine. Concurrent use of NSAIDs increases the risk of haematological, renal and hepatic toxicity.

DOSES
See Appendix for chemotherapy protocols and conversion of body weight to body surface area.

Dogs: All uses: 2.5–5 mg/m² p.o. twice weekly. Adjust the frequency of dosing according to toxic effects.

Cats: All uses: 2.5 mg/m² p.o. twice weekly. Adjust the frequency of dosing according to toxic effects.

References

Methylene blue see Methylthioninium chloride

Methylprednisolone
(Depo-Medrone, Medrone, Solu-Medrone)
POM-V

Formulations: Injectable: 40 mg/ml depot suspension (Depo-Medrone); 125 mg, 500 mg powder for reconstitution (Solu-Medrone). Oral: 2 mg, 4 mg tablets (Medrone).

Action: Alters the transcription of DNA leading to alterations in cellular metabolism which result in anti-inflammatory, immunosuppressive and antifibrotic effects. Also acts in dogs as an ADH antagonist.

Use: Anti-inflammatory agent with five times the anti-inflammatory potency of hydrocortisone and 20% more potency than prednisolone. On a dose basis, 0.8 mg methylprednisolone is equivalent to 1 mg prednisolone. The oral formulation of methylprednisolone is suitable for alternate-day use. The use of steroids in shock and acute spinal cord injury is controversial and many specialists do not use them. Any value in administering steroids declines rapidly after the onset of shock or injury, while the side effects remain constant and may be substantial. Doses should be tapered to the lowest effective dose. Animals on chronic therapy should be tapered off steroids when discontinuing the drug.
Safety and handling: Normal precautions should be observed.

Contraindications: Do not use in pregnant animals. Systemic corticosteroids are generally contraindicated in patients with renal disease and diabetes mellitus.

Adverse reactions: Prolonged use suppresses the hypothalamic–pituitary axis and causes adrenal atrophy. Catabolic effects of glucocorticoids lead to weight loss and cutaneous atrophy. Iatrogenic hyperadrenocorticism may develop with long-term use. Vomiting and diarrhoea may be seen and Gl ulceration may develop. Glucocorticoids may increase urine glucose levels and decrease serum T3 and T4. Impaired wound healing and delayed recovery from infections may be seen.

Drug interactions: There is an increased risk of Gl ulceration if used concurrently with NSAIDs. Hypokalaemia may develop if amphotericin B or potassium-depleting diuretics (furosemide, thiazides) are administered concomitantly with corticosteroids. Insulin requirements are likely to increase in patients taking glucocorticoids. The metabolism of corticosteroids may be enhanced by phenobarbital or phenytoin and decreased by antifungals (e.g. itraconazole).

DOSES

Dogs:
- Inflammation: initially 1.1 mg/kg i.m. (methylprednisolone acetate depot injection) q1–3wk or 0.2–0.5 mg/kg p.o. q12h.
- Hypoadrenocorticism (acute crisis): 1 mg/kg i.v. once daily until oral supplementation started.
- Immunosuppression: 1–3 mg/kg p.o. q12h reducing to 1–2 mg/kg p.o. q48h.

Cats:
- Asthma: 1–2 mg/kg (depot injection) i.m. q1–3wk.
- Inflammation/flea allergy: 5 mg/kg i.m. (depot injection) every 2 months or 1 mg/kg p.o. q24h reducing to 2–5 mg/cat p.o. q48h.

Methylthioninium chloride
(Methylene blue)
(Methylthioninium chloride*) POM

Formulations: Injectable: 10 mg/ml (1% solution).

Action: Acts as an electron donor to methaemoglobin reductase.

Use:
- Treatment of methaemoglobinaemia.

Use an in-line filter if possible.

Safety and handling: Normal precautions should be observed.

Contraindications: Do not use unless adequate renal function is demonstrated.
Adverse reactions: May cause a Heinz body haemolytic anaemia, especially in cats (relatively contraindicated in this species), and renal failure.

Drug interactions: No information available.

DOSES
Dogs: Methaemoglobinaemia: 1–1.5 mg/kg i.v. slowly once; can be repeated if necessary.
Cats: Methaemoglobinaemia: Use with extreme caution (many consider contraindicated in this species): 1–1.5 mg/kg i.v. slowly once only.

References

Metoclopramide
(Emeprid, Metomotyl, Vomend) POM-V

Formulations: Injectable: 5 mg/ml solution. Oral: 1 mg/ml solution.

Action: Has an antiemetic effect via central dopamine (D2) receptor antagonism, and at higher doses 5HT3 antagonism, at the chemoreceptor trigger zone. Dopamine receptors are more important in the vomiting reflex in dogs than in cats, and so metoclopramide is less likely to be effective in cats. A gastric prokinetic effect is a result of local D2 antagonism and stimulation of muscarinic acetylcholine and 5HT4 receptors leading to increases in oesophageal sphincter pressure, the tone and amplitude of gastric contractions and peristaltic activity in the duodenum and jejunum, and relaxation of the pyloric sphincter. Prokinetic effects appear to be weak and distal intestinal motility is not significantly affected.

Use:
• Treatment of vomiting of many causes.
• Prokinetic effect may be beneficial in reflux oesophagitis.

Safety and handling: Injection is light-sensitive. Obscure fluid bag if used in a constant rate infusion.

Contraindications: Do not use where GI obstruction or perforation is present or for >48 hours without a definitive diagnosis. Do not use in the case of gastrointestinal haemorrhage. Do not use in epileptic patients. Reduce dose by 50% in animals with reduced kidney or liver function. Avoid in dogs with pseudopregnancy. In animals with phaeochromocytoma, metoclopramide may induce a hypertensive crisis.

Adverse reactions: Unusual, although more common in cats than dogs, and probably relate to relative overdosing and individual variations in bioavailability. The observed effects are transient and disappear when treatment is stopped. They include changes in
mentation and behaviour (agitation, ataxia, abnormal positions and/or movements, prostration, tremors, aggression and vocalization). It may also cause sedation. Cats may exhibit signs of frenzied behaviour or disorientation. Very rarely allergic reactions may occur.

**Drug interactions:** The activity of metoclopramide may be inhibited by antimuscarinic drugs (e.g. atropine) and narcotic analgesics. The effects of metoclopramide may decrease (e.g. cimetidine, digoxin) or increase (e.g. oxytetracycline) drug absorption. The absorption of nutrients may be accelerated, thereby altering insulin requirements and/or timing of its effects in diabetics. Phenothiazines may potentiate the extrapyramidal effects of metoclopramide. The CNS effects of metoclopramide may be enhanced by narcotic analgesics or sedatives.

**DOSES**

**Dogs, Cats:** All uses: 0.25–0.5 mg/kg i.v., i.m., s.c., p.o. q12h or 0.17–0.33 mg/kg i.v., i.m., s.c., p.o. q8h or 1–2 mg/kg i.v. over 24 hours as a constant rate infusion.

**References**


---

**Metronidazole**

(Metrobactin, Stomorgyl, Metronidazole*)

**POM-V, POM**

**Formulations:** Injectable: 5 mg/ml i.v. infusion. Oral: 250 mg, 500 mg tablets; 25 mg metronidazole + 46.9 mg spiramycin tablets, 125 mg metronidazole + 234.4 mg spiramycin tablets, 250 mg metronidazole + 469 mg spiramycin tablets (Stomorgyl 2, 10 and 20, respectively); 40 mg/ml oral solution.

**Action:** Synthetic nitroimidazole with antibacterial and antiprotozoal activity. Its mechanism of action on protozoans is unknown but in bacteria it appears to be reduced spontaneously under anaerobic conditions to compounds that bind to DNA and cause cell death. Spiramycin is a macrolide antibacterial that inhibits bacterial protein synthesis.

**Use:**

- Treatment of anaerobic infections, including GI infections caused by *Clostridia* spp.
- Management of hepatic encephalopathy.
- Metronidazole may be used to treat chronic enteropathy due to potential effects on the immune system (modulation of cell-mediated immune responses) although evidence of efficacy in cats and dogs is limited.
It is absorbed well from the GI tract and diffuses into many tissues including bone, CSF and abscesses. Spiramycin (a constituent of Stomorgyl) is active against Gram-positive aerobes including *Staphylococcus*, *Streptococcus*, *Bacillus* and *Actinomyces*. Metronidazole is frequently used in combination with penicillin or aminoglycoside antimicrobials to extend the spectrum of activity. There is a greater risk of adverse effects with rapid i.v. infusion or high total doses. It is no longer used in dogs and cats for the treatment of giardiasis as fenbendazole and others are preferred.

**Safety and handling:** Normal precautions should be observed. Impervious gloves should be used when handling metronidazole and hands washed thoroughly to avoid skin contact.

**Contraindications:** Avoid use during pregnancy (may be a teratogen especially in early pregnancy). Reduce the dose if drug is used in animals with hepatic disease.

**Adverse reactions:** Adverse effects are generally limited to vomiting, CNS toxicity (nystagmus, ataxia, knuckling, head tilt and seizures), hepatotoxicity, neutropenia and haematuria. Excessive salivation/foaming is noted in some cats. Impaired sense of smell has been reported in explosive detection dogs (resolved following withdrawal of drug). Prolonged therapy or the presence of pre-existing hepatic disease may predispose to CNS toxicity.

**Drug interactions:** Phenobarbital or phenytoin may enhance metabolism of metronidazole. Cimetidine may decrease the metabolism of metronidazole and increase the likelihood of dose-related adverse effects. Spiramycin should not be used concurrently with other antibiotics of the macrolide group as the combination may be antagonistic.

**DOSES**

*See Appendix for guidelines on responsible antibacterial use.*

**Dogs, Cats:**

- **Metronidazole:** 7.5–25 mg/kg (standard dose 10–15 mg/kg) p.o. q12h. 10–15 mg/kg s.c., slow i.v. infusion q12h. Injectable solution may be given intrapleurally to treat empyema.

- **Stomorgyl:** 12.5 mg metronidazole + 23.4 mg spiramycin/kg p.o. (equivalent to 1 tablet/2 kg of Stomorgyl 2, 1 tablet/10 kg of Stomorgyl 10 and 1 tablet/20 kg of Stomorgyl 20) q24h for 5–10 days.

**References**


**Mexiletine**  
(Mexitil\*, Ritalmex\*) POM

**Formulations:** Oral: 50 mg, 100 mg, 200 mg capsules. Only available by Special Import Licence in the UK. Alternative special reformulations now available in 50 mg and 100 mg tablets.

**Action:** Class 1b antiarrhythmic agent similar to lidocaine. It is an inhibitor of the inward sodium current (fast sodium channel), which reduces the rate of rise of the action potential. In the Purkinje fibres it decreases automaticity, the action potential duration and the effective refractory period.

**Use:**
- Management of rapid or haemodynamically significant ventricular arrhythmias such as frequent complex ventricular premature complexes or ventricular tachycardia.
- Also proven to be effective in some dogs with supraventricular tachycardia due to the presence of an accessory conduction pathway (bypass tract).

Often effective if there has been a response to i.v. lidocaine. Has been combined with sotalol in dogs not fully responsive to sotalol alone, with enhanced effect. Can be given orally at the same time as beta-blockers, such as atenolol at 0.5–1 mg/kg q12–24h. Not proven to prevent sudden death in dogs with severe ventricular arrhythmias. Use cautiously in patients with severe CHF, sinus node dysfunction, hepatic dysfunction and seizure disorders. Administer oral dose with food to alleviate adverse GI effects.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** 2nd or 3rd degree AV block not treated by pacemaker therapy.

**Adverse reactions:** Nausea, anorexia, vomiting, depression, convulsions, tremor, nystagmus, bradycardia, hypotension, jaundice and hepatitis.

**Drug interactions:** The absorption of mexiletine may be delayed by atropine and opioid analgesics. Mexiletine excretion may be reduced by acetazolamide and alkaline urine, and increased by urinary acidifying drugs (e.g. methionine). The action of mexiletine may be antagonized by hypokalaemia. Cimetidine decreases the rate of mexiletine elimination.

**DOSES**

**Dogs:** Oral: 4–8 mg/kg p.o. q8–12h. Dose for i.v. not established for dogs.

**Cats:** No information available.

**References**

Gelzer ARM, Kraus MS, Rishniw M et al. (2010) Combination therapy with mexiletine and sotalol suppresses inherited ventricular arrhythmias in German Shepherd Dogs better than mexiletine or sotalol monotherapy: a randomized cross-over study. *Journal of Veterinary Cardiology* **12**, 93–106
**Miconazole**
(Adaxio, Aurimic, Easotic, Malaseb, Surolan, Daktarin*) **POM-V, P**

**Formulations:** Topical: 2% shampoo (Adaxio); 23 mg/ml suspension (Aurimic); 2% cream/powder (Daktarin); 15.1 mg/ml with hydrocortisone and gentamicin (Easotic); 2% shampoo (Malaseb); 23 mg/ml suspension with prednisolone and polymyxin (Surolan).

**Action:** Inhibits cytochrome P450-dependent synthesis of ergosterol in fungal cells causing increased cell wall permeability and allowing leakage of cellular contents. Miconazole has activity against *Malassezia, Cryptococcus, Candida* and *Coccidioides*.

**Use:**
- Treatment of fungal skin and ear infections, including dermatophytosis.
- Miconazole shampoo is useful in the treatment of dermatophytosis in cats but concurrent itraconazole administration is required.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.

**Adverse reactions:** No information available.

**Drug interactions:** No information available.

**DOSES**

**Dogs:**
- **Fungal otitis:** 2–12 drops in affected ear q12–24h (Surolan). 1 ml per ear q24h for 5 days (Easotic). 5 drops in affected ear q12h (Aurimic).
- **Dermatophytosis:** apply a thin layer of cream topically to affected area twice daily. Continue for 2 weeks after a clinical cure and negative fungal cultures.
- **Malassezia dermatitis:** shampoo twice weekly until the clinical signs subside and weekly thereafter or as necessary to keep the condition under control (Malaseb, Adaxio).
- **Small localized skin infections:** apply a few drops to affected skin q12h (Aurimic).

**Cats:**
- **Fungal otitis:** doses as for dogs.
- **Dermatophytosis:** topical; doses as for dogs.
- **Microsporum canis:** shampoo twice weekly while administering itraconazole for 6–10 weeks or until coat brushings are negative for the culture of *M. canis*, whichever is the longer (Malaseb). The maximum length of the treatment period should not exceed 16 weeks.
- **Small localized skin infections:** doses as for dogs.

**References**
**Midazolam**
(Buccolam*, Epistatus*, Hypnovel* and several others) **POM**

**Formulations:** Injectable: 1 mg/ml, 2 mg/ml, 5 mg/ml solutions. Oromucosal solution: 5 mg/ml in pre-filled syringes of 0.5 ml, 1 ml, 1.5 ml, 2 ml; 10 mg/ml pre-filled syringe.

**Action:** Causes neural inhibition by increasing the effect of GABA on the GABA\(_A\) receptor, resulting in sedation, anxiolytic effects, hypnotic effects, amnesia, muscle relaxation and anticonvulsive effects. Compared with diazepam it is more potent, has a shorter onset and duration of action (<1 hour in dogs) and is less irritant to tissues.

**Use:**
- Provides sedation with amnesia; as part of a premedication regime or as part of combined anaesthetic protocols.
- Emergency control of epileptic seizures (including status epilepticus).

It provides unreliable sedation on its own, although it will sedate depressed animals. It is often used with ketamine to offset the muscle hypertonicity caused by the ketamine. It is used with opioids and/or acepromazine for pre-anaesthetic medication in the critically ill. If used at induction, it may reduce propofol requirement.

Midazolam can be diluted with saline, but avoid fluids containing calcium as this may result in precipitation of midazolam. Use with caution in severe hypotension, cardiac disease and respiratory disease. As it is metabolized by the cytochrome P450 enzyme system care should be taken in animals with hepatic impairment.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Avoid in neonates.

**Adverse reactions:** In human patients, i.v. administration of midazolam has been associated with respiratory depression and severe hypotension. Excitement may occasionally develop.

**Drug interactions:** Midazolam potentiates the effect of some anaesthetic agents, reducing the dose required, including propofol and some inhalation agents. Concurrent use of midazolam with NSAIDs (in particular diclofenac), antihistamines, barbiturates, opioid analgesics or CNS depressants may enhance the sedative effect. Opioid analgesics may increase the hypnotic and hypotensive effects of midazolam. Erythromycin inhibits the metabolism of midazolam.

**DOSES**

When used for sedation is generally given as part of a combination. See Appendix for sedation protocols in cats and dogs.

**Dogs, Cats:** Emergency management of seizures including status epilepticus: bolus dose of 0.2–0.3 mg/kg i.v. or intrarectally if venous access is not available. Time to onset of clinical effect is
rapid for i.v. use, therefore, repeat q10min if there is no clinical effect up to 3 times. Midazolam may be used in conjunction with diazepam for emergency control of seizures. In dogs, additional doses may be administered if appropriate supportive care facilities are available (for support of respiration). Once the seizures have been controlled, the dog can be maintained on a constant i.v. infusion of 0.3 mg/kg/h.

References

Milbemycin
(Milbactor, Milbemax, Milprazon, Milpro, Milquantel, Nexgard Spectra, Program plus, Trifexis) POM-V

Formulations: Always in combination with other agents. Oral: 2.5 mg and 12.5 mg milbemycin with praziquantel tablets (Milbemax for dogs and several others); 4 mg and 16 mg with praziquantel tablets (Milbemax for cats); 2.3 mg, 5.75 mg, 11.5 mg, 23 mg milbemycin with lufenuron (ratio 20 mg lufenuron:1 mg milbemycin) tablets (Program plus); 1.875 mg, 3.75 mg, 7.5 mg, 15 mg, 30 mg milbemycin with afoxolaner (Nexgard Spectra); 4.5 mg, 7.1 mg, 11.1 mg, 17.4 mg, 27 mg milbemycin with spinosad (Trifexis).

Action: Interacts with GABA and glutamate-gated channels, leading to flaccid paralysis of parasites.

Use:
- Treatment of adult nematode infestation; roundworms (Toxocara canis, T. cati), hookworms (Ancylostoma caninum, A. tubaeforme), whipworms (Trichuris vulpis) and cestodes (Dipylidium caninum, Taenia spp., Echinococcus spp., Mesocestoides spp.).
- It is also used for the prevention of heartworm disease (Dirofilaria immitis) in countries where this parasite is endemic.
- Can also be used to treat nasal mite infestations by weekly administration for 3 weeks.
- For treatment of Angiostrongylus vasorum infections, milbemycin oxime should be given 4 times at weekly intervals. Reduction of the level of infection of Crenosoma vulpis.
- For the treatment of Thelazia callipaeda, milbemycin oxime should be given in 2 treatments, 7 days apart.
- Some efficacy against adult fleas.

Can be used in pregnant and lactating females.

Safety and handling: Normal precautions should be observed.

Contraindications: Do not use in animals suspected of having heartworm disease. Not for use in dogs <2 weeks old or cats <6 weeks old or in any animal <0.5 kg.
Adverse reactions: No information available. The safety of milbemycin in dogs with an MDR1 (ABCB1) mutation has not been demonstrated and these dogs may be at increased risk of adverse effects.

Drug interactions: No information available.

DOSES
Dogs: Nematodes: 0.5 mg milbemycin/kg p.o. q30d. For Angiostrongylus vasorum, administer same dose 4 times at weekly intervals.
Cats: Nematodes: 2 mg milbemycin/kg p.o. q30d.

Miltefosine
(Milteforan) POM-V

Formulations: Oral: 20 mg/ml solution.

Action: Directly toxic to Leishmania and also enhances T cell and macrophage activation.

Use:
• Treatment of canine leishmaniosis leading to a substantial reduction in the parasitic load without complete elimination (similar to other treatment strategies).

Nearly as effective as the allopurinol/meglumine antimonate protocol with fewer serious side effects. A Special Treatment Authorization is required to obtain this product (it is authorized for veterinary use in Spain and Germany). It is recommended to pour the product on to the animal’s feed to reduce digestive side effects. Allopurinol is recommended as an adjunctive treatment and should be continued after the course of miltefosine is complete.

Safety and handling: May cause eye and skin irritation and sensitization: personal protective equipment consisting of gloves and glasses should be worn when handling. Do not shake the vial to avoid foaming.

Contraindications: Do not use during pregnancy, lactation or in breeding animals.

Adverse reactions: Moderate and transient vomiting and diarrhoea are very common and can last up to 7 days. The side effects do not affect the efficacy of the product and do not require discontinuation of treatment or dose change. Overdoses may produce uncontrollable vomiting.

Drug interactions: No information available.

DOSES
Dogs: Leishmaniosis: 2 mg/kg p.o. q24h for 28 days (it is particularly important that the full course is completed and given with allopurinol).
Cats: No information available.
References

Mineral oil see Paraffin

Minocycline (Aknemin*, Minocin*) POM

Formulations: Oral: 50 mg, 100 mg capsules or tablets.
Action: Inhibition of bacterial protein synthesis by binding to the 30S subunit of the bacterial ribosome. Minocycline is the most lipid-soluble tetracycline with a broad spectrum of antibacterial activity in addition to antirickettsial, antimycoplasmal and antichlamydial activity. Due to its superior lipid solubility it tends to have greater clinical efficacy compared with other tetracyclines.
Use: Treatment of bacterial, rickettsial, mycoplasmal and chlamydial diseases. Its rate of excretion is not affected by renal function as it is cleared by hepatic metabolism and is therefore recommended when tetracyclines are indicated in animals with renal impairment. Being extremely lipid-soluble, it penetrates well into prostatic fluid and bronchial secretions. Use with care in animals with hepatic disease. If oral dosing in cats, avoid dry pilling as for doxycycline and follow with a water bolus to reduce the risk of oesophageal erosions. Recommended doses for veterinary species have not been clearly defined and recommendations are made on anecdote and a small number of studies.
Safety and handling: Normal precautions should be observed.
Contraindications: No specific information available. Should not be used in pregnancy or young animals.
Adverse reactions: Nausea, vomiting and diarrhoea. In common with other tetracyclines may cause bone and teeth abnormalities if used in developing animals.
Drug interactions: Absorption of minocycline is reduced by antacids, calcium, magnesium and iron salts and sucralfate. Phenobarbital and phenytoin may increase its metabolism, decreasing plasma levels.
DOSES
See Appendix for guidelines on responsible antibacterial use.
Dogs, Cats: 5–10 mg/kg p.o. q12h.

References
Mirtazapine  
(Zispin)  POM

Formulations: Oral: 15 mg tablets, 15 mg/ml solution. Also available as a transdermal formulation on a named patient basis.

Action: Tricyclic antidepressant that acts on central alpha-2 receptors which leads to increased noradrenaline levels within the brain. Also inhibits several types of serotonin receptors and histamine (H1) receptors.

Use:  
- Appetite stimulation in dogs and cats. Efficacy in cats with stable chronic kidney disease has been demonstrated.  
- Antiemetic role in conjunction with other drugs, but authorized preparations should be used.  
- Anecdotal use beginning to appear concerning its use in the management of social fears in dogs.

Monitor animal carefully when using mirtazapine, particularly if there is also cardiac, hepatic or renal disease.

Safety and handling: Normal precautions should be observed.

Contraindications: Do not use in patients with pre-existing haematological disease.

Adverse reactions: Sedation is common and can be profound. Can affect behaviour in many different ways, increased vocalization and interaction with others. Has been associated with blood dyscrasias in humans.

Drug interactions: Several interactions known in humans, principally involving other behaviour-modifying drugs.

DOSES  
Dogs: 1.1–1.3 mg/kg p.o. q24h.  
Cats: 1.9 mg/cat p.o. q48h (can double dose if needed or increase frequency to q24h but not both).

Misoprostol  
(Cytotec*)  POM

Formulations: Oral: 200 μg tablet.

Action: Cytoprotection of the gastric mucosa: it inhibits gastric acid secretion and increases bicarbonate and mucus secretion, epithelial cell turnover and mucosal blood flow. It prevents, and promotes healing of, gastric and duodenal ulcers, particularly those associated with the use of NSAIDs. Some reports suggest it may not prevent gastric bleeding associated with high doses of methylprednisolone. It may also be useful in the management of canine atopy, although other treatments are likely safer.
Use:
- Protection against NSAID-induced gastric ulceration. In humans, higher doses (20 μg [micrograms]/kg p.o. q6–12h) are used to manage pre-existing NSAID-induced gastric ulceration, while doses of 2–5 μg/kg p.o. q6–8h are used prophylactically to prevent ulceration.
- Has been used in combination with aplepristone to induce abortion in dogs and cats.

Give with food. Combinations with diclofenac are available for humans, but are not suitable for small animals because of different NSAID pharmacokinetics.

Safety and handling: Women who are, or might be, pregnant should avoid handling this drug.

Contraindications: Do not use in pregnant animals.

Adverse reactions: Diarrhoea, abdominal pain, nausea, vomiting and abortion.

Drug interactions: Use of misoprostol with gentamicin may exacerbate renal dysfunction.

DOSES
Dogs:
- Protection against NSAID-induced gastric ulceration: 2–5 μg (micrograms)/kg p.o. q8–12h.
- Atopic dermatitis: 3–6 μg/kg p.o. q8h has been suggested.

Cats: Protection against NSAID-induced gastric ulceration: 5 μg (micrograms)/kg p.o. q8h.

Mitotane (o,p’-DDD) (Lysodren*) POM

Formulations: Oral: 500 mg tablet or capsule.

Action: Necrosis of the adrenal cortex reducing the production of adrenal cortical hormones.

Use:
- Management of pituitary-dependent hyperadrenocorticism (HAC) in dogs. However, other medications are authorized for this condition (see Trilostane).
- Has been used in the management of adrenal-dependent HAC, but with variable success.

Mitotane is available from Europe for animals that have failed trilostane therapy. It should be given with food high in fat/oil to improve its absorption. Closely monitor for any decrease in appetite (typically seen within 3–10 days of therapy); an ACTH stimulation test should be performed to monitor treatment efficacy. In diabetic animals the insulin dose should be reduced by 30%. The addition of prednisolone is generally not
recommended. If switching from trilostane to mitotane, then post-ACTH cortisol concentrations should be >200 nmol/l before starting mitotane. Not recommended in cats as trilostane is more likely to be effective.

**Safety and handling:** Drug crosses skin and mucous membrane barriers. Wear gloves when handling this drug and avoid inhalation of dust.

**Contraindications:** No information available.

**Adverse reactions:** Anorexia, vomiting, diarrhoea and weakness, generally associated with too rapid a drop in plasma cortisol levels. They usually resolve with steroid supplementation. Acute-onset of neurological signs may be seen 2–3 weeks after initiation of therapy, possibly due to rapid growth of a pituitary tumour. Provide supplemental glucocorticoids during periods of stress. Approximately 5% of dogs require permanent glucocorticoid and mineralocorticoid replacement therapy if given mitotane overdose.

**Drug interactions:** Barbiturates and corticosteroids increase the hepatic metabolism of mitotane. There may be enhanced CNS depression with concurrent use of CNS depressants. Spironolactone blocks the action of mitotane. Diabetic animals may have rapidly changing insulin requirements during the early stages of therapy.

**DOSES**

**Dogs:** 30–50 mg/kg p.o. (with/after food) q24h to effect (generally 3–10 days) then 50 mg/kg p.o. q7–14 days in 2–3 divided doses as required. Higher doses (50–150 mg/kg p.o. q24h) may become necessary for adrenal carcinomas.

**Cats:** Similar dose to dogs but efficacy in cats is very variable, with many showing no response at non-toxic levels.

---

**Mitoxantrone**  
*(Novantrone*)  
POM

**Formulations:** Injectable: 2 mg/ml.

**Action:** Antitumour antibiotic which inhibits topoisomerase II. It is cell cycle non-specific, but most active during S phase.

**Use:**

- Treatment of canine and feline lymphoma, squamous cell carcinoma (SCC), and transitional cell carcinoma.
- Its use has also been described in renal adenocarcinoma, fibroid sarcoma, anal gland adenocarcinoma, thyroid carcinoma, prostate carcinoma, mammary gland adenocarcinoma, feline injection site sarcoma, haemangiopericytoma and as a radiosensitizer in cats with oral SCC.

Renal excretion is minimal, so it is far safer to administer to cats with renal insufficiency than doxorubicin, although ancedotally acute renal failure in cats can occur following administration.
Safety and handling: Potent cytotoxic drug that should only be prepared and administered by trained personnel. See Appendix and specialist texts for further advice on chemotherapeutic agents. Mitoxantrone should be stored at room temperature. While the manufacturer recommends against freezing, one study demonstrated that the drug maintained cytotoxic effects when frozen and thawed at various intervals over a 12-month period.

Contraindications: Avoid in patients with myelosuppression, concurrent infection, hepatic disease or impaired cardiac function (although it is likely to be much less cardiotoxic than doxorubicin). Cardiotoxicity is not yet reported in dogs and only very rarely reported in humans.

Adverse reactions: GI signs (vomiting, anorexia, diarrhoea) and bone marrow depression are the most common signs of toxicity. White blood cell counts are generally lowest 10 days after administration. Seizure activity in cats has been reported. In very rare cases there may be discoloration of the urine and sclera (blue tinge).

Drug interactions: Use with extreme caution if administering other myelosuppressive or immunosuppressive agents. Chemically incompatible with heparin.

DOSES
See Appendix for chemotherapy protocols and conversion of body weight to body surface area.

Dogs:
• All uses: 5–6 mg/m² i.v. once every 3 weeks. It should be diluted with up to 50 ml of 0.9% NaCl.
• Intrapleural/intraperitoneal dose: 5 mg/m²–5.5 mg/m² diluted in 0.9% NaCl over a 5–10 min period. In one text this is diluted 1:1 in 0.9% NaCl then again in 1 ml per 4.5 kg body weight (it is advised to consult a veterinary oncology specialist before administering via this route).

Cats: All uses: 5.5–6.5 mg/m² i.v. once every 3 weeks. It should be diluted with up to 50 ml of 0.9% NaCl.

References
Morphine
(Morphine*, Oramorph*) POM CD SCHEDULE 2

Formulations: Injectable: 10 mg/ml, 15 mg/ml, 20 mg/ml, 30 mg/ml solution. Oral: 10 mg, 30 mg, 60 mg, 100 mg tablets. In addition, there are suspensions, slow-release capsules, and granules in a wide range of strengths. Rectal: suppositories are available in a wide range of strengths.

Action: Analgesia mediated by the mu opioid receptor.

Use:
• Management of moderate to severe pain in the perioperative period.
• Morphine can be given as a constant rate infusion to provide analgesia intraoperatively and in the postoperative period.
• Incorporation into sedative and pre-anaesthetic medication protocols to provide improved sedation and analgesia.
• Preservative-free morphine can be administered into the epidural space where it will provide analgesia for up to 24 hours.

Methadone should be used in preference to morphine as the licensed alternative for single or repeated bolus administration to dogs and cats. The greater availability of data describing morphine by continuous rate infusion may justify its use over methadone for this method of administration. Morphine is the reference opioid with which all others are compared. It provides profound analgesia and forms the mainstay of postoperative analgesic protocols in humans. In dogs it has a short duration of action and needs to be given frequently to be effective. Constant rate infusions can also be used to overcome this limitation. The duration of action in cats has not been rigorously evaluated, but it appears to have a duration of action of 3–4 hours. Accumulation is likely to occur after prolonged repeated dosing, which may allow the dose to be reduced or the dose interval extended. Morphine causes histamine release when given rapidly i.v., so it should be diluted and given slowly i.v. It commonly causes vomiting when given to animals preoperatively that are not in pain, therefore morphine should be avoided when vomiting is contraindicated (e.g. animals with raised intraocular pressure). Transient excitation may occur when morphine is given i.v. Oral morphine is rarely used in cats and dogs due to a high first-pass metabolism, leading to a low plasma concentration after oral administration. Respiratory function should be monitored when morphine is given to anaesthetized patients. The response to all opioids appears to vary between individual patients, therefore, assessment of pain after administration is imperative. Morphine is metabolized in the liver, some prolongation of effect may be seen with impaired liver function.

Safety and handling: Normal precautions should be observed.

Contraindications: No information available.
**Adverse reactions:** In common with other mu agonists morphine can cause respiratory depression, although this is unlikely when used at clinical doses in awake cats and dogs. Respiratory depression may occur when given i.v. during general anaesthesia due to increased depth of anaesthesia. Vomiting is common after morphine administration and it causes constriction of GI sphincters (such as the pyloric sphincter) and may cause a reduction in GI motility when given over a long period. Morphine crosses the placenta and may exert sedative effects in neonates born to bitches treated prior to parturition. Severe adverse effects can be treated with naloxone.

**Drug interactions:** Other CNS depressants (e.g. anaesthetics, antihistamines, barbiturates, phenothiazines, tranquillizers) may cause increased CNS or respiratory depression when used concurrently with narcotic analgesics.

**DOSES**

*When used for sedation is generally given as part of a combination. See Appendix for sedation protocols in cats and dogs.*

**Dogs:**
- **Analgesia:** a dose of 0.5 mg/kg i.v., i.m. q2h is required to produce analgesia in experimental models. Pain should be assessed frequently and the dose adjusted based on requirement for analgesia.
- **Continuous rate infusion:** 0.15–0.2 mg/kg/h i.v.
- **Epidural morphine (use Duramorph as it is preservative-free):** 0.1–0.2 mg/kg diluted with 0.26 ml/kg of sterile saline (up to a total maximum volume of 6 ml in all dogs). There is a latent period of 30–60 minutes following epidural administration; duration of action is 18–24 hours.

**Cats:**
- **Analgesia:** 0.1–0.4 mg/kg i.v., i.m. q3–4h. Pain should be assessed frequently and the dose adjusted based on requirement for analgesia.
- **Continuous rate infusions of morphine have not been widely evaluated in cats.**
- **Epidural morphine:** dose as for dogs.

**References**


Moxidectin
(Advocate, Bravecto plus, Endectrid, Moxiclear, Prinovox) POM-V

Formulations: Topical for cat: 10 mg/kg body weight imidacloprid and 1.0 mg/kg body weight moxidectin in spot-on pipette. Topical for dog: 10 mg/kg body weight imidacloprid and 2.5 mg/kg body weight moxidectin in spot-on pipette. Bravecto: Each ml of solution contains 280 mg fluralaner and 14 mg moxidectin (cats).

Action: Interacts with GABA and glutamate-gated channels, leading to flaccid paralysis of parasites.

Use:
- Also used for the prevention of heartworm disease (*Dirofilaria immitis*), cutaneous dirofilariosis (*Dirofilaria repens*), angiostrongylosis, *Crenosoma vulpis* and spirocercosis.
- Product containing fluralaner: flea and tick control 12 weeks, heartworm (*Dirofilaria immitis*) prevention 8 weeks, treatment of *Toxacara cati* and *Ancylostoma tubaeforme*.

For effective treatment of canine sarcoptic mange the product should be applied on 3 occasions at 2-week intervals. Although approved for the treatment of canine demodicosis this product is not uniformly efficacious. Frequent shampooing may reduce the efficacy of the product.

Safety and handling: Normal precautions should be observed. Highly toxic to aquatic organisms.

Contraindications: Not for use in kittens, <9 weeks old, dogs <7 weeks old. Do not use in dogs with class 4 heartworm disease. Moxidectin/fluralaner: not for use in breeding males, kittens <9 weeks of age and cats <1.2 kg.

Adverse reactions: Transient pruritus and erythema at the site of application may occur. Severe effects may be seen if applied to cats with adult heartworm disease. Fluralaner/moxidectin: uncommonly dyspnoea after licking the application site, hypersalivation, emesis, haematemesis, diarrhoea, lethargy, pyrexia, tachypnoea, mydriasis.

Drug interactions: Do not use concurrently with other P-glycoprotein substrates or macrocyclic lactones.
DOSES

*Dogs:*
- **Parasites (many):** 2.5 mg/kg moxidectin. Apply once every month. Minimum dose recommendation 0.1 ml/kg.
- **Demodicosis (severe):** apply product weekly.

*Cats:*
- **Parasites (many):** 1.0 mg/kg moxidectin. Apply once every month. Minimum dose recommendation 0.1 ml/kg.

---

**Mupirocin (Pseudomonic acid A)**
(Bactroban*) POM

**Formulations:** Topical: 2% cream, ointment.

**Action:** Mupirocin has a novel chemical structure unrelated to any other known class of antibiotic. It blocks protein synthesis in bacteria by inhibiting bacterial isoleucyl-tRNA synthetase.

**Use:** Routine use of this agent cannot be advocated since in human medicine this agent is reserved for the eradication of MRSA within the nasal cavity and low-level resistance to mupirocin is emerging. It is generally indicated for the management of resistant infections. Use only if there are no alternative treatment options and do not use for longer than 7 days to limit the development of resistance.

- Management of bacterial skin infections, especially those associated with *Staphylococcus*. As a consequence of this unique mode of action, mupirocin lacks cross-resistance with other antibacterial agents and exhibits activity against multiresistant strains of bacteria.
- Uses for mupirocin include canine pyotraumatic (acute moist) dermatitis, intertrigo (fold pyoderma), callus pyoderma and canine and feline acne.
- Mupirocin inhibits growth of several pathogenic fungi, including a range of dermatophytes and *Pityrosporum*; topical application may be useful in controlling such infections, although data are currently lacking as to its efficacy *in vivo*.

**Safety and handling:** Use impervious gloves for application.

**Contraindications:** Avoid if renal impairment present.

**Adverse reactions:** Application in humans has been associated with a stinging sensation.

**Drug interactions:** No information available.

**DOSES**

*See Appendix for guidelines on responsible antibacterial use.*

*Dogs, Cats:* Apply a thin layer of cream to infected areas q8h. 10 minutes contact time is required for activity.

**References**

Mycophenolate mofetil (MMF, Mycophenolic acid) (CellCept* (MMF), Myfortic* (MPA)) POM

Formulations: Oral: 250 mg capsule, 500 mg tablet, 1 g/5 ml powder for oral suspension (MMF); 180 mg, 360 mg tablets.
Injectable: 500 mg powder for reconstitution and slow i.v. infusion (mycophenolic acid).

Action: Inhibits the enzyme that controls the rate of synthesis of guanine monophosphate in the de novo pathway of purine synthesis. This pathway is important in the proliferation of B and T lymphocytes. This action is similar to azathioprine.

Use:
• Management of immune-mediated disease including immune-mediated haemolytic anaemia, immune-mediated polyarthritis, immune-mediated skin disease, immune-mediated thrombocytopenia and myasthenia gravis.

The use of MPA has not been reported in veterinary medicine. Clinical veterinary experience of this drug is limited; however, in humans, mycophenolate is more lymphocyte-specific and less bone marrow suppressive than azathioprine.

Safety and handling: Cytotoxic drug; see Appendix and specialist texts for further advice on chemotherapeutic agents.

Contraindications: Bone marrow suppression, pre-existing infections.

Adverse reactions: Bone marrow suppression, nausea, vomiting, diarrhoea and an increased incidence of infections (pyoderma, Malassezia). In humans there is a risk for increased lymphoma associated with its use. In humans, headache, hypertension, peripheral oedema, confusion, coughs and tremours are also reported.

Drug interactions: Competes with other drugs that undergo active renal tubular secretion resulting in increased concentration of either drug. Concomitant administration of antacids (such as omeprazole) may decrease absorption.

DOSES
See Appendix for immunosuppression protocols.

Dogs:
• Immune-mediated disease: 8–12 mg/kg (typically 10 mg/kg) p.o., i.v. (give slowly over at least 2 hours) q12h (MMF), the dose can be reduced or given q24h if adverse effects are observed.
• Pemphigus: 7–13 mg/kg p.o. q8h (MMF).

Cats: Immune-mediated haemolytic anaemia: 10 mg/kg p.o. q12h based on limited experience. Other immunosuppressants may be preferable.
References


**Naloxone**
(Naloxone*, Narcan*) **POM**

**Formulations:** Injectable: 0.02 mg/ml, 0.4 mg/ml solutions.

**Action:** Competitive antagonist for opioid receptors, reversing the effects of opioid agonists.

**Use:**
- Treatment of opioid overdose.
- Also used to identify persistent activity of opioid drugs.

Onset of action i.v. is very rapid, but duration is short (30–40 min). Repeated doses or an infusion may be required to manage overdose of longer acting opioids such as morphine and methadone or high-dose fentanyl. Naloxone will also antagonize the effects of endogenous opioids; therefore, it can cause antanalgesic effects in opioid naïve subjects. Administration to animals that could be in pain must therefore be considered carefully. Low dose naloxone i.v. will cause a transient elevation of unconsciousness when persistent opioid activity contributes to an unexpectedly long recovery from anaesthesia.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.

**Adverse reactions:** Indiscriminate use in animals that have undergone major surgery or trauma will expose the recipient to acute severe discomfort. In such cases the effects of opioid overdose (respiratory depression) should be managed by endotracheal intubation and artificial ventilation. Naloxone should be reserved for emergency situations when the effects of opioid overdose are severe.

**Drug interactions:** No information available.

**DOSES**

**Dogs, Cats:** 0.01–0.02 mg/kg i.v.; 0.04 mg/kg i.m., s.c., intratracheal. Naloxone can be administered as a continuous rate infusion at 0.02 mg/kg/h i.v. if a longer duration of opioid antagonism is required.

**References**


---

**Nandrolone**
(Laurabolin, Decadurabolin*) **POM-V, POM**

**Formulations:** Injectable: 25 mg/ml, 50 mg/ml (in oil).

**Action:** Binds to testosterone receptors and stimulates protein synthesis.

**Use:**
- In cases where excessive tissue breakdown or extensive repair processes are taking place.
- Management of aplastic anaemia.
• Management of anaemia associated with renal failure; however, may also have adverse effects on renal failure by increasing protein turnover. Monitor haematology to determine the efficacy of treatment and liver enzyme activities to monitor for hepatotoxicity.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not use in breeding bitches or queens, in pregnant animals or in those with diabetes mellitus.

**Adverse reactions:** Androgenic effects may develop. Use in immature animals may result in early closure of epiphyseal growth plates.

**Drug interactions:** The concurrent use of anabolic steroids with adrenal steroids may potentiate the development of oedema.

**DOSES**
- **Dogs:** 1–5 mg/kg i.m., s.c. q21d. Maximum dose 40–50 mg/dog.
- **Cats:** 1–5 mg/kg i.m., s.c. q21d. Maximum dose 20–25 mg/cat.

---

**Neomycin**  
(Neopen, Maxitrol*, Nivemycin*) **POM-V, POM**

**Formulations:** Oral: 500 mg tablets (Nivemycin). Parenteral: 100 mg/ml neomycin combined with 200 mg/ml penicillin G (Neopen). Topical: many dermatological, ophthalmic and otic preparations contain 0.25–0.5% neomycin.

**Action:** A concentration-dependent antimicrobial agent that inhibits bacterial protein synthesis once it has gained access to the bacterial cell via an oxygen-dependent carrier mechanism. As other aminoglycosides, the concentration-dependent cell-killing mechanism confers a marked post-antibiotic effect.

**Use:** Active primarily against Gram-negative bacteria, although some *Staphylococcus* and *Enterococcus* species are sensitive. All obligate anaerobic bacteria and many haemolytic streptococci are resistant. Since parenteral neomycin is extremely nephrotoxic and ototoxic it is used topically for infections of the skin, ear, or mucous membranes. It is also used orally to reduce the intestinal bacterial population in the management of hepatic encephalopathy. As with other aminoglycosides it is not absorbed after oral administration unless GI ulceration is present. This drug has been used (often combined with antimuscarinic agents) in the treatment of non-specific bacterial enteritides. However, other antibacterial drugs, if required at all, are better indicated for such use. Neomycin is more active in an alkaline environment.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** For systemic use, do not use in animals with pre-existing renal disease. Do not use ear preparations if the tympanum is ruptured.
Adverse reactions: Systemic toxicity, ototoxicity and nephrotoxicity may very occasionally occur following prolonged high-dose oral therapy or where there is severe GI ulceration/inflammatory bowel disease, as sufficient neomycin may be absorbed. Nephrotoxicity and ototoxicity are potential side effects associated with parenteral use. Some patients may develop a severe diarrhoea/malabsorption syndrome and bacterial or fungal superinfections. Topical ophthalmic preparation may cause local irritation.

Drug interactions: Absorption of digoxin, methotrexate, potassium and vitamin K may be decreased. Other ototoxic and nephrotoxic drugs, e.g. furosemide, should be used with caution in patients on oral neomycin therapy as the combinations are likely to have synergistic toxicity.

DOSES
See Appendix for guidelines on responsible antibacterial use.

Dogs, Cats:
- Oral: 20 mg/kg p.o. q6–8h; or per rectum as a retention enema for management of acute hepatic encephalopathy only. As the drug is not absorbed, it is not an effective treatment for other sites of infection. In stable animals, decrease frequency to q12h.
- Ophthalmic: 1 drop/eye q6–8h.
- Otic: 2–12 drops/ear or apply liberally to skin q4–12h.

**Neostigmine**
(Neostigmine*, Neostigmine/Glycopyrronium bromide*) POM

Formulations: Injectable: 2.5 mg/ml solution (on special order), glycopyrronium bromide 0.5 mg/ml and neostigmine metilsulfate 2.5 mg/ml solution. Oral: 15 mg tablets.

Action: Prolongs the action of acetylcholine at the neuromuscular junction, but with low CNS penetration due to its polar structure. In comparison with edrophonium, it has a slower onset but a longer duration of action of approximately 30 minutes to 2 hours.

Use:
- Treatment of acute myasthenic crises if oral dosing with pyridostigmine is not possible.
- When the availability of edrophonium is restricted, can be used as an alternative diagnostic test for myasthenia gravis.
- Also used to antagonize non-depolarizing neuromuscular blocking agents.

Historically, a dose of 0.05 mg neostigmine has been suggested but there is a more recent report of this dose causing a cholinergic crisis. To reduce the risk, it is recommended that the combined formulation with glycopyrronium is used. If neostigmine is being used to diagnose myasthenia gravis then atropine (0.05 mg/kg i.v.) should be available for immediate administration to control
cholinergic side effects (e.g. salivation, urination). Improvement should be noted within 5–10 minutes, with the effects dissipating within 2–4 hours. Due to its longer duration of effect it is used in the diagnosis of myasthenia gravis when the collapse episodes are brief. In these cases, instead of injecting the anticholinesterase drug after the collapse episodes, the dog is pretreated with neostigmine and then exercised to assess whether the collapse episodes have been abolished. If an overdose of neostigmine has been administered, maintenance of respiration should take priority. Atropine does not antagonize the nicotinic effects, including muscle weakness and paralysis. If muscle twitching is severe, these can be controlled with small doses of a competitive neuromuscular blocker. The cholinesterase reactivator pralidoxime can be used as an adjunct to atropine. Supportive treatment should be provided as required. Use with extreme caution in patients with bronchial disease (especially feline asthma), bradycardia (and other arrhythmias), hypotension, renal impairment or epilepsy.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Contraindicated in mechanical GI or urinary tract obstruction and in peritonitis.

**Adverse reactions:** Primarily due to excessive cholinergic stimulation and most commonly include nausea, vomiting, increased salivation and diarrhoea. Overdosage may lead to muscle fasciculations and paralysis. Severe bradyarrhythmias, even asystole, may occur if neostigmine is used to antagonize neuromuscular block without the co-injection of atropine. Overdosage may lead to a ‘cholinergic crisis’, with both muscarinic and nicotinic effects. These effects may include lacrimation, defecation and urination, miosis, nystagmus, bradycardia and other arrhythmias, hypotension, muscle cramps, fasciculations, weakness and paralysis, respiratory signs and increased bronchial secretion combined with bronchoconstriction. CNS side effects include ataxia, seizures and coma.

**Drug interactions:** Effect may be antagonized by drugs with neuromuscular blocking activity, including aminoglycosides, clindamycin and halogenated inhalational anaesthetics. Drugs that may increase the clinical severity of myasthenia gravis may reduce the effectiveness of neostigmine treatment in these cases, including quinine and related compounds and beta-blockers. Concurrent use of neostigmine and beta-blockers may result in bradycardia. Neostigmine, as well as other anticholinesterases, inhibits the metabolism of suxamethonium, thereby prolonging and enhancing its clinical effect; combined use is not recommended. Neostigmine antagonizes the effect of non-depolarizing muscle relaxants. Antimuscarinic drugs such as atropine antagonize the muscarinic effects of neostigmine.

**DOSES**

**Dogs:**
- **Diagnosis of myasthenia gravis:** 0.02 mg/kg i.v of neostigmine (in combination with glycopyrrolate). If there is no response
within 4 hours and no apparent side effects, then the test can be repeated using 0.03 mg/kg.

- **Treatment of myasthenia gravis if pyridostigmine is not available or oral medication cannot be given due to regurgitation:** 0.04 mg/kg i.m, s.c. q6h.
- **Myasthenic crisis:** 0.01–0.1 mg/kg i.v., i.m., s.c., interval dependent upon duration of response. For longer term use 0.1–0.25 mg/kg p.o. q4h (total daily dose not to exceed 2 mg/kg).
- **Antagonism of non-depolarizing neuromuscular blocking agents:** neostigmine (0.05 mg/kg) is mixed with glycopyrronium (0.01 mg/kg) and injected i.v. over 2 min, once signs of spontaneous recovery from ‘block’, e.g. diaphragmatic ‘twitching’, are present. Continued ventilatory support should be provided until full respiratory muscle activity is restored. If glycopyrronium is unavailable, atropine (0.04 mg/kg) is given i.v., followed by neostigmine (0.05 mg/kg) as soon as heart rate rises.

**Cats:**
- **Myasthenic crisis:** use not reported in cats but extrapolation from dogs seems reasonable.
- **Antagonism of non-depolarizing neuromuscular blocking agents:** doses as for dogs.

**References**

**Niacinamide** see **Nicotinamide**

**Nicotinamide** *(Niacinamide, Vitamin B3)*
(Numerous trade names) general sale

**Formulations:** Oral: 50 mg, 250 mg tablets.

**Action:** Blocks antigen-induced histamine release, inhibits phosphodiesterase activity and protease release.

**Use:** Has been used in combination with oxytetracycline/tetracycline or doxycycline in the management of certain immune-mediated dermatoses such as lupoid onychodystrophy, discoid lupus erythematosus and pemphigus foliaceus.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not use nicotinic acid (niacin) as it causes vasodilation.

**Adverse reactions:** May cause mild GI irritation.

**Drug interactions:** No information available.
DOSES

**Dogs:** Immunomodulation: 250 mg/dog q8h (dogs up to 25 kg), 500 mg/dog q8h (dogs >25 kg). Taper to effect.

**Cats:** No information available.

References

Wiemelt SP, Goldschmidt MH, Greek JS et al. (2004) A retrospective study comparing the histopathological features and response to treatment in two canine nasal dermatoses, DLE and MCP. *Veterinary Dermatology* 15, 341–348

**Nitenpyram**

*(Bob Martin Flea Tablets, Capstar, Johnson’s 4 Fleas)* **AVM-GSL**

**Formulations:** Oral: 11.4 mg, 57 mg tablets.

**Action:** Post-synaptic binding to insect nicotinic receptors leads to insect paralysis and death. Kills fleas on animal within 30 minutes.

**Use:**

- Fleas on dogs and cats.

Should be used as part of a fully integrated flea control programme. All animals in the affected household should be treated. Safe in pregnancy and lactation.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not use 11.4 mg tablet in animals <1 kg or 4 weeks old. Do not use the 57 mg tablet in dogs <11 kg.

**Adverse reactions:** Transient increase in pruritus may be seen after administration due to fleas reacting to the product.

**Drug interactions:** No information available.

**DOSES**

**Dogs, Cats:** Fleas: 1 mg/kg once (minimum dose) or q24h.

**Nitrofurantoin**

*(Furadantin*, Nitrofurantoin*) **POM**

**Formulations:** Oral: 50 mg, 100 mg tablets; 25 mg/5 ml suspension.

**Action:** Reacts with bacterial nitroreductase enzymes to form products that interact with bacterial DNA and cause strand breakage.

**Use:** Urinary tract infections especially those caused by multidrug resistant organisms, confirmed-sensitive to nitrofurantoin. Active against many Gram-positive and Gram-negative bacteria. Well absorbed following oral administration but rapidly excreted in urine. Therapeutic levels are **only** attained in the urinary tract and not in
serum or tissues (not appropriate for treatment of pyelonephritis or any infections outside of the urinary tract). The concentration of nitrofurantoin is highest in alkaline urine; however, urine should not be alkalinized as the activity of nitrofurantoin is significantly decreased. Use is limited due to toxicity and concerns about mutagenicity and carcinogenicity.

**Safety and handling:** Mutagenic so wear gloves when handling.

**Contraindications:** Do not use in patients with significant renal impairment, as serum levels will rise and give an increased risk of serious toxicity. Since nitrofurans are mutagenic, they should not be given to pregnant animals.

**Adverse reactions:** In humans, may rarely cause a peripheral neuritis, pulmonary complications, hepatotoxicity, emesis, diarrhoea and GI bleeding. High oral doses may cause thrombocytopenia, anaemia and leucopenia, with prolonged bleeding times.

**Drug interactions:** The bioavailability of nitrofurantoin may be increased by antimuscarinic drugs and food as they delay gastric emptying time and increase absorption of this weak acid from the stomach. Antagonism may be observed with fluoroquinolones. May increase the hyperkalaemic effects of spironolactone.

**DOSES**

See Appendix for guidelines on responsible antibacterial use.

**Dogs, Cats:** For urinary tract infections only: 4.4–5 mg/kg p.o. q8h.

**References**


---

**Nitroglycerin(e)** see **Glyceryl trinitrate**

**Nitrous oxide**

(Entonox*, Nitrous oxide*) **POM**

**Formulations:** Inhalational: 100% nitrous oxide (N₂O) gas. Entonox is N₂O plus oxygen.

**Action:** Causes CNS depression.

**Use:**

- Used with oxygen to carry volatile anaesthetic agents such as isoflurane for the induction and maintenance of anaesthesia.
- N₂O reduces the concentration of inhalant agent required to maintain anaesthesia.

Administration of N₂O at the beginning of volatile agent anaesthesia increases the speed of uptake of volatile agent from the alveoli (via the 2nd gas effect and concentration effect), hastening attainment of a stable plane of volatile agent anaesthesia. Oxygen must be
supplemented for 5–10 minutes after N₂O is discontinued to prevent diffusion hypoxia. N₂O causes minimal respiratory and cardiovascular effects and is a useful addition to a balanced anaesthesia technique. A minimum oxygen concentration of 30% is required during anaesthesia. The inspired concentration of oxygen may fall to critically low levels when N₂O is used in rebreathing circuits during low flow rates. Do not use in such systems unless the inspired oxygen concentration can be measured on a breath-by-breath basis.

**Safety and handling:** Prolonged exposure can have serious adverse effects on human health. Scavenging is essential. N₂O is not absorbed by charcoal in passive scavenging systems utilizing activated charcoal.

**Contraindications:** Do not give to patients with air-filled spaces within the body, e.g. pneumothorax or gastric dilatation. N₂O will cause a rapid expansion of any gas-filled space, increasing volume or pressure. Do not give to animals with marked respiratory compromise, due to the risks of hypoxia. Do not give to animals with raised intracranial pressure due to an increase in cerebral blood flow associated with administration.

**Adverse reactions:** The cobalt ion present in vitamin B12 is oxidized by N₂O so that it is no longer able to act as the cofactor for methionine synthase. The result is reduced synthesis of methionine, thymidine, tetrahydrofolate and DNA. Exposure lasting only a few hours may lead to megaloblastic changes in bone marrow but more prolonged exposure (a few days) may result in agranulocytosis.

**Drug interactions:** No information available.

**DOSES**

**Dogs, Cats:** Inspired concentrations of 50–70%.

**References**


---

**Nystatin**

*(Canaural, Nystan*, Nystatin*) **POM-V, POM**

**Formulations:** Oral: 100,000 IU/ml suspension. Topical: various products.

**Action:** Binds to ergosterol, a major component of the fungal cell membrane, and forms pores in the membrane that lead to potassium leakage and death of the fungus.

**Use:** Antifungal agent with a broad spectrum of activity but noted for its activity against *Candida*, particularly *C. albicans*. Not absorbed from the GI tract.
Safety and handling: Normal precautions should be observed.  
Contraindications: No information available.  
Adverse reactions: No information available.  
Drug interactions: No information available.  

DOSES  
Dogs, Cats: Topical antifungal therapy: apply to affected areas q8–12h.

References  
**Oclacitinib**
*(Apoquel)* POM-V

**Formulations:** Oral: 3.6 mg, 5.4 mg, 16 mg tablets.

**Action:** Inhibits janus-kinases (particularly JAK1) thereby inhibiting the function of a variety of cytokines, particularly proinflammatory cytokines associated with the allergic response.

**Use:**
- For the treatment of pruritus associated with allergic dermatitis in dogs.

Dogs receiving long-term oclacitinib should be monitored regularly with complete blood counts and serum biochemistry. The optimum dose, pharmacokinetics and safety profile of oclacitinib in cats have not been studied in detail.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** For use in dogs >12 months old and >3 kg body weight. Not to be used during pregnancy or lactation.

**Adverse reactions:** Diarrhoea, vomiting, anorexia, new cutaneous or subcutaneous swellings, lethargy, polyphagia, polydipsia and increased aggression have all been reported. May increase susceptibility to infection and demodicosis. May increase the incidence of histiocytomas. Proteinuria has been reported in dogs on chronic therapy.

**Drug interactions:** No information available.

**DOSES**

*Dogs, Cats:* Atopic dermatitis: 0.4–0.6 mg/kg p.o. q12h for 14 days, then q24h for maintenance.

**References**


---

**Octreotide**
*(Sandostatin*, *Sandostatin LAR*) POM

**Formulations:** Injectable: 50 μg/ml, 100 μg/ml, 200 μg/ml, 500 μg/ml solutions; depot preparation: 10 mg, 20 mg, 30 mg vials.

**Action:** Somatostatin analogue that inhibits the release of several hormones.
Use:
- Management of pancreatic endocrine tumours (e.g. insulinoma, gastrinoma).
- Management of acromegaly.

Research suggests that octreotide is not useful in most insulinomas. Tumours not expressing somatostatin receptors will not respond. In humans, doses up to 200 μg/person q8h are used. Similar doses of the aqueous preparation may be required in animals, but dosages for the depot preparation are not known. Newer somatostatin analogues such as pasireotide hold more promise for treatment of acromegaly but are expensive.

Safety and handling: Normal precautions should be observed.

Contraindications: No information available.

Adverse reactions: GI disturbances (anorexia, vomiting, abdominal pain, bloating, diarrhoea and steatorrhoea), hepatopathy and pain at injection sites have been recorded in humans.

Drug interactions: No information available.

DOSES
Dogs, Cats: 10–20 μg (micrograms)/animal s.c. q8–12h or 10 μg/kg s.c. q8h.

References

Oestriol see Estriol

Ofloxacin (Exocin*) POM

Formulations: Topical: 0.3% solution in 5 ml bottle.

Action: Concentration-dependent antimicrobial which works by inhibiting the bacterial DNA gyrase enzyme, causing damage to the bacterial DNA.

Use: Fluoroquinolone use should be reserved for infections where culture and sensitivity testing predicts a clinical response and where first- and second-line antimicrobials would not be effective. For ophthalmic use when other antibacterial agents are ineffective. Active against many ocular pathogens, including Staphylococcus and Pseudomonas aeruginosa, although there is increasing resistance among some staphylococcal and streptococcal organisms. Better corneal penetration than ciprofloxacin.
Safety and handling: Normal precautions should be observed.
Contraindications: No information available.
Adverse reactions: May cause local irritation after application.
Drug interactions: No information available.

DOSES
See Appendix for guidelines on responsible antibacterial use.

Dogs, Cats: 1 drop to affected eye q6h; intensive therapy q30–120min for short-term use (1–2 days).

Olsalazine  
(Olsalazine*) POM

Formulations: Oral: 250 mg capsule, 500 mg tablet.

Action: Olsalazine is a dimer of 5-aminosalicylic acid (5-ASA) that is cleaved by colonic bacteria into free 5-ASA, which has a local anti-inflammatory effect.

Use: Management of colitis, especially in patients sensitive to sulfasalazine. Although the incidence of keratoconjunctivitis sicca is much lower than with sulfasalazine, it is still a potential risk, and periodic Schirmer tear tests should be performed.

Safety and handling: Normal precautions should be observed.
Contraindications: Do not use in patients sensitive to salicylates.
Adverse reactions: Keratoconjunctivitis sicca.

Drug interactions: Activity will be potentiated by administration of other NSAIDs.

DOSES
Dogs: All uses: 10–20 mg/kg p.o. q12h.
Cats: No information available.

Omeprazole  
(Gastrogard, Losec*, Mepradec*, Mezzopram*, Zanprol*) POM-V, POM

Formulations: Oral: 10 mg, 20 mg, 40 mg gastro-resistant capsules, gastro-resistant tablets, MUPS (multiple unit pellet system) tablets. Injectable: 40 mg vial for reconstitution for i.v. injection. Powder for solution for infusion must only be dissolved in either 100 ml of 0.9% NaCl or 5% dextrose. Powder should be initially dissolved in 5 ml of liquid to dissolve the powder then immediately diluted to 100 ml. Do not use if any particles are present in the reconstituted solution. Once reconstituted, stability has been demonstrated for
12 hours when dissolved in NaCl 0.9% solution and for 6 hours in 5% glucose when reconstituted under controlled aseptic conditions and stored below 25°C. Chemical and physical in-use stability has also been demonstrated for 24 hours at 2–8°C in both NaCl 0.9% solution and 5% glucose.

**Action:** Proton-pump inhibitor.

**Use:**
- Management of gastric and duodenal ulcers, oesophagitis, and hypersecretory conditions secondary to gastrinoma (Zollinger–Ellison syndrome) or mast cell neoplasia.
- Preoperative administration of omeprazole reduces the incidence of gastro-oesophageal reflux during anaesthesia in dogs.

Gastrogard is licensed for use in equids, but the formulation (370 mg/g paste) makes accurate dosing of small animals impossible. Lansoprazole, rabeprazole and pantoprazole are similar drugs but have no known clinical advantage over omeprazole. Esomeprazole is a newer preparation containing only the active isomer of omeprazole. Studies have shown that omeprazole produces mild increases in canine gastric pH but that the effects are significantly greater than that produced by famotidine, cimetidine or ranitidine. Twice daily administration of omeprazole raises intragastric pH enough to suggest potential therapeutic efficacy for acid-related disease when assessed by criteria used for human patients, but once daily administration does not.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.

**Adverse reactions:** Chronic suppression of acid secretion has caused hypergastrinaemia in laboratory animals, leading to mucosal cell hyperplasia, rugal hypertrophy and the development of carcinoids, and so treatment for a maximum of 8 weeks has been recommended. However, such problems have not been reported in companion animals. Adverse effects do include nausea, diarrhoea, constipation, skin rashes and tooth fractures. An i.v. preparation of rabeprazole causes pulmonary oedema in dogs at high doses.

**Drug interactions:** Omeprazole may enhance the effects of phenytoin. There is a risk of interaction with tacrolimus, mycophenolate mofetil, clopidogrel, digoxin and itraconazole.

**DOSES**

**Dogs:** All uses: 0.5–1.5 mg/kg i.v., p.o. q12–24h for a maximum of 8 weeks.

**Cats:** All uses: 0.75–1 mg/kg p.o. q24h for a maximum of 8 weeks.

**References**


**Ondansetron**  
(Setofilm*, Zofran*) **POM**

**Formulations:**  
**Injectable:** 2 mg/ml solution in 2 ml and 4 ml ampoules. **Oral:** 4 mg, 8 mg tablets; 4 mg/5 ml syrup. **Rectal:** 16 mg suppositories.

**Action:** Potent antiemetic effects through action on the GI tract and the chemoreceptor trigger zone. It was developed for, and is particularly useful in, the control of emesis induced by chemotherapeutic drugs. Its mechanism of action makes it a suitable choice as part of the management of vomiting caused by peripheral emetogenic stimuli (e.g. irritation of the GI tract).

**Use:** Indicated for the management of nausea and vomiting in patients whose signs are not controlled by other drugs (e.g. maropitant, metoclopramide). Dolasetron, granisetron, palanosetron and tropisetron are similar drugs but have yet to be extensively used in companion animals. Oral bioavailability considered to be low. Subcutaneous administration of ondansetron to healthy cats is more bioavailable and results in a more prolonged exposure than oral administration.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Intestinal obstruction.

**Adverse reactions:** Well tolerated. In humans, constipation, headaches, occasional alterations in liver enzymes and, rarely, hypersensitivity reactions have been reported.

**Drug interactions:** Ondansetron may reduce the effectiveness of tramadol and so the dose of tramadol may need to be increased.

**DOSES**

**Dogs, Cats:** All uses: 0.5 mg/kg i.v. loading dose followed by 0.5 mg/kg/h infusion for 6 hours or 0.5–1 mg/kg p.o. q12–24h.

**References**
Sedlacek HS, Ramsey DS, Boucher JF et al. (2008) Comparative efficacy of maropitant and selected drugs in preventing emesis induced by centrally or peripherally acting emetogens in dogs. *Journal of Veterinary Pharmacology and Therapeutics* 31, 533–537

---

**Orbifloxacin**  
(Orbax, Posatex) **POM-V**

**Formulations:** **Oral:** 30 mg/ml suspension. **Otic:** Ear drops containing 8.5 mg/ml orbifloxacin combined with mometasone (steroid) and posaconazole (antifungal).

**Action:** Concentration-dependent inhibition of DNA gyrase meaning that pulse dosing regimens may be effective.
Use: Fluoroquinolone use should be reserved for infections where culture and sensitivity testing predicts a clinical response and where first- and second-line antimicrobials would not be effective. Broad-spectrum agent. Particularly active against mycoplasmas, many Gram-negative organisms and some Gram-positives including Pasteurella, Staphylococcus, Pseudomonas, Escherichia coli, Proteus and Salmonella. The fluoroquinolones are effective against beta-lactamase-producing bacteria. Orbifloxacin is ineffective in treating obligate anaerobic infections. It is a highly lipophilic drug, attaining high concentrations within cells in many tissues and is particularly effective in the management of soft tissue, urogenital (including prostatic) and skin infections. Caution should be exercised before using dose rates above those recommended by the manufacturer.

Safety and handling: Normal precautions should be observed.

Contraindications: Due to concerns regarding cartilage damage, orbifloxacin is contraindicated in giant-breed dogs <18 months old, large breeds <12 months old, and small and medium-sized breeds <8 months old. Should not be used in pregnant or lactating bitches or animals for breeding. Do not use the otic preparation in animals <4 months of age or if the tympanum is not intact.

Adverse reactions: Cartilage abnormalities have been reported with other fluoroquinolones in growing animals. Such abnormalities have not been specifically reported following the use of orbifloxacin. These drugs should be used with caution in epileptics until further information is available for dogs, as they potentiate CNS adverse effects when administered concurrently with NSAIDs in humans. Fluoroquinolones have been associated with retinal blindness in cats (see Enrofloxacin) and, although considered less likely with orbifloxacin, caution should be exercised with higher doses.

Drug interactions: Absorbents and antacids containing cations (Mg²⁺, Al³⁺) may bind fluoroquinolones, preventing their absorption from the GI tract. Their absorption may also be inhibited by sucralfate and zinc salts; separate dosing by at least 2 hours. Fluoroquinolones increase plasma theophylline concentrations. Cimetidine may reduce the clearance of fluoroquinolones and so should be used with caution with these drugs. Some fluoroquinolones may decrease the metabolism and increase nephrotoxicity of ciclosporin and tacrolimus in humans and therefore concurrent use in animals is best avoided until more research has been performed. May increase the action of orally administered anticoagulants.

DOSES
See Appendix for guidelines on responsible antibacterial use.

Dogs: 2.5 mg/kg p.o. q24 for the treatment of bacterial cystitis. 7.5 mg/kg p.o. q24h for the treatment of skin and other soft tissue infections. For the otic preparation: 2–8 drops per ear q24h. The number of drops is determined by the weight of the dog.

Cats: 7.5 mg/kg p.o. q24h for skin and other soft tissue infections.

References
Osaterone  
(Ypozane) POM-V

**Formulations:** Oral: 1.875 mg, 3.75 mg, 7.5 mg, 15 mg tablets.

**Action:** Competitively prevents the binding of androgens to their prostatic receptors and blocks the transport of testosterone into the prostate.

**Use:** Treatment of benign prostatic hypertrophy (BPH) in male dogs. In dogs with BPH associated with prostatitis, osaterone can be administered concurrently with antimicrobials. Quick onset of decrease in size (40% reduction within 2 weeks) without loss of fertility. Non-invasive treatment that can be used in dogs that are not fit for surgical castration or that are still used as stud dogs. Effects of treatment last for about 6 months. Use with caution in dogs with a history of liver disease.

**Safety and handling:** Women of child-bearing age should avoid contact with, or wear disposable gloves when administering, the product.

**Contraindications:** No information available.

**Adverse reactions:** A transient reduction of plasma cortisol concentration may occur; this may continue for several weeks after administration. Appropriate monitoring should be implemented in dogs under stress (e.g. following surgery) or those with hypoadrenocorticism. The response to an ACTH stimulation test may also be suppressed for several weeks after administration of osaterone. Transient increases in appetite and changes in behaviour occur commonly. Other adverse reactions include transient vomiting and/or diarrhoea, polyuria/polydipsia, lethargy and feminization syndrome including mammary gland hyperplasia. Treatment of some dogs with liver disease has resulted in reversible increases in ALT and ALP.

**Drug interactions:** No information available.

**DOSES**

**Dogs:** Benign prostatic hypertrophy: 0.25–0.5 mg/kg q24h for 7 days.

**Cats:** No indication.

**References**

**Oxantel** see **Pyrantel**
**Oxybutynin hydrochloride**  
(Ditropan*, Lyrinel*, Oxybutynin*)  
**POM**

**Formulations:** Oral: 2.5 mg, 3 mg, 5 mg tablets; 5 mg, 10 mg modified-release tablets; 2.5 mg/5 ml, 5 mg/5 ml solution.

**Action:** Works as a urinary antispasmodic with antimuscarinic and spasmolytic effects on smooth muscle.

**Use:** May be useful for the treatment of detrusor hyperreflexia/overactive bladder in cats and dogs.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Limited animal data but in humans contraindications include obstructive GI disease/ileus, gastro-oesophageal reflux/hiatal hernia, glaucoma, cardiac disease, myasthenia gravis and obstructive urinary disease.

**Adverse reactions:** Diarrhoea, constipation, urinary retention and sedation have all been reported in small animals. In humans, other reported adverse effects include dry mouth/eyes, skin reactions, tachycardia, vomiting, palpitations, vomiting and confusion.

**Drug interactions:** Use with caution in patients receiving other anticholinergic agents, azole antifungals, CNS depressants and macrolide antibiotics.

**DOSES**

**Dogs:** Detrusor hyperreflexia (refractory incontinence): 0.2 mg/kg p.o. q8–12h.

**Cats:** Detrusor hyperreflexia: 0.5–1.25 mg per cat p.o. q8–12h.

**Oxypentifylline** see **Pentoxifylline**

**Oxytetracycline**  
(Engemycin, Oxycare)  
**POM-V**

**Formulations:** Injectable: 100 mg/ml solution. Oral: 50 mg, 100 mg, 250 mg tablets.

**Action:** Time-dependent antimicrobial agent inhibiting protein synthesis by inhibiting the 30S ribosomal subunit in bacteria.

**Use:** Active against many Gram-positive and Gram-negative bacteria, rickettsiae, mycoplasmas, spirochaetes and other microbes. One of the less lipid-soluble tetracyclines, it is excreted unchanged in urine and bile and undergoes enterohepatic recirculation. Has been used in combination with nicotinamide in the management of immune-mediated conditions, including discoid lupus erythematosus and lupoid onychodystrophy. Resistance to tetracyclines is widespread.
Safety and handling: Normal precautions should be observed.

Contraindications: The concentrated injectable depot formulations used for cattle and sheep should never be given to small animals. Only use in cats when no other agent is suitable.

Adverse reactions: Include vomiting, diarrhoea, depression, hepatotoxicity (rare), fever, hypotension (following i.v. administration) and anorexia (cats). Prolonged use may lead to development of superinfections. Oral tetracyclines may cause GI disturbances. Although not well documented in veterinary medicine, tetracyclines induce dose-related functional changes in renal tubules in several species, which may be exacerbated by dehydration, haemoglobinuria, myoglobinuria or concomitant administration of other nephrotoxic drugs. Severe tubular damage has occurred following the use of outdated or improperly stored products and occurs due to the formation of a degradation product. Tetracyclines stain the teeth of children when used in the last 2–3 weeks of pregnancy or the first month of life. Although this phenomenon has not been well-documented in animals, it does occur in dogs and it is prudent to restrict the use of tetracyclines in all young animals.

Drug interactions: The bactericidal action of penicillins may be inhibited by oxytetracycline. Antacids containing divalent or trivalent cations (Mg$^{2+}$, Ca$^{2+}$, Al$^{3+}$), food or milk products bind tetracycline, reducing its absorption. Tetracyclines may increase the nephrotoxic effects of methoxyflurane. The GI effects of tetracyclines may be increased if administered concurrently with theophylline products.

DOSES
See Appendix for guidelines on responsible antibacterial use.

**Dogs:** 10 mg/kg i.m., s.c. q24h; 50 mg/kg loading dose, then 25 mg/kg p.o. q12h for up to 5 days. Give oral dose on an empty stomach.

**Cats:** 10 mg/kg i.m., s.c. q24h.

**Oxytocin**
(Oxytocin S) POM-V

Formulations: Injectable: 10 IU/ml solution.

Action: Synthetic oxytocin.

Use:
- Induces contractions during parturition and up to 24 hours postpartum facilitating evacuation of uterine contents.
- Decreases haemorrhage following parturition.
- Promotes milk ‘let-down’.

Before oxytocin is used, it is important to ensure that there is no evidence of obstructive dystocia and that blood calcium levels are adequate. If calcium deficiency is the cause of inertia calcium borogluconate should be administered 20 minutes before oxytocin. Can also be used i.v. diluted in water for injection.
Safety and handling: Store in refrigerator.

Contraindications: Closed cervix.

Adverse reactions: Overstimulation of the uterus can be hazardous to both mother and fetuses.

Drug interactions: Severe hypertension may develop if used with sympathomimetic pressor amines.

DOSES

Dogs:
- Obstetric indications: 0.1–0.5 IU/kg i.v., i.m., s.c. q30min for up to 3 doses.
- Milk let-down: 2–20 IU/dog i.v., i.m., s.c. once.

Cats:
- Obstetric indications: 0.1–0.5 IU/kg i.v., i.m., s.c. q30min for up to 2 doses.
- Milk let-down: 1–10 IU/cat i.v., i.m., s.c. once.
Pamidronate
(Aredia*, Pamidronate*)

Formulations: Injectable: 15 mg, 30 mg, 90 mg powders in vials for reconstitution and i.v. infusion.

Action: Inhibits osteoclast activity and induces osteoclast apoptosis.

Use:
- Treatment of hypercalcaemia (especially associated with vitamin D toxicosis and hypercalcaemia of malignancy).
- Some studies support the use of pamidronate as an adjunctive analgesic for pain associated with bone tumours in dogs.
- In human medicine it is also used to treat osteolytic lesions and bone pain due to bone metastases associated with breast cancer, multiple myeloma and Paget’s disease.

Safety and handling: Normal precautions should be observed.

Contraindications: Renal dysfunction.

Adverse reactions: Can cause renal toxicity, nausea, diarrhoea, hypocalcaemia, hypophosphataemia, hypomagnesaemia and hypersensitivity reactions. In humans, ophthalmic syndromes, bone pain, electrolytes abnormalities, and blood dyscrasias have also been reported.

Drug interactions: Concurrent use of aminoglycosides may result in severe hypocalcaemia. Use with caution with NSAIDs.

DOSES
Dogs: 0.65–2 mg/kg (typically 1 mg/kg) i.v. slow infusion with NaCl 0.9% over 2–4 hours can be repeated q28days if required. Some clinicians advocate 0.9% NaCl i.v. for 2 hours before and after the infusion. For cholecalciferol-induced toxicosis, give on days 1 and 4 post-ingestion.
Cats: 1.0–2.0 mg/kg i.v. slow (over 4 hours) infusion.

References

Pancreatic enzyme supplements
(Lypex*, Pancreatic Enzyme for cats and dogs*, Panzym*, Pro-Enzorb*)

Formulations: Oral: the formulations vary in the amount and type of enzyme present. Readers are referred to individual products for further details.
**Action:** Exogenous replacement enzymes.

**Use:** Pancreatic enzymes (lipase, protease, amylase) are used to control signs of exocrine pancreatic insufficiency (EPI). Fresh raw, or fresh-frozen pig pancreas (approximately 100 g per meal) can also be an effective treatment (and is not a Specified Risk Material) but availability is limited and there is a risk of pathogen ingestion by this method. Non-enteric-coated powders and enteric-coated granules and tablets are available. Efficacy may be augmented by vitamin B12 therapy for any associated hypocobalaminaemia. Concomitant administration of acid blockers is not cost-effective and there is no requirement for pre-incubation with food. Follow dosing with food or water.

**Safety and handling:** Powder spilled on hands should be washed off or skin irritation may develop. Avoid inhaling powder as it causes mucous membrane irritation and may trigger asthma attacks in susceptible individuals. These risks are not associated with enteric-coated pancreatic granules.

**Contraindications:** No information available.

**Adverse reactions:** Contact dermatitis of the lips is occasionally seen with powdered non-coated enzyme and some dogs develop an offensive odour. Non-coated pancreatic enzymes may cause oral or oesophageal ulcers, and so dosing should be followed with food or water. High doses may cause diarrhoea and signs of GI cramping.

**Drug interactions:** The effectiveness may be diminished by antacids (magnesium hydroxide, calcium carbonate).

**DOSES**

**Dogs, Cats:** Use the manufacturer’s recommendations to determine the minimum required initially. The dose should be adjusted to obtain faeces of normal consistency and will thus be variable. When signs are controlled, it is advisable to reduce the dose gradually over a 7-day period in order to determine the minimally effective dose. Lypex capsules must be opened and the contents sprinkled in with food for every meal.

**References**

Batchelor DJ, Noble PJ, Taylor RH et al. (2007) Prognostic factors in canine exocrine pancreatic insufficiency: prolonged survival is likely if clinical remission is achieved. *Journal of Veterinary Internal Medicine* 21, 54–60

---

**Pancuronium** (Pancuronium*) **POM**

**Formulations:** Injectable: 2 mg/ml solution.

**Action:** Inhibits the actions of acetylcholine at the neuromuscular junction by binding competitively to the nicotinic acetylcholine receptor on the postjunctional membrane.

**Use:**
- Provision of neuromuscular blockade during anaesthesia.
• This may be to improve surgical access through muscle relaxation, facilitate positive pressure ventilation, or for intraocular surgery.

Medium to long duration of action (>45 min), although there is marked variation between individuals. Can also have a modest stimulatory effect on the cardiovascular system, causing an increase in heart rate via a vagolytic effect. Monitoring (using a nerve stimulator) and reversal of the neuromuscular blockade is recommended to ensure complete recovery before the end of anaesthesia. Hypothermia, acidosis and hypokalaemia will prolong the duration of action of neuromuscular blockade. Neostigmine is preferred to edrophonium as the reversal agent because of the potency and duration of action of pancuronium.

Safety and handling: Store in refrigerator.

Contraindications: Do not administer unless the animal is adequately anaesthetized and facilities to provide positive pressure ventilation are available.

Adverse reactions: No information available.

Drug interactions: Neuromuscular blockade is more prolonged when pancuronium is given in combination with volatile anaesthetics, aminoglycosides, clindamycin and lincomycin.

DOSES

Dogs, Cats: 0.025–0.075 mg/kg i.v.; initially use a higher dose and repeat doses at increments of 0.01 mg/kg. Repeated doses may be cumulative and lead to difficulty in antagonism.

Pantoprazole
(Pantoprazole*, Protium*) POM

Formulations: Oral: 20 mg, 40 mg gastro-resistant tablets. Injectable: 40 mg powder in vial for i.v. injection.

Action: Reduces gastric acid secretion, under both basal and stimulated conditions. Pharmacological action can last >24 hours.

Use:
• Management of gastric and duodenal ulcers, oesophagitis, and hypersecretory conditions secondary to gastrinoma (Zollinger–Ellison syndrome) or mast cell neoplasia.

To date there is relatively little information available on the use of pantoprazole in dogs or cats. Parenteral pantoprazole must be administered slowly i.v. over at least 2 minutes, preferably more. After reconstitution with 10 ml of 0.9% NaCl the compound is stable for up to 2 hours at room temperature. If further diluted with 100 ml of 5% dextrose, 0.9% NaCl or lactated Ringer’s solution it is stable for up to 22 hours at room temperature. Do not freeze. Do not use the i.v. solution if discoloration or precipitates are seen.
**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not give i.m. or s.c.

**Adverse reactions:** Appears well tolerated. Adverse effects in humans include diarrhoea, headache, hyperglycaemia (rare), and an increased risk of pneumonia. Thrombophlebitis has been associated with i.v. injection.

**Drug interactions:** May affect absorption of drugs requiring low gastric pH for absorption, e.g. itraconazole, ketoconazole.

**DOSES**

**Dogs, Cats:** All uses: 0.7–1.0 mg/kg i.v. over 15 min q24h. Oral dose not established in cats/dogs but likely similar to i.v. dose.

**References**


---

**Papaveretum**

(Omnopon*, Papaveretum*) POM CD

**SCHEDULE 2**

**Formulations:** Injectable: 7.7 mg/ml, 15.4 mg/ml papaveretum solutions; 15.4 mg/ml papaveretum and 0.4 mg/ml hyoscine (scopolamine) solution. 7.7 mg/ml and 15.4 mg/ml solutions provide the equivalent of 5 mg and 10 mg anhydrous morphine per ml, respectively.

**Action:** Analgesia mediated by the mu opioid receptor.

**Use:**

- Management of moderate to severe pain in the perioperative period.
- Incorporation into sedative and pre-anaesthetic medication protocols to provide improved sedation and analgesia.

Papaveretum is a mixture of the alkaloids of opium containing the equivalent of anhydrous morphine 85.5%, anhydrous codeine 6.8% and papaverine 7.8%. It has a similar effect to morphine and is thought to have a 4-hour duration of action. Papaveretum is not widely used to provide postoperative analgesia in dogs and cats and tends to be used in combination with acepromazine to provide good sedation in aggressive dogs. The comparative sedation produced by papaveretum and other mu agonists combined with acepromazine has not been evaluated in rigorous clinical studies. It has not been widely evaluated in experimental or clinical analgesia studies. Methadone should be used in preference to papaveretum as the licensed alternative for single or repeated bolus administration to dogs and cats.
Safety and handling: Normal precautions should be observed.

Contraindications: No information available.

Adverse reactions: In common with other mu agonists papaveretum can cause respiratory depression, although this is unlikely when used at clinical doses in conscious cats and dogs. Respiratory depression may occur when papaveretum is given i.v. during general anaesthesia, due to the increased depth of anaesthesia that accompanies administration. Respiratory function should be monitored when it is given to anaesthetized patients. Vomiting is common after papaveretum administration. It causes constriction of GI sphincters (such as the pyloric sphincter) and may cause a reduction in GI motility when given over a long period. The response to all opioids appears to be very variable between individual patients, therefore, assessment of pain after administration is imperative. Papaveretum is metabolized in the liver; some prolongation of effect may be seen with impaired liver function. Papaveretum crosses the placenta and may exert sedative effects in neonates born to bitches treated prior to parturition. Severe adverse effects can be treated with naloxone.

Drug interactions: Other CNS depressants (e.g. anaesthetics, antihistamines, barbiturates, phenothiazines and tranquillizers) may cause increased CNS or respiratory depression when used concurrently with narcotic analgesics.

DOSES
When used for sedation is generally given as part of a combination. See Appendix for sedation protocols in cats and dogs.

Dogs: Analgesia: 0.2–0.8 mg/kg i.v., i.m., s.c.; use lower doses i.v.; only use higher doses when deep sedation is required.

Cats: Analgesia: 0.2–0.3 mg/kg i.v., i.m., s.c.

Paracetamol (Acetaminophen)
(Pardale-V (paracetamol and codeine phosphate), Paracetamol*, Perfalgan*) P, POM, POM-V

Formulations: Oral: 500 mg tablet; 120 mg/5 ml, 250 mg/5 ml suspensions; 400 mg paracetamol and 9 mg codeine phosphate tablet (Pardale-V); 10 mg/ml injectable solution.

Action: It has been proposed that its antipyretic actions are due to decreased prostaglandin synthesis within the CNS, possibly via indirect actions on the cannabinoid system; however, its exact mechanism of action is unclear.

Use:
• Control of mild to moderate pain.
• Antipyretic action.
• Injectable paracetamol may be useful to provide adjunctive analgesia in dogs during the perioperative period.
There are limited data describing the analgesic efficacy of paracetamol in dogs. Paracetamol has poor anti-inflammatory effects. It is believed to produce few GI side effects and therefore is commonly administered to patients with gastric ulceration, particularly if traditional NSAIDs are contraindicated; however, there are limited clinical data to support this practice. Although common practice in human anaesthesia, the combination of an NSAID and paracetamol to provide perioperative analgesia has not undergone rigorous investigation in dogs in terms of either safety or analgesic efficacy. The licensed oral preparation of paracetamol contains codeine; however, due to a high first-pass metabolism of opioids, this codeine is not bioavailable and therefore does not contribute to the analgesia.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not use in cats as they lack the glucuronyl transferase enzymes required to metabolize the drug.

**Adverse reactions:** Overdose of paracetamol causes liver damage through the production of N-acetyl-p-aminobenzoquinonimine during metabolism, which causes hepatocyte cell death and centrilobular hepatic necrosis. Treatment of overdose with oral methionine or i.v. acetylcysteine is directed at replenishing hepatic glutathione though this treatment is not backed by clinical data. Fatal toxicosis has been recognized in cats due to methaemoglobinemia.

**Drug interactions:** Metoclopramide enhances absorption of paracetamol, thereby enhancing its effects. Drugs which have the capacity to induce cytochrome p450 enzymes, including NSAIDs, may enhance toxicity.

**DOSES**

**Dogs:** 10–20 mg/kg p.o., i.v. q8h. Authorized dose of Pardale-V preparation is 1 tablet per 12 kg body weight (equivalent to 33 mg/kg) q8h. After 7 days the dose should be titrated down to lowest effective dose. For acute pain management, doses at the top of the suggested range (20 mg/kg q8h), for a period not exceeding 5–7 days, have been advocated.

**Cats:** Do not use.

**Paraffin (Liquid paraffin, Mineral oil)**

(Katalax*, Lacri-Lube*, Liquid paraffin oral emulsion*, Simple Eye Ointment*)

**Formulations:** Oral: white soft paraffin paste (Katalax); liquid paraffin (50/50 oil/water mix). **Topical:** 3.5 g, 4 g or 5 g ophthalmic ointment.

**Action:** Paraffin is a laxative; it softens stools by interfering with intestinal water resorption. It is also a lipid-based tear substitute that mimics the lipid portion of the tear film and helps prevent evaporation of tears.
Use:
- Used to manage constipation.
- It is beneficial in the management of keratoconjunctivitis sicca, during general anaesthesia and for eyelid paresis. It is a long-acting ocular lubricant and is used when frequent application is difficult.

Safety and handling: Normal precautions should be observed.
Contraindications: Do not give orally in patients with a reduced gag reflex.
Adverse reactions: As paraffin is tasteless, normal swallowing may not be elicited if syringing orally; thus, inhalation and subsequent lipoid pneumonia are a significant risk. Paraffin ointment may blur vision, although this is not often a problem in dogs/cats.
Drug interactions: Reduced absorption of fat-soluble vitamins may follow prolonged use.

**DOSES**

**Dogs:**
- Constipation: 1–2 tablespoons per meal as required.
- Ocular: apply to eye at night or q6–12h prn.

**Cats:**
- Constipation: adults 25 mm Katalax paste p.o. q12–24h; kittens 10 mm Katalax paste p.o. q12–24h.
- Ocular: apply to eye at night or q6–12h prn.

**Paroxetine**
(Paxil*, Seroxat*) POM

**Formulations:** Oral: 20 mg, 30 mg tablets, 2 mg/ml liquid suspension.

**Action:** Blocks serotonin reuptake in the brain, resulting in antidepressive activity and a raising in motor activity thresholds.

**Use:**
- Treatment of generalized anxiety and impulsivity in dogs.
- Treatment of urine marking in cats, especially when accompanied with overt aggression.

The specific serotonin reuptake inhibitor fluoxetine has been approved for use in dogs, although the veterinary formulation is not currently available; the non-specific serotonin reuptake inhibitor clomipramine is authorized and available for use in dogs. Accordingly, these may be preferable to use for these indications as there is no empirical evidence to support the use of paroxetine over these agents.

Safety and handling: Normal precautions should be observed.
Contraindications: Known sensitivity to paroxetine or other SSRIs, history of seizures. Do not use alongside other serotonergic agents due to risk of serotonin syndrome.
**Adverse reactions:** Possible reactions include lethargy, decreased appetite and vomiting. Trembling, restlessness, GI disturbance and an apparent paradoxical increase in anxiety may occur in some cases. Owners should be warned of a potential increase in aggression in response to medication and frequency of urination should be monitored when used in cats.

**Drug interactions:** Paroxetine should not be used within 2 weeks of treatment with an MAOI (e.g. selegiline) and an MAOI should not be used within 6 weeks of treatment with paroxetine. Paroxetine, like other SSRIs, antagonizes the effects of anticonvulsants and so is not recommended for use with epileptic patients or in association with other agents which lower seizure threshold, e.g. phenothiazines. Caution is warranted if paroxetine is used concomitantly with aspirin or other anticoagulants, since the risk of increased bleeding in the case of tissue trauma may be increased.

Should not generally be used alongside other serotonergic agents given the risk of serotonin syndrome, although use alongside trazodone may be considered in exceptional cases, so long as patient carefully monitored for signs of serotonin syndrome.

**DOSES**

**Dogs:** 1–2 mg/kg p.o. q24h.

**Cats:** 0.5–1 mg/kg p.o. q24h; can be increased to 2 mg/kg p.o. q24h but close monitoring is required.

**References**


---

**Penicillamine**

(Pendramine*, Penicillamine*) **POM**

**Formulations:** Oral: 125 mg, 250 mg tablets.

**Action:** Penicillamine is an orally administered chelating agent that binds copper, mercury and lead. It also binds to cystine.

**Use:**

- Management of copper storage disease in Bedlington Terriers and copper-associated hepatopathy in other susceptible breeds. Penicillamine is not helpful in an acute crisis as copper chelation can take weeks to months.
- Used in cystinuria as it decreases cystine excretion by combining with cystine to form the soluble complex, cystine-D-penicillamine disulphide.
- May be used in the management of lead toxicity, when injecting EDTA is too difficult or long-term chelation is required.

Dogs that fail to tolerate even the lower dose regimes may be pretreated with antiemetic drugs (phenothiazines or antihistamines).
30–60 minutes before penicillamine. Penicillamine is used for treating rheumatoid arthritis in humans, but has not yet been used in immune-mediated erosive arthropathies in companion animals.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Moderate to marked renal impairment and a history of penicillamine-related blood dyscrasias. Penicillamine can reduce gastrointestinal absorption of dietary minerals, including zinc, iron, copper and calcium and, therefore, cause deficiencies with long-term use.

**Adverse reactions:** Anorexia, vomiting, pyrexia and nephrotic syndrome are seen in dogs. Serious adverse effects that have been described in humans given penicillamine include leucopenia, thrombocytopenia, fever, lymphadenopathy, skin hypersensitivity reactions and lupus-like reactions. For this reason weekly initial monitoring including a full blood count and urinalysis is advised. In humans, patients who are allergic to penicillin may react similarly to penicillamine, but cross-sensitivity appears to be rare.

**Drug interactions:** The absorption of penicillamine is decreased if administered with antacids, food, or iron or zinc salts. An increase in the renal and haematological effects of penicillamine have been recorded in humans receiving it with cytotoxic drugs. Concomitant use of NSAIDs and other nephrotoxic drugs may increase the risk of renal damage.

**DOSES**

**Dogs:**
- **Copper storage disease and copper-associated hepatitis:** 10 mg/kg p.o. q12h given on an empty stomach at least 1 hour before feeding.
- **Cystinuria:** 10–15 mg/kg p.o. q12h.
- **Lead poisoning:** patients commonly receive CaEDTA before receiving penicillamine 30 minutes before feeding at 30 mg/kg p.o. q6–8h for 1–2 weeks. Dose may then be reduced to 5 mg/kg p.o. q6–8h if serum lead levels remain high despite the resolution of clinical signs.

**Cats:** **Lead poisoning:** patients commonly receive CaEDTA before receiving penicillamine 30 minutes before feeding at 15 mg/kg p.o. q6–8h for 1 week. Dose may then be reduced to 5 mg/kg p.o. q6–8h if serum lead levels remain high despite the resolution of clinical signs.

**References**
**Penicillin G** (Benzyl penicillin)  
(Crystapen, Depocillin, Neopen, Norocillin)  
POM-V

**Formulations:** Injectable: comes in a variety of salts (sodium, procaine and benzathine), which affect solubility. **Penicillin G sodium** (highly soluble): 3 g powder for reconstitution for i.v. use; **procaine penicillin** (less soluble): 300 mg/ml suspension for s.c. use, slower release. 200 mg/ml combined with 100 mg/ml neomycin for i.m use; procaine penicillin 15% w/v and benzathine penicillin 11.5% w/v combined to provide long-acting preparation.

**Action:** Binds to penicillin-binding proteins involved in cell wall synthesis, decreasing bacterial cell wall strength and rigidity, and affecting cell division, growth and septum formation. As animal cells lack a cell wall the beta-lactam antibiotics are safe. Kills bacteria in a time-dependent fashion.

**Use:** A beta-lactamase-susceptible antimicrobial. Narrow spectrum of activity and susceptible to acid degradation in the stomach. Used parenterally to treat infections caused by sensitive organisms (e.g. *Streptococcus*, *Clostridium*, *Borrelia burgdorferi*, fusospirochaetes). The sodium salt is absorbed well from s.c. or i.m. sites. Procaine penicillin is sparingly soluble, providing a ‘depot’ from which it is slowly released. As penicillin kills in a time-dependent fashion, it is important to maintain tissue concentrations above the MIC for the organism throughout the interdosing interval. Patients with significant renal or hepatic dysfunction may need dosage adjustment.

**Safety and handling:** After reconstitution penicillin G sodium is stable 24 hours when refrigerated.

**Contraindications:** Do not use in animals sensitive to beta-lactam antimicrobials.

**Adverse reactions:** 600 mg of penicillin G sodium contains 1.7 mEq of Na⁺. This may be clinically important for patients on restricted sodium intakes. The i.m. administration of >600 mg/ml may cause discomfort.

**Drug interactions:** The aminoglycosides may inactivate penicillins when mixed in parenteral solutions *in vitro*, but they act synergistically when administered at the same time *in vivo*. Procaine can antagonize the action of sulphonamides and so procaine penicillin G should not be used with them.

**DOSES**
See Appendix for guidelines on responsible antibacterial use.

**Dogs, Cats:**  
Penicillin G sodium: 15–25 mg/kg i.v., i.m. q4–6h;  
Penicillin G procaine: 30 mg/kg s.c. q24h;  
**Penicillin G procaine and benzathine combined:** 15 mg/kg procaine penicillin with 11.25 mg/kg benzathine penicillin equivalent to 1 ml per 10 kg body weight.
**Pentamidine isethionate** *(Pentacarinat*) POM

**Formulations:** Injectable: 300 mg vials of powder for reconstitution.

**Action:** Kills protozoans by interacting with DNA. It is rapidly taken up by the parasites by a high-affinity energy-dependent carrier.

**Use:**
- Treatment of leishmaniosis when resistance to the pentavalent antimony drugs (meglumine antimonate and sodium stibogluconate) has occurred.

Pentamidine is a toxic drug and the potential to cause toxic damage to kidney and liver in particular should be carefully considered prior to use. Seek expert advice before using it to treat leishmaniosis.

**Safety and handling:** Care should be taken by staff handling this drug as it is a highly toxic agent. Similar precautions to those recommended when handling cytotoxic agents used in cancer chemotherapy (see Appendix) should be taken.

**Contraindications:** Impaired liver or kidney function. Never administer by rapid i.v. injection due to cardiovascular effects.

**Adverse reactions:** Pain and necrosis at the injection site, hypotension, nausea, salivation, vomiting and diarrhoea. Hypoglycaemia and blood dyscrasias are also reported in humans.

**Drug interactions:** No information available.

**DOSES**

**Dogs:** Leishmaniosis: 4 mg/kg i.m. q48–72h (seek expert advice on treatment duration).

**Cats:** No information available.

**References**

---

**Pentobarbital (Pentobarbitone)** *(Dolethal, Euthanimal, Euthasal, Euthatal, Euthoxin, Lethobarb, Pentobarbital for euthanasia, Pentoject) POM-V CD SCHEDULE 3

**Formulations:** Injectable: 200 mg/ml, 400 mg/ml, 500 mg/ml as either a blue, yellow or pink non-sterile aqueous solution.

**Action:** CNS depressant: direct action on the medulla results in rapid depression of the respiratory centre followed by cardiac arrest.

**Use:**
- For euthanasia of cats and dogs.
When it is predicted that euthanasia may be problematical (e.g. aggressive patients), it is recommended that premedication with an appropriate sedative is given. The animal should be restrained in order to forestall narcotic excitement until anaesthesia supervenes. This is particularly important with cats. The route of choice is i.v. if possible, but alternatives such as intraperitoneal (preferred) or intrathoracic are possible when venepuncture is difficult to achieve. The intrathoracic route is usually the last resort. There is a risk of injection into the lungs, which causes coughing and distress. Direct injection into a chamber of the heart is rapid, but it may be difficult to locate the heart chambers accurately and repeated attempts could cause unnecessary pain and distress. There is no authorized pentobarbital product in the UK that is suitable for the emergency control of seizures and there are several other, more suitable, products.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Should not be given i.m. as it is painful and slow to act. Do not use solutions intended for euthanasia to try to control seizures.

**Adverse reactions:** Narcotic excitement may be seen with agitated animals. Agonal gasping is sometimes seen.

**Drug interactions:** Antihistamines and opioids increase the effect of pentobarbital.

**DOSES**

*Dogs, Cats: Euthanasia:* 80 mg/kg in debilitated animals, up to 120–160 mg/kg in younger and fitter animals, rapid i.v. injection.

---

**Pentosan polysulphate**

(Cartrophen) **POM-V**

**Formulations:** Injectable: 100 mg/ml solution.

**Action:** Semi-synthetic polymer of pentose carbohydrates with heparin-like properties that binds to damaged cartilage matrix comprising aggregated proteoglycans and stimulates the synthesis of new aggregated glycosaminoglycan (GAG) molecules. Ability to inhibit a range of proteolytic enzymes may be of particular importance. Modulates cytokine action, stimulates hyaluronic acid secretion, preserves proteoglycan content and stimulates articular cartilage blood flow, resulting in analgesic and regenerative effects.

**Use:**
- In dogs, licensed as a disease modifying agent that reduces the pain and inflammation associated with osteoarthritis.
- It has been suggested that pentosan polysulphate may be of benefit in the management of cats suffering from chronic idiopathic, non-obstructive, lower urinary tract disease because cats suffering from this condition have been shown to have reduced concentrations of GAGs within the protective mucosal
layer of the bladder; however, there is currently no evidence to support this contention. There is good evidence to suggest that this drug is of minimal value in acute cases.

Administered by aseptic s.c. injection, using an insulin syringe for accurate dosing. The manufacturer recommends monitoring haematocrit and total solids.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not use if septic arthritis is present or if renal or hepatic impairment exists. As it may induce spontaneous bleeding, do not use in animals with bleeding disorders.

**Adverse reactions:** Pain at the injection site has been reported. Because of its fibrinolytic action the possibility of bleeding from undiagnosed tumours or vascular abnormalities exists.

**Drug interactions:** The manufacturers state that pentosan polysulphate should not be used concurrently with steroids or non-steroidal drugs, including aspirin, or used concomitantly with coumarin-based anticoagulants or heparin. However, many dogs suffering from osteoarthritis that might benefit from pentosan polysulphate treatment are concurrently receiving NSAID therapy. The risk of bleeding associated with concurrent administration of pentosan polysulphate and COX-2 preferential and COX-2 selective NSAIDs is probably low in animals with no history of blood clotting disorders.

**DOSES**

**Dogs:** 3 mg/kg (0.3 ml/10 kg) s.c. q5–7d on four occasions. 10–20 mg per joint intra-articularly in non-septic joints.

**Cats:** Oral formulations available in other countries have been used in cats for osteoarthritis and for chronic refractory cases of feline lower urinary tract disease. The use of the injectable form has not been well reported in this species, one study reports the use of 3 mg/kg s.c. in cats with FLUTD.

**References**


**Pentoxifylline (Oxypentifylline)**

**(Trental*) POM**

**Formulations:** Oral: 400 mg tablet.

**Action:** Reduces blood viscosity. Anti-inflammatory through reduction of TNF-alpha production.

**Use:**

- Treatment of vasculitis and vasculopathies.
- Modest effect in the treatment of atopic dermatitis and contact dermatitis.
**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.

**Adverse reactions:** GI irritation.

**Drug interactions:** There is a possible increased risk of bleeding when pentoxifylline is given with NSAIDs.

**DOSES**

**Dogs:** Vasculopathies: 15 mg/kg q8–12h.

**Cats:** No information available.

**References**


---

**Permethrin**

*(Activyl Tick Plus, Advantix, Frontect, Indorex, Vectra 3D)* POM-V, general sale

**Formulations:** Topical: 480 mg/ml permethrin and indoxacarb (Activyl Tick Plus), 500 mg/ml permethrin and imidacloprid (Advantix); 504 mg/ml permethrin with fipronil (Frontect); 397 mg/ml permethrin with dinotefuran and pyriproxyfen (Vectra 3D), all in spot-on pipettes of various sizes. Environmental spray: permethrin and pyriproxyfen/piperonyl butoxide (Indorex). Also found in many proprietary products.

**Action:** Acts as a sodium ‘open-channel blocker’ resulting in muscular convulsions and death in arthropods. It also repels ticks and insects.

**Use:**

- Treatment and prevention of flea (*Ctenocephalides felis, C. canis*) infestations.
- Has acaricidal (killing) and repellent (anti-feeding) efficacy against tick infestations (*Ixodes ricinus, Rhipicephalus sanguineus, Dermacentor reticulatus*).
- Also used for the treatment of canine biting/chewing lice (*Trichodectes canis*) infestation.

**Safety and handling:** Normal precautions apply. Toxic to aquatic organisms, dogs should not be allowed to swim for 48 hours after application. Care with disposal.

**Contraindications:** Do not use on cats.

**Adverse reactions:** Transient pruritus and erythema at the site of application may occur.

**Drug interactions:** No information available.
DOSES

**Dogs:** Flea control: apply 1 pipette per dog according to body weight. Treatment should be repeated not more frequently than every 4 weeks. Check individual product details.

**Cats:** Do not use.

References


---

**Pethidine (Meperidine)**

*(Pethidine, Demerol*, Meperidine*) **POM, POM-V CD SCHEDULE 2**

**Formulations:** Injectable: 10–50 mg/ml solutions. 50 mg/ml solution is usually used in veterinary practice.

**Action:** Analgesia mediated by the mu opioid receptor.

**Use:**
- Management of mild to moderate pain.
- Incorporation into sedative and pre-anaesthetic medication protocols to provide improved sedation and analgesia.

Pethidine has a fast onset (10–15 min) and short duration (45–60 min) of action. Frequent redosing is required for analgesia. The short duration of action may be desirable in some circumstances (e.g. when a rapid recovery is required or in animals with compromised liver function). It shares common opioid effects with morphine but also has anticholinergic effects, producing a dry mouth and sometimes an increase in heart rate. It causes less biliary tract spasm than morphine, suggesting that it may be useful for the management of pain in dogs and cats with pancreatitis. Due to the concentration of commercially available solutions the injection volume can be 2–3 ml in large dogs, which can cause pain on i.m. injection.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not give i.v. Not advisable to use in animals at risk from histamine release (e.g. some skin allergies, asthma, mast cell tumours).

**Adverse reactions:** Histamine released during i.v. injection causes hypotension, tachycardia and bronchoconstriction. Histamine-mediated reactions may also occur after i.m. injection, resulting in local urticaria. Pethidine crosses the placenta and may exert sedative effects in neonates born to bitches treated prior to parturition. Severe adverse effects can be treated with naloxone.

**Drug interactions:** Other CNS depressants (e.g. anaesthetics, antihistamines, barbiturates, phenothiazines and tranquillizers) may
cause increased CNS or respiratory depression when used concurrently with narcotic analgesics. Pethidine may produce a serious interaction if administered with monoamine oxidase inhibitors (MAOIs). The mechanism of this interaction is not clear but effects include coma, convulsions and hyperpyrexia.

**DOSES**

When used for sedation is generally given as part of a combination. See Appendix for sedation protocols in cats and dogs.

**Dogs:** Analgesia: 2–10 mg/kg i.m., s.c. q1–2h depending on pain assessment.

**Cats:** Analgesia: 5–10 mg/kg i.m., s.c. q1–2h depending on pain assessment.

**References**


---

**Phenobarbital** *(Phenobarbitone)*

*(Epiphen, Epityl, Phenoleptil, Phenobarbital*)

**POM-V, POM CD SCHEDULE 3**

**Formulations:** Oral: 12.5 mg, 15 mg, 25 mg, 30 mg, 50 mg, 60 mg, 100 mg tablets; 4% (40 mg/ml), 15 mg/5 ml solution. **Injectable:** 15 mg/ml, 30 mg/ml, 60 mg/ml, 200 mg/ml solutions (phenobarbital sodium BP).

**Action:** Thought to mediate its antiepileptic effect through affinity for the GABA<sub>A</sub> receptor, resulting in a GABA-ergic effect; GABA being the major inhibitory mammalian neurotransmitter with prolonged opening of the chloride channel. Phenobarbital also blocks the AMPA receptor, inhibiting release of the excitatory neurotransmitter glutamate. This combined potentiation of GABA and inhibition of glutamate leads to reduced neuronal excitability.

**Use:**

- Phenobarbital and imepitoin are the initial medications of choice for the management of epileptic seizures due to idiopathic epilepsy in dogs. The choice of initial medication is guided by patient requirements: phenobarbital is less expensive and more efficacious, while imepitoin has a more rapid onset of action than phenobarbital (does not need to achieve a steady state), does not require the determination of serum concentrations and has a less severe adverse effect profile.
- Also licensed for the management of epileptic seizures due to structural brain disease in dogs.
- Used for the management of epileptic seizures in cats.
- Phenobarbital may also be used in dogs in combination with propranolol and a behaviour modification programme for the control of fears and anxieties, especially those with a large physiological component which may be antagonizing the condition through biofeedback processes.
Phenobarbital is rapidly absorbed after oral administration in dogs; maximal plasma concentrations reached within 4–8 hours. Wide range of elimination half-life (40–90 hours) in different dogs. Steady state serum concentrations are not reached until 7–10 days after treatment is initiated and the full clinical effect of a dose cannot be ascertained until this point. Serum concentrations should be determined after starting treatment or dose alterations, once a steady state has been reached. If <15 μg (micrograms)/ml the dose should be increased accordingly. If seizures are not adequately controlled the dose may be increased up to a maximum serum concentration of 45 μg/ml. Plasma concentrations above this level are associated with increased hepatotoxicity. Blood samples for serum concentration determination should be collected at the same time of day relative to the time of dose administration in dogs on higher daily doses, but timing is not normally important in dogs on a total daily dose of <8 mg/kg. For accuracy of dosing, dogs <12 kg should commence therapy with the oral solution formulation. With chronic therapy, induction of the hepatic microsomal enzyme system results in a decreased half-life, particularly in dogs during the first 6 months of therapy. As a result, the dose may need to be increased. Phenobarbital levels should be assessed every 6–12 months. Any termination of phenobarbital therapy should be performed gradually with a recommended protocol of: reduce the dose by 25% of the original dose each month (month 1: 75% of the original phenobarbital dose; month 2: 50% of the original phenobarbital dose; month 3: 25% of the original phenobarbital dose).

Safety and handling: Normal precautions should be observed.

Contraindications: Do not administer to animals with impaired hepatic function. Not for use in pregnant animals and nursing bitches, although the risk associated with uncontrolled seizures may be greater than the risk associated with phenobarbital. Do not use to control seizures resulting from hepatic disease (e.g. portosystemic shunt), hypoglycaemia or toxic causes where the clinical signs are mediated through the GABA channels (ivermectin and moxidectin toxicity) as this may exacerbate the seizures. Do not administer high doses by i.v. or i.m. injection in animals with marked respiratory depression. When used in combination with propranolol, the normal contraindications of propranolol also apply.

Adverse reactions: Sedation, ataxia, polyphagia and PU/PD. Polyphagia and PU/PD are likely to persist throughout therapy. Ataxia and sedation occur commonly following initiation of therapy but usually resolve within 1 week, although they may continue if high doses are used. Hepatic toxicity is rare but may occur at high serum concentrations (or as a rare idiosyncratic reaction within 2 weeks of starting treatment). Hyperexcitability has been reported in dogs on subtherapeutic dose levels. Haematological abnormalities, including neutropenia, anaemia and thrombocytopenia, may occur. Rarely, it may cause a superficial necrolytic dermatitis. Long-term administration in the absence of hepatotoxicity is associated with: moderate increase in liver size on abdominal radiographs; no
change in liver echogenicity or architecture on ultrasonography; no evidence of morphological liver damage on histology; significant increase in ALP and, to a lesser extent, ALT activity; transiently decreased albumin (up to 6 months after starting therapy) and increased GGT; and no changes in AST, bilirubin or fasting bile acids. Therefore, liver function should be assessed by other parameters, in particular a bile acid assay, persistent decrease in albumin levels, serum AST, bilirubin and ultrasonographic examination of the liver. Phenobarbital treatment does not affect adrenal function tests (ACTH stimulation test and low dose dexamethasone test) despite acceleration of dexamethasone metabolism. Phenobarbital significantly decreases total T4 and free T4, and cholesterol levels tend to increase towards the upper limits of the normal range.

**Drug interactions:** The effect of phenobarbital may be increased by other CNS depressants (antihistamines, narcotics, phenothiazines). Phenobarbital may enhance the metabolism of, and therefore decrease the effect of, corticosteroids, beta-blockers, metronidazole and theophylline. The chronic administration of phenobarbital has been found to alter the binding, bioavailability, metabolism and pharmacokinetics of propranolol, and so long-term use of this combination for the control of anxiety needs to be monitored carefully. It also increases the clearance of levetiracetum. Barbirturates may enhance the effects of other antiepileptics. Cimetidine, itraconazole and chloramphenicol increase serum phenobarbital concentration through inhibition of the hepatic microsomal enzyme system.

**DOSES**

**Dogs:**

- **Initial therapy:** 1–2.5 mg/kg p.o. q12h (authorized dose). However, in one study only 40% of dogs started on this dose achieved therapeutic serum concentrations. Therefore, initial dose recommendation is usually 2.5–3 mg/kg p.o. q12h. Incremental modifications of the initial dose, based on serum concentrations, are essential.

- **Emergency management of status epilepticus or severe cluster seizures in dogs that have not been on maintenance phenobarbital:** aim for a total loading dose of 18–24 mg/kg, followed by a maintenance dose of 2–3 mg/kg q12h. The loading dose is given as an initial 12 mg/kg slow i.v. and then after 20 minutes, two further doses of 4–6 mg/kg slow i.v. 20 minutes apart. Always wait 20 minutes before giving additional doses as CNS levels take 20 minutes to respond, and do not administer if the dog is excessively sedated or has evidence of respiratory depression. Higher doses may be required in very small dogs.

- **Emergency management in dogs that have been on maintenance phenobarbital:** 4–6 mg/kg i.v. or i.m. to increase the blood levels slightly in case these were subtherapeutic. Always take a serum sample for phenobarbital level determination first, before giving the top-up dose.

- **Control of fear and anxiety:** 2–3 mg/kg p.o. q12h with propranolol also at 2–3 mg/kg p.o. q12h.
Cats:
• Initial therapy: 1.5–3 mg/kg p.o. q12h.
• Emergency management: doses as for dogs.

References

**Phenoxybenzamine**
(Dibenylène*, Phenoxybenzamine*) POM

Formulations: Oral: 10 mg capsule. Injectable: 50 mg/ml solution.

Action: An alpha-adrenergic antagonist that irreversibly blocks pre-synaptic and post-synaptic receptors, producing a chemical sympathectomy (interruption of the sympathetic nervous pathway).

Use:
• Reflex dyssynergia or functional urethral obstruction due to urethral spasm.
• Treatment of severe hypertension in animals with phaeochromocytoma prior to surgery to reduce mortality. If concurrent beta-blockers are also used (for severe tachycardia/arrhythmias), only start these once alpha blockade is in place (to avoid a hypertensive crisis).

Use with extreme caution in animals with pre-existing cardiovascular disease.

Safety and handling: Normal precautions should be observed.

Contraindications: No information available.

Adverse reactions: Adverse effects associated with alpha-adrenergic blockade include hypotension, miosis, tachycardia and nasal congestion.

Drug interactions: There is an increased risk of a first dose hypotensive effect if administered with beta-blockers or diuretics. Phenoxybenzamine will antagonize effects of alpha-adrenergic sympathomimetic agents (e.g. phenylephrine).

**DOSES**

*Dogs:*
• Reflex dyssynergia: 0.25–1 mg/kg p.o. q8–24h for a minimum of 5 days.
• Hypertension associated with phaeochromocytoma: 0.25–0.5 mg/kg p.o. q12h for 10–14 days prior to surgery, titrating up to...
an effective dose (maximum of 2.5 mg/kg q12h) as required or administer long term for medical management if adrenalectomy not possible.

**Cats:** 0.5–1 mg/kg p.o. q12h for 5 days before evaluating efficacy.

**References**

---

**Phenylbutazone**  
(Phenylbutazone*) **POM**

**Formulations:** Oral: 100 mg, 200 mg tablets. As licensed form is currently unavailable, other licensed alternatives should be used in preference.

**Action:** Non-selective COX enzyme inhibitor, limiting prostaglandin production.

**Use:**
- Management of mild to moderate pain and inflammation in osteoarthritic conditions.

Not selective for COX-2 and likely to cause more adverse effects than more selective COX-2 inhibitors that have superseded the use of phenylbutazone. Not authorized for preoperative administration to dogs. Liver disease will prolong the metabolism of phenylbutazone, leading to the potential for drug accumulation and overdose with repeated dosing. Administration of phenylbutazone to animals with renal disease must be carefully evaluated. Do not use in cats.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not give to dehydrated, hypovolaemic or hypotensive patients or those with GI disease or blood clotting problems. Do not administer perioperatively until the animal is fully recovered from anaesthesia and normotensive. Do not give to pregnant animals or animals <6 weeks of age.

**Adverse reactions:** GI signs may occur in all animals after NSAID administration. Stop therapy if this persists beyond 1–2 days. Some animals develop signs with one NSAID and not another. A 3–5 day wash-out period should be allowed before starting another NSAID after cessation of therapy. Stop therapy immediately if GI bleeding is suspected. There is a small risk that NSAIDs precipitate cardiac failure in humans and this risk in animals is unknown. Phenylbutazone may infrequently cause bone marrow suppression, including aplastic anaemias. It may also cause false low T3 and T4 values.

**Drug interactions:** Do not administer concurrently or within 24 hours of other NSAIDs and glucocorticoids. Do not administer with other potentially nephrotoxic agents, e.g. aminoglycosides.
DOSES

**Dogs:** 2–20 mg/kg p.o. q8–12h. Maximum dose 800 mg. The manufacturers recommend a starting dose of 10 mg/kg twice daily for 7 days, reducing to 5 mg/kg twice daily thereafter. The 200 mg tablet strength should not be used in dogs weighing <20 kg. The 100 mg tablet strength should not be used in dogs weighing <5 kg.

**Cats:** Do not use.

### Phenylephrine
(Phenylephrine hydrochloride*) **POM**

**Formulations:** **Injectable:** 1% (10 mg/ml) solution. **Ophthalmic:** 2.5%, 10% solution (single-dose vials).

**Action:** Alpha-1 selective adrenergic agonist that causes peripheral vasoconstriction when given i.v., resulting in increased diastolic and systolic blood pressure, a small decrease in cardiac output and an increased circulation time. Directly stimulates the alpha-adrenergic receptors in the iris dilator musculature.

**Use:**
- Used in conjunction with fluid therapy to treat hypotension secondary to drugs or vascular failure.
- When applied topically to the eye, causes vasoconstriction and mydriasis (pupil dilation).
- Ophthalmic uses include mydriasis prior to intraocular surgery (often in conjunction with atropine), differentiation of involvement of superficial conjunctival vasculature from deep episcleral vasculature (by vasoconstriction), and to reduce haemorrhage during ophthalmic surgery.
- It is also used in the diagnosis of Horner’s syndrome (HS) (denervation hypersensitivity) by determining the time to pupillary dilation, following administration of 1% phenylephrine topically to both eyes. Essentially, the shorter the time to pupillary dilation, the closer the lesion to the iris: <20 minutes suggests third-order HS; 20–45 minutes suggests second-order HS; 60–90 minutes suggests first-order HS or no sympathetic denervation of the eye. If 10% phenylephrine is used, mydriasis occurs in 5–8 minutes in post-ganglionic (third-order neuron) lesions.

Phenylephrine is not a cycloplegic in the dog, so its use in uveitis is limited to mydriasis to reduce posterior synechiae formation. It is inappropriate for diagnostic mydriasis because its onset of action is too slow (2 hours in the dog). Vasoconstrictors should be used with care; although they raise blood pressure, they do so at the expense of perfusion of vital organs (e.g. kidney). In many patients with shock, peripheral resistance is already high and to raise it further is unhelpful. Has minimal effects on cardiac beta-adrenergic receptors.

**Safety and handling:** Normal precautions should be observed.
**Contraindications:** No information available. Care in cats and small dogs; use lower concentrate solutions. Do not apply once ophthalmic surgery has started (to avoid direct arterial absorption).

**Adverse reactions:** These include hypertension, tachycardia, and reflex bradycardia. Extravasation injuries can be serious (necrosis and sloughing).

**Drug interactions:** There is a risk of arrhythmias if phenylephrine is used in patients receiving digoxin or with volatile anaesthetic agents. When used concurrently with oxytocic agents the pressor effects may be enhanced, leading to severe hypertension.

**DOSES**

**Dogs:**
- **Hypotension:** correct blood volume then infuse 0.01 mg/kg very slowly i.v. q15min. Continuously monitor blood pressure if possible.
- **Ophthalmic use:** 1 drop approximately 2 hours before intraocular surgery (for mydriasis). 1 drop as a single dose for vasoconstriction. 1 drop of 1% solution to both eyes for diagnosis of Horner’s syndrome.

**Cats:** Ophthalmic use: as for dogs (NB: ineffective for mydriasis as sole agent).

**References**
Franci P, Leece EA and McConnell JF (2011) Arrhythmias and transient changes in cardiac function after topical administration of one drop of phenylephrine 10% in an adult cat undergoing conjunctival graft. Veterinary Anaesthesia and Analgesia 38, 208–212

---

**Phenylpropanolamine** *(Diphenylpyraline)*
*(Proin, Propalin, Urilin)* **POM-V**

**Formulations:** Oral: 40 mg/ml phenylpropanolamine syrup (equivalent to 50 mg/ml phenylpropanolamine hydrochloride); 15 mg and 50 mg phenylpropanolamine hydrochloride tablets (equivalent to 12 mg and 40 mg phenylpropanolamine respectively).

**Action:** Sympathomimetic – increases urethral outflow resistance and has some peripheral vasoconstrictive effects.

**Use:**
- Treatment of urinary incontinence secondary to urethral sphincter incompetence.

Incontinence may recur if doses are delayed or missed. The onset of action may take several days. Use with caution in the presence of cardiovascular disease, renal or hepatic insufficiency, glaucoma, diabetes mellitus, hyperthyroidism.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.
Adverse reactions: May include restlessness, aggressiveness, irritability, gastrointestinal signs and hypertension. Cardiotoxicity has been reported.

Drug interactions: Concurrent administration with estriol may potentiate efficacy.

DOSES

Dogs: Urethral sphincter incompetence: 0.8 mg phenylpropanolamine/kg (equivalent to 1 mg/kg phenylpropanolamine hydrochloride/kg) p.o. q8h or 1.2 mg/kg phenylpropanolamine/kg (equivalent to 1.5 mg/kg phenylpropanolamine hydrochloride/kg) p.o. q12h.

Cats: Urethral sphincter incompetence: (extra-label) doses as for dogs.

References

Phenytoin (Diphenylhydantoin) (Epanutin*, pro-Epanutin*) POM

Formulations: Oral: 25 mg, 50 mg, 100 mg, 300 mg capsules; 100 mg tablets; 50 mg chewable tablets; 30 mg/5 ml suspension. Injectable: 50 mg/ml or as fosphenytoin 75 mg/ml equivalent to 50 mg/ml phenytoin.

Action: Diminishes the spread of focal neural discharges by promoting sodium efflux from neurons via the voltage-gated sodium channels thereby stabilizing the membrane and threshold against hyperexcitability.

Use:
• Used to control most forms of epilepsy in humans. In dogs it is metabolized very rapidly so that high doses need to be given often, and is associated with hepatic toxicity; cats metabolize the drug very slowly and toxicity easily develops. These undesirable pharmacokinetic properties mean that the drug is not recommended for use in dogs and cats as a maintenance therapy as there are alternative drugs with a better efficacy and fewer adverse effects.
• Recent evidence suggests that it may be effective as treatment for status epilepticus especially when used as the fosphenytoin preparation which has less risk of cardiac, blood-pressure and infusion-site adverse effects.
• It has been employed as an oral or i.v. antiarrhythmic agent in cats and dogs.
• Described in various case reports in both species as a treatment of myokymia (undulating vermiform movements of the overlying skin due to contraction of small bands of muscle fibres) with variable success.

Safety and handling: Normal precautions should be observed.
Contraindications: Do not use as anticonvulsant in cats. No longer recommended as a long-term treatment of epilepsy in dogs.

Adverse reactions: Adverse effects include ataxia, vomiting, hepatic toxicity, peripheral neuropathy, toxic epidermal necrolysis and pyrexia.

Drug interactions: A large number of potential drug interactions are reported in human patients, in particular complex interactions with other antiepileptics. The plasma concentration of phenytoin may be increased by cimetidine, diazepam, metronidazole, phenylbutazone, sulphonamides and trimethoprim. The absorption, effects or plasma concentration of phenytoin may be decreased by antacids, barbiturates and calcium. The metabolism of corticosteroids, doxycycline, theophylline and thyroxine may be increased by phenytoin. The analgesic properties of pethidine may be reduced by phenytoin, whereas the toxic effects may be enhanced. Concomitant administration of two or more antiepileptics may enhance toxicity without a corresponding increase in antiepileptic effect.

DOSES

Dogs:
- For treatment of ventricular arrhythmias: 10 mg/kg i.v. slowly; 30–50 mg/kg p.o. q8h.
- For treatment of status epilepticus: following a benzodiazepine, fosphenytoin at 15 mg/kg phenytoin equivalent (22.5 mg/kg) i.v. slowly (1 ml/min).
- For treatment of myokymia: 50–100 mg/kg p.o. q24h sustained release phenytoin.

Cats: Do not use.

References

Pheromones see Dog appeasing pheromone, Feline facial fraction F3

Pholcodine
(Benylin Children’s Dry Cough Mixture*, Galenphol*) general sale

Formulations: Oral: 2 mg/5 ml, 5 mg/5 ml, 10 mg/5 ml solutions. Note that many adult cough mixtures contain dextromethorphan (another opiate derivative about which little is known in dogs) and/or guaifenesin (an expectorant).

Action: A derivative of codeine that acts as an antitussive and has
mild sedating but no analgesic properties. It depresses the cough reflex by acting on the cough centre in the CNS. It has a lower potential than codeine for inducing dependence.

**Use:**
- Cough suppression where the cause of the cough cannot be removed and the coughing is becoming detrimental to the animal’s health (e.g. in chronic bronchitis, tracheal or mainstem bronchial collapse). It is not effective in respiratory tract infections in humans and would be unlikely to be effective in kennel cough in dogs. In humans it is effective in reducing the cough associated with lung tumours.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Respiratory depression, raised intracranial pressure.

**Adverse reactions:** Sedation, constipation (although less than codeine). Has been associated with anaphylaxis in humans.

**Drug interactions:** Likely to interact with other opiates (including tramadol).

**DOSES**
- **Dogs:** 0.1–0.2 mg/kg up to 4 times daily (anecdotal).
- **Cats:** No information available.

---

**Phosphate (Toldimphos)**
(Foston, Phosphate-Sandoz*) **POM-V, GSL**

**Formulations:** Injectables: 140 mg/ml phosphate (as a 20% w/v solution of toldimphos, an organically combined phosphorus preparation) (Foston), potassium sodium phosphate (contains 40 mmol phosphate, 30 mmol potassium and 30 mmol sodium in 20 ml vials). Oral: Effervescent tablets containing 1.936 g sodium acid phosphate, 350 mg sodium bicarbonate, 315 mg potassium bicarbonate equivalent to 500 mg (16.1 mmol) phosphate, 468.8 mg (20.4 mmol) sodium and 123 mg (3.1 mmol) potassium.

**Action:** Phosphate is essential for intermediary metabolism, ATP production, DNA and RNA synthesis, nerve, muscle and RBC function. Phosphate is filtered by the kidneys but 80% is resorbed.

**Use:**
- To correct hypophosphataemic states.
- To supplement patients on large volume i.v. fluid therapy that have inadequate intake or patients that become hypophosphataemic following administration of insulin therapy or parenteral nutrition.
- In diabetic ketoacidotic patients a combination of potassium chloride and potassium phosphate in equal parts may be indicated to meet the patient’s potassium needs and to treat or prevent significant hypophosphataemia.
Safety and handling: Normal precautions should be observed.

Contraindications: Hyperphosphataemia, hypocalcaemia, oliguric renal failure or if significant tissue necrosis is present.

Adverse reactions: May result in hypotension, renal failure or metastatic calcification of soft tissue. Hyperkalaemia or hypernatraemia may result in patients predisposed to these abnormalities and monitoring of electrolyte profiles is needed. Overdose or administration to patients with renal compromise may lead to hyperphosphataemia.

Drug interactions: Phosphates are incompatible with metals, including calcium and magnesium.

DOSES

Dogs:
• Acute severe hypophosphataemia: 0.06–0.18 mmol/kg of potassium phosphate i.v. over 6 hours, adjust according to response.
• Chronic hypophosphataemia: 140–280 mg (1–2 ml) i.m., s.c. q48h for 5–10 doses, 0.5–2 mmol phosphate/kg/day p.o.

Cats:
• Acute severe hypophosphataemia: dose as for dogs.
• Chronic hypophosphataemia: 0.5–2 mmol phosphate/kg/day p.o.

Phosphate enema (Sodium acid phosphate) (Fleet Enema*, Fletchers’ Phosphate Enema*)

Formulations: Rectal: 133 ml tube containing 21.4 g sodium acid phosphate and 9.4 g sodium phosphate (Fleet); 128 ml tube containing 12.8 g sodium acid phosphate and 10.24 g sodium phosphate (Fletchers’).

Action: Osmotic laxative.

Use: Cathartic used to initiate rapid emptying of the colon in dogs.

Safety and handling: Normal precautions should be observed.

Contraindications: Phosphate enemas are contraindicated for use in cats or small dogs (<5 kg) as they may develop electrolyte abnormalities (hypocalcaemia and hyperphosphataemia), which can be fatal.

Adverse reactions: Electrolyte abnormalities (hypocalcaemia and hyperphosphataemia), which can be fatal.

Drug interactions: No information available.

DOSES

Dogs: All uses: 60–128 ml per rectum (dogs 5–10 kg); 128 ml per rectum (dogs >10 kg).

Cats: Do not use.
References

Phytomenadione  
see Vitamin K1

Pilocarpine
(Pilocarpine hydrochloride*) POM

Formulations: Ophthalmic: 1%, 2%, 4% solutions in 10 ml bottles, single-use vials (2%). Most common concentration used in dogs is 1%.

Action: Direct-acting parasympathomimetic that stimulates cholinergic receptors. It lowers intraocular pressure by causing ciliary body muscle contraction, miosis and improved aqueous humour outflow.

Use:
- Used in the management of glaucoma, although this role has been superseded by other topical drugs such as carbonic anhydrase inhibitors and prostaglandin analogues. Pilocarpine produces miosis in 10–15 minutes for 6–8 hours in the dog.
- Oral pilocarpine increases lacrimation and can be used in the management of neurogenic keratoconjunctivitis (KCS or dry eye) in the dog; topical ophthalmic pilocarpine can also be used but can be irritant.

Pilocarpine is rarely used for ophthalmic purposes in the cat because of potential toxicity.

Safety and handling: Normal precautions should be observed.

Contraindications: Avoid in uveitis and anterior lens luxation.

Adverse reactions: Conjunctival hyperaemia (vasodilation) and local irritation (due to low pH). Signs of systemic toxicity include salivation, lacrimation, urinary incontinence, gastrointestinal disturbances, and cardiac arrhythmias.

Drug interactions: No information available.

DOSES
Dogs:
- Open-angle glaucoma: 1 drop per eye of 1% solution q8–12h.
- Neurogenic KCS: 1 drop of 1–2% solution per 10 kg p.o. q12h (with food) as initial dose. Dose is increased by 1 drop q2–3days until Schirmer tear test (STT) values improve or signs of systemic toxicity are observed (see Adverse Reactions) and then lowered to previously tolerated dose.

Cats: No information available.
References

**Pimobendan**
(Cardisure, Fortekor-Plus, Pimocard, Vetmedin)

**POM-V**

**Formulations:** Injectable: 0.75 mg/ml solution (5 ml vial, Vetmedin). Oral: 5 mg hard capsules or 1.25 mg, 5 mg or 10 mg chewable tablets (Vetmedin); 1.25 mg, 2.5 mg, 5 mg, 10 mg flavoured tablets (Cardisure, Pimocard). Available in compound preparations with benazepril (1.25 mg pimobendan/2.5 mg benazepril; 5 mg pimobendan/10 mg benazepril) (Fortekor-Plus).

**Action:** Inodilator producing both positive inotropic and vasodilatory effects. Inotropic effects are mediated via sensitization of the myocardial contractile apparatus to intracellular calcium and by phosphodiesterase (PDE) III inhibition. Calcium sensitization allows for a positive inotropic effect without an increase in myocardial oxygen demand. Vasodilation is mediated by PDE III and V inhibition, resulting in arterio- and venodilation. It is also a positive lusitrope and has a mild inhibitory action on platelet aggregation in dogs at standard doses.

**Use:**
- Management of congestive heart failure due to valvular insufficiency (mitral and/or tricuspid regurgitation) or dilated cardiomyopathy (DCM) in the dog. Indicated for use with concurrent congestive heart failure therapy (e.g. furosemide, ACE inhibitors).
- Has been shown to delay the onset of heart failure or sudden death in Dobermanns with preclinical DCM and dogs weighing 4–15 kg, aged 6 years or over with myxomatous mitral valve disease (MMVD). Licensed for use in preclinical DCM in Dobermanns (Vetmedin) and MMVD.
- There is evidence of efficacy in the treatment of pulmonary hypertension secondary to mitral valve disease in dogs.
- Has also been used in cats with heart failure associated with systolic dysfunction, although it is not authorized; the pharmacokinetics in cats may differ from that in dogs.

The presence of food may reduce bioavailability.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not use in hypertrophic cardiomyopathy and in cases where augmentation of cardiac output via increased contractility is not possible (e.g. aortic stenosis).
Adverse reactions: A moderate positive chronotropic effect and vomiting may occur in some cases, which may be avoided by dose reduction.

Drug interactions: The positive inotropic effects are attenuated by drugs such as beta-blockers and calcium-channel blockers (especially verapamil). No interaction with digitalis glycosides has been noted.

DOSES

**Dogs:** 0.15 mg/kg i.v. single dose. Oral pimobendan can be continued 12 hours after administration of the injection.

**Dogs, Cats:** 0.1–0.3 mg/kg p.o. q12h 1 hour before food.

References


**Piperacillin**

*(Tazocin*) POM

Formulations: Injectable: 2.25 g, 4.5 g powder (2 g or 4 g piperacillin sodium + 0.25 g or 0.5 g tazobactam (Tazocin)).

Action: Time-dependent, beta-lactam antibiotic that binds penicillin-binding proteins involved in cell wall synthesis, decreasing bacterial cell wall strength and rigidity, and affecting cell division, growth and septum formation. As animal cells lack a cell wall the beta-lactam antibiotics are extremely safe.

Use: Piperacillin is a ureidopenicillin, classified with ticarcillin as an antipseudomonal penicillin. It is reserved for life-threatening infections (e.g. endocarditis or septicaemia) where culture and sensitivity testing predict a clinical response. These include infections caused by *Pseudomonas aeruginosa* and *Bacteroides fragilis* in neutropenic patients, although it has activity against other Gram-negative bacilli including *Proteus*. For pseudomonal septicaemias, antipseudomonal penicillins should be given with an aminoglycoside (e.g. gentamicin) as there is a synergistic effect. Piperacillin should usually be combined with a beta-lactamase inhibitor and therefore is co-formulated with tazobactam. Experience in veterinary species is limited, especially cats, and doses are largely empirical. Piperacillin inhibits the excretion of the tazobactam component in the dog.

Safety and handling: Normal precautions should be observed.

Contraindications: No information available.
**Adverse reactions:** Nausea, diarrhoea and skin rashes are the commonest adverse effects in humans. Painful if given by i.m. injection. The sodium content of each formulation may be clinically important for patients on restricted sodium intakes.

**Drug interactions:** Piperacillin enhances the effects of non-depolarizing muscle relaxants. Gentamicin inactivates piperacillin if mixed in the same syringe. Clinical experience with this drug is limited. There is synergism between the beta-lactams and the aminoglycosides.

**DOSES**  
*See Appendix for guidelines on responsible antibacterial use.*

**Dogs:** Very little information is available to guide dosing. The human paediatric recommended dose is 80–100 mg/kg by slow i.v. injection/infusion q8h which could be used as a guide; 25–50 mg/kg i.v. q4–6h.

**Cats:** No information available.

**References**

---

**Piperazine**  
(Various authorized proprietary products)  
**AVM-GSL**

**Formulations:** Oral: 500 mg tablets. There is a variety of different formulations.

**Action:** An anti-ascaridial anthelmintic that blocks acetylcholine, thus affecting neurotransmission and paralysing the adult worm; it has no larvicidal activity.

**Use:**
- Active against *Toxocara cati, T. canis, Toxascaris leonine* and *Uncinaria stenocephala*.

Ineffective against tapeworms and lung worms. High doses are required to treat hookworm infection. Puppies and kittens may be wormed from 6–8 weeks of age and should be weighed accurately to prevent overdosing. Fasting is not necessary. Piperazine may be used in pregnant animals.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.

**Adverse reactions:** Uncommon but occasionally vomiting or muscle tremors and ataxia have been reported.

**Drug interactions:** Piperazine and pyrantel have antagonistic mechanisms of action; do not use together.
DOSES

Dogs, Cats:
- Puppies and kittens: 200 mg/kg as a single dose. Then dose every 2 weeks until 3 months of age and then at 3-monthly intervals.
- Adult dogs and cats: 200 mg/kg as a single dose. Repeat treatment at 3-monthly intervals.

Piroxicam
(Brexidol*, Feldene*, Piroxicam*) POM

Formulations: Oral: 10 mg, 20 mg capsules, 20 mg dissolving tablet. Injectable: 20 mg/ml solution.

Action: Inhibition of COX enzymes limits the production of prostaglandins involved in inflammation. Also limits tumour growth but the mechanism is still to be determined.

Use:
- In veterinary medicine, piroxicam has been used to treat certain tumours expressing COX receptors, e.g. transitional cell carcinoma of the bladder, prostatic carcinoma and colonic-rectal carcinoma and polyps.

Piroxicam suppositories are available in the human field and are useful in the management of colorectal polyps/neoplasia. Other NSAIDs are authorized for veterinary use in various inflammatory conditions but there is no information on the effect of these drugs in neoplastic conditions.

Safety and handling: Normal precautions should be observed.

Contraindications: Gastric ulceration, renal disease, concurrent use of corticosteroids.

Adverse reactions: As a non-specific COX inhibitor it may cause general adverse effects associated with NSAIDs, including GI toxicity, gastric ulceration and renal papillary necrosis (particularly if patient is dehydrated). There is a small risk that NSAIDs may precipitate cardiac failure in humans and this risk in animals is unknown. Ulcerative skin lesions have been reported in the cat.

Drug interactions: Do not use with corticosteroids or other NSAIDs (increased risk of gastric ulceration). Concurrent use with diuretics or aminoglycosides may increase risk of nephrotoxicity. Piroxicam is highly protein-bound and may displace other protein-bound drugs. The clinical significance of this is not well established.

DOSES
See Appendix for chemotherapy protocols.

Dogs: All uses: 0.3 mg/kg p.o. q24–72h; start at least frequent administration and slowly increase if no side effects observed.

Piroxicam suppositories: usually 20 mg/dog per rectum q2–3days (dose equivalent to 0.24–0.4 mg/kg/day).
Cats: All uses: 0.3 mg/kg p.o. q24–96h; start at least frequent administration and slowly increase if no side effects observed.

References
Knapp DW, Richardson RC, Chan TC et al. (1994) Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. Journal of Veterinary Internal Medicine 8, 273–278

Polymyxin B
(Surolan, Polyfax*) POM-V, POM

Formulations: Topical: Surolan 5,500 IU polymyxin/ml suspension combined with miconazole and prednisolone for dermatological and otic use. Polyfax: 10,000 IU polymyxin/g ointment combined with bacitracin for dermatological and ophthalmic use.

Action: Concentration-dependent disruption of the outer membrane of Gram-negative bacteria through its action as a cationic surface acting agent.

Use: Effective against Gram-negative organisms; Gram-positives usually resistant. Particularly effective in the treatment of external pseudomonal infections, e.g. keratoconjunctivitis, otitis externa. Polymyxins are too toxic for systemic use and because of their strongly basic nature are not absorbed from the GI tract.

Safety and handling: Normal precautions should be observed.

Contraindications: Do not use if the tympanum is ruptured.

Adverse reactions: Should not be used systemically as is nephrotoxic. Potentially ototoxic.

Drug interactions: Acts synergistically with a number of other antibacterial agents as it disrupts the outer and cytoplasmic membranes, thus improving penetration of other agents into bacterial cells. Cationic detergents (e.g. chlorhexidine) and chelating agents (e.g. EDTA) potentiate the antibacterial effects of polymyxin B against Pseudomonas aeruginosa.

DOSES
See Appendix for guidelines on responsible antibacterial use.

Dogs, Cats:
- Skin: apply a few drops and rub in well q12h.
- Otic: clean ear and apply a few drops into affected ear q12h.
- Ophthalmic: apply ointment q6–8h.
Polyvinyl alcohol
(Liquifilm Tears*, Refresh Ophthalmic*, Sno Tears*)

Formulations: Ophthalmic: 1.4% (0.4 ml vials, 15 ml bottle).

Action: Polyvinyl alcohol is a synthetic water-based tear substitute, which mimics the aqueous layer of the trilaminar tear film (lacromimetic).

Use: It is used for lubrication of dry eyes. In cases of keratoconjunctivitis sicca (KCS or dry eye) it will improve ocular surface lubrication, tear retention and patient comfort while lacrostimulation therapy (e.g. topical ciclosporin) is initiated. It is more adherent and less viscous than hypromellose. Patient compliance is poor if administered >q4h; consider using a longer acting tear replacement.

Safety and handling: Normal precautions should be observed.

Contraindications: No information available.

Adverse reactions: No information available.

Drug interactions: No information available.

DOSES
Dogs, Cats: 1 drop per eye q1h.

Potassium bromide
(Bromilep, Epilease, Libromide, Potassium bromide solution) POM-V, AVM-GSL

Formulations: Oral: 325 mg tablets; 100 mg, 250 mg, 1000 mg capsules; 250 mg/ml solution.

Action: Within the CNS it competes with transmembrane chloride transport and inhibits sodium, resulting in membrane hyperpolarization and elevation of the seizure threshold. Bromide competes with chloride in post-synaptic anion channels following activation by inhibitory neurotransmitters and therefore potentiates the effect of GABA. Acts synergistically with other therapeutic agents that have GABA-ergic effects (such as phenobarbital).

Use:
• Control of seizures in dogs in which the seizures are refractory to treatment with phenobarbital or where the use of phenobarbital or imepitoin is contraindicated. KBr is usually used in conjunction with phenobarbital. Although not authorized for this use, KBr has been used in conjunction with imepitoin.

Bromide has a long half-life (>20 days) and steady state plasma concentrations may not be achieved for 3–4 months. Monitoring of
serum drug concentrations should be performed and dose levels adjusted accordingly. The serum KBr concentration should reach 0.8–1.5 mg/ml to be therapeutic. In some cases, the dog may need to be started on a loading dose to raise levels in the blood rapidly to therapeutic levels. Loading doses of KBr are associated with an increased incidence of adverse effects (primarily sedation and ataxia) and should only be used in dogs with poorly controlled severe seizures. The loading dose can be administered via enema if an animal is not conscious enough to receive oral medication, but side effects of increased sedation and transient diarrhoea may be seen. Serum samples should be taken after the end of loading to check the serum concentration. The slow rise of plasma bromide levels after enteral administration limits its usefulness in status epilepticus. Bromide is well absorbed from the GI tract and eliminated slowly by the kidney in competition with chloride. High levels of dietary salt increase renal elimination of bromide. Consequently, it is important that the diet be kept constant once bromide therapy has started. Bromide will be measured in assays for chloride and will therefore produce falsely high ‘chloride’ results. Use with caution in dogs with renal disease.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not use in the cat due to the development of severe coughing due to eosinophilic bronchitis, which may be fatal. Avoid use in dogs with a history, or a predisposition for the development, of pancreatitis.

**Adverse reactions:** Ataxia, sedation and somnolence are seen with overdosage and loading doses. Skin reactions have been reported in animals with pre-existing skin diseases, e.g. flea bite dermatitis. Vomiting may occur after oral administration, particularly if high concentrations (>250 mg/ml) are used. Polyphagia, polydipsia and pancreatitis have also been reported. In the case of acute bromide toxicity, 0.9% NaCl i.v. is the treatment of choice. Less commonly, behavioural changes, including irritability or restlessness, may be evident.

**Drug interactions:** Bromide competes with chloride for renal reabsorption. Increased dietary salt, administration of fluids or drugs containing chloride, and use of loop diuretics (e.g. furosemide) may result in increased bromide excretion and decreased serum bromide concentrations.

**DOSES**

**Dogs:** The initial daily maintenance dose is 20–40 mg/kg p.o q24h. It is not necessary to dose more frequently, but more frequent dosing is not detrimental. The loading dose is 200 mg/kg/day p.o. divided into 4–6 hour doses for 5 days, after which the dose is decreased to the maintenance dose (20–40 mg/kg p.o. q24h). If seizures resolve sooner, it is advisable to decrease the loading dose to maintenance levels earlier to reduce adverse effects. A single loading dose of 600–1000 mg/kg p.o. can be given but this is likely to result in excessive sedation, ataxia and potentially vomiting.
Intrarectal bromide can be loaded over a 24-hour period. The loading schedule for liquid bromide (250 mg/ml) by rectum is 100 mg/kg q4h for 6 doses (total 600 mg/kg).

**Cats:** Do not use.

**References**
Charalambous M, Brodbelt D and Volk HA (2014) Treatment in canine epilepsy–a systematic review. *BMC Veterinary Research* 10, 257

**Potassium chloride** see **Potassium salts**

**Potassium citrate**
*(Cystopurin*, Potassium citrate BP*) **AVM-GSL**

**Formulations:** Oral: 30% solution. Various preparations are available.

**Action:** Enhances renal tubular resorption of calcium, and alkalinizes urine.

**Use:**
- Management of calcium oxalate and urate urolithiasis, and fungal urinary tract infections.
- May be used to treat hypokalaemia, although potassium chloride or gluconate is preferred.
- Used to treat some forms of metabolic acidosis.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Renal impairment or cardiac disease.

**Adverse reactions:** Rare, but may include GI signs and hyperkalaemia.

**Drug interactions:** No information available.

**DOSES**
**Dogs, Cats:** Urinary alkalinization: 75 mg/kg or 2 mmol/kg p.o. q12h.

**References**

**Potassium gluconate** see **Potassium salts**

**Potassium phosphate** see **Phosphate**
Potassium salts (Potassium chloride, Potassium gluconate)  
(Kaminox, Tumil-K) **general sale**

**Formulations:**  
**Injectable:** 20% KCl solution (2 g KCl/10 ml; 26 mmol K⁺). Before use, dilute the solution with at least 70 times its volume of sodium chloride intravenous fluid.  
**Oral:** tablets containing 2 mEq potassium gluconate; powder (2 mEq per ¼ teaspoon) (Tumil-K); liquid 1 mEq/ml potassium gluconate formulated with a range of amino acids, B vitamins and iron (Kaminox). NB: 1 mmol/l = 1 mEq/l.

**Action:** Replacement of potassium.  

**Use:**  
- Treatment or prevention of known hypokalaemic states; prolonged anorexia and chronic renal failure are the most common, but can also use with diuretics that are not potassium sparing.  
If rapid correction is not necessary, may be added to s.c. fluids but do not exceed 30 mEq/l as higher levels are irritating. As potassium is primarily an intracellular electrolyte, serum concentrations may not immediately reflect clinical effect. Do not give rapid i.v. injections. Concentrated solutions must be diluted before i.v. use. Use with caution in any renal failure patient as 80–90% of excretion is renal. Use with caution in digitalized patients.

**Safety and handling:** Normal precautions should be observed.  

**Contraindications:** Hyperkalaemia, acute or obstructive renal failure, untreated Addison’s disease, acute dehydration and diseases with impaired or obstructed GI motility.

**Adverse reactions:** Primarily development of hyperkalaemia when administered too rapidly or to patients with impaired renal function. Clinical signs range from muscle weakness to GI disturbances to cardiac arrhythmias and cardiac arrest. Concentrations >60 mmol/l can cause pain, peripheral vein sclerosis and increase the risk of overdose.

**Drug interactions:** Potassium retention leading to severe hyperkalaemia may develop when used with angiotensin-converting enzyme inhibitors (e.g. captopril, enalapril) or potassium-sparing diuretics (e.g. spironolactone). Potassium chloride is not compatible with many drugs especially those in sodium salt form.

<table>
<thead>
<tr>
<th>Serum potassium</th>
<th>Amount to be added to 250 ml 0.9% NaCl</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;2 mmol/l</td>
<td>20 mmol</td>
</tr>
<tr>
<td>2–2.5 mmol/l</td>
<td>15 mmol</td>
</tr>
<tr>
<td>2.5–3 mmol/l</td>
<td>10 mmol</td>
</tr>
<tr>
<td>3–3.5 mmol/l</td>
<td>7 mmol</td>
</tr>
<tr>
<td>3.5–5.5 mmol/l</td>
<td>5 mmol (minimum daily need in anorectic patients)</td>
</tr>
</tbody>
</table>
DOSES

Dogs:

- **Correction of hypokalaemia:** intravenous doses must be titrated for each patient; dilute concentrated solutions prior to use (normally to 20–60 mmol/l). Rate of i.v. infusion should not exceed 0.5 mmol/kg/h, especially when concentration in replacement fluid is >60 mmol/l. Use of fluid pumps is recommended.
- **Oral:** replacement dose needs to be titrated to effect to maintain mid-range normal values in each individual patient. Starting doses are 2 mEq per 4.5 kg in food q12h or 2.2 mEq per 100 kcal required energy intake.

Cats:

- **Correction of hypokalaemia:** intravenous doses as for dogs.
- **Oral:** replacement dose needs to be titrated to effect to maintain mid-range normal values in each individual patient. Starting doses are 2.2 mEq per 4.5 kg in food q12h or 2–6 mEq/cat/day p.o. in divided doses q8–12h.

**Potentiated sulphonamides** see **Trimethoprim/Sulphonamide**

**Pradofloxacin** (Veraflox) POM-V

**Formulations:** Oral: 15 mg, 60 mg, 120 mg tablets; 25 mg/ml solution.

**Action:** Broad-spectrum, concentration-dependent antibiotic that inhibits DNA gyrase and topoisomerase IV, blocking bacterial replication.

**Use:** Fluoroquinolone use should be reserved for infections where culture and sensitivity testing predicts a clinical response and where first- and second-line antimicrobials would not be effective. Active against many Gram-negative and Gram-positive organisms. Much improved activity versus anaerobes compared with earlier generation fluoroquinolones. Like other members of the class, pradofloxacin has exceptional lipid solubility, attaining high concentrations especially in the urogenital tract including the prostate gland. Specific indications include superficial and deep pyodermas and wound infections associated with susceptible organisms such as *Staphylococcus pseudintermedius*, urinary tract infections associated with susceptible organisms such as *Escherichia coli* and *S. pseudintermedius*, severe periodontal disease associated with anaerobes such as *Porphyromonas* spp. and *Prevotella* spp. and acute severe upper respiratory tract infections associated with organisms such as *E. coli*, *Staphylococcus* spp. and *Pasteurella multocida*. 
**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not use in pregnant or lactating animals. Do not use in dogs <12 months of age (<18 months for giant-breeds) or cats <6 weeks of age due to potential adverse effects on cartilage. Do not use in animals with persistent cartilage lesions. Do not use in dogs or cats with neurological disease especially epilepsy.

**Adverse reactions:** Most common is mild GI upset.

**Drug interactions:** Absorbents and antacids containing cations (Mg$^{2+}$, Al$^{3+}$) may bind fluoroquinolones, preventing their absorption from the GI tract. Their absorption may also be inhibited by sucralfate and zinc salts; separate dosing by at least 2 hours. Fluoroquinolones increase plasma theophylline concentrations. Cimetidine may reduce the clearance of fluoroquinolones and so should be used with caution with these drugs. Some fluoroquinolones may decrease the metabolism and increase nephrotoxicity of ciclosporin and tacrolimus in humans and therefore concurrent use in animals is best avoided until more research has been performed. May increase the action of orally administered anticoagulants.

**DOSES**

*See Appendix for guidelines on responsible antibacterial use.*

**Dogs:** 3–5 mg/kg p.o. q24h.

**Cats:** 3–5 mg/kg p.o. q24h (tablet), 5.0 mg/kg p.o. q24h (suspension).

**References**


---

**Pralidoxime** *(Pralidoxime*) **POM**

**Formulations:** Powder for reconstitution: 1 g vial which produces 50 mg/ml solution.

**Action:** Reactivates the cholinesterase enzyme damaged by organophosphate (OP) and allows the destruction of accumulated acetylcholine at the synapse to be resumed. In addition, pralidoxime detoxifies certain OPs by direct chemical inactivation and retards the ‘ageing’ of phosphorylated cholinesterase to a non-reactive form.

**Use:**

- Management of OP toxicity.

Most effective if given within 24 hours. Pralidoxime does not appreciably enter the CNS, thus CNS toxicity is not reversed. If given
within 24 hours of exposure, treatment is usually only required for 24–36 hours. Respiratory support may be necessary. Treatment of OP toxicity should also include atropine. Use at a reduced dose with renal failure.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not use for poisoning due to carbamate or OP compounds without anticholinesterase activity.

**Adverse reactions:** Nausea, tachycardia, hyperventilation, and muscular weakness are reported in humans.

**Drug interactions:** Aminophylline, morphine, phenothiazines or theophylline should be avoided in these patients.

**DOSES**

**Dogs, Cats:** Organophosphate toxicity: dilute to a 20 mg/ml solution and administer 20–50 mg/kg slowly i.v. (over 2 min at least – 500 mg/min max.) i.m., s.c. Repeat after 1 hour if still severe signs, then q8–12h.

**References**

---

**Praziquantel**

(Anthelmin, Broadline Spot-on, Cazitel, Cestem, Dolpac, Droncit, Droncit Spot-on, Drontspot Spot-on, Drontal, Endoguard, Milbactor, Milbemax, Milprazon, Milpro, Prazitel, Profender Spot-on, Veloxa, WORMclear, Various other authorized proprietary preparations) **POM-V, NFA-VPS, AVM-GSL**

**Formulations:** Oral: 10 mg, 20 mg, 25 mg, 30 mg, 40 mg, 50 mg, 125 mg, 144 mg, 150 mg, 175 mg tablets. **Topical:** 20 mg, 25 mg, 30 mg, 60 mg, 75 mg, 96 mg in spot-on pipettes.

**Action:** Cestocide that increases cell membrane permeability of susceptible worms, resulting in loss of intracellular calcium and paralysis. This allows the parasites to be phagocytosed or digested.

**Use:**
- Treatment of *Dipylidium caninum, Taenia, Echinococcus granulosus* and *Mesocestoides* in dogs and cats.

As it kills all intestinal forms of *Echinococcus*, it is the preferred drug in most *Echinococcus* control programmes. The PETS travel scheme requires animals to be treated with praziquantel prior to entry into the UK. The inclusion of pyrantel and febantel in some preparations increases the spectrum of efficacy. Drontal plus can be used from...
2 weeks of age. Drontal cat tablets can be used from 6 weeks of age. Retreatment is usually unnecessary unless reinfection takes place.

**Safety and handling:** Normal precautions should be observed. Solutions containing emodepside should not be handled by women of child-bearing age.

**Contraindications:** Do not use in unweaned puppies or kittens, as they are unlikely to be affected by tapeworms. Do not use the spot-on preparation in animals <1 kg.

**Adverse reactions:** Injection may cause localized tissue sensitivity, particularly in cats. Can cause transient hypersalivation if a cat licks the site of spot-on application. Oral administration can occasionally result in anorexia, vomiting, lethargy and diarrhoea.

**Drug interactions:** No information available.

**DOSES**

- **Dogs:** 5.0 mg/kg p.o.; 8 mg/kg spot-on.
- **Cats:** 5.0 mg/kg p.o.; 8 mg/kg spot-on.

---

**Prazosin**

**(Hypovase*, Prazosin*) POM**

**Formulations:** Oral: 0.5 mg, 1 mg, 2 mg, 5 mg tablets.

**Action:** Prazosin is a post-synaptic alpha-1 blocking agent causing arterial and venous vasodilation. This leads to reduction in blood pressure and systemic vascular resistance.

**Use:**
- Promoting urine flow in patients with functional urethral obstruction.
- Management of systemic or pulmonary hypertension.
- Adjunctive therapy of congestive heart failure secondary to mitral or aortic regurgitation in cases refractory to standard therapy (not often used for this indication).

Efficacy may decline over time.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Hypotension, renal failure.

**Adverse reactions:** Hypotension, syncope, drowsiness, weakness, GI upsets.

**Drug interactions:** Concomitant use of beta-blockers (e.g. propranolol) or diuretics (e.g. furosemide) may increase the risk of a first dose hypotensive effect. Calcium-channel blockers may cause additive hypotension. Prazosin is highly protein-bound and so may be displaced by, or displace, other highly protein-bound drugs (e.g. sulphonamide) from plasma proteins.
DOSES

Dogs:
• To decrease urethral resistance in idiopathic vesico-urethral reflex dyssynergia: 1 mg/15 kg body weight p.o. q12h.
• For adjunctive treatment for heart failure: 1 mg/dog p.o. q8–12h (dogs up to 15 kg); 2 mg/dog p.o. q8–12h (dogs >15 kg). Monitor efficacy by measuring blood pressure and clinical response.

Cats: 0.25–1 mg/cat p.o. q8–12h given initially for 5–7 days then wean off if possible.

References

Prednisolone
(PLT, Prednicare, Prednidale, Pred-forte*) POM-V

Formulations: Ophthalmic: prednisolone acetate 0.5%, 1% suspensions in 5 ml, 10 ml bottles (Pred-forte). Topical: prednisolone is a component of many topical dermatological, otic and ophthalmic preparations. Injectable: prednisolone sodium succinate 10 mg/ml solution; 7.5 mg/ml suspension plus 2.5 mg/ml dexamethasone. Oral: 1 mg, 5 mg, 25 mg tablets. PLT is a compound preparation containing cinchophen.

Action: Binds to specific cytoplasmic receptors which then enter the nucleus and alter the transcription of DNA, leading to alterations in cellular metabolism which result in anti-inflammatory, immunosuppressive and antifibrotic effects. Also has glucocorticoid activity and acts in dogs as an ADH antagonist.

Use: Management of:
• Chronic allergic/inflammatory conditions (e.g. atopy, inflammatory bowel disease)
• Immune-mediated conditions
• Hypoadrenocorticism
• Lymphoproliferative and other neoplasms
• In combination with cinchophen (PLT) it is used in the management of osteoarthritis (see Cinchophen).

Prednisolone has approximately 4 times the anti-inflammatory potency and half the relative mineralocorticoid potency of hydrocortisone. It, like methylprednisolone, is considered to have an intermediate duration of activity and is suitable for alternate-day use. Animals on chronic therapy should be tapered off their steroids when discontinuing the drug. There are no studies comparing protocols for tapering immunosuppressive or anti-inflammatory therapy; it is appropriate to adjust the therapy according to laboratory or clinical parameters. For example, cases with immune-mediated haemolytic anaemia should have their therapy adjusted following monitoring of their haematocrit. There is no evidence that
long-term low doses of glucocorticoids do, or do not, prevent relapse of immune-mediated conditions. Impaired wound healing and delayed recovery from infections may be seen. The use of steroids in most cases of shock and spinal cord injury is of no benefit and may be detrimental.

**Safety and handling:** Shake suspension before use.

**Contraindications:** Do not use in pregnant animals. Systemic corticosteroids are generally contraindicated in patients with renal disease and diabetes mellitus. Topical corticosteroids are contraindicated in ulcerative keratitis.

**Adverse reactions:** Prolonged use of glucocorticoids suppresses the hypothalamic–pituitary axis (HPA), causing adrenal atrophy, and may cause significant proteinuria and glomerular changes in the dog. Catabolic effects of glucocorticoids leads to weight loss and muscle atrophy. Iatrogenic hyperadrenocorticism may develop with chronic use. Vomiting, diarrhoea and GI ulceration may develop; the latter may be more severe when corticosteroids are used in animals with neurological injury. Hyperglycaemia and decreased serum T4 values may be seen in patients receiving prednisolone.

**Drug interactions:** There is an increased risk of GI ulceration if used concurrently with NSAIDs. Hypokalaemia may develop if acetazolamide, amphotericin B or potassium-depleting diuretics (e.g. furosemide, thiazides) are administered concurrently with corticosteroids. Glucocorticoids may antagonize the effect of insulin. The metabolism of corticosteroids may be enhanced by phenytoin or phenobarbital and decreased by antifungals (e.g. itraconazole).

**DOSES**

*See Appendix for chemotherapy and immunosuppression protocols.*

**Dogs:**

- **Ophthalmic:** dosage frequency and duration of therapy is dependent upon type of lesion and response to therapy. Usually 1 drop in affected eye(s) q4–24h tapering in response to therapy.
- **Hypoadrenocorticism:** starting dose 0.2 mg/kg with desoxycorticone pivalate (DOCP), 0.1 mg/kg with fludrocortisone. The dose of prednisolone may be reduced considerably in most cases once the animal is stable. In cases on fludrocortisone it may be discontinued but in cases on DOCP it should be continued albeit at a low dose.
- **Allergy:** 0.5–1 mg/kg p.o. q12h initially, tapering to lowest q48h dose.
- **Anti-inflammatory:** 0.5 mg/kg p.o. q12–24h; taper to 0.25–0.5 mg/kg q48h.
- **Immunosuppression:** 1–2 mg/kg p.o. q24h, tapering slowly to 0.5 mg/kg q48h (for many conditions this will take 6 months).
- **Lymphoma:** see Appendix.

**Cats:**

- **Ophthalmic, hypoadrenocorticism, allergy:** doses as for dogs.
• **Anti-inflammatory:** 0.5–1 mg/kg p.o. q12–24h; taper to 0.5 mg/kg q48h.
• **Immunosuppression:** 1–2 mg/kg p.o. q12–24h, tapering slowly to 0.5–1 mg/kg q48h (for many conditions this will take 6 months).
• **Lymphoma:** see Appendix.

**Pregabalin**
*(Alzain*, Axalid*, Lyrica*) **POM CD SCHEDULE 3**

**Formulations:** Oral: 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, 300 mg capsules; 20 mg/ml solution.

**Action:** Similar mechanism of action to gabapentin, binding to voltage-dependent calcium channels in the CNS reducing calcium influx and release of excitatory neurotransmitters such as glutamate and substance P. It also increases neuronal GABA levels. Pregabalin is more potent than gabapentin (3–10 times) owing to a greater affinity for the binding site and generally has a longer duration of action.

**Use:**
• Adjunctive therapy in the treatment of epileptic seizures refractory to conventional treatment.
• Treatment of neuropathic pain.

Pregabalin seems to be well absorbed after oral administration in dogs and can reach serum levels shown to be effective in humans with neuropathic pain. In cats the longer half-life suggests that a dosing schedule of every 12 hours may be appropriate, which is an advantage compared with gabapentin. Use with care in patients with renal impairment as the majority is excreted by the kidneys.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Avoid use in pregnant animals as toxicity has been demonstrated in experimental studies. Do not discontinue abruptly.

**Adverse reactions:** Many dogs develop sedation or ataxia, although not usually severe enough to warrant cessation of the therapy. Mild increases in hepatic enzyme activities may also occur following prolonged therapy.

**Drug interactions:** No information available.

**DOSES**

**Dogs:**
• **For refractory epilepsy:** 3–4 mg/kg p.o. q8h, starting at 2 mg/kg and gradually increasing.
• **For neuropathic pain:** 4 mg/kg p.o. q12h (limited evidence).

**Cats:** 1–2 mg/kg p.o. q12h (limited anecdotal evidence).

**References**
**Procaine hydrochloride with epinephrine bitartrate**
*(Willcain)* POM-VPS

**Formulations:** Solution for injection.

**Action:** Local anaesthetic action is dependent on reversible blockade of the sodium channel, preventing propagation of an action potential along the nerve fibre. Sensory nerve fibres are blocked before motor nerve fibres, allowing a selective sensory blockade at low doses. Addition of epinephrine to procaine increases the duration of action by reducing the rate of systemic absorption.

**Use:**
- To provide local anaesthesia via perineural injection.

Procaine has a shorter duration of action than lidocaine or bupivacaine (50 minutes in humans), although the addition of epinephrine will prolong the duration of action compared to the administration of procaine alone.

**Safety and handling:** Take care to avoid accidental self-injection.

**Contraindications:** Do not administer intravenously, intra-articularly or epidurally. Do not use for i.v. regional anaesthesia. Vasoconstrictors such as epinephrine should be used with caution in lower limb blocks due to the risk of digital ischaemia or when significant systemic absorption of the drug is expected.

**Adverse reactions:** Inadvertent intravascular injection may precipitate severe cardiac arrhythmias that are refractory to treatment.

**Drug interactions:** Procaine may inhibit the action of sulphonamides and their concurrent administration should be avoided.

**DOSES**
- **Dogs:** 0.25–1.0 ml s.c.
- **Cats:** 0.25–1.0 ml s.c.

**Prochlorperazine**
*(Prochlorperazine*, *Stemetil*) POM

**Formulations:** Injectable: 12.5 mg/ml solution in 1 ml ampoule.
Oral: 3 mg, 5 mg tablets; 5 mg/5 ml syrup.

**Action:** Blocks dopamine, muscarinic acetylcholine and 5-HT3 receptors in chemoreceptor trigger zone and vomiting centre.

**Use:** Predominantly to control motion sickness and emesis associated with vestibular disease. Maropitant and metoclopramide are authorized as antiemetics in dogs and cats so prochlorperazine is not a first choice.
Safety and handling: Normal precautions should be observed.

Contraindications: Use with caution where there is hepatic dysfunction or cardiac disease.

Adverse reactions: Sedation, depression, hypotension and extrapyramidal reactions (e.g. rigidity, tremors, weakness, restlessness).

Drug interactions: CNS depressant agents (e.g. anaesthetics, narcotic analgesics) may cause additive CNS depression if used with prochlorperazine. Antacids or anti diarrhoeal preparations (e.g. bismuth subsalicylate or kaolin/pectin mixtures) may reduce GI absorption of oral phenothiazines. Increased blood levels of both drugs may result if propranolol is administered with phenothiazines. Phenothiazines block alpha-adrenergic receptors, which may lead to unopposed beta activity causing vasodilation and increased cardiac rate if adrenaline is given.

DOSES

Dogs, Cats: All uses: 0.1–0.5 mg/kg i.v., i.m., s.c. q6–8h; 0.5–1 mg/kg p.o. q8–12h.

References


**Proligestone**

*(Delvosteron)* POM-V

Formulations: Injectable: 100 mg/ml suspension.

Action: Alters the transcription of DNA, leading to alterations in cellular metabolism which mimic those caused by progesterone.

Use: Postponement of oestrus in the bitch and queen. As coat colour changes may occasionally occur, injection into the medial side of the flank fold is recommended for thin-skinned or show animals. Although authorized for use in miliary dermatitis in cats, specific glucocorticoids are preferred.

Safety and handling: Normal precautions should be observed.

Contraindications: Best avoided in diabetic animals, as insulin requirements are likely to change unpredictably. Do not give to bitches before or at first oestrus.

Adverse reactions: The time the animal will stay in anoestrus cannot be predicted reliably and some bitches will remain in anoestrus for up to 3 years. Proligestone does not appear to be associated with as many or as serious adverse effects as other progestogens (e.g. megestrol acetate, medroxyprogesterone acetate). However, adverse effects associated with long-term progestogen use, e.g. temperament changes (listlessness and depression), increased thirst or appetite, cystic endometrial
hyperplasia/pyometra, diabetes mellitus, acromegaly, adrenocortical suppression, mammary enlargement/neoplasia and lactation, may be expected. Irritation at site of injection may occur and calcinosis circumscripta at the injection site has been reported.

**Drug interactions:** No information available.

**DOSES**

**Dogs:** 10–33 mg/kg depending on body weight:

<table>
<thead>
<tr>
<th>Body weight (kg)</th>
<th>Dose (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;5</td>
<td>100–150</td>
</tr>
<tr>
<td>5–10</td>
<td>150–250</td>
</tr>
<tr>
<td>10–20</td>
<td>250–350</td>
</tr>
<tr>
<td>20–30</td>
<td>350–450</td>
</tr>
<tr>
<td>30–45</td>
<td>450–550</td>
</tr>
<tr>
<td>45–60</td>
<td>550–600</td>
</tr>
<tr>
<td>thereafter</td>
<td>10 mg/kg</td>
</tr>
</tbody>
</table>

This dose should be given once for the suppression of oestrus. If permanent postponement of oestrus is required, dose is given preferably before onset of pro-oestrus, a second dose 3 months later, a third dose 4 months after the second, and subsequent doses given every 5 months thereafter. Once dosing ceases bitches may come into oestrus, on average 6–7 months later, but it may take longer in some cases. Doses for treatment of acromegaly are as above, given monthly by injection until signs of hair growth are evident.

**Cats:**

- **Oestrus postponement:** 100 mg/cat s.c.
- **Miliary dermatitis:** 33–50 mg/kg s.c. repeated once after 14 days if the response is inadequate.

---

**Promethazine**

*(Phenergan*) **POM**

**Formulations:** Oral: 10 mg, 25 mg tablets; 1 mg/ml syrup.

Injectable: 25 mg/ml solution.

**Action:** Binds to H1 histamine receptors and prevents histamine from binding.

**Use:**

- Management of allergic disease.
- Early treatment of anaphylaxis.

Specific doses for dogs and cats have not been determined by pharmokinetic studies. Not widely used. Use with caution in cases with urinary retention, angle-closure glaucoma and pyloroduodenal obstruction.

**Safety and handling:** Normal precautions should be observed.
Contraindications: No information available.
Adverse reactions: May cause mild sedation. May reduce seizure threshold.
Drug interactions: No information available.
DOSES
Dogs, Cats: 0.2–0.4 mg/kg i.v., i.m. q6–8h, 12.5–25 mg/dog p.o. q24h.

**Propantheline**
(Pro-Banthine*) POM

Formulations: Oral: 15 mg tablet.
Action: Quarternary antimuscarinic agent.
Use:
- Treatment of anticholinergic-responsive bradycardia.
- Management of incontinence caused by detrusor hyperreflexia.
- Peripherally acting antiemetic.
- Adjunctive therapy to treat GI disorders associated with smooth muscle spasm.

Safety and handling: Normal precautions should be observed.
Contraindications: No information available.
Adverse reactions: Antimuscarinics may cause constipation and paralytic ileus with resultant dysbiosis. Other adverse effects include sinus tachycardia, ectopic complexes, mydriasis, photophobia, cycloplegia, increased intraocular pressure, vomiting, abdominal distension, urinary retention and drying of bronchial secretions.
Drug interactions: Antihistamines and phenothiazines may enhance the activity of propantheline and its derivatives. Chronic corticosteroid use may potentiate the adverse effects of propantheline (and its derivatives) on intraocular pressure. Propantheline and its derivatives may enhance the actions of sympathomimetics and thiazide diuretics. Propantheline and its derivatives may antagonize the actions of metoclopramide.
DOSES
Dogs:
- Bradycardia: 0.25–0.5 mg/kg p.o. q8–12h.
- Urge incontinence: 0.2 mg/kg p.o. q6–8h.
- GI indications: 0.25 mg/kg p.o. q8–12h (round dose to nearest 3.75 mg).
Cats:
- Urge incontinence: 0.25–0.5 mg/kg p.o. q12–24h.
- GI indications: doses as for dogs.

References
**Proparacaine** see **Proxymetacaine**

**Propentofylline**  
(Propentofylline, Vitofyllin, Vivitonin) **POM-V**

**Formulations:** Oral: 50 mg, 100 mg tablets.

**Action:** Propentofylline is a xanthine derivative that increases blood flow to the heart, muscle and CNS via inhibition of phosphodiesterase. It also has an antiarrhythmic action, bronchodilator effects, positive inotropic and chronotropic effects on the heart, inhibitory effects on platelet aggregation and reduces peripheral vascular resistance.

**Use:**
- Improvement of demeanour in animals.
- Treatment of age-related behaviour problems, in particular in combination with selegiline and dietary management for canine cognitive dysfunction.

Use with care in patients with cardiac disease.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not administer to pregnant bitches or breeding animals, as it has not yet been evaluated in this class of animal.

**Adverse reactions:** May increase myocardial oxygen demand.

**Drug interactions:** No information available.

**DOSES**
- **Dogs:** 2.5–5 mg/kg p.o. q12h. Administer 30 min prior to food.
- **Cats:** Cognitive dysfunction: 12.5 mg/cat p.o. q24h.

**References**

**Propofol**  
(Norofol, Procare, PropoFlo Plus, PropoFol, Propofol-Lipuro Vet, Rapinovet) **POM-V**

**Formulations:** Injectable: 10 mg/ml solution: lipid emulsion available both without a preservative or antibacterial or with a preservative (benzyl alcohol), 20 ml, 50 ml and 100 ml glass bottles. The solution containing a preservative can be used for up to 28 days after the vial is first broached.

**Action:** The mechanism of action is not fully understood but it is thought to involve modulation of the inhibitory activity of GABA at GABA<sub>A</sub> receptors.
Use:
• Induction of anaesthesia and maintenance of anaesthesia using intermittent boluses or a continuous rate infusion.

The solution containing benzyl alcohol preservative should not be used for maintenance of anaesthesia by continuous rate infusion due to the risk of toxicity caused by prolonged administration. Injection i.v. produces a rapid loss of consciousness as the CNS takes up the highly lipophilic drug. Over the next few minutes propofol distributes to peripheral tissues and the concentration in the CNS falls such that, in the absence of further doses, the patient wakes up. In dogs, propofol is rapidly metabolized in the liver and other extrahepatic sites, although the clinical relevance of extrahepatic metabolism in animals is not established and may be species-dependent: in cats recovery is less rapid due to the phenolic nature of the compound. Propofol does not have analgesic properties, therefore, it is better used in combination with other drugs to maintain anaesthesia; for example, a continuous rate infusion of a potent opioid. Considerable care must be taken with administration in hypovolaemic animals and those with diminished cardiopulmonary, hepatic and renal reserves.

Safety and handling: Shake the lipid emulsion well before use and do not mix with other therapeutic agents or therapeutic fluids prior to administration. If using a preparation that contains no bacteriostat, opened bottles should be stored in a refrigerator and used within 8 hours or discarded. Once broached, the lipid preparation with a preservative has a shelf-life of 28 days.

Contraindications: No information available.

Adverse reactions: The rapid injection of large doses causes apnoea, cyanosis, bradycardia and severe hypotension. Problems are less likely when injection is made over 30–60 seconds. Muscle rigidity, paradoxical muscle movements and tremors can sometimes occur in dogs immediately after i.v. administration. The muscle movements are unresponsive to management with diazepam, and further doses of propofol compound the problem. The tremors and movements wane with time without treatment. One study has shown that repeated daily administration (for 5 days) of the lipid preparation was associated with Heinz body anaemia in cats, although more recent studies have found conflicting results. Propofol is not irritant to tissues but a pain reaction is commonly evident during i.v. injection; the underlying mechanism causing pain is unknown.

Drug interactions: No information available.

DOSES
**Dogs:** Unpremedicated: 6–7 mg/kg i.v.; premedicated 1–4 mg/kg i.v. Continuous rate infusion for sedation or maintenance of anaesthesia: 0.1–0.4 mg/kg/min. Lower doses are required when propofol is combined with other drugs for maintenance of anaesthesia.
**Cats:** Unpremedicated: 8 mg/kg i.v.; premedicated 2–5 mg/kg i.v.
Continuous rate infusion for maintenance of anaesthesia is likely to result in a prolonged recovery in cats, doses of 0.1–0.4 mg/kg/min are appropriate depending on other agents given in combination.

References

**Propranolol**
(Propranolol*, Syprol*) POM

**Formulations:** Injectable: 1 mg/ml solution. Oral: 10 mg, 40 mg, 80 mg, 160 mg tablets. 5 mg/5 ml, 10 mg/5 ml, 40 mg/5 ml, 50 mg/5 ml oral solution.

**Action:** Non-selective beta-blocker. Blocks the chronotropic and inotropic effects of beta-1 adrenergic stimulation on the heart, thereby reducing myocardial oxygen demand. Blocks the dilatory effects of beta-2 adrenergic stimulation on the vasculature and bronchial smooth muscle, leading to vaso- and bronchoconstriction. The antihypertensive effects are mediated through reducing cardiac output, altering the baroreceptor reflex sensitivity and blocking peripheral adrenoceptors.

**Use:**
- Management of cardiac arrhythmias (sinus tachycardia, atrial fibrillation or flutter, supraventricular tachycardia, ventricular arrhythmias).
- Treatment of hypertrophic cardiomyopathy or obstructive cardiac disease (severe aortic or pulmonic stenosis).
- Potential efficacy as an additional antihypertensive drug.
- Can be used following introduction of alpha-blockade in management of phaeochromocytoma.
- Used to reverse some of the clinical features of thyrotoxicosis prior to surgery in patients with hyperthyroidism.
- May be used in behavioural therapy to reduce somatic signs of anxiety and is therefore useful in the management of situational anxieties and behavioural problems where contextual anxiety is a component. Some authors suggest using propranolol in combination with phenobarbital for the management of fear- and phobia-related behaviour problems.

There is a significant difference between i.v. and oral doses. This is a consequence of propranolol’s lower bioavailability when administered orally as a result of decreased absorption and a high first-pass effect. Wean off slowly when using chronic therapy.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not use in patients with bradyarrhythmias, acute or decompensated congestive heart failure. Relatively contraindicated in animals with medically controlled congestive heart failure as is poorly tolerated. Do not administer concurrently...
with alpha-adrenergic agonists (e.g. adrenaline). Care in cats with lower airway disease.

**Adverse reactions:** Bradycardia, AV block, myocardial depression, heart failure, syncope, hypotension, hypoglycaemia, bronchospasm, diarrhoea and peripheral vasoconstriction. Depression and lethargy are occasionally seen as a result of CNS penetration. Propranolol may exacerbate any pre-existing renal impairment. Sudden withdrawal of propranolol may result in exacerbation of arrhythmias or the development of hypertension.

**Drug interactions:** The hypotensive effect of propranolol is enhanced by many agents that depress myocardial activity including anaesthetic agents, phenothiazines, antihypertensive drugs, diuretics and diazepam. There is an increased risk of bradycardia, severe hypotension, heart failure and AV block if propranolol is used concurrently with calcium-channel blockers. Concurrent digoxin administration potentiates bradycardia. The metabolism of propranolol is accelerated by thyroid hormones, thus reducing its effect. The dose of propranolol may need to be decreased when initiating carbimazole therapy. Oral aluminium hydroxide preparations reduce propranolol absorption. Cimetidine may decrease the metabolism of propranolol, thereby increasing its blood levels. Propranolol enhances the effects of muscle relaxants (e.g. suxamethonium, tubocurarine). Hepatic enzyme induction by phenobarbital or phenytoin may increase the rate of metabolism of propranolol. There is an increased risk of lidocaine toxicity if administered with propranolol due to a reduction in lidocaine clearance. The bronchodilatory effects of theophylline may be blocked by propranolol. Although the use of propranolol is not contraindicated in patients with diabetes mellitus, insulin requirements should be monitored as propranolol may enhance the hypoglycaemic effect of insulin.

**DOSES**

**Dogs:**
- **Cardiac indications:** 0.02–0.08 mg/kg i.v. slowly over 5 min q8h; 0.1–1.5 mg/kg p.o. q8h. Start at the lower doses if myocardial function is poor and titrate upwards cautiously.
- **Phaeochromocytoma:** 0.15–0.5 mg/kg p.o. q8h in conjunction with an alpha-blocker.
- **Behavioural modification:** 0.5–3.0 mg/kg p.o. as required up to q12h.

**Cats:**
- **Cardiac indications and severe thyrotoxicosis (thyroid storm):** 0.02–0.06 mg/kg i.v. slowly (i.e. dilute 0.25 mg in 1 ml of saline and administer 0.1–0.2 ml boluses i.v. to effect); 2.5–5 mg/cat p.o. q8h.
- **Behavioural modification:** 0.2–1.0 mg/kg p.o. as required up to q8h.

**References**

Prostaglandin F2 see Dinoprost tromethamine

Protamine sulphate (Protamine sulphate*) POM

**Formulations:** Injectable: 10 mg/ml solution.

**Action:** An anticoagulant that, when administered in the presence of heparin, forms a stable salt, causing the loss of anticoagulant activity of both compounds.

**Use:**
- Treatment of heparin overdosage.

The effects of heparin are neutralized within 5 minutes of protamine administration, with the effect persisting for approximately 2 hours. In humans, protamine is also used for low molecular weight heparin (LMWH) overdose, however anti-Xa activity is not completely inhibited and no information is available for LMWH neutralization in cats and dogs.

**Safety and handling:** Do not store diluted solutions.

**Contraindications:** No information available.

**Adverse reactions:** Anaphylaxis, hypotension, bradycardia, nausea, vomiting, pulmonary hypertension and lethargy are seen in humans.

**Drug interactions:** No information available.

**DOSES**

**Dogs, Cats:** Heparin overdosage: 1 mg of protamine inactivates 80–100 IU of heparin. Heparin disappears rapidly from the circulation. Decrease the dose of protamine by half for each 30-minute period since the heparin was administered. Give protamine i.v. very slowly over 1–3 minutes. Do not exceed 50 mg in any 10-minute period. Dilute protamine in 5% dextrose or normal saline.

Proxymetacaine (Proparacaine) (Proxymetacaine*) POM

**Formulations:** Ophthalmic: 0.5% solution (single-use vials).

**Action:** Local anaesthetic action is dependent on reversible blockade of the sodium channel, preventing propagation of an action potential along the nerve fibre. Sensory nerve fibres are blocked before motor nerve fibres, allowing a selective sensory blockade at low doses.
Use: Proxymetacaine is used on the ocular surface (cornea and conjunctival sac), the external auditory meatus and the nares. It acts rapidly (within 1 minute) and provides anaesthesia for 25–55 minutes in the conjunctival sac depending on the species. Serial application increases duration and depth of anaesthesia. Topical anaesthetics block reflex tear production and should not be applied before a Schirmer tear test.

Safety and handling: Store in refrigerator and in the dark; reduced efficacy if stored at room temperature for >2 weeks.

Contraindications: Do not use for therapeutic purposes.

Adverse reactions: Conjunctival hyperaemia is common; local irritation manifested by chemosis may occasionally occur for several hours after administration (less likely than with tetracaine). All topical anaesthetics are toxic to the corneal epithelium and repeated application delays healing of ulcers.

Drug interactions: No information available.

DOSES

Dogs: Ophthalmic: 1–2 drops/eye; maximal effect at 15 min, duration 45–55 min. Aural/nasal: 5–10 drops/ear or nose every 5–10 min (maximum 3 doses if used intranasally).

Cats: Ophthalmic: 1–2 drops/eye; maximal effect at 15 min, duration 25 min.

Pyrantel

(Anthelmin, Cazitel, Cestem, Dolpac, Drontal, Endoguard, Prazitel, Veloxa, WORMclear, Various authorized proprietary products) POM-V

Formulations: Oral: 10 mg, 50 mg, 80 mg, 87 mg, 120 mg, 125 mg, 175 mg tablets; 5 mg/ml liquid. NB: some formulations and doses give content of pyrantel (febantel, oxantel) in terms of pyrantel embonate/pamonate (50 mg pyrantel is equivalent to 144 mg pyrantel embonate/pamonate).

Action: A cholinergic agonist which interferes with neuronal transmission in parasites and thereby kills them. Febantel and oxantel are derivatives of pyrantel with increased activity against whipworms.

Use: Control of Toxocara canis, Toxascaris leonina, Trichuris vulpis, Uncinaria stenocephala, and Ancylostoma caninum.

Safety and handling: Normal precautions should be observed.

Contraindications: Do not use in puppies <2 months or <1 kg. Safety has not been established in pregnant or lactating animals and therefore its use is not recommended.

Adverse reactions: Vomiting and diarrhoea may be observed.
Drug interactions: The addition of febantel or oxantel has a synergistic effect. Do not use with levamisole, piperazine or cholinesterase inhibitors.

DOSES
Dogs: 5 mg/kg pyrantel + 15 mg/kg febantel or 20 mg/kg oxantel p.o., repeat as required.
Cats: 57.5 mg/kg pyrantel embonate.

**Pyridostigmine**
(Mestinon*) POM

Formulations: Oral: 60 mg tablets (oral syrup 60 mg/5 ml available on import licence).

Action: Reversible inhibitor of cholinesterase activity, with a similar mechanism of action to neostigmine, but with a slower onset of activity and longer duration of action. It inhibits the enzymatic hydrolysis of acetylcholine by acetylcholinesterase and other cholinesterases, thereby prolonging and intensifying the physiological actions of acetylcholine. It may also have direct effects on skeletal muscle.

Use:
- Treatment of myasthenia gravis.
- Also used to reverse the neuromuscular blockade produced by competitive neuromuscular blockers, but in general is less effective than neostigmine.
- It may also have a role in the treatment of paralytic ileus.

It is specifically used to increase the activity of acetylcholine at nicotinic receptors and thereby stimulate skeletal muscle, the autonomic ganglia, and the adrenal medulla. However, it also prolongs the effect of acetylcholine released from postganglionic parasympathetic nerves, and also from some postganglionic sympathetic nerves to produce peripheral actions which correspond to those of muscarine. The muscarinic actions primarily comprise vasodilation, cardiac depression, stimulation of the vagus and parasympathetic nervous system, and increases in lacrimal, salivary and other secretions. The dosage should be reduced by 25% if muscarinic adverse effects appear. Overdose in myasthenic patients can be difficult to distinguish from the effects associated with myasthenic crisis. Treat muscarinic adverse effects with atropine. Animals with megaoesophagus should receive injectable therapy until able to swallow liquid or tablets.

Safety and handling: Normal precautions should be observed.

Contraindications: Do not use in patients with mechanical GI or urinary tract obstructions or peritonitis. Use with caution in patients with bronchial disease (especially feline asthma), bradycardia (and other arrhythmias), hypotension, renal impairment or epilepsy.
Adverse reactions: Vomiting, increased salivation, diarrhoea and abdominal cramps. Clinical signs of overdosage are related to muscarinic adverse effects and are generally less severe for pyridostigmine than for other parasympathomimetics (particularly neostigmine), but may include bronchoconstriction, increased bronchial secretions, lacrimation, involuntary defecation and micturition, miosis, nystagmus, bradycardia, heart block, arrhythmias, hypotension, agitation and weakness eventually leading to fasciculation and paralysis.

Drug interactions: Aminoglycosides, clindamycin, lincomycin and propranolol may antagonize the effect of pyridostigmine. Pyridostigmine may enhance the effect of depolarizing muscle relaxants (e.g. suxamethonium) but antagonize the effect of non-depolarizing muscle relaxants (e.g. pancuronium and vecuronium).

DOSES
Dogs: 0.2–5 mg/kg p.o. q8–12h. Dose should be incrementally adjusted to maximize muscle strength and minimize adverse effects.
Cats: 0.25 mg/kg p.o. q8–12h.

References

Pyrimethamine
(Daraprim*) P

Formulations: Oral: 25 mg tablet.
Action: Interference with folate metabolism of the parasite and thereby prevents purine synthesis (and therefore DNA synthesis).
Use:
- Treatment of infections caused by Toxoplasma gondii and Neospora caninum.
Should not be used in pregnant or lactating animals without adequate folate supplementation.
Safety and handling: Normal precautions should be observed.
Contraindications: No information available.
Adverse reactions: Depression, anorexia and reversible bone marrow suppression (within 6 days of the start of therapy). Folate supplementation (5 mg/day) may prevent bone marrow suppression.
Drug interactions: Increased antifolate effect if given with phenytoin or sulphonamides. Folate supplementation for the host will reduce the efficacy of the drug if given concomitantly and should thus be given a few hours before pyrimethamine.
DOSES

**Dogs, Cats:** Toxoplasmosis/neosporosis: 1 mg/kg p.o. q24h or divided q12h for 4 weeks, alongside sulphonamides.

**References**


---

**Pyriprole**

(Prac-tic) **POM-V**

**Formulations:** Topical: 125 mg/ml spot-on pipettes of various sizes.

**Action:** Interaction with ligand-gated (GABA) chloride channels, blocking pre- and post-synaptic transfer of chloride ions, leads to death of parasites.

**Use:**

- Treatment and prevention of flea infestations (*Ctenocephalides canis, C. felis*) and tick prevention in dogs >8 weeks and >2 kg.

For treatment of flea infestations, the additional use of an approved insect growth regulator is recommended. For large dogs, the 5 ml dose should be applied in 2–3 spots. Bathing is not recommended for 48 hours prior to and 24 hours after application.

**Safety and handling:** Normal precautions should be observed. May be harmful to aquatic organisms.

**Contraindications:** Safety has not been established in pregnant and lactating females. Do not use on cats.

**Adverse reactions:** Pruritus/dermatitis at application site, lethargy, ataxia, convulsions, emesis, diarrhoea.

**Drug interactions:** No information available.

**DOSES**

**Dogs:** Fleas and ticks: minimum dose 12.5 mg/kg topically q4wk.

**Cats:** Do not use.

**References**

Pyriproxyfen
(Duowin, Effipro, Fipralone Duo, Fipronil, 4fleas spot-on, Indorex household spray, Pyriproxyfen 1% premix for dogs, Pyriproxyfen spot-on, Vectra 3D, Vectra felis) **POM-V, AVM-GSL**

**Formulations:** Environmental spray with permethrin/piperonyl butoxide. Spot-on products (various sizes) with fipronil, (cats, dogs) or permethrin (dogs). Also available as combination with dinotefuran (an insecticide of the neonicotinoid class) and permethrin (Vectra 3D). **Oral:** 1% premix feed in 1.5 kg and 22.5 kg bags or barrels.

**Action:** Juvenile hormone analogue. Arrests the development of flea larvae in the environment.

**Use:** Use as part of a comprehensive flea control programme in conjunction with on-animal adulticide products.

**Safety and handling:** Normal precautions should be observed. The product should not enter watercourses as this may be dangerous for fish and other organisms.

**Contraindications:** Do not use environmental spray directly on animals. Products also containing permethrin should not be used on cats.

**Adverse reactions:** None reported.

**Drug interactions:** None reported.

**DOSES**

**Dogs, Cats:**
- **Fleas:** spot-on/spray products apply monthly.
- **Feed mix:** 100 g/10 kg body weight (equivalent to 500 μg (micrograms) pyriproxyfen/kg) per day.
- **Household spray:** one can covers 79 m². Use in the environment as directed.
Quinalbarbitone/Cinchocaine see Secobarbital

Rabacfosadine (Tanovea-CA1) POM-V

Formulations: Injectable: Sterile lyophilized powder for reconstitution before use. After reconstitution with 2 ml 0.9% NaCl, the reconstituted solution contains 8.2 mg/ml of rabacfosadine.

Action: Prodrug of the nucleotide analogue PMEG; causes cytotoxicity in dividing cells due to inhibition of DNA polymerases.

Use: Rabacfosadine has been trialled in canine lymphoma (B and T cell) and multiple myeloma.

Safety and handling: Potent cytotoxic drug that should only be prepared and administered by trained personnel. See Appendix and specialist texts for further advice on chemotherapeutic agents.

Contraindications: Contraindicated in patients with known hypersensitivity. Do not use in patients with pre-existing bone marrow suppression or liver dysfunction. Do not use in patients with known pulmonary disease or those susceptible to pulmonary fibrosis.

Adverse reactions: May cause myelosuppression and gastrointestinal adverse events (including haemorrhagic gastroenteritis). Liver enzyme activity elevation, azotaemia, fever, weight loss, lethargy, dermatological signs, pulmonary fibrosis, injected sclera and urinary signs/proteinuria/glycosuria are also reported.

Drug interactions: Not known at present.

DOSES
Dogs: 0.82–1 mg/kg i.v. over 30 min once every 21 days. Has been used in combination with doxorubicin at weeks 0, 6, 12 as part of an alternating protocol.

Cats: Unknown.

References
Saba CF, Vickery KR, Clifford CA et al. (2017) Rabacfosadine for relapsed canine B-cell lymphoma: efficacy and adverse event profiles of 2 different doses. Veterinary and Comparative Oncology 16, 76–82

Ramipril (Vasotop) POM-V

Formulations: Oral: 1.25 mg, 2.5 mg, 5 mg tablets.

Action: Angiotensin converting enzyme (ACE) inhibitor. It inhibits conversion of angiotensin I to angiotensin II and inhibits the breakdown of bradykinin. Overall effect is a reduction in preload and
afterload via venodilation and arteriodilation, decreased salt and water retention via reduced aldosterone production and inhibition of the angiotensin-aldosterone-mediated cardiac and vascular remodelling. Efferent arteriolar dilation in the kidney can reduce intraglomerular pressure and therefore glomerular filtration. This may decrease proteinuria.

**Use:**
- Treatment of congestive heart failure in dogs. Often used in conjunction with diuretics when heart failure is present as most effective when used in these cases. Can be used in combination with other drugs to treat heart failure (e.g. pimobendan, spironolactone, digoxin).
- Can also be used for heart failure in cats. The use of ACE inhibitors in cats with cardiac disease stems from extrapolation from theoretical benefits and studies showing a benefit in other species with heart failure and different cardiac diseases (mainly dogs and humans).
- Management of proteinuria associated with chronic renal insufficiency, glomerular disorders and protein-losing nephropathies.
- ACE inhibitors are more likely to cause or exacerbate prerenal azotaemia in hypotensive animals and those with poor renal perfusion (e.g. acute, oliguric renal failure). Use cautiously if hypotension, hyponatraemia or outflow tract obstruction are present.

May reduce blood pressure in hypertension. Regular monitoring of blood pressure, serum creatinine, urea and electrolytes is strongly recommended with ACE inhibitor treatment.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not use in cases of haemodynamically relevant outflow tract obstruction (e.g. valvular stenosis, obstructive hypertrophic cardiomyopathy).

**Adverse reactions:** Potential adverse effects include hypotension, hyperkalaemia and azotaemia. Monitor blood pressure, serum creatinine and electrolytes when used in cases of heart failure. Dosage should be reduced if there are signs of hypotension (weakness, disorientation). Anorexia, vomiting and diarrhoea are rare. It is not recommended for breeding, pregnant or lactating bitches, as safety has not been established.

**Drug interactions:** Concomitant use of potassium-sparing diuretics (e.g. spironolactone) or potassium supplements could result in hyperkalaemia. However, in practice, spironolactone and ACE inhibitors appear safe to use concurrently. There may be an increased risk of nephrotoxicity and decreased clinical efficacy when used with NSAIDs. There is a risk of hypotension with concomitant administration of diuretics, vasodilators (anaesthetic agents, antihypertensive agents) or negative inotropes (beta-blockers).
DOSES

**Dogs:** 0.125 mg/kg p.o. q24h increasing to 0.25 mg/kg p.o. q24h after 2 weeks depending on the severity of pulmonary congestion.

**Cats:** 0.125 mg/kg p.o. q24h increasing to 0.25 mg/kg p.o. q24h for systemic arterial hypertension.

References


---

**Ranitidine**

(Ranitidine*, Zantac*) POM

**Formulations:** Injectable: 25 mg/ml solution. Oral: 75 mg, 150 mg, 300 mg tablets; 15 mg/ml syrup.

**Action:** Ranitidine is a histamine (H2) receptor antagonist blocking histamine-induced gastric acid secretion. It is more potent than cimetidine but has lower bioavailability (50%) and undergoes hepatic metabolism. It also has some prokinetic effect through stimulation of local muscarinic acetylcholine receptors, which may be of benefit when gastric motility is impaired by gastritis or ulceration, and in feline idiopathic megacolon.

**Use:**
- Management of gastric and duodenal ulcers, idiopathic, uraemic or drug-related erosive gastritis, oesophagitis, and hypersecretory conditions secondary to gastrinoma, mast cell neoplasia or short bowel syndrome.
- GI prokinetic effect.

Studies show minimal increases in gastric pH in healthy dogs given ranitidine. Ranitidine was not an effective acid suppressant in healthy cats. If used for the treatment of ulceration, then treatment should continue for 2 weeks after remission of clinical signs which means typically a 1-month course. Absorption is not clinically significantly affected by food intake, anticholinergic agents, or antacids.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.

**Adverse reactions:** Rarely reported but include cardiac arrhythmias and hypotension, particularly if administered rapidly i.v.

**Drug interactions:** It is advisable, although not essential, that sucralfate is administered 2 hours before H2 blockers. Stagger oral doses of ranitidine when used with other antacids, digoxin or metoclopramide by 2 hours as it may reduce their absorption or effect.
DOSES

Dogs: All uses: 2 mg/kg slow i.v., s.c., p.o. q8–12h.

Cats: All uses: 2 mg/kg/day constant i.v. infusion, 2.5 mg/kg i.v. slowly q12h, 3.5 mg/kg p.o. q12h.

References


Retinol see Vitamin A

Rifampin (Rifampicin)
(Rifadin*, Rifampicin*, Rimactane*) POM

Formulations: Oral: 150 mg, 300 mg capsules; 20 mg/ml syrup.

Action: Binds to the beta subunit of RNA polymerase causing abortive initiation of RNA synthesis.

Use:

• Wide spectrum of antimicrobial activity including bacteria (particularly Gram-positives), Chlamydia, Rickettsia, some protozoans and poxviruses. Active against Staphylococcus aureus, S. pseudintermedius and Mycobacteria. Gram-negative aerobic bacteria are usually innately resistant. Obligate anaerobes (Gram-positive or Gram-negative) are usually susceptible. Exact indications for small animal veterinary practice remain to be fully established.

• It has been suggested as part of the combination of treatments for tuberculous and non-tuberculous mycobacterial infections and for lesions in cats associated with Rhodococcus equi.

• It may also have a place in the management of chlamydiosis, erlichiosis and bartonellosis.

• May be useful in the treatment of staphylococcal pyoderma resistant to 1st line treatments.

Chromosomal mutations readily lead to resistance, therefore, rifampin should be used in combination with other antimicrobial drugs to prevent the emergence of resistant organisms. Various combinations of clarithromycin, enrofloxacin, clofazamine and doxycycline have been used with rifampin in the management of mycobacteriosis. Until controlled studies are conducted to investigate the value of rifampin in these infections, recommendations remain empirical.

Safety and handling: Women of child-bearing age should not handle crushed or broken tablets or the syrup without the use of gloves.
Contraindications: Rifampin may be teratogenic at high doses and should not be administered to pregnant animals. It should not be administered to animals with liver disease.

Adverse reactions: In dogs, increases in serum levels of hepatic enzymes are commonly seen and this can progress to clinical hepatitis. Rifampin metabolites may colour urine, saliva and faeces orange-red.

Drug interactions: Rifampin is a potent hepatic enzyme inducer and increases the rate of metabolism of other drugs in humans, including barbiturates, theophylline and itraconazole. Increased dosages of these drugs may be required if used in combination with rifampin.

DOSES
See Appendix for guidelines on responsible antibacterial use.

Dogs, Cats: 10–15 mg/kg p.o. q24h.

References


Robenacoxib
(Onsior) POM-V

Formulations: Oral: 5 mg, 10 mg, 20 mg, 40 mg flavoured tablets for dogs; 6 mg flavoured tablets for cats. Injectable: 20 mg/ml solution.

Action: Selectively inhibits COX-2 enzyme, thereby limiting the production of prostaglandins involved in inflammation. Robenacoxib is tissue selective, defined as being preferentially distributed and concentrated at sites of inflammation combined with having a short half-life in plasma (approximately 2 hours). This may confer advantages in terms of reducing exposure of target side effect organs (e.g. liver and kidneys) to robenacoxib in a 24-hour dose interval, although there are currently no clinical data to support this contention.

Use:
- Alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.
- Reduction of postoperative pain and inflammation following orthopaedic and soft tissue surgery in dogs.
- Treatment of acute and chronic musculoskeletal pain and inflammation in cats.

Administer injectable preparation s.c. approximately 30 minutes before the start of surgery in order to provide perioperative analgesia. One injection provides pain control for up to 24 hours. All NSAIDs should be administered cautiously in the perioperative
period as they may adversely affect renal perfusion during periods of hypotension. If hypotension during anaesthesia is anticipated, delay robenacoxib administration until the animal is fully recovered and normotensive. The oral dose may be administered directly into the mouth or for cats mixed with a small amount of food. It is recommended not to administer to dogs with food as this has been shown to reduce efficacy. In the cat, due to the longer half-life and narrower therapeutic index of NSAIDs, particular care should be taken to ensure the accuracy of dosing and not to exceed the recommended dose. The tablets are very palatable to cats and many cats will eat spontaneously facilitating dosing. In dogs, treatment with the oral preparation should be discontinued after 10 days if no clinical improvement is apparent.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not give to dehydrated, hypovolaemic or hypotensive patients, or those with GI disease or blood clotting problems. Administration of robenacoxib to animals with renal disease must be carefully evaluated and is not advisable in the perioperative period. Do not give to pregnant animals or animals <12 weeks (dogs), <16 weeks (cats) or <2.5 kg body weight (cats and dogs).

**Adverse reactions:** GI signs are commonly reported, but most cases are mild and recover without treatment. Stop therapy if signs persist beyond 1–2 days. Some animals develop signs with one NSAID and not another. A 3–5-day wash-out period should be allowed before starting therapy with another NSAID. Stop therapy immediately if GI bleeding is suspected. There is a small risk that NSAIDs may precipitate cardiac failure in humans and this risk in animals is unknown. Liver disease will prolong the metabolism of robenacoxib, leading to the potential for drug accumulation and overdose with repeated dosing.

**Drug interactions:** Do not administer concurrently or within 24 hours of other NSAIDs and glucocorticoids. Do not administer with other potentially nephrotoxic agents, e.g. aminoglycosides.

**DOSES**

**Dogs, Cats:** 2 mg/kg s.c. q24h for a maximum of 2 doses; 1–2 mg/kg p.o. q24h. Monitoring of long term treatment (>12 weeks) is recommended in cats and dogs.

**References**


Rocuronium
(Esmeron*) POM

Formulations: Injectable: 10 mg/ml solution.

Action: Inhibits the actions of acetylcholine at the neuromuscular junction by binding competitively to the nicotinic acetylcholine receptor on the postjunctional membrane.

Use:
- Provision of neuromuscular blockade during anaesthesia.
- Improve surgical access through muscle relaxation, facilitate positive pressure ventilation or intraocular surgery.

Rocuronium is very similar to vecuronium but it has a more rapid onset of action and shorter duration to spontaneous recovery in dogs. Its availability in aqueous solution and longer shelf life increase convenience. Monitoring (using a nerve stimulator) and reversal of the neuromuscular blockade is recommended to ensure complete recovery before the end of anaesthesia. The neuromuscular blockade caused by rocuronium can be rapidly reversed using sugammadex (a cyclodextrin developed to reverse aminosteroidal neuromuscular blocking agents) at a dose of 8 mg/kg i.v. in dogs. Hypothermia, acidosis and hypokalaemia will prolong the duration of action of neuromuscular blockade. Hepatic disease may prolong duration of action of rocuronium; atracurium is preferred in this group of patients. The effects of renal disease on duration of action of rocuronium require further investigation; in an experimental study in cats, recovery from rocuronium was found to be independent of renal perfusion.

Safety and handling: Normal precautions should be observed.

Contraindications: Do not administer unless the animal is adequately anaesthetized and facilities to provide positive pressure ventilation are available.

Adverse reactions: Causes an increase in heart rate and a mild hypertension when used at high doses.

Drug interactions: Neuromuscular blockade is more prolonged when rocuronium is given in combination with volatile anaesthetics, aminoglycosides, clindamycin and lincomycin.

DOSES

Dogs: 0.4 mg/kg i.v. followed, when required, by a maintenance dose of 0.16 mg/kg i.v. prn or continuous rate infusion of 0.2 mg/kg/h. Considerably lower doses are required to centralize the globe for ophthalmic surgery (0.05–0.1 mg/kg i.v.).

Cats: Doses of 0.3–0.6 mg/kg i.v. have been evaluated in cats. 0.6 mg/kg had a rapid onset and short duration of action (20 min). Rocuronium has been evaluated to improve conditions for endotracheal intubation in cats at a dose of 0.6 mg/kg; however, this strategy requires prompt successful intubation and ventilation until the effects of the neuromuscular blockade wane (or the effects are reversed) and spontaneous respiration resumes.
Ronidazole
(Ronidazole) Special

Formulations: Chemical grade formulated for the treatment of an individual animal.

Action: Ronidazole is converted into polar autotoxic anion radicals within the organism.

Use:
- Treatment of Tritrichomonas foetus infections in cats.

Although licensed for use in pigeons, the formulation is not suitable for cats. However, as ronidazole is currently considered to be the treatment of choice for T. foetus, a special order on a named patient basis can be reformulated by an appropriate company and prescribed under the cascade.

Safety and handling: Embryotoxic and potentially teratogenic and carcinogenic. Care must be taken to avoid exposure, especially in women of reproductive age. Wear impervious gloves when handling and pilling and wash hands carefully after use.

Contraindications: Do not use in patients with hypersensitivity to nitroimidazoles such as metronidazole. Avoid use in pregnancy and use milk replacer if used in nursing cats.

Adverse reactions: Neurotoxicity has been reported in cats and signs may include lethargy, ataxia, nystagmus, seizures, agitation, tremors and anorexia.

Drug interactions: Likely to see similar interactions to metronidazole. Cimetidine and ketoconazole may decrease the metabolism and increase toxicity of ronidazole. Ronidazole may increase serum levels of ciclosporin and fluorouracil. Oxytetracycline may antagonize the efficacy of ronidazole. Phenobarbital, rifampin and phenytoin may increase the metabolism and decrease the efficacy of ronidazole. Ronidazole may potentiate the anticoagulant effects of warfarin.

DOSES
Dogs: No indication.
Cats: For treatment of T. foetus 20–30 mg/kg p.o. q24h for 14 days. Use reduced dose of 10 mg/kg p.o. q24h in kittens and cats with hepatopathy.

References
Ropinirole
(Clevor) POM-V

Formulations: Ophthalmic: 30 mg/ml eye drop solution in single-dose container.

Action: Dopamine agonist. Induces emesis by activating D2-like receptors in the chemoreceptor trigger zone.

Use: Induction of vomiting. Most dogs respond to a single dose. In healthy dogs, time to first vomit was 3–37 minutes (median 10 minutes). The median duration of vomiting was 16 minutes. Some dogs will require a second dose. A very small proportion of dogs may fail to respond to the second dose. It is not recommended to administer further doses to these dogs.

Safety and handling: Can cause eye irritation to humans. The product should not be administered by pregnant or breast-feeding women as ropinirole might reduce the level of prolactin.

Contraindications: Do not use in dogs with CNS depression, seizures or reduced gag reflex. Do not use in dogs that are hypoxic or dyspnoeic. Do not use in cases of ingestion of sharp foreign objects, corrosives, volatile substances or organic solvents. Safety has not been studied in dogs with cardiac disease/dysfunction, liver dysfunction or in dogs with clinical signs due to the ingestion of foreign materials. Safety and efficacy have not been studied in dogs with ocular disease. In cases of a pre-existing ocular condition with clinical signs, use the product only according to risk-benefit assessment. Not recommended in pregnant or lactating bitches.

Adverse reactions: Mild ocular irritation is common. May cause a transient increase in heart rate for up to 2 hours. May cause extended vomiting (>60 minutes). Administer antiemetic treatment if vomiting persists – metoclopramide is recommended.

Drug interactions: Dopamine antagonists (such as metoclopramide), chlorpromazine, acepromazine and other drugs with antiemetic properties (e.g. maropitant or antihistamines) may reduce effectiveness.

DOSES

Dogs: Induction of vomiting: 2–15 μl (microlitres)/kg in dogs, i.e. 1–8 drops given into the eye. Each eye drop is 27 μl and contains 810 μg (micrograms) of ropinirole. Dogs weighing 1.8–5 kg: 1 drop; 5.1–10 kg: 2 drops; 10.1–20 kg: 3 drops; 20.1–35 kg: 4 drops; 35.1–60 kg: 6 drops; 60.1–100 kg: 8 drops. When 2 to 4 drops are to be administered, divide between both eyes. When 6 to 8 drops are to be administered, the dose should be divided into two administrations given 1–2 minutes apart. If the dog does not vomit within 15 minutes, a second dose may be given. The second dose should be the same as the initial dose.

Cats: No information available.
Ropivacaine
(Naropin) POM

Formulations: 2 mg, 5 mg, 7.5 mg, 10 mg/ml solutions.

Action: Reversible blockade of the sodium channel in nerve fibres produces local anaesthesia.

Use:
- Provision of analgesia by perineural nerve blocks, regional and epidural techniques.

Onset of action (10–20 minutes for epidural analgesia) is slower than lidocaine, but quicker than bupivacaine, duration of action is still relatively prolonged (3–8 hours). Ropivacaine is less cardiotoxic than bupivacaine and is more selective for sensory nerves than bupivacaine, decreasing the degree of associated motor blockade following administration. Lower doses should be used when systemic absorption is likely to be high (e.g. intrapleural analgesia). Small volumes of ropivacaine can be diluted with normal saline to enable wider distribution of the drug for perineural blockade. Doses of ropivacaine up to 4 mg/kg q8h are unlikely to be associated with systemic side effects if injected perineurally, epidurally or intrapleurally in dogs. The toxic dose has not been established in cats; it is recommended not to exceed 2 mg/kg.

Safety and handling: Normal precautions should be observed.

Contraindications: Do not give i.v. or use for i.v. regional anaesthesia.

Adverse reactions: Inadvertent intravascular injection may precipitate cardiac arrhythmias that are refractory to treatment.

Drug interactions: All local anaesthetics share similar side effects, therefore, the dose of ropivacaine should be reduced when used in combination with other local anaesthetics. The addition of adrenaline does not appear to alter the duration of the block.

DOSES

Dogs:
- Perineural: volume of injection depends on the site of placement and size of the animal. As a guide: 0.1 ml/kg per injection site for femoral and sciatic nerve blocks; 0.1 ml/kg for each of the three injection sites for the combined radial, ulnar, musculocutaneous and median nerve blocks; 0.3 ml/kg for brachial plexus nerve block; 0.25–1 ml total volume for blockade of the infraorbital, mental, maxillary and mandibular nerves. Choose an appropriate concentration of ropivacaine to achieve a 2–3 mg/kg dose within these volume guidelines.
- Epidural: 1–2 mg/kg ropivacaine combined with preservative-free morphine 0.1–0.2 mg/kg. Limit the total volume of solution injected into the epidural space to 1 ml/4.5 kg up to a maximum volume of 6 ml in order to limit the cranial distribution of drugs in the epidural space and prevent adverse pressure effects.
• **Interpleural**: 1 mg/kg diluted with normal saline to a total volume of 5–20 ml depending on the size of the animal. The solution can be instilled via a thoracotomy tube. Dilution reduces pain on injection due to the acidity of ropivacaine.

**Cats**: Do not exceed 2 mg/kg total dose; accurate dosing in cats is essential to prevent overdose.

**References**

**S-Adenosylmethionine (SAMe)**

(Denamarin, Denosyl, Doxion, Hepaticare, Hepatosupport, Hepatosyl Plus, MaxxiSAMe, Novifit, Samylin, Zentonil Advanced, Various authorized proprietary products)

**GSL, general sale**

**Formulations:** Oral: 90 mg, 100 mg, 200 mg, 225 mg, 400 mg, 425 mg tablets; 50 mg, 100 mg, 200 mg capsules; 75 mg, 150 mg, 300 mg, 400 mg powder. Also included in some nutraceutical mixtures that may help cognitive functioning or reduce cognitive decline.

**Action:** S-Adenosylmethionine (SAMe) is an endogenous molecule synthesized by cells throughout the body and is a component of several biochemical pathways. SAMe is especially important in hepatocytes because of their central role in metabolism. SAMe is required for the production of glutathione (GSH), which is important in many metabolic processes and cell detoxification and is a potent antioxidant which protects hepatocytes from toxins and death. In liver disease, the level of GSH may be reduced, SAMe has been shown to increase hepatic GSH levels. SAMe also appears to have mood elevating effects in older animals, although the mechanism is unclear, since the evidence for neuronal penetration from oral administration is limited, but it may affect monoamine metabolism and membrane fluidity resulting in improved cell functioning. Supplementation with SAMe may also improve signs of age-related mental decline in dogs. In humans, antidepressant effects of SAMe are also documented.

**Use:**
- Adjunctive treatment for liver disease, especially for acute hepatotoxin-induced liver disease.
- Can also be used in patients on long-term therapy with potentially hepatotoxic drugs including lomustine (CCNU).
- SAMe may improve bile flow in cats.
- Used as an aid in the management of age-related behaviour problems and cognitive dysfunction in dogs and cats.

Administration should begin at the first signs of age-related behaviour problems. Tablets should be given whole. The use as an antidepressant therapy in animals has yet to be established. The safety of exogenous SAMe has not been proven in pregnancy; therefore, it should be used with caution.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.

**Adverse reactions:** GI signs (nausea, vomiting, diarrhoea), dry mouth, headache, sweating and dizziness are occasionally reported in humans. Paradoxical increase in anxiety may occur.
**Drug interactions:** Concurrent use of SAMe with tramadol, meperidine, pentazocine, MAOIs including selegiline, SSRIs such as fluoxetine, or other antidepressants (e.g. clomipramine, amitriptyline) could cause additive serotonergic effects. SAMe may increase the clearance of drugs that undergo hepatic glucuronidation, including paracetamol, diazepam and morphine.

**DOSES**

**Dogs:** All uses: At least 100 mg for every 10 kg p.o. q24h.

**Cats:** All uses: 100 mg/cat p.o. q24h.

Refer to individual products for dosing advice as regimens vary.

Suggested starting dose in absence of other information is 20 mg/kg p.o. q24h. Administer on an empty stomach at least 1 hour before food.

**References**


---

**Salbutamol**

*(Ventolin*) **POM**

**Formulations:** Inhalational: 100 μg per metered inhalation (Evohaler).

**Action:** Selective beta-2 stimulation causes smooth muscle relaxation and bronchodilation.

**Use:**

- Treatment of bronchospasm in inflammatory airway disease and irritation in cats and dogs.

Experimental studies have shown chronic use in cats can exacerbate airway inflammation, leading to recommendations that salbutamol be reserved for acute/short-term management in this species.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.

**Adverse reactions:** In humans, side effects of the beta-2 agonists include headache, muscle cramps and palpitation. Other side effects include tachycardia, arrhythmias, peripheral vasodilation, and disturbances of sleep and behaviour. Shivering and agitation is occasionally seen in dogs.

**Drug interactions:** In humans, there is an increased risk of side effects if salbutamol is used by patients also taking diuretics, digoxin, theophylline or corticosteroids.
DOSES

**Dogs:** Bronchodilation: 100–300 μg (micrograms)/dog q4–6h or as needed for relief of bronchospasm.

**Cats:** Bronchodilation: 100 μg (micrograms)/cat q4–6h or as needed for relief of bronchospasm.

References

---

**Sarolaner**
*(Simparica, Stronghold Plus)* **POM-V**

**Formulations:** Oral: 5 mg, 10 mg, 20 mg, 40 mg, 80 mg, 120 mg tablets. **Spot-on solution for cats with selamectin:** 3 sizes.

**Action:** Sarolaner acts at ligand-gated chloride channels, in particular those gated by the neurotransmitter gamma-aminobutyric acid (GABA), thereby blocking pre- and post-synaptic transfer of chloride ions across cell membranes.

**Use:**
- Treatment of fleas, ticks, ear mite infestations (*Otodectes cynotis*) in dogs and cats, demodicosis (*Demodex canis*) and *Sarcoptes scabiei* in dogs. Parasites need to start feeding on the host to become exposed to sarolaner; therefore, the transmission of infectious parasite-borne diseases cannot be excluded.
- Treatment of biting lice infestations (*Felicola subrostratus*), adult roundworms (*Toxocara cati*) and adult intestinal hookworms (*Ancylostoma tubaeforme*) (spot-on for cats).
- Prevention of heartworm disease caused by *Dirofilaria immitis*.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not use in dogs <8 weeks or <1.3 kg. Do not use in cats <8 weeks old or <1.25 kg.

**Adverse reactions:** Mild GI signs may occur. Mild pruritus at site of application of spot-on product.

**Drug interactions:** Sarolaner is highly bound to plasma proteins and might compete with other highly bound drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) and the cumarin derivative warfarin. No interactions were observed when sarolaner was co-administered with milbemycin oxime, moxidectin and pyrantel pamoate.

**DOSES**

**Dogs:** 2–4 mg/kg. Administer every month.

**Cats:** 6 mg/kg selamectin and 1 mg/kg sarolaner. Administer monthly.

References
Secobarbital (Quinalbarbitone/Cinchocaine) (Somulose) POM-V CD SCHEDULE 2

Formulations: Injectable: 400 mg/ml secobarbital with 25 mg/ml cinchocaine solution.

Action: Rapidly and profoundly depresses the CNS, including the respiratory centres. Cinchocaine has marked cardiotoxic effects at high doses. When given in combination, the barbiturate produces rapid loss of consciousness and cessation of respiration while the cinchocaine depresses cardiac conduction, resulting in early cardiac arrest. Since cardiac arrest is not dependent on development of profound hypoxia, euthanasia with the secobarbital/cinchocaine combination is generally not accompanied by the gasping that may occur with other agents.

Use:
- For euthanasia of cats and dogs.

Speed of injection is very important. An injection rate that is too slow may induce normal collapse but prolong the period until death. It is always advisable to have an alternative method of euthanasia available. Perivascular administration of secobarbital may delay the onset of effect and cause pain and result in excitement. Placement of a venous catheter is therefore recommended and care should be taken to ensure that the injection is correctly placed in the vein.

Safety and handling: This is a potent drug which is rapidly and highly toxic to humans. Extreme care should be taken to avoid accidental self-administration. Use an i.v. catheter instead of a needle whenever possible. Only administer in the presence of an assistant/other individual. Wear suitable protective gloves when handling. Wash off splashes from skin and eyes immediately. In the event of accidental self-administration, by injection or skin absorption, do not leave the person unattended, seek urgent medical assistance advising the medical services of barbiturate and local anaesthetic poisoning, and show the label advice to a doctor. Maintain airways in the injured person and give symptomatic and supportive treatment. Cinchocaine can cause hypersensitivity following skin contact; this can lead to contact dermatitis, which can become severe.

Contraindications: Somulose must not be used for anaesthesia as it is non-sterile and cardiotoxic.

Adverse reactions: No information available.

Drug interactions: No information available.

DOSES

Dogs, Cats: Euthanasia: 0.25 ml/kg i.v. over 10–15 seconds to minimize premature cardiac arrest.
Selamectin
(Selehold, Stronghold, Stronghold plus) POM-V

Formulations: Topical: spot-on pipettes, 5 sizes for dogs, 2 sizes for cats, containing 6% or 12% selamectin. Combined with sarolaner for cats.

Action: Interacts with GABA and glutamate-gated channels leading to flaccid paralysis of parasite.

Use:
- Treatment and prevention of flea and heartworm infestation (*Dirofilaria immitis*).
- Treatment of roundworms, biting lice, ear mites (cats and dogs), hookworms (cats).

Frequent shampooing may reduce the efficacy of the product. Can be used in lactation and pregnancy.

Safety and handling: Highly toxic to aquatic organisms; therefore, take care with disposal.

Contraindications: Not for use in cats and dogs <6 weeks.

Adverse reactions: Transient pruritus and erythema at the site of application may occur.

Drug interactions: Avoid use with other P-glycoprotein substrates.

DOSES
Dogs, Cats: Parasiticide: minimum dose recommendation 6 mg/kg. For flea and heartworm prevention apply monthly. For the treatment of roundworms, hookworms, lice and ear mites one application. For effective treatment of sarcoptic mange apply product on three occasions at 2-week intervals.

References

Selegiline (l-Deprenyl)
(Selgian) POM-V

Formulations: Oral: 4 mg, 10 mg tablets.

Action: Selegiline modifies the concentration of monoaminergic neurotransmitters, especially phenylethylamine and dopamine, by selectively inhibiting the activity of Type-B monoamine oxidase (which normally breaks down these chemicals). It also appears to have neuroprotective properties.

Use:
- Authorized for the treatment of behavioural disorders of purely emotional origin, such as depression and anxiety, and, in association with behaviour therapy, for the treatment of signs of
emotional origin observed in behavioural conditions such as overactivity, separation problems, generalized phobia and unsociable behaviour. These emotional disorders are characterized by a modification of feeding, drinking, autostimulatory behaviour, sleep, exploratory behaviour, aggression related to fear and/or irritation, social behaviour and somatic disorders (tachycardia, emotional micturition).

- It may also enhance learning in certain contexts and is indicated for the treatment of canine cognitive dysfunction, especially when signs of anxiety and/or social withdrawal are associated with these problems.
- It may also be used to treat signs of cognitive decline in older cats. Treatment can be stopped suddenly without gradual dose reduction.

Safety and handling: Normal precautions should be observed.

Contraindications: Selegiline should not be used in animals with a known sensitivity to the drug or administered to lactating or pregnant bitches as it may act on prolactin secretion.

Adverse reactions: No information available.

Drug interactions: Selegiline should not be administered with alpha-2 antagonists (or within 24 hours before or after their use), pethidine, ephedrine, potential monoamine oxidase inhibitors (e.g. amitraz) or phenothiazines. The effect of morphine is potentiated when used simultaneously. Potential interactions with metronidazole, prednisolone and trimethoprim may exist. Selegeline should not be used for at least 2–3 weeks after the use of tricyclic antidepressants (e.g. amitriptyline, doxepin, clomipramine), or 6 weeks after the long term use of fluoxetine.

DOSES
Dogs: 0.5–1 mg/kg p.o. q24h for a minimum of 2 months.
Cats: 1 mg/kg p.o. q24h.

References

Sertraline
(Lustral*) POM

Formulations: Oral: 50 mg, 100 mg tablets.
Action: Blocks serotonin reuptake in the brain, resulting in antidepressive activity and a raising in motor activity thresholds.
Use:
- Treatment of anxiety-related behaviours, including compulsive type behaviour such as acral lick in dogs.
- Used to increase inhibitory control in cats (e.g. play-related aggressive behaviour) has been suggested, but there are no good empirical studies published to support this.
The specific serotonin reuptake inhibitor fluoxetine has been approved for use in dogs, although the veterinary formulation is not currently available; the non-specific serotonin reuptake inhibitor clomipramine is authorized and available for use in dogs, accordingly these drugs should generally be used in preference, although there is some anecdotal evidence to suggest sertraline may have less appetite suppressant effects than generic formulations of fluoxetine.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Known sensitivity to sertraline or other SSRIs, history of seizures.

**Adverse reactions:** Possible reactions include lethargy, decreased appetite and vomiting. Trembling, restlessness, GI disturbance and an apparent paradoxical increase in anxiety may occur in some cases. Owners should be warned of a potential increase in aggression in response to medication.

**Drug interactions:** Sertraline should not be used within 2 weeks of treatment with an MAOI (e.g. selegiline) and a MAOI should not be used within 6 weeks of treatment with sertraline. Sertraline, like other SSRIs, antagonizes the effects of anticonvulsants and so is not recommended for use with epileptic patients or in association with other agents which lower seizure threshold, e.g. phenothiazines. Caution is warranted if sertraline is used concomitantly with aspirin or other anticoagulants since the risk of increased bleeding in the case of tissue trauma may be increased. Should not generally be used alongside other serotonergic agents given risk of serotonin syndrome, although use alongside trazodone may be considered in exceptional cases, so long as patient carefully monitored for signs of serotonin syndrome.

**DOSES**

**Dogs:** 1–3 mg/kg p.o. q24h, although higher doses are described in the literature.

**Cats:** 0.5–1.5 mg/kg p.o. q24h.

**Sevelamer hydrochloride**

(Renagel) **POM**

**Formulations:** Oral: 800 mg tablets.

**Action:** Sevelamer is an organic ion-exchange resin that binds intestinal phosphate.

**Use:**
- Reduction of serum phosphate in azotaemia.

Hyperphosphataemia is implicated in the progression of chronic renal failure. Phosphate-binding agents are usually only used if low phosphate diets are unsuccessful. Monitor serum phosphate levels at 4–6 week intervals and adjust dosage accordingly if trying to
achieve target serum concentrations. May inhibit vitamin absorption including vitamin K; consider monitoring prothrombin time.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** GI obstruction.

**Adverse reactions:** Pills are hygroscopic and will expand. Constipation is possible.

**Drug interactions:** No information available.

**DOSES**

**Dogs, Cats:** Chronic kidney disease: 30–40 mg/kg p.o. q8h, titrated to the desired serum phosphate concentration. Should be given with meals and at least 1 hour before or 3 hours after other medications.

---

**Sevoflurane**

(SevoFlo, Sevotek*) **POM-V**

**Formulations:** Inhalational: 250 ml bottle containing liquid sevoflurane.

**Action:** The mechanism of action of volatile anaesthetic agents is not fully understood.

**Use:**

- Induction and maintenance of anaesthesia.

Sevoflurane is potent and highly volatile so should only be delivered from a suitable calibrated vaporizer. It is less soluble in blood than halothane and isoflurane; therefore, induction and recovery from anaesthesia are quicker. Sevoflurane has a less pungent smell than isoflurane and induction of anaesthesia using chambers or masks is usually well tolerated in small dogs and cats. The concentration of sevoflurane required to maintain anaesthesia depends on the other drugs used in the anaesthesia protocol; the concentration should be adjusted according to clinical assessment of anaesthetic depth. The cessation of administration results in rapid recovery, which may occasionally be associated with signs of agitation. Sevoflurane does not sensitize the myocardium to catecholamines to the extent that halothane does.

**Safety and handling:** Measures should be adopted to prevent contamination of the environment.

**Contraindications:** No information available.

**Adverse reactions:** Causes a dose-dependent hypotension that does not wane with time. The effects of sevoflurane on respiration are dose-dependent and comparable to isoflurane, i.e. more depressant than halothane. Sevoflurane crosses the placental barrier and will affect neonates delivered by caesarean section. Sevoflurane is degraded by soda lime to compounds that are nephrotoxic in rats (principally Compound A). Conditions accelerating degradation
(i.e. low gas flows, high absorbent temperatures and high sevoflurane concentrations) should be avoided in long operations, although no studies in dogs have demonstrated Compound A to accumulate in concentrations capable of causing renal toxicity.

Drug interactions: Sedatives, opioid agonists and nitrous oxide reduce the concentration of sevoflurane required to achieve surgical anaesthesia. The effects of sevoflurane on the duration of action of non-depolarizing neuromuscular blocking agents are similar to those of isoflurane, i.e. greater potentiation compared with halothane.

DOSES
Dogs, Cats: The expired concentration required to maintain surgical anaesthesia in 50% of recipients is about 2.5% in animals (minimum alveolar concentration). Administration of other anaesthetic agents and opioid analgesics reduces the dose requirement of sevoflurane; therefore, the dose should be adjusted according to individual requirement. 6–8% sevoflurane concentration is required to induce anaesthesia in unpremedicated patients.

Sildenafil
(Revatio*, Sildenafil*, Viagra*) POM

Formulations: Oral: 20 mg, 25 mg, 50 mg tablets, 10 mg/ml oral suspension (Revatio). Injectable: 0.08 mg/ml (Revatio IV). Special reformulations available: 6.25 mg, 10 mg and 12.5 mg tablets.

Action: Pulmonary vasculature vasodilation, due to an increase in vascular levels of cGMP caused by inhibition of cGMP-specific phosphodiesterase type V.

Use: Indicated for the treatment of pulmonary arterial hypertension. Data from clinical studies suggest that while sildenafil therapy in dogs with pulmonary hypertension does not significantly reduce the echocardiographic measurements, patients receiving therapy may have improvements in quality of life.

Safety and handling: Normal precautions should be observed.

Contraindications: Systemic hypotension, significant hepatic or renal impairment or bleeding disorders.

Adverse reactions: Vomiting, dizziness and raised intraocular pressure.

Drug interactions: Cimetidine, erythromycin, itraconazole and phenobarbital increase plasma sildenafil concentration. Sildenafil treatment should not be started at the same time as an alpha-adrenergic blocker. Avoid concomitant use of nitrates, which significantly enhance its hypotensive effect.

DOSES
Dogs: 0.5–2.7 mg/kg p.o. q8–24h; suggested median dose from clinical studies in dogs is 3 mg/kg/day.
Cats: Reported dose of 1.6 mg/kg p.o. q12h tolerated and clinically efficacious.

References

Silver sulfadiazine (Flamazine*) POM

Formulations: Topical: 1% cream (water-soluble).

Action: Slowly releases silver in concentrations that are toxic to bacteria and yeasts. The sulfadiazine component also has anti-infective qualities.

Use:
- Topical antibacterial and antifungal drug particularly active against Gram-negative organisms such as *Pseudomonas aeruginosa*.
- Used in the management of second and third degree burns to prevent infection.

Up to 10% may be absorbed, depending on the size of area treated.

Safety and handling: Use gloves.

Contraindications: Do not use in neonates or pregnant animals.

Adverse reactions: Patients hypersensitive to sulphonamides may react to silver sulfadiazine. It may accumulate in patients with impaired hepatic or renal function.

Drug interactions: No information available.

DOSES
See Appendix for guidelines on responsible antibacterial use.

Dogs, Cats: Localized skin infections: Apply a thin film twice daily after cleaning area with antiseptic.

References
Silybin (Milk thistle, Silibinin, Silymarin)  
(Denamarin, Doxion, Hepaticare, Hepatosupport,  
Hepatosyl Plus, Samylin, Zentonil Advanced,  
Various authorized proprietary products)  
AVM-GSL, general sale

Formulations: Oral: 9 mg, 24 mg, 25 mg, 35 mg, 40 mg, 50 mg,  
70 mg, 100 mg tablets; 10 mg, 40 mg, 53 mg powder.

Action: Silybin is the active component of milk thistle or silymarin. 
It acts as an antioxidant and free radical scavenger, promotes 
hepatocyte protein synthesis, increases the level of glutathione, and 
stimulates biliary flow and the production of hepatoprotective bile 
acids. It also inhibits leukotriene production so reducing the 
inflammatory response.

Use:  
• Adjunctive treatment for liver disease, especially for acute 
hepatotoxin-induced liver disease.  
• Can also be used in patients on long-term therapy with 
potentially hepatotoxic drugs including lomustine (CCNU).

Safety and handling: Normal precautions should be observed.

Contraindications: No information available.

Adverse reactions: None reported. GI signs, pruritus and 
headaches have been recognized in primates.

Drug interactions: Silybin may inhibit microsomal cytochrome 
P450 isoenzyme 2C9 (CYP2C9). May increase plasma levels of 
beta-blockers (e.g. propranolol), calcium-channel blockers (e.g. 
verapamil), diazepam, lidocaine, metronidazole, pethidine and 
theophylline. Silymarin may increase the clearance of drugs that 
undergo hepatic glucuronidation, including paracetamol, diazepam 
and morphine. Clinical significance has not been determined for this 
interaction and the usefulness of silymarin for treating paracetamol 
toxicity has not been determined.

DOSES  
Dogs, Cats: Therapeutic dosage is unknown, but suggested doses 
range from 50–250 mg/kg p.o. q 24h. Refer to individual products 
for dosing advice.

References  
Vandeweerd JM, Cambier C and Gustin P (2013) Nutraceuticals for canine liver disease: 
assessing the evidence. Veterinary Clinics of North America: Small Animal Practice 43, 
1171–1179

Sodium acid phosphate see Phosphate enema
Sodium bicarbonate
(Sodium bicarbonate*) POM

Formulations: Injectable: 1.26%, 4.2%, 8.4% solutions for i.v. infusion (8.4% solution = 1 mmol/ml). Oral: 300 mg, 500 mg, 600 mg tablets.

Action: Provision of bicarbonate ions.

Use:
- Management of severe metabolic acidosis.
- Urine alkalinization.
- Adjunctive therapy in the treatment of hypercalcaemic or hyperkalaemic crisis.

Active correction of acid–base imbalance requires blood gas analysis. Do not attempt specific therapy unless this facility is immediately available. 1 g of sodium bicarbonate provides 11.9 mEq of Na\(^+\) and 11.9 mEq of bicarbonate. In hypocalcaemic patients use sodium bicarbonate cautiously and administer slowly. As oral sodium bicarbonate (especially at higher doses) may contribute significant amounts of sodium, use with caution in patients on salt-restricted intakes, e.g. those with congestive heart failure.

Safety and handling: Normal precautions should be observed.

Contraindications: Should not be used in animals that are unable to effectively expel carbon dioxide (e.g. hypoventilating, hypercapnoeic patients).

Adverse reactions: Excessive use of sodium bicarbonate i.v. can lead to metabolic alkalosis, hypernatraemia, congestive heart failure, a shift in the oxygen dissociation curve causing decreased tissue oxygenation, and paradoxical CNS acidosis leading to respiratory arrest.

Drug interactions: Sodium bicarbonate is incompatible with many drugs and calcium salts: do not mix unless checked beforehand. Alkalinization of the urine by sodium bicarbonate decreases the excretion of sympathomimetic drugs, and increases the excretion of aspirin, phenobarbital and tetracyclines (especially doxycycline).

DOSES

Dogs, Cats:
- Severe metabolic acidosis: mmol NaHCO\(_3\) required = base deficit × 0.5 × body weight (kg) (0.3 is recommended instead of 0.5 in some references). Give half the dose slowly over 3–4 hours, recheck blood gases and clinically re-evaluate the patient. Avoid over-alkalinization.
- Adjunctive therapy of hypercalcaemia: 0.5–1 mmol/kg i.v. over 30 min.
- Adjunctive therapy of hyperkalaemia: 1–2 mmol/kg i.v. over 30 min.
• Metabolic acidosis secondary to renal failure or to alkalinize the urine: initial dose 8–12 mg/kg p.o q8h and then adjust dose to maintain total CO₂ concentration at 18–24 mEq/l. The dose may be increased to 50 mg/kg to adjust urine pH in patients with normal renal, hepatic and cardiac function.

**Sodium chloride**
*(Aqupharm, Hypertonic saline, Sodium chloride, Vetivex) POM-V*

**Formulations:** Injectable: 0.45% to 7% NaCl solutions; 0.18% NaCl with 4% glucose and 0.9% NaCl with 5% glucose solutions. Oral: 300 mg, 600 mg tablets. Ophthalmic: 5% ointment (compounded by an ocular pharmacy).

**Action:** Isotonic and hypertonic formulations expand plasma volume and replaces lost extracellular fluid. Hypotonic formulations provide free water and may promote oedema formation. When used for fluid replacement NaCl (0.45% and 0.9%) will expand the plasma volume compartment. Compared with colloids, 2.5 to 3.0 times as much fluid must be given because the crystalloid is distributed to other fluid compartments.

**Use:**
- Intravenous fluid replacement, including treatment of choice for patients with hypercalcaemia or hyperchloraemic alkalosis.
- Sodium chloride solutions are often used as a drug diluent.
- Hypertonic saline is used to expand the circulating blood volume rapidly in animals with shock, particularly during the preoperative period.
- The hypertonic ophthalmic ointment is used in the management of corneal oedema.
- Oral sodium supplementation is recommended by some authors in the long-term management of hypoadrenocorticism.

Hypertonic saline solutions have very high sodium concentrations and it is important to monitor serum sodium concentrations before and after their administration; maintenance with an isotonic crystalloid is usually required after administration to correct electrolyte and fluid disturbances created by the administration of the hypertonic solution.

**Safety and handling:** Hypertonic saline solutions should be regarded as drugs and not as intravenous fluids and should be stored separately to prevent confusion.

**Contraindications:** Hypertonic saline should not be administered to dehydrated animals and hypotonic solutions should not be administered to hypovolaemic animals.

**Adverse reactions:** Peripheral oedema is more likely to occur after crystalloids because muscle and subcutaneous capillaries are less permeable to protein. Normal saline contains higher amounts of
chloride than plasma, which will increase the risk of acidosis. The degree of acidosis is not likely to be a problem in a healthy patient but acidosis may be exacerbated in a compromised patient. Hypertonic saline administered at fluid rates >1 ml/kg/min can cause a vagally mediated bradycardia, therefore the rate of fluid administration must be carefully controlled. Enteric-coated products for oral use may not be adequately absorbed by dogs and therefore may be of unpredictable efficacy. The ophthalmic ointment may cause a stinging sensation.

**Drug interactions:** No information available.

**DOSES**

**Dogs, Cats:**

- **Fluid therapy:** fluid requirements depend on the degree of dehydration and ongoing losses. In uncomplicated cases 0.45–3% solutions should be administered at a dose of 50–60 ml/kg/day i.v., p.o. Higher doses are required if the animal is dehydrated. Solutions containing 0.9% to 3% NaCl are suitable for replacing deficits. Solutions containing 0.45% NaCl (with added potassium) are indicated for longer-term maintenance.

- **Hypotension/shock:** 5% to 7.5% NaCl solutions (hypertonic saline) at doses of 3–8 ml/kg i.v. Solutions of this concentration are hypertonic, therefore, they should be used with caution and with other appropriate fluid replacement strategies. Hypertonic NaCl may be combined with colloid solutions to stabilize the increase in vascular volume provided by the hypertonic solution.

- **Salt-wasting syndromes (hypoadrenocorticism):** 1–5 g p.o. q24h.

- **Corneal oedema:** apply a small amount of ointment q4–24h.

**References**


**Sodium chromoglycate** see **Sodium cromoglicate**

**Sodium citrate**

*(Micolette*, Micralax*, Relaxit*)

**Formulations:** Rectal: micro-enemas containing 450 ml sodium citrate with 45 mg sodium alkylsulphoacetate (Micralax) or 45 mg sodium lauryl sulphoacetate (Micolette) or 75 mg sodium lauryl sulphate (Relaxit).

**Action:** An osmotic laxative that causes water to be retained within the lumen of the GI tract. It is formulated with a stool softener that augments its action.

**Use:** Low-volume enema used to treat constipation and to prepare the lower GI tract for proctoscopy and radiography.
Safety and handling: Normal precautions should be observed.

Contraindications: Not recommended for use in cases with inflammatory bowel disease.

Adverse reactions: Uncommon. Largely due to water and electrolyte disturbances.

Drug interactions: No information available.

DOSES
Dogs, Cats: All uses: 1 enema inserted per rectum to full length of nozzle.

Sodium cromoglicate (Sodium chromoglycate)
(Catacrom*, Intal*, Nalcrom*, Opticrom*, Optrex allergy Pollinase*, Sodium cromoglicate*, Vividrin*) P, POM

Formulations: Topical: 2% ocular drops; 2%, 4% nasal spray. Oral: 100 mg tablet.

Action: Stabilizes mast cell membranes, preventing degranulation.

Use:
• Management of allergic conjunctivitis and rhinitis.

Action is localized to the site of application.

Safety and handling: Normal precautions should be observed.

Contraindications: No information available.

Adverse reactions: May cause local irritation.

Drug interactions: No information available.

DOSES
Dogs, Cats: Allergic reactions: 1–2 drops in eye or nose q6h.

Sodium hypochlorite (Hypochlorous acid)
(Renasan spray, Vetericyn Regular, Vetericyn VF ) GSL

Formulations: Vetericyn VF (veterinary formulation) contains 150 ppm free active chlorine, 250 ml, 500 ml bottles. Vetericyn Regular contains 80 ppm, 89 ml, 236 ml, 473 ml bottles. Renasan contains 140 ppm, 60 ml, 100 ml, 250 ml, 500 ml, 750 ml bottles.

Action: Assists in the mechanical removal of cellular debris, senescent cells, necrotic tissue, and foreign material from the skin
and wound surface through debridement and has antibacterial and antifungal action. The hypochlorous acid is pH balanced to a physiological range.

**Use:** For the topical treatment of wounds and skin infections.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** None reported.

**Adverse reactions:** None reported.

**Drug interactions:** None reported.

**DOSES**

*Dogs, Cats:* Spray affected areas up to twice daily.

**References**


---

**Sodium stibogluconate (Pentostam*) POM**

**Formulations:** Injectable: 100 mg/ml solution.

**Action:** Active against the amastigote stages of *Leishmania*; exact mode of action unknown.

**Use:**

- Treatment of leishmaniosis in dogs.

Animals may be clinically normal after treatment but remain carriers, and follow-on treatment with allopurinol may be beneficial. Seek expert advice before treating leishmaniosis. Use with caution in patients with hepatic impairment.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Significant renal impairment; lactating animals.

**Adverse reactions:** Pain and inflammation at the injection site, anorexia and vomiting, and myalgia. Meglumine antimonate is said to be less toxic.

**Drug interactions:** No information available.

**DOSES**

*Dogs:* Leishmaniosis: 30–50 mg/kg i.v., s.c. q24h for 3–4 weeks. If giving i.v., administer slowly (over at least 5 min) to avoid cardiac toxicity.

*Cats:* No information available.

**References**

**Somatotropin** *(Growth hormone)*  
*(Genotropin*, *Humatrope*, *Norditropin*)  
POM

**Formulations:** Injectable: 2–16 IU vials for reconstitution.

**Action:** Recombinant human growth hormone that mimics growth hormone action in other species.

**Use:** Treatment of growth hormone deficiency. Serum IGF-1 measurements may be helpful to monitor therapy. Antibody formation may limit its effectiveness in the long term.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.

**Adverse reactions:** Growth hormone is diabetogenic; monitor blood glucose. Local reactions may be seen; rotate injection sites.

**Drug interactions:** No information available.

**DOSES**

*Dogs, Cats:* Growth hormone replacement: 0.3–0.7 IU/kg weekly divided into 3–5 doses s.c., i.m. (painful). Continue for at least 6 weeks to evaluate response.

---

**Sotalol**  
*(Sotacor*, *Sotalol*)  
POM

**Formulations:** Oral: 40 mg, 80 mg, 160 mg, 200 mg tablets. Injectable: 10 mg/ml solution. Special reformulations available: 10 mg, 30 mg tablets.

**Action:** Produces a prolongation of action potential duration and refractory period, via selective inhibition of potassium channels (Class III antiarrhythmic). Also has non-selective beta-adrenergic blocking effects, but considered a weak beta-blocker.

**Use:**

- Treatment of ventricular arrhythmias, less so supraventricular arrhythmia (most associated with accessory pathway). Used most commonly in dogs with ventricular arrhythmias secondary to myocardial disease.

The beta-blocking activity is about one-third that of propranolol. Preferable to assess efficacy with repeated Holter ECG monitoring. Can be used successfully in combination with mexilitine for severe ventricular arrhythmia. Use with caution in patients with renal failure or medically controlled CHF.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Asthma, sinus bradycardia, AV block or decompensated CH, long QT on ECG.
Adverse reactions: The non-selective beta-blocking effects can decrease heart rate, stroke volume and cardiac output in dogs and may precipitate congestive heart failure. The drug is eliminated in urine and faeces and elimination half-life may increase with renal insufficiency, leading to accumulation at standard doses. Adverse effects include hypotension, bradyarrhythmias, bronchospasm, depression, nausea, vomiting and diarrhoea. The drug is potentially proarrhythmic and high doses can cause prolonged QT interval and increase the risk of torsades de pointes, especially if hypokalaemia is present.

Drug interactions: Sympathomimetics (e.g. terbutaline, phenylpropanolamine, adrenaline) may have their actions blocked by sotalol and they may, in turn, reduce the efficacy of sotalol. Additive myocardial depression may occur with the concurrent use of sotalol and other beta-blockers or myocardial depressant anaesthetic agents. Hypotensive effects may be enhanced by phenothiazines, furosemide, hydralazine and other vasodilators. Sotalol may prolong the hypoglycaemic effects of insulin therapy. Concurrent use of negative inotropics (e.g. calcium-channel blockers) should be done with caution, particularly in patients with pre-existing systolic dysfunction or CHF.

DOSES
Dogs: 0.5–3 mg/kg p.o. q12h. Start with lower doses if myocardial function is reduced. Anecdotal doses starting at 0.5 mg/kg i.v. given over 2 min, up to 3 times (to a total dose of 1.5 mg/kg i.v.).
Cats: 10–20 mg/cat p.o. q12h.

References
Gelzer ARM, Kraus MS, Rishniw M et al. (2010) Combination therapy with mexiletine and sotalol suppresses inherited ventricular arrhythmias in German Shepherd Dogs better than mexiletine or sotalol monotherapy: a randomized cross-over study. Journal of Veterinary Cardiology 12, 93–106
Meurs KM, Spier AW, Wright NA et al. (2002) Comparison of the effects of four antiarrhythmic treatments for familial ventricular arrhythmias in Boxers. Journal of the American Veterinary Medical Association 221, 522–527

Spinosad
(Comfortis, Trifexis) POM-V

Formulations: Oral: 90 mg, 140 mg, 270 mg, 425 mg, 665 mg, 1040 mg, 1620 mg chewable tablets. Also available with milbemycin (Trifexis).

Action: Activation of nicotinic acetylcholine receptors.

Use:
• Treatment and prevention of flea infestations.

As it acts on larvae and adults, there will be a short lag phase after administration due to the emergence of adult fleas from pupae already in the environment. If used as part of a treatment programme for flea allergy dermatitis, then combine with an insect
growth regulator. Give with food. Do not administer spinosad/milbemycin (Trifexis) for any more than 6 consecutive months in 1 year. Caution in epileptic animals. Safety in pregnancy, lactation and breeding unknown.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Avoid in dogs and cats weighing <1.2 kg or <14 weeks of age as accurate dosing not possible. The safety of spinosad/milbemycin in dogs with an MDR1 mutation has not been demonstrated and these dogs may be at increased risk of adverse effects.

**Adverse reactions:** Vomiting occurs occasionally. Rare side effects include lethargy, diarrhoea, anorexia, ataxia and seizures.

**Drug interactions:** This is a P-glycoprotein substrate, therefore, use with caution if combining with other substrate drugs (e.g. digoxin, doxorubicin). Do not use in combination with macrocyclic lactones (e.g. the avermectins).

**DOSES**

**Dogs:** Fleas: 45–70 mg/kg p.o. q28d with or immediately after food. 
**Cats:** Fleas: 50–75 mg/kg p.o. q28d with or immediately after food.

**Spiramycin** see **Metronidazole**

**Spironolactone**

(Cardalis, Prilactone, Aldactone*, Spironolactone*) **POM-V, POM**

**Formulations:** Oral: 10 mg, 40 mg, 50 mg, 80 mg, 100 mg tablets. Available in compound preparations with benazepril (2.5 mg benazepril/20 mg spironolactone; 5 mg benazepril/40 mg spironolactone; 10 mg benazepril/80 mg spironolactone) (Cardalis).

**Action:** Aldosterone receptor antagonist that acts on the kidneys as a weak potassium-sparing diuretic (preventing sodium resorption in the distal tubule) via competition with aldosterone for the mineralocorticoid receptor in the principle cells of the collecting duct and acts on the myocardium and vasculature to inhibit aldosterone-mediated fibrosis and remodelling.

**Use:**

- Used in the management of ascites secondary to hepatic failure (when hypokalaemia can exacerbate hepatic encephalopathy).
- Treatment of hyperaldosteronism due to adrenal tumours.

Spironolactone is a weak diuretic and does not have a significant diuretic effect in healthy dogs. Its beneficial effects in heart failure...
appear to be related to inhibition of myocardial fibrosis, vascular remodelling and endothelial dysfunction. It is particularly useful for hypokalaemic patients with heart failure. Use with caution in patients with renal or hepatic dysfunction.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not use in animals with hypoadrenocorticism, hyperkalaemia or hyponatraemia. Do not give in conjunction with NSAIDs to animals with renal insufficiency. Do not use during pregnancy, lactation, or in animals intended for breeding.

**Adverse reactions:** Hyponatraemia and hyperkalaemia may develop. Discontinue if hyperkalaemia occurs. Reversible prostatic atrophy may occur in entire male dogs. Severe ulcerative facial dermatitis has been reported in Maine Coon cats. Hepatotoxicity is reported in humans.

**Drug interactions:** Potentiates thiazide and loop diuretics. Hyperkalaemia may result if ACE inhibitors, NSAIDs, ciclosporin or potassium supplements are administered in conjunction with spironolactone. However, in practice, spironolactone and ACE inhibitors appear safe to use concurrently. Monitor renal function and serum potassium levels in animals receiving spironolactone and ACE inhibitors. There is an increased risk of nephrotoxicity if spironolactone is administered with NSAIDs. The plasma concentration of digoxin may be increased by spironolactone.

**DOSES**

**Dogs, Cats:** 2–4 mg/kg p.o. q24h.

**References**


Lefebvre HP, Ollivier E, Atkins CE et al. (2013) Safety of spironolactone in dogs with chronic heart failure because of degenerative valvular disease: a population-based, longitudinal study. *Journal of Veterinary Internal Medicine* 27, 1083–1091

---

**Sterculia**

*(Peridale, Normacol*) **AVM-GSL, GSL**

**Formulations:** Oral: 98% granules (Peridale); 118 mg capsules (Normacol).

**Action:** Bulk-forming agent that increases faecal mass and stimulates peristalsis.

**Use:**

- Management of impacted anal sacs, diarrhoea and constipation, and the control of stool consistency after surgery.

Sterculia is inert and not absorbed. During treatment, fluid should be provided or a moist diet given. As the preparations swell in contact with water, they should be administered with plenty of water available.
Safety and handling: Normal precautions should be observed.

Contraindications: Do not use in cases of intestinal obstruction or where enterotomy or enterectomy is to be performed.

Adverse reactions: No information available.

Drug interactions: No information available.

DOSES

**Dogs:** All uses: 1.5 g p.o. q24h (dogs <5 kg); 3 g p.o. q12–24h (5–15 kg); 4 g p.o. q12–24h (>15 kg). Sprinkle over feed or place on tongue.

**Cats:** All uses: Kittens: 1 capsule q24h. Adults: 1 capsule q12h.

**Sucralfate**

(antepsin*, antepsin suspension*, carafate*)

POM

Formulations: Oral: 1 g tablet; 0.2 g/ml suspension.

Action: In an acidic medium an aluminium ion detaches from the compound, leaving a very polar, relatively non-absorbable ion. This ion then binds to proteinaceous exudates in the upper GI tract, forming a chemical diffusion barrier over ulcer sites, preventing further erosion from acid, pepsin and bile salts. However, its major action appears to relate to stimulation of mucosal defences and repair mechanisms (stimulation of bicarbonate and PGE production and binding of epidermal growth factor). These effects are seen at neutral pH.

Use:

- Treatment of oesophageal, gastric and duodenal ulceration.
- The efficacy of sucralfate as a phosphate binder in renal failure is uncertain.

Can be used alongside an H2 receptor antagonist or proton-pump inhibitor but should be given separately.

Safety and handling: Normal precautions should be observed.

Contraindications: Perforated ulcer.

Adverse reactions: Minimal; constipation is the main problem in humans. Bezoar formation and hypophosphataemia are also reported in humans.

Drug interactions: Sucralfate may decrease the bioavailability of H2 antagonists, phenytoin and tetracyclines. It may be a wise precaution to administer sucralfate at least 2 hours before or after these drugs. Sucralfate interferes significantly with the absorption of fluoroquinolones and digoxin.
DOSES

**Dogs:** All uses: 500 mg/dog p.o. q6–8h (dogs up to 20 kg); 1–2 g/dog p.o. q6–8h (>20 kg).

**Cats:** All uses: 250 mg/cat p.o. q8–12h.

References


**Sulfasalazine**
(Salazopyrin*, Sulphasalazine*) POM

**Formulations:** Oral: 500 mg tablet; 250 mg/5 ml oral suspension.

**Action:** Sulfasalazine is a prodrug: a diazo bond binding sulfapyridine to 5-ASA is cleaved by colonic bacteria to release free 5-ASA, which acts locally in high concentrations in the colon as an anti-inflammatory.

**Use:** Used in the management of colitis. There is a significant risk of keratoconjunctivitis sicca and periodic Schirmer tear tests should be performed.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Dobermanns appear to be sensitive to adverse effects associated with sulfapyridine.

**Adverse reactions:** Uncommon but include keratoconjunctivitis sicca (KCS), vomiting, allergic dermatitis and cholestatic jaundice. Owners should be made aware of the seriousness of KCS and what signs to monitor. The cause of the KCS is not clear. Historically sulfapyridine has been blamed. Olsalazine has been recommended as the incidence of KCS is less with its use, although not completely abolished. It is possible that 5-ASA may sometimes be responsible.

**Drug interactions:** The absorption of digoxin may be inhibited by sulfasalazine, and the measurement of serum folate concentration may be affected. Sulfasalazine may cause a reduction in serum thyroxine concentrations.

DOSES

**Dogs:** All uses: 15–30 mg/kg p.o. q8–12h, maximum 6 g/day.

**Cats:** All uses: 10–20 mg/kg p.o. q8–12h.

**Sulphonamide** see Trimethoprim/sulphonamide
**Suxamethonium** *(Succinylcholine)*
*(Suxamethonium*) **POM**

**Formulations:** Injectable: 50 mg/ml solution.

**Action:** Competitively binds to the nicotinic acetylcholine receptor. The persistent depolarization prevents the transmission of further action potentials, resulting in muscle relaxation.

**Use:**
- Used to facilitate intubation in cats.

There are no indications for suxamethonium in dogs. Suxamethonium has a very rapid onset of action (5–15 seconds) and short duration of action (3–5 minutes). However, use of neuromuscular blockade to facilitate intubation is rarely required in small animals and suxamethonium has been largely replaced by non-depolarizing drugs. Use with caution in patients with hepatic disease.

**Safety and handling:** Store in refrigerator.

**Contraindications:** Do not administer unless the animal is adequately anaesthetized and facilities to provide positive pressure ventilation are available. Do not use in animals exposed to organophosphate compounds.

**Adverse reactions:** Can cause arrhythmias (sinus bradycardia, ventricular arrhythmias) via stimulation of muscarinic receptors in the sinus node. A small rise in potassium concentration is expected after suxamethonium; patients with burns and neuromuscular disorders are at severe risk of hyperkalaemia.

**Drug interactions:** The actions of suxamethonium may be enhanced by beta-adrenergic blockers (e.g. propranolol), furosemide, isoflurane, lidocaine, magnesium salts and phenothiazines. Diazepam may reduce the duration of action of suxamethonium. Neostigmine and pyridostigmine should not be administered with suxamethonium as they inhibit pseudocholinesterases, thereby enhancing suxamethonium’s effect.

**DOSES**

**Dogs:** Do not use.

**Cats:** 1.0 mg/kg i.v. A total dose of 3.5 mg is satisfactory in cats >3.5 kg.
**T3** see Liothyronine

**T4** see L-Thyroxine

**Tacrolimus (FK 506)**
(Protopic*, Tacrolimus*) **POM**

**Formulations:** Topical: 0.03%, 0.1% skin ointments (30 g, 60 g tubes); 0.02% eye drop (solution) (15 ml). **Oral:** various preparations – avoid switching between brands.

**Action:** T-lymphocyte inhibition.

**Use:**
- Topical aqueous and oil-based formulations have been used in eyes to treat canine keratoconjunctivitis sicca that is unresponsive to topical ciclosporin.

Prior to availability of an ophthalmic preparation in the UK, there were anecdotal reports that the skin ointment (0.1%) formulation has been used successfully and without adverse effects. Has also been used for localized autoimmune dermatoses and localized lesions of atopic dermatitis. Long-term effects, potential adverse effects and toxicities are as yet unknown and tacrolimus must be reserved for special cases only. Systemic (oral) administration has been used for a limited number of cases of anal furunculosis where ciclosporin has failed.

**Safety and handling:** Use gloves.

**Contraindications:** No information available.

**Adverse reactions:** Discomfort on application (blepharospasm). Topical treatment may be associated with an increased risk of malignancy (e.g corneal squamous cell carcinoma). May affect circulating levels of insulin and cause hyperglycaemia; in the presence of diabetes mellitus, the effect of treatment on glycaemic control must be monitored.

**Drug interactions:** Suspected to be similar to ciclosporin.

**DOSES**
See Appendix for immunosuppression protocols.

**Dogs:** Apply 1 drop to the affected eye q12h.

**Cats:** No information available.

**References**
**Tamsulosin hydrochloride**  
*(Flomax relief*, *Flomaxtra*) **POM, P**

**Formulations:** 0.4 mg tablets or capsules.

**Action:** Alpha-1 adrenergic antagonist with selectivity for the urinary tract; relaxes smooth muscle in the prostate, urethra and bladder neck aiding urine flow. Longer acting than prazosin or phenoxybenzamine.

**Use:**
- Reflex dyssynergia/urethral spasm. May also aid passage of urethroliths/ureteroliths.
- An alternative to prazosin or phenoxybenzamine in refractory cases of reflex dyssynergia, with less effect on systemic blood pressure.

**Safety and handling:** No information available.

**Contraindications:** No information available.

**Adverse reactions:** Hypotension possible (especially at high doses).

**Drug interactions:** Concurrent use of other alpha-1 blockers (e.g. prazosin) or sildenafil may exacerbate hypotensive effects.

**DOSES**

**Dogs:** Urethral relaxant: 10 μg (micrograms)/kg p.o. q24h (up to 0.4 mg/dog q24h), can increase to q12h if necessary. Capsules should not be split and compounding may be required.

**Cats:** (Limited clinical experience or safety data exists.) Urethral relaxant: 4–6 μg (micrograms)/kg p.o. q12–24h.

**References**


---

**Telmisartan**  
*(Semintra) POM-V*  

**Formulations:** Oral: 4 mg/ml, 10 mg/ml solution.

**Action:** Angiotensin II receptor (type AT1) antagonist which acts to inhibit the effects of angiotensin (i.e. vasoconstriction, increased aldosterone synthesis, sodium and water retention and renal, vascular and cardiac remodelling). In the kidney, angiotensin II may result in glomerular capillary hypertension and increased protein in the glomerular filtrate, which could trigger or potentiate interstitial fibrosis.

**Use:**
- Authorized for the reduction of proteinuria associated with chronic kidney disease in cats.
• Treatment of systemic hypertension in cats.

The effects on the long-term prognosis of feline kidney disease are currently not established. Telmisartan would appear to be as effective as benazepril at delaying deterioration in proteinuria over 6 months in cats with chronic kidney disease (IRIS stages IIa to IV, urine specific gravity <1.035 and no co-morbid conditions). The safety and efficacy of telmisartan for the management of systemic hypertension above 200 mmHg has not been investigated. Monitoring of blood pressure is recommended in cats that develop clinical signs referable to hypotension or cats undergoing general anaesthesia. Both oral solutions seem to be accepted well by most cats. There are case reports of its successful use to treat protein-losing nephropathy and hypertension (in combination with amlodipine) in dogs.

Safety and handling: Normal precautions should be observed.

Contraindications: The safety of telmisartan has not been established in breeding, pregnant or lactating cats or cats <6-months of age.

Adverse reactions: Mild and transient GI signs (regurgitation, vomiting, diarrhoea). Rare increased ALT activity that resolved within a few days of stopping therapy. Healthy cats administered 5 times the recommended dose for 6 months experienced decreases in blood pressure and RBC count and increases in BUN.

Drug interactions: Cats that received concomitant therapy with amlodipine at the recommended dose did not experience clinical evidence of hypotension. Avoid concurrent use of ACE inhibitors.

DOSES
Dogs: 0.5–1 mg/kg p.o. q24h (limited information).
Cats: For proteinuria: 1 mg/kg p.o. q24h. For hypertension: 2 mg/kg p.o. q24h.

References

Temozolomide
(Temcad*, Temodal*, Temodar*) POM

Formulations: Oral: 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, 250 mg.

Action: Oral alkylating agent. Has the ability to alkylate or methylate DNA (which most often occurs at the N–7 or O–6
positions of guanine residues). This methylation damages DNA and leads to cell death.

**Use:** Preliminary investigations have evaluated temozolomide in canine lymphoma, melanoma and gliomas.

**Safety and handling:** Potent cytotoxic drug that should only be prepared and administered by trained personnel. See Appendix and specialist texts for further advice on chemotherapeutic agents.

**Contraindications:** Contraindicated in patients with known hypersensitivity. Do not use in patients with pre-existing bone marrow suppression. Should be used with caution in patients with reduced hepatic or renal function.

**Adverse reactions:** May cause myelosuppression and gastrointestinal adverse events, lethargy, polydipsia and altered renal and hepatic parameters are also described.

**Drug interactions:** Not reported at present.

**DOSES**

**Dogs:** 60–65 mg/m² p.o. q24h for 5 consecutive days on a monthly basis (28 days) for 4 to 6 cycles. 100 mg/m² p.o. q24h for 5 consecutive days every 2 weeks is described for relapsed lymphoma.

**Cats:** Not advised based on early toxicity studies.

**References**


Treggiari E, Elliot JW, Baines SJ et al. (2017) Temozolomide alone or in combination with doxorubicin as a rescue agent in 37 cases of canine multicentric lymphoma. *Veterinary and Comparative Oncology* **16**, 194–201

---

**Terbinafine**

*(Osurnia, Lamisil*) **POM-V, POM**

**Formulations:** Oral: 250 mg tablets. Topical: 1% cream, gel and spray. Ear gel 10 mg terbinafine, also contains florfenicol and betamethasone.

**Action:** Inhibits ergosterol synthesis by inhibiting squalene epoxidase, an enzyme that is part of the fungal cell wall synthesis pathway.

**Use:**


The gel is authorized for the treatment of acute otitis externa and acute exacerbation of recurrent otitis externa associated with *Staphylococcus pseudintermedius* and *Malassezia* pachydermatis. Ear gel should be instilled in a cleaned ear. Administer one tube per infected ear. Repeat the administration after 7 days. The maximum
clinical response may not be seen until 21 days after the second administration. Optimal therapeutic regimens for systemic use (e.g. for refractory nasal aspergillosis) are still under investigation: pretreatment and monitoring CBC, renal and liver function tests are advised.

Safety and handling: Normal precautions should be observed. Ear gel should be stored in a refrigerator.

Contraindications: Do not use ear gel if the eardrum is perforated. Do not use topically or systemically in dogs with generalized demodicosis or in pregnant or breeding animals.

Adverse reactions: Vomiting, diarrhoea, increased liver enzymes, pruritus (cats). Topical solutions contain alcohol and may cause irritation. Transient deafness, impaired hearing may occur in elderly dogs after administration of the ear gel.

Drug interactions: No information available.

DOSES

Dogs, Cats: Antifungal: 20–40 mg/kg p.o. q24h; doses greater than 30 mg/kg may be required to reach therapeutic levels in the skin of dogs. Cream may be used to treat localized Malassezia infections.

References

Balda C, Otsuka M, Gambale W et al. (2004) P-12 Comparative study of griseofulvin and terbinafine therapy in the treatment of canine and feline dermatophytosis. Veterinary Dermatology 15(S1), 44


Terbutaline (Bricanyl*, Monovent*) POM

Formulations: Injectable: 0.5 mg/ml solution. Oral: 5 mg tablets; 1.5 mg/5 ml syrup.

Action: Selective beta-2 adrenergic agonist that directly stimulates bronchodilation.

Use:
- Bronchodilation.
- Maintenance of heart rate in animals with sick sinus syndrome.

Use with caution in patients with diabetes mellitus, hyperthyroidism, hypertension or seizure disorders.

Safety and handling: Normal precautions should be observed.

Contraindications: No information available.

Adverse reactions: Fine tremor, tachycardia, hypokalaemia, hypotension and hypersensitivity reactions. Administration i.m. may be painful.

Drug interactions: There is an increased risk of hypokalaemia if theophylline or high doses of corticosteroids are given with high
doses of terbutaline. Use with digitalis glycosides or inhalational anaesthetics may increase the risk of cardiac arrhythmias. Beta-blockers may antagonize its effects. Other sympathomimetic amines may increase the risk of adverse cardiovascular effects.

**DOSES**

**Dogs:**
- **Bronchodilation:** 1.25–5 mg/dog p.o. q8–12h, 0.01 mg/kg i.m., s.c., i.v. q4h.
- **Bradyarrhythmias:** 0.2 mg/kg p.o. q8–12h.

**Cats:**
- **Bronchodilation:** 0.312–1.25 mg/cat p.o. q8–12h, 0.01 mg/kg i.m., s.c., i.v. q4h.
- **Bradyarrhythmias:** 0.625 mg/cat p.o. q8–12h.

**References**

---

**Tetanus antitoxin**

*(Tetanus antitoxin Behring)* **POM-V**

**Formulations:** Injectable: 1000 IU/ml solution.

**Action:** Antibody binds to tetanus toxin.

**Use:**
- Preventive measure in animals at risk of developing tetanus from wounds.
- Best used in developing cases of tetanus (i.e. immediately clinical signs are seen or when contamination of wound is severe and progression to a severe form of tetanus is possible). In established tetanus cases it is less effective as it does not displace bound toxin.

Risk of tetanus in dogs and cats is very low and therefore routine prophylaxis is not warranted.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Avoid in cats (cannot metabolize phenol preservative).

**Adverse reactions:** All antisera have the potential to produce anaphylactoid reactions, particularly if the patient has previously received products containing horse protein. Repeated doses may lead to hypersensitivity reactions. Adrenaline or antihistamines may be used to manage these adverse effects.

**Drug interactions:** No information available.

**DOSES**

**Dogs:**
- **Prophylactic:** 80 IU/kg (maximum of 2500 IU/dog) i.m., s.c. once.
- Therapy of developing tetanus: 100–1000 IU/kg (maximum 20,000 IU/animal) i.m., s.c. once (off-licence i.v. administration following a s.c./intradermal test dose is reported).

**Cats:** Not required.

**References**


---

**Tetracaine (Amethocaine)**

(*Amethocaine hydrochloride*) **POM**

**Formulations:** **Ophthalmic:** 0.5%, 1% solution (single-use vials).

**Action:** Local anaesthetic action is dependent on reversible blockade of the sodium channel, preventing propagation of an action potential along the nerve fibre. Sensory nerve fibres are blocked before motor nerve fibres, allowing a selective sensory blockade at low doses.

**Use:** Local anaesthesia of the ocular surface (cornea and conjunctival sac). Although effective, it is uncommonly used in small animal practice. An alternative topical ophthalmic anaesthetic such as proxymetacaine is advised. Duration of action has not been reported in small animal species. Topical anaesthetics block reflex tear production and should not be applied before a Schirmer tear test.

**Safety and handling:** Check conditions for storage (unlike proxymetacaine, refrigeration is not required).

**Contraindications:** Do not use for therapeutic purposes.

**Adverse reactions:** Tetracaine often causes marked conjunctival irritation, chemosis and pain on application (more so than proxymetacaine). All topical anaesthetics are toxic to the corneal epithelium and repeated administration can delay healing of ulcers.

**Drug interactions:** No information available.

**DOSES**

**Dogs, Cats:** **Ophthalmic:** 1 drop per eye, single application.

**Tetracosactide (Tetracosactrin, ACTH)**

(*Tetracosactide, Synacthen*) **POM, Special**

**Formulations:** **Injectable:** 0.25 mg/ml solution for intravenous use. A 0.1 mg/ml solution is available on a named patient basis. In the event of availability problems, an alternative lyophilized formulation (0.25 mg/ml) for intramuscular use may be imported on a named patient basis.

**Action:** ACTH analogue that binds to specific receptors on the cell membrane of adrenocortical cells and induces the production of steroids from cholesterol.
Use: To stimulate cortisol production in the diagnosis of hyperadrenocorticism (Cushing’s syndrome) and hypoadrenocorticism (Addison’s disease). See BSAVA Manual of Canine and Feline Endocrinology for advice on performance and interpretation of ACTH stimulation test. It is recommended to use lower doses than previously published and in case of availability problems then supplies should be reserved for diagnosis of hypoadrenocorticism. Value of the ACTH stimulation test in monitoring treatment of hyperadrenocorticism may be limited. The effect on cortisol production in cats is less dramatic than in dogs, so the same reference ranges cannot be used.

Safety and handling: Normal precautions should be observed. Small aliquots of the intravenous and intramuscular preparations may be frozen and thawed once without undue loss of activity.

Contraindications: No information available.

Adverse reactions: Intramuscular administration tends to produce a pain reaction so i.v. is preferred.

Drug interactions: None reported.

DOSES

Dogs: ACTH stimulation test: 5 μg (micrograms)/kg i.v., i.m. The same doses may be used for the lyophilized product but must be administered i.m.

Cats: ACTH stimulation test: 5 μg (micrograms)/kg or 125 μg/cat. i.v., i.m.

2,2,2-Tetramine see Trientine

L-Theanine (N-ethyl-L-glutamine, suntheanine, green tea leaf extract) (Anxitane) GSL

Formulations: 50 mg, 100 mg tablets. Also included in some other formulations alongside other potentially calming nutraceuticals.

Action: Binds to AMPA, kainate, and NMDA receptors and blocks the binding of L-glutamic acid to the glutamate receptors in the cerebral cortex. This results in increases in brain serotonin, dopamine and GABA levels which, through diverse mechanisms, result in anxiolysis. May also have neuroprotective effects.

Use:

- Used to aid in the management of mild anxieties and fears including social anxiety without aggression towards people, by dogs.

Clinical evidence to date is largely based on open label studies. Not intended for use in cases of severe phobia or separation anxiety, or aggressive behaviour.
Theophylline (Corvental-D) POM-V

Formulations: Oral: 100 mg, 200 mg, 500 mg sustained-release capsules.

Action: Causes inhibition of phosphodiesterase, alteration of intracellular calcium, release of catecholamine, and antagonism of adenosine and prostaglandin, leading to bronchodilation and other effects. Spasmolytic agent and has a mild diuretic action.

Use:
- Used in the treatment of small airway disease. Beneficial effects include bronchodilation, enhanced mucociliary clearance, stimulation of respiratory centre, increased sensitivity to $P_aCO_2$, increased diaphragmatic contractility, stabilization of mast cells and a mild inotropic effect.

Theophylline has a low therapeutic index and should be dosed on a lean body weight basis. Administer with caution in patients with severe cardiac disease, gastric ulcers, hyperthyroidism, renal or hepatic disease, severe hypoxia or severe hypertension. Therapeutic plasma theophylline values are 5–20 $\mu$g (micrograms)/ml.

Safety and handling: Normal precautions should be observed.

Contraindications: Patients with a known history of arrhythmias or seizures.

Adverse reactions: Vomiting, diarrhoea, polydipsia, polyuria, reduced appetite, tachycardia, arrhythmias, nausea, twitching, restlessness, agitation, excitement and convulsions. Hyperaesthesia is seen in cats. Most adverse effects are related to the serum level and may be symptomatic of toxic serum concentrations. The severity of these effects may be decreased by the use of modified-release preparations. They are more likely to be seen with more frequent administration.

Drug interactions: Agents that may increase the serum levels of theophylline include cimetidine, diltiazem, erythromycin,
fluoroquinolones and allopurinol. Phenobarbital may decrease the serum concentration of theophylline. Theophylline may decrease the effects of pancuronium. Theophylline and beta-adrenergic blockers (e.g. propranolol) may antagonize each other’s effects. Theophylline administration with halothane may cause an increased incidence of cardiac dysrhythmias and with ketamine an increased incidence of seizures.

**DOSES**

**Dogs:** Bronchodilation: 20 mg/kg p.o. q24h or 10 mg/kg p.o. q12h which may be increased to 15 mg/kg p.o. q12h if no side effects on lower dose (NB: manufacturer only recommends q24h dosing). Some texts indicate q12h dosing of the sustained-release preparation is required to maintain therapeutic serum levels.

**Cats:** Bronchodilation: 15–19 mg/kg p.o. q24h (sustained-release preparation).

**References**


**Thiamazole (Methimazole)**

*(Felimazole, Thiafeline, Thyronorm) POM-V*

**Formulations:** Oral: 1.25 mg, 2.5 mg, 5 mg tablets. Oral: 5 mg/ml solution. Also available as a transdermal formulation on a named patient basis.

**Action:** Interferes with the synthesis of thyroid hormones by inhibiting peroxidase-catalysed reactions (blocks oxidation of iodide), the iodination of tyrosyl residues of thyroglobulin, and the coupling of mono- or di-iodotyrosines to form T3 and T4. Has no effect on iodine uptake, peripheral de-iodination of T4 to T3 or release of stored hormone.

**Use:** Control of thyroid hormone levels in cats with hyperthyroidism. 2 to 3 weeks of treatment are generally needed to establish euthyroidism. Monitor therapy on the basis of serum thyroxine concentrations (4–6 hours after dosing) and adjust dose accordingly for long-term medical management. Assess haematology, biochemistry and serum total T4 after 3, 6, 10 and 20 weeks and thereafter every 3 months, adjusting dosage as necessary. Transdermal thiamazole gels are also used in hyperthyroid cats, particularly in fractious cats or in those that develop GI side effects from the oral formulations. However, this route is not as reliable as oral medication or as safe for humans who apply the gel.
Safety and handling: Oral: normal precautions should be observed. Transdermal formulation: wear gloves when administering or handling the product. Do not touch area of application for at least a couple of hours. Thiamazole is a human teratogen and crosses the placenta concentrating in the fetal thyroid gland.

Contraindications: Do not use in pregnant or lactating queens.

Adverse reactions: Vomiting and inappetence/anorexia may be seen but are often transient. Jaundice, cytopenias, immune-mediated diseases (including myasthenia gravis) and dermatological changes (pruritus, alopecia and self-induced trauma) are reported, but rare; withdrawal of treatment may be necessary. Treatment of hyperthyroidism can decrease glomerular filtration rate, thereby raising serum urea and creatinine values, and can occasionally unmask occult renal failure. Animals that have an adverse reaction to carbimazole are likely also to have an adverse reaction to thiamazole.

Drug interactions: Phenobarbital may reduce clinical efficacy. Benzimidazole drugs reduce hepatic oxidation and may lead to increased circulating drug concentrations. Thiamazole should be discontinued before iodine-131 treatment. Do not use with low-iodine prescription diets.

DOSES

Dogs: Hyperthyroidism: 2.5–5 mg/dog p.o. q12h depending on size.
Cats: Hyperthyroidism: 2.5 mg/cat p.o. q12h. Apply transdermal gel to pinna.

References

Thiamine see Vitamin B1

Thyroid stimulating hormone
(Thyrotropin alfa, TSH)
(Thyrogen*) POM

Formulations: Injectable: 1.1 mg vial; after reconstitution with 1.2 ml sterile water the TSH concentration is 0.9 mg/ml.

Action: Binds to specific receptors on thyroid follicular cell membranes and in so doing stimulates the proteolytic degradation of thyroglobulin and the release of thyroxine (T4) and smaller quantities of tri-iodothyronine (T3).

Use: Stimulation of thyroid hormone production in the diagnosis of canine hypothyroidism (not suitable for evaluation of thyroid function in patients receiving levothyroxine). The diagnostic value in cats has not been fully assessed.
Safety and handling: Normal precautions should be observed.

Contraindications: Repeated administration is not advisable.

Adverse reactions: Chemical grade TSH may be associated with anaphylactic responses; do not use.

Drug interactions: Anabolic or androgenic steroids, carbimazole, barbiturates, corticosteroids, diazepam, heparin, mitotane (o, p’-DDD), phenylbutazone, phenytoin and salicylates may all decrease serum T4 levels. Fluorouracil, insulin, oestrogens, propranolol and prostaglandins may cause T4 levels to be increased. All these drugs will make the TSH stimulation test hard to interpret.

DOSES

Dogs: TSH stimulation test: 50–150 μg (micrograms)/dog. Higher doses offer increased discriminatory power in dogs with comorbidities or those receiving thyroid-suppressing drugs.

Cats: TSH stimulation test: 25 μg (micrograms)/cat.

References


**L-Thyroxine (T4, Levothyroxine)**

(Leventa, Soloxine, Thyforon) POM-V

Formulations: Oral: 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg, 0.8 mg tablets; 1 mg/ml solution.

Action: Binds to specific intracellular receptors and alters gene expression.

Use: Treatment of hypothyroidism. Cases with pre-existing cardiac disorders require lower doses initially.

Safety and handling: Normal precautions should be observed.

Contraindications: Uncorrected adrenal insufficiency.

Adverse reactions: Clinical signs of overdosage include tachycardia, excitability, nervousness and excessive panting. Can unmask Addison’s disease in patients with autoimmune polyglandular syndrome.

Drug interactions: The actions of catecholamines and sympathomimetics are enhanced by thyroxine. Diabetic patients receiving thyroid hormones may have altered insulin requirements; monitor carefully during the initiation of therapy. Oestrogens may increase thyroid requirements by increasing thyroxine-binding globulin. The therapeutic effect of ciclosporin, digoxin and digitoxin may be reduced by thyroid hormones. Tachycardia and hypertension may develop when ketamine is given to patients receiving thyroid hormones. In addition, many drugs may affect thyroid function tests and therefore monitoring of therapy.
DOSES
See Appendix for conversion of body weight to body surface area.

**Dogs, Cats:** Hypothyroidism: 0.02–0.04 mg/kg/day. Alternatively, dose at 0.5 mg/m$^2$ body surface area daily. Dose given with food once or divided twice a day. Monitor serum T4 levels pre-dosing and 4–8 hours after dosing.

References


Lewis VA, Morrow CMK, Jacobsen JA et al. (2018) A pivotal field study to support the registration of levothyroxine sodium tablets for canine hypothyroidism. *Journal of the American Animal Hospital Association** 54, 201–208

---

**Ticarcillin**

*(Timentin*®) **POM**

**Formulations:** Injectable: 3 g ticarcillin and 200 mg clavulanic acid powder for reconstitution.

**Action:** Time dependent, beta-lactam antibiotic that binds penicillin-binding proteins involved in cell wall synthesis, decreasing bacterial cell wall strength and rigidity, and affecting cell division, growth and septum formation. Clavulanic acid acts as a non-competitive ‘suicide’ inhibitor for beta-lactamase enzymes.

**Use:** A carboxypenicillin that, like piperacillin, is indicated for the treatment of serious (usually but not exclusively life-threatening) infections caused by *Pseudomonas aeruginosa*, although it also has activity against certain other Gram-negative bacilli including *Proteus* spp. and *Bacteroides fragilis*. For *Pseudomonas* septicaemias antipseudomonal penicillins are often given with an aminoglycoside (e.g. gentamicin) as there is a synergistic effect. As ticarcillin kills bacteria by a time-dependent mechanism, dosing regimens should be designed to maintain tissue concentration above the MIC throughout the interdosing interval. Pharmacokinetic information on the ticarcillin/clavulanic acid combination is limited in veterinary species. After reconstitution, stability is limited depending on the diluent used.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.

**Adverse reactions:** Nausea, diarrhoea and skin rashes may be seen.

**Drug interactions:** Do not mix with aminoglycosides in the same syringe because there is mutual inactivation. There is synergism *in vivo* between the beta-lactams and the aminoglycosides.

**DOSES**

See Appendix for guidelines on responsible antibacterial use.

**Dogs, Cats:** For serious systemic infections: 15–25 mg/kg i.v., followed by CRI at 7.5–15 mg/kg/h; topical to the ear as an adjunct
to *Pseudomonas* otitis, instil 0.25–0.5 ml of a 100 mg/ml injectable ticarcillin solution into the affected ear q8h.

**References**

**Tiletamine** see **Zolazepam**

**Timolol maleate**
(Azarga*, CoSopt*, Timolol*, Timoptol*) POM

**Formulations:** Ophthalmic: 0.25%, 0.5% solutions (5 ml bottle, single-use vials; 0.5% solution most commonly used); 1% brinzolamide with 0.5% timolol (Azarga); 2% dorzolamide with 0.5% timolol (CoSopt) (5 ml bottle, single-use vials).

**Action:** A topical non-selective beta-blocker that decreases aqueous humour production via beta-adrenoreceptor blockade in the ciliary body. See also Brinzolamide and Dorzolamide.

**Use:**
- Management of canine and feline glaucoma.

It can be used alone or in combination with other topical glaucoma drugs, such as a topical carbonic anhydrase inhibitor. Dorzolamide/timol or brinzolamide/timolol can be used in the control of most types of glaucoma in dogs: the combination may be more effective than either drug alone. In cats, dorzolamide alone reaches maximal IOP lowering efficiency. Timolol causes miosis and may therefore not be the drug of choice in uveitis, anterior lens luxation or pupil block.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Avoid in uncontrolled heart failure and asthma.

**Adverse reactions:** Ocular adverse effects include miosis, conjunctival hyperaemia and local irritation. Systemic absorption may occur following topical application causing bradycardia and reduced blood pressure.

**Drug interactions:** Additive adverse effects may develop if given concurrently with oral beta-blockers. Prolonged AV conduction times may result if used with calcium antagonists or digoxin.

**DOSES**
**Dogs:** One drop per affected eye q8–12h.
**Cats:** One drop per affected eye q12h.

**References**
**Tobramycin**  
(Nebcin*, Tobramycin*)  

**POM**

**Formulations:** Injectable: 40 mg/ml solution.

**Action:** Aminoglycosides inhibit bacterial protein synthesis; their mechanism of killing is concentration-dependent, leading to a marked post-antibiotic effect, allowing pulse-dosing regimens which may limit toxicity.

**Use:** Treatment of Gram-negative infections. It is less active against most Gram-negative organisms than gentamicin, but appears to be more active against *Pseudomonas aeruginosa*. Aminoglycosides are ineffective at sites of low oxygen tension (e.g. abscesses) and all obligate anaerobic bacteria are resistant. More pharmacokinetic work is necessary to be sure of the dose rate, particularly in cats who may be more sensitive to toxicity. The doses below are for general guidance only, and should be assessed according to the clinical response. Nephrotoxicity and ototoxicity are potential side effects. Cellular casts in urine sediment are an early sign of impending nephrotoxicity; however, urine must be examined immediately to detect their presence and their absence is not a guarantee of safety. Serum creatinine levels rise later and fatal acute renal failure may be inevitable when they do. Monitor renal function during use. If giving i.v., administer slowly. Geriatric animals or those with decreased renal function should only be given this drug systemically when absolutely necessary.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not use ophthalmic product where corneal ulceration is present.

**Adverse reactions:** Tobramycin is considered to be less nephrotoxic than gentamicin.

**Drug interactions:** Avoid concurrent use of other nephrotoxic, ototoxic or neurotoxic agents (e.g. amphotericin B, furosemide). Increase monitoring and adjust dosages when these drugs must be used together. Aminoglycosides may be chemically inactivated by beta-lactam antibiotics (e.g. penicillins, cephalosporins) or heparin when mixed *in vitro*. The effect of non-depolarizing muscle relaxants (e.g. pancuronium) may be enhanced by aminoglycosides. Synergism may occur when aminoglycosides are used with penicillins or cephalosporins.

**DOSES**

*See Appendix for guidelines on responsible antibacterial use.*

**Dogs, Cats:** Parenteral: 4–6 mg/kg i.v., s.c., i.m. q24h. For severe infections (including sepsis), doses as high as 12 mg/kg/day have been advocated, but should be used with caution given potential adverse effects.
Toceranib
(Palladia) POM-V

Formulations: Oral: 10 mg, 15 mg, 50 mg film-coated tablets.

Action: Selective protein tyrosine kinase inhibitor with particular effects on the split kinase TK family, which may also have an effect on angiogenesis.

Use:
• Treatment of non-resectable grade 2 or 3 (Patnaik grading scheme) recurrent cutaneous mast cell tumours.
• Phase I trials have also demonstrated some efficacy in other canine malignancies (including mammary gland carcinomas, soft tissue sarcomas, multiple myelomas, melanomas and other carcinomas).

Studies are ongoing to evaluate the combination of toceranib and a number of other chemotherapeutics (vinblastine, cyclophosphamide, carboplatin, lomustine, piroxicam, prednisolone and calcitriol). Dogs should be monitored closely during treatment. As a guideline blood pressure, urinalysis, haematology and biochemistry should be undertaken before starting therapy, and then at least once a month (some clinicians may also check these parameters 1–2 weeks after drug initiation). Full coagulation profiles and faecal occult blood tests should be undertaken if adverse clinical signs are witnessed. It is good practice to contact owners once a week for the first 6 weeks of therapy to check for potential side effects, so that prompt action can be taken if these occur. Use with caution in dogs with pre-existing liver disease.

Safety and handling: Cytotoxic drug; see Appendix and specialist texts for further advice on chemotherapeutic agents.

Contraindications: Do not use in pregnant or lactating bitches, in dogs <2 years old, in dogs <5 kg, if there are any signs of GI haemorrhage, or if the patient has shown previous hypersensitivity to toceranib. Wait at least 3 days after stopping the drug before performing any surgery.

Adverse reactions: Weight loss, GI signs (diarrhoea, haemorrhage, anorexia, vomiting), lethargy, myelosuppression, lameness/musculoskeletal disorders, dermatitis and pruritus. Can also cause anaemia, increase in ALT activity, coagulation derangements (including pulmonary thromboembolism), decrease in albumin and raised blood pressure. Uncommon events that may be related to toceranib administration include seizures, epistaxis, circulatory shock and death.

Drug interactions: No information available, but use with caution when combining with chemotherapeutic agents and drugs that have the potential to cause GI toxicity (i.e. steroids, NSAIDs) until further information is available.
DOSES
See Appendix for chemotherapy protocols.

**Dogs:** All uses: 2.5–3.25 mg/kg p.o. q48h or on a Monday, Wednesday, Friday basis.

**Cats:** Limited information: 2.5 mg/kg (range 1.5–3.25 mg/kg) p.o. on a Monday, Wednesday, Friday basis (or less frequently q48h).

References

London CA, Malpas PB, Wood-Follis SL et al. (2009) Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. *Clinical Cancer Research* 15, 3856–3865

**Toldimphos** see **Phosphate**

**Tolfenamic acid**
(Tolfedine) POM-V

**Formulations:** Injectable: 40 mg/ml solution. Oral: 6 mg, 20 mg, 60 mg tablets.

**Action:** Inhibition of cyclo-oxygenase but uncertain if preferentially inhibits COX-2 over COX-1. COX inhibition limits the production of prostaglandins involved in inflammation. Also reported to have a direct antagonistic action on prostaglandin receptors.

**Use:**
- Alleviation of inflammation and pain in dogs and cats.
- Also used in the management of chronic locomotor disease in dogs.
- Management of fever.

The injectable preparation is authorized for preoperative administration to cats and dogs. Liver disease will prolong the metabolism of tolfenamic acid leading to the potential for drug accumulation and overdose with repeated dosing. In the cat, due to the longer half-life and narrower therapeutic index, particular care should be taken not to exceed the recommended dose and the use of a 1 ml graduated syringe is recommended to measure the dose accurately. Use with caution in renal diseases and in the perioperative period, as may adversely affect renal perfusion during periods of hypotension. There is emerging evidence, using in vitro models and dog tumour cell lines, that tolfenamic acid may have anticancer activity against some tumour types.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not give to dehydrated, hypovolaemic or hypotensive patients or those with GI disease or blood clotting problems. Do not give to pregnant animals or animals <6 weeks old. Do not give i.m. to cats.
**Adverse reactions:** GI signs may occur in all animals after NSAID administration. Stop therapy if this persists beyond 1–2 days. Some animals develop signs with one NSAID drug and not another. A 3–5-day wash-out period should be allowed before starting another NSAID after cessation of therapy. Stop therapy immediately if GI bleeding is suspected. There is a small risk that NSAIDs may precipitate cardiac failure in humans and this risk in animals is unknown.

**Drug interactions:** Do not administer concurrently with, or within 24 hours of, other NSAIDs and glucocorticoids. Do not administer with other potentially nephrotoxic agents, e.g. aminoglycosides.

**DOSES**

**Dogs:** 4 mg/kg i.m., s.c., may be repeated once after 24 hours; 4 mg/kg p.o. for 3 days. Treatment starts with a single injection on day 1. The oral dosage regimen may be repeated once a week (i.e. 4 days of treatment with 3 days rest).

**Cats:** 4 mg/kg s.c., may be repeated once after 24 hours; 4 mg/kg p.o. for 3 days. Treatment starts with a single injection on day 1. Repeated dosing on a weekly basis is not recommended in cats.

**References**

---

**Toltrazuril**

*(Procox) POM-V*

**Formulations:** Oral: 18 mg/ml oral suspension with emodepside. Available on a named patient basis in the UK.

**Action:** Coccidiocidal but the exact mode of action is not well understood.

**Use:** Treatment of *Isospora* spp. It stops both the replication of the parasites and also the shedding of oocysts. Although treatment will reduce the spread of infection, it will not be effective against the clinical signs of infection in animals that are already infected. Also some efficacy against *Hepatozoon canis*. Not authorized for use in cats but appears to be effective.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not use in puppies/kittens <2 weeks of age or weighing <0.4 kg.

**Adverse reactions:** Mild diarrhoea and/or vomiting may occasionally be seen.

**Drug interactions:** None known but see Emodepside.
DOSES

**Dogs:** 9 mg/kg p.o. once, further treatment is only indicated if oocyst shedding persists. Higher doses up to 20 mg/kg can be used if required.

**Cats:** 9 mg/kg p.o. once, further treatment is only indicated if oocyst shedding persists. Higher doses up to 20 mg/kg can be used if required.

**References**


**Topiramate**

*(Topamax®, Topiramate®)* POM

**Formulations:** Oral: 25 mg, 50 mg, 100 mg, 200 mg tablets; 15 mg, 25 mg, 50 mg sprinkle capsules; 15 mg, 25 mg, 50 mg capsules.

**Action:** The exact antiepileptic mode of action is unknown, but may involve inhibition of voltage-dependent sodium channels and enhancement of GABA activity at GABA<sub>A</sub> receptors.

**Use:**

- As an adjunctive therapy in animals refractory to standard anticonvulsant therapies and where other adjunctive therapies have been unsuccessful.
- Its use has also been reported in animals with neuropathic pain although alternative medications should be considered first.

It has a short half-life (2–4 hours) in dogs but therapeutic activity may persist for longer.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Avoid rapid withdrawal. Use with caution in patients with impaired hepatic or renal function.

**Adverse reactions:** Nausea, anorexia, sedation and ataxia.

**Drug interactions:** Use cautiously with other carbonic anhydrase inhibitors as topiramate also acts as a mild inhibitor.

**DOSES**

**Dogs:**

- **Anticonvulsant:** 2–20 mg/kg p.o. q8–12h. Start at lower end of dose range and adjust incrementally.

**Cats:**

- **Anticonvulsant:** no clinical data but experimentally a single dose of 30 mg/kg p.o. has been described and anecdotally 12.5–25 mg/cat q12h is suggested.
- **Feline idiopathic ulcerative dermatitis:** a single case report used 5 mg/kg p.o. q12h.
References
Plessas IN, Volk HA, Rusbridge C et al. (2015) Comparison of gabapentin versus topiramate on clinically affected dogs with Chiari-like malformation and syringomyelia. Veterinary Record 177, 288

Torasemide (Torsemide)
(UpCard) POM-V

Formulations: Oral: 0.75 mg, 3 mg, 7.5 mg (UpCard).

Action: Loop diuretic inhibiting the Na⁺/K⁺/Cl⁻ co-transporter in the thick ascending limb of the loop of Henle. The net effect is a loss of sodium, potassium, chloride and water in the urine. Potassium excretion is less than with an equivalent dose of furosemide. Torasemide also increases excretion of calcium, magnesium and hydrogen, as well as renal blood flow and glomerular filtration rate. It has an antialdosteronergic effect, which is the result of dose-dependent inhibition of receptor-bound aldosterone. The diuretic effect of torasemide is equivalent to 20 times the effect of furosemide (mg for mg) using current veterinary licensed products (and only 10 times the effect of furosemide based on human generic torasemide products).

Use:
• Torasemide is authorized to treat the clinical signs of congestive heart failure in dogs (UpCard).

Compared with furosemide at an equivalent dose, torasemide has a higher bioavailability, a longer duration of action (12 hours with a peak effect of 2 hours in dogs and 4 hours in cats) and results in less kaliuresis and calciuresis. Dogs receiving torasemide for 14 days experienced less diuretic resistance and had greater increases in BUN compared with dogs receiving furosemide for 14 days. Long-term therapy should be aimed at lowest effective dose to control congestive heart failure signs. Torasemide has also been used to treat oedema associated with hepatic cirrhosis and renal failure in humans. Use with caution in patients with severe electrolyte depletion, hepatic failure, renal failure and diabetes mellitus. In contrast to furosemide, torasemide is not authorized for use in cats.

Safety and handling: Normal precautions should be observed.

Contraindications: Dehydration and anuria.

Adverse reactions: Hypokalaemia, hypochloraemia, hypocalcaemia, hypomagnesaemia, hyponatraemia, dehydration, polyuria/polydipsia and prerenal azotaemia occur readily. A marked reduction in cardiac output can occur in animals with diseases in which cardiac output is already impaired, such as severe pulmonary hypertension, low-output heart failure, hypertrophic cardiomyopathy, pericardial or myocardial disorders and cardiac...
tamponade. Other adverse effects reported in humans include ototoxicity, blurred vision, GI disturbances, leucopenia, anaemia, weakness and dermatological reactions.

**Drug interactions:** No information available.

**DOSES**

**Dogs:** 0.1 to 0.6 mg/kg p.o. q24h. Anecdotally, doses are calculated and then divided into q12h intervals. Most dogs will be stabilized at less than or equal to 0.3 mg/kg p.o. q24h. Dose should be titrated up/down in 0.1 mg/kg p.o. increments.

**Cats:** Replace furosemide p.o. with torasemide p.o. at a daily dose that is 1/20th of the total daily furosemide dose divided q12–24h.

**References**


---

**Tramadol**

(Tralieve, Tramadol ER*, Ultracet*, Ultram*, Zamadol*) **POM-V, POM CD Schedule 3**

**Formulations:** Oral: 50 mg tablets; 100 mg, 200 mg, 300 mg immediate-release tablets; 20 mg, 80 mg chewable tablets for dogs; sustained-release tablets are also available in various tablet sizes; smaller tablet sizes (10 mg, 25 mg) are available from some veterinary wholesalers; 5 mg/ml oral liquid. **Injectable:** 50 mg/ml solution.

**Action:** Some metabolites of tramadol are agonists at all opioid receptors, particularly mu receptors. The parent compound also inhibits the reuptake of noradrenaline and 5-HT, and stimulates pre-synaptic 5-HT release, which provides an alternative pathway for analgesia involving the descending inhibitory pathways within the spinal cord. In people, good and poor metabolizers of tramadol are described, with good metabolizers developing more opioid-like effects following drug administration and improved analgesia. Whether similar individual differences in metabolism of tramadol occur in cats and dogs is currently unknown.

**Use:**

- Chewable tablets are authorized for use in dogs for the management of mild acute and chronic soft tissue and musculoskeletal pain.
- Perioperatively, injectable tramadol is used instead of opioids to provide analgesia for acute pain.
- Injectable tramadol has also been administered epidurally in dogs but does not appear to confer advantages over systemic administration.

There is an increasing body of literature describing pharmacokinetics (PK) and pharmacodynamics (PD) in dogs and cats, although the
recommended dose range is currently largely empirical due to a lack of combined PK/PD studies. The PK of sustained-release tramadol tablets have been investigated in dogs; plasma concentrations of tramadol and metabolites were low after administration suggesting that once a day dosing of sustained-release tramadol tablets is unsuitable to provide analgesia in dogs. One study has shown tramadol 2 mg/kg to provide equivalent analgesia to morphine 0.2 mg/kg i.v. after ovariohysterectomy in dogs, and there are a number of studies that show tramadol 2 mg/kg to be efficacious for the management of acute pain in cats and dogs with dosing 3–4 times daily. Tramadol has similar actions to morphine but causes less respiratory depression, sedation and GI side effects. It is attractive as an adjunct to manage chronic pain because it can be given orally; however, a larger body of evidence to support dose recommendations is needed. Cats seem to be more susceptible to the dysphoric effects of tramadol, although both dogs and cats can develop nausea and behavioural changes or sedation following repeated dosing. The oral preparations are unpalatable to cats and therefore difficult to administer, even when reformulated in gelatin capsules.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.

**Adverse reactions:** Sedation can occur after administration of high doses to dogs. Dysphoria is more likely in cats. Contraindicated in humans with epilepsy. Owners should be informed that there may be a slightly increased risk of seizures in treated animals.

**Drug interactions:** Tramadol can be given in combination with other classes of analgesic drugs such as NSAIDs, amantadine and gabapentin. It has the potential to interact with drugs that inhibit central 5-HT and noradrenaline reuptake, such as tricyclic antidepressants (e.g. amitriptyline), monoamine oxidase inhibitors (e.g. selegiline), selective serotonin reuptake inhibitors and some opioids (e.g. fentanyl, pethidine and buprenorphine), causing serotonin syndrome that can result in seizures and death. Should signs of serotonin syndrome develop (manifest in mild form as hyperthermia, elevated blood pressure and CNS disturbances such as hypervigilance and excitation) these must be managed symptomatically and contributing drug treatments stopped.

**DOSES**

**Dogs:** 2–5 mg/kg p.o. q8h, 2 mg/kg i.v.

**Cats:** 2–4 mg/kg p.o. q8h, 1–2 mg/kg i.v., s.c.

**References**


Tranexamic acid
(Cyklokapron*) POM

Formulations: Injectable: 500 mg/5 ml solution for injection ampoules. Oral: 500 mg tablets.

Action: Tranexamic acid is a synthetic lysine analogue that reversibly binds to the lysine binding sites of plasminogen. This prevents the action of plasmin on fibrin, thereby delaying fibrin dissolution and reduces bleeding. The interruption of fibrinolysis may be beneficial in patients with hyperfibrinolytic conditions and some forms of coagulopathy.

Use:
• To treat bleeding tendencies, particularly if hyperfibrinolysis is believed to be a major contributor to the bleeding.
• The use of tranexamic acid has been suggested as an adjunct treatment in dogs with angiostrongylosis, splenic haemangiosarcoma and trauma.

Safety and handling: No special handling requirements.

Contraindications: Animals with a history or at increased risk of thrombosis (e.g. thromboembolism) should not be treated with tranexamic acid. Disorders involving renal parenchyma resulting in haematuria are a contraindication to tranexamic acid use in humans; use in this setting should be considered carefully.

Adverse reactions: The most common adverse reactions reported in dogs are nausea, vomiting and diarrhoea and these clinical signs appear to be dose-dependent. In dogs and cats, retinal changes have been reported with prolonged treatment at higher doses. Hypersensitivities, dizziness, visual disturbances and thromboses have been reported in humans.

Drug interactions: No studies of interactions between tranexamic acid and other drugs have been conducted. Potential drug-drug interactions leading to myocardial infarction could occur with coadministration with hormonal contraceptives, hydrochlorothiazide, desmopressin, sulbactam-ampicillin, ranitidine or nitroglycerin.

DOSES
Dogs: 15–20 mg/kg p.o. q8h; 10 mg/kg i.v. q8h slow i.v. infusion.
Cats: Use not reported in cats.

References
Fletcher DJ, Rozanski EA, Brainard BM et al. (2016) Assessment of the relationships among coagulopathy, hyperfibrinolysis, plasma lactate, and protein C in dogs with spontaneous hemoperitoneum. Journal Veterinary Emergency and Critical Care 26, 41–51
**Travoprost**
(Travatan*) POM

**Formulations:** Ophthalmic: 40 μg/ml (0.004%) solution in 2.5 ml bottle.

**Action:** Agonist for receptors specific for prostaglandin F. It reduces intraocular pressure by increasing uveoscleral outflow and may have a profound effect on intraocular pressure in the dog.

**Use:**
- Its main indication is in the management of primary canine glaucoma and it is useful in the emergency management of acute primary glaucoma. Often used in conjunction with other topical antiglaucoma drugs such as carbonic anhydrase inhibitors.
- It may be useful in the management of lens subluxation and posterior luxation despite being contraindicated in anterior lens luxation.

Travoprost has comparable activity to latanoprost. There is little published data on its use in the cat; the effect of latanoprost is variable.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Uveitis and anterior lens luxation. Avoid in pregnant animals.

**Adverse reactions:** Miosis in dogs; conjunctival hyperaemia and mild irritation may develop. Increased iridal pigmentation has been noted in humans but not in dogs.

**Drug interactions:** Do not use in conjunction with thiomersal-containing preparations.

**DOSES**

*Dogs:* 1 drop per eye once daily (evening), or q8–12h.

*Cats:* No information available.

**Trazodone**
(Desyrel*, Molipaxin*, Oleptro*, Trazodone*) POM

**Formulations:** Oral: 50 mg, 100 mg, 150 mg tablets/capsules; 10 mg/ml liquid.

**Action:** Trazodone is an atypical antidepressant with mixed serotonergic agonistic (5HT1A) and antagonistic actions (other 5HT receptor sites).

**Use:**
- Chronic anxiety-related problems in dogs that are unresponsive to other pharmacological interventions. Should be used in conjunction with a behaviour modification plan. Use with
caution and carefully monitor patients with renal disease. Less risk in patients with cardiac disease than tricyclic antidepressants such as amitriptyline.

- Reduction of anxiety associated with hospitalization, including postoperative confinement in dogs.
- In cats, may be used for the management of short-term anxiety-related problems, e.g. travel or examination anxiety.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Glaucoma, history of seizures or urinary retention and severe liver disease.

**Adverse reactions:** Sedation, vomiting, excitability and dry mouth. Third eyelid protrusion described in some cats.

**Drug interactions:** Should not be used with monoamine oxidase inhibitors or drugs metabolized by cytochrome P450 2D6 (e.g. chlorphenamine, cimetidine). There is a risk of serotonin syndrome if combined with other serotonergic substances, but adjunctive therapy is sometimes used (see below). Ketoconazole will inhibit the breakdown of trazodone, leading to increased blood levels, while carbamazepine will have the opposite effect; itraconazole may be similar, although there is no clinical evidence of this.

**DOSES**

**Dogs:**
- For management of short-term anxiety associated with hospitalization: 4 mg/kg p.o. q12h titrated upwards to 10–12 mg/kg as needed to a maximum of 300 mg per dose.
- For chronic anxiety issues: initial dose for 5–10 kg, 25 mg p.o. q24h; 11–20 kg, 50 mg p.o. q24h; >21 kg, 100 mg p.o. q24h. Doses may be titrated upwards every 10–14 days to a maximum of double the recommended initial dose. Doses for dogs >40 kg may be titrated to a maximum of 300 mg p.o. q24h.
- Dose may need to be increased if used long term as tolerance over time is common. Lower end doses may be used adjunctively with SSRIs (e.g. fluoxetine) but not MAOIs, but the risk of serotonin syndrome should be recognized.

**Cats:** 50–100 mg/cat p.o. q24h; for short-term use only; 50 mg/cat administered 1 hour before travel to address transport and examination-related anxiety.

**References**


Gruen ME, Roe SC, Griffith E et al. (2014). Use of trazodone to facilitate postsurgical confinement in dogs. *Journal of the American Veterinary Medical Association* 245, 296–301

Stevens BJ, Frantz EM, Orlando JM et al. (2016). Efficacy of a single dose of trazodone hydrochloride given to cats prior to veterinary visits to reduce signs of transport- and examination-related anxiety. *Journal of the American Veterinary Medical Association* 249, 202–207
**Tretinoin** see **Vitamin A**

**Triamcinolone**
(Kenalog*, Recicort*) **POM**

**Formulations:**
- **Injectable:** 40 mg/ml suspension for deep i.m., intra-articular or intralesional use.
- **Topical:** Solution containing 1.77 mg/ml with 17.7 mg/ml salicylic acid.

**Action:** Alters the transcription of DNA, leading to alterations in cellular metabolism which reduces inflammatory response.

**Use:**
- Used topically for otitis externa and for the symptomatic treatment of seborrhoeic dermatitis in dogs and cats.
- Intralesional injections in the management of various strictures (rectal, nasal, oesophageal and others).
- Has also been used in the management of inflammatory arthritides and dermatoses but is controversial in these uses.
- Suggested as a treatment for lipomas that impair mobility as an alternative to surgery.
- Treatment of mast cell tumours.

Unsuitable for alternate-day use because of its duration of activity. Has 1.25 times the anti-inflammatory potency of prednisolone. On a dose basis, 0.8 mg triamcinolone is equivalent to 1 mg prednisolone. It has negligible mineralocorticoid activity. Animals on chronic therapy should be tapered off their steroids when discontinuing the drug.

**Safety and handling:** Normal precautions should be observed. Avoid direct skin contact with products.

**Contraindications:** Do not use in pregnant animals. Systemic corticosteroids are generally contraindicated in patients with renal disease and diabetes mellitus.

**Adverse reactions:** Prolonged use of glucocorticoids suppresses the hypothalamic–pituitary axis (HPA) and causes adrenal atrophy. Catabolic effects of glucocorticoids lead to weight loss and cutaneous atrophy. Iatrogenic hyperadrenocorticism may develop with chronic use. Vomiting and diarrhoea may be seen in some patients. GI ulceration may develop. Glucocorticoids may increase urine glucose levels and decrease serum T3 and T4 values. Impaired wound healing and delayed recovery from infections may be seen.

**Drug interactions:** There is an increased risk of GI ulceration if systemic glucocorticoids are used concurrently with NSAIDs. Hypokalaemia may develop if potassium-depleting diuretics (e.g. furosemide, thiazides) are administered with corticosteroids. Insulin requirements may increase in patients taking glucocorticoids. Metabolism of corticosteroids may be enhanced by phenobarbital or phenytoin and decreased by antifungals (e.g. itraconazole).
DOSES

Dogs:
- **Systemic:** 0.1–0.2 mg/kg i.m. initially then 0.02–0.04 mg/kg maintenance. A single i.m. dose of the long-acting preparations is effective for 3–4 weeks.
- **Intralesional:** 1.2–1.8 mg (total dose) injected intralesionally. Maximum 0.6 mg at any one site; separate injections by 0.5–2.5 cm.
- **Mast cell tumours:** 1 mg injected intralesionally per cm of tumour (longest dimension).
- **Topical:** 8–10 drops in affected ear once or twice daily for a maximum of 14 days. Do not exceed 7 drops per kg total daily dose.

Cats:
- **Systemic, intralesional:** as for dogs.
- **Intra-articular:** 1–3 mg.

References


**Trientine (2,2,2-Tetramine)**
(Metalite, Trientine*) POM

Formulations: Oral: 250 mg, 300 mg capsule.

Action: Trientine is a copper chelator used in the management of copper toxicosis and acts primarily to increase the urinary elimination of copper.

Use: Treatment of dogs with copper hepatotoxicosis, especially those intolerant of penicillamine. Compared with penicillamine, it has greater affinity for plasma copper but reduced affinity for tissue copper.

Safety and handling: Normal precautions should be observed.

Contraindications: No information available.

Adverse reactions: Nausea, vomiting, abdominal pain, melaena and weakness. Rarely, chronic therapy can lead to copper deficiency.

Drug interactions: Inhibits the absorption of iron, zinc and other minerals; separate doses by a minimum of 2 hours.

DOSES

Dogs: 10–15 mg/kg p.o. q12h. Vomiting may be reduced by giving in divided doses with food.

Cats: No information available.
References

L-Tri-iodothyronine see Liothyronine

Trilostane
(Vetoryl) POM-V

Formulations: Oral: 10 mg, 30 mg, 60 mg, 120 mg capsules. 5 mg capsules and a liquid formulation are available on a named patient basis.

Action: Blocks adrenal synthesis of glucocorticoids. Effects on mineralocorticoids are relatively minor.

Use:
- Treatment of canine pituitary- and adrenal-dependent hyperadrenocorticism.
- Reportedly useful in the treatment of feline hyperadrenocorticism.
- Canine ‘alopecia X’ syndrome.

Treatment should be monitored after 10 days, 4 weeks, 12 weeks and then every 3–4 months using a combination of clinical signs and either an ACTH stimulation test (start test 3 hours post-dosing, aim for a post-ACTH cortisol of 40–120 nmol/l); or pre-pill cortisol measurement (aim for pre-pill cortisol of 40–140 nmol/l). Twice-daily dosing advocated in those cases when clinical signs persist despite an increased once-daily dose or polydipsia appears within the 24-hour period or in patients with concurrent diabetes mellitus. Dosage adjustments may be necessary even after prolonged periods of stability. Trilostane should be given with food.

Safety and handling: Normal precautions should be observed.

Contraindications: Do not use in patients with renal or hepatic insufficiency.

Adverse reactions: Reported adverse effects in dogs include mild GI signs, mild increases in serum potassium, bilirubin and calcium. Clinical hypoadrenocorticism can be seen. Adrenal necrosis has been reported. Adrenal hyperplasia has been noted with prolonged treatment but the effects of this are unknown. Prolonged adrenal suppression after drug withdrawal has been noted in some cases.

Drug interactions: Trilostane should not be administered concurrently with other drugs that suppress adrenal function, e.g. mitotane, itraconazole.
DOSES

**Dogs:** Hyperadrenocorticism: 2 mg/kg p.o. q24h or 1 mg/kg p.o. q12h.

**Cats:** Hyperadrenocorticism: 10–30 mg/cat p.o. q12–24h.

References


Macfarlane L, Parkin T and Ramsey I (2016) Pre-trilostane and three-hour post-trilostane cortisol to monitor trilostane therapy in dogs. *Veterinary Record* 179, 597


---

**Trimethoprim/Sulphonamide**

*(Potentiated sulphonamides)*

*(Duphatrim, Norodine, Trimacare, Trimedoxine, Septrin*) POM-V, POM

**Formulations:** Trimethoprim and sulphonamide are formulated in a ratio of 1:5. **Injectable:** trimethoprim 40 mg/ml and sulfadiazine 200 mg/ml (240 mg/ml total) solution. **Oral:** trimethoprim and sulfadiazine in a variety of tablet sizes designated by the amount of trimethoprim, e.g. 20 mg, 80 mg. Each 5 ml of paediatric suspension contains 200 mg sulfamethoxazole and 40 mg trimethoprim = 48 mg/ml suspension. Tablets contain 80 mg trimethoprim and 400 mg sulfamethoxazole. If availability of veterinary formulations is limited, POM products may be used on a named patient basis.

**Action:** Trimethoprim and sulphonamides block sequential steps in the synthesis of tetrahydrofolate, a cofactor required for the synthesis of many molecules, including nucleic acids. The two-step mechanism ensures that bacterial resistance develops more slowly than to either agent alone. Time-dependent mechanism of action.

**Use:** Many organisms are susceptible, including *Nocardia*, *Brucella*, Gram-negative bacilli, some Gram-positive organisms (*Streptococcus*), plus *Pneumocystis carinii*, *Toxoplasma gondii* and other coccidians. *Pseudomonas* and *Leptospira* are usually resistant. Trimethoprim/sulphonamide is useful in the management of urinary, respiratory tract and prostatic infections, but ineffective in the presence of necrotic tissue. Trimethoprim alone may be used for urinary, prostatic, systemic salmonellosis and respiratory tract infections. Fewer adverse effects are seen with trimethoprim alone. Trimethoprim is a weak base which becomes ion-trapped in fluids that are more acidic than plasma (e.g. prostatic fluid and milk). Ensure patients receiving sulphonamides are well hydrated and are not receiving urinary acidifying agents.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Avoid use in animals with keratoconjunctivitis sicca (KCS) or previous history of adverse reaction to sulphonamides such as KCS or polyarthritis.
Adverse reactions: Drowsiness, anorexia, leucopenia, anaemia and hypersalivation may be seen in cats. Hepatic necrosis, vomiting, immune-mediated thrombocytopenia and an immune-mediated polyarthritis may be seen in dogs. Dobermanns seem to be more susceptible to the development of immune-mediated systemic adverse effects. Acute hypersensitivity reactions are possible with sulphonamide products and may manifest as a type III hypersensitivity reaction. Sulphonamides may reversibly suppress thyroid function. KCS has been reported in dogs treated with sulfapyridine and other sulphonamides. Monitor tear production particularly during long-term use and in breeds susceptible to keratoconjunctivitis sicca.

Drug interactions: Antacids may decrease the bioavailability of sulphonamides if administered concomitantly. Urinary acidifying agents will increase the tendency for sulphonamide crystals to form within the urinary tract. Concomitant use of drugs containing procaine may inhibit the action of sulphonamides since procaine is a precursor for para-amoeno benzoic acid.

DOSES
See Appendix for guidelines on responsible antibacterial use.

Doses (mg) of total product (trimethoprim + sulphonamide).

**Dogs, Cats:** 15–30 mg/kg p.o. q12h. 30 mg/kg s.c. q24h.

References

Tropicamide
(Mydriacyl*, Tropicamide*) POM

Formulations: Ophthalmic: 0.5%, 1% solution (single-use vials), 1% (5 ml bottle).

Action: Inhibits acetylcholine at the iris sphincter and ciliary body muscles, causing mydriasis (pupil dilation) and cycloplegia (paralysis of the ciliary muscle).

Use: Synthetic, short-acting anticholinergic used for mydriasis and cycloplegia. It is the mydriatic of choice for intraocular examination due to its rapid onset (20–30 minutes) and short duration of action (2–12 hours in dogs, 4–9 hours in cats). Tropicamide is more effective as a mydriatic than as a cycloplegic and is therefore less effective than atropine in relieving ciliary body muscle spasm associated with uveitis. Use with care in patients with lens luxation.

Safety and handling: Normal precautions should be observed.

Contraindications: Avoid in glaucoma.
**Tylosin**
(Bilosin, Tylan, Tyluvet) POM-V

**Formulations:** Injectable: 200 mg/ml solutions (Bilosin, Tylan, Tyluvet). Oral: 100 g/bottle soluble powder (Tylan).

**Action:** A time-dependent macrolide antibiotic that binds to the 50S ribosomal subunit, suppressing bacterial protein synthesis.

**Use:** Tylosin has good activity against mycoplasmas and has the same antibacterial spectrum of activity as erythromycin but is generally less active against bacteria. Although rarely indicated in small animal medicine, it has been used for the treatment of antibiotic-responsive diarrhoea in dogs and for cryptosporidiosis. Administration is predominantly by the oral route in dogs and cats.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** No information available.

**Adverse reactions:** GI disturbances. The activity of tylosin is enhanced in an alkaline pH. Tylosin can cause pain at the site of injection.

**Drug interactions:** Not well documented in small animals. It does not appear to inhibit the same hepatic enzymes as erythromycin.

**DOSES**

**Dogs:** Various doses: 7–15 mg/kg p.o. q12–24h. In colitis, higher doses recommended 12–20 mg/kg q8h with food gradually increasing the dosing interval to q24h.

**Cats:** 7–15 mg/kg p.o. q12–24h.

**References**
**Ursodeoxycholic acid (UDCA)**
(Cholurso*, Destolit*, Ursodeoxycholic acid*, Ursofalk*) POM

**Formulations:** Oral: 150 mg, 250 mg, 300 mg, 500 mg tablets; 250 mg capsule; 50 mg/ml suspension.

**Action:** A relatively hydrophilic bile acid with cytoprotective effects in the biliary system. It inhibits ileal absorption of hydrophobic bile acids, thereby reducing their concentration in the body pool; hydrophobic bile acids are toxic to hepatobiliary cell membranes and may potentiate cholestasis. It also has an immunomodulatory effect, and may modify apoptosis of hepatocytes.

**Use:**
- Adjunctive therapy for patients with liver disease, particularly where cholestasis is present.

The administration of UDCA does not alter the bile acid stimulation test of normal healthy dogs, but a small but significant increase has been demonstrated in both the pre- and postprandial bile acids in healthy cats.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Occlusion of the biliary tract.

**Adverse reactions:** Ursofalk suspension contains xylitol as an excipient, so care should be used when administering this product to dogs and cats. Safety has not been demonstrated in dogs or cats but side effects appear to be rare. Diarrhoea is the more frequently reported adverse effect in human patients. Some human patients have an inability to sulphate lithocholic acid (a natural metabolite of UDCA), which is a known hepatotoxin; the veterinary significance of this is unclear.

**Drug interactions:** Aluminium-containing antacids may bind to UDCA, thereby reducing its efficacy. UDCA can increase the absorption of ciclosporin leading to raised serum levels.

**DOSES**
**Dogs, Cats:** 10–15 mg/kg p.o. q24h or divided daily.

**References**

Vecuronium
(Norcuron*) POM

Formulations: Injectable: 10 mg powder for reconstitution.

Action: Inhibits the actions of acetylcholine at the neuromuscular junction by binding competitively to the alpha subunit of the nicotinic acetylcholine receptor on the postjunctional membrane.

Use:
- Provision of neuromuscular blockade during anaesthesia.
- Improve surgical access through muscle relaxation, to facilitate positive pressure ventilation or for intraocular surgery.

Intermediate dose-dependent duration of action of approximately 20 minutes. Has no cardiovascular effects and does not cause histamine release. Monitoring (using a nerve stimulator) and reversal of the neuromuscular blockade are recommended to ensure complete recovery before the end of anaesthesia. Hypothermia, acidosis and hypokalaemia will prolong the duration of neuromuscular blockade. In healthy animals, repeated doses are relatively non-cumulative and it can be given by infusion i.v. to maintain neuromuscular blockade. It is metabolized by the liver; therefore, in animals with liver dysfunction atracurium is advised rather than vecuronium. The duration of action of vecuronium is shorter in diabetic dogs compared with non-diabetic animals, although the underlying reasons for this difference are unclear. This may be clinically relevant when using vecuronium to provide neuromuscular blockade in diabetic dogs undergoing ocular surgery. Sugammadex (a cyclodextrin) developed to reverse neuromuscular blockade induced by rocuronium, can also be used to reverse neuromuscular blockade caused by vecuronium in dogs at a dose of 8 mg/kg i.v.

Safety and handling: Unstable in solution and so is presented as a freeze-dried powder. The prepared solution can be diluted further if required.

Contraindications: Do not administer unless the animal is adequately anaesthetized and facilities to provide positive pressure ventilation are available.

Adverse reactions: No information available.

Drug interactions: Neuromuscular blockade is more prolonged when vecuronium is given in combination with volatile anaesthetics, aminoglycosides, clindamycin and lincomycin.

DOSES
Dogs, Cats: 0.1 mg/kg initially produces neuromuscular blockade for 25–30 min. The block can be maintained by increments of 0.03 mg/kg or a constant rate infusion of 0.1–0.2 mg/kg/h. Lower loading doses of 0.05 mg/kg i.v. produce neuromuscular blockade of shorter duration (16–19 min).

References
Mosing M, Auer U, West E et al. (2012) Reversal of profound rocuronium or vecuronium induced neuromuscular block with sugammadex in isoflurane anaesthetised dogs. The Veterinary Journal 192, 467–471
**Verapamil**  
(Securon*, Verapamil*) **POM**

**Formulations:** Injectable: 2.5 mg/ml solution (Securon). Oral: 40 mg, 80 mg, 120 mg, 160 mg tablets (Verapamil); 40 mg/5 ml oral solution (Verapamil).

**Action:** Inhibits inward movement of calcium ions through slow (L-type) calcium channels in myocardial cells, cardiac conduction tissue and vascular smooth muscle. Verapamil causes a reduction in myocardial contractility (negative inotrope), depressed electrical activity (slows AV conduction) and vasodilation (cardiac vessels and peripheral arteries and arterioles).

**Use:** Primarily used to control supraventricular tachyarrhythmias, such as accessory pathway-mediated SVT, atrial tachycardia and flutter. Verapamil is a second-choice calcium-channel blocker behind diltiazem as it has a more pronounced negative inotropic effect. Patients with severe hepatic disease may have a reduced ability to metabolize the drug; reduce the dose by 70%.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not use in patients with 2nd or 3rd degree AV block, hypotension, sick sinus syndrome, left ventricular dysfunction or heart failure.

**Adverse reactions:** Can cause hypotension, bradycardia, dizziness, precipitation or exacerbation of congestive heart failure, nausea, constipation and fatigue in humans.

**Drug interactions:** Do not use concurrently with beta-blockers. Both drugs have a negative inotropic and chronotropic effect and the combined effect can be profound. Co-administration with sodium-channel blockers may also lead to cardiovascular depression and hypotension. Verapamil activity may be adversely affected by vitamin D or calcium salts. Cimetidine may increase the effects of verapamil. Verapamil may increase the blood levels of digoxin, digitoxin or theophylline, leading to potentially toxic effects from these drugs. Calcium-channel blockers may increase intracellular vincristine. The neuromuscular blocking effects of non-depolarizing muscle relaxants may be enhanced by verapamil.

**DOSES**

**Dogs:** 0.5–3 mg/kg p.o. q8h or 0.05 mg/kg slowly i.v. over 5 minutes (with ECG monitoring). Up to 4 repeat i.v. administrations at a reduced dose of 0.025 mg/kg q5min if necessary.

**Cats:** 0.5–1 mg/kg p.o. q8h or 0.025 mg/kg slowly i.v. over 5 minutes (with ECG monitoring). Up to 3 repeat i.v. administrations q5min if necessary.
**Vinblastine**  
(Velbe*, Vinblastine*)  
**POM**

**Formulations:** Injectable: 1 mg/ml solution.

**Action:** Interferes with microtubule assembly, causing metaphase arrest and ultimately resulting in cell death.

**Use:**
- Vinblastine is used less frequently than vincristine for treatment of lymphoproliferative disorders.
- Used with prednisolone for treatment of canine mast cell tumours.
- Treatment of bladder transitional carcinomas.

Use with care in patients with abnormal liver function; dose reduction recommended. Potentially a neurotoxic substrate of P-glycoprotein, use with caution in herding breeds (e.g. collies) that may have the gene mutation (ABCB1 (MDR1)) that causes a non-functional glycoprotein. Drug is locally irritant and must be administered i.v. through a carefully pre-placed catheter.

**Safety and handling:** Cytotoxic drug; see Appendix and specialist texts for further advice on chemotherapeutic agents. Store under refrigeration.

**Contraindications:** Bone marrow suppression, a dose reduction is recommended in patients with liver dysfunction.

**Adverse reactions:** Main dose-limiting toxicity is myelosuppression with neutropenia. Mucositis, stomatitis, ileus, jaw/muscle pain, loss of deep tendon reflexes and GI tract toxicity may also occur. Cats may develop neurotoxicity manifesting as constipation and/or ileus.

**Drug interactions:** Any drugs that inhibit metabolism via hepatic cytochrome P450 system may reduce metabolism and thus increase toxicity of vinblastine, e.g. calcium-channel blockers, cimetidine, ciclosporin, erythromycin, metoclopramide and itraconazole. Drugs that are inhibitors of P-glycoprotein (ciclosporin, verapamil, phenothiazines and itraconazole) may increase the toxicity.

**DOSES**

See Appendix for chemotherapy protocols and conversion of body weight to body surface area.

**Dogs, Cats:** All uses: 1.5–3 mg/m² q7–14d (depending on the protocol used).

**References**

Vincristine
(Oncovin*, Vincristine*)  POM

Formulations: Injectable: 1 mg, 2 mg, 5 mg vials.

Action: Interferes with microtubule assembly, causing metaphase arrest and ultimately resulting in cell death.

Use:
- With other neoplastic agents in the treatment of canine and feline neoplastic diseases, particularly lymphoproliferative disorders.
- Management of immune-mediated thrombocytopenia to stimulate release of platelets.
- Treatment of transmissible venereal tumour.

Use with caution in patients with hepatic disease, leucopenia, infection, or pre-existing neuromuscular disease. Potentially a neurotoxic substrate of P-glycoprotein, use with caution in herding breeds (e.g. collies) that may have the ABCB1 (MDR1) gene mutation that causes a non-functional glycoprotein. Solution is locally irritant and must be administered i.v. through a carefully pre-placed catheter.

Safety and handling: Cytotoxic drug; see Appendix and specialist texts for further advice on chemotherapeutic agents. Store under refrigeration.

Contraindications: No information available.

Adverse reactions: Include peripheral neuropathy, ileus, GI tract toxicity/constipation and severe local irritation if administered perivascularly. Potentially myelosuppressive.

Drug interactions: Concurrent administration of vincristine with drugs that inhibit cytochromes of the CYP3A family may result in decreased metabolism of vincristine and increased toxicity. If vincristine is used in combination with L-asparaginase it should be given 12–24 hours before the enzyme. Administration of L-asparaginase with or before vincristine may reduce clearance of vincristine and increase toxicity.

DOSES
See Appendix for chemotherapy protocols and conversion of body weight to body surface area.

Dogs, Cats:
- Transmissible venereal tumours: 0.5 mg/m² (up to a maximum dose of 1 mg) i.v. q7d for 4–6 weeks.
- Other neoplastic diseases: usual doses are 0.5–0.75 mg/m² i.v. every 1–3 weeks. (Dependent upon protocol used.)
- To increase circulating platelet numbers: 0.02 mg/kg i.v. once (limited reports of the use of vincristine to raise circulating platelet numbers in cats, in three reported cases it had minimal or no improvement to their platelet count).

References
**Vitamin A (Retinol, Isotretinoin, Tretinoin)**
(Isotrext*, Isotrexin*, Roaccutane*) POM

**Formulations:** *Injectable:* vitamin A (retinol) 50,000 IU/ml. *Oral:* 10 mg, 20 mg isotretinoin capsules (Roaccutane). *Topical:* 0.05% isotretinoin gel (Isotrex, Isotrexin).

**Action:** Nutritional fat-soluble hormone that regulates gene expression. Tretinoin (all-trans retinoic acid) is the acid form of vitamin A and isotretinoin (13-cis retinoic acid) is an isomer of tretinoin.

**Use:**
- Treatment of hypovitaminosis A.
- Also used in conjunction with other appropriate therapies for sebaceous adenitis or primary seborrhoea of Cocker Spaniels.

Animals receiving oral dosing should be monitored for vitamin A toxicity. Avoid concurrent use of oral and topical preparations because of toxicity. Avoid using formulations of vitamins A, D3 and E that are authorized for farm animals or horses as they are too concentrated for small animal use.

**Safety and handling:** Vitamin A is teratogenic; gloves should be worn when applying topical preparations. Avoid contact with eyes, mouth or mucous membranes. Minimize exposure of the drug to sunlight.

**Contraindications:** Do not use in pregnant animals.

**Adverse reactions:** Many adverse effects are reported in humans following the use of oral isotretinoin, predominantly involving the skin, haematological parameters, hepatotoxicity, nervous system and bone changes. Similar abnormalities are reported in dogs and cats receiving high doses. Teratogenic if administered in the first trimester or at high doses. Redness and skin pigmentation may be seen after several days. It changes the lipid content of tears, which can result in keratoconjunctivitis sicca (KCS). It may also cause hyperlipidaemia and can be hepatotoxic at high doses. Prolonged use of vitamin A can promote loss of calcium from bone and lead to hypercalcaemia. Do not use topical preparations simultaneously with other topical drugs.

**Drug interactions:** Numerous, depending on preparation and route given. Consult specialist texts before using with another drug. Oral vitamin A may alter ciclosporin levels, which should therefore be monitored closely.

**DOSES**

**Dogs:**
- **Hypovitaminosis A:** 10,000–100,000 IU/dog i.m. q3d, no more than 2 doses; 10,000 IU/dog p.o. q24h for 3 days.
- **Dermatological lesions:** 10,000 IU/dog p.o. q24h or apply isotretinoin/tretinoin gel/cream to clean skin q12h; 1 mg isotretinoin/kg p.o. q12h for 1 month, reducing the dosage to 1 mg/kg p.o. q24h if improvement is seen.
**Cats:** Hypovitaminosis A: 10,000–100,000 IU/cat i.m. q3d, no more than 2 doses; 10,000 IU/cat p.o. q24h for 3 days.

**References**
Lam AT, Affolter VK, Outerbridge CA et al. (2011) Oral vitamin A as an adjunct treatment for canine sebaceous adenitis. *Veterinary Dermatology* 22, 305–311

---

**Vitamin B complex**
(Anivit 4BC, Dupharal, Duphafral Extravite, Multivitamin injection, Vitamin B tablets)
**POM-VPS, general sale**

**Formulations:** Various preparations containing varying quantities of vitamins are available, authorized for farm animals only. Most are for parenteral use and all those are POM-VPS.

**Action:** Cofactors for enzymes of intermediary metabolism and biosynthesis.

**Use:** Multiple deficiencies of B vitamins may occur in patients with renal or hepatic disease or significant anorexia. However, parenteral administration of B vitamins is not a substitute for nutritional support. Dosages and routes vary with individual products. Check manufacturer’s recommendations prior to use. Most products are intended for large animal use and some may contain vitamin C and other vitamins or minerals.

**Safety and handling:** All B vitamins are photosensitive and must be protected from light once reconstituted. Multidose vials require aseptic technique for repeated use.

**Contraindications:** No information available.

**Adverse reactions:** Anaphylaxis may be seen when used i.v. and products should be given slowly and/or diluted with i.v. fluids. Use of large animal products which also contain fat-soluble vitamins (A, D, E, K) may lead to toxicity.

**Drug interactions:** None reported.

**DOSES**
**Dogs:** 1 ml/dog (dogs up to 15 kg), 2–4 ml/dog (dogs >15 kg) s.c., i.m., i.v. q24h.
**Cats:** 1 ml/cat s.c., i.m., i.v. q24h or as required.
**Vitamin B₁ (Thiamine)**

*(Vitamin B₁) POM-V, general sale*

**Formulations:** Injectable: 100 mg/ml solution (authorized for veterinary use, although only in farm animals). Oral: various.

**Action:** Cofactor for enzymes in carbohydrate metabolism, it forms a compound with ATP to form thiamine diphosphate/thiamine pyrophosphate employed in carbohydrate metabolism. It does not affect blood glucose.

**Use:**
- Thiamine supplementation is required in deficient animals.
- Thiamine may be beneficial in alleviating signs of lead poisoning and ethylene glycol intoxication.

Although uncommon deficiency may occur in animals fed raw fish diets or uncooked soy products.

**Safety and handling:** Protect from air and light; multidose vials require aseptic technique for repeated use.

**Contraindications:** Do not use in pregnant animals unless absolutely necessary.

**Adverse reactions:** Anaphylaxis can be seen with i.v. use; dilute with fluids and/or give slowly if using i.v. Adverse effects in pregnant animals are documented.

**Drug interactions:** There are no specific clinical interactions reported, although thiamine may enhance the activity of neuromuscular blocking agents.

**DOSES**

**Dogs:**
- Vitamin B₁ deficiency: 50–250 mg/dog i.m., s.c., p.o. q12–24h for several days until signs resolve.
- Lead poisoning: 2 mg/kg i.m., s.c. q12h.
- Ethylene glycol intoxication: 100 mg/dog i.m., s.c., p.o. q24h.

**Cats:** Vitamin B₁ deficiency: 10–25 mg/cat i.m., s.c. q12–24h for several days until signs resolve or 10–20 mg/kg i.m. until signs resolve then 10 mg/kg p.o. for 21 days.

**Vitamin B₃** see **Nicotinamide**
Vitamin B12 (Cyanocobalamin, Hydroxocobalamin)
(Anivit B12 250 and 1000, Cobalaplex, Cyanocobalamin PXN-B12, Neo-Cytamen (hydroxocobalamin), Vitbee 250 and 1000)
POM-VPS

Formulations: Injectable: 0.25 mg/ml, 1 mg/ml solutions. Oral: 0.5 mg capsule (Cyanocobalamin).

Action: Essential cofactor for enzymes involved in DNA and RNA synthesis and in carbohydrate metabolism.

Use:
• Used to treat vitamin B12 deficiency. Such a deficiency may develop in patients with significant, malabsorptive disease of the distal ileum and exocrine pancreatic insufficiency.

Safety and handling: Injectable preparations must be protected from light.

Contraindications: Do not give i.v.

Adverse reactions: Hypersensitivity to the phenol preservative in the injectable solutions can occur; patients should be monitored after injections for rash, fever and urticaria.

Drug interactions: None reported.

DOSES

Dogs:
• Injectable: 0.02 mg/kg s.c., i.m. q7d for 4–6 weeks until the serum concentration normalizes. Then as required to maintain normal serum levels.
• Oral: <10 kg: ½ capsule per day or 1 capsule every other day; 10–20 kg: 1 capsule per day; >20 kg: 2 capsules per day. The number of capsules can be increased or decreased as needed to maintain normal cobalamin.

Cats:
• Injectable: 0.02 mg/kg s.c., i.m. q7d for approximately 4 weeks until the serum concentration normalizes. Then as required to maintain normal serum levels.
• Oral: <10 kg: ½ capsule per day or 1 capsule every other day. The number of capsules can be increased or decreased as needed to maintain normal cobalamin.

References
Batchelor DJ, Noble PJ, Taylor RH et al. (2007) Prognostic factors in canine exocrine pancreatic insufficiency: prolonged survival is likely if clinical remission is achieved. Journal of Veterinary Internal Medicine 21, 54–60
**Vitamin C** *(Ascorbic acid)*
 *(Various trade names)* **POM, general sale**

**Formulations:** *Injectable:* 100 mg/ml. *Oral:* various strength tablets, capsules, powders and liquids.

**Action:** Water-soluble antioxidant, also critical for cross-linking collagen precursors (growth and repair of tissue) and is involved in protein, lipid and carbohydrate metabolism.

**Use:**
- Vitamin C is used to reduce methaemoglobinaemia associated with paracetamol toxicity.
- Supplemental vitamin C may be required in conditions of increased oxidative stress, in cachexic patients and in those requiring nutritional support.

There is no evidence to support long-term or high-dose therapy in dogs and cats, as they are able to synthesize vitamin C de novo to meet their needs.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Avoid use in patients with liver disease.

**Adverse reactions:** May cause anaphylaxis if given intravenously. Vitamin C supplementation may increase liver damage by increasing iron accumulation. Prolonged use can increase the risk of urate, oxalate and cystine crystalluria and stone formation.

**Drug interactions:** Large doses (oral or injectable) will acidify the urine and may increase the renal excretion of some drugs (e.g. mexiletine) and reduce the effect of some antibacterial drugs in the genitourinary system (e.g. aminoglycosides).

**DOSES**
*Dogs, Cats:* Methaemoglobinaemia: 30–40 mg/kg s.c. q6h for 7 treatments.

---

**Vitamin D** *(1,25-dihydroxycolecalciferol (active vitamin D3), colecalciferol (vitamin D3)) (Alfacalcidol*, Calcijex*, Calcitriol*, One-alpha*, Rocaltrol*) **POM-VPS, POM**

**Formulations:** *Oral:* Alfacalcidol 2 μg/ml solution (One-alpha), 0.25–1 μg capsules (Alfacalcidol; One-alpha), Calcitriol 0.25 μg capsules (Calcitriol; Rocaltrol). *Injectable:* Calcitriol 1 μg/ml solution (Calcijex). Vitamin D is a general term used to describe a range of hormones that influence calcium and phosphorus metabolism. They include vitamin D2 (ergocalciferol or calciferol),
vitamin D3 (colecalciferol), dihydrotachysterol, alfacalcidol and calcitriol (1,25-dihydroxycolecalciferol, the active form of vitamin D3). These different drugs have differing rates of onset and durations of action.

**Action:** In conjunction with other hormones (calcitonin and parathormone) regulates calcium homeostasis through numerous complex mechanisms, including accretion of calcium to bone stores, absorption of calcium from dietary sources.

**Use:**
- Chronic management of hypocalcaemia when associated with low parathyroid hormone concentrations which are most commonly associated with immune-mediated hypoparathyroidism and iatrogenic hypoparathyroidism following thyroidectomy.
- Calcitriol has also been used in the management of renal secondary hyperparathyroidism; in this circumstance it reduces serum parathyroid hormone concentrations.

Calcitriol and alfacalcidol (1-alpha-hydroxycolecalciferol) have a rapid onset of action (1–2 days) and a short half-life (<1 day); they are the preferred forms for use. Vitamin D2 (ergocalciferol) has a very slow onset of action and has limited use in dogs and cats. Vitamin D requires two hydroxylations (one in the liver and the other in the kidney) to become active. Thus, only the active form (calcitriol) should be used in patients with renal failure. Vitamin D has a very narrow therapeutic index and toxic doses are easily achieved. Serum calcium and preferably ionized calcium concentrations need to be monitored closely and frequently. Avoid using formulations of vitamins A, D3 and E that are authorized for farm animals as they are too concentrated for small animal use.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not use in patients with hyperphosphataemia or malabsorption syndromes. Do not use in pregnant animals.

**Adverse reactions:** Hypercalcaemia, hyperphosphataemia.

**Drug interactions:** Corticosteroids may negate the effect of vitamin D preparations. Sucralfate decreases absorption of vitamin D. Drugs that induce hepatic enzyme systems (e.g. barbiturates) will increase the metabolism of vitamin D and lower its effective dose. Magnesium or calcium containing antacids may cause hypermagnesaemia or hypercalcaemia when used with vitamin D. Thiazide diuretics may also cause hypercalcaemia with concurrent use. Hypercalcaemia may potentiate the toxic effects of verapamil or digoxin; monitor carefully.

**DOSES**

**Dogs:**
- **Hypocalcaemia/vitamin D deficiency:** calcitriol: 10–15 ng (nanograms)/kg p.o. q12h for 3–4 days, then decrease to 2.5–7.5
**Vitamin E (Alpha tocopheryl acetate)**
*(Vitamin E suspension*) **POM-VPS**

**Formulations:** Oral: 20 mg/ml, 100 mg/ml suspension. Several oral preparations for humans and injectable preparations for other veterinary species, some of which also contain selenium, are available. Various nutraceuticals, often also containing SAMe, are available.

**Action:** Lipid-soluble antioxidant also regulates gene expression and is involved in cellular metabolism of sulphur compounds.

**Use:**
- Patients with exocrine pancreatic insufficiency and other severe malabsorptive diseases may be at risk of developing deficiency.
- Vitamin E has been shown to be an effective antioxidant in dogs with liver disease, especially in patients with copper storage disease and copper-associated hepatopathy.
- Its use has been suggested for numerous conditions, including discoid lupus, demodicosis and hepatic diseases including fibrosis. These are, however, only anecdotal suggestions and there may be some significant risks.

Vitamin E supplementation is very rarely required in small animals. Avoid using Formulations: of vitamins A, D3 and E that are authorized for farm animals as they are too concentrated for small animal use.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Do not use in patients at high risk for thrombosis. Do not use in neonates.

**Adverse reactions:** Thrombosis. Anaphylactoid reactions have been reported.
Drug interactions: Vitamin E may enhance vitamin A absorption, utilization and storage. Vitamin E may alter ciclosporin pharmacokinetics and, if used concurrently, ciclosporin therapy should be monitored by checking levels.

DOSES

**Dogs:** 1.6–8.3 mg/kg p.o. q24h for the first 30 days, then as needed. An alternative dose is 100–400 IU/dog.

**Cats:** 1.6–8.3 mg/kg p.o. for the first 30 days, then as needed. An alternative dose is 30 IU/cat.

### Vitamin K1 (Phytomenadione)  
(Vitamine K1 Laboratoire TVM, Konakion*)

**POM-V, NFA-VPS, POM**

**Formulations:** Injectable: 10 mg/ml. Oral: 50 mg tablets. Some nutraceuticals also contain small amounts of vitamin K.

**Action:** Involved in the formation of active coagulation factors II, VII, IX and X by the liver.

**Use:**
- Treatment of toxicity due to coumarin and its derivatives.
- Before performing liver biopsy in patients with prolonged coagulation times.

Deficient states may also occur in prolonged significant anorexia. Although vitamin K is a fat-soluble vitamin its biological behaviour is like that of a water-soluble vitamin; it has a relatively short half-life and there are no significant storage pools. It may still require 6–12 hours for effect. Oral absorption is increased 4–5-fold in dogs if given with tinned food, especially those with increased fat content. Prothrombin time is the best method of monitoring therapy. Use a small gauge needle when injecting s.c. or i.m. in a patient with bleeding tendencies.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Avoid giving i.v. if possible.

**Adverse reactions:** Anaphylactic reactions have been reported following i.v. administration. Safety not documented in pregnant animals. Haemolytic anaemia occurs in cats when overdosed.

**Drug interactions:** Many drugs will antagonize the effects of vitamin K, including aspirin, chloramphenicol, allopurinol, diazoxide, cimetidine, metronidazole, erythromycin, itraconazole, propranolol and thyroid drugs as well as coumarin-based anticoagulants. If the patient is on other long-term medications it is advisable to check specific literature. The absorption of oral vitamin K is reduced by mineral oil.
DOSES

**Dogs, Cats:** Coumarin rodenticide toxicity:

- **Known 1st generation coumarin toxicity or vitamin K1 deficiency:** initially 2.5 mg/kg s.c. in several sites, then 1–2.5 mg/kg in divided doses p.o. q8–12h for 5–7 days.

- **Known 2nd generation coumarin (brodifacoum) toxicity:** initially 5 mg/kg s.c. in several sites, then 2.5 mg/kg p.o. q12h for 3 weeks, then re-evaluate coagulation status. The patient’s activity should be restricted for 1 week following treatment. Evaluate the coagulation status 3 weeks after cessation of treatment.

- **Known inandione (diphacinone) or unknown anticoagulant toxicity:** initially 2.5–5 mg/kg s.c. over several sites. Then 2.5 mg/kg p.o. divided q8–12h for 3–4 weeks. Re-evaluate coagulation status 2 days after stopping therapy. If the prothrombin (PT) time is elevated, continue therapy for 2 additional weeks. If not elevated repeat PT in 2 days. If normal, the animal should be rested for 1 week, if abnormal then continue therapy for an additional week and recheck PT times as above.

- **Liver disease (pre-biopsy):** 0.5–1.0 mg/kg s.c. q12h. After 1–2 days re-evaluate coagulation time and if normal proceed with biopsy. If not, the dose should be increased and procedure delayed. If there is further minimal improvement in coagulation times, fresh frozen plasma may be required.

**References**

Xylazine
(Chanazine, Nerfasin, Rompun, Sedaxylan, Virbaxyl, Xylacare, Xylapan) POM-V

Formulations: Injectable: 20 mg/ml solution.

Action: Agonist at peripheral and central alpha-2 adrenoreceptors, producing dose-dependent sedation, muscle relaxation and analgesia.

Use:
- Licensed to provide sedation and premedication when used alone or in combination with opioid analgesics.
- Xylazine combined with ketamine is used to provide a short duration (20–30 min) of surgical anaesthesia.
- Xylazine stimulates growth hormone production and may be used to assess the pituitary's ability to produce this hormone (xylazine stimulation test). Consult specialist texts for protocol.
- Has been used to induce self-limiting emesis in cats where vomiting is desirable (e.g. following the ingestion of toxic, non-caustic foreign material). Emesis generally occurs rapidly and within a maximum of 10 min. Further doses depress the vomiting centre and may not result in any further vomiting.

In cats and dogs has been largely superseded by medetomidine or dexmedetomidine and is no longer recommended for sedation. Xylazine is less specific for the alpha-2 adrenoreceptor than are medetomidine and dexmedetomidine and causes significant alpha-1 adrenoreceptor effects. This lack of specificity is likely to be associated with the poorer safety profile of xylazine compared with medetomidine and dexmedetomidine. Xylazine also sensitizes the myocardium to catecholamine arrhythmias, which increases the risk of cardiovascular complications. Xylazine is a potent drug that causes marked changes in the cardiovascular system. It should not be used in animals with cardiovascular or systemic disease affecting cardiovascular performance. Atipamezole is not licensed as a reversal agent for xylazine, but it is effective and can be used to reverse the effects of xylazine if an overdose is given. Spontaneous arousal from deep sedation following stimulation can occur with all alpha-2 agonists; aggressive animals sedated with xylazine must still be managed with caution.

Safety and handling: Normal precautions should be observed.

Contraindications: Do not use in animals with cardiovascular or other systemic disease. Use of xylazine in geriatric patients is also not advisable. It causes increased uterine motility and should not be used in pregnant animals, nor in animals likely to require or receiving sympathomimetic amines. Due to effects on blood glucose, use in diabetic animals is not recommended. Avoid when vomiting is contraindicated (e.g. foreign body, raised intraocular pressure). Induction of emesis is contraindicated if a strong acid or alkali has been ingested, due to the risk of further damage to the oesophagus.
Induction of vomiting is contraindicated if the dog or cat is unconscious, fitting or has a reduced cough reflex, or if the poison has been ingested for >2 hours or if the ingesta contains paraffin, petroleum products or other oily or volatile organic products, due to the risk of inhalation. Do not use for emesis in other species.

**Adverse reactions:** Xylazine has diverse effects on many organ systems as well as the cardiovascular system. It causes a diuresis by suppressing ADH secretion, a transient increase in blood glucose by decreasing endogenous insulin secretion, mydriasis and decreased intraocular pressure. Vomiting after xylazine is common, especially in cats.

**Drug interactions:** When used for premedication, xylazine will significantly reduce the dose of all other anaesthetic agents required to maintain anaesthesia.

**DOSES**

When used for sedation is generally given as part of a combination. See Appendix for sedation protocols in cats and dogs.

**Dogs:** Growth hormone response test: 100 μg (micrograms)/kg i.v.

**Cats:**
- Emesis: 0.6 mg/kg i.m. or 1 mg/kg s.c. once (effective in >75% of cats).
- Growth hormone suppression test: 100 μg (micrograms)/kg i.v.

**References**

**Zidovudine (Azidothymidine, AZT)**
(Azidothymidine*, Retrovir*) POM

**Formulations:** Oral: 100 mg, 250 mg capsules; 50 mg/5 ml syrup. Injectable: 10 mg/ml solution for use as i.v. infusion.

**Action:** Competitive inhibition of reverse transcriptase. Requires activation to the 5’-triphosphate form by cellular kinases.

**Use:**
- Treatment of FIV-positive cats.

In cats not showing clinical signs, it may delay the onset of the clinical phase. In cats showing clinical signs, it may improve recovery in combination with other therapies. In human medicine it is used in combination with other nucleoside reverse transcriptase inhibitors, e.g. abacavir, didanosine, lamivudine, stavudine, tenofovir and zalcitabine. Two of these drugs are usually used with either a non-nucleotide reverse transcriptase inhibitor or a protease inhibitor. Use of drug combinations in HIV-positive people aims to avoid the development of drug resistance. The protease inhibitors currently used in human medicine seem to lack efficacy against FIV, thus hampering this approach for FIV-infected cats in the clinical phase. However, lamivudine (3TC) when combined with zidovudine seems to be more effective at reducing viral load and increasing CD4/CD8 ratios over a 1 year period than zidovudine on its own. Combining zidovudine with interferon does not improve either parameter. These studies used small numbers of cats. Haematological monitoring is recommended.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Animals that are severely anaemic or leucopenic should not be given this drug.

**Adverse reactions:** Hepatotoxicity and severe anaemia can occur at doses higher than those recommended. Long-term adverse effects of lower doses have not been ascertained.

**Drug interactions:** No information available.

**DOSES**
**Cats:** FIV infection: 5 mg/kg daily p.o., s.c. q12h. The dose may be increased to 10 mg/kg q12h.

**Dogs:** Not applicable.

**References**
**Zinc salts**  
(Various trade names*) **POM, P, general sale**

**Formulations:** Oral: various zinc sulphate, zinc gluconate, zinc acetate and chelated zinc preparations.

**Action:** Primarily involved in DNA and RNA synthesis, although also involved in essential fatty acid synthesis, WBC function and numerous reactions in intermediary metabolism. When administered orally, can reduce GI absorption and hepatic uptake of copper.

**Use:**
- Treatment of zinc-responsive dermatoses.
- Reduction of copper in dogs with copper storage disease and copper-associated hepatopathy.
- Proposed benefits also exist in chronic hepatitis and hepatic encephalopathy.

Bioavailability of elemental zinc varies depending on formulation: zinc acetate and chelated forms are highest; gluconate is intermediate; sulphate is lowest. Higher bioavailability is also associated with improved tolerance. Zinc gluconate is associated with fewer GI side effects. Concurrent supplementation with EFAs is advised for the treatment of skin disorders.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Patients with copper deficiency.

**Adverse reactions:** Nausea, vomiting and occasional diarrhoea. Haemolysis may occur with large doses or serum levels >10 mg/ml particularly if a coexistent copper deficiency exists.

**Drug interactions:** Significant interactions with other divalent heavy metals such as iron and copper can occur and long-term administration of zinc may lead to decreased hepatic copper or iron stores and functional deficiency. Penicillamine and ursodeoxycholic acid may potentially inhibit zinc absorption; the clinical significance is unclear. Zinc salts may chelate oral tetracycline and reduce its absorption; separate doses by at least 2 hours. Zinc salts may reduce the absorption of fluoroquinolone antibiotics.

**DOSES**

**Dogs, Cats:** 1–2 mg elemental zinc p.o. q24h (zinc sulphate: 5 mg/kg p.o. q24h or in divided doses; zinc gluconate: 2 mg/kg p.o. q24h; zinc acetate: 1 mg/kg p.o. q24h). Give with food to minimize vomiting.

**References**

Zolazepam/Tiletamine
(Zoletil) POM-V

**Formulations:** Injectable: when reconstituted contains zolazepam 50 mg/ml and tiletamine 50 mg/ml (i.e. 100 mg/ml).

**Action:** Zolazepam (like diazepam) enhances the activity of gamma-aminobutyric acid (GABA) which is the major inhibitory neurotransmitter within the CNS. Tiletamine (like ketamine) antagonizes glutamic acid receptors.

**Use:**
- Used for general anaesthesia in dogs and cats.

Zolazepam (like diazepam) has a sedative, anxiolytic and muscle-relaxing action. Tiletamine generates a so-called dissociative anaesthesia because it depresses certain cerebral regions such as the thalamus and the cortex while other regions, in particular the limbic system, remain active. The duration of anaesthesia is 20–60 minutes depending on dose. The combined product should not be used as sole anaesthetic agent for painful operations. For these operations the product should be combined with an appropriate analgesic. Following anaesthesia, return to normal is progressive and can last 2–6 hours in a calm environment (avoid excessive noise and light). Recovery may be delayed in obese, old or debilitated animals. Remove an antiparasitic collar 24 hours before anaesthesia. Excessive salivation can occur after administration; this can be controlled by the administration of an anticholinergic. Muscle rigidity during recovery is common. Higher doses are more likely to be associated with a prolonged and excitable recovery in dogs. Premedication has been shown to increase the smoothness of recovery after tiletamine/zolazepam. Recovery from anaesthesia after tiletamine/zolazepam is more prolonged in cats than in dogs.

**Safety and handling:** Normal precautions apply. Pregnant women should avoid handling the product.

**Contraindications:** Do not use the product in animals with severe cardiac, respiratory or hypertensive disease, or renal, pancreatic or hepatic insufficiency, or with head trauma or intracranial tumours. The product crosses the placenta and may cause respiratory depression that can be fatal for puppies and kittens.

**Adverse reactions:** Injection may sometimes cause pain in cats.

**Drug interactions:** Premedication with phenothiazine tranquilizers (e.g. acepromazine) can cause increased cardiorespiratory depression and an increased hypothermic effect that occurs in the last phase of anaesthesia. Do not use medications containing chloramphenicol during the pre- or intraoperative period, as this slows down elimination of the anaesthetics.
DOSES

**Dogs:** 5–10 mg/kg i.v.; 7–25 mg/kg i.m. depending on the degree of pain expected and the depth of anaesthesia required. Dose refers to the tiletamine/zolazepam combination (100 mg/ml when properly reconstituted).

**Cats:** 5–7.5 mg/kg i.v.; 10–15 mg/kg i.m. depending on the degree of pain expected and the depth of anaesthesia required. Dose refers to the tiletamine/zolazepam combination (100 mg/ml when properly reconstituted).

---

**Zonisamide**

(Zonegran*) POM

**Formulations:** Oral: 25 mg, 50 mg, 100 mg capsules.

**Action:** The exact antiepileptic mode of action is unknown, but it is speculated that zonisamide may exert its effect by blocking repetitive firing of voltage-gated sodium channels, inhibiting calcium channels and modulating GABA-ergic and glutamatergic neurotransmission.

**Use:**

- Zonisamide is a sulphonamide anticonvulsant, which is usually used in dogs and cats as an adjunctive therapy in animals refractory to standard anticonvulsant therapy (in dogs, phenobarbital, imepitoin and potassium bromide).

It is well absorbed with a half-life of 15–17 hours in the dog. The drug is metabolized by the liver and then mostly excreted by the kidneys.

**Safety and handling:** Normal precautions should be observed.

**Contraindications:** Avoid use in patients with severe hepatic impairment. Do not use in pregnant animals as toxicity has been demonstrated in experimental studies. Do not discontinue abruptly.

**Adverse reactions:** Ataxia, sedation, vomiting and anorexia have been reported in a few dogs and, experimentally, in cats. Doses up to 75 mg/kg q24h or divided q12h have been used experimentally for up to 52 weeks in dogs; initially there was weight loss and, in the longer term, minor hepatic and haematological changes.

**Drug interactions:** Phenobarbital increases clearance of zonisamide up to 10 weeks after phenobarbital discontinuation. If using as an adjunctive to phenobarbital consider using doses at the higher end of the dose range.

---

**DOSES**

**Dogs:** Starting dose of 5–10 mg/kg p.o. q12h.

**Cats:** Starting dose of 5–10 mg/kg p.o. q24h is suggested.

**References**


Appendix I: General information

Abbreviations

In general, abbreviations should not be used in prescription writing; however, it is recognized that at present some Latin abbreviations are used when prescribing. These should be limited to those listed here.

Abbreviations used in prescription writing

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Meaning</th>
</tr>
</thead>
<tbody>
<tr>
<td>a.c.</td>
<td>Before meals</td>
</tr>
<tr>
<td>ad. lib.</td>
<td>At pleasure</td>
</tr>
<tr>
<td>amp.</td>
<td>Ampoule</td>
</tr>
<tr>
<td>b.i.d.</td>
<td>Twice a day</td>
</tr>
<tr>
<td>cap.</td>
<td>Capsule</td>
</tr>
<tr>
<td>g</td>
<td>Gram</td>
</tr>
<tr>
<td>h</td>
<td>Hour</td>
</tr>
<tr>
<td>i.m.</td>
<td>Intramuscular</td>
</tr>
<tr>
<td>i.p.</td>
<td>Intraperitoneal</td>
</tr>
<tr>
<td>i.v.</td>
<td>Intravenous</td>
</tr>
<tr>
<td>m²</td>
<td>Square metre</td>
</tr>
<tr>
<td>mg</td>
<td>Milligram</td>
</tr>
<tr>
<td>ml</td>
<td>Millilitre</td>
</tr>
<tr>
<td>o.m.</td>
<td>In the morning</td>
</tr>
<tr>
<td>o.n.</td>
<td>At night</td>
</tr>
<tr>
<td>p.c.</td>
<td>After meals</td>
</tr>
<tr>
<td>prn</td>
<td>As required</td>
</tr>
<tr>
<td>q</td>
<td>Every, e.g. q8h = every 8 hours</td>
</tr>
<tr>
<td>q.i.d./q.d.s</td>
<td>Four times a day</td>
</tr>
<tr>
<td>q.s.</td>
<td>A sufficient quantity</td>
</tr>
<tr>
<td>s.c.</td>
<td>Subcutaneous</td>
</tr>
<tr>
<td>s.i.d.</td>
<td>Once a day</td>
</tr>
<tr>
<td>Sig</td>
<td>Directions/label</td>
</tr>
<tr>
<td>stat</td>
<td>Immediately</td>
</tr>
<tr>
<td>susp.</td>
<td>Suspension</td>
</tr>
<tr>
<td>tab</td>
<td>Tablet</td>
</tr>
<tr>
<td>t.i.d./t.d.s</td>
<td>Three times a day</td>
</tr>
</tbody>
</table>

Other abbreviations used in this Formulary

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Meaning</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACE</td>
<td>Angiotensin converting enzyme</td>
</tr>
<tr>
<td>ACTH</td>
<td>Adrenocorticotropic hormone</td>
</tr>
<tr>
<td>AV</td>
<td>Atrioventricular</td>
</tr>
<tr>
<td>CBC</td>
<td>Complete blood count</td>
</tr>
<tr>
<td>CHF</td>
<td>Congestive heart failure</td>
</tr>
<tr>
<td>CNS</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>COX</td>
<td>Cyclo-oxygenase</td>
</tr>
<tr>
<td>CRI</td>
<td>Continuous rate infusion</td>
</tr>
<tr>
<td>CSF</td>
<td>Cerebrospinal fluid</td>
</tr>
<tr>
<td>Day(s)</td>
<td>Disseminated intravascular coagulation</td>
</tr>
<tr>
<td>GI</td>
<td>Gastrointestinal</td>
</tr>
<tr>
<td>Hb</td>
<td>Haemoglobin</td>
</tr>
<tr>
<td>min</td>
<td>Minute</td>
</tr>
<tr>
<td>p.o.</td>
<td>By mouth, orally</td>
</tr>
<tr>
<td>PU/PD</td>
<td>Polyuria/polydipsia</td>
</tr>
<tr>
<td>RBC</td>
<td>Red blood cell</td>
</tr>
<tr>
<td>SLE</td>
<td>Systemic lupus erythematosus</td>
</tr>
<tr>
<td>STC</td>
<td>Special Treatment Certificate</td>
</tr>
<tr>
<td>VPC</td>
<td>Ventricular premature contraction</td>
</tr>
<tr>
<td>WBC</td>
<td>White blood cell</td>
</tr>
<tr>
<td>wk</td>
<td>Week(s)</td>
</tr>
</tbody>
</table>
Writing a prescription

A ‘veterinary prescription’ is defined by EU law as ‘any prescription for a veterinary medicinal product issued by a professional person qualified to do so in accordance with applicable national law’. The word ‘veterinary’ takes its normal meaning ‘of or for animals’. In the UK there are two classes of medicines available only on veterinary prescription, POM-V and POM-VPS, described in the Introduction. Only in the case of POM-V medicines does the veterinary prescription have to be issued by a veterinary surgeon. The act of prescribing is taken to mean the decision made by the prescriber as to which product should be supplied, taking account of the circumstances of the animals being treated, the available authorized veterinary medicinal products and the need for responsible use of medicines. Good prescription principles include the following. Only 1, 8, 10 and 12 are legal requirements; the remainder are good practice.

1. Print or write legibly in ink or otherwise so as to be indelible. Sign in ink with your normal signature. Include the date on which the prescription was signed.

2. Use product or approved generic name for drugs in capital letters – do not abbreviate. Ensure the full name is stated, to include the pharmaceutical form and strength.

3. State duration of treatment where known and the total quantity to be supplied.


5. Always put a 0 before an initial decimal point (e.g. 0.5 mg), but avoid the unnecessary use of a decimal point (e.g. 3 mg not 3.0 mg).

6. Give precise instructions concerning route/dose/formulation. Directions should preferably be in English without abbreviation. It is recognized that some Latin abbreviations are used (p.441).

7. Any alterations invalidate the prescription – rewrite.

8. Prescriptions for Schedule 2 and most Schedule 3 Controlled Drugs must be entirely handwritten and include the total quantity in both words and figures, the form and strength of the drug, and are only valid for 28 days; repeat prescriptions are not allowed. In addition, the RCVS Registration Number of the prescribing veterinary surgeon must be stated. Prescriptions for Schedule 4 Controlled Drugs do not require the RCVS Registration Number and repeat prescriptions are allowed.

9. The prescription should not be repeated more than three times without re-checking the patient.

10. Include both the prescriber’s and the client’s names and addresses.

11. Include the directions that the prescriber wishes to appear on the labelled product. It is good practice to include the words ‘For animal treatment only’.

12. Include a declaration that, ‘This prescription is for an animal under my care’ or words to that effect.

13. If drugs that are not authorized for veterinary use are going to be used when there is an alternative that is ‘higher’ in the prescribing cascade, there should be a clear clinical justification made on an individual basis and recorded in the clinical notes or on the prescription.
The following is a standard form of prescription used:

<table>
<thead>
<tr>
<th>From: Address of practice</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Telephone No.</td>
<td></td>
</tr>
<tr>
<td>Animal’s name and identification</td>
<td>Owner’s name</td>
</tr>
<tr>
<td>(species, breed, age and sex)</td>
<td>Owner’s address</td>
</tr>
<tr>
<td>Rx</td>
<td></td>
</tr>
<tr>
<td>• Print name, strength and formulation of drug</td>
<td></td>
</tr>
<tr>
<td>• Total quantity to be supplied</td>
<td></td>
</tr>
<tr>
<td>• Amount to be administered</td>
<td></td>
</tr>
<tr>
<td>• Frequency of administration</td>
<td></td>
</tr>
<tr>
<td>• Duration of treatment</td>
<td></td>
</tr>
<tr>
<td>• Any warnings</td>
<td></td>
</tr>
<tr>
<td>• If not a POM-V and prescribed under the ‘Cascade’, this must be stated</td>
<td></td>
</tr>
</tbody>
</table>

For animal treatment only
For an animal under my care
Non-repeat/repeat X 1, 2 or 3
Name, qualifications and signature of veterinary surgeon

**Topical polypharmaceuticals for ear disease**

The following POM-V preparations contain two or more drugs and are used topically in the ear. For further information, see relevant monographs. In addition, there are a number of AVM-GSL preparations used for ear cleaning etc. that are not listed here.

<table>
<thead>
<tr>
<th>Trade name</th>
<th>Antibacterial</th>
<th>Steroid</th>
<th>Antifungal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aurizon</td>
<td>Marbofloxacin</td>
<td>Dexamethasone</td>
<td>Clotrimazole</td>
</tr>
<tr>
<td>Canaural⁹</td>
<td>Fusidic acid</td>
<td>Prednisolone</td>
<td>Nystatin</td>
</tr>
<tr>
<td>Framycetin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Easotic</td>
<td>Gentamicin</td>
<td>Hydrocortisone aceponate</td>
<td>Miconazole</td>
</tr>
<tr>
<td>Osurnia</td>
<td>Florfenicol</td>
<td>Betamethasone</td>
<td>Terbinafine</td>
</tr>
<tr>
<td>Otomax</td>
<td>Gentamicin</td>
<td>Betamethasone</td>
<td>Clotrimazole</td>
</tr>
<tr>
<td>Posatex</td>
<td>Orbifloxacin</td>
<td>Mometasone</td>
<td>Posaconazole</td>
</tr>
<tr>
<td>Surolan⁹</td>
<td>Polymixin B</td>
<td>Prednisolone</td>
<td>Miconazole</td>
</tr>
</tbody>
</table>

⁹ Note that there is some evidence from clinical trials that products that do not contain a specific acaricidal compound may nevertheless be effective at treating infestations of ear mites. The mode of action is unclear but the vehicle for these polypharmaceutical products may be involved.
Guidelines for responsible antibacterial use

While antibacterials are essential medicines for treating bacterial infections, it is important to remember that their use leads to selection of resistant strains of bacteria. Resistance may be inherent, evolved (by chromosomal DNA changes) or acquired (by plasmid transfer).

It is important that the veterinary profession uses antibacterials responsibly in order to:

- Minimize the selection of resistant veterinary pathogens (and therefore safeguard animal health)
- Minimize possible resistance transfer to human pathogens
- Retain the right to prescribe certain antibacterials.

Following these guidelines will help to maximize the therapeutic success of antibacterial agents while at the same time minimizing the development of antibacterial resistance, thereby safeguarding antimicrobials for future veterinary and human use. These guidelines should be read in conjunction with the updated BSAVA Guide to the Use of Veterinary Medicines, the PROTECT ME guidance and individual drug monographs (www.bsavalibrary.com).

Following the PROTECT ME guidance can help reduce resistance:

**Prescribe only when necessary**
Consider non-bacterial disease (e.g. viral infection), nutritional imbalance or metabolic disorders where antibacterial therapy would be redundant. Remember also that some bacterial disease will self-resolve without antibacterials. Offer a non-prescription form to support a decision not to prescribe antibacterial therapy.

**Reduce prophylaxis**
Antibacterials are not a substitute for surgical asepsis and the need for prophylactic antibacterials in surgery should be carefully considered. Prophylactic antibacterials are only appropriate in a few medical cases (e.g. immunocompromised patients).

**Offer other options**
Consider therapeutic alternatives (e.g. lavage and debridement of infected material, analgesia, cough suppressants, fluid therapy or nutritional modification). Use topical preparations as these reduce the selection pressure on resident intestinal flora (the microbiome). Use effective hygiene techniques and antiseptics to prevent infections.

**Treat effectively**
Before prescribing antibacterials, consider which bacteria are likely to be involved and how effectively the chosen drug will penetrate the target site. Use the shortest effective course and avoid underdosing. Ensure compliance with appropriate formulation and clear instructions.

**Employ narrow spectrum**
Unnecessarily broad-spectrum antibacterials could promote antibacterial resistance, whilst selecting narrow-spectrum
antibacterials limits the effects on commensal bacteria. Use culture results to support de-escalation (switching to a narrower spectrum antibacterial) whenever possible.

**Culture appropriately**
A sample for culture should be collected before starting antibacterial therapy. Culture is essential when prolonged (>1 week) treatment courses are anticipated, when resistance is likely (e.g. hospital-acquired infections) and with life-threatening infections. If first-line treatment fails, do not use another antibacterial without culture and sensitivity results (avoid cycling antibacterials).

**Tailor practice policy to patients**
A customised practice policy can guide antibacterial selection to address the bacterial infections and resistance patterns that you encounter, minimizing inappropriate use. Complete the tick boxes in your PROTECT ME poster to highlight YOUR practice’s first-line approach to each condition.

**Monitor culture results**
Track and record culture profiles and update your practice policy accordingly. Monitor for preventable infections (e.g. postoperative) and alter practices if needed. Audit your own antibacterial use, particularly of critically important antibacterials (e.g. fluoroquinolones and cefovecin).

**Educate others**
Share this important message to reduce the threat from multi-resistant strains of bacteria and improve the health of pets and people.

**Guidelines on prescribing glucocorticoids**
Glucocorticoids are among the most effective anti-inflammatory and antipruritic drugs available. Glucocorticoids are also rapidly effective in treating several important immune-mediated diseases (Whitley and Day, 2011) as well as many neoplastic conditions. However, chronic systemic glucocorticoid treatment is accompanied by several common, serious, but dose-dependent, adverse effects, such as polyuria, polydipsia, alopecia, muscle weakness, panting, lethargy and obesity. Several of these adverse effects appear to be of greater concern to pet owners than to the animals themselves. Systemic glucocorticoid treatment is also associated with less common, non-dose-dependent and unpredictable (stochastic) side effects such as diabetes mellitus or thromboembolic disease, which have significant implications for animal welfare. It is not possible to separate the beneficial effects of glucocorticoids from their adverse effects; however, reducing systemic exposure through topical, local and inhaled delivery may alter the balance between the beneficial and adverse effects.

There are very few objective studies examining the optimal doses or dosing intervals for any glucocorticoids for any conditions in dogs or cats. There are wide inter-subject variations in plasma concentrations after administration, which suggest variable drug
absorption. Furthermore, no relationship has been demonstrated between these plasma concentrations (unbound or total concentration) and clinical response. As many glucocorticoid effects are due to alteration of gene transcription, their biological activities exceed the plasma half-lives of the drugs. Different glucocorticoids have varying biological half-lives and are presented in varying formulations, which also affect their duration of action and tissue targeting. For example, a single dose of a long-acting ester of methylprednisolone is capable of altering ACTH stimulation testing in dogs for at least 5 weeks (Kemppainen et al., 1981).

Considerations before using glucocorticoids

Many problems that develop with glucocorticoid use arise when a treatment plan is not discussed with the pet owner at the time these drugs are initially prescribed. It is worthwhile considering the following questions before glucocorticoids are used (adapted from Thorn, 1966):

- How serious is the underlying disorder when compared with the predictable adverse effects of glucocorticoids?
- Is the patient likely to be predisposed to more severe, stochastic complications of glucocorticoid therapy (e.g. diabetes mellitus)?
- What is the starting glucocorticoid dose and the predicted length of treatment; when and how will this be adjusted?
- Which glucocorticoid preparation would minimize the adverse effects, while retaining the beneficial effects?
- Are there other types of treatment that could be used to minimize the glucocorticoid dose?

Considerations when using glucocorticoids

Starting doses: Although doses reported in this Formulary and other texts do provide a useful starting point when choosing an initial dose, given the lack of published evidence for many doses and the individual variability in response, ultimately glucocorticoids should be used to the desired effect. Providing the side effects are acceptable, there is no strict maximum dose for glucocorticoids, but when using doses above those reported in this Formulary, it may be wise to obtain the guidance of a relevant veterinary specialist. The duration and magnitude of hypothalamic–pituitary–adrenal axis suppression caused by daily oral administration of a glucocorticoid varies between animals, doses administered, formulation and specific pharmacokinetics of the glucocorticoid used. Larger individuals within a given species generally need proportionately lower doses on a mg/kg basis to achieve the same biological effect. For this reason, some authors dose on a mg/m² basis in some medium to large patients. Pharmacological studies evaluating effects of glucocorticoids in cats are lacking. Currently, recommended dosing regimens for cats vary considerably. The predominant opinion, however, is that the cat requires a higher dose than the dog (on a mg/kg basis) (Lowe et al., 2008). Adverse effects of glucocorticoids are very likely in all treated animals and it is worthwhile warning owners about them. A client information leaflet (CIL) is available to BSAVA members for this purpose.
Adjusting doses: As there are few studies comparing protocols for tapering immunosuppressive or anti-inflammatory therapy with glucocorticoids, it is appropriate to adjust the therapy according to laboratory or clinical parameters. For example, cases with immune-mediated haemolytic anaemia should have their therapy adjusted following monitoring of their haematocrit. Most of the beneficial effects of glucocorticoids are seen in the short term. If the expected benefits are not apparent, then either the dose needs to be increased until limited by adverse effects, or alternative drugs and/or treatment modalities added and the dose of glucocorticoids reduced. Doses can be reduced to alternate-day therapy as soon as clinical control of the disease is achieved – regardless of the dose needed to achieve control. Although alternate-day dosing of medium-acting glucocorticoids (such as prednisolone) is accepted clinical practice, it assumes that the beneficial effects of these drugs last longer than the side effects. Evidence for this assumption is very limited and whether alternate-day dosing really avoids suppression of the hypothalamic–pituitary–adrenal axis while retaining beneficial therapeutic effect is debatable. Consideration should also be given to using short-acting glucocorticoids in ‘pulse doses’ to control acute recurrences of disease. Protracted use of any topical glucocorticoid can lead to thinning of the skin and owners should be advised of this possibility.

When not to use glucocorticoids

Glucocorticoids should not be given to animals with disc disease, hypercalcaemia, cutaneous or subcutaneous masses or large lymph nodes without a specific diagnosis and indication to do so. The use of glucocorticoids in most cases of shock is of no benefit and may be detrimental. Glucocorticoids are not analgesics; if animals are in pain then analgesics are required.

References


Radiographic contrast agents

Barium and iodinated contrast media

MRI contrast media
Several gadolinium chelates are used for magnetic resonance imaging (MRI) contrast studies. None of them is authorized for veterinary use and all are POM.

Action
Gadolinium is a paramagnetic agent and exerts its effects due to seven unpaired electrons, which cause a shortening of T1 and T2 relaxation times of adjacent tissues. This results in increased signal intensity on T1-weighted MR images. Unbound gadolinium is highly toxic and so is chelated to reduce toxicity. Gadolinium chelates do not cross the normal blood–brain barrier due to their large molecular size.

Use
- During MRI examination to identify areas of abnormal vascularization or increased interstitial fluid, delineate masses and demonstrate disruption of the blood–brain barrier and areas of inflammation.
- Gadodiamide, gadobutrol, gadoteric acid and gadobenic acid are also used for contrast-enhanced magnetic resonance angiography (MRA).
- The low concentration form of gadopentetic acid (2 mmol/l) is authorized for intra-articular use for MR arthrography in humans.
- Gadobenic acid and gadoxetic acid are also transported across hepatocyte cell membranes (gadoxetic acid via organic anionic-acid transporting peptide 1) and are used in the characterization of liver lesions.

Safety and handling
Contact with skin and eyes may cause mild irritation.

Contraindications
Use with caution in cardiac disease, pre-existing renal disease and neonates. Contraindicated in severe renal impairment.

Adverse reactions
Nephrogenic systemic fibrosis (most commonly associated with gadodiamide but also gadopentetic acid and gadoversetamide) reported in humans but not in animals. Increase in QT interval and other arrhythmias have also been reported, and cardiac monitoring is recommended in the event of accidental overdosage. Transient episodes of shortness of breath following intravenous administration of gadoxetic acid have been reported in humans. Many are hyper-osmolar and irritant if extravasation occurs, (although studies in animals have shown gadopentetic acid and gadoteridol to be less toxic to subcutaneous tissues than an equal volume of iodinated contrast media), and therefore should be given
through an intravenous catheter. Anaphylaxis occurs rarely (0.001%–0.01% in human studies). May cause a transient increase in serum bilirubin if there is pre-existing hepatic disease. Retained gadolinium deposits in certain areas of the brain have been reported recently in human patients, the clinical significance of these deposits is unknown at present. In experimental studies may cause fetal abnormalities in rabbits.

**Drug interactions**
May have interactions with Class 1a and 3 antiarrhythmics. Gadobenic acid may compete for canalicular multispecific organic anionic transporter sites. Caution should be used if administering anthracyclines, vinca alkyloids and other drugs using this transporter. Anionic drugs excreted in bile (e.g. rifampicin) may reduce hepatic uptake of gadoxetic acid, reducing contrast enhancement. May affect some laboratory results, e.g. serum iron determination using complexometric methods, transient increase in liver enzymes, some linear non-ionic gadolinium based contrast media (gadodiamide, gadoversetamide) may cause false reduction in serum calcium measurement.

**Doses and further advice on use**
Should be used routinely for MRI examinations of the brain. Use for MRI of other body regions if suspect abnormal vascularization, inflammation, neoplasia, for postsurgical evaluation or if MRI study is normal despite significant clinical signs. Post-contrast images should ideally be obtained within 30 minutes of contrast administration. Total doses should not exceed 0.3 mmol/kg (varies with product).
<table>
<thead>
<tr>
<th>Generic name</th>
<th>Trade name</th>
<th>Manufacturer</th>
<th>Authorized indications in humans</th>
<th>Excretion</th>
<th>Properties</th>
<th>Protein binding</th>
<th>Dose</th>
<th>Formulations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gadopentetic acid</td>
<td>Magnevist</td>
<td>Bayer</td>
<td>CNS; whole body (excluding heart); arthrography</td>
<td>Renal</td>
<td>Linear Ionic 1960 mOsm/kg</td>
<td>0</td>
<td>0.1–0.3 mmol/kg</td>
<td>469 mg/ml; 2 mmol/l; 5, 10, 15, 20 ml vials; 10, 15, 20 ml pre-filled syringes; 50, 100 ml pharmacy bulk package</td>
</tr>
<tr>
<td>Gadoteric acid</td>
<td>Dotarem</td>
<td>Guerbet Laboratories Ltd</td>
<td>CNS; whole body; MRA</td>
<td>Renal</td>
<td>Cyclic Ionic 1350 mOsm/kg</td>
<td>0</td>
<td>0.1–0.3 mmol/kg</td>
<td>279.3 mg/ml; 5, 10, 15, 20 ml vials; 15, 20 ml pre-filled syringes</td>
</tr>
<tr>
<td>Gadoteridol</td>
<td>Prohance</td>
<td>Bracco</td>
<td>CNS; whole body</td>
<td>Renal</td>
<td>Cyclic Non-ionic 630 mOsm/kg</td>
<td>0</td>
<td>0.1 mmol/kg</td>
<td>279.3 mg/ml; 5, 10, 15, 20 ml vials; 5, 10, 15, 17 ml pre-filled syringes</td>
</tr>
<tr>
<td>Gadodiamide</td>
<td>Omniscan</td>
<td>Nycomed Amersham</td>
<td>CNS; whole body</td>
<td>Renal</td>
<td>Linear Non-ionic 789 mOsm/kg</td>
<td>0</td>
<td>0.1–0.3 mmol/kg</td>
<td>287 mg/ml; 5, 10, 15, 20, 40, 50 ml vials; 10, 15, 20 ml pre-filled syringes</td>
</tr>
<tr>
<td>Gadobutrol</td>
<td>Gadovist</td>
<td>Bayer</td>
<td>CNS</td>
<td>Renal</td>
<td>Cyclic Non-ionic 1603 mOsm/kg</td>
<td>0</td>
<td>0.1 mmol/kg</td>
<td>604.72 mg/ml; 7.5, 10, 15 ml vials; 7.5, 10, 15 ml pre-filled syringes; 30, 65 ml bulk packages</td>
</tr>
<tr>
<td>Gadoxetic acid</td>
<td>Primovist</td>
<td>Bayer</td>
<td>Liver</td>
<td>50% renal, 50% biliary</td>
<td>Linear Ionic 688 mOsm/kg</td>
<td>&lt;15%</td>
<td>0.025 mmol/kg</td>
<td>181.43 mg/ml; 10 ml pre-filled syringes</td>
</tr>
<tr>
<td>Gadobenic acid</td>
<td>MultiHance</td>
<td>Bracco</td>
<td>CNS; liver; MRA; breast</td>
<td>Renal (biliary up to 4%)</td>
<td>Linear Ionic 1970 mOsm/kg</td>
<td>&lt;5%</td>
<td>CNS: 0.1 mmol/kg; liver: 0.05 mmol/kg</td>
<td>334 mg/ml; 5, 10, 15, 20 ml vials</td>
</tr>
<tr>
<td>Gado-verse tamide</td>
<td>Optimark</td>
<td>Covidien</td>
<td>CNS; liver</td>
<td>Renal</td>
<td>Linear Non-ionic 1110 mOsm/kg</td>
<td>0</td>
<td>0.1 mmol/kg</td>
<td>330 mg/ml; 10, 15, 20, 30 ml pre-filled syringes</td>
</tr>
</tbody>
</table>
**Dogs:** 0.1 mmol/kg i.v. (all except gadoxetic acid). Give as bolus if performing MRA, dynamic contrast or liver studies; 0.025 mmol/kg i.v. bolus of gadoxetic acid for liver studies; 0.05 mmol/kg of gadobenic acid for liver studies. Repeat doses (not gadoxetic acid) of up to 0.3 mmol/kg total dose may be helpful in some cases if poor contrast enhancement with standard dose or for detection of metastases and if using low-field scanner. Enhancement visible up to 45–60 minutes post-administration.

### Composition of intravenous fluids

<table>
<thead>
<tr>
<th>Fluid</th>
<th>Na⁺ (mmol/l)</th>
<th>K⁺ (mmol/l)</th>
<th>Ca²⁺ (mmol/l)</th>
<th>Cl⁻ (mmol/l)</th>
<th>HCO₃⁻ (mmol/l)</th>
<th>Dext. (g/l)</th>
<th>Osmol. (mosl/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.45% NaCl</td>
<td>77</td>
<td>77</td>
<td>155</td>
<td></td>
<td></td>
<td></td>
<td>155</td>
</tr>
<tr>
<td>0.9% NaCl</td>
<td>154</td>
<td>154</td>
<td>308</td>
<td></td>
<td></td>
<td></td>
<td>308</td>
</tr>
<tr>
<td>5% NaCl</td>
<td>856</td>
<td>856</td>
<td>1722</td>
<td></td>
<td></td>
<td></td>
<td>1722</td>
</tr>
<tr>
<td>Ringer’s</td>
<td>147</td>
<td>4</td>
<td>2</td>
<td>155</td>
<td></td>
<td></td>
<td>310</td>
</tr>
<tr>
<td>Lactated Ringer’s (Hartmann’s)</td>
<td>131</td>
<td>5</td>
<td>2</td>
<td>111</td>
<td>29 *</td>
<td></td>
<td>280</td>
</tr>
<tr>
<td>Darrow’s</td>
<td>121</td>
<td>35</td>
<td>103</td>
<td>53 *</td>
<td></td>
<td></td>
<td>312</td>
</tr>
<tr>
<td>0.9% NaCl + 5.5% Dext.</td>
<td>154</td>
<td>154</td>
<td>50</td>
<td>560</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.18% NaCl + 4% Dext.</td>
<td>31</td>
<td>31</td>
<td>40</td>
<td>264</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duphalyte **</td>
<td>2.6</td>
<td>1.0</td>
<td>3.6</td>
<td>454</td>
<td>Unknown</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Dext. = Dextrose; Osmol. = Osmolality. * Bicarbonate is present as lactate. ** Also contains a mixture of vitamins and small quantities of amino acids and 1.2 mmol/l of MgSO₄

### Safety and handling of chemotherapeutic agents

Most drugs used in veterinary practice do not pose a major hazard to the person handling them or handling an animal treated with them (or its waste). Chemotherapeutic agents are the exception. People who are exposed to these drugs during their use in animals risk serious side effects. In addition, chemotherapeutic agents pose a serious risk to patient welfare if not used correctly. They should only be used when absolutely indicated (i.e. histologically-confirmed diseases that are known to be responsive to them). Investigational use should be confined to controlled clinical trials.

### Personnel

- The preparation and administration of cytotoxic drugs should only be undertaken by trained staff.
- Owners and staff (including cleaners, animal caretakers, veterinary surgeons) involved in the care of animals being treated with cytotoxic drugs must be informed (and proof available that they have been informed) of:
- The risks of working with cytotoxic agents
- The potential methods for preventing aerosol formation and the spread of contamination
- The proper working practices for a safety cabinet
- The instructions in case of contamination
- The principles of good personal protection and hygiene practice.

- As a general rule, pregnant women and immunocompromised personnel should not be involved in the process of preparing and/or administering cytotoxic agents, caring for animals that have been treated with cytotoxic drugs, or cleaning of the areas with which these animals have come into contact. It is the responsibility of the employee to warn their supervisors if they are pregnant, likely to become pregnant or are immunocompromised.

**Equipment and facilities**

- All areas where cytotoxic agents are prepared and/or administered, or where animals who have received cytotoxic drugs are being cared for, should be identified by a clear warning sign. Access to these areas should be restricted.
- Ideally, a negative pressure pharmaceutical isolator with externally ducted exhaust filters, which has been properly serviced and checked, should be used. If such an isolator is not available, then a suitably modified Class 2B Biological Safety Cabinet (BSC) may be used.
- There must be adequate materials for cleaning of spilled cytotoxic agents (cytotoxic spill kit).
- Closed or semi-closed systems should be used to prevent aerosol formation and control exposure to carcinogenic compounds. Special spike systems (e.g. Codan and Braun) can be used. Other systems specifically developed for the use of cytotoxic agents are recommended (e.g. Spiros, Tevadaptor, Oncovial and PhaSeal). If such systems are not available, then at the very least infusion sets and syringes with Luer-lock fittings should be used.

**Preparation of cytotoxic drugs**

- Manipulation of oral or topical medicines containing cytotoxic drugs should be avoided. If a drug concentration is required that is not readily available, then a specialist laboratory with a Veterinary Specials Authorization should be contacted to reformulate the drug to the desired concentration. This may be useful for drugs such as piroxicam, hydroxycarbamide, cyclophosphamide and lomustine. Tablets should never be crushed or split. If reformulation is not possible, then using smaller sized tablets or adjusting the dosage regimen is often sufficient.
- When drug preparation is complete, the final product should be sealed in a plastic bag or other container for transport before it is taken out of the ventilated cabinet. It should be clearly labelled as containing cytotoxic drugs.
• All potentially contaminated materials should be discarded in special waste disposal containers, which can be opened without direct contact with hands/gloves (e.g. a foot pedal). Local regulations as to the disposal of this waste should be followed.
• There should be a clear procedure regarding how to handle cytotoxic drugs following an injection accident.
• During the preparation and administration of cytotoxic drugs, personal protection should be worn, including special disposable chemoprotective gloves, disposable protective clothing, and eye and face protection.
• After the preparation and/or administration of cytotoxic drugs, or after nursing a treated animal, the area used should be properly cleaned using a specific protocol before other activities commence.

**Administration of cytotoxic drugs**

• All necessary measures should be taken to ensure that the animal being treated is calm and cooperative. If the temperament of the animal is such that a safe administration is not to be expected, then the veterinary surgeon has the right (and is obliged) not to treat these animals.
• Many cytotoxic drugs are irritant and must be administered via a preplaced i.v. catheter. Administration of bolus injections should be done through a catheter system, which should be flushed with 0.9% NaCl before, during and after the injection.
• Heparinized saline should be avoided as it can interact with some chemotherapeutic drugs (e.g. doxorubicin).
• Drugs should be administered safely using protective medical devices (such as needleless and closed systems) and techniques (such as priming of i.v. tubing by pharmacy personnel inside a ventilated cabinet or priming in-line with non-drug solutions).
• The tubing should never be removed from a fluid bag containing a hazardous drug, nor should it be disconnected at other points in the system until the tubing has been thoroughly flushed. The i.v. catheter, tubing and bag should be removed intact when possible.
• Hands should be washed with soap and water before leaving the drug administration area.
• Procedures should be in place for dealing with any spillages that occur and for the safe disposal of waste. In the event of contact with skin or eyes, the affected area should be washed with copious amounts of water or normal saline. Medical advice should be sought if the eyes are affected.

**Procedures for nursing patients receiving chemotherapy**

• Special wards or designated kennels with clear identification that the patients are being treated with cytotoxic agents are required.
• Excreta (saliva, urine, vomit, faeces) are all potentially hazardous after the animal has been treated with cytotoxic drugs, and should be handled and disposed of accordingly.
• During the period of risk, personal protective equipment (such as disposable gloves and protective clothing) should be worn when carrying out nursing procedures.
• All materials that have come into contact with the animal during the period of risk should be considered as potentially contaminated.
• After the animal has left the ward, the cage should be cleaned according to the cleaning protocol.

Guidelines for owners
• All owners should be given written information on the potential hazards of the cytotoxic drugs. Written information on how to deal with the patient’s excreta (saliva, urine, vomit, faeces) must also be provided.
• If owners are to administer tablets themselves, then written information on how to do this must also be provided. Drug containers should be clearly labelled with ‘cytotoxic contents’ warning tape.

Further information
For further information, readers are advised to consult specialist texts and the guidelines issued by the European College of Veterinary Internal Medicine – Companion Animals (ECVIM-CA) on ‘Preventing occupational and environmental exposure to cytotoxic drugs in veterinary medicine’.
## Body weight (BW) to body surface area (BSA) conversion tables

### Dogs
(Formula: $\text{BSA (m}^2\text{)} = 0.101 \times (\text{body weight in kg})^{\frac{2}{3}}$)

<table>
<thead>
<tr>
<th>BW (kg)</th>
<th>BSA (m²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.5</td>
<td>0.06</td>
</tr>
<tr>
<td>1</td>
<td>0.1</td>
</tr>
<tr>
<td>2</td>
<td>0.16</td>
</tr>
<tr>
<td>3</td>
<td>0.21</td>
</tr>
<tr>
<td>4</td>
<td>0.25</td>
</tr>
<tr>
<td>5</td>
<td>0.30</td>
</tr>
<tr>
<td>6</td>
<td>0.33</td>
</tr>
<tr>
<td>7</td>
<td>0.37</td>
</tr>
<tr>
<td>8</td>
<td>0.4</td>
</tr>
<tr>
<td>9</td>
<td>0.44</td>
</tr>
<tr>
<td>10</td>
<td>0.47</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>BW (kg)</th>
<th>BSA (m²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td>0.50</td>
</tr>
<tr>
<td>12</td>
<td>0.53</td>
</tr>
<tr>
<td>13</td>
<td>0.56</td>
</tr>
<tr>
<td>14</td>
<td>0.59</td>
</tr>
<tr>
<td>15</td>
<td>0.61</td>
</tr>
<tr>
<td>16</td>
<td>0.64</td>
</tr>
<tr>
<td>17</td>
<td>0.67</td>
</tr>
<tr>
<td>18</td>
<td>0.69</td>
</tr>
<tr>
<td>19</td>
<td>0.72</td>
</tr>
<tr>
<td>20</td>
<td>0.74</td>
</tr>
<tr>
<td>22</td>
<td>0.79</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>BW (kg)</th>
<th>BSA (m²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>24</td>
<td>0.84</td>
</tr>
<tr>
<td>26</td>
<td>0.89</td>
</tr>
<tr>
<td>28</td>
<td>0.93</td>
</tr>
<tr>
<td>30</td>
<td>0.98</td>
</tr>
<tr>
<td>35</td>
<td>1.08</td>
</tr>
<tr>
<td>40</td>
<td>1.18</td>
</tr>
<tr>
<td>45</td>
<td>1.28</td>
</tr>
<tr>
<td>50</td>
<td>1.37</td>
</tr>
<tr>
<td>55</td>
<td>1.46</td>
</tr>
<tr>
<td>60</td>
<td>1.55</td>
</tr>
</tbody>
</table>

### Cats
(Formula: $\text{BSA (m}^2\text{)} = 0.1 \times (\text{body weight in kg})^{\frac{2}{3}}$)

<table>
<thead>
<tr>
<th>BW (kg)</th>
<th>BSA (m²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.5</td>
<td>0.06</td>
</tr>
<tr>
<td>1</td>
<td>0.1</td>
</tr>
<tr>
<td>1.5</td>
<td>0.134</td>
</tr>
<tr>
<td>2</td>
<td>0.163</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>BW (kg)</th>
<th>BSA (m²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.5</td>
<td>0.184</td>
</tr>
<tr>
<td>3</td>
<td>0.208</td>
</tr>
<tr>
<td>3.5</td>
<td>0.231</td>
</tr>
<tr>
<td>4</td>
<td>0.252</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>BW (kg)</th>
<th>BSA (m²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.5</td>
<td>0.273</td>
</tr>
<tr>
<td>5</td>
<td>0.292</td>
</tr>
<tr>
<td>5.5</td>
<td>0.316</td>
</tr>
<tr>
<td>6</td>
<td>0.33</td>
</tr>
</tbody>
</table>

### Percentage solutions

The concentration of a solution may be expressed on the basis of weight per unit volume (w/v) or volume per unit volume (v/v).

- $\% \text{ w/v} = \frac{\text{number of grams of a substance in 100 ml of a liquid}}{100}$
- $\% \text{ v/v} = \frac{\text{number of ml of a substance in 100 ml of liquid}}{100}$

<table>
<thead>
<tr>
<th>% Solution</th>
<th>g or ml/100 ml</th>
<th>mg/ml</th>
<th>Solution strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>100</td>
<td>100</td>
<td>1000</td>
<td>1:1</td>
</tr>
<tr>
<td>10</td>
<td>10</td>
<td>100</td>
<td>1:10</td>
</tr>
<tr>
<td>1</td>
<td>1</td>
<td>10</td>
<td>1:100</td>
</tr>
<tr>
<td>0.1</td>
<td>0.1</td>
<td>1</td>
<td>1:1000</td>
</tr>
<tr>
<td>0.01</td>
<td>0.01</td>
<td>0.1</td>
<td>1:10,000</td>
</tr>
</tbody>
</table>
Drugs usage in renal and hepatic insufficiency

With failure of liver or kidney, the excretion of some drugs may be impaired, leading to increased serum concentrations.

Renal failure

a. Double the dosing interval or halve the dosage in patients with severe renal insufficiency. Use for drugs that are relatively non-toxic.

b. Increase dosing interval 2-fold when creatinine clearance (Ccr) is 0.5–1.0 ml/min/kg, 3-fold when Ccr is 0.3–0.5 ml/min/kg and 4-fold when Ccr is <0.3 ml/min/kg.

c. Precise dose modification is required for some toxic drugs that are excreted solely by glomerular filtration, e.g. aminoglycosides. This is determined by using the dose fraction Kf to amend the drug dose or dosing interval according to the following equations:

- Modified dose reduction = normal dose × Kf
- Modified dose interval = normal dose interval/Kf
- where Kf = patient Ccr/normal Ccr

Where Ccr is unavailable, Ccr may be estimated at 88.4/serum creatinine (μmol/l) (where serum creatinine is <350 μmol/l). Kf may be estimated at 0.33 if urine is isosthenuric or 0.25 if the patient is azotaemic.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Nephrotoxic</th>
<th>Dose adjustment in renal failure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amikacin</td>
<td>Yes</td>
<td>c</td>
</tr>
<tr>
<td>Amoxicillin</td>
<td>No</td>
<td>a</td>
</tr>
<tr>
<td>Amphotericin B</td>
<td>Yes</td>
<td>c</td>
</tr>
<tr>
<td>Ampicillin</td>
<td>No</td>
<td>a</td>
</tr>
<tr>
<td>Cefalexin</td>
<td>No</td>
<td>b</td>
</tr>
<tr>
<td>Chloramphenicol</td>
<td>No</td>
<td>N, A</td>
</tr>
<tr>
<td>Digoxin</td>
<td>No</td>
<td>c</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>Yes</td>
<td>c</td>
</tr>
<tr>
<td>Nitrofurantoin</td>
<td>No</td>
<td>CI</td>
</tr>
<tr>
<td>Oxytetracycline</td>
<td>Yes</td>
<td>CI</td>
</tr>
<tr>
<td>Penicillin</td>
<td>No</td>
<td>a</td>
</tr>
<tr>
<td>Tobramycin</td>
<td>Yes</td>
<td>c</td>
</tr>
<tr>
<td>Trimethoprim/</td>
<td>Yes</td>
<td>b, A</td>
</tr>
<tr>
<td>sulfonamide</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

a, b, c = Refer to section above on dose adjustment; A = Avoid in severe renal failure; CI = Contraindicated; N = normal dose.
Hepatic insufficiency
Drug clearance by the liver is affected by many factors and thus it is not possible to apply a simple formula to drug dosing. The table below is adapted from information in the human literature.

<table>
<thead>
<tr>
<th>Drug</th>
<th>DI</th>
<th>CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aspirin</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Azathioprine</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Cefotaxime</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Chloramphenicol</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Clindamycin</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Diazepam</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Doxorubicin</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Doxycycline</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Fluorouracil</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Furosemide</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Hydralazine</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Lidocaine</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Morphine</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>NSAIDs</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Oxytetracycline</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Pentobarbital</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Phenobarbital</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Propranolol</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Theophylline</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Vincristine</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

Cl = Contraindicated; avoid use if at all possible. DI = A change in dose or dosing interval may be required.
Suspected Adverse Reaction Surveillance Scheme (SARSS)

The Veterinary Medicines Directorate (VMD) has a website (www.gov.uk/government/organisations/veterinary-medicines-directorate) to report any and all suspected adverse reactions in an animal or a human to a veterinary medicinal product, or in an animal treated with a human medicine. Anyone can report a suspected adverse reaction in this way. An ‘adverse reaction’ includes lack of efficacy and known side effects. It is only by completing such forms that the changes in the prevalence of problems can be documented.

The online report form is preferred; however, if you would prefer to use a paper copy you can download and print an Animal Form to report an adverse reaction in an animal to a veterinary medicine or to a human product. Alternatively, download and print a Human Form to report an adverse reaction in a human to a veterinary medicinal product. Post the forms to the address at the top of the reports.

If you have any questions, please call the VMD pharmacovigilance team on 01932 336911.

Further reading


Useful websites

www.bnf.org
British National Formulary – registration required through academic institutions to use BNF online but can order paper copy of BNF from this site.

www.bsavalibrary.com
British Small Animal Veterinary Association online Library – links to *Journal of Small Animal Practice*, and contains the *BSAVA Guide to the Use of Veterinary Medicines* and searchable online Formularies (free access for BSAVA members).

www.bva.co.uk/News-campaigns-and-policy/Policy/Medicines/Veterinary-medicines/

www.emea.europa.eu/ema/
European Medicines Agency.
www.ncbi.nlm.nih.gov/pubmed
PubMed is a widely used free service of the U.S. National Library of Medicine and the National Institutes of Health that allows users to search abstracts in the medical literature. All major veterinary publications covered.

www.noahcompendium.co.uk/Compendium/Overview/
NOAH compendium site.

veterinary-medicines/
Royal College of Veterinary Surgeons. Information on the Prescribing Cascade.

www.gov.uk/government/organisations/
veterinary-medicines-directorate
Veterinary Medicines Directorate – in particular is useful for repeat applications for special import certificates (SICs) and special treatment certificates (STCs) and the electronic Summary of Product Characteristics (eSPCs).

www.wiley.com
Journal of Small Animal Practice – free for BSAVA members, free abstracts and pay per article for others.

Websites relating to manufacturers of extemporaneous products (veterinary specials)
The current Register of Sites that hold a Manufacturer’s ‘Specials’ Authorization - (veterinary only extemporaneous preparations manufacturers).

List of combined human and veterinary extemporaneous preparations manufacturers.

www.bova.co.uk
Site for a company that will reformulate many drugs into conveniently sized tablets, liquids, pastes and transdermal gels.

www.chemopet.co.uk
A company that will reformulate a wide range of injectable and oral chemotherapy drugs.

www.novalabs.co.uk/
Site for a company that will reformulate many drugs into conveniently sized tablets or liquids.

www.specialslab.co.uk
Site for a company that will reformulate many drugs into conveniently sized tablets.

www.summitvetpharma.co.uk
Site for a company that will reformulate many drugs into conveniently sized tablets, liquids and transdermal gels.
Appendix II: Protocols

Chemotherapy protocols for lymphoma

Various protocols are described in the literature. Three examples are provided below.

Note that oral cytotoxic drugs cannot be split or divided and should not be crushed. It is also important that patients are not overdosed with cytotoxic medications. Ideally, for these reasons a compounding/reformulating pharmacy should be used to match patient requirements exactly; there are now companies (e.g. ChemoPet) who will prepare single per patient doses of chemotherapy to allow accurate dosing and save potential wastage due to bulk compounding. If this is not possible, then patients should be underdosed rather than overdosed based on the available tablet sizes. Extended dosing frequency or alternating administered dose on different days can occasionally be used to average out to the required dose. Refer to specialist texts or seek advice from a veterinary oncologist for further information regarding protocols.

When administering chemotherapy, appropriate personal protective equipment must be worn. Closed administration systems are recommended. The ‘ACVIM Small Animal Consensus Statement on Safe Use of Cytotoxic Chemotherapeutics in Veterinary Practice’ (Smith et al. (2018) Journal of Veterinary Internal Medicine) is a useful resource.

Protocol 1: Combination cytotoxic therapy COP (low dose)

**Induction:**
Cyclophosphamide: 50 mg/m² p.o. on alternate days or 50 mg/m² p.o. for the first 4 days of each week
Vincristine: 0.5 mg/m² i.v. q7d
Prednisolone: 2 mg/kg p.o. q24h (week 1), 1.5 mg/kg p.o. q24h (week 2), 1 mg/kg p.o. q24h (week 3), 1 mg/kg p.o. q48h thereafter.

**Maintenance after a minimum of 2 months:**
Cyclophosphamide: 50 mg/m² p.o. on alternate days or 50 mg/m² p.o. for the first 4 days of each second week (alternate-week therapy)
Vincristine: 0.5 mg/m² i.v. q14d
Prednisolone: 1 mg/kg p.o. q48h.

**Maintenance after 6 months (if disease in remission):**
Cyclophosphamide: 50 mg/m² p.o. q48h (one week in three) or 50 mg/m² p.o. for the first 4 days of each third week (one week in three)
Vincristine: 0.5 mg/m² i.v. q21d
Prednisolone: 1 mg/kg p.o. q48h.

**Maintenance after 12 months:**
Stop and monitor for relapse (see below for options at recurrence/relapse)

**General notes:**
- Catheters should be placed in all cases and only catheters placed by ‘first-stick’ should be used for chemotherapy.
• GI protectants are recommended for the first 14 days. Omeprazole (1 mg/kg q24h or q12h) is often used by oncologists. Ranitidine with sucralfate is an alternative approach. Cimetidine is avoided due to its effect on the hepatic cytochrome P450 enzyme pathway and the potential for altering metabolism of chemotherapeutics.
• Certain breeds (generally Collie type) are very sensitive to vincristine due to the \textit{MDR1} mutation; a commercial test is available.
• Co-administration of 1 mg/kg of furosemide q12h on each cyclophosphamide treatment day reduces the frequency of sterile haemorrhagic cystitis.
• Chlorambucil (5 mg/m\textsuperscript{2} p.o. on alternate days) may be given as an alternative for cyclophosphamide if haemorrhagic cystitis develops.
• Most oncologists prefer a CHOP type or the high dose COP protocol.

Recommended monitoring:
• Haematology should be checked prior to each vincristine treatment.
• Biochemistry is checked prior to the first treatment and then a minimum of every 6 months.
• Check free-catch urine by dipstick prior to and then each week that the patient receives cyclophosphamide. If blood is noted, suspend cyclophosphamide and culture urine. If urine culture is negative, start chlorambucil as described above.

\textbf{Contraindications and adverse effects}
Myelosuppression, haemorrhagic cystitis (cyclophosphamide only) or GI effects may occur. Vincristine is a vesicant, therefore catheters should be placed in all cases and only catheters placed by ‘first-stick’ should be used. Discontinue cyclophosphamide therapy if the neutrophil count decreases to $<2 \times 10^9$/l; check count weekly and do not resume treatment until neutrophil count is $>3 \times 10^9$/l. If neutropenia recurs following re instituted therapy, decrease dose by 10–25%.

\textbf{Protocol 2: Combination cytotoxic therapy COP (high dose)}

\textit{Induction:}
Cyclophosphamide: 250 mg/m\textsuperscript{2} p.o. q21d
Vincristine: 0.70 mg/m\textsuperscript{2} i.v. q7d for 4 weeks then 0.70 mg/m\textsuperscript{2} i.v. q21d on same day as cyclophosphamide.
Prednisolone: 2 mg/kg p.o. q24h (week 1), 1.5 mg/kg p.o. q24h (week 2), 1 mg/kg p.o. q24h (week 3), 1 mg/kg p.o. q48h thereafter
Furosemide: 1 mg/kg p.o. q12h for 48h (i.e. 4 doses), administration with cyclophosphamide.

\textit{Maintenance after 6 months:}
Cyclophosphamide: 250 mg/m\textsuperscript{2} p.o. q28d
Vincristine: 0.70 mg/m\textsuperscript{2} i.v. q28d with cyclophosphamide
Prednisolone: 1 mg/kg p.o. q48h
Furosemide: 1 mg/kg p.o. q12h for 48h (i.e. 4 doses), administration with cyclophosphamide.
**Maintenance after 12 months:**
Stop and monitor for relapse (see below for options at recurrence/relapse).

**General notes:**
- Catheters should be placed in all cases and only catheters placed by ‘first-stick’ should be used for chemotherapy.
- GI protectants are recommended for the first 21 days. Omeprazole (1 mg/kg q24h or q12h) is often used by oncologists. Ranitidine with sucralfate is an alternative approach. Cimetidine is avoided due to its effect on the hepatic cytochrome P450 enzyme pathway and the potential for altering metabolism of chemotherapeutics.
- Certain breeds (generally Collie type) are very sensitive to vincristine due to the MDR1 mutation; a commercial test is available.
- Chlorambucil (20 mg/m² p.o.) may be given as an alternative for cyclophosphamide if haemorrhagic cystitis develops.
- Most oncologists prefer a CHOP type, but high dose COP is a useful and relatively straightforward protocol for use in a non-specialist setting.

Recommended monitoring:
- Haematology should be checked prior to each vincristine treatment.
- Biochemistry is checked prior to the first treatment and then a minimum of every 6 months.
- Check free-catch urine by dipstick prior to each cyclophosphamide administration. If blood is noted, suspend cyclophosphamide and culture urine. If urine culture is negative, start chlorambucil as above.

**Contraindications and adverse effects**
Myelosuppression, haemorrhagic cystitis (cyclophosphamide only) or GI effects are relatively common. Vincristine is a vesicant, therefore catheters should be placed in all cases and only catheters placed by ‘first-stick’ should be used. Should an extravasation occur, contact an oncologist. Treatment can be given if the neutrophil count is >3 x 10⁹/l and platelet count >100 x 10⁹/l. If the neutrophil count is <3 x 10⁹/l, then suspend treatment and recheck in 5–7 days. If neutrophil count is <1 x 10⁹/l, prescribe prophylactic antibiotics (until neutrophil count is >1 x 10⁹/l). If neutrophil count is <1 x 10⁹/l and the patient is pyrexic or unwell, administer i.v. antibiotics and contact an oncologist for advice. If a neutrophil count of <1 x 10⁹/l is noted, decrease dose of one chemotherapy drug by 10% at the next administration; if recurrent, contact an oncologist for advice.

**Protocol 3: 25-week CHOP/CEOP protocol**

**Week 1**
Vincristine: 0.7 mg/m² i.v. once
Prednisolone: 2 mg/kg p.o. q24h
Appendix II: protocols

**Week 2**
Cyclophosphamide: 250 mg/m² p.o. once  
Prednisolone: 1.5 mg/kg p.o. q24h  
Furosemide: 1 mg/kg p.o. q12h for 48h (i.e. 4 doses), administration with cyclophosphamide

**Week 3**
Vincristine: 0.7 mg/m² i.v. once  
Prednisolone: 1 mg/kg p.o. q24h

**Week 4**
Doxorubicin or epirubicin: 30 mg/m² i.v. once (in 0.9% NaCl (not Hartmann’s)) given over 20 minutes. For patients <15 kg, use 1 mg/kg  
Maropitant: 1 mg/kg s.c. once is given before doxorubicin/epirubicin  
Prednisolone: 0.5 mg/kg p.o. q24h for one week

**Week 5**
No medication (prednisolone is stopped)

**Week 6**
Vincristine: 0.7 mg/m² i.v. once

**Week 7**
Cyclophosphamide: 250 mg/m² p.o., i.v.  
Furosemide: 1 mg/kg p.o. q12h for 48h (i.e. 4 doses), administration with cyclophosphamide

**Week 8**
Vincristine: 0.7 mg/m² i.v. once

**Week 9**
Doxorubicin or epirubicin: 30 mg/m² i.v. once (in 0.9% NaCl (not Hartmann’s)) given over 20 minutes. For patients <15 kg, use 1 mg/kg  
Maropitant: 1 mg/kg s.c. once is given before doxorubicin/epirubicin

**Week 10**
No medication

**Week 11**
Vincristine: 0.7 mg/m² i.v. once

**Week 12**
No medication

**Week 13**
Cyclophosphamide: 250 mg/m² p.o., i.v. once  
Furosemide: 1 mg/kg p.o. q12h for 48h (i.e. 4 doses), administration with cyclophosphamide

**Week 14**
No medication

**Week 15**
Vincristine: 0.7 mg/m² i.v. once

**Week 16**
No medication
**Week 17**
Doxorubicin or epirubicin: 30 mg/m² i.v. once (in 0.9% NaCl (not Hartmann’s)) given over 20 minutes. For patients <15 kg, use 1 mg/kg
Maropitant: 1 mg/kg s.c. once is given before doxorubicin/epirubicin

**Week 18**
No medication

**Week 19**
Vincristine: 0.7 mg/m² i.v. once

**Week 20**
No medication

**Week 21**
Cyclophosphamide: 250 mg/m² p.o., i.v. once
Furosemide: 1 mg/kg p.o. q12h for 48h (i.e. 4 doses), administration with cyclophosphamide

**Week 22**
No medication

**Week 23**
Vincristine: 0.7 mg/m² i.v. once

**Week 24**
No medication

**Week 25**
Doxorubicin or epirubicin: 30 mg/m² i.v. once (in 0.9% NaCl (not Hartmann’s)) given over 20 minutes. For patients <15 kg, use 1 mg/kg
Maropitant: 1 mg/kg s.c. once is given before doxorubicin/epirubicin

**Week 26 and thereafter**
Stop chemotherapy and monitor for relapse (see below for options at recurrence/relapse)

**General notes:**
- Catheters should be placed in all cases and only catheters placed by ‘first-stick’ should be used for chemotherapy.
- GI protectants are recommended for the first 21 days. Omeprazole (1 mg/kg q24h or q12h) is often used by oncologists. Ranitidine with sucralfate is an alternative approach. Cimetidine is avoided due to its effect on the hepatic cytochrome P450 enzyme pathway and the potential for altering metabolism of chemotherapeutics.
- Certain breeds (generally Collie type) are very sensitive to vincristine and doxorubicin/epirubicin due to the MDR1 mutation; a commercial test is available.
- Chlorambucil (20 mg/m² p.o.) may be given as an alternative for cyclophosphamide if haemorrhagic cystitis develops.
- In case of cardiac dysfunction, mitoxantrone 5.5 mg/m² over 10 minutes can be considered as an alternative to doxorubicin/epirubicin.
- After initial 6 months, all medication is stopped until a relapse occurs.
Suggested monitoring:

- Haematology is checked prior to each treatment.
- A nadir neutrophil count should be assessed 7 days after the first doxorubicin treatment.
- Check free-catch urine by dipstick prior to each cyclophosphamide administration. If blood is noted, suspend cyclophosphamide and culture urine. If urine culture is negative, start chlorambucil as above.
- Biochemistry is checked prior to the first treatment and then a minimum of every 6 months.
- Baseline echocardiography can be considered in all patients and should be done before giving doxorubicin/epirubicin if evidence of pre-existing heart disease.

**Contraindications and adverse effects**

Myelosuppression, haemorrhagic cystitis (cyclophosphamide only) or GI effects may occur. Vincristine is a vesicant and doxorubicin/epirubicin are severe vesicants, therefore catheters should be placed in all cases and only catheters placed by ‘first-stick’ should be used. Should an extravasation occur, contact an oncologist. Doxorubicin/epirubicin can cause cardiotoxicity (arrythmia if given too quickly or systolic dysfunction at high cumulative doses (>180 mg/m²)). Treatment can be given if the neutrophil count is >3 x 10⁹/l and platelet count >100 x 10⁹/l. If the neutrophil count is <3 x 10⁹/l, then suspend treatment and recheck in 5–7 days. If neutrophil count is <1 x 10⁹/l, prescribe prophylactic antibiotics (until neutrophil count is >1 x 10⁹/l). If neutrophil count is <1 x 10⁹/l and the patient is pyrexic or unwell, administer i.v. antibiotics and contact an oncologist for advice. If the neutrophil count is <1 x 10⁹/l, decrease dose of the causative chemotherapy drug by 10%; if recurrent, contact an oncologist for advice.

**Disease monitoring and relapse**

**Restaging:** Ideally, restaging should be performed at the end of the induction phase (after week 4) and at treatment cessation.

**Remission:** Attaining complete remission is an important prognostic indicator (especially in cats). Complete remission is defined as the lack of identifiable disease (for example, the lymph nodes should be normal on palpation and a cytological assessment should not yield evidence of tumour cells).

**Relapse:** If a patient completes treatment in remission, they should be monitored monthly. Most canine multicentric lymphoma patients relapse after 1–3 months. Many patients that relapse after cessation of treatment can reattain remission by reintroduction of the original chemotherapy protocol. For patients who relapse during treatment or fail to respond to reintroduction of treatment, rescue therapy is indicated; commonly used rescue protocols in dogs include L-asparaginase (single agent), LOPP and DMAC (or single agent doxorubicin if COP used originally). Rescue therapy in cats is less successful than in dogs.
Chemotherapy protocols for mast cell tumour

Chemotherapy is used in the neoadjuvant setting (to shrink tumours and make excision possible) or as anti-metastatic treatment in tumours that have metastasized or high-risk tumours (high grade and/or elevated miotic index). Conventional chemotherapy is not recommended for the prevention of recurrence of incompletely resected MCTs, as further surgery or radiation are considered more effective; if a medical option is required in this context, a tyrosine kinase inhibitor (toceranib or masitinib) should be used first prior to conventional chemotherapy.

A number of chemotherapy protocols have been reported. The most commonly used protocol includes vinblastine and prednisolone as shown below.

12-week vinblastine and prednisolone protocol

Week 1
Vinblastine: 2 mg/m² i.v. once
Prednisolone: 2 mg/kg p.o. q24h

Week 2
Vinblastine: 2 mg/m² i.v. once
Prednisolone: 1.5 mg/kg p.o. q24h

Week 3
Vinblastine: 2 mg/m² i.v. once
Prednisolone: 1 mg/kg p.o. q24h

Week 4
Vinblastine: 2 mg/m² i.v. once
Prednisolone: 1 mg/kg p.o. q24h

Week 6
Vinblastine: 2 mg/m² i.v. once
Prednisolone: 1 mg/kg p.o. q24h

Week 8
Vinblastine: 2 mg/m² i.v. once
Prednisolone: 1 mg/kg p.o. q24h

Week 10
Vinblastine: 2 mg/m² i.v. once
Prednisolone: 1 mg/kg p.o. q24h

Week 12
Vinblastine: 2 mg/m² i.v. once
Prednisolone: 1 mg/kg p.o. q24h

General notes:
- Catheters should be placed in all cases and only catheters placed by ‘first-stick’ should be used for chemotherapy.
- GI protectants are recommended. Omeprazole (1 mg/kg q24h or q12h) is often used by oncologists. Ranitidine with sucralfate

• Catheters should be placed in all cases and only catheters placed by ‘first-stick’ should be used for chemotherapy. 
• GI protectants are recommended. Omeprazole (1 mg/kg q24h or q12h) is often used by oncologists. Ranitidine with sucralfate
is an alternative approach. Cimetidine is avoided due to its effect on the hepatic cytochrome P450 enzyme pathway and the potential for altering metabolism of chemotherapeutics.

- Certain breeds (generally Collie type) may be more sensitive to vinblastine due to the MDR1 mutation; a commercial test is available.

Suggested monitoring:

- Haematology is checked prior to each treatment.
- Biochemistry is checked prior to the first treatment.

**Contraindications and adverse effects**

Myelosuppression or GI effects may occur. Vinblastine is a vesicant, therefore catheters should be placed in all cases and only catheters placed by ‘first-stick’ should be used. Should an extravasation occur, contact an oncologist. Treatment can be given if the neutrophil count is \( >3 \times 10^9/l \) and platelet count \( >100 \times 10^9/l \). If the neutrophil count is \( <3 \times 10^9/l \), then suspend treatment and recheck in 5–7 days. If neutrophil count is \( <1 \times 10^9/l \), prescribe prophylactic antibiotics (until neutrophil count is \( >1 \times 10^9/l \)). If neutrophil count is \( <1 \times 10^9/l \) and the patient is pyrexic or unwell, administer i.v. antibiotics and contact an oncologist for advice. If the neutrophil count is \( <1 \times 10^9/l \), decrease dose of the causative chemotherapy drug by 10%; if recurrent, contact an oncologist for advice.

**Disease monitoring and relapse**

*Restaging:* Ideally, restaging should be performed at week 12 for high-risk tumours without known metastasis and after week 4 and at week 12 for tumours with known metastasis. If restaging is clear, further restaging is recommended every 3 months (for a year) for high-risk tumours.

*Relapse:* If additional metastatic lesions are identified (liver, spleen or lymph nodes), or treatment fails to yield remission further, treatment with lomustine or a tyrosine kinase inhibitor is indicated (contact an oncologist).

**Immunosuppression protocols**

There are many protocols described in the literature for different immune-mediated diseases and it is essential that the regimen should be individualized with consideration of the animal’s weight, body condition, previous exposure/response to glucocorticoids and responsiveness once treatment has started. Three examples are provided here. It is vitally important that the diagnosis of immune-mediated disease is confirmed before undertaking any of these protocols.
Protocol 1: Canine immune-mediated haemolytic anaemia (IMHA) and immune-mediated thrombocytopenia (IMTP)

Induction

**Immunosuppression:**

*Starting doses:*

Prednisolone 40 mg/m$^2$ (or 2 mg/kg if <15 kg) p.o. q24h, with or without:

- Azathioprine 2 mg/kg p.o. q24h
- Ciclosporin 5 mg/kg p.o. q12h
- Mycophenolate mofetil 8–10 mg/kg p.o. q12h

See Appendix I for safety and handling of chemotherapeutic agents.

Dexamethasone (0.4 mg/kg i.v. q24h) may be substituted for prednisolone if the patient is unable to tolerate oral medications. Mycophenolate mofetil (MMF) (7–10 mg/kg i.v. q12h) can be used where oral medication is not tolerated.

Once the patient is able to tolerate oral medications, then substitute prednisolone for dexamethasone and switch to oral dosing of mycophenolate mofetil (8 mg/kg p.o. q12h) or, if preferred, azathioprine at the above doses. A single dose of vincristine (0.02 mg/kg i.v.) may be used in cases of IMTP, as it may increase platelet number but extent of its benefits are unclear. Dyserythropoiesis may be seen in such cases but is clinically insignificant.

**Antithrombotics:** Clopidogrel 1–2 mg/kg per day is indicated for dogs with IMHA, with or without low molecular weight heparins (dalteparin 150–175 IU/kg q8h) if there is clinical evidence of thromboembolic disease. Discontinue on remission (or once the prednisolone is discontinued).

**Antibiotics:** Not required unless there is a documented infection or known risk of infection (e.g. previous endocarditis). Empirical treatment with doxycycline (10 mg/kg p.o. q24h) may be indicated pending tests for tick-borne diseases in dogs with a history of travel or known tick exposure.

**Gastrointestinal protection:** In general, not required. In cases with known or suspected GI bleeding (melaena, haematemesis), omeprazole (1 mg/kg p.o. or i.v. q12h) offers effective suppression of gastric acid secretion. The practice of administering ranitidine etc. to every animal receiving high doses of steroids is not necessary and likely ineffective.

**Relapse and rescue**

If a mild relapse (e.g. a fall in PCV of <5% without any clinical signs of anaemia) occurs following documented remission, this may be treated by reinstigating the drug dosages used at the last visit when the patient was in remission. Severe relapses should be treated by reinstigation of induction doses of all drugs used initially. If this is ineffective, or if rescue is to be attempted during initial induction phase of treatment (due to progressive deterioration), then additional immunosuppressants may be added. In cases of poor disease control, three immunosuppressive drugs may be used.
concurrently, with a risk of opportunistic (fungal) infections. An infusion of immunoglobulin (0.5–1.0 g/kg i.v. over 6–8 hours) may be administered in dogs not responding to other forms of treatment, but clinical benefit is not proven. In the non-acute setting, or if long-term control is necessary in a patient that has previously failed all other orally administered drugs, then consider leflunomide (2 mg/kg p.o. q24h).

**Decreasing doses**

**Principles for dose reduction:** Consider reduction of the prednisolone dose as soon as clinical response is apparent (resolution of agglutination, spherocytosis, hyperbilirubinaemia/haemolysed plasma and the PCV is stable or increasing). Decrease the prednisolone dose by 25–33% every 2–3 weeks, depending on severity of side effects and if features of disease are well controlled. Expected overall duration of treatment is approximately 3–5 months provided there is no relapse.

<table>
<thead>
<tr>
<th>Week</th>
<th>Glucocorticoid</th>
<th>Ciclosporin/ MMF</th>
<th>Azathioprine (if used)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Remission</td>
<td>1 mg/kg q24h</td>
<td>UC</td>
<td>Reduce to 1 mg/kg or every other day</td>
</tr>
<tr>
<td>2</td>
<td>0.5 mg/kg q24h</td>
<td>UC</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>UC</td>
<td>50% dose reduction (or extention of dosing interval)</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>0.5 mg/kg every other day</td>
<td>UC</td>
<td>STOP if using as 3rd immunosupressant</td>
</tr>
<tr>
<td>8</td>
<td>UC</td>
<td>Alternate day dosing with prednisolone</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>0.25 mg/kg every other day</td>
<td>UC</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>STOP (or further 4 w)</td>
<td>UC</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td></td>
<td></td>
<td>STOP</td>
</tr>
</tbody>
</table>

UC = dose unchanged.

**General notes:**

Haematology to be rechecked at each visit (including 4 and 8 weeks after cessation of therapy) and remission confirmed prior to each dose reduction. Liver parameters should be rechecked at remission and monthly if on azathioprine.

**Protocol 2: Feline immune-mediated haemolytic anaemia**

**Induction**

**Immunosuppression:** Prednisolone: 3–4 mg/kg p.o. q24h, with or without:

- Chlorambucil: >4 kg body weight, 2 mg p.o. q48h; <4 kg body weight, 2 mg p.o. q72h
• Ciclosporin: 5 mg/kg p.o. q12h
• Mycophenolic acid (MPA): 10 mg/kg p.o. q12h

See Appendix I for safety and handling of chemotherapeutic agents.

If the patient is unable to tolerate oral medications, then dexamethasone (0.6–1.0 mg/kg i.v. q24h) may be substituted for prednisolone and mycophenolate mofetil (MMF) (7–10 mg/kg i.v. q12h) may be substituted for mycophenolic acid.

**Antithrombotics:** Avoid in cats as there is no evidence of a risk of thrombosis in cats with IMHA currently, and risk of side effects.

**Antibiotics:** Not required unless there is a documented infection or known risk of infection (e.g. previous endocarditis) or known exposure to ticks. Empirical treatment with doxycycline (10 mg/kg p.o. q24h) may be indicated pending tests for *Mycoplasma* spp.

**Gastrointestinal protection:** Not required unless GI bleeding has been diagnosed. Effective suppression of gastric acid production is then required. Current evidence suggests that only famotidine and omeprazole will provide this. The practice of administering ranitidine etc. to every animal receiving high doses of steroids is not necessary and likely ineffective.

**Relapse and rescue**

See Protocol 1: Canine immune-mediated haemolytic anaemia and immune-mediated thrombocytopenia for details.

**Decreasing doses**

See Protocol 1: Canine immune-mediated haemolytic anaemia and immune-mediated thrombocytopenia for details.

(NB: reports of feline immune-mediated thrombocytopenia are too rare to provide a protocol for treatment, but it is likely that a similar approach should be adopted.)

**Protocol 3: Steroid-responsive meningitis**

**Induction**

**Immunosuppression:** Prednisolone: 2 mg/kg p.o. q24h (as single dose or divided) for 7–14 days. Dexamethasone (0.4 mg/kg i.v. q24h) may be substituted for prednisolone for the first 2 days if the patient is unable to tolerate oral medications.

**Remission:** If remission is achieved, then 1 mg/kg p.o. q24h for 6 weeks followed by 0.5 mg/kg p.o. q24h for 6 weeks, followed by 0.5 mg/kg p.o. q48h for 6 weeks, followed by 0.5 mg/kg p.o. q72h for 6 weeks, then stop.

**Relapse:** In the event of a relapse during or after completion of the protocol (or if remission is not achieved), then 2 mg/kg p.o. q24h can be reinstigated (or continued if remission not achieved) for a further 2 weeks, and then continued as the 24-week remission protocol.

**Antibiotics:** Not required unless there is a documented infection, known risk of infection (e.g. previous endocarditis) or known exposure to ticks.

**Gastrointestinal protection:** In general, not required.
Appendix II: protocols

**Sedation/immobilization protocols**

**Sedative combinations for dogs**

**Acepromazine (ACP) as sole agent:** Acepromazine alone is not a particularly effective sedative. For further information, see monograph. Because larger breeds seem to be more sensitive to acepromazine, it is recommended not to exceed a total dose of 1 mg/patient.

**ACP/opioid mixtures (neuroleptanalgesia):** Acepromazine used in combination with opioid analgesics reduces the dose requirement of both components and also the incidence of adverse effects. Acepromazine (0.01–0.03 mg/kg, except in Boxers 0.005–0.01 mg/kg) can be combined with:

- Pethidine (2–10 mg/kg i.m.)
- Methadone (0.1–0.5 mg/kg i.m., i.v.)
- Papaveretum (0.05–0.4 mg/kg i.v., i.m.)
- Buprenorphine (0.02–0.03 mg/kg i.v., i.m)
- Butorphanol (0.1–0.4 mg/kg i.v., i.m.)
**Alpha-2 agonists as sole agents:** Although authorized for single-agent use, it is generally preferable to use medetomidine or dexmedetomidine in combination with opioids (see below).

Recommended dose in dogs and cats of medetomidine is 5–20 μg (micrograms)/kg i.m. and of dexmedetomidine is 2.5–10 μg/kg i.m. Lower doses (1–10 μg/kg) of medetomidine or (1–5 μg/kg) dexmedetomidine may be given intravenously. At higher doses, marked cardiovascular effects (mainly bradyarrhythmias) should be expected.

Adverse effects may be antagonized with i.m. atipamezole at 5 times the agonist dose rate. The (unauthorized) i.v. route is preferable in critical situations.

For information on xylazine see below.

The use of alpha-2 agonists for sedation is only recommended in healthy animals.

**Alpha-2 agonist/opioid mixtures:** Including opioids with medetomidine or dexmedetomidine lowers the dose required to achieve a given level of sedation, thereby limiting the marked effects that alpha-2 agonists exert on cardiopulmonary function. If sedation is still inadequate, it is better to proceed to induction of general anaesthesia using an i.v. induction agent, such as alfaxalone or propofol, rather than by giving a repeated or higher dose of alpha-2 agonist.

Medetomidine or dexmedetomidine, at the doses described above, can be combined with:

- Pethidine (2–10 mg/kg i.m.)
- Methadone (0.1–0.5 mg/kg i.m., slow i.v.)
- Buprenorphine (0.02–0.03 mg/kg slow i.v., i.m.)
- Butorphanol (0.1–0.4 mg/kg slow i.v., i.m.).

Although xylazine (1–3 mg/kg) may be used alone or in combinations with opioids, given i.m. or i.v. (unauthorized), its use in dogs and cats has been superseded by use of medetomidine or dexmedetomidine, and it is not recommended. Adverse effects may be antagonized with i.m. or i.v. atipamezole, although this use is unauthorized.

**Acepromazine/alpha-2 agonist/opioid mixtures:** A mixture of acepromazine (up to 0.03 mg/kg) with any of the combinations given for alpha-2 agonists and alpha-2 agonist/opioid mixtures (higher end of dose ranges) is suitable for the chemical restraint of aggressive dogs. Severe depression can be antagonized using naloxone and atipamezole.

Low doses of acepromazine (0.01 mg/kg) and medetomidine (5–10 μg [micrograms]/kg) or dexmedetomidine (2.5–5 μg [micrograms]/kg) combined with opioid agonist drugs provide profound sedation with less cardiovascular depression than when an alpha-2 agonist or acepromazine as the sole agent in combination with the opioid.
Benzodiazepines and benzodiazepine/opioid mixtures: 
Benzodiazepines do not reliably sedate healthy dogs when used alone; indeed, stimulation ranging from increased motor activity to gross excitation may be seen. The risk of excitation is proportional to the health of the recipient: the chances of producing sedation are highest (but not guaranteed) in very sick, young or older cases. Diazepam (authorized) or midazolam (unauthorized) (0.2–0.3 mg/kg i.v.) given during anaesthesia can smooth recovery in animals prone to excitability, provided adequate analgesia is present.

Opioid/benzodiazepine mixtures are satisfactory and relatively safe in critically ill animals. These combinations are more effective when given i.v. (with the exception of pethidine). Transient excitation may occur when given by this route. When given i.m., excitation is unlikely although the depth of sedation is also reduced. Midazolam or diazepam at the dose described above can be given with:

- Pethidine (2–10 mg/kg i.m.)
- Methadone (0.1–0.5 mg/kg i.v., i.m.)
- Papaveretum (0.2–0.5 mg/kg i.v., i.m.)
- Buprenorphine (0.02–0.03 mg/kg i.v., i.m.)
- Butorphanol (0.1–0.4 mg/kg i.v., i.m.)
- Fentanyl (0.01 mg/kg slow i.v).

It is preferable to use midazolam (unauthorized) when choosing the i.m. route, as the absorption of diazepam via this route can be variable.

Alfaxalone: Although not authorized for this use, 2 mg/kg i.m. will provide sedation in dogs lasting 10–15 minutes. The volume of injectate precludes use of this technique in medium- to large-breed dogs. Alfaxalone can be used in conjunction with opioids and benzodiazepines.

General notes:
- A well-managed light level of general (inhalational) anaesthesia is frequently safer than heavy sedation in sick animals.
- Neuroleptanalgesic combinations are safer than alpha-2 agonist/opioid mixtures, but are less likely to produce adequate conditions for minor operations or investigations involving abnormal body positions. Furthermore, only the opioid component can be antagonized.
- Most of the aforementioned combinations will have a profound sparing effect on i.v. and inhalational anaesthetics, should a general anaesthetic be required after sedation. This is particularly true of combinations containing alpha-2 agonists.
- Any stress induced in the patient may decrease the effectiveness of sedative drugs and higher initial doses may be required.
- Close monitoring of the cardiorespiratory system is recommended during sedation.
Sedative combinations for cats

**Acepromazine:** Acepromazine alone is not a particularly effective sedative and increasing the dose incurs the same problems as in dogs. Doses of 0.01–0.05 mg/kg may be given i.v., i.m. or s.c. Cats often require higher doses of acepromazine than dogs to achieve comparable sedation. Recumbency is normally not achievable in cats with acepromazine sedation.

**Neuroleptanalgesia:** Neuroleptanalgesic combinations confer the same advantages in cats as in dogs. Acepromazine (0.01–0.05 mg/kg) can be combined with:

- Pethidine (2–10 mg/kg i.m.)
- Methadone (0.1–0.5 mg/kg i.v., i.m.)
- Buprenorphine (0.02–0.03 mg/kg i.v., i.m.)
- Butorphanol (0.1–0.4 mg/kg i.v., i.m.).

Use the lower end of the dose ranges i.v.

**Alpha-2 agonists as sole agents and alpha-2 agonist/opioid mixtures:** See information given for dogs. Adverse effects may be antagonized with i.m. atipamezole at 2.5 times the agonist dose rate; the (unauthorized) i.v. route is preferable in critical situations.

**Benzodiazepines:** Diazepam (0.2–0.3 mg/kg) or midazolam (0.2–0.3 mg/kg) i.v. can provide satisfactory sedation in very sick cats. The inclusion of opioids at doses given for alpha-2 agonist/opioid mixtures may improve conditions, but benzodiazepine/opioid combinations do not provide reliable sedation in most cats.

**Ketamine and ketamine-based techniques:** Ketamine is relatively safe in ill animals, but high doses cause prolonged recoveries and are associated with muscle rigidity. Acepromazine (0.05–0.1 mg/kg) with midazolam (0.25 mg/kg) and ketamine at 2.5–7.5 mg/kg, mixed and injected i.m., provides good conditions with only modest cardiopulmonary depression. The higher doses of ketamine should be used in excitable animals undergoing more stimulating interventions.

**Alternatives:** Ketamine (2.5 mg/kg) combined with diazepam or midazolam (0.2–0.3 mg/kg) i.v. provides profound sedation which lasts for about 15–20 minutes. Higher doses of ketamine (5 mg/kg) may be required if given i.m. This combination is preferred over ketamine/acepromazine combinations in sick cats. Diazepam can cause pain on injection, therefore, use of midazolam is preferred.

Ketamine (5 mg/kg) with medetomidine 10–40 μg (micrograms)/kg i.m. produces profound sedation but should only be used in healthy cats. An opioid can be added to this mixture to provide analgesia or further sedation. Atipamezole may be given if severe problems are encountered.

Although ketamine elimination depends heavily on renal function in cats, a full recovery still occurs, albeit more slowly, in animals with renal disease or urinary tract obstruction. However, low doses should be used in such cases.
**Alfaxalone:** Although not authorized for this use, 2–3 mg/kg i.m. or s.c. will provide sedation in cats lasting 10–15 minutes. Alfaxalone can be combined with an opioid and/or midazolam to improve sedation.

**General notes:**
- Careful handling and restraint to achieve injection of sedative is preferred, but a crush cage is useful for restraining violent cats. If injection of sedatives proves impossible, anaesthesia can be induced using a large induction chamber into which volatile anaesthetic agents can be delivered via an anaesthetic machine. Most of the aforementioned combinations will have a profound sparing effect on i.v. and inhalational anaesthetics should a general anaesthetic be required after sedation. This is particularly true of combinations containing alpha-2 agonists.
- The high body surface area to volume ratio of cats results in rapid heat loss compared with dogs. Attention to thermoregulation must be diligent.
- A well-managed light level of general (inhalational) anaesthesia is frequently safer than heavy sedation in sick animals.
- Any stress induced in the patient may decrease the effectiveness of sedative drugs and higher initial doses may be required.
- Close monitoring of the cardiorespiratory system is recommended during sedation.
## Anaesthetics, analgesics and NSAIDs

### Adrenoreceptor antagonists
- Atipamezole 35

### Antiarthritis drugs
- Pentosan polysulphate 310

### Inhalational anaesthetics
- Halothane 190
- Isoflurane 213
- Nitrous oxide 286
- Sevoflurane 374

### Injectable anaesthetics
- Alfaxalone 9
- Ketamine 217
- Procaine hydrochloride with epinephrine bitartrate 342
- Propofol 346
- Zoletil/Tiletamine 439

### Local anaesthetics
- Bupivacaine 52
- Lidocaine 228
- Mepivacaine 253
- Ropivacaine 365

### Muscle relaxants
- Atracurium 36
- Cisatracurium 88
- Dantrolene 107
- Methocarbamol 256
- Pancuronium 300
- Rocuronium 362
- Suxamethonium 389
- Vecuronium 422

### Non-opioid analgesics
- Amantadine 15
- Tramadol 410

### Non-steroidal anti-inflammatory drugs
- Aspirin 32
- Carprofen 63
- Cimicoxib 84
- Cinchophen 85
- Dimethylsulfoxide 127
- Firocoxib 165
- Flumazenil 169
- Grapiprant 189
- Ketoprofen 220
- Mavacoxib 246
- Meloxicam 250
- Paracetamol 303
- Phenylbutazone 318
- Piroxicam 329
- Robenacoxib 360
- Tolfenamic acid 406

### Opioid analgesics
- Alfentanil 10
- Buprenorphine 53
- Butorphanol 54
- Fentanyl 160
- Methadone 254
- Morphine 274
- Papaveretum 302
- Pethidine 313
- Tramadol 410

### Opioid antagonists
- Naloxone 280

### Parasympatholytics
- Atropine 37
- Glycopyrronium 187

### Sedatives
- Acepromazine 1
- Dexamethasone 116
- Diazepam 118
- Medetomidine 247
- Midazolam 266
- Xylazine 435

### Sympathomimetics
- Adrenaline 5

### Antivirals
- Aciclovir 4
- Famciclovir 157
- Ganciclovir 180
- Lamivudine 223
- Zidovudine 437

### Antibacterials
- Aminoglycosides
  - Amikacin 15
  - Chlortetracycline 80
- Framycetin 175
- Gentamicin 182
- Neomycin 281
- Tobramycin 404

### Anti-infectives

(see also Guidelines for responsible antibacterial use in the Appendix)
<table>
<thead>
<tr>
<th>Index: therapeutic class</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INDEX:</strong> GENERIC AND TRADE NAMES INDEX: THERAPEUTIC CLASS</td>
</tr>
<tr>
<td><strong>APPENDIX I:</strong> GENERAL INFORMATION APPENDIX II: PROTOCOLS</td>
</tr>
<tr>
<td><strong>Anti-infectives continued</strong></td>
</tr>
<tr>
<td><strong>Beta-lactams</strong></td>
</tr>
<tr>
<td>Amoxicillin 24</td>
</tr>
<tr>
<td>Ampicillin 27</td>
</tr>
<tr>
<td>Cloxacillin 98</td>
</tr>
<tr>
<td>Co-amoxiclav 98</td>
</tr>
<tr>
<td>Penicillin G 309</td>
</tr>
<tr>
<td>Piperacillin 327</td>
</tr>
<tr>
<td>Ticarcillin 402</td>
</tr>
<tr>
<td><strong>Cephalosporins</strong></td>
</tr>
<tr>
<td>Cefalexin 67</td>
</tr>
<tr>
<td>Cefotaxime 68</td>
</tr>
<tr>
<td>Cefovecin 69</td>
</tr>
<tr>
<td>Cefazidime 70</td>
</tr>
<tr>
<td>Ceftiofur 71</td>
</tr>
<tr>
<td>Cefuroxime 72</td>
</tr>
<tr>
<td><strong>Fluoroquinolones</strong></td>
</tr>
<tr>
<td>Ciprofloxacin 86</td>
</tr>
<tr>
<td>Enrofloxacin 147</td>
</tr>
<tr>
<td>Marbofloxacin 242</td>
</tr>
<tr>
<td>Ofloxacin 290</td>
</tr>
<tr>
<td>Orbifloxacin 293</td>
</tr>
<tr>
<td>Pradofloxacin 335</td>
</tr>
<tr>
<td><strong>Lincosamides</strong></td>
</tr>
<tr>
<td>Clindamycin 91</td>
</tr>
<tr>
<td>Lincomycin 230</td>
</tr>
<tr>
<td><strong>Macrolides</strong></td>
</tr>
<tr>
<td>Azithromycin 40</td>
</tr>
<tr>
<td>Clarithromycin 89</td>
</tr>
<tr>
<td>Erythromycin 152</td>
</tr>
<tr>
<td>Tylosin 420</td>
</tr>
<tr>
<td><strong>Nitrofurans</strong></td>
</tr>
<tr>
<td>Nitrofurantoin 285</td>
</tr>
<tr>
<td><strong>Nitroimidazoles</strong></td>
</tr>
<tr>
<td>Metronidazole 262</td>
</tr>
<tr>
<td><strong>Sulphonamides</strong></td>
</tr>
<tr>
<td>Silver sulfadiazine 376</td>
</tr>
<tr>
<td>Trimethoprim/sulphonamide 418</td>
</tr>
<tr>
<td><strong>Tetracyclines</strong></td>
</tr>
<tr>
<td>Doxycycline 140</td>
</tr>
<tr>
<td>Minocycline 269</td>
</tr>
<tr>
<td>Oxytetracycline 296</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
Anti-neoplastic

(see also Safety and handling of chemotherapeutic agents and Chemotherapy protocols in the Appendix)

**Alkylating agents**
- Chlorambucil 75
- Cyclophosphamide 102
- Dacarbazine 106
- Melphalan 252
- Temozolomide 392

**Anthracycline glycosides**
- Doxorubicin 138
- Epirubicin 149

**Antimetabolites**
- Cytarabine 104
- Gemcitabine 181
- Hydroxyurea 198

**Platinum analogues**
- Carboplatin 62

**Vinca alkaloids**
- Vinblastine 424
- Vincristine 425

**Antineoplastic NSAIDs**
- Piroxicam 324

**Tyrosine kinase inhibitors**
- Masitinib mesylate 245
- Toceranib 405

**Others**
- Asparaginase (L-Asparaginase, Crisantaspase) 31
- Bleomycin 47
- Dactinomycin 106
- Dexrazoxane 118
- Fluorouracil 170
- Lomustine 235
- Methotrexate 258
- Mitoxantrone 272
- Rabacfosadine 356

**Behaviour modifiers**

- Alprazolam 12
- Amitriptyline 22
- a-Casozepine 66
- Cat appeasing pheromone 66
- Clomipramine 93
- Diphenhydramine 129
- Dog appeasing pheromone 133
- Doxepin 138
- Feline facial fraction 158
- Fluoxetine 171
- Lorazepam 237
- Mirtazapine 270
- Paroxetine 305
- Sertraline 372
- Trazodone 413

**Blood and immune system**

**Anticoagulants**
- Aspirin 32
- Clopidogrel 96
- Heparin (low molecular weight) 191
- Heparin (unfractionated) 192

**Colony-stimulating growth factors**
- Darbepoetin 180
- Erythropoietin 153
- Filgrastim 162
- Lenograstim 226
- Lithium carbonate 233

**Immunostimulants**
- Interferon omega 210

**Immunosuppressives**
- Azathioprine 38
- Ciclosporin 81
- Immunoglobulins 206
- Leflunomide 225
- Mycophenolate mofetil 278
- Tacrolimus 390
Cardiovascular

Alpha-blockers
Phenoxybenzamine 317

Beta-blockers
Atenolol 34
Carvedilol 64
Propranolol 348

Antiarhythmics
Amiodarone 20
Digoxin 123
Esmolol 154
Mexiletine 264
Sotalol 383
Verapamil 423

Antihypertensives
Amlodipine 23

Antiplatelet aggregators
Aspirin 32
Clopidogrel 96

Diuretics
Amiloride 16
Furosemide 176
Hydrochlorothiazide 195
Spironolactone 385
Torasemide 409

Positive inotropes
Dobutamine 131
Dopamine 135
Pimobendan 326

Vasoconstrictors
Ephedrine 148

Vasodilators
Benazepril 42
Diltiazem 125
Enalapril 145
Glyceryl trinitrate 186
Hydralazine 194
Imidapril 203
Prazosin 338
Ramipril 356
Sildenafil 375
Telmisartan 391

Others
Dexrazoxane 118

Dermatological

Cleansers and sebolytics
Chlorhexidine 78
Sodium hypochlorite 381

Antihistamines
Cetirizine 73
Chlorphenamine 79
Clemastine 90
Cyproheptadine 103
Diphenhydramine 129
Hydroxyzine 199
Loratadine 236
Promethazine 344

Anti-inflammatory topical steroids
Hydrocortisone aceponate 197

Anti-inflammatory – others
Lokivetmab 234
Nicotinamide 289
Oclacitinib 289
Sodium cromoglicate 381

Ectoparasiticide
Afoxolaner 6
Amitraz 21
Deltamethrin 110
Dinetofuran 128
Fipronil 164
Flumethrin see Imidacloprid 202
Fluralaner 172
Imidacloprid 202
Lotilaner 238
Lufenuron 238
Moxidectin 276
Nitenpyram 285
Permethrin 312
Pyriproxyfen 355
Sarolaner 369

Environmental ectoparasiticides
Methoprene 257
Pyriproxyfen 355

Hormonal replacements
See Endocrine

Immunosuppressives
Ciclosporin 81

Vasodilator
Pentoxifylline 311

## Endocrine

**Abortifacients**  
Aglepristone 7

**Adrenal suppressants**  
Mitotane 271  
Trilostane 417

**Growth hormone stimulants**  
Clonidine 95  
Proligestone 343

**Anabolic steroids**  
Nandrolone 280

**Antidiuretics**  
Desmopressin 112

**Glucocorticoids**  
Betamethasone 43  
Budesonide 50  
Dexamethasone 114  
Fluticasone 174  
Hydrocortisone 196  
Methylprednisolone 259  
Prednisolone 339  
Triamcinolone 416

**Antithyroid hormones**  
Carbimazole 60  
Methimazole see Thiamazole 399

**Hyperglycaemic drugs**  
Diazoxide 121  
Glucagon 185

**Hypoglycaemic drugs**  
Glipizide 184  
Insulin 208

**Mineralocorticoid**  
Desoxycorticosterone pivalate 113  
Fludrocortisone 168  

**Pituitary hormones and their analogues**  
Chorionic gonadotrophin 81  
Melatonin 250  
Somatropin 383  
Tetracosactide 396

**Prolactin inhibitors**  
Cabergoline 57

**Prostaglandins**  
Dinoprost tromethamine 129

**Sex hormones**  
Delmadinone 109  
Osaterone 295  
Proligestone 343

**Somatostatin analogue**  
Octreotide 289

**Testosterone inhibition**  
Deslorelin 111  
Finasteride 163

**Thyroid hormones**  
Liothyronine 231  
Thyroid stimulating hormone 400  
L-Thyroxine 401

**Uterine stimulant**  
Oxytocin 297

## Gastrointestinal and hepatic

**Antibacterials**  
Bismuth salts 46

**Antidiarrhoeals**  
Diphenoxylate 130  
Kaolin 217  
Loperamide 236

**Motility modifiers**  
Cisapride 87  
Ispaghula 214  
Sterculia 387

**Antispasmodic**  
Butylscopolamine 55

**Antiemetics**  
Domperidone 134  
Maropitant 244  
Metoclopramide 261  
Ondansetron 293  

**Prochlorperazine** 342  
**Propantheline** 345

**Antifibrotic**  
Colchicine 100  

**Anti-inflammatory drugs**  
Budesonide 50  
Olsalazine 291  
Sulfasalazine 388

**Chelating agents**  
Penicillamine 306  
Trientine 416

**Anti-oxidants**  
S-Adenosylmethionine 367  
Silybin 377

**Choleretics**  
Ursodeoxycholic acid 421
## Digestive enzymes

Pancreatic enzyme supplements 299

## Emetics

- Apomorphine 30
- Ropinirole 364
- Xylazine 435

## Laxatives

- Bisacodyl 46
- Bowel cleansing solutions 48
- Docusate sodium 132
- Lactulose 222  

## Ulcer-healing drugs

- Aluminium antacids 13
- Cimetidine 83
- Famotidine 157  
- Misoprostol 270
- Omeprazole 291  
- Pantoprazole 301
- Ranitidine 358  
- Sucralfate 387  

## Genito-urinary tract

### Antifibrotic

- Colchicine 100  

### Urinary acidifiers

- Methionine 256

### Urinary alkalinizers

- Potassium citrate 333

### Urinary antiseptics

- Methenamine 256

### Urethral relaxants

- Diazepam 118  
- Oxybutynin hydrochloride 296
- Phenoxybenzamine 317  
- Tamsulosin hydrochloride 391  

### Urinary incontinence

- Ephedrine 148
- Estriol 155
- Phenylpropanolamine 320
- Propantheline 345

### Urinary retention

- Bethanecol 45

### Urolithiasis

- Allopurinol 11  
- Penicillamine 306
- Potassium citrate 333

### Phosphate binders

- Calcium acetate 57
- Chitosan 75
- Lanthanum carbonate 223
- Sevelamer hydrochloride 373

## Metabolic

### Antidotes

- Acetylcysteine 3
- Antivenom (European Adder) 29
- Charcoal 74
- Colestyramine 101
- Deferoxamine 109
- Dextrazoxane 118
- Dimercaprol 126
- Edetate calcium disodium 142
- Ethanol 156
- Fomepizole 175

- Methylthioninium chloride 260
- Penicillamine 306
- Pralidoxime 336
- Protamine sulphate 350
- Tetanus antitoxin 395

### Anti-hypercalcaemics

- Alendronate 8  
- Pamidronate 299

### Antitoxins

- Tetanus antitoxin 395
Neuromuscular system

Anticholinesterases
- Edrophonium 142
- Neostigmine 282
- Pyridostigmine 352
  [CIL]

Antiepileptics
- Clonazepam 94
- Diazepam 118
- Gabapentin 179
- Imepitoin 201
- Levetiracetam 227
- Midazolam 266
- Phenobarbital 314

Euthanasia
- Pentobarbital 309
- Secobarbital 370

Osmotic diuretic
- Mannitol 241

Others
- Acetazolamide 2

Nutritional/fluids

(see also table of composition of intravenous fluids in the Appendix)

Nutritional supplements
- Amino acid solutions 17
- Lipid infusions 232

Crystalloids
- Sodium chloride 379

Glucose supplements
- Glucose 185

Mineral and electrolyte supplements
- Calcium salts 58
- Iron salts 211
- Magnesium salts 240
- Phosphate 323
- Potassium salts 334
- Sodium bicarbonate 378
- Zinc salts 438

Plasma substitutes
- Gelatine 180

Vitamin supplements
- Nicotinamide 284
- Vitamin A 426
- Vitamin B complex 427
- Vitamin B1 428
- Vitamin B12 429
- Vitamin C 430
- Vitamin D 430
- Vitamin E 432
- Vitamin K1 432
  [CIL]

Ophthalmic

Antivirals
- Aciclovir 4
- Ganciclovir 180
- Lysine 239

Antibacterials
- Ciprofloxacin 86
- Chlortetracycline 80
- Ofloxacin 290
  [CIL]

Glaucoma therapy
- Apraclonidine 31
- Betaxolol 45
- Brinzolamide 49
- Dorzolamide 137
  [CIL]
- Latanoprost 224
  [CIL]
- Timolol maleate 403
- Travoprost 413

Miotic/lacrimalmimetic
- Pilocarpine 325

Mydriatics
- Atropine 37
  [CIL]
- Phenylenephrine 319
- Tropicamide 419

Non-steroidal
anti-inflammatory drugs
- Diclofenac 122
- Flurbiprofen 173
- Ketorolac 221
Ophthalmic continued

Tear substitutes
  Carbomer 980 61
  Hyaluronate 193
  Hypermellose 200
  Polyvinyl alcohol 331

Topical anaesthetics
  Proxymetacaine 350
  Tetracaine 396

Immunosuppressives
  Ciclosporin 81
  Tacrolimus 390

Respiratory system

Anti-inflammatory steroids
  Fluticasone 174

Antitussives
  Codeine 100
  Pholcodine 322

Bronchodilators
  Aminophylline 19
  Propentofylline 346

Salbutamol 368
  Terbutaline 394
  Theophylline 398

Mucolytics
  Bromhexine 50

Nasal decongestants
  Phenylpropanolamine 230

Veterinary surgeons should supply written information to clients about the drugs that they prescribe. Client Information Leaflets on many unauthorized preparations are available for BSAVA members to download from the BSAVA website.
Generic names are in plain type. Trade names are in italics; asterisks denote products not authorized for use in veterinary species.

Client Information Leaflets (CIL) available for BSAVA members to download from the BSAVA website (www.bsavalibrary.com).

Abelcet* 25
Acclaim spray 257
Acepromazine 1, 471–4
Acetaminophen see Paracetamol 303
Acetazolamide 2
Acetylcysteine 3
Acetylsalicyclic acid see Aspirin 32 CIL
Aciclovir 4
Acidi* 13
ACP see Acepromazine 1
ACTH see Tetracosactide 396
Actidose-Aqua* 74
Actimarbo 242
Actinomycin-D see Dactinomycin 106
Activated charcoal see Charcoal 74
Activyl 207
Activyl Tick Plus 207, 312
Actrapid* 208
Acular* 221
Adaptil 133
Adaxio 78, 265
S-Adenosylmethionine 367
ADH see Desmopressin 112
Adizem* 125
Adrenaline 5
Adriamycin see Doxorubicin 138
Advantage 202
Advantix 202, 312
Advocate 202, 276
Afoxolaner 6
Aglupepristine 7
Aknemin* 269
Alcohol* 156
Aldactone* 385
Alendronate 8 CIL
Alendronate sodium 8
Alfalcacidol* 430
Alfalone 9, 472–3, 475
Alfavan 9
Alfentanil 10
Alizin 7
Alkeran* 252
Allopurinol 11 CIL
Alpha tocopheryl acetate see Vitamin E 432

Alphaxalone see Alfaxalone 9
Alprazolam 12 CIL
Alucap* 13
Aludex 21
Aluminium antacids 13
Aluminium hydroxide see Aluminium antacids 13
Alvegesic 54
Alzain* 341
Alzane 35
Amantadine 15, 11 CIL
AmBisome* 25
Amethocaine see Tetracaine 396
Amethocaine hydrochloride* 396
Amfipen 27
Amikacin 15, 456
Amikin* 15
Amiloride 16
Amiloride hydrochloride* 16
Amino acid solutions 17
Aminophylline 19
Aminoplasma* 17
Aminover* 17
Amiodarone 20 CIL
Amitraz 21
Amtriptyline 22 CIL
Amodip 23
Ampicare 27
Ampicillin 25, 456
Ampicillin/Clavulanate see Co-amoxiclav 98
Amoxycare 24
Amoxycillin see Amoxicillin 24
Amoxypen 24
Amphocil 27
Amphoterin B 25, 456
Ampicar 27
Ampicillin 27, 456
Amprolium 28
Anaestamine 217
Ancotil 168
An-Hypro 193
Anivit 4BC 427
Anivit B12 250 and 1000 429
Anitpsin* 387
Ampicar suspension* 387
Antigil* 125
Antelmin 337, 351
Antirobe 91
Antisedan 35
Antisept 78
Antivenom (European Adder) 29
Antizol* 175
Anxitane 397
Apometic 30
Apomorphine 30
Apoquel 289
Apraclonidine 31
Aprokan* 72
Aquapharm 58, 185, 379
Ara-C see Cytarabine 104
Aranesp* 108
Arava* 225
Aredia* 299
Ascorbic acid see Vitamin C 430
Asilone* 13
Asparaginase 31, 465
Aspirin 32, 457
Aspirin BP* 32
Atarax* 199
Atenolol 34
Atipam 35
Atipamezole 35, 472, 474
Ativan* 237
Atopica 81
Atopica Cat 81
Atracurium 36
Atrocare 37
Atropine 37, 130
Augmentin* 98
Aurimic 265
Aurizon 114, 242, 443
Axalid* 341
Azarga* 49, 403
Azathioprine 38, 457, 468–9
Azidothymidine see Zidovudine 437
Azidothymidine* 437
Azithromycin 40
Azopt* 49
AZT see Zidovudine 437
Azyter* 40
Bactroban* 277
Baytril 147
Benacort* 50
Benadryl* 129
Benazecare Flavour 42
Benazepril 42
Benefortin 42
Benylin Children’s Dry Cough Mixture* 322
Benzyl penicillin see Penicillin G 308
Betafuse 178
Betamethasone 43, 443
Betaxolol 24
Betaxolol 45
Bethanechol 45
Betnesol* 43
Betoptic* 45
Bilosin 420
Bimoxyl 24
Bisacodyl 46
Bismuth salts 46
Bismuth carbonate, subnitrate and subsalicylate see Bismuth salts 46
Bisolvon 50
Bleomycin 47
Bob Martin Flea Tablets 285
Bowel cleansing solutions 48
Bravecto 172
Bravecto Plus 267
Bravecto Plus Spot-on solution for cats 172
Bravecto Spot-on 172
Brevibloc* 154
Brexidol* 329
Bricanyl* 394
Brinzolamide 49
British anti-lewisite see Dimercaprol 126
Broadline 151, 164, 257, 337
Bromhexine 50
Bromilep 331
Buccolam* 266
Budelin* 47
Budenofalk* 47
Budenofalk Rectal Foam* 50
Budesonide 50
Bupaq 53
Bupivacaine 52
Buprecare 53
Buprenodale 53
Buprenorphine 53, 471–4
Buprevet 53
Buscopan 55
Butorphanol 53, 471–4
Butylscopolamine 55
Cabergoline 57
CaEDTA see Edetate calcium disodium 142
Calcibor 58
Calcichew* 58
Calcijex* 430
Calcitriol* 430
Calcium acetate 57
Calcium salts 58
Camcolit* 233
Canaural 175, 178, 287, 443
Canesten* 97
Canidryl 63
Canishield 110
Caninsulin 208
Capstar 285
Carafate* 387
Carbimazole 60
Carborner 980, 61
Carboplatin 62
Index: generic and trade names

APPENDIX I: GENERAL INFORMATION

APPENDIX II: PROTOCOLS

INDEX: THERAPEUTIC CLASS

INDEX: GENERIC AND TRADE NAMES

Carboxamide* 106
Cardalis 42, 385
Cardoxane* 118
Cardisure 326
Carprofen 63
Carprofen 63
Carprodyl 63
Carprofen 63
Carprofen Vet 63
Carprofen 63
Cartrophen 310
Carvedilol 64
a-Casozepine 66
Catapres 95
Catacrom* 381
Cat appeasing pheromone 66
Catapres* 95
CCNU see Lomustine 235
Cefalexin 67, 456
Cefaseptin 67
Cefotaxime 68, 457
Cefuroxime 72
CellCept 278
Ciclosporin 81, 468, 470
Cicloxan 86
Cimetidine 83
Cimicoxib 84
Circliphephn 85
Ciprofloxacin 86
Circadin 250
Cisapride 87
Cisatracurium 88
Clamelelle* 40
Clamoxyl 24
Clarithromycin 89
Clavabactin 98
Clavaseptin 98
Clavucill 98
Clavudale 98
Clemastine 90
Clevor 364
Clexane (enoxaparin)* 191
Clintezol 91
Clinacin 91
ClindaDry 193
Clingel Vet 182
Clindacyl 91
Clindamycin 91, 457
Clindaseptin 91
Clinimix* 17
ClinOleic* 232
Clofazimine 92
Clomicalm 93
Clomipramine 93
Clonazepam 94
Clonidine 95
Clopidogrel 96
Clofazimine 97, 443
Cloxacillin 98
CLX wipes 78, 11
Co-amlozide* 195
Co-amoxiclav 98
Cobalaplex 429
Co-danthrusate* 132
Codeine 100
Clofichicine 100
Colesticalfer (vitamin D3) see
Vitamin D 430
Colestyramine 101
Combimox 98
Comfortan 254
Comfortis 384
Convenia 69
Co-phenotrope see Diphenoxylate
130
Cordarone* 20
Cordycepic acid see Mannitol 241
Corsodyl* 78
Cortavance 197
Cortiment* 50
Corvental-D 398
Cosmegen* 106
CosmoFer* 211
CoSopt* 137, 403
Credelio 238
Crisantaspase see Asparaginase 102
Crystapen 308
Cyanocobalamin see Vitamin B12 429
Cyanocobalamin 429
Cyclavance 81
 Cyclophosphamide 102, 457, 460–5
 Cyclosporin(e) see Ciclosporin 81
Cyproheptadine 103
Cytopoint 234
Cytotec 270
Dacarbazine 106
Dactinomycin 106
Dalteparin 191
Dantrium 107
Dapoxetine 333
Cytarabine 104
Cytosar-U* 104
Cytosine arabinoside see Cytarabine 104
Cytotec 270
Dexadreson 114
Dexafort 114
Dexa-ject 114
Dexamethasone 114, 443, 468, 470
Dexdomitor 116
Dexmedetomidine 116, 472
Dextrose see Glucose 185
Diflucan* 211
Diah-Limit* 236
Diamox* 2
Diarlaeeze* 236
Diazedor 118
Diazemuls* 118
Diazepam 118, 457, 473–4
Diazepam Rectubes* 118
Diazepam 118, 457, 473–4
Diflucan* 167
Digoxin 123, 456
Dioctyl sodium sulfosuccinate see Docusate sodium 132
Dioctyl* 132
Diphenhydramine 129
Diphenoxylate 130
Diphenylhydantoin see Phenytoin 321
Diphenylpyraline see Phenylpropanolamine 320
Ditropam* 296
DMSO 127
Dobutamine 131
Dobutrex* 131
Docusate sodium 132
Docusate sodium 132
Dog appeasing pheromone 133
Dolagis 63
Dolethal 409
Dolorex 54
Dolpac 337, 351
Domitor 247
Domperidone 134
Dopamine 135
Dorbene 247
<table>
<thead>
<tr>
<th>Index: generic and trade names</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dormilan 247</td>
</tr>
<tr>
<td>Dorzolamide 137</td>
</tr>
<tr>
<td>Dorzolamide with Timolol* 137</td>
</tr>
<tr>
<td>Doxu Pyo  78, 91</td>
</tr>
<tr>
<td>Doxepin 138</td>
</tr>
<tr>
<td>Doxion 367, 377</td>
</tr>
<tr>
<td>Doxorubicin 138, 453, 457, 463–5</td>
</tr>
<tr>
<td>Doxycycline 140, 457</td>
</tr>
<tr>
<td>Drontic 337</td>
</tr>
<tr>
<td>Drontic Spot-on 337</td>
</tr>
<tr>
<td>Drontal 337, 351</td>
</tr>
<tr>
<td>DSS 132</td>
</tr>
<tr>
<td>DTIC* 106</td>
</tr>
<tr>
<td>DulcoEase* 132</td>
</tr>
<tr>
<td>Dulcolax* 14</td>
</tr>
<tr>
<td>Duoflect 257</td>
</tr>
<tr>
<td>Duowin 355</td>
</tr>
<tr>
<td>Duphacort Q 114</td>
</tr>
<tr>
<td>Duaphafral Extravite 427</td>
</tr>
<tr>
<td>Dupalac* 222</td>
</tr>
<tr>
<td>Dupaldehyde 17, 451</td>
</tr>
<tr>
<td>Dupalur 427</td>
</tr>
<tr>
<td>Dupalrim 418</td>
</tr>
<tr>
<td>Duramorph* 275</td>
</tr>
<tr>
<td>Durogesic* 160</td>
</tr>
<tr>
<td>Easotic 182, 197, 265, 443</td>
</tr>
<tr>
<td>Edetate calcium disodium 135</td>
</tr>
<tr>
<td>Edrophenium 142</td>
</tr>
<tr>
<td>Edrophonium Injection BP* 142</td>
</tr>
<tr>
<td>Efcoortesol* 196</td>
</tr>
<tr>
<td>Efex 242</td>
</tr>
<tr>
<td>Effiporo 355</td>
</tr>
<tr>
<td>Efudix* 170</td>
</tr>
<tr>
<td>Elspar* 31</td>
</tr>
<tr>
<td>Emeprid 261</td>
</tr>
<tr>
<td>EMLA 228</td>
</tr>
<tr>
<td>Emodepside 144</td>
</tr>
<tr>
<td>Enacard 145</td>
</tr>
<tr>
<td>Enalapril 145</td>
</tr>
<tr>
<td>Endectrid 276</td>
</tr>
<tr>
<td>Endoguard 337, 351</td>
</tr>
<tr>
<td>Endoxana* 102</td>
</tr>
<tr>
<td>Engemycin 296</td>
</tr>
<tr>
<td>Eniconazole 146</td>
</tr>
<tr>
<td>Enisyl 239</td>
</tr>
<tr>
<td>Enoxaparin 191</td>
</tr>
<tr>
<td>Enlon*(US) 142</td>
</tr>
<tr>
<td>Enrocare 147</td>
</tr>
<tr>
<td>Enrofloxacin 147</td>
</tr>
<tr>
<td>Enrotron 147</td>
</tr>
<tr>
<td>Enrox 147</td>
</tr>
<tr>
<td>Enrixol 147</td>
</tr>
<tr>
<td>Entocort* 50</td>
</tr>
<tr>
<td>Entocalm* 236</td>
</tr>
<tr>
<td>Entrolax* 46</td>
</tr>
<tr>
<td>Entonox* 286</td>
</tr>
<tr>
<td>Enurace 148</td>
</tr>
<tr>
<td>Enzaprof 129</td>
</tr>
<tr>
<td>Epanutin* 321</td>
</tr>
<tr>
<td>Ephedrine 148</td>
</tr>
<tr>
<td>Ephedrine hydrochloride* 148</td>
</tr>
<tr>
<td>4’-Epi-doxorubicin see Epirubicin 149</td>
</tr>
<tr>
<td>Epiplease 331</td>
</tr>
<tr>
<td>Epinephrine see Adrenaline 5</td>
</tr>
<tr>
<td>Epiphen 314</td>
</tr>
<tr>
<td>Epirubicin 149</td>
</tr>
<tr>
<td>Epistatus* 266</td>
</tr>
<tr>
<td>Epityl 314</td>
</tr>
<tr>
<td>Epoetin alfa and beta see</td>
</tr>
<tr>
<td>Erythropoietin 152</td>
</tr>
<tr>
<td>Eprex* 153</td>
</tr>
<tr>
<td>Eprinomectin 151</td>
</tr>
<tr>
<td>Epivir* 223</td>
</tr>
<tr>
<td>Ermimid foam 78</td>
</tr>
<tr>
<td>Erwinase* 31</td>
</tr>
<tr>
<td>Erythrin* 152</td>
</tr>
<tr>
<td>Erythromycin 152</td>
</tr>
<tr>
<td>Erythroped* 144</td>
</tr>
<tr>
<td>Erythropoietin 152</td>
</tr>
<tr>
<td>Esmeron* 362</td>
</tr>
<tr>
<td>Esmol 154</td>
</tr>
<tr>
<td>Estradiol 155</td>
</tr>
<tr>
<td>Ethanol 156</td>
</tr>
<tr>
<td>N-ethyl-L-glutamine see</td>
</tr>
<tr>
<td>L-Theanine 397</td>
</tr>
<tr>
<td>S-Etracetam see Leveteram 227</td>
</tr>
<tr>
<td>Eudemine* 121</td>
</tr>
<tr>
<td>Euthanimal 309</td>
</tr>
<tr>
<td>Euthasil 309</td>
</tr>
<tr>
<td>Euthatal 309</td>
</tr>
<tr>
<td>Euthoxin 309</td>
</tr>
<tr>
<td>Exocin* 290</td>
</tr>
<tr>
<td>Famciclovir 157</td>
</tr>
<tr>
<td>Famotidine 157</td>
</tr>
<tr>
<td>Famvir* 157</td>
</tr>
<tr>
<td>Febantel see Pyrantel 351</td>
</tr>
<tr>
<td>Feldene* 329</td>
</tr>
<tr>
<td>Felifriend 158</td>
</tr>
<tr>
<td>Felimazole 399</td>
</tr>
<tr>
<td>Feliway 158</td>
</tr>
<tr>
<td>Feline facial fraction F3 158</td>
</tr>
<tr>
<td>Feline facial pheromone F3 158</td>
</tr>
<tr>
<td>Feliway Friends 66</td>
</tr>
<tr>
<td>Fenbendazole 159</td>
</tr>
<tr>
<td>Fenoflox 147</td>
</tr>
<tr>
<td>Fentadon 160</td>
</tr>
<tr>
<td>Fentanyl 160, 473</td>
</tr>
<tr>
<td>Fentora* 160</td>
</tr>
<tr>
<td>Ferrous fumarate see Iron salts 211</td>
</tr>
<tr>
<td>Ferrous gluconate see Iron salts 211</td>
</tr>
<tr>
<td>Ferrous sulphate see Iron salts 211</td>
</tr>
<tr>
<td>Filgrastim 162</td>
</tr>
</tbody>
</table>
Finasteride 163
Fipronil Duo 355
Fipronil 164
Fiprotec 257
Firocoxib 165
FK 506 see Tacrolimus 390
Fleas spot-on 355
Flamazine* 376
Fleascreen Combo 257
Fleet Enema* 324
Flebogamma* 206
Fletchers' Phosphate Enema* 324
Flixotide* 174
Flomax relief* 391
Flomaxtra* 391
Florfenicol 166, 443
Floxabactin 147
Fluconazole 167
Flucytosine 168
Fludrocortisone 168
Flumazenil 169
Flumethrin see Imidacloprid 202
Fluorouracil 170, 457
Fluothane 190
Fluxetine 171
Fluralaner 172
Flurbiprofen 173
Fluticasone 174
Fomipizole 175
Fortekor 42
Fortekor-Plus 42, 326
Fortum* 70
Fosamax 8
Fosrenol* 223
Foston 323
Fragmin (dalteparin)* 191
Francytyn 175, 443
Frontect 164, 312
Frontline 164
Frontline Combo/Plus 164, 257
Frucecare 176
Frucedale 176
Frusemide see Furosemide 176
Frusol* 176
5-FU see Fluorouracil 170
Fungiconazole 219
Fungizone* 25
Furadantin* 285
Furosemide 176, 457, 461, 463–4
Fybogel* 214
Fusidic acid 178, 443
Gabapentin 179
Gabapentinum see Gabapentin 179
Galastop 57
Galensol* 322
Galliprant 189
Gammagard* 206
Ganciclovir 180
Gastrocet* 13
Gastrogard 291
Gaviscon Advance* 13
G-CSF see Filgrastim 162
Gelatine 180
Gelofusine 180
Gemcitabine 181
Gemzar* 181
Genotropin* 383
Genta 182
Gentamicin 182, 443, 456
Genticin* 182
Glamin* 17
Gleptosil 211
Glipizide 184
Glucagen 185
Glucagon 185
Glucantime* 249
Glucose 185
50% Glucose for injection* 185
Glyceryl trinitrate 186
Glycopyrrolate 187
Glycopyrronium 187
Glycopyrronium Bromide Andipharm* 282
Glytrin* 186
Granocyte* 226
Granofen 159
Granulocyte colony stimulating factor 162
Grapiprant 189
Green tea leaf extract see l-Theanine 397
Growth hormone see Somatotropin 383
Haemaccel 180
Halothane 190
Harkers Pigeon Coccidiosis Treatment 28
hCG see Chorionic gonadotrophin 81
Heparin (low molecular weight) 191
Heparin (unfractionated) 192
Heparin* 192
Hepaticare* 367, 377
Hepatosupport 367, 377
Hepatosyl Plus 367, 377
Hepsol* 192
Hexamine hippurate see Methenamine 255
Hibiscrub 78
Hiprex* 255
Human chorionic gonadotrophin see Chorionic gonadotrophin 81
<table>
<thead>
<tr>
<th>Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Humatrope</td>
<td>383</td>
</tr>
<tr>
<td>Humulin</td>
<td>208</td>
</tr>
<tr>
<td>Hyabak</td>
<td>193</td>
</tr>
<tr>
<td>Hyaluronate</td>
<td>193</td>
</tr>
<tr>
<td>Hydralazine</td>
<td>194, 457</td>
</tr>
<tr>
<td>Hydrea</td>
<td>198</td>
</tr>
<tr>
<td>Hydrochlorothiazide</td>
<td>195</td>
</tr>
<tr>
<td>Hydrocortisone</td>
<td>196</td>
</tr>
<tr>
<td>Hydrocortisone aceponate</td>
<td>197, 443</td>
</tr>
<tr>
<td>Hydroxocobalamin</td>
<td>379</td>
</tr>
<tr>
<td>Hydroxy carbamid</td>
<td>198</td>
</tr>
<tr>
<td>Hydroxyurea</td>
<td></td>
</tr>
<tr>
<td>Hydroxyzine</td>
<td>199</td>
</tr>
<tr>
<td>Hylo-Forte</td>
<td>193</td>
</tr>
<tr>
<td>Hylo-Tear</td>
<td>193</td>
</tr>
<tr>
<td>Hyoscine</td>
<td></td>
</tr>
<tr>
<td>Hyperamine</td>
<td>55</td>
</tr>
<tr>
<td>Hypercard</td>
<td>125</td>
</tr>
<tr>
<td>Hypertonic saline</td>
<td>379</td>
</tr>
<tr>
<td>Hypnovel</td>
<td>266</td>
</tr>
<tr>
<td>Hypochlorous acid</td>
<td></td>
</tr>
<tr>
<td>Hypovase</td>
<td>338</td>
</tr>
<tr>
<td>Hypromellose</td>
<td>200</td>
</tr>
<tr>
<td>Hypurin</td>
<td>208</td>
</tr>
<tr>
<td>Ilube</td>
<td>2</td>
</tr>
<tr>
<td>Imaverol</td>
<td>146</td>
</tr>
<tr>
<td>Imepitoin</td>
<td>201</td>
</tr>
<tr>
<td>Imidacloprid</td>
<td>202</td>
</tr>
<tr>
<td>Imidapril</td>
<td>203</td>
</tr>
<tr>
<td>Imidazole</td>
<td>106</td>
</tr>
<tr>
<td>Imidocarb dipropionate</td>
<td>204</td>
</tr>
<tr>
<td>Imipramine</td>
<td>205</td>
</tr>
<tr>
<td>Imizol</td>
<td>204</td>
</tr>
<tr>
<td>Immunoglobulins</td>
<td>206</td>
</tr>
<tr>
<td>Imodium</td>
<td>236</td>
</tr>
<tr>
<td>Imuran</td>
<td>38</td>
</tr>
<tr>
<td>Incurin</td>
<td>155</td>
</tr>
<tr>
<td>Indorex</td>
<td>312</td>
</tr>
<tr>
<td>Indorex household spray</td>
<td>355</td>
</tr>
<tr>
<td>Indoxacarb</td>
<td>207</td>
</tr>
<tr>
<td>Inflicam</td>
<td>250</td>
</tr>
<tr>
<td>Insulatard</td>
<td>208</td>
</tr>
<tr>
<td>Insulin</td>
<td>208</td>
</tr>
<tr>
<td>Intal</td>
<td>381</td>
</tr>
<tr>
<td>Intensol</td>
<td>237</td>
</tr>
<tr>
<td>Interferon omega</td>
<td>210</td>
</tr>
<tr>
<td>Intra-epicaine</td>
<td>253</td>
</tr>
<tr>
<td>Intrafusin</td>
<td>17</td>
</tr>
<tr>
<td>Intralipid</td>
<td>232</td>
</tr>
<tr>
<td>Intubeaze</td>
<td>228</td>
</tr>
<tr>
<td>Iopidine</td>
<td>31</td>
</tr>
<tr>
<td>Ipakitine</td>
<td>75</td>
</tr>
<tr>
<td>Iryplus eye wipes</td>
<td>78</td>
</tr>
<tr>
<td>Iron dextran</td>
<td></td>
</tr>
<tr>
<td>Iron salts</td>
<td>211</td>
</tr>
<tr>
<td>Isaderm</td>
<td>43, 178</td>
</tr>
<tr>
<td>Isalabal</td>
<td>178</td>
</tr>
<tr>
<td>Isoba</td>
<td>213</td>
</tr>
<tr>
<td>Isocare</td>
<td>213</td>
</tr>
<tr>
<td>Isofane</td>
<td>213</td>
</tr>
<tr>
<td>IsoFlo</td>
<td>213</td>
</tr>
<tr>
<td>Isoflurane</td>
<td>213</td>
</tr>
<tr>
<td>Isoflurane Vet</td>
<td>213</td>
</tr>
<tr>
<td>Isopto Plain</td>
<td>200</td>
</tr>
<tr>
<td>Isotretinoin</td>
<td></td>
</tr>
<tr>
<td>Isotrex</td>
<td>426</td>
</tr>
<tr>
<td>Isotrexin</td>
<td>426</td>
</tr>
<tr>
<td>Ispagel</td>
<td>214</td>
</tr>
<tr>
<td>Ispaghula</td>
<td>214</td>
</tr>
<tr>
<td>Istin</td>
<td>23</td>
</tr>
<tr>
<td>Itraconazole</td>
<td>214</td>
</tr>
<tr>
<td>Itrafungol</td>
<td>214</td>
</tr>
<tr>
<td>Ivelip</td>
<td>232</td>
</tr>
<tr>
<td>Ivermectin</td>
<td>216</td>
</tr>
<tr>
<td>Johnson’s 4 Fleas</td>
<td>285</td>
</tr>
<tr>
<td>Kabiven</td>
<td>17</td>
</tr>
<tr>
<td>Kabiven Peripheral</td>
<td>17</td>
</tr>
<tr>
<td>Kaminox</td>
<td>334</td>
</tr>
<tr>
<td>Kaogel VP</td>
<td>217</td>
</tr>
<tr>
<td>Kaolin</td>
<td>217</td>
</tr>
<tr>
<td>Katalax</td>
<td>304</td>
</tr>
<tr>
<td>Kelactin</td>
<td>57</td>
</tr>
<tr>
<td>Kelapril</td>
<td>42</td>
</tr>
<tr>
<td>Kemicetine</td>
<td>77</td>
</tr>
<tr>
<td>Kenalog</td>
<td>415</td>
</tr>
<tr>
<td>Keppra</td>
<td>227</td>
</tr>
<tr>
<td>Kesium</td>
<td>98</td>
</tr>
<tr>
<td>Ketamine</td>
<td>217, 474</td>
</tr>
<tr>
<td>Ketaset injection</td>
<td>217</td>
</tr>
<tr>
<td>Ketavet</td>
<td>217</td>
</tr>
<tr>
<td>Ketoconazole</td>
<td>219</td>
</tr>
<tr>
<td>Ketofen</td>
<td>220</td>
</tr>
<tr>
<td>Ketorolac</td>
<td>221</td>
</tr>
<tr>
<td>Kiovig</td>
<td>206</td>
</tr>
<tr>
<td>Klaricid</td>
<td>89</td>
</tr>
<tr>
<td>Klean-Prep</td>
<td>48</td>
</tr>
<tr>
<td>Klonopin</td>
<td>94</td>
</tr>
<tr>
<td>Konakion</td>
<td>433</td>
</tr>
<tr>
<td>Lacri-Lube</td>
<td>304</td>
</tr>
<tr>
<td>Lactated Ringer’s solution</td>
<td>451</td>
</tr>
<tr>
<td>Lactugal</td>
<td>222</td>
</tr>
<tr>
<td>Lactulose</td>
<td>222</td>
</tr>
<tr>
<td>Laevolac</td>
<td>222</td>
</tr>
<tr>
<td>Lamisil</td>
<td>393</td>
</tr>
<tr>
<td>Lamivudine</td>
<td>223</td>
</tr>
<tr>
<td>Lanoxin</td>
<td>123</td>
</tr>
<tr>
<td>Brand Name</td>
<td>Page</td>
</tr>
<tr>
<td>------------------</td>
<td>------</td>
</tr>
<tr>
<td>Lanthanum PG*</td>
<td>123</td>
</tr>
<tr>
<td>Lanthanum carbonate</td>
<td>223</td>
</tr>
<tr>
<td>Lanthreneol see Lanthanum carbonate</td>
<td>223</td>
</tr>
<tr>
<td>Lantus*</td>
<td>208</td>
</tr>
<tr>
<td>Latanoprost</td>
<td>224</td>
</tr>
<tr>
<td>Laronabolin</td>
<td>280</td>
</tr>
<tr>
<td>Ledclair*</td>
<td>142</td>
</tr>
<tr>
<td>Leflunomide</td>
<td>225</td>
</tr>
<tr>
<td>Lenograstim</td>
<td>226</td>
</tr>
<tr>
<td>Lethobarb</td>
<td>309</td>
</tr>
<tr>
<td>Leukaeran*</td>
<td>75</td>
</tr>
<tr>
<td>Levienta</td>
<td>401</td>
</tr>
<tr>
<td>Levetiracetam</td>
<td>227</td>
</tr>
<tr>
<td>Levethyroxine see l-Thyroxine</td>
<td>228, 401</td>
</tr>
<tr>
<td>Libeo</td>
<td>176</td>
</tr>
<tr>
<td>Libromide</td>
<td>331</td>
</tr>
<tr>
<td>Lidocaine</td>
<td>228, 457</td>
</tr>
<tr>
<td>Lidoderm*</td>
<td>228</td>
</tr>
<tr>
<td>Lignadrin</td>
<td>228</td>
</tr>
<tr>
<td>Lignocaine see Lidocaine</td>
<td>228</td>
</tr>
<tr>
<td>Lignol</td>
<td>228</td>
</tr>
<tr>
<td>Lincocin</td>
<td>228</td>
</tr>
<tr>
<td>Lincoject</td>
<td>228</td>
</tr>
<tr>
<td>Lincomycin</td>
<td>228</td>
</tr>
<tr>
<td>Lintrol*</td>
<td>94</td>
</tr>
<tr>
<td>Lipid infusions</td>
<td>232</td>
</tr>
<tr>
<td>Lipidem*</td>
<td>232</td>
</tr>
<tr>
<td>Lipofundin*</td>
<td>232</td>
</tr>
<tr>
<td>Liqui-Char*</td>
<td>74</td>
</tr>
<tr>
<td>Liquid paraffin</td>
<td>304</td>
</tr>
<tr>
<td>Liquid paraffin oral emulsion*</td>
<td>304</td>
</tr>
<tr>
<td>Liquifilm Tears*</td>
<td>331</td>
</tr>
<tr>
<td>Liskonum*</td>
<td>233</td>
</tr>
<tr>
<td>Lithium carbonate</td>
<td>233</td>
</tr>
<tr>
<td>Locaine</td>
<td>228</td>
</tr>
<tr>
<td>Locovetic</td>
<td>228</td>
</tr>
<tr>
<td>Lofenoxal*</td>
<td>130</td>
</tr>
<tr>
<td>Lokivetmab</td>
<td>234</td>
</tr>
<tr>
<td>Lomotil* (with atropine)</td>
<td>130</td>
</tr>
<tr>
<td>Lomustine</td>
<td>235</td>
</tr>
<tr>
<td>Loperamide</td>
<td>236</td>
</tr>
<tr>
<td>Loradatine</td>
<td>236</td>
</tr>
<tr>
<td>Lorazepam</td>
<td>237</td>
</tr>
<tr>
<td>Losec*</td>
<td>291</td>
</tr>
<tr>
<td>Lotilamer</td>
<td>238</td>
</tr>
<tr>
<td>Lotriderm*</td>
<td>97</td>
</tr>
<tr>
<td>Loxicom</td>
<td>250</td>
</tr>
<tr>
<td>Lubrithal</td>
<td>61</td>
</tr>
<tr>
<td>Lufenuron</td>
<td>238</td>
</tr>
<tr>
<td>Lustral*</td>
<td>372</td>
</tr>
<tr>
<td>Lytalyse</td>
<td>129</td>
</tr>
<tr>
<td>Lyovac*</td>
<td>106</td>
</tr>
<tr>
<td>Lypex*</td>
<td>299</td>
</tr>
<tr>
<td>Lyrilac*</td>
<td>341</td>
</tr>
<tr>
<td>Lyrinel*</td>
<td>296</td>
</tr>
<tr>
<td>Lysine</td>
<td>239</td>
</tr>
<tr>
<td>Lysodren*</td>
<td>271</td>
</tr>
<tr>
<td>Lysovir*</td>
<td>15</td>
</tr>
<tr>
<td>Maalox*</td>
<td>13</td>
</tr>
<tr>
<td>Macrogol</td>
<td>48</td>
</tr>
<tr>
<td>Magnesium salts</td>
<td>240</td>
</tr>
<tr>
<td>Magnesium sulphate injection BP (Vet) 25% w/v</td>
<td>240</td>
</tr>
<tr>
<td>Malaseb</td>
<td>78, 265</td>
</tr>
<tr>
<td>Mannitol</td>
<td>241</td>
</tr>
<tr>
<td>Marbocare</td>
<td>242</td>
</tr>
<tr>
<td>Marbocyl</td>
<td>242</td>
</tr>
<tr>
<td>Marbodex</td>
<td>242</td>
</tr>
<tr>
<td>Marbopoxacin</td>
<td>242</td>
</tr>
<tr>
<td>Marbotab</td>
<td>242</td>
</tr>
<tr>
<td>Marboxidin</td>
<td>242</td>
</tr>
<tr>
<td>Marcain*</td>
<td>52</td>
</tr>
<tr>
<td>Marfloquin</td>
<td>242</td>
</tr>
<tr>
<td>Maropitant</td>
<td>244</td>
</tr>
<tr>
<td>Masitinib mesylate</td>
<td>245</td>
</tr>
<tr>
<td>Masivet</td>
<td>245</td>
</tr>
<tr>
<td>Matrex*</td>
<td>258</td>
</tr>
<tr>
<td>Mavacoxib</td>
<td>246</td>
</tr>
<tr>
<td>Maxidex*</td>
<td>43, 114</td>
</tr>
<tr>
<td>Maxitrol*</td>
<td>114, 281</td>
</tr>
<tr>
<td>MaxiSAMe</td>
<td>367</td>
</tr>
<tr>
<td>Medetomidine</td>
<td>246, 472, 474</td>
</tr>
<tr>
<td>Medetor</td>
<td>247</td>
</tr>
<tr>
<td>Medrone</td>
<td>259</td>
</tr>
<tr>
<td>Meglumine antimonate</td>
<td>249</td>
</tr>
<tr>
<td>Melanotonin</td>
<td>250</td>
</tr>
<tr>
<td>Meloxicam</td>
<td>250</td>
</tr>
<tr>
<td>Meloxidyl</td>
<td>250</td>
</tr>
<tr>
<td>Meloxivet</td>
<td>250</td>
</tr>
<tr>
<td>Melphalan</td>
<td>252</td>
</tr>
<tr>
<td>Meperidine see Pethidine</td>
<td>313</td>
</tr>
<tr>
<td>Mepivacaine</td>
<td>253</td>
</tr>
<tr>
<td>Mepradec*</td>
<td>291</td>
</tr>
<tr>
<td>Mestinon*</td>
<td>352</td>
</tr>
<tr>
<td>Metacam</td>
<td>250</td>
</tr>
<tr>
<td>Metalite</td>
<td>416</td>
</tr>
<tr>
<td>Metformin</td>
<td>184</td>
</tr>
<tr>
<td>Methadone</td>
<td>254, 471–4</td>
</tr>
<tr>
<td>Methenamine</td>
<td>255</td>
</tr>
<tr>
<td>Methimazole see Thiamazole</td>
<td>399</td>
</tr>
<tr>
<td>Methionine</td>
<td>256</td>
</tr>
<tr>
<td>Methocarbamol</td>
<td>256</td>
</tr>
<tr>
<td>Methoprene</td>
<td>257</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>258</td>
</tr>
<tr>
<td>Methylene blue see</td>
<td>Methylythioninium chloride 260</td>
</tr>
<tr>
<td>Methylythioninium chloride</td>
<td>260</td>
</tr>
<tr>
<td>Methylprednisolone</td>
<td>259</td>
</tr>
<tr>
<td>4-Methylpyrazole see Fomepizole</td>
<td>175</td>
</tr>
<tr>
<td>Methylthioninium chloride</td>
<td>260</td>
</tr>
</tbody>
</table>
Index: generic and trade names

APPENDIX I: GENERAL INFORMATION

APPENDIX II: PROTOCOLS

INDEX: GENERIC AND TRADE NAMES

INDEX: THERAPEUTIC CLASS

Metoclopramide 261
Metomotyl 261
Metrobactin 262
Metronidazole 262, 457
Mexiletine 264
Mexitil* 264
Mezzopram* 291
Micolette* 380
Miconazole 265, 443
Micralax* 380
Microbex 78
Midazolam 266, 473–4
Milbactor 267, 337
Milbemax 267, 337
Milbemycin 267
Milk thistle see Silybin 377
Minlims* 77
Minitrab* 186
Minocin* 269
Minodiab* 184
Mirtazapine 270
Misoprostol 270
Mitotane 271
Mitofosine 268
Mineral oil see Paraffin 304
Mycophenolate mofetil 278
Modulis 81
Moduret* 195
Moduretic* 195
Molipaxin* 413
Monoflu* 211
Monover* 394
Morphine 274, 457
Motilium* 134
Moviprep* 48
Moxiclear 202, 276
Moxidectin 276
Mucogel* 13
Multivitamin injection 427
Mupirocin 277
Mycinor 91
Mycophenolate mofetil 277, 468, 470
Mycophenolic acid see
  Mycophenolate mofetil 278
Mydriacyl* 419
Myfortic* 278
Myotonine* 45
Nalcrom* 381
Naloxone 280
Nandrolone 280
Narcan* 280
Narketan-10 217
Naropin 365
Nebcin* 404
Nelio 42
Neo-Cytamn (hydroxocobalamin) 429
Neomycin 281
Neopen 281, 308
Neorecombin* 153
Neostigmine 282
Neostigmine/Glycopyruronium bromide* 282
Nerfasin 435
N-ethyl-L-glutamine see
  L-Theanine 397
Neupogen* 162
Neurontin* 179
Nexgard 6
Nexgard Spectra 6, 267
Niacinamide see Nicotinamide 284
Nicotinamide 284
Nimbex* 88
Nisinjekt 98
Nitenpyram 285
Nitrocin* 186
Nitrofurantoin 285, 456
Nitroglycerin(e) see Glyceril trinitrate 186
Nitroln* 186
Nitrous oxide 286
Nivemycin* 281
Norcuron* 422
Nordotropin* 383
Norgalax* 132
Norimode* 236
Normacol* 386
Norocillin 308
Noroclaw 98
Norodine 418
Norofol 346
NorOtic 242
Novantrone* 272
Novifit 367
Nutriflex 367
Nystant* 127
Nystatin 287
Oclacitinib 289
Ocri-gel 61
Ocufen* 173
Oestriol see Estriol 155
Ofloxacin 290
Oclacitinib 289
Ocri-gel 61
Ocufen* 173
Oestriol see Estriol 155
Ofloxacin 290
Oleptro* 413
Olsalazine 291
Omegaven* 429
Omnopon* 302
Oncovin* 425
Ondansetron 293
One-alpha* 430
Onsiro 360
o,p’-DDD see Mitotane 271
Opticrom 80
OptiCare 75
OptiCare Pollinase 381
Optifax 61
Optrex 77
Optrex allergy Pollinase* 381
Oramorph* 274
Orbax 293
Orbenin 98
Orbifloxacin 293, 443
Osaterone 295
Osurnia 43, 166, 393, 443
Otinecint Vet 216
Otodine* 78
Otomax 43, 182, 443
Oxantel see Pyrantel 351
Oxybutynin hydrochloride 296
Ozycare 296
Oxypentifylline see Pentoxifylline 311
Oxypolygelatine see Gelatine 180
Oxycare 266, 456, 457
Oxycare 297
Oxytocin S 297

Palladia 405
Pamidronate 299
Panacur 159
Pancreatic Enzyme for cats and dogs 299
Pancreatic enzyme supplements 299
Pancuronium 300
Pantoprazole 301
Panzym* 299
Papaveretum 302, 471, 473
Paracetamol 303
Paraffin 304
Paraldehyde* 62
Pardale-V 100, 303
Paroxetine 305
Parvolex* 2
Paxil* 305
Pendramine* 306
Penicillamine 306
Penicillin G 308
Pentacarminat* 309

Pentamidine isethionate 309
Pentobarbital 309, 457
Pentobarbital for euthanasia 309
Pentobarbitone see Pentobarbital 309
Pentoject 309
Pentosan polysulphate 310
Pentostam* 382
Pentoxifylline 311
Peptac* 13
Pepto-Bismol* 46
Percurtol* 186
Perfalgan 303
Periactin* 103
Peridale 386
Permethrin 312
Pethidine 313, 471–4
Pexion 201
Pharmorubicin* 149
Phenergan* 344
Phenobarbital 314, 457
Phenobarbitone see Phenobarbital 314
Phenoleptil 314
Phenoxybenzamine 317
Phenylbutazone 318
Phenylephrine 319
Phenylephrine hydrochloride* 319
Phenylpropanolamine 320
Phenytoin 321
Pheromones see Dog appeasing pheromone 133
Pheromones see Feline facial fraction F3 158
Pholcodine 322
Phos* 57
PhosLo* 57
Phosphate 323
Phosphate enema 324
Phosphate-Sandoz* 323
Phytomenadione see Vitamin K1 433
Pilocarpine 325
Pilocarpine hydrochloride* 325
Pimobendan 326
Pimocard 326
Piperacillin 327
Piperazine 328
Pyriproxyfen 1% premix for dogs 355
Piriteze* 73
Pirital* 79
Piroxicam 329
Plavix* 96
PLT 339
PLT tablets 85
Polyethylene glycol see Bowel cleansing solutions 48
Polyfax* 330
Polygeline see Gelatine 180
Polymyxin B 330
Polyvinyl alcohol 331
Posatex 293, 443
Posject* 131
Potassium bromide 331
Potassium bromide solution see Potassium salts 334
Potassium citrate 333
Potassium citrate BP* 333
Potassium gluconate see Potassium salts 334
Potassium phosphate see Phosphate 323
Potassium salts 334
Potentiated sulphonamides see Trimethoprim/Sulphonamide 418
Powerflo 147
Prac-tic 354
Pradofloxacin 335
Pralidoxime 336
Praziquantel 337
Prazosin 338
Pred-forte* 339
Prednicare 339
Prednidale 339
Prednisolone 339, 460–3, 466, 468–71
Pregabalin 341
Previcox 165
Prevomax 244
Priadel* 233
Prilactone 385
Prilben 42
Prilium 203
Prinovox 202, 276
Pro-Banthine* 345
Procaicne hydrochloride with epinephrine bitartrate 342
Procain 346
Prochlorperazine 342
Procox 144, 407
Pro-Enzorb* 299
pro-Epanutin* 321
Profender Spot on 144, 337
Program 238
Program plus 267
Proin 320
Prokolin 217
Proligestone 343
Promethazine 344
Propalin 320
Propantheline 345
Proparacaine see Proxymetacaine 350
Propentofylline 346
PropoFlo Plus 346
Propofol 346, 472
Propofol 346
Propofol-Liuro Vet 346
Propranolol 348, 457
Proscar* 163
Prostaglandin F2 see Dinoprost tromethamine 129
Protamine sulphate 350
Protium* 301
Protopic* 390
Pyrimethamine 353
Pyriprole 354
Pyriproxyfen 355
Pyriproxyfen 1% premix for dogs 355
Pyriproxyfen Spot on 355
Questran* 101
Quiflor 242
Quinalbarbitone/Cincochaine see Secobarbital 370
Quinoflox 147
Rabafocsadine 356
Ramipril 356
Ranitidine 358
Rapidexon 114
Rapifen* 10
Rapinove 346
Recicort* 415
Reconcile 171
Refresh Ophthalmic* 331
Relaxit* 380
Remend Corneal Lubricant* 193
Remend Corneal Repair Gel* 193
Renagel 373
Renasan spray 381
Retinol see Vitamin A 426
Retrovir* 437
Revatio* 375
Revertor 35
Rheumocam 250
Rhinocort* 50
rhG-CSF see Lenograstim 226
Rifadin* 359
Rifampicin see Rifampin 359
Rifampin 359
<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Index/Class</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rilexine</td>
<td>Generic/Trade</td>
</tr>
<tr>
<td>Rimactane*</td>
<td>359</td>
</tr>
<tr>
<td>Rimadyl</td>
<td>63</td>
</tr>
<tr>
<td>Rimifin</td>
<td>63</td>
</tr>
<tr>
<td>Rimso-50*</td>
<td>127</td>
</tr>
<tr>
<td>Ringer's solution</td>
<td>451</td>
</tr>
<tr>
<td>Ritamox*</td>
<td>264</td>
</tr>
<tr>
<td>Rivotrill*</td>
<td>94</td>
</tr>
<tr>
<td>Roaccutane*</td>
<td>426</td>
</tr>
<tr>
<td>Robaxin*</td>
<td>256</td>
</tr>
<tr>
<td>Robenacoxib</td>
<td>360</td>
</tr>
<tr>
<td>Robinul*</td>
<td>187</td>
</tr>
<tr>
<td>Rocaltril*</td>
<td>430</td>
</tr>
<tr>
<td>Rocuronium</td>
<td>362</td>
</tr>
<tr>
<td>Romazicon*</td>
<td>169</td>
</tr>
<tr>
<td>Rompun</td>
<td>435</td>
</tr>
<tr>
<td>Ronaxan</td>
<td>140</td>
</tr>
<tr>
<td>Ronidazole</td>
<td>363</td>
</tr>
<tr>
<td>Ropinirole</td>
<td>364</td>
</tr>
<tr>
<td>Ropivacaine</td>
<td>365</td>
</tr>
<tr>
<td>S-Adenosylmethionine</td>
<td>367</td>
</tr>
<tr>
<td>Salazopyrin*</td>
<td>388</td>
</tr>
<tr>
<td>Salbutamol</td>
<td>368</td>
</tr>
<tr>
<td>SAMe*</td>
<td>367</td>
</tr>
<tr>
<td>Samylin</td>
<td>367, 377</td>
</tr>
<tr>
<td>Sandostatin*</td>
<td>289</td>
</tr>
<tr>
<td>Sandostatin LAR*</td>
<td>289</td>
</tr>
<tr>
<td>Sarolaner</td>
<td>369</td>
</tr>
<tr>
<td>Savlon*</td>
<td>78</td>
</tr>
<tr>
<td>Scalibor Protectorband</td>
<td>110</td>
</tr>
<tr>
<td>Secobarbital</td>
<td>370</td>
</tr>
<tr>
<td>Securon*</td>
<td>423</td>
</tr>
<tr>
<td>Sedadex</td>
<td>116</td>
</tr>
<tr>
<td>Sedastart</td>
<td>247</td>
</tr>
<tr>
<td>Sedatop</td>
<td>35</td>
</tr>
<tr>
<td>Sedator</td>
<td>247</td>
</tr>
<tr>
<td>Sedaxylan</td>
<td>435</td>
</tr>
<tr>
<td>Sededorm</td>
<td>247</td>
</tr>
<tr>
<td>Selamectin</td>
<td>371</td>
</tr>
<tr>
<td>Selhold</td>
<td>371</td>
</tr>
<tr>
<td>Selegiline</td>
<td>371</td>
</tr>
<tr>
<td>Selgian</td>
<td>371</td>
</tr>
<tr>
<td>Semintra</td>
<td>391</td>
</tr>
<tr>
<td>Sensorcaine*</td>
<td>52</td>
</tr>
<tr>
<td>Setacon*</td>
<td>388</td>
</tr>
<tr>
<td>Seresto</td>
<td>202</td>
</tr>
<tr>
<td>Seroxat*</td>
<td>305</td>
</tr>
<tr>
<td>Sertraline</td>
<td>372</td>
</tr>
<tr>
<td>S-Etracetam see Levetiracetam</td>
<td>227</td>
</tr>
<tr>
<td>Setofilm*</td>
<td>293</td>
</tr>
<tr>
<td>Sevelamer hydrochloride</td>
<td>373</td>
</tr>
<tr>
<td>SevoFlo</td>
<td>374</td>
</tr>
<tr>
<td>Sevoflurane</td>
<td>374</td>
</tr>
<tr>
<td>Sevotec*</td>
<td>374</td>
</tr>
<tr>
<td>Sildenafil</td>
<td>375</td>
</tr>
<tr>
<td>Sileo</td>
<td>116</td>
</tr>
<tr>
<td>Silibinin see Silybin</td>
<td>377</td>
</tr>
<tr>
<td>Silver sulfadiazine</td>
<td>376</td>
</tr>
<tr>
<td>Silybin</td>
<td>377</td>
</tr>
<tr>
<td>Silymarin see Silybin</td>
<td>377</td>
</tr>
<tr>
<td>Simparica</td>
<td>369</td>
</tr>
<tr>
<td>S-Methoprene see Methoprene</td>
<td>257</td>
</tr>
<tr>
<td>Simple eye ointment*</td>
<td>304</td>
</tr>
<tr>
<td>Sinepin*</td>
<td>138</td>
</tr>
<tr>
<td>Sinequan*</td>
<td>138</td>
</tr>
<tr>
<td>Slozem*</td>
<td>125</td>
</tr>
<tr>
<td>Sno Tears*</td>
<td>331</td>
</tr>
<tr>
<td>Sodium acid phosphate see Phosphate enema</td>
<td>324</td>
</tr>
<tr>
<td>Sodium bicarbonate</td>
<td>378</td>
</tr>
<tr>
<td>Sodium chloride</td>
<td>379</td>
</tr>
<tr>
<td>Sodium chromoglycate see Sodium cromoglicate</td>
<td>381</td>
</tr>
<tr>
<td>Sodium citrate</td>
<td>380</td>
</tr>
<tr>
<td>Sodium cromoglicate</td>
<td>381</td>
</tr>
<tr>
<td>Sodium hypochlorite</td>
<td>381</td>
</tr>
<tr>
<td>Sodium stibogluconate</td>
<td>382</td>
</tr>
<tr>
<td>Softiflox</td>
<td>242</td>
</tr>
<tr>
<td>Soloxine</td>
<td>401</td>
</tr>
<tr>
<td>Solu-cortef*</td>
<td>196</td>
</tr>
<tr>
<td>Solu-Medrone</td>
<td>259</td>
</tr>
<tr>
<td>Somatotropin</td>
<td>383</td>
</tr>
<tr>
<td>Somulose</td>
<td>370</td>
</tr>
<tr>
<td>Sotacor*</td>
<td>383</td>
</tr>
<tr>
<td>Sotalol</td>
<td>383</td>
</tr>
<tr>
<td>Spinosad</td>
<td>384</td>
</tr>
<tr>
<td>Spiramycin see Metronidazole</td>
<td>262</td>
</tr>
<tr>
<td>Spironolactone</td>
<td>385</td>
</tr>
<tr>
<td>Sporano*</td>
<td>214</td>
</tr>
<tr>
<td>Sporimmune</td>
<td>81</td>
</tr>
<tr>
<td>Staykill</td>
<td>257</td>
</tr>
<tr>
<td>Stemetil*</td>
<td>342</td>
</tr>
<tr>
<td>Sterculia</td>
<td>386</td>
</tr>
<tr>
<td>Stesolid*</td>
<td>118</td>
</tr>
<tr>
<td>Stomidine F</td>
<td>78</td>
</tr>
<tr>
<td>Stomorgyl</td>
<td>262</td>
</tr>
<tr>
<td>Stronghold</td>
<td>371</td>
</tr>
<tr>
<td>Sublimaze*</td>
<td>160</td>
</tr>
<tr>
<td>Succinylcholine see Suxamethonium</td>
<td>389</td>
</tr>
<tr>
<td>Suxamethonium</td>
<td>389</td>
</tr>
<tr>
<td>Sucralfate</td>
<td>387</td>
</tr>
<tr>
<td>Sulfasalazine</td>
<td>388</td>
</tr>
<tr>
<td>Sulphasalazine*</td>
<td>388</td>
</tr>
<tr>
<td>Sulphonamide see Trimethoprim/ Sulphonamide</td>
<td>418</td>
</tr>
<tr>
<td>Suntheanine see L-Theanine</td>
<td>397</td>
</tr>
<tr>
<td>Suprenerin</td>
<td>111</td>
</tr>
<tr>
<td>Surolan</td>
<td>265, 330, 443</td>
</tr>
<tr>
<td>Suxamethonium</td>
<td>389</td>
</tr>
<tr>
<td>Symmetrel*</td>
<td>15</td>
</tr>
<tr>
<td>Synacthen*</td>
<td>396</td>
</tr>
<tr>
<td>Synthadon</td>
<td>254</td>
</tr>
</tbody>
</table>
Synuclav 98
Synulox 98
Syprol* 348

T3 see Liothyronine 231
T4 see L-Thyroxine 401
Tacrolimus 390
Tagamet* 83
Tamsulosin hydrochloride 391
Tanovea-CA1 256
Tardak 109
Tavegilt 90
Tazocin* 327
3TC 233
Telmisartan 391
Temcad* 392
Temodal* 392
Temodar* 392
Temozolomide 392
Temporad 366
Tenormin* 34
Terbinafine 393
Terbutaline 394
Tetanus antitoxin 395
Tetanus antitoxin Behring 395
Tetracosactide 396
Tetracosactrin 396
2,2,2-Tetramine see Trientine 416
L-Theanine 397
Theophylline 398, 457
Therios 67
Thiafeline 399
Thiamazole 399
Thiamine see Vitamin B1 428
Thyforon 401
Thyrogen* 400
Thyroid stimulating hormone 400
Thyrinorm 399
Thyrotropin alfa see Thyroid stimulating hormone 400
L-Thyroxine 401
Ticil 182
Ticarcillin 402
Tildiem* 125
Tiletamine see Zolazepam 439
Timentin* 402
Timolol* 403
Timolol maleate 403
Timoptol* 403
Tipafar 35
Tobramycin 404, 456
Toceranib 405
Tofranil 205
Toldimphos see Phosphate 323
Tolledine 406
Tolfenamic acid 406
Toltrazuril 407
Topamax* 408
Topiramate 408
Torasemide 409
Torbegesic 54
Torbutrol 54
Torphasol 54
Torsemide see Torasemide 409
Tracrium* 36
Tralieve 410
Tramadol 410
Tramadol ER* 410
Tranexamic acid 412
Transderm-Nitro* 186
Travatan* 413
Travoprost 413
Trazodone 413
Trental* 311
Tretinoin see Vitamin A 426
Triamcinolone 415
Trientine 416
Trifexis 267, 384
Trigogron 178
L-Tri-iodothyronine see Liothyronine 231
Trilostane 417
Trimacare 418
Trimedoxine 418
Trimethoprim/Sulphonamide 418, 456
TrizChlor* 78
Trocoxil 246
Tropicamide 419
Trusopt* 137
Tsefalen 67
TSH see Thyroid stimulating hormone 400
Tumil-K 334
Twinox 98
Tylan 420
Tylosin 420
Tyluvet 420
Ubiclox 242
Ucerax* 199
UDCA see Ursodeoxycholic acid 421
UFH see Heparin (unfractionated) 192
Ultracet* 410
Ultram* 410
UpCard 409
Urilin 320
Ursodeoxycholic acid 421
Ursofalk* 421
Veterinary surgeons should supply written information to clients about the drug that they prescribe. Client Information Leaflets (CIL) on many unauthorized preparations are available for BSAVA members to download from the BSAVA website.
When you become a member of BSAVA, you join a community of over 10,000 vets and nurses. Together, we are helping to improve the welfare of countless small animals by sharing and developing our skills and knowledge.

**MEMBER BENEFITS**

As a member, you have access to a wide range of resources including:

- A FREE copy of the Small Animal Formulary
- Massive discounts on BSAVA Congress
- Discounted and FREE CPD
- Exclusive discounts on BSAVA publications and events
- Annual subscriptions to Companion – our monthly membership magazine – and JSAP (worth over £300)

...and so much more – check out [bsava.com](http://bsava.com) for all your BSAVA benefits.

Join or renew online
[www.bsava.com/membership](http://www.bsava.com/membership)
Keeping you up to date

BSAVA’s resources on veterinary medicines help keep you and your practice up to date

Your essential daily reference
The BSAVA Formulary is one of the Association’s most valued and trusted resources. Now available in two volumes covering dogs/cats and exotic species, BSAVA members can also access the Formularies via the BSAVA Library and BSAVA app.
bsavalibrary.com/formulary

Fulfil your obligations
Our range of client information leaflets can be used to provide the required information when prescribing drugs that are not authorized for that use. Available to BSAVA members.
bsavalibrary.com/cil

Keep up to date with medicines regulations
A free online guide to help you navigate the minefield of issues, changes and regulations to promote best practice.
bsavalibrary.com/medicinesguide

PROTECT antibacterials
Put your practice policy on antibacterial use on the BSAVA/SAMSoC PROTECT ME poster, with free online supporting information. We also sell pads of ‘no antibiotic prescription required’ forms to aid conversations with clients.
bsavalibrary.com/PROTECTME